PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33915156-0	2021	A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERalpha mutants in breast cancer.	celastrol	54-63	estrogen receptor 1	Homo sapiens	91-98
33915156-6	2021	We then collected and screened a natural product library for potential ERalpha antagonists via GLPCA and identified celastrol and gambogic acid as new antagonists of the ERalpha Y537S mutant.	celastrol	116-125	estrogen receptor 1	Homo sapiens	170-177
33915156-8	2021	Importantly, we further demonstrated that celastrol and gambogic acid exhibit synergistic antiproliferative and pro-apoptotic effects when combined with an approved CDK4/6 inhibitor abemaciclib in breast cancer cells expressing ERalpha Y537S.	celastrol	42-51	cyclin dependent kinase 4	Homo sapiens	165-171
33915156-8	2021	Importantly, we further demonstrated that celastrol and gambogic acid exhibit synergistic antiproliferative and pro-apoptotic effects when combined with an approved CDK4/6 inhibitor abemaciclib in breast cancer cells expressing ERalpha Y537S.	celastrol	42-51	estrogen receptor 1	Homo sapiens	228-235
33965112-0	2021	Improved delivery system for celastrol-loaded magnetic Fe3O4/alpha-Fe2O3 heterogeneous nanorods: HIF-1alpha-related apoptotic effects on SMMC-7721 cell.	celastrol	29-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	97-107
33845380-0	2021	Discovery of novel celastrol-triazole derivatives with Hsp90-Cdc37 disruption to induce tumor cell apoptosis.	celastrol	19-28	heat shock protein 90 alpha family class A member 1	Homo sapiens	55-60
33845380-0	2021	Discovery of novel celastrol-triazole derivatives with Hsp90-Cdc37 disruption to induce tumor cell apoptosis.	celastrol	19-28	cell division cycle 37, HSP90 cochaperone	Homo sapiens	61-66
33999692-8	2021	Celastrol treatment inhibited the production of both IL-23 and IL-17 in PBMCs of SO patients in a dose-dependent manner.	celastrol	0-9	interleukin 23 subunit alpha	Homo sapiens	53-58
34053427-10	2022	(4) Compared with the control group, the Celastrol treatment also reduced the expression of the mTOR signaling pathway related proteins, suggesting that the mTOR signaling pathway may be involved in the process of Celastrol inhibiting the proliferation of the SGC7901/DDP cells and reducing their drug resistance.	celastrol	41-50	mechanistic target of rapamycin kinase	Homo sapiens	96-100
34053427-10	2022	(4) Compared with the control group, the Celastrol treatment also reduced the expression of the mTOR signaling pathway related proteins, suggesting that the mTOR signaling pathway may be involved in the process of Celastrol inhibiting the proliferation of the SGC7901/DDP cells and reducing their drug resistance.	celastrol	41-50	mechanistic target of rapamycin kinase	Homo sapiens	157-161
34053427-10	2022	(4) Compared with the control group, the Celastrol treatment also reduced the expression of the mTOR signaling pathway related proteins, suggesting that the mTOR signaling pathway may be involved in the process of Celastrol inhibiting the proliferation of the SGC7901/DDP cells and reducing their drug resistance.	celastrol	214-223	mechanistic target of rapamycin kinase	Homo sapiens	96-100
34053427-10	2022	(4) Compared with the control group, the Celastrol treatment also reduced the expression of the mTOR signaling pathway related proteins, suggesting that the mTOR signaling pathway may be involved in the process of Celastrol inhibiting the proliferation of the SGC7901/DDP cells and reducing their drug resistance.	celastrol	214-223	mechanistic target of rapamycin kinase	Homo sapiens	157-161
34053427-11	2022	(5) Significantly, the combination of Celastrol and DDP reduced the expression of P-gp, MRP1, and BCRP in the SGC7901/DPP cells.	celastrol	38-47	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
34053427-11	2022	(5) Significantly, the combination of Celastrol and DDP reduced the expression of P-gp, MRP1, and BCRP in the SGC7901/DPP cells.	celastrol	38-47	ATP binding cassette subfamily C member 1	Homo sapiens	88-92
34053427-11	2022	(5) Significantly, the combination of Celastrol and DDP reduced the expression of P-gp, MRP1, and BCRP in the SGC7901/DPP cells.	celastrol	38-47	BCR pseudogene 1	Homo sapiens	98-102
34053427-12	2022	CONCLUSION: Celastrol can inhibit the proliferation of the SGC7901/DDP cells, induce their apoptosis, and reduce the expression of drug resistance genes, probably by inhibiting the expression of the proteins related to the mTOR signaling pathway.	celastrol	12-21	mechanistic target of rapamycin kinase	Homo sapiens	223-227
33846813-0	2021	Celastrol attenuates the inflammatory response by inhibiting IL-1beta expression in triple-negative breast cancer cells.	celastrol	0-9	interleukin 1 alpha	Homo sapiens	61-69
33846813-2	2021	In the present study, the functional roles of IL-1beta (IL1B) and the inhibitory effect of celastrol on IL1B expression were investigated in triple-negative breast cancer (TNBC) cells.	celastrol	91-100	interleukin 1 beta	Homo sapiens	104-108
33846813-3	2021	The data revealed that celastrol markedly decreased IL1B expression and suppressed TNBC cell proliferation in a dose-dependent manner.	celastrol	23-32	interleukin 1 beta	Homo sapiens	52-56
33846813-7	2021	Celastrol also promoted IL1B downregulation through the suppression of the MEK/ERK-dependent pathway.	celastrol	0-9	interleukin 1 beta	Homo sapiens	24-28
33846813-7	2021	Celastrol also promoted IL1B downregulation through the suppression of the MEK/ERK-dependent pathway.	celastrol	0-9	mitogen-activated protein kinase kinase 7	Homo sapiens	75-78
33846813-7	2021	Celastrol also promoted IL1B downregulation through the suppression of the MEK/ERK-dependent pathway.	celastrol	0-9	mitogen-activated protein kinase 1	Homo sapiens	79-82
33846813-8	2021	Furthermore, the results also revealed a decrease in IL1B-induced IL8, MMP-1, and MMP-9 expression in response to celastrol treatment.	celastrol	114-123	interleukin 1 beta	Homo sapiens	53-57
33846813-8	2021	Furthermore, the results also revealed a decrease in IL1B-induced IL8, MMP-1, and MMP-9 expression in response to celastrol treatment.	celastrol	114-123	C-X-C motif chemokine ligand 8	Homo sapiens	66-69
33846813-8	2021	Furthermore, the results also revealed a decrease in IL1B-induced IL8, MMP-1, and MMP-9 expression in response to celastrol treatment.	celastrol	114-123	matrix metallopeptidase 1	Homo sapiens	71-76
33846813-8	2021	Furthermore, the results also revealed a decrease in IL1B-induced IL8, MMP-1, and MMP-9 expression in response to celastrol treatment.	celastrol	114-123	matrix metallopeptidase 9	Homo sapiens	82-87
33846813-9	2021	The induction of cellular invasion by IL1B was also markedly decreased by celastrol.	celastrol	74-83	interleukin 1 beta	Homo sapiens	38-42
33846813-10	2021	Collectively, the present study results suggested celastrol as an effective drug for the treatment of TNBC, involving a reduction in IL1B expression, activity or signaling pathways.	celastrol	50-59	interleukin 1 beta	Homo sapiens	133-137
34053427-9	2022	However, after treating with Celastrol, the expression levels of P-gp, MRP1, and BCRP in the SGC7901/DPP cells were significantly reduced (P<0.05).	celastrol	29-38	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
34053427-9	2022	However, after treating with Celastrol, the expression levels of P-gp, MRP1, and BCRP in the SGC7901/DPP cells were significantly reduced (P<0.05).	celastrol	29-38	ATP binding cassette subfamily C member 1	Homo sapiens	71-75
34053427-9	2022	However, after treating with Celastrol, the expression levels of P-gp, MRP1, and BCRP in the SGC7901/DPP cells were significantly reduced (P<0.05).	celastrol	29-38	BCR pseudogene 1	Homo sapiens	81-85
33999692-8	2021	Celastrol treatment inhibited the production of both IL-23 and IL-17 in PBMCs of SO patients in a dose-dependent manner.	celastrol	0-9	interleukin 17A	Homo sapiens	63-68
33999692-9	2021	In PBMCs isolated from SO patients and healthy controls, the administration of recombinant human IL-23 (rIL-23) enhanced the production of IL-17, which was then suppressed by co-stimulation with celastrol.	celastrol	195-204	interleukin 23 subunit alpha	Homo sapiens	97-102
33999692-9	2021	In PBMCs isolated from SO patients and healthy controls, the administration of recombinant human IL-23 (rIL-23) enhanced the production of IL-17, which was then suppressed by co-stimulation with celastrol.	celastrol	195-204	interleukin 17A	Homo sapiens	139-144
33999692-10	2021	Also, celastrol treatment reduced rIL-23-induced phosphorylation of STAT3 in PBMCs isolated from SO patients.	celastrol	6-15	signal transducer and activator of transcription 3	Homo sapiens	68-73
33999692-11	2021	Conclusions: Celastrol can reduce the production of IL-17 in PBMCs of SO patients.	celastrol	13-22	interleukin 17A	Homo sapiens	52-57
33753246-4	2021	In reported studies, the anti-obesity effect of celastrol resulted from regulating leptin sensitivity, energy metabolism, inflammation, lipid metabolism and even gut microbiota.	celastrol	48-57	leptin	Homo sapiens	83-89
34000513-9	2021	RESULTS: Findings indicated that tripterine suppressed BC cells" viability, proliferation, migration, invasion capacity and Bcl-2 protein expression, but it induced BC cells" Bax protein expression.	celastrol	33-43	BCL2 apoptosis regulator	Homo sapiens	124-129
34000513-9	2021	RESULTS: Findings indicated that tripterine suppressed BC cells" viability, proliferation, migration, invasion capacity and Bcl-2 protein expression, but it induced BC cells" Bax protein expression.	celastrol	33-43	BCL2 associated X, apoptosis regulator	Homo sapiens	175-178
34000513-10	2021	It was also found miR-184 expression was high in the BC cell lines treated with tripterine and that miR-184 overexpression reduced the viability, proliferation, and invasion abilities of BC cells under tripterine treatment.	celastrol	80-90	microRNA 184	Homo sapiens	18-25
34000513-10	2021	It was also found miR-184 expression was high in the BC cell lines treated with tripterine and that miR-184 overexpression reduced the viability, proliferation, and invasion abilities of BC cells under tripterine treatment.	celastrol	202-212	microRNA 184	Homo sapiens	18-25
34000513-10	2021	It was also found miR-184 expression was high in the BC cell lines treated with tripterine and that miR-184 overexpression reduced the viability, proliferation, and invasion abilities of BC cells under tripterine treatment.	celastrol	202-212	microRNA 184	Homo sapiens	100-107
34000513-11	2021	Interference with miR-184 neutralized the effects of tripterine on BC cell viability, proliferation and invasion.	celastrol	53-63	microRNA 184	Homo sapiens	18-25
34000513-12	2021	CONCLUSION: This research suggested that by interacting with miR-184, tripterine could restrain the progression of BC.	celastrol	70-80	microRNA 184	Homo sapiens	61-68
32176932-8	2021	RESULTS: The results demonstrated that the effect of HFD on inflammatory cytokines in mice with apoE-/- background was reversed by celastrol administration, and celastrol treatment inhibited the NOD-like receptor family, pyrin domain containing 3 (NLRP3)/caspase-1/interleukin-1beta signaling cascades in peripheral blood mononuclear cells from HFD-fed apoE-/- mice.	celastrol	161-170	interferon activated gene 208	Mus musculus	221-246
32176932-8	2021	RESULTS: The results demonstrated that the effect of HFD on inflammatory cytokines in mice with apoE-/- background was reversed by celastrol administration, and celastrol treatment inhibited the NOD-like receptor family, pyrin domain containing 3 (NLRP3)/caspase-1/interleukin-1beta signaling cascades in peripheral blood mononuclear cells from HFD-fed apoE-/- mice.	celastrol	161-170	NLR family, pyrin domain containing 3	Mus musculus	248-253
32176932-8	2021	RESULTS: The results demonstrated that the effect of HFD on inflammatory cytokines in mice with apoE-/- background was reversed by celastrol administration, and celastrol treatment inhibited the NOD-like receptor family, pyrin domain containing 3 (NLRP3)/caspase-1/interleukin-1beta signaling cascades in peripheral blood mononuclear cells from HFD-fed apoE-/- mice.	celastrol	161-170	caspase 1	Mus musculus	255-264
32176932-8	2021	RESULTS: The results demonstrated that the effect of HFD on inflammatory cytokines in mice with apoE-/- background was reversed by celastrol administration, and celastrol treatment inhibited the NOD-like receptor family, pyrin domain containing 3 (NLRP3)/caspase-1/interleukin-1beta signaling cascades in peripheral blood mononuclear cells from HFD-fed apoE-/- mice.	celastrol	161-170	interleukin 1 beta	Mus musculus	265-282
32176932-8	2021	RESULTS: The results demonstrated that the effect of HFD on inflammatory cytokines in mice with apoE-/- background was reversed by celastrol administration, and celastrol treatment inhibited the NOD-like receptor family, pyrin domain containing 3 (NLRP3)/caspase-1/interleukin-1beta signaling cascades in peripheral blood mononuclear cells from HFD-fed apoE-/- mice.	celastrol	161-170	apolipoprotein E	Mus musculus	353-357
32176932-10	2021	Furthermore, celastrol inhibited the pro-thrombotic effects of HFD in apoE-/- mice, and the underlying mechanism was mediated, at least partially, through the suppression of matrix metalloproteinase-2 and -9 expression.	celastrol	13-22	apolipoprotein E	Mus musculus	70-74
32176932-10	2021	Furthermore, celastrol inhibited the pro-thrombotic effects of HFD in apoE-/- mice, and the underlying mechanism was mediated, at least partially, through the suppression of matrix metalloproteinase-2 and -9 expression.	celastrol	13-22	matrix metallopeptidase 2	Mus musculus	174-207
32176932-11	2021	CONCLUSIONS: Celastrol administration significantly attenuated HFD-induced inflammatory reaction, platelet aggregation and thrombosis in apoE-/- mice, and celastrol may be used as a drug for the prevention of HFD-induced inflammatory reaction and thrombus.	celastrol	13-22	apolipoprotein E	Mus musculus	137-141
32176932-0	2021	Enhanced Inflammatory Reaction and Thrombosis in High-Fat Diet-Fed ApoE-/- Mice are Attenuated by Celastrol.	celastrol	98-107	CD36 molecule	Mus musculus	54-57
32176932-0	2021	Enhanced Inflammatory Reaction and Thrombosis in High-Fat Diet-Fed ApoE-/- Mice are Attenuated by Celastrol.	celastrol	98-107	apolipoprotein E	Mus musculus	67-71
33753246-5	2021	Celastrol reversed insulin resistance via multiple routes to protect against type 2 diabetes.	celastrol	0-9	insulin	Homo sapiens	19-26
33924995-0	2021	Celastrol and Triptolide Suppress Stemness in Triple Negative Breast Cancer: Notch as a Therapeutic Target for Stem Cells.	celastrol	0-9	notch receptor 1	Homo sapiens	77-82
33904854-0	2021	Correction: Systematic identification of celastrol-binding proteins reveals that Shoc2 is inhibited by celastrol.	celastrol	41-50	SHOC2 leucine rich repeat scaffold protein	Homo sapiens	81-86
33904854-0	2021	Correction: Systematic identification of celastrol-binding proteins reveals that Shoc2 is inhibited by celastrol.	celastrol	103-112	SHOC2 leucine rich repeat scaffold protein	Homo sapiens	81-86
33924995-9	2021	Both celastrol or triptolide reduced Notch -1 activation and expression of its downstream target proteins HES-1 and HEY-1.	celastrol	5-14	notch receptor 1	Homo sapiens	37-45
33924995-9	2021	Both celastrol or triptolide reduced Notch -1 activation and expression of its downstream target proteins HES-1 and HEY-1.	celastrol	5-14	hes family bHLH transcription factor 1	Homo sapiens	106-111
33924995-9	2021	Both celastrol or triptolide reduced Notch -1 activation and expression of its downstream target proteins HES-1 and HEY-1.	celastrol	5-14	hes related family bHLH transcription factor with YRPW motif 1	Homo sapiens	116-121
33870466-13	2021	Finally, mTOR was determined as the most likely therapeutic target of celastrol in OA.	celastrol	70-79	mechanistic target of rapamycin kinase	Homo sapiens	9-13
33930802-0	2021	Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1alpha pathway.	celastrol	27-36	hypoxia inducible factor 1, alpha subunit	Mus musculus	93-103
33930802-1	2021	Four series of hypoxia-inducible factor-1 alpha (HIF-1alpha) functioning derivatives stemming from modifications to the C-29 carboxyl group of celastrol were designed and synthesized, and their anticancer activities were evaluated.	celastrol	143-152	hypoxia inducible factor 1, alpha subunit	Mus musculus	15-47
33930802-1	2021	Four series of hypoxia-inducible factor-1 alpha (HIF-1alpha) functioning derivatives stemming from modifications to the C-29 carboxyl group of celastrol were designed and synthesized, and their anticancer activities were evaluated.	celastrol	143-152	hypoxia inducible factor 1, alpha subunit	Mus musculus	49-59
33870466-16	2021	mTOR is the most likely therapeutic target of celastrol in OA.	celastrol	46-55	mechanistic target of rapamycin kinase	Homo sapiens	0-4
33675143-8	2021	Furthermore, co-treatment with erastin and celastrol initiated ATG5/ATG7-dependent autophagy, PINK1/Parkin-dependent mitophagy, as well as the expression of heat shock proteins (HSP) in an HSF1-dependent manner.	celastrol	43-52	autophagy related 5	Homo sapiens	63-67
33935779-0	2021	Celastrol Attenuates Lipid Accumulation and Stemness of Clear Cell Renal Cell Carcinoma via CAV-1/LOX-1 Pathway.	celastrol	0-9	caveolin 1	Homo sapiens	92-97
33935779-0	2021	Celastrol Attenuates Lipid Accumulation and Stemness of Clear Cell Renal Cell Carcinoma via CAV-1/LOX-1 Pathway.	celastrol	0-9	oxidized low density lipoprotein receptor 1	Homo sapiens	98-103
33935779-8	2021	Celastrol reduced lipid accumulation and caveolae abundance, inhibited the binding of CAV-1 and lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in ccRCC cells.	celastrol	0-9	caveolin 1	Homo sapiens	86-91
33935779-8	2021	Celastrol reduced lipid accumulation and caveolae abundance, inhibited the binding of CAV-1 and lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in ccRCC cells.	celastrol	0-9	oxidized low density lipoprotein receptor 1	Homo sapiens	153-158
33935779-9	2021	Furthermore, celastrol attenuated stemness through blocking Wnt/beta-catenin pathway after knockdown of CAV-1 and LOX-1.	celastrol	13-22	catenin beta 1	Homo sapiens	64-76
33935779-9	2021	Furthermore, celastrol attenuated stemness through blocking Wnt/beta-catenin pathway after knockdown of CAV-1 and LOX-1.	celastrol	13-22	caveolin 1	Homo sapiens	104-109
33935779-9	2021	Furthermore, celastrol attenuated stemness through blocking Wnt/beta-catenin pathway after knockdown of CAV-1 and LOX-1.	celastrol	13-22	oxidized low density lipoprotein receptor 1	Homo sapiens	114-119
33675143-8	2021	Furthermore, co-treatment with erastin and celastrol initiated ATG5/ATG7-dependent autophagy, PINK1/Parkin-dependent mitophagy, as well as the expression of heat shock proteins (HSP) in an HSF1-dependent manner.	celastrol	43-52	autophagy related 7	Homo sapiens	68-72
33675143-8	2021	Furthermore, co-treatment with erastin and celastrol initiated ATG5/ATG7-dependent autophagy, PINK1/Parkin-dependent mitophagy, as well as the expression of heat shock proteins (HSP) in an HSF1-dependent manner.	celastrol	43-52	PTEN induced kinase 1	Homo sapiens	94-99
33675143-8	2021	Furthermore, co-treatment with erastin and celastrol initiated ATG5/ATG7-dependent autophagy, PINK1/Parkin-dependent mitophagy, as well as the expression of heat shock proteins (HSP) in an HSF1-dependent manner.	celastrol	43-52	heat shock transcription factor 1	Homo sapiens	189-193
33472404-0	2021	Identification of Celastrol As a Novel Therapeutic Agent for Pulmonary Arterial Hypertension and Right Ventricular Failure Through Suppression of Bsg (Basigin)/CyPA (Cyclophilin A).	celastrol	18-27	basigin	Mus musculus	146-149
33472404-0	2021	Identification of Celastrol As a Novel Therapeutic Agent for Pulmonary Arterial Hypertension and Right Ventricular Failure Through Suppression of Bsg (Basigin)/CyPA (Cyclophilin A).	celastrol	18-27	basigin	Mus musculus	151-158
33472404-0	2021	Identification of Celastrol As a Novel Therapeutic Agent for Pulmonary Arterial Hypertension and Right Ventricular Failure Through Suppression of Bsg (Basigin)/CyPA (Cyclophilin A).	celastrol	18-27	peptidylprolyl isomerase A	Mus musculus	160-164
33472404-0	2021	Identification of Celastrol As a Novel Therapeutic Agent for Pulmonary Arterial Hypertension and Right Ventricular Failure Through Suppression of Bsg (Basigin)/CyPA (Cyclophilin A).	celastrol	18-27	peptidylprolyl isomerase A	Mus musculus	166-179
33472404-8	2021	Treatment with celastrol, which we identified as a suppressor of Bsg and CyPA by drug screening, decreased proliferation, reactive oxygen species, and inflammatory cytokines in pulmonary artery smooth muscle cells.	celastrol	15-24	basigin	Mus musculus	65-68
33472404-8	2021	Treatment with celastrol, which we identified as a suppressor of Bsg and CyPA by drug screening, decreased proliferation, reactive oxygen species, and inflammatory cytokines in pulmonary artery smooth muscle cells.	celastrol	15-24	peptidylprolyl isomerase A	Mus musculus	73-77
33472404-9	2021	Furthermore, celastrol treatment ameliorated RV systolic pressure, hypertrophy, fibrosis, and dysfunction in hypoxia-induced PH in mice and SU5416/hypoxia-induced PH in rats with reduced Bsg, CyPA, and inflammatory cytokines in the hearts and lungs.	celastrol	13-22	basigin (Ok blood group)	Rattus norvegicus	187-190
33472404-9	2021	Furthermore, celastrol treatment ameliorated RV systolic pressure, hypertrophy, fibrosis, and dysfunction in hypoxia-induced PH in mice and SU5416/hypoxia-induced PH in rats with reduced Bsg, CyPA, and inflammatory cytokines in the hearts and lungs.	celastrol	13-22	peptidylprolyl isomerase A	Rattus norvegicus	192-196
33472404-10	2021	CONCLUSIONS: These results indicate that elevated Bsg in pressure-overloaded RV exacerbates RV dysfunction and that celastrol ameliorates RV dysfunction in PH model animals by suppressing Bsg and its ligand CyPA.	celastrol	116-125	basigin (Ok blood group)	Rattus norvegicus	188-191
33472404-10	2021	CONCLUSIONS: These results indicate that elevated Bsg in pressure-overloaded RV exacerbates RV dysfunction and that celastrol ameliorates RV dysfunction in PH model animals by suppressing Bsg and its ligand CyPA.	celastrol	116-125	peptidylprolyl isomerase A	Rattus norvegicus	207-211
33472404-11	2021	Thus, celastrol can be a novel drug for PH and RV failure that targets Bsg and CyPA.	celastrol	6-15	basigin (Ok blood group)	Rattus norvegicus	71-74
33472404-11	2021	Thus, celastrol can be a novel drug for PH and RV failure that targets Bsg and CyPA.	celastrol	6-15	peptidylprolyl isomerase A	Rattus norvegicus	79-83
33591981-7	2021	Finally, we found that drugs targeting the identified RB1 interacting genes/pathways, such as UNC3230, PYR-41, TAK-243, isoginkgetin, madrasin, and celastrol also elicit SL in human cancer cell lines.	celastrol	148-157	RB transcriptional corepressor 1	Homo sapiens	54-57
33559709-0	2021	Tripterine ameliorates monosodium urate crystal-induced gouty arthritis by altering macrophage polarization via the miR-449a/NLRP3 axis.	celastrol	0-10	microRNA 449a	Mus musculus	116-124
33559709-0	2021	Tripterine ameliorates monosodium urate crystal-induced gouty arthritis by altering macrophage polarization via the miR-449a/NLRP3 axis.	celastrol	0-10	NLR family, pyrin domain containing 3	Mus musculus	125-130
33574707-13	2021	Furthermore, celastrol exerted the anti-HCC effect in vitro through the miR-223-3p/CXCR4 axis.	celastrol	13-22	microRNA 223	Homo sapiens	72-79
33574707-13	2021	Furthermore, celastrol exerted the anti-HCC effect in vitro through the miR-223-3p/CXCR4 axis.	celastrol	13-22	C-X-C motif chemokine receptor 4	Homo sapiens	83-88
33106373-5	2021	The potential SHOC2 inhibitor celastrol phenocopied SHOC2 depletion.	celastrol	30-39	SHOC2 leucine rich repeat scaffold protein	Homo sapiens	14-19
33383300-0	2021	Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy.	celastrol	0-9	CD274 molecule	Homo sapiens	64-69
33383300-3	2021	Herein, we show that celastrol (CEL) induced not only strong ICD but also downregulation of PD-L1 expression of tumor cells.	celastrol	21-30	CD274 molecule	Homo sapiens	92-97
33383300-3	2021	Herein, we show that celastrol (CEL) induced not only strong ICD but also downregulation of PD-L1 expression of tumor cells.	celastrol	32-35	CD274 molecule	Homo sapiens	92-97
33106373-5	2021	The potential SHOC2 inhibitor celastrol phenocopied SHOC2 depletion.	celastrol	30-39	SHOC2 leucine rich repeat scaffold protein	Homo sapiens	52-57
33641477-0	2021	EXPRESSION OF CONCERN: "Tripterine up-regulates miR-223 to alleviate lipopolysaccharides-induced damage in murine chondrogenic ATDC5 cells".	celastrol	24-34	microRNA 223	Mus musculus	48-55
33554800-8	2021	Among which sVCAM-1 and sICAM-1 of leucocyte, NB4 cell, P-selectin and adhesion molecules in tripterine group showed significant difference as compared with arsenic trioxide group (P<0.05).	celastrol	93-103	selectin P	Homo sapiens	56-66
33387968-0	2021	Celastrol attenuates ischemia/reperfusion-mediated memory dysfunction by downregulating AK005401/MAP3K12.	celastrol	0-9	mitogen-activated protein kinase kinase kinase 12	Mus musculus	97-104
33387968-10	2021	Celastrol increased antioxidant capacity, inhibited cell apoptosis, and improved mitochondrial function, effectively improving learning and memory by downregulating AK005401 and MAP3K12 and activating PI3K/Akt.	celastrol	0-9	mitogen-activated protein kinase kinase kinase 12	Mus musculus	178-185
33387968-10	2021	Celastrol increased antioxidant capacity, inhibited cell apoptosis, and improved mitochondrial function, effectively improving learning and memory by downregulating AK005401 and MAP3K12 and activating PI3K/Akt.	celastrol	0-9	thymoma viral proto-oncogene 1	Mus musculus	206-209
33387968-11	2021	CONCLUSIONS: The AK005401/MAP3K12 signaling pathway has an important role in I/R-mediated hippocampal injury, and celastrol can potentially reduce or possibly prevent I/R-induced neuronal injury by downregulating AK005401/MAP3K12 signaling.	celastrol	114-123	mitogen-activated protein kinase kinase kinase 12	Mus musculus	26-33
33387968-11	2021	CONCLUSIONS: The AK005401/MAP3K12 signaling pathway has an important role in I/R-mediated hippocampal injury, and celastrol can potentially reduce or possibly prevent I/R-induced neuronal injury by downregulating AK005401/MAP3K12 signaling.	celastrol	114-123	mitogen-activated protein kinase kinase kinase 12	Mus musculus	222-229
33255023-0	2021	Lactoferrin-dual drug nanoconjugate: Synergistic anti-tumor efficacy of docetaxel and the NF-kappaB inhibitor celastrol.	celastrol	110-119	lactotransferrin	Mus musculus	0-11
33255023-0	2021	Lactoferrin-dual drug nanoconjugate: Synergistic anti-tumor efficacy of docetaxel and the NF-kappaB inhibitor celastrol.	celastrol	110-119	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	90-99
32776627-5	2021	Further studies found that celastrol decreased the infiltration of macrophage as well as its inflammatory products (IL-1beta, IL-18, MCP-1alpha, and TNF-alpha) in liver and adipose tissues, which also displayed an obvious inhibition of TLR3/NLRP3 inflammasome molecules.	celastrol	27-36	interleukin 1 alpha	Mus musculus	116-124
32776627-5	2021	Further studies found that celastrol decreased the infiltration of macrophage as well as its inflammatory products (IL-1beta, IL-18, MCP-1alpha, and TNF-alpha) in liver and adipose tissues, which also displayed an obvious inhibition of TLR3/NLRP3 inflammasome molecules.	celastrol	27-36	interleukin 18	Mus musculus	126-131
32776627-5	2021	Further studies found that celastrol decreased the infiltration of macrophage as well as its inflammatory products (IL-1beta, IL-18, MCP-1alpha, and TNF-alpha) in liver and adipose tissues, which also displayed an obvious inhibition of TLR3/NLRP3 inflammasome molecules.	celastrol	27-36	tumor necrosis factor	Mus musculus	149-158
33130474-0	2021	Celastrol ameliorates Propionibacterium acnes/LPS-induced liver damage and MSU-induced gouty arthritis via inhibiting K63 deubiquitination of NLRP3.	celastrol	0-9	NLR family pyrin domain containing 3	Homo sapiens	142-147
32776627-5	2021	Further studies found that celastrol decreased the infiltration of macrophage as well as its inflammatory products (IL-1beta, IL-18, MCP-1alpha, and TNF-alpha) in liver and adipose tissues, which also displayed an obvious inhibition of TLR3/NLRP3 inflammasome molecules.	celastrol	27-36	toll-like receptor 3	Mus musculus	236-240
32776627-5	2021	Further studies found that celastrol decreased the infiltration of macrophage as well as its inflammatory products (IL-1beta, IL-18, MCP-1alpha, and TNF-alpha) in liver and adipose tissues, which also displayed an obvious inhibition of TLR3/NLRP3 inflammasome molecules.	celastrol	27-36	NLR family, pyrin domain containing 3	Mus musculus	241-246
33303989-0	2021	Celastrol induces lipophagy via the LXRalpha/ABCA1 pathway in clear cell renal cell carcinoma.	celastrol	0-9	nuclear receptor subfamily 1 group H member 3	Homo sapiens	36-44
33130474-3	2021	PURPOSE: This study aims to investigate whether the inhibition of NLRP3 inflammasome is engaged in the anti-inflammatory activities of celastrol and delineate the underlying mechanism.	celastrol	135-144	NLR family pyrin domain containing 3	Homo sapiens	66-71
33130474-4	2021	METHODS: The influence of celastrol on NLRP3 inflammasome activation was firstly studied in lipopolysaccharide (LPS)-primed mouse bone marrow-derived macrophages (BMDMs) and phorbol 12-myristate 13-acetate (PMA)-primed THP-1 cells treated with nigericin.	celastrol	26-35	NLR family, pyrin domain containing 3	Mus musculus	39-44
33130474-8	2021	RESULTS: Celastrol significantly suppressed the cleavage of pro-caspase-1 and pro-IL-1beta, while not affecting the protein expressions of NLRP3, ASC, pro-caspase-1 and pro-IL-1beta in THP-1 cells, BMDMs and HEK293T cells.	celastrol	9-18	interleukin 1 beta	Homo sapiens	78-90
33130474-9	2021	Celastrol suppressed NLRP3 inflammasome activation and alleviated P. acnes/LPS-induced liver damage and MSU-induced gouty arthritis.	celastrol	0-9	NLR family pyrin domain containing 3	Homo sapiens	21-26
33130474-10	2021	Mechanism study revealed that celastrol could interdict K63 deubiquitination of NLRP3, which may concern interaction of celastrol and BRCA1/BRCA2-containing complex subunit 3 (BRCC3), and thereby prohibited the formation of NLRP3, ASC and pro-caspase-1 complex to block the generation of mature IL-1beta.	celastrol	30-39	NLR family pyrin domain containing 3	Homo sapiens	80-85
33130474-10	2021	Mechanism study revealed that celastrol could interdict K63 deubiquitination of NLRP3, which may concern interaction of celastrol and BRCA1/BRCA2-containing complex subunit 3 (BRCC3), and thereby prohibited the formation of NLRP3, ASC and pro-caspase-1 complex to block the generation of mature IL-1beta.	celastrol	30-39	NLR family pyrin domain containing 3	Homo sapiens	224-229
33130474-10	2021	Mechanism study revealed that celastrol could interdict K63 deubiquitination of NLRP3, which may concern interaction of celastrol and BRCA1/BRCA2-containing complex subunit 3 (BRCC3), and thereby prohibited the formation of NLRP3, ASC and pro-caspase-1 complex to block the generation of mature IL-1beta.	celastrol	30-39	PYD and CARD domain containing	Homo sapiens	231-234
33130474-11	2021	CONCLUSION: Celastrol suppresses NLRP3 inflammasome activation in P. acnes/LPS-induced liver damage and MSU-induced gouty arthritis via inhibiting K63 deubiquitination of NLRP3, which presents a novel insight into inhibition of celastrol on NLRP3 inflammasome and provides more evidences for its application in the therapy of inflammation-related diseases.	celastrol	12-21	NLR family pyrin domain containing 3	Homo sapiens	33-38
33130474-11	2021	CONCLUSION: Celastrol suppresses NLRP3 inflammasome activation in P. acnes/LPS-induced liver damage and MSU-induced gouty arthritis via inhibiting K63 deubiquitination of NLRP3, which presents a novel insight into inhibition of celastrol on NLRP3 inflammasome and provides more evidences for its application in the therapy of inflammation-related diseases.	celastrol	12-21	NLR family pyrin domain containing 3	Homo sapiens	171-176
33130474-11	2021	CONCLUSION: Celastrol suppresses NLRP3 inflammasome activation in P. acnes/LPS-induced liver damage and MSU-induced gouty arthritis via inhibiting K63 deubiquitination of NLRP3, which presents a novel insight into inhibition of celastrol on NLRP3 inflammasome and provides more evidences for its application in the therapy of inflammation-related diseases.	celastrol	12-21	NLR family pyrin domain containing 3	Homo sapiens	171-176
33303989-0	2021	Celastrol induces lipophagy via the LXRalpha/ABCA1 pathway in clear cell renal cell carcinoma.	celastrol	0-9	ATP binding cassette subfamily A member 1	Homo sapiens	45-50
33303989-8	2021	Moreover, we revealed that celastrol dramatically activated LXRalpha signaling, and degraded lipid droplets by inducing lipophagy in 786-O cells.	celastrol	27-36	nuclear receptor subfamily 1 group H member 3	Homo sapiens	60-68
33303989-9	2021	Finally, celastrol promoted cholesterol efflux from 786-O cells via ABCA1.	celastrol	9-18	ATP binding cassette subfamily A member 1	Homo sapiens	68-73
33303989-12	2021	In conclusion, this study reveals that celastrol triggers lipophagy in ccRCC by activating LXRalpha, promotes ABCA1-mediated cholesterol efflux, suppresses EMT progress, and ultimately inhibits cell proliferation, migration, and invasion as well as tumor growth.	celastrol	39-48	nuclear receptor subfamily 1 group H member 3	Homo sapiens	91-99
33303989-12	2021	In conclusion, this study reveals that celastrol triggers lipophagy in ccRCC by activating LXRalpha, promotes ABCA1-mediated cholesterol efflux, suppresses EMT progress, and ultimately inhibits cell proliferation, migration, and invasion as well as tumor growth.	celastrol	39-48	ATP binding cassette subfamily A member 1	Homo sapiens	110-115
32862144-3	2020	We previously showed that celastrol fitted pharmacophore criteria for activating calcium- and voltage-gated potassium channels of large conductance ("BK") made of subunits cloned from cerebrovascular smooth muscle (SM).	celastrol	26-35	synaptotagmin 17	Rattus norvegicus	150-152
33238517-11	2020	Celastrol, a nature extract compound, was demonstrated to effectively inhibit SPC25 expression and reverse CR phenotype.	celastrol	0-9	SPC25 component of NDC80 kinetochore complex	Homo sapiens	78-83
33238517-12	2020	In conclusion, the development of SPC25 inhibitors, such as the application of celastrol, maybe a novel strategy to sensitize cisplatin for the treatment of refractory HNC.	celastrol	79-88	SPC25 component of NDC80 kinetochore complex	Homo sapiens	34-39
33250707-8	2020	Both celastrol and indomethacin prevented ketamine-induced enhancement in TNF-alpha and IL-1beta levels, however, they had no effects on increased IL-6 amount resulting from ketamine exposure in postnatal life.	celastrol	5-14	tumor necrosis factor	Mus musculus	74-83
33250707-8	2020	Both celastrol and indomethacin prevented ketamine-induced enhancement in TNF-alpha and IL-1beta levels, however, they had no effects on increased IL-6 amount resulting from ketamine exposure in postnatal life.	celastrol	5-14	interleukin 1 alpha	Mus musculus	88-96
32954678-9	2020	Furthermore, celastrol prevented the up-regulation of BMPRII and down-regulation of Smad6 induced by high calcium, and this protectory effect can be abolished by BMP2 overexpression.	celastrol	13-22	SMAD family member 6	Homo sapiens	84-89
32954678-9	2020	Furthermore, celastrol prevented the up-regulation of BMPRII and down-regulation of Smad6 induced by high calcium, and this protectory effect can be abolished by BMP2 overexpression.	celastrol	13-22	bone morphogenetic protein 2	Mus musculus	162-166
32954678-10	2020	In conclusion, our data for the first time demonstrate that celastrol attenuates high calcium-induced arterial and valvular calcification by inhibiting BMP2/Smad1/5 signalling, which may provide a novel therapeutic strategy for arterial and valvular calcification in patients with CKD.	celastrol	60-69	bone morphogenetic protein 2	Homo sapiens	152-156
32954678-10	2020	In conclusion, our data for the first time demonstrate that celastrol attenuates high calcium-induced arterial and valvular calcification by inhibiting BMP2/Smad1/5 signalling, which may provide a novel therapeutic strategy for arterial and valvular calcification in patients with CKD.	celastrol	60-69	SMAD family member 1	Homo sapiens	157-164
32781326-1	2020	Palmitic acid-modified bovine serum albumin (PAB) was synthetized and found to own remarkable scavenger receptor-A (SR-A) targeting ability in vitro and in vivo, through which activated macrophages took up PAB nanoparticles (PAB NPs) 9.10 times more than bovine serum albumin nanoparticles (BSA NPs) and PAB NPs could delivery anti-inflammatory drugs celastrol (CLT) to inflamed tissues more effectively than BSA NPs.	celastrol	351-360	albumin	Rattus norvegicus	30-43
32781326-1	2020	Palmitic acid-modified bovine serum albumin (PAB) was synthetized and found to own remarkable scavenger receptor-A (SR-A) targeting ability in vitro and in vivo, through which activated macrophages took up PAB nanoparticles (PAB NPs) 9.10 times more than bovine serum albumin nanoparticles (BSA NPs) and PAB NPs could delivery anti-inflammatory drugs celastrol (CLT) to inflamed tissues more effectively than BSA NPs.	celastrol	362-365	albumin	Rattus norvegicus	30-43
32954678-0	2020	Celastrol attenuates arterial and valvular calcification via inhibiting BMP2/Smad1/5 signalling.	celastrol	0-9	bone morphogenetic protein 2	Homo sapiens	72-76
32954678-0	2020	Celastrol attenuates arterial and valvular calcification via inhibiting BMP2/Smad1/5 signalling.	celastrol	0-9	SMAD family member 1	Homo sapiens	77-84
32954678-7	2020	At the molecular level, celastrol inhibited the increase of BMP2, phosphorylated Smad1/5 (p-Smad1/5) and non-phosphorylated beta-catenin (n-p-beta-catenin) induced by high-calcium medium both in vitro and in vivo.	celastrol	24-33	bone morphogenetic protein 2	Mus musculus	60-64
32954678-7	2020	At the molecular level, celastrol inhibited the increase of BMP2, phosphorylated Smad1/5 (p-Smad1/5) and non-phosphorylated beta-catenin (n-p-beta-catenin) induced by high-calcium medium both in vitro and in vivo.	celastrol	24-33	SMAD family member 1	Mus musculus	81-88
32954678-7	2020	At the molecular level, celastrol inhibited the increase of BMP2, phosphorylated Smad1/5 (p-Smad1/5) and non-phosphorylated beta-catenin (n-p-beta-catenin) induced by high-calcium medium both in vitro and in vivo.	celastrol	24-33	SMAD family member 1	Mus musculus	92-99
32954678-7	2020	At the molecular level, celastrol inhibited the increase of BMP2, phosphorylated Smad1/5 (p-Smad1/5) and non-phosphorylated beta-catenin (n-p-beta-catenin) induced by high-calcium medium both in vitro and in vivo.	celastrol	24-33	catenin beta 1	Homo sapiens	124-136
32954678-7	2020	At the molecular level, celastrol inhibited the increase of BMP2, phosphorylated Smad1/5 (p-Smad1/5) and non-phosphorylated beta-catenin (n-p-beta-catenin) induced by high-calcium medium both in vitro and in vivo.	celastrol	24-33	catenin beta 1	Homo sapiens	142-154
32954678-8	2020	Also, BMP2 overexpression reversed the anti-calcification effects of celastrol by recovering the decrease of p-Smad1/5 and n-p-beta-catenin.	celastrol	69-78	bone morphogenetic protein 2	Mus musculus	6-10
32954678-8	2020	Also, BMP2 overexpression reversed the anti-calcification effects of celastrol by recovering the decrease of p-Smad1/5 and n-p-beta-catenin.	celastrol	69-78	SMAD family member 1	Mus musculus	111-118
32954678-8	2020	Also, BMP2 overexpression reversed the anti-calcification effects of celastrol by recovering the decrease of p-Smad1/5 and n-p-beta-catenin.	celastrol	69-78	catenin beta 1	Homo sapiens	127-139
32954678-9	2020	Furthermore, celastrol prevented the up-regulation of BMPRII and down-regulation of Smad6 induced by high calcium, and this protectory effect can be abolished by BMP2 overexpression.	celastrol	13-22	bone morphogenetic protein receptor type 2	Homo sapiens	54-60
32862144-8	2020	Selective BK block with 1 microM paxilline blunts celastrol vasodilation.	celastrol	50-59	synaptotagmin 17	Rattus norvegicus	10-12
32862144-11	2020	MCA constriction by ethanol concentrations reached in blood during moderate-heavy alcohol drinking (50 mM), which involves SM BK inhibition, is both prevented and reverted by celastrol.	celastrol	175-184	synaptotagmin 17	Rattus norvegicus	126-128
32862144-12	2020	We conclude that celastrol could be an effective cerebrovascular dilator and antagonist of alcohol-induced cerebrovascular constriction, its efficacy being uncompromised by conditions that disrupt endothelial and/or BK function.	celastrol	17-26	synaptotagmin 17	Rattus norvegicus	216-218
32862144-14	2020	Celastrol actions are endothelium-independent but mediated through voltage-gated potassium and calcium/voltage-gated, big-conductance (BK) potassium channels.	celastrol	0-9	synaptotagmin 17	Rattus norvegicus	135-137
33097050-0	2020	Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway.	celastrol	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	83-86
33097050-5	2020	RESULTS: High dose of Celastrol (1.5 mg/kg/d) not only improved the kidney function of diabetic nephropathy (DN) rats, and decreased the blood glucose and 24 h urinary albumin, but also increased the expression of LC3II and nephrin, and downregulated the expression of PI3K, p-AKT, and the mRNA level of NF-kappaB and mTOR.	celastrol	22-31	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	214-219
33097050-5	2020	RESULTS: High dose of Celastrol (1.5 mg/kg/d) not only improved the kidney function of diabetic nephropathy (DN) rats, and decreased the blood glucose and 24 h urinary albumin, but also increased the expression of LC3II and nephrin, and downregulated the expression of PI3K, p-AKT, and the mRNA level of NF-kappaB and mTOR.	celastrol	22-31	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	224-231
33097050-5	2020	RESULTS: High dose of Celastrol (1.5 mg/kg/d) not only improved the kidney function of diabetic nephropathy (DN) rats, and decreased the blood glucose and 24 h urinary albumin, but also increased the expression of LC3II and nephrin, and downregulated the expression of PI3K, p-AKT, and the mRNA level of NF-kappaB and mTOR.	celastrol	22-31	AKT serine/threonine kinase 1	Rattus norvegicus	277-280
33097050-5	2020	RESULTS: High dose of Celastrol (1.5 mg/kg/d) not only improved the kidney function of diabetic nephropathy (DN) rats, and decreased the blood glucose and 24 h urinary albumin, but also increased the expression of LC3II and nephrin, and downregulated the expression of PI3K, p-AKT, and the mRNA level of NF-kappaB and mTOR.	celastrol	22-31	mechanistic target of rapamycin kinase	Rattus norvegicus	318-322
33097050-6	2020	CONCLUSION: Celastrol functions as a potential therapeutic substance, acting via the PI3K/AKT pathway to attenuate renal injury, inhibit glomerular basement membrane thickening, and achieve podocyte homeostasis in diabetic nephropathy.	celastrol	12-21	AKT serine/threonine kinase 1	Rattus norvegicus	90-93
32920591-0	2020	Celastrol Inhibits Migration and Invasion of Triple-Negative Breast Cancer Cells by Suppressing Interleukin-6 via Downregulating Nuclear Factor-kappaB (NF-kappaB).	celastrol	0-9	interleukin 6	Homo sapiens	96-109
32965124-0	2020	Inflammation-targeted celastrol nanodrug attenuates collagen-induced arthritis through NF-kappaB and Notch1 pathways.	celastrol	22-31	nuclear factor kappa B subunit 1	Homo sapiens	87-96
32965124-0	2020	Inflammation-targeted celastrol nanodrug attenuates collagen-induced arthritis through NF-kappaB and Notch1 pathways.	celastrol	22-31	notch receptor 1	Homo sapiens	101-107
32431112-5	2020	We then treated leptin knockout rats with celastrol and explored the changes in energy metabolism.	celastrol	42-51	leptin	Rattus norvegicus	16-22
32431112-9	2020	Hypothalamic transcriptome analysis showed a significant enrichment of the leptin signaling pathway, and we found that celastrol significantly enhanced energy expenditure, which was mediated by the leptin signaling pathway.	celastrol	119-128	leptin	Mus musculus	198-204
32431112-11	2020	CONCLUSION: Our study revealed that celastrol decreased the BW of obese rats by enhancing energy expenditure but not by suppressing food intake and that this effect was mediated by the improvement of the gut microbiota and the activation of the hypothalamic leptin signaling pathway.	celastrol	36-45	leptin	Rattus norvegicus	258-264
32818610-3	2020	Therefore, we aimed in this study is to combine the merits of NF-kappaB inhibiting potential of celastrol (CST) with glutathione inhibitory effect of sulfasalazine (SFZ) which prevents CST inactivation and thus enhances its anti-tumor activity.	celastrol	96-105	nuclear factor kappa B subunit 1	Homo sapiens	62-71
32712089-0	2020	Celastrol attenuates inflammatory responses in adipose tissues and improves skeletal muscle mitochondrial functions in high fat diet-induced obese rats via upregulation of AMPK/SIRT1 signaling pathways.	celastrol	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	172-176
32712089-0	2020	Celastrol attenuates inflammatory responses in adipose tissues and improves skeletal muscle mitochondrial functions in high fat diet-induced obese rats via upregulation of AMPK/SIRT1 signaling pathways.	celastrol	0-9	sirtuin 1	Rattus norvegicus	177-182
32712089-6	2020	Celastrol noticeably improved insulin-stimulated glucose uptake activity and increased expression of plasma membrane GLUT4 protein in skeletal muscle.	celastrol	0-9	solute carrier family 2 member 4	Rattus norvegicus	117-122
32712089-9	2020	Mechanistically, celastrol stimulated mitochondrial biogenesis attributed by upregulation of the adenosine monophosphate-activated protein kinase (AMPK) and sirtuin 1 (SIRT1) signaling pathways.	celastrol	17-26	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	97-145
32712089-9	2020	Mechanistically, celastrol stimulated mitochondrial biogenesis attributed by upregulation of the adenosine monophosphate-activated protein kinase (AMPK) and sirtuin 1 (SIRT1) signaling pathways.	celastrol	17-26	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	147-151
32712089-9	2020	Mechanistically, celastrol stimulated mitochondrial biogenesis attributed by upregulation of the adenosine monophosphate-activated protein kinase (AMPK) and sirtuin 1 (SIRT1) signaling pathways.	celastrol	17-26	sirtuin 1	Rattus norvegicus	157-166
32712089-9	2020	Mechanistically, celastrol stimulated mitochondrial biogenesis attributed by upregulation of the adenosine monophosphate-activated protein kinase (AMPK) and sirtuin 1 (SIRT1) signaling pathways.	celastrol	17-26	sirtuin 1	Rattus norvegicus	168-173
33096778-7	2020	Consequently, we identified amphotericin B and celastrol as new non-substrate-based XT-I protein inhibitors.	celastrol	47-56	xylosyltransferase 1	Homo sapiens	84-88
33282271-7	2020	Celastrol had effects to depress TG, TC, LDL-C, GPT, GOT, and MDA concentration and increase HDL-C and SOD concentration (p < .05, respectively) with dose-dependent.	celastrol	0-9	glutamic pyruvic transaminase, soluble	Mus musculus	48-51
33282271-10	2020	Celastrol can inhibit the oxidative stress reaction and liver cell apoptosis via regulation Nrf2/HO-1 pathway in T2DM mice with NAFLD.	celastrol	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	92-96
33282271-10	2020	Celastrol can inhibit the oxidative stress reaction and liver cell apoptosis via regulation Nrf2/HO-1 pathway in T2DM mice with NAFLD.	celastrol	0-9	heme oxygenase 1	Mus musculus	97-101
32920591-0	2020	Celastrol Inhibits Migration and Invasion of Triple-Negative Breast Cancer Cells by Suppressing Interleukin-6 via Downregulating Nuclear Factor-kappaB (NF-kappaB).	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	129-150
32920591-0	2020	Celastrol Inhibits Migration and Invasion of Triple-Negative Breast Cancer Cells by Suppressing Interleukin-6 via Downregulating Nuclear Factor-kappaB (NF-kappaB).	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	152-161
32920591-5	2020	The expression of interleukin-6 (IL-6) was measured after transfection of short-hairpin RNA against IL-6 or celastrol treatment via quantitative real-time polymerase chain reaction, Western blot, or enzyme-linked immunosorbent analysis (ELISA).	celastrol	108-117	interleukin 6	Homo sapiens	18-31
32920591-5	2020	The expression of interleukin-6 (IL-6) was measured after transfection of short-hairpin RNA against IL-6 or celastrol treatment via quantitative real-time polymerase chain reaction, Western blot, or enzyme-linked immunosorbent analysis (ELISA).	celastrol	108-117	interleukin 6	Homo sapiens	33-37
32920591-7	2020	The interaction between celastrol and NF-kappaB-mediated IL-6 was investigated by luciferase reporter assay.	celastrol	24-33	nuclear factor kappa B subunit 1	Homo sapiens	38-47
32920591-7	2020	The interaction between celastrol and NF-kappaB-mediated IL-6 was investigated by luciferase reporter assay.	celastrol	24-33	interleukin 6	Homo sapiens	57-61
32920591-10	2020	Moreover, treatment with celastrol decreased IL-6 expression at mRNA and protein levels.	celastrol	25-34	interleukin 6	Homo sapiens	45-49
32920591-11	2020	IL-6 overexpression mitigated celastrol-mediated suppression of cell migration and invasion.	celastrol	30-39	interleukin 6	Homo sapiens	0-4
32920591-12	2020	Additionally, celastrol blocked the NF-kappaB pathway to inhibit IL-6 levels.	celastrol	14-23	nuclear factor kappa B subunit 1	Homo sapiens	36-45
32920591-12	2020	Additionally, celastrol blocked the NF-kappaB pathway to inhibit IL-6 levels.	celastrol	14-23	interleukin 6	Homo sapiens	65-69
32920591-13	2020	CONCLUSIONS Celastrol repressed migration and invasion through decreasing IL-6 levels by inactivation of NF-kappaB signaling in triple-negative breast cancer cells, providing a novel basis for use of celastrol in treating triple-negative breast cancer.	celastrol	12-21	interleukin 6	Homo sapiens	74-78
32920591-13	2020	CONCLUSIONS Celastrol repressed migration and invasion through decreasing IL-6 levels by inactivation of NF-kappaB signaling in triple-negative breast cancer cells, providing a novel basis for use of celastrol in treating triple-negative breast cancer.	celastrol	12-21	nuclear factor kappa B subunit 1	Homo sapiens	105-114
32920591-13	2020	CONCLUSIONS Celastrol repressed migration and invasion through decreasing IL-6 levels by inactivation of NF-kappaB signaling in triple-negative breast cancer cells, providing a novel basis for use of celastrol in treating triple-negative breast cancer.	celastrol	200-209	interleukin 6	Homo sapiens	74-78
32920591-13	2020	CONCLUSIONS Celastrol repressed migration and invasion through decreasing IL-6 levels by inactivation of NF-kappaB signaling in triple-negative breast cancer cells, providing a novel basis for use of celastrol in treating triple-negative breast cancer.	celastrol	200-209	nuclear factor kappa B subunit 1	Homo sapiens	105-114
32307774-0	2020	Celastrol mitigates high glucose-induced inflammation and apoptosis in rat H9c2 cardiomyocytes via miR-345-5p/growth arrest-specific 6.	celastrol	0-9	growth arrest specific 6	Rattus norvegicus	99-134
32524263-3	2020	After treatment with poly(I:C)-LMW, poly (I:C)-LMW/LyoVec, and Imiquimod, the replication of IBV was significantly suppressed after 24 h. However, treatment with TLR3 pathway inhibitors such as Pepinh-TRIF, celastrol, chloroquine, and BX795 resulted in increased replication of IBV after 36 h. These results also showed that chloroquine and celastrol were most effective inhibitors of the antiviral response at 48 hpi.	celastrol	207-216	toll like receptor 3	Homo sapiens	162-166
32524263-3	2020	After treatment with poly(I:C)-LMW, poly (I:C)-LMW/LyoVec, and Imiquimod, the replication of IBV was significantly suppressed after 24 h. However, treatment with TLR3 pathway inhibitors such as Pepinh-TRIF, celastrol, chloroquine, and BX795 resulted in increased replication of IBV after 36 h. These results also showed that chloroquine and celastrol were most effective inhibitors of the antiviral response at 48 hpi.	celastrol	341-350	toll like receptor 3	Homo sapiens	162-166
33015082-8	2020	Results: Doses higher than 2.5 mug/g/day of celastrol reduced the inflammatory score and ankle swelling, preserved joint structure, halted bone destruction, and diminished the number of synovial CD68+ macrophages.	celastrol	44-53	Cd68 molecule	Rattus norvegicus	195-199
32649040-8	2020	Importantly, the addition of resveratrol upregulated the proliferation of HPLF cells, while osteoclastogenesis of BMM cells treated with mCSF-RANKL was significantly downregulated by celastrol.	celastrol	183-192	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	137-141
32649040-8	2020	Importantly, the addition of resveratrol upregulated the proliferation of HPLF cells, while osteoclastogenesis of BMM cells treated with mCSF-RANKL was significantly downregulated by celastrol.	celastrol	183-192	TNF superfamily member 11	Homo sapiens	142-147
32307774-9	2020	Moreover, Cel exhibited the ability to antagonize HG-induced cardiomyocyte apoptosis and suppress the elevated Bax/Bcl-2 ratio elicited by HG stimulation.	celastrol	10-13	BCL2 associated X, apoptosis regulator	Rattus norvegicus	111-114
32307774-9	2020	Moreover, Cel exhibited the ability to antagonize HG-induced cardiomyocyte apoptosis and suppress the elevated Bax/Bcl-2 ratio elicited by HG stimulation.	celastrol	10-13	BCL2, apoptosis regulator	Rattus norvegicus	115-120
32307774-10	2020	Intriguingly, Cel treatment revoked the HG-triggered repression of Gas6 protein expression, and Gas6 loss-of-function accelerated HG-induced cardiomyocyte apoptosis.	celastrol	14-17	growth arrest specific 6	Rattus norvegicus	67-71
32307774-14	2020	CONCLUSIONS: Our findings have demonstrated that Cel administration antagonized HG-induced cardiomyocyte apoptosis and inflammation through upregulating Gas6 expression by restraining miR-345-5p.	celastrol	49-52	growth arrest specific 6	Rattus norvegicus	153-157
32848589-0	2020	Neuroprotective Effects of Celastrol on Transient Global Cerebral Ischemia Rats via Regulating HMGB1/NF-kappaB Signaling Pathway.	celastrol	27-36	high mobility group box 1	Rattus norvegicus	95-100
32815304-6	2020	Through suppressing the phosphorylation of upstream EGFR and downstream Akt in the EGFR pathway by gefitinib and celastrol, respectively, the nanodrug exhibits high inhibition efficacy against orthotopic NSCLC in mouse models.	celastrol	113-122	epidermal growth factor receptor	Mus musculus	52-56
32815304-6	2020	Through suppressing the phosphorylation of upstream EGFR and downstream Akt in the EGFR pathway by gefitinib and celastrol, respectively, the nanodrug exhibits high inhibition efficacy against orthotopic NSCLC in mouse models.	celastrol	113-122	thymoma viral proto-oncogene 1	Mus musculus	72-75
32815304-6	2020	Through suppressing the phosphorylation of upstream EGFR and downstream Akt in the EGFR pathway by gefitinib and celastrol, respectively, the nanodrug exhibits high inhibition efficacy against orthotopic NSCLC in mouse models.	celastrol	113-122	epidermal growth factor receptor	Mus musculus	83-87
32929349-0	2020	Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells.	celastrol	0-9	peroxiredoxin 2	Homo sapiens	64-79
32929349-8	2020	Results: Our data show that Celastrol directly binds to an antioxidant enzyme, peroxiredoxin-2 (Prdx2), which then inhibits its enzyme activity at both molecular and cellular level.	celastrol	28-37	peroxiredoxin 2	Homo sapiens	79-94
32929349-8	2020	Results: Our data show that Celastrol directly binds to an antioxidant enzyme, peroxiredoxin-2 (Prdx2), which then inhibits its enzyme activity at both molecular and cellular level.	celastrol	28-37	peroxiredoxin 2	Mus musculus	96-101
32929349-9	2020	Inhibition of Prdx2 by Celastrol increased cellular ROS levels and led to ROS-dependent endoplasmic reticulum stress, mitochondrial dysfunction, and apoptosis in gastric cancer cells.	celastrol	23-32	peroxiredoxin 2	Mus musculus	14-19
32929349-10	2020	Functional tests demonstrated that Celastrol limits gastric cancer cells, at least in part, through targeting Prdx2.	celastrol	35-44	peroxiredoxin 2	Mus musculus	110-115
32929349-11	2020	Celastrol treatment of mice implanted with gastric cancer cells also inhibited tumor growth, associated with Prdx2 inhibition and increased ROS.	celastrol	0-9	peroxiredoxin 2	Mus musculus	109-114
32929349-13	2020	Conclusion: Our studies have uncovered a potential Celastrol-interacting protein Prdx2 and a ROS-dependent mechanism of its action.	celastrol	51-60	peroxiredoxin 2	Homo sapiens	81-86
32848589-6	2020	Our results indicated that celastrol dose-dependently reduced hippocampal and serum concentration of pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) and oxidative stress marker (MDA), whereas the anti-inflammatory marker IL-10 and antioxidant markers (GSH, SOD, and CAT) were increased significantly in celastrol treated tGCI/R rats.	celastrol	27-36	tumor necrosis factor	Rattus norvegicus	127-136
32848589-6	2020	Our results indicated that celastrol dose-dependently reduced hippocampal and serum concentration of pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) and oxidative stress marker (MDA), whereas the anti-inflammatory marker IL-10 and antioxidant markers (GSH, SOD, and CAT) were increased significantly in celastrol treated tGCI/R rats.	celastrol	27-36	interleukin 1 alpha	Rattus norvegicus	138-146
32848589-6	2020	Our results indicated that celastrol dose-dependently reduced hippocampal and serum concentration of pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) and oxidative stress marker (MDA), whereas the anti-inflammatory marker IL-10 and antioxidant markers (GSH, SOD, and CAT) were increased significantly in celastrol treated tGCI/R rats.	celastrol	27-36	interleukin 6	Rattus norvegicus	152-156
32848589-6	2020	Our results indicated that celastrol dose-dependently reduced hippocampal and serum concentration of pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) and oxidative stress marker (MDA), whereas the anti-inflammatory marker IL-10 and antioxidant markers (GSH, SOD, and CAT) were increased significantly in celastrol treated tGCI/R rats.	celastrol	27-36	interleukin 10	Rattus norvegicus	230-235
32848589-6	2020	Our results indicated that celastrol dose-dependently reduced hippocampal and serum concentration of pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) and oxidative stress marker (MDA), whereas the anti-inflammatory marker IL-10 and antioxidant markers (GSH, SOD, and CAT) were increased significantly in celastrol treated tGCI/R rats.	celastrol	27-36	catalase	Rattus norvegicus	275-278
32848589-8	2020	Simultaneously, we found that mechanisms responsible for the neuroprotective effect of celastrol could be attributed to its anti-inflammatory and antioxidant actions via inhibiting HMGB1/NF-kappaB signaling pathway.	celastrol	87-96	high mobility group box 1	Rattus norvegicus	181-186
32953791-10	2020	After the addition of celastrol, MCL treatment significantly reduced the levels of p-p65, NLRP3, caspase-1, and ASC.	celastrol	22-31	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	85-88
32953791-10	2020	After the addition of celastrol, MCL treatment significantly reduced the levels of p-p65, NLRP3, caspase-1, and ASC.	celastrol	22-31	NLR family, pyrin domain containing 3	Mus musculus	90-95
32953791-10	2020	After the addition of celastrol, MCL treatment significantly reduced the levels of p-p65, NLRP3, caspase-1, and ASC.	celastrol	22-31	caspase 1	Mus musculus	97-106
32953791-10	2020	After the addition of celastrol, MCL treatment significantly reduced the levels of p-p65, NLRP3, caspase-1, and ASC.	celastrol	22-31	PYD and CARD domain containing	Mus musculus	112-115
32565148-0	2020	Celastrol ameliorates autoimmune disorders in Trex1-deficient mice.	celastrol	0-9	three prime repair exonuclease 1	Mus musculus	46-51
32470546-0	2020	Celastrol ameliorates acute liver injury through modulation of PPARalpha.	celastrol	0-9	peroxisome proliferator activated receptor alpha	Mus musculus	63-72
32470546-2	2020	In the present study, the protective effect of celastrol on carbon tetrachloride (CCl4)-induced acute liver injury was investigated.	celastrol	47-56	chemokine (C-C motif) ligand 4	Mus musculus	82-86
32470546-3	2020	Celastrol improved the increased transaminase activity, inflammation, and oxidative stress induced by CCl4, resulting in improved metabolic disorders found in mice with liver injury.	celastrol	0-9	chemokine (C-C motif) ligand 4	Mus musculus	102-106
32470546-4	2020	Dual-luciferase reporter assays and primary hepatocyte studies demonstrated that the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling mediated the protective effect of celastrol, which was not observed in Ppara-null mice, and co-treatment of wild-type mice with the PPARalpha antagonist GW6471.	celastrol	190-199	peroxisome proliferator activated receptor alpha	Mus musculus	85-133
32470546-4	2020	Dual-luciferase reporter assays and primary hepatocyte studies demonstrated that the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling mediated the protective effect of celastrol, which was not observed in Ppara-null mice, and co-treatment of wild-type mice with the PPARalpha antagonist GW6471.	celastrol	190-199	peroxisome proliferator activated receptor alpha	Mus musculus	135-144
32470546-4	2020	Dual-luciferase reporter assays and primary hepatocyte studies demonstrated that the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling mediated the protective effect of celastrol, which was not observed in Ppara-null mice, and co-treatment of wild-type mice with the PPARalpha antagonist GW6471.	celastrol	190-199	peroxisome proliferator activated receptor alpha	Mus musculus	288-297
32470546-6	2020	These data demonstrate a novel role for celastrol in protection against acute liver injury through modulating PPARalpha signaling.	celastrol	40-49	peroxisome proliferator activated receptor alpha	Mus musculus	110-119
32565148-3	2020	Here we showed that celastrol caused inhibition of interferon regulatory factor 3 (IRF3) activation leading to the down-regulation of the interferon response triggered by cytosolic nucleic acids in vitro and in vivo.	celastrol	20-29	interferon regulatory factor 3	Mus musculus	51-81
32565148-3	2020	Here we showed that celastrol caused inhibition of interferon regulatory factor 3 (IRF3) activation leading to the down-regulation of the interferon response triggered by cytosolic nucleic acids in vitro and in vivo.	celastrol	20-29	interferon regulatory factor 3	Mus musculus	83-87
32565148-4	2020	Moreover, celastrol treatment markedly ameliorates the autoimmune phenotypes including myocarditis, aberrant interferon response and autoantibody production, as well as the excessive T-cell activation in Trex1-/- autoimmune disease mouse model.	celastrol	10-19	three prime repair exonuclease 1	Mus musculus	204-209
32565148-5	2020	Collectively, our results indicate that celastrol inhibits interferon response by targeting IRF3 activation and may be used as an effective treatment for interferon response-dependent autoimmune diseases.	celastrol	40-49	interferon regulatory factor 3	Mus musculus	92-96
32470352-0	2020	Celastrol augments sensitivity of NLRP3 to CP-456773 by modulating HSP-90 and inducing autophagy in dextran sodium sulphate-induced colitis in rats.	celastrol	0-9	NLR family, pyrin domain containing 3	Rattus norvegicus	34-39
31065693-10	2020	In an in vivo iKspCre-Pkd1lox,lox mouse model for PKD, celastrol inhibited the growth of renal cysts and maintained kidney function.	celastrol	55-64	lysyl oxidase	Mus musculus	26-29
32470352-0	2020	Celastrol augments sensitivity of NLRP3 to CP-456773 by modulating HSP-90 and inducing autophagy in dextran sodium sulphate-induced colitis in rats.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	67-73
32201950-0	2020	Celastrol ameliorates endoplasmic stress-mediated apoptosis of osteoarthritis via regulating ATF-6/CHOP signalling pathway.	celastrol	0-9	activating transcription factor 6	Rattus norvegicus	93-98
32723973-4	2020	Mechanistically, Celastrol was able to control the differentiation of BM-MSCs by stimulating PGC-1alpha signaling.	celastrol	17-26	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	93-103
32647287-10	2020	Our findings suggest that targeting ROCK2-ezrin signaling is a potential therapeutic niche for celastrol-based intervention of cancer progression in hepatocellular carcinoma.	celastrol	95-104	ezrin	Homo sapiens	42-47
32222543-6	2020	Celastrol treatment led to a significant increase in mutant PMM2 protein concentration and activity, while MG132 had a small effect on protein concentration only.	celastrol	0-9	phosphomannomutase 2	Homo sapiens	60-64
32902404-9	2020	Tripterine administration induced the growth inhibition of NIH/3T3 cells indicated by a trend toward the decreased expression of matrix metallopeptidase (MMPs), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).	celastrol	0-10	vascular endothelial growth factor A	Mus musculus	161-195
32902404-9	2020	Tripterine administration induced the growth inhibition of NIH/3T3 cells indicated by a trend toward the decreased expression of matrix metallopeptidase (MMPs), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).	celastrol	0-10	vascular endothelial growth factor A	Mus musculus	197-201
32902404-9	2020	Tripterine administration induced the growth inhibition of NIH/3T3 cells indicated by a trend toward the decreased expression of matrix metallopeptidase (MMPs), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).	celastrol	0-10	fibroblast growth factor 2	Mus musculus	207-237
32902404-9	2020	Tripterine administration induced the growth inhibition of NIH/3T3 cells indicated by a trend toward the decreased expression of matrix metallopeptidase (MMPs), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).	celastrol	0-10	fibroblast growth factor 2	Mus musculus	239-243
32902404-13	2020	Tripterine exhibited an anti-scarring bioactivity in NIH/3T3 cells by inhibiting ANRIL, and this process was accompanied by the blockade of nuclear factor-kappa B (NF-kappaB) and beta-catenin cascades.	celastrol	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	140-162
32902404-13	2020	Tripterine exhibited an anti-scarring bioactivity in NIH/3T3 cells by inhibiting ANRIL, and this process was accompanied by the blockade of nuclear factor-kappa B (NF-kappaB) and beta-catenin cascades.	celastrol	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	164-173
32902404-13	2020	Tripterine exhibited an anti-scarring bioactivity in NIH/3T3 cells by inhibiting ANRIL, and this process was accompanied by the blockade of nuclear factor-kappa B (NF-kappaB) and beta-catenin cascades.	celastrol	0-10	catenin (cadherin associated protein), beta 1	Mus musculus	179-191
32723973-6	2020	Together, these results recommended that Celastrol could regulate BM-MSCs fate and bone-fat balance in OP and skeletal aging by stimulating PGC-1alpha, which might act as a possible therapeutic target for OP and for the prevention of skeletal aging.	celastrol	41-50	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	140-150
32647287-0	2020	Celastrol inhibits ezrin-mediated migration of hepatocellular carcinoma cells.	celastrol	0-9	ezrin	Homo sapiens	19-24
32647287-5	2020	Here we show that ROCK2 is a novel target of celastrol and inhibition of ROCK2 suppresses elicited ezrin activation and liver cancer cell migration.	celastrol	45-54	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	18-23
32647287-5	2020	Here we show that ROCK2 is a novel target of celastrol and inhibition of ROCK2 suppresses elicited ezrin activation and liver cancer cell migration.	celastrol	45-54	ezrin	Homo sapiens	99-104
32647287-7	2020	The molecular target of celastrol was identified as ROCK2 using celastrol affinity pull-down assay.	celastrol	24-33	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	52-57
32647287-7	2020	The molecular target of celastrol was identified as ROCK2 using celastrol affinity pull-down assay.	celastrol	64-73	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	52-57
32647287-8	2020	Our molecular docking analyses indicated celastrol binds to the active site of ROCK2 kinase.	celastrol	41-50	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	79-84
32647287-9	2020	Mechanistically, celastrol inhibits the ROCK2-mediated phosphorylation of ezrin at Thr567 which harnesses liver cancer cell migration.	celastrol	17-26	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	40-45
32647287-9	2020	Mechanistically, celastrol inhibits the ROCK2-mediated phosphorylation of ezrin at Thr567 which harnesses liver cancer cell migration.	celastrol	17-26	ezrin	Homo sapiens	74-79
32647287-10	2020	Our findings suggest that targeting ROCK2-ezrin signaling is a potential therapeutic niche for celastrol-based intervention of cancer progression in hepatocellular carcinoma.	celastrol	95-104	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	36-41
32222543-7	2020	The increase in enzymatic activity with celastrol correlated with an increase in the transcriptional and proteome levels of the heat shock proteins Hsp90 and Hsp70.	celastrol	40-49	heat shock protein 90 alpha family class A member 1	Homo sapiens	148-153
32222543-7	2020	The increase in enzymatic activity with celastrol correlated with an increase in the transcriptional and proteome levels of the heat shock proteins Hsp90 and Hsp70.	celastrol	40-49	heat shock protein family A (Hsp70) member 4	Homo sapiens	158-163
32222543-8	2020	The use of specific Hsp70 or Hsp90 inhibitors showed the positive effect of celastrol on PMM2 stability and activity to occur through Hsp90-driven modulation of the proteostasis network.	celastrol	76-85	heat shock protein family A (Hsp70) member 4	Homo sapiens	20-25
32222543-8	2020	The use of specific Hsp70 or Hsp90 inhibitors showed the positive effect of celastrol on PMM2 stability and activity to occur through Hsp90-driven modulation of the proteostasis network.	celastrol	76-85	heat shock protein 90 alpha family class A member 1	Homo sapiens	29-34
32222543-8	2020	The use of specific Hsp70 or Hsp90 inhibitors showed the positive effect of celastrol on PMM2 stability and activity to occur through Hsp90-driven modulation of the proteostasis network.	celastrol	76-85	phosphomannomutase 2	Homo sapiens	89-93
32222543-8	2020	The use of specific Hsp70 or Hsp90 inhibitors showed the positive effect of celastrol on PMM2 stability and activity to occur through Hsp90-driven modulation of the proteostasis network.	celastrol	76-85	heat shock protein 90 alpha family class A member 1	Homo sapiens	134-139
32222543-9	2020	The synergistic effect of celastrol and a previously described pharmacological chaperone was also examined, and a mutation-dependent synergistic effect on PMM2 activity was noted.	celastrol	26-35	phosphomannomutase 2	Homo sapiens	155-159
32402948-7	2020	The increased levels of inflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and interferon (IFN)-gamma, were abolished by celastrol treatment.	celastrol	167-176	tumor necrosis factor	Rattus norvegicus	56-89
32402948-7	2020	The increased levels of inflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and interferon (IFN)-gamma, were abolished by celastrol treatment.	celastrol	167-176	interleukin 1 alpha	Rattus norvegicus	91-113
32402948-7	2020	The increased levels of inflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and interferon (IFN)-gamma, were abolished by celastrol treatment.	celastrol	167-176	interleukin 6	Rattus norvegicus	115-119
32402948-7	2020	The increased levels of inflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and interferon (IFN)-gamma, were abolished by celastrol treatment.	celastrol	167-176	interferon gamma	Rattus norvegicus	125-147
32402948-9	2020	Nox4 overexpression reversed the attenuating effects of celastrol on paw swelling and arthritis scores in CIA rats.	celastrol	56-65	NADPH oxidase 4	Rattus norvegicus	0-4
32402948-10	2020	The celastrol-induced improvement in spleen and thymus indexes in CIA rats was inhibited by Nox4 overexpression.	celastrol	4-13	NADPH oxidase 4	Rattus norvegicus	92-96
32402948-11	2020	Nox4 overexpression reversed the abolishing effects of celastrol on the increases of TNF-alpha, IL-1beta, IL-6, and IFN-gamma levels in the serum of CIA rats.	celastrol	55-64	NADPH oxidase 4	Rattus norvegicus	0-4
32402948-11	2020	Nox4 overexpression reversed the abolishing effects of celastrol on the increases of TNF-alpha, IL-1beta, IL-6, and IFN-gamma levels in the serum of CIA rats.	celastrol	55-64	tumor necrosis factor	Rattus norvegicus	85-94
32402948-11	2020	Nox4 overexpression reversed the abolishing effects of celastrol on the increases of TNF-alpha, IL-1beta, IL-6, and IFN-gamma levels in the serum of CIA rats.	celastrol	55-64	interleukin 1 alpha	Rattus norvegicus	96-104
32402948-11	2020	Nox4 overexpression reversed the abolishing effects of celastrol on the increases of TNF-alpha, IL-1beta, IL-6, and IFN-gamma levels in the serum of CIA rats.	celastrol	55-64	interleukin 6	Rattus norvegicus	106-110
32402948-11	2020	Nox4 overexpression reversed the abolishing effects of celastrol on the increases of TNF-alpha, IL-1beta, IL-6, and IFN-gamma levels in the serum of CIA rats.	celastrol	55-64	interferon gamma	Rattus norvegicus	116-125
32201950-0	2020	Celastrol ameliorates endoplasmic stress-mediated apoptosis of osteoarthritis via regulating ATF-6/CHOP signalling pathway.	celastrol	0-9	DNA-damage inducible transcript 3	Rattus norvegicus	99-103
32201950-9	2020	Celastrol reduced enzyme activity and protein expression of caspase-3, caspase-6 and caspase-9, decreased Bip, Atf6, Chop and Xbp-1 expression both at protein and mRNA levels.	celastrol	0-9	caspase 3	Rattus norvegicus	60-69
32201950-9	2020	Celastrol reduced enzyme activity and protein expression of caspase-3, caspase-6 and caspase-9, decreased Bip, Atf6, Chop and Xbp-1 expression both at protein and mRNA levels.	celastrol	0-9	caspase 6	Rattus norvegicus	71-80
32201950-9	2020	Celastrol reduced enzyme activity and protein expression of caspase-3, caspase-6 and caspase-9, decreased Bip, Atf6, Chop and Xbp-1 expression both at protein and mRNA levels.	celastrol	0-9	caspase 9	Rattus norvegicus	85-94
32201950-9	2020	Celastrol reduced enzyme activity and protein expression of caspase-3, caspase-6 and caspase-9, decreased Bip, Atf6, Chop and Xbp-1 expression both at protein and mRNA levels.	celastrol	0-9	growth differentiation factor 10	Rattus norvegicus	106-109
32201950-9	2020	Celastrol reduced enzyme activity and protein expression of caspase-3, caspase-6 and caspase-9, decreased Bip, Atf6, Chop and Xbp-1 expression both at protein and mRNA levels.	celastrol	0-9	activating transcription factor 6	Rattus norvegicus	111-115
32201950-9	2020	Celastrol reduced enzyme activity and protein expression of caspase-3, caspase-6 and caspase-9, decreased Bip, Atf6, Chop and Xbp-1 expression both at protein and mRNA levels.	celastrol	0-9	DNA-damage inducible transcript 3	Rattus norvegicus	117-121
32201950-9	2020	Celastrol reduced enzyme activity and protein expression of caspase-3, caspase-6 and caspase-9, decreased Bip, Atf6, Chop and Xbp-1 expression both at protein and mRNA levels.	celastrol	0-9	X-box binding protein 1	Rattus norvegicus	126-131
32277035-8	2020	NRF2 is a celastrol target expressed in the habenula (HB), known to play a critical role in the pathophysiology of depression.	celastrol	10-19	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4
32237164-5	2020	Herein, we present a microfluidic 3D co-flow device to generate human serum albumin/celastrol nanoparticles by co-flowing an aqueous protein solution with celastrol in ethanol.	celastrol	84-93	albumin	Homo sapiens	70-83
32237164-5	2020	Herein, we present a microfluidic 3D co-flow device to generate human serum albumin/celastrol nanoparticles by co-flowing an aqueous protein solution with celastrol in ethanol.	celastrol	155-164	albumin	Homo sapiens	70-83
32098592-0	2020	Celastrol Attenuates Angiotensin II-Induced Cardiac Remodeling by Targeting STAT3.	celastrol	0-9	angiotensinogen	Rattus norvegicus	21-35
32098592-0	2020	Celastrol Attenuates Angiotensin II-Induced Cardiac Remodeling by Targeting STAT3.	celastrol	0-9	signal transducer and activator of transcription 3	Rattus norvegicus	76-81
32098592-3	2020	Objective: We have examined the potential effect of Celastrol, a bioactive compound derived from the Celastraceae family, on Ang II-induced cardiac dysfunction.	celastrol	52-61	angiotensinogen	Rattus norvegicus	125-131
32098592-4	2020	Methods and Results: In rat primary cardiomyocytes and H9C2 cells, Celastrol attenuates Ang II-induced cellular hypertrophy and fibrotic responses.	celastrol	67-76	angiotensinogen	Rattus norvegicus	88-94
31931051-0	2020	Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity.	celastrol	21-30	fibronectin 1	Mus musculus	74-85
32098592-6	2020	Our data showed that Celastrol directly binds to and inhibits signal transducer and activator of transcription-3 (STAT3) phosphorylation and nuclear translocation.	celastrol	21-30	signal transducer and activator of transcription 3	Rattus norvegicus	62-112
32098592-6	2020	Our data showed that Celastrol directly binds to and inhibits signal transducer and activator of transcription-3 (STAT3) phosphorylation and nuclear translocation.	celastrol	21-30	signal transducer and activator of transcription 3	Rattus norvegicus	114-119
32098592-7	2020	Functional tests demonstrated that the protection of Celastrol is afforded through targeting STAT3.	celastrol	53-62	signal transducer and activator of transcription 3	Rattus norvegicus	93-98
32098592-8	2020	Overexpression of STAT3 dampens the effect of Celastrol by partially rescuing STAT3 activity.	celastrol	46-55	signal transducer and activator of transcription 3	Rattus norvegicus	18-23
32098592-8	2020	Overexpression of STAT3 dampens the effect of Celastrol by partially rescuing STAT3 activity.	celastrol	46-55	signal transducer and activator of transcription 3	Rattus norvegicus	78-83
32098592-9	2020	Finally, we investigated the in vivo effect of Celastrol treatment in mice challenged with Ang II and in the Transverse aortic constriction (TAC) model.	celastrol	47-56	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	91-97
32098592-10	2020	We show that Celastrol administration protected heart function in Ang II- and TAC-challenged mice by inhibiting cardiac fibrosis and hypertrophy.	celastrol	13-22	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	66-72
32098592-11	2020	Conclusions: Our studies show that Celastrol inhibits Ang II-induced cardiac dysfunction by inhibiting STAT3 activity.	celastrol	35-44	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	54-60
32098592-11	2020	Conclusions: Our studies show that Celastrol inhibits Ang II-induced cardiac dysfunction by inhibiting STAT3 activity.	celastrol	35-44	signal transducer and activator of transcription 3	Rattus norvegicus	103-108
31904241-0	2020	Celastrol-loaded galactosylated liposomes effectively inhibit AKT/c-Met-triggered rapid hepatocarcinogenesis in mice.	celastrol	0-9	thymoma viral proto-oncogene 1	Mus musculus	62-65
32308429-0	2020	Tripterine Restrains the Aggressiveness of Hepatocellular Carcinoma Cell via Regulating miRNA-532-5p/CXCL2 Axis.	celastrol	0-10	C-X-C motif chemokine ligand 2	Homo sapiens	101-106
32308429-10	2020	Under tripterine treatment, the level of miR-532-5p was strikingly raised, and overexpression of miR-532-5p reduced cell viability and metastatic-related traits.	celastrol	6-16	microRNA 532	Homo sapiens	41-48
32308429-12	2020	Rescue experiments indicated that overexpression of CXCL2 restored the migration and invasive capacity of HCC cells inhibited by miR-532-5p or tripterine treatment.	celastrol	143-153	C-X-C motif chemokine ligand 2	Homo sapiens	52-57
32308429-14	2020	The expression of CXCL2 was distinctly decreased and miR-532-5p level was increased by tripterine in vivo.	celastrol	87-97	C-X-C motif chemokine ligand 2	Homo sapiens	18-23
32308429-15	2020	Conclusion: In conclusion, tripterine inhibits the growth, migration ability and invasiveness of HCC cells through intervening miR-532-5p/CXCL2.	celastrol	27-37	microRNA 532	Homo sapiens	127-134
32308429-15	2020	Conclusion: In conclusion, tripterine inhibits the growth, migration ability and invasiveness of HCC cells through intervening miR-532-5p/CXCL2.	celastrol	27-37	C-X-C motif chemokine ligand 2	Homo sapiens	138-143
32112120-8	2020	RESULTS: We found celastrol ameliorated IL-1beta-induced chondrocyte apoptosis and increased the expression of LC3-II and Beclin-1.	celastrol	18-27	interleukin 1 alpha	Rattus norvegicus	40-48
32112120-8	2020	RESULTS: We found celastrol ameliorated IL-1beta-induced chondrocyte apoptosis and increased the expression of LC3-II and Beclin-1.	celastrol	18-27	beclin 1	Rattus norvegicus	122-130
32112120-10	2020	Moreover, celastrol decreased the IL-1beta-stimulated phosphorylation degree of IkappaBalpha and P65.	celastrol	10-19	interleukin 1 alpha	Rattus norvegicus	34-42
32112120-10	2020	Moreover, celastrol decreased the IL-1beta-stimulated phosphorylation degree of IkappaBalpha and P65.	celastrol	10-19	NFKB inhibitor alpha	Rattus norvegicus	80-92
32112120-10	2020	Moreover, celastrol decreased the IL-1beta-stimulated phosphorylation degree of IkappaBalpha and P65.	celastrol	10-19	synaptotagmin 1	Rattus norvegicus	97-100
31904241-0	2020	Celastrol-loaded galactosylated liposomes effectively inhibit AKT/c-Met-triggered rapid hepatocarcinogenesis in mice.	celastrol	0-9	met proto-oncogene	Mus musculus	66-71
31982489-0	2020	SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells.	celastrol	72-81	ATP binding cassette subfamily B member 1	Homo sapiens	10-24
31982489-6	2020	Here, we unraveled SERCA and P-gp as double targets of the triterpenoid, celastrol to reverse MDR.	celastrol	73-82	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
31982489-7	2020	Celastrol inhibited both SERCA and P-gp to stimulate calcium-mediated autophagy and ATP depletion, thereby induced collateral sensitivity in MDR cancer cells.	celastrol	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	35-39
31841695-0	2020	Preventive effects of "ovalbumin-conjugated celastrol-loaded nanomicelles"" in a mouse model of ovalbumin-induced allergic airway inflammation.	celastrol	44-53	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	23-32
32110017-1	2020	Background: Celastrol (CEL), a triterpene extracted from the Chinese herb tripterygium wilfordii, has been reported to have profound anticancer activities.	celastrol	12-21	carboxyl ester lipase	Mus musculus	23-26
31841695-0	2020	Preventive effects of "ovalbumin-conjugated celastrol-loaded nanomicelles"" in a mouse model of ovalbumin-induced allergic airway inflammation.	celastrol	44-53	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	96-105
31841695-3	2020	We constructed ovalbumin (OVA)-conjugated celastrol-loaded nanomicelles (OVA-NMs-celastrol), wherein celastrol (a bioactive anti-inflammatory compound) was loaded into carboxyl-functioned polymeric nanomicelles using a thin-film hydration method.	celastrol	42-51	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	15-24
31841695-3	2020	We constructed ovalbumin (OVA)-conjugated celastrol-loaded nanomicelles (OVA-NMs-celastrol), wherein celastrol (a bioactive anti-inflammatory compound) was loaded into carboxyl-functioned polymeric nanomicelles using a thin-film hydration method.	celastrol	81-90	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	15-24
31841695-3	2020	We constructed ovalbumin (OVA)-conjugated celastrol-loaded nanomicelles (OVA-NMs-celastrol), wherein celastrol (a bioactive anti-inflammatory compound) was loaded into carboxyl-functioned polymeric nanomicelles using a thin-film hydration method.	celastrol	81-90	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	15-24
31841695-8	2020	Further, in vivo results showed that treatment with OVA-NMs-celastrol could decrease OVA specific IgE and histamine levels, Th2 cytokine (IL-4, IL-5) levels, and inflammatory cell infiltration in the lung tissues.	celastrol	60-69	heart and neural crest derivatives expressed 2	Mus musculus	124-127
31841695-8	2020	Further, in vivo results showed that treatment with OVA-NMs-celastrol could decrease OVA specific IgE and histamine levels, Th2 cytokine (IL-4, IL-5) levels, and inflammatory cell infiltration in the lung tissues.	celastrol	60-69	interleukin 4	Mus musculus	138-142
31841695-8	2020	Further, in vivo results showed that treatment with OVA-NMs-celastrol could decrease OVA specific IgE and histamine levels, Th2 cytokine (IL-4, IL-5) levels, and inflammatory cell infiltration in the lung tissues.	celastrol	60-69	interleukin 5	Mus musculus	144-148
32041250-6	2020	Moreover, inflammatory responses induced by gamma irradiation, as demonstrated by increased levels of IL-6, TNF-alpha, and IL-1beta, were also blocked by celastrol.	celastrol	154-163	interleukin 6	Homo sapiens	102-106
32041250-6	2020	Moreover, inflammatory responses induced by gamma irradiation, as demonstrated by increased levels of IL-6, TNF-alpha, and IL-1beta, were also blocked by celastrol.	celastrol	154-163	tumor necrosis factor	Homo sapiens	108-117
32041250-6	2020	Moreover, inflammatory responses induced by gamma irradiation, as demonstrated by increased levels of IL-6, TNF-alpha, and IL-1beta, were also blocked by celastrol.	celastrol	154-163	interleukin 1 alpha	Homo sapiens	123-131
32041250-7	2020	The increased activity of NF-kappaB DNA binding following gamma radiation was significantly attenuated after celastrol treatment.	celastrol	109-118	nuclear factor kappa B subunit 1	Homo sapiens	26-35
32116702-0	2020	Celastrol Suppresses Glioma Vasculogenic Mimicry Formation and Angiogenesis by Blocking the PI3K/Akt/mTOR Signaling Pathway.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	97-100
32116702-0	2020	Celastrol Suppresses Glioma Vasculogenic Mimicry Formation and Angiogenesis by Blocking the PI3K/Akt/mTOR Signaling Pathway.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	101-105
32116702-6	2020	Periodic acid Schiff (PAS)-CD31 staining revealed that celastrol inhibited both VM and angiogenesis in tumor tissues.	celastrol	55-64	platelet and endothelial cell adhesion molecule 1	Homo sapiens	27-31
32116702-7	2020	Additionally, celastrol reduced the expression levels of the angiogenesis-related proteins CD31, vascular endothelial growth factor receptor (VEGFR) 2, angiopoietin (Ang) 2 and VEGFA, VM-related proteins ephrin type-A receptor (EphA) 2, and vascular endothelial (VE)-cadherin.	celastrol	14-23	platelet and endothelial cell adhesion molecule 1	Homo sapiens	91-95
32116702-7	2020	Additionally, celastrol reduced the expression levels of the angiogenesis-related proteins CD31, vascular endothelial growth factor receptor (VEGFR) 2, angiopoietin (Ang) 2 and VEGFA, VM-related proteins ephrin type-A receptor (EphA) 2, and vascular endothelial (VE)-cadherin.	celastrol	14-23	kinase insert domain receptor	Homo sapiens	97-140
32116702-7	2020	Additionally, celastrol reduced the expression levels of the angiogenesis-related proteins CD31, vascular endothelial growth factor receptor (VEGFR) 2, angiopoietin (Ang) 2 and VEGFA, VM-related proteins ephrin type-A receptor (EphA) 2, and vascular endothelial (VE)-cadherin.	celastrol	14-23	kinase insert domain receptor	Homo sapiens	142-147
32116702-7	2020	Additionally, celastrol reduced the expression levels of the angiogenesis-related proteins CD31, vascular endothelial growth factor receptor (VEGFR) 2, angiopoietin (Ang) 2 and VEGFA, VM-related proteins ephrin type-A receptor (EphA) 2, and vascular endothelial (VE)-cadherin.	celastrol	14-23	angiopoietin 2	Homo sapiens	152-172
32041250-8	2020	In the irradiated mice, treatment with celastrol significantly improved overall survival rate, reduced the excessive inflammatory responses, and decreased NF-kappaB activity.	celastrol	39-48	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	155-164
32116702-7	2020	Additionally, celastrol reduced the expression levels of the angiogenesis-related proteins CD31, vascular endothelial growth factor receptor (VEGFR) 2, angiopoietin (Ang) 2 and VEGFA, VM-related proteins ephrin type-A receptor (EphA) 2, and vascular endothelial (VE)-cadherin.	celastrol	14-23	vascular endothelial growth factor A	Homo sapiens	177-182
32041250-9	2020	As a NF-kappaB pathway blocker and antioxidant, celastrol may represent a promising pharmacological agent with protective effects against gamma irradiation-induced injury.	celastrol	48-57	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	5-14
31989218-0	2020	Novel complementary antitumour effects of celastrol and metformin by targeting IkappaBkappaB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis.	celastrol	42-51	NLR family, pyrin domain containing 3	Mus musculus	108-113
32116702-7	2020	Additionally, celastrol reduced the expression levels of the angiogenesis-related proteins CD31, vascular endothelial growth factor receptor (VEGFR) 2, angiopoietin (Ang) 2 and VEGFA, VM-related proteins ephrin type-A receptor (EphA) 2, and vascular endothelial (VE)-cadherin.	celastrol	14-23	EPH receptor A2	Homo sapiens	228-235
32116702-7	2020	Additionally, celastrol reduced the expression levels of the angiogenesis-related proteins CD31, vascular endothelial growth factor receptor (VEGFR) 2, angiopoietin (Ang) 2 and VEGFA, VM-related proteins ephrin type-A receptor (EphA) 2, and vascular endothelial (VE)-cadherin.	celastrol	14-23	cadherin 5	Homo sapiens	241-275
32116702-8	2020	Hypoxia inducible factor (HIF)-1alpha, phosphorylated PI3K, Akt, and mTOR were also downregulated by treatment with celastrol.	celastrol	116-125	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-37
32116702-8	2020	Hypoxia inducible factor (HIF)-1alpha, phosphorylated PI3K, Akt, and mTOR were also downregulated by treatment with celastrol.	celastrol	116-125	thymoma viral proto-oncogene 1	Mus musculus	60-63
32116702-8	2020	Hypoxia inducible factor (HIF)-1alpha, phosphorylated PI3K, Akt, and mTOR were also downregulated by treatment with celastrol.	celastrol	116-125	mechanistic target of rapamycin kinase	Mus musculus	69-73
32116702-9	2020	In vitro, we further demonstrated that celastrol inhibited the growth, migration, and invasion of U87 and U251 cells, disrupted VM formation, and blocked the activity of PI3K, Akt, and mTOR.	celastrol	39-48	AKT serine/threonine kinase 1	Homo sapiens	176-179
32116702-9	2020	In vitro, we further demonstrated that celastrol inhibited the growth, migration, and invasion of U87 and U251 cells, disrupted VM formation, and blocked the activity of PI3K, Akt, and mTOR.	celastrol	39-48	mechanistic target of rapamycin kinase	Homo sapiens	185-189
32116702-10	2020	Collectively, our data suggest that celastrol inhibits VM formation and angiogenesis likely by regulating the PI3K/Akt/mTOR signaling pathway.	celastrol	36-45	AKT serine/threonine kinase 1	Homo sapiens	115-118
32116702-10	2020	Collectively, our data suggest that celastrol inhibits VM formation and angiogenesis likely by regulating the PI3K/Akt/mTOR signaling pathway.	celastrol	36-45	mechanistic target of rapamycin kinase	Homo sapiens	119-123
31989218-8	2020	In contrast, in the celastrol and celastrol + metformin groups, the apoptotic potential was amplified, as revealed by the increase in the caspase-9 and caspase-3 levels and Bax:BCL-2 ratio.	celastrol	20-29	caspase 9	Mus musculus	138-147
31989218-8	2020	In contrast, in the celastrol and celastrol + metformin groups, the apoptotic potential was amplified, as revealed by the increase in the caspase-9 and caspase-3 levels and Bax:BCL-2 ratio.	celastrol	20-29	BCL2-associated X protein	Mus musculus	173-176
31989218-8	2020	In contrast, in the celastrol and celastrol + metformin groups, the apoptotic potential was amplified, as revealed by the increase in the caspase-9 and caspase-3 levels and Bax:BCL-2 ratio.	celastrol	20-29	B cell leukemia/lymphoma 2	Mus musculus	177-182
31989218-8	2020	In contrast, in the celastrol and celastrol + metformin groups, the apoptotic potential was amplified, as revealed by the increase in the caspase-9 and caspase-3 levels and Bax:BCL-2 ratio.	celastrol	34-43	caspase 9	Mus musculus	138-147
31989218-8	2020	In contrast, in the celastrol and celastrol + metformin groups, the apoptotic potential was amplified, as revealed by the increase in the caspase-9 and caspase-3 levels and Bax:BCL-2 ratio.	celastrol	34-43	caspase 3	Mus musculus	152-161
31989218-8	2020	In contrast, in the celastrol and celastrol + metformin groups, the apoptotic potential was amplified, as revealed by the increase in the caspase-9 and caspase-3 levels and Bax:BCL-2 ratio.	celastrol	34-43	BCL2-associated X protein	Mus musculus	173-176
31989218-8	2020	In contrast, in the celastrol and celastrol + metformin groups, the apoptotic potential was amplified, as revealed by the increase in the caspase-9 and caspase-3 levels and Bax:BCL-2 ratio.	celastrol	34-43	B cell leukemia/lymphoma 2	Mus musculus	177-182
31989218-9	2020	In addition to their repressive effect on the gene expression of NFkappaBp65, TNFR and TLR4, metformin and celastrol inhibited phosphorylation-induced activation of IkappaBkappaB and NFkappaBp65 and decreased IkappaBalpha degradation.	celastrol	107-116	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	78-82
31989218-9	2020	In addition to their repressive effect on the gene expression of NFkappaBp65, TNFR and TLR4, metformin and celastrol inhibited phosphorylation-induced activation of IkappaBkappaB and NFkappaBp65 and decreased IkappaBalpha degradation.	celastrol	107-116	toll-like receptor 4	Mus musculus	87-91
31989218-9	2020	In addition to their repressive effect on the gene expression of NFkappaBp65, TNFR and TLR4, metformin and celastrol inhibited phosphorylation-induced activation of IkappaBkappaB and NFkappaBp65 and decreased IkappaBalpha degradation.	celastrol	107-116	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	209-221
31989218-10	2020	Combination therapy with metformin and celastrol repressed markers of angiogenesis, metastasis and tumour proliferation, as revealed by the decreased hepatic levels of VEGF, MMP-2/9 and cyclin D1 mRNA, respectively.	celastrol	39-48	vascular endothelial growth factor A	Mus musculus	168-172
31989218-10	2020	Combination therapy with metformin and celastrol repressed markers of angiogenesis, metastasis and tumour proliferation, as revealed by the decreased hepatic levels of VEGF, MMP-2/9 and cyclin D1 mRNA, respectively.	celastrol	39-48	matrix metallopeptidase 2	Mus musculus	174-181
31989218-10	2020	Combination therapy with metformin and celastrol repressed markers of angiogenesis, metastasis and tumour proliferation, as revealed by the decreased hepatic levels of VEGF, MMP-2/9 and cyclin D1 mRNA, respectively.	celastrol	39-48	cyclin D1	Mus musculus	186-195
31989218-11	2020	In conclusion, by inhibiting NLRP3 inflammasome and its prerequisite NFkappaB signalling, simultaneous administration of metformin and celastrol appears to have additive benefits in the treatment of HCC compared to cela monotherapy.	celastrol	135-144	NLR family, pyrin domain containing 3	Mus musculus	29-34
31989218-11	2020	In conclusion, by inhibiting NLRP3 inflammasome and its prerequisite NFkappaB signalling, simultaneous administration of metformin and celastrol appears to have additive benefits in the treatment of HCC compared to cela monotherapy.	celastrol	135-144	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	69-77
31949255-13	2020	We are the first to identify the involvement of a cysteine metabolism/reactive oxygen species/p53/Bax/caspase 9/caspase 3 pathway in celastrol-triggered mitochondrial apoptosis in HL-60 and NB-4 cells, providing a novel underlying mechanism through which celastrol could be used to treat acute myeloid leukaemia, especially acute promyelocytic leukaemia.	celastrol	133-142	tumor protein p53	Homo sapiens	94-97
31901889-0	2020	Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis.	celastrol	0-9	cannabinoid receptor 2 (macrophage)	Mus musculus	42-64
31901889-8	2020	RESULTS: Celastrol was identified as a new agonist of CB2 by using SLCA.	celastrol	9-18	cannabinoid receptor 2 (macrophage)	Mus musculus	54-57
31901889-9	2020	Furthermore, celastrol triggers several CB2-mediated downstream signaling pathways, including calcium mobilization, inhibition of cAMP accumulation, and receptor desensitization in a dose-dependent manner, and it has a moderate selectivity on CB1.	celastrol	13-22	cannabinoid receptor 2 (macrophage)	Mus musculus	40-43
31901889-9	2020	Furthermore, celastrol triggers several CB2-mediated downstream signaling pathways, including calcium mobilization, inhibition of cAMP accumulation, and receptor desensitization in a dose-dependent manner, and it has a moderate selectivity on CB1.	celastrol	13-22	cannabinoid receptor 1 (brain)	Mus musculus	243-246
31901889-12	2020	CONCLUSION: Taken together, celastrol is identified a novel selective CB2 agonist using a new developed arrestin-based SLCA, and CB2 activation by celastrol reduces the inflammatory response, and prevents the development of dermal fibrosis in bleomycin-induced systemic sclerosis mouse model.	celastrol	28-37	cannabinoid receptor 2 (macrophage)	Mus musculus	70-73
31901889-12	2020	CONCLUSION: Taken together, celastrol is identified a novel selective CB2 agonist using a new developed arrestin-based SLCA, and CB2 activation by celastrol reduces the inflammatory response, and prevents the development of dermal fibrosis in bleomycin-induced systemic sclerosis mouse model.	celastrol	147-156	cannabinoid receptor 2 (macrophage)	Mus musculus	129-132
31949255-13	2020	We are the first to identify the involvement of a cysteine metabolism/reactive oxygen species/p53/Bax/caspase 9/caspase 3 pathway in celastrol-triggered mitochondrial apoptosis in HL-60 and NB-4 cells, providing a novel underlying mechanism through which celastrol could be used to treat acute myeloid leukaemia, especially acute promyelocytic leukaemia.	celastrol	133-142	BCL2 associated X, apoptosis regulator	Homo sapiens	98-101
31949255-13	2020	We are the first to identify the involvement of a cysteine metabolism/reactive oxygen species/p53/Bax/caspase 9/caspase 3 pathway in celastrol-triggered mitochondrial apoptosis in HL-60 and NB-4 cells, providing a novel underlying mechanism through which celastrol could be used to treat acute myeloid leukaemia, especially acute promyelocytic leukaemia.	celastrol	133-142	caspase 9	Homo sapiens	102-111
31949255-13	2020	We are the first to identify the involvement of a cysteine metabolism/reactive oxygen species/p53/Bax/caspase 9/caspase 3 pathway in celastrol-triggered mitochondrial apoptosis in HL-60 and NB-4 cells, providing a novel underlying mechanism through which celastrol could be used to treat acute myeloid leukaemia, especially acute promyelocytic leukaemia.	celastrol	133-142	caspase 3	Homo sapiens	112-121
31957323-0	2020	Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.	celastrol	22-31	thymoma viral proto-oncogene 1	Mus musculus	124-127
31957323-8	2020	To further find the mechanism involved in the celastrol-induced biological functions, LY204002, a PI3K/Akt signaling inhibitor, and an Akt-1 overexpression plasmid were employed to find whether PI3K/Akt pathway was involved in the celastrol-induced CCA cell inhibition.	celastrol	46-55	thymoma viral proto-oncogene 1	Mus musculus	103-106
31957323-8	2020	To further find the mechanism involved in the celastrol-induced biological functions, LY204002, a PI3K/Akt signaling inhibitor, and an Akt-1 overexpression plasmid were employed to find whether PI3K/Akt pathway was involved in the celastrol-induced CCA cell inhibition.	celastrol	46-55	thymoma viral proto-oncogene 1	Mus musculus	135-140
31957323-8	2020	To further find the mechanism involved in the celastrol-induced biological functions, LY204002, a PI3K/Akt signaling inhibitor, and an Akt-1 overexpression plasmid were employed to find whether PI3K/Akt pathway was involved in the celastrol-induced CCA cell inhibition.	celastrol	46-55	thymoma viral proto-oncogene 1	Mus musculus	135-138
31957323-9	2020	Additionally, short interfering RNA (siRNA) was also used to investigate the mechanism involved in the celastrol-induced PI3K/Akt signaling inhibition.	celastrol	103-112	thymoma viral proto-oncogene 1	Mus musculus	126-129
31957323-13	2020	Further mechanistic study identified that celastrol regulated the PI3K/Akt signaling pathway, and the antitumor efficacy was likely due to the upregulation of PTEN, a negative regulator of PI3K/Akt.	celastrol	42-51	thymoma viral proto-oncogene 1	Mus musculus	71-74
31957323-13	2020	Further mechanistic study identified that celastrol regulated the PI3K/Akt signaling pathway, and the antitumor efficacy was likely due to the upregulation of PTEN, a negative regulator of PI3K/Akt.	celastrol	42-51	phosphatase and tensin homolog	Mus musculus	159-163
31957323-13	2020	Further mechanistic study identified that celastrol regulated the PI3K/Akt signaling pathway, and the antitumor efficacy was likely due to the upregulation of PTEN, a negative regulator of PI3K/Akt.	celastrol	42-51	thymoma viral proto-oncogene 1	Mus musculus	194-197
31957323-14	2020	Blockage of PTEN abolished the celastrol-induced PI3K/Akt signaling inhibition.	celastrol	31-40	phosphatase and tensin homolog	Mus musculus	12-16
31957323-14	2020	Blockage of PTEN abolished the celastrol-induced PI3K/Akt signaling inhibition.	celastrol	31-40	thymoma viral proto-oncogene 1	Mus musculus	54-57
31957323-16	2020	CONCLUSIONS: Overall, our study elucidated a mechanistic framework for the anti-CCA effects of celastrol via PTEN/PI3K/Akt pathway.	celastrol	95-104	phosphatase and tensin homolog	Mus musculus	109-113
31957323-16	2020	CONCLUSIONS: Overall, our study elucidated a mechanistic framework for the anti-CCA effects of celastrol via PTEN/PI3K/Akt pathway.	celastrol	95-104	thymoma viral proto-oncogene 1	Mus musculus	119-122
31742890-0	2020	Celastrol exerts anti-inflammatory effect in liver fibrosis via activation of AMPK-SIRT3 signalling.	celastrol	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	78-82
31742890-11	2020	We further found that depletion of AMPK significantly attenuated the inhibitory effect of celastrol on inflammation.	celastrol	90-99	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	35-39
31742890-12	2020	Collectively, celastrol attenuated liver fibrosis mainly through inhibition of inflammation by activating AMPK-SIRT3 signalling, which makes celastrol be a potential candidate compound in treating or protecting against liver fibrosis.	celastrol	14-23	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	106-110
31742890-0	2020	Celastrol exerts anti-inflammatory effect in liver fibrosis via activation of AMPK-SIRT3 signalling.	celastrol	0-9	sirtuin 3	Homo sapiens	83-88
31742890-12	2020	Collectively, celastrol attenuated liver fibrosis mainly through inhibition of inflammation by activating AMPK-SIRT3 signalling, which makes celastrol be a potential candidate compound in treating or protecting against liver fibrosis.	celastrol	14-23	sirtuin 3	Homo sapiens	111-116
31742890-3	2020	This study was to investigate the anti-inflammatory effect of celastrol in liver fibrosis and to further reveal mechanisms of celastrol-induced anti-inflammatory effects with a focus on AMPK-SIRT3 signalling.	celastrol	126-135	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	186-190
31742890-12	2020	Collectively, celastrol attenuated liver fibrosis mainly through inhibition of inflammation by activating AMPK-SIRT3 signalling, which makes celastrol be a potential candidate compound in treating or protecting against liver fibrosis.	celastrol	141-150	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	106-110
31742890-12	2020	Collectively, celastrol attenuated liver fibrosis mainly through inhibition of inflammation by activating AMPK-SIRT3 signalling, which makes celastrol be a potential candidate compound in treating or protecting against liver fibrosis.	celastrol	141-150	sirtuin 3	Homo sapiens	111-116
31742890-3	2020	This study was to investigate the anti-inflammatory effect of celastrol in liver fibrosis and to further reveal mechanisms of celastrol-induced anti-inflammatory effects with a focus on AMPK-SIRT3 signalling.	celastrol	126-135	sirtuin 3	Homo sapiens	191-196
31742890-6	2020	Interestingly, celastrol increased SIRT3 promoter activity and SIRT3 expression both in fibrotic liver and in activated HSCs.	celastrol	15-24	sirtuin 3	Homo sapiens	35-40
31742890-6	2020	Interestingly, celastrol increased SIRT3 promoter activity and SIRT3 expression both in fibrotic liver and in activated HSCs.	celastrol	15-24	sirtuin 3	Homo sapiens	63-68
31742890-7	2020	Furthermore, SIRT3 silencing evidently ameliorated the anti-inflammatory potential of celastrol.	celastrol	86-95	sirtuin 3	Homo sapiens	13-18
31742890-8	2020	Besides, we found that celastrol could increase the AMPK phosphorylation.	celastrol	23-32	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	52-56
31906147-8	2019	In neurons, celastrol enhances autophagy, autophagosome biogenesis (Beclin 1 , Ambra1 , Vps34 , Atg7 , Atg12 , and LC3-II ), and mitophagy (PINK1 , DJ-1 , and LRRK2 ), and these might be associated with MPAK signaling pathways.	celastrol	12-21	beclin 1, autophagy related	Mus musculus	68-76
31734262-5	2020	RESULTS: The results suggest that celastrol acts against SLE by regulating the function of several signaling proteins, such as interleukin 10, tumor necrosis factor, and matrix metalloprotein 9, which regulate signaling pathways involving mitogen-activated protein kinase and tumor necrosis factor as well as apoptosis pathways.	celastrol	34-43	interleukin 10	Homo sapiens	127-141
31734262-5	2020	RESULTS: The results suggest that celastrol acts against SLE by regulating the function of several signaling proteins, such as interleukin 10, tumor necrosis factor, and matrix metalloprotein 9, which regulate signaling pathways involving mitogen-activated protein kinase and tumor necrosis factor as well as apoptosis pathways.	celastrol	34-43	tumor necrosis factor	Homo sapiens	143-193
31906147-8	2019	In neurons, celastrol enhances autophagy, autophagosome biogenesis (Beclin 1 , Ambra1 , Vps34 , Atg7 , Atg12 , and LC3-II ), and mitophagy (PINK1 , DJ-1 , and LRRK2 ), and these might be associated with MPAK signaling pathways.	celastrol	12-21	autophagy/beclin 1 regulator 1	Mus musculus	79-85
31906147-8	2019	In neurons, celastrol enhances autophagy, autophagosome biogenesis (Beclin 1 , Ambra1 , Vps34 , Atg7 , Atg12 , and LC3-II ), and mitophagy (PINK1 , DJ-1 , and LRRK2 ), and these might be associated with MPAK signaling pathways.	celastrol	12-21	phosphatidylinositol 3-kinase catalytic subunit type 3	Mus musculus	88-93
31906147-8	2019	In neurons, celastrol enhances autophagy, autophagosome biogenesis (Beclin 1 , Ambra1 , Vps34 , Atg7 , Atg12 , and LC3-II ), and mitophagy (PINK1 , DJ-1 , and LRRK2 ), and these might be associated with MPAK signaling pathways.	celastrol	12-21	autophagy related 7	Mus musculus	96-100
31906147-8	2019	In neurons, celastrol enhances autophagy, autophagosome biogenesis (Beclin 1 , Ambra1 , Vps34 , Atg7 , Atg12 , and LC3-II ), and mitophagy (PINK1 , DJ-1 , and LRRK2 ), and these might be associated with MPAK signaling pathways.	celastrol	12-21	autophagy related 12	Mus musculus	103-108
31906147-8	2019	In neurons, celastrol enhances autophagy, autophagosome biogenesis (Beclin 1 , Ambra1 , Vps34 , Atg7 , Atg12 , and LC3-II ), and mitophagy (PINK1 , DJ-1 , and LRRK2 ), and these might be associated with MPAK signaling pathways.	celastrol	12-21	PTEN induced putative kinase 1	Mus musculus	140-145
31906147-8	2019	In neurons, celastrol enhances autophagy, autophagosome biogenesis (Beclin 1 , Ambra1 , Vps34 , Atg7 , Atg12 , and LC3-II ), and mitophagy (PINK1 , DJ-1 , and LRRK2 ), and these might be associated with MPAK signaling pathways.	celastrol	12-21	Parkinson disease (autosomal recessive, early onset) 7	Mus musculus	148-152
31906147-8	2019	In neurons, celastrol enhances autophagy, autophagosome biogenesis (Beclin 1 , Ambra1 , Vps34 , Atg7 , Atg12 , and LC3-II ), and mitophagy (PINK1 , DJ-1 , and LRRK2 ), and these might be associated with MPAK signaling pathways.	celastrol	12-21	leucine-rich repeat kinase 2	Mus musculus	159-164
31906147-10	2019	In the PD mouse model, celastrol suppresses motor symptoms and neurodegeneration in the substantia nigra and striatum and enhances mitophagy (PINK1  and DJ-1 ) in the striatum.	celastrol	23-32	PTEN induced putative kinase 1	Mus musculus	142-147
31906147-10	2019	In the PD mouse model, celastrol suppresses motor symptoms and neurodegeneration in the substantia nigra and striatum and enhances mitophagy (PINK1  and DJ-1 ) in the striatum.	celastrol	23-32	Parkinson disease (autosomal recessive, early onset) 7	Mus musculus	153-157
31725288-0	2019	Discovery of novel celastrol derivatives as Hsp90-Cdc37 interaction disruptors with antitumour activity.	celastrol	19-28	heat shock protein 90 alpha family class A member 1	Homo sapiens	44-49
32043019-0	2020	Celastrol Alleviates Aortic Valve Calcification Via Inhibition of NADPH Oxidase 2 in Valvular Interstitial Cells.	celastrol	0-9	cytochrome b-245 heavy chain	Oryctolagus cuniculus	66-81
32043019-9	2020	Mechanistically, either celastrol treatment or knockdown of Nox2 significantly inhibited glycogen synthase kinase 3 beta/beta-catenin signaling, leading to attenuation of fibrogenic and osteogenic responses of AVICs.	celastrol	24-33	glycogen synthase kinase-3 beta	Oryctolagus cuniculus	89-120
32043019-9	2020	Mechanistically, either celastrol treatment or knockdown of Nox2 significantly inhibited glycogen synthase kinase 3 beta/beta-catenin signaling, leading to attenuation of fibrogenic and osteogenic responses of AVICs.	celastrol	24-33	catenin alpha-1	Oryctolagus cuniculus	121-133
32043019-12	2020	Celastrol is effective to alleviate CAVD, likely through the inhibition of Nox2-mediated glycogen synthase kinase 3 beta/beta-catenin pathway in AVICs.	celastrol	0-9	cytochrome b-245 heavy chain	Oryctolagus cuniculus	75-79
32043019-12	2020	Celastrol is effective to alleviate CAVD, likely through the inhibition of Nox2-mediated glycogen synthase kinase 3 beta/beta-catenin pathway in AVICs.	celastrol	0-9	glycogen synthase kinase-3 beta	Oryctolagus cuniculus	89-120
32043019-12	2020	Celastrol is effective to alleviate CAVD, likely through the inhibition of Nox2-mediated glycogen synthase kinase 3 beta/beta-catenin pathway in AVICs.	celastrol	0-9	catenin alpha-1	Oryctolagus cuniculus	121-133
31725288-1	2019	To develop novel and efficient heat shock protein 90-cell division cycle 37 (Hsp90-Cdc37) interaction disruptors, several lipophilic fragments were introduced into celastrol (CEL) to synthesize 48 new CEL derivatives.	celastrol	175-178	heat shock protein 90 alpha family class A member 1	Homo sapiens	77-82
31725288-1	2019	To develop novel and efficient heat shock protein 90-cell division cycle 37 (Hsp90-Cdc37) interaction disruptors, several lipophilic fragments were introduced into celastrol (CEL) to synthesize 48 new CEL derivatives.	celastrol	175-178	cell division cycle 37, HSP90 cochaperone	Homo sapiens	83-88
31725288-1	2019	To develop novel and efficient heat shock protein 90-cell division cycle 37 (Hsp90-Cdc37) interaction disruptors, several lipophilic fragments were introduced into celastrol (CEL) to synthesize 48 new CEL derivatives.	celastrol	201-204	heat shock protein 90 alpha family class A member 1	Homo sapiens	77-82
31725288-1	2019	To develop novel and efficient heat shock protein 90-cell division cycle 37 (Hsp90-Cdc37) interaction disruptors, several lipophilic fragments were introduced into celastrol (CEL) to synthesize 48 new CEL derivatives.	celastrol	201-204	cell division cycle 37, HSP90 cochaperone	Homo sapiens	83-88
31725288-0	2019	Discovery of novel celastrol derivatives as Hsp90-Cdc37 interaction disruptors with antitumour activity.	celastrol	19-28	cell division cycle 37, HSP90 cochaperone	Homo sapiens	50-55
31725288-1	2019	To develop novel and efficient heat shock protein 90-cell division cycle 37 (Hsp90-Cdc37) interaction disruptors, several lipophilic fragments were introduced into celastrol (CEL) to synthesize 48 new CEL derivatives.	celastrol	164-173	heat shock protein 90 alpha family class A member 1	Homo sapiens	77-82
31725288-3	2019	The capability to disrupt the Hsp90-Cdc37 interaction was stronger than that of CEL.	celastrol	80-83	heat shock protein 90 alpha family class A member 1	Homo sapiens	30-35
31725288-3	2019	The capability to disrupt the Hsp90-Cdc37 interaction was stronger than that of CEL.	celastrol	80-83	cell division cycle 37, HSP90 cochaperone	Homo sapiens	36-41
31725288-1	2019	To develop novel and efficient heat shock protein 90-cell division cycle 37 (Hsp90-Cdc37) interaction disruptors, several lipophilic fragments were introduced into celastrol (CEL) to synthesize 48 new CEL derivatives.	celastrol	164-173	cell division cycle 37, HSP90 cochaperone	Homo sapiens	83-88
31694174-0	2019	Early Celastrol Administration Prevents Ketamine-Induced Psychotic-Like Behavioral Dysfunctions, Oxidative Stress and IL-10 Reduction in The Cerebellum of Adult Mice.	celastrol	6-15	interleukin 10	Mus musculus	118-123
31663764-0	2019	Transferrin-Functionalized Microemulsions Coloaded with Coix Seed Oil and Tripterine Deeply Penetrate To Improve Cervical Cancer Therapy.	celastrol	74-84	transferrin	Mus musculus	0-11
31663764-2	2019	In this study, we showed that coix seed oil and tripterine coloaded microemulsions with a transferrin modification (Tf-CT-MEs) could improve the treatment of cervical cancer.	celastrol	48-58	transferrin	Mus musculus	90-101
31694174-16	2019	While no changes were observed for IL-6 and IL-1beta levels, ketamine determined a reduction of cerebellar IL-10 expression, which was prevented by early celastrol treatment.	celastrol	154-163	interleukin 10	Mus musculus	107-112
31735550-0	2019	Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin.	celastrol	0-9	FA complementation group D2	Homo sapiens	33-39
31735550-5	2019	METHODS: We determined the capacity of celastrol, a BBB-penetrable compound that degrades FANCD2, to sensitize glioma cells to the archetypical DNA-crosslinking agent carboplatin in vitro in seven patient-derived pHGG models.	celastrol	39-48	FA complementation group D2	Homo sapiens	90-96
31735550-8	2019	FINDINGS: FANCD2 is overexpressed in HGGs and depletion of FANCD2 by celastrol synergises with carboplatin to induce cytotoxicity.	celastrol	69-78	FA complementation group D2	Homo sapiens	59-65
31735550-10	2019	In addition, our results suggest that celastrol treatment stalls ongoing replication forks, causing sensitivity to DNA-crosslinking in FANCD2-dependent glioma cells.	celastrol	38-47	FA complementation group D2	Homo sapiens	135-141
31739592-0	2019	Celastrol Induces Necroptosis and Ameliorates Inflammation via Targeting Biglycan in Human Gastric Carcinoma.	celastrol	0-9	biglycan	Homo sapiens	73-81
31739592-5	2019	More importantly, celastrol down-regulated biglycan (BGN) protein, which is critical for gastric cancer migration and invasion.	celastrol	18-27	biglycan	Homo sapiens	43-51
31739592-5	2019	More importantly, celastrol down-regulated biglycan (BGN) protein, which is critical for gastric cancer migration and invasion.	celastrol	18-27	biglycan	Homo sapiens	53-56
31739592-6	2019	Furthermore, celastrol activated receptor-interacting protein 1 and 3 (RIP1 and RIP3) and subsequently promoted the translation of mixed-lineage kinase domain-like (MLKL) from cytoplasm to plasma membrane, leading to necroptosis of gastric cancer cell, which was blocked by over-expression BGN.	celastrol	13-22	receptor interacting serine/threonine kinase 1	Homo sapiens	33-69
31739592-6	2019	Furthermore, celastrol activated receptor-interacting protein 1 and 3 (RIP1 and RIP3) and subsequently promoted the translation of mixed-lineage kinase domain-like (MLKL) from cytoplasm to plasma membrane, leading to necroptosis of gastric cancer cell, which was blocked by over-expression BGN.	celastrol	13-22	receptor interacting serine/threonine kinase 1	Homo sapiens	71-75
31739592-6	2019	Furthermore, celastrol activated receptor-interacting protein 1 and 3 (RIP1 and RIP3) and subsequently promoted the translation of mixed-lineage kinase domain-like (MLKL) from cytoplasm to plasma membrane, leading to necroptosis of gastric cancer cell, which was blocked by over-expression BGN.	celastrol	13-22	receptor interacting serine/threonine kinase 3	Homo sapiens	80-84
31739592-6	2019	Furthermore, celastrol activated receptor-interacting protein 1 and 3 (RIP1 and RIP3) and subsequently promoted the translation of mixed-lineage kinase domain-like (MLKL) from cytoplasm to plasma membrane, leading to necroptosis of gastric cancer cell, which was blocked by over-expression BGN.	celastrol	13-22	mixed lineage kinase domain like pseudokinase	Homo sapiens	131-163
31739592-6	2019	Furthermore, celastrol activated receptor-interacting protein 1 and 3 (RIP1 and RIP3) and subsequently promoted the translation of mixed-lineage kinase domain-like (MLKL) from cytoplasm to plasma membrane, leading to necroptosis of gastric cancer cell, which was blocked by over-expression BGN.	celastrol	13-22	mixed lineage kinase domain like pseudokinase	Homo sapiens	165-169
31739592-6	2019	Furthermore, celastrol activated receptor-interacting protein 1 and 3 (RIP1 and RIP3) and subsequently promoted the translation of mixed-lineage kinase domain-like (MLKL) from cytoplasm to plasma membrane, leading to necroptosis of gastric cancer cell, which was blocked by over-expression BGN.	celastrol	13-22	biglycan	Homo sapiens	290-293
31739592-7	2019	In addition, celastrol suppressed the release of pro-inflammatory cytokines TNF-alpha and IL-8 in HGC27 and AGS cells, which was reversed by over-expression BGN.	celastrol	13-22	tumor necrosis factor	Homo sapiens	76-85
31739592-7	2019	In addition, celastrol suppressed the release of pro-inflammatory cytokines TNF-alpha and IL-8 in HGC27 and AGS cells, which was reversed by over-expression BGN.	celastrol	13-22	C-X-C motif chemokine ligand 8	Homo sapiens	90-94
31739592-7	2019	In addition, celastrol suppressed the release of pro-inflammatory cytokines TNF-alpha and IL-8 in HGC27 and AGS cells, which was reversed by over-expression BGN.	celastrol	13-22	biglycan	Homo sapiens	157-160
31739592-8	2019	Taken together, we identified celastrol as a necroptosis inducer, activated RIP1/RIP3/MLKL pathway and suppressed the level of pro-inflammatory cytokines by down-regulating BGN in HGC-27 and AGS cells, which supported the feasibility of celastrol in gastric cancer therapy.	celastrol	30-39	receptor interacting serine/threonine kinase 1	Homo sapiens	76-80
31739592-8	2019	Taken together, we identified celastrol as a necroptosis inducer, activated RIP1/RIP3/MLKL pathway and suppressed the level of pro-inflammatory cytokines by down-regulating BGN in HGC-27 and AGS cells, which supported the feasibility of celastrol in gastric cancer therapy.	celastrol	30-39	receptor interacting serine/threonine kinase 3	Homo sapiens	81-85
31739592-8	2019	Taken together, we identified celastrol as a necroptosis inducer, activated RIP1/RIP3/MLKL pathway and suppressed the level of pro-inflammatory cytokines by down-regulating BGN in HGC-27 and AGS cells, which supported the feasibility of celastrol in gastric cancer therapy.	celastrol	30-39	mixed lineage kinase domain like pseudokinase	Homo sapiens	86-90
31739592-8	2019	Taken together, we identified celastrol as a necroptosis inducer, activated RIP1/RIP3/MLKL pathway and suppressed the level of pro-inflammatory cytokines by down-regulating BGN in HGC-27 and AGS cells, which supported the feasibility of celastrol in gastric cancer therapy.	celastrol	30-39	biglycan	Homo sapiens	173-176
31694174-6	2019	Furthermore, celastrol effects on ketamine-induced alterations of proinflammatory (TNF-alpha, IL-6 and IL-1beta) and anti-inflammatory (IL-10) cytokines in this brain region were evaluated.	celastrol	13-22	tumor necrosis factor	Mus musculus	83-92
31694174-6	2019	Furthermore, celastrol effects on ketamine-induced alterations of proinflammatory (TNF-alpha, IL-6 and IL-1beta) and anti-inflammatory (IL-10) cytokines in this brain region were evaluated.	celastrol	13-22	interleukin 6	Mus musculus	94-98
31694174-6	2019	Furthermore, celastrol effects on ketamine-induced alterations of proinflammatory (TNF-alpha, IL-6 and IL-1beta) and anti-inflammatory (IL-10) cytokines in this brain region were evaluated.	celastrol	13-22	interleukin 1 alpha	Mus musculus	103-111
31694174-6	2019	Furthermore, celastrol effects on ketamine-induced alterations of proinflammatory (TNF-alpha, IL-6 and IL-1beta) and anti-inflammatory (IL-10) cytokines in this brain region were evaluated.	celastrol	13-22	interleukin 10	Mus musculus	136-141
31694174-11	2019	Celastrol per se induced NOX1 decrease in the cerebellum.	celastrol	0-9	NADPH oxidase 1	Mus musculus	25-29
31637185-0	2019	Celastrol inhibits migration, proliferation and transforming growth factor-beta2-induced epithelial-mesenchymal transition in lens epithelial cells.	celastrol	0-9	transforming growth factor beta 2	Homo sapiens	48-80
31635084-0	2019	Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP/TAZ-TEAD Biosensors.	celastrol	18-27	Yes1 associated transcriptional regulator	Homo sapiens	39-42
31635084-0	2019	Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP/TAZ-TEAD Biosensors.	celastrol	18-27	Yes1 associated transcriptional regulator	Homo sapiens	126-129
31635084-0	2019	Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP/TAZ-TEAD Biosensors.	celastrol	18-27	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	130-133
31635084-5	2019	Using this biosensor, we have performed an in vitro high throughput screen (HTS) of small molecule compounds and have identified and validated the drug Celastrol as a novel inhibitor of YAP/TAZ-TEAD interaction.	celastrol	152-161	Yes1 associated transcriptional regulator	Homo sapiens	186-189
31635084-5	2019	Using this biosensor, we have performed an in vitro high throughput screen (HTS) of small molecule compounds and have identified and validated the drug Celastrol as a novel inhibitor of YAP/TAZ-TEAD interaction.	celastrol	152-161	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	190-193
31637185-2	2019	METHODS: Human LEC line SRA01/04 was treated with celastrol and transforming growth factor-beta2 (TGF-beta2).	celastrol	50-59	C-C motif chemokine ligand 16	Homo sapiens	15-18
31637185-7	2019	Moreover, celastrol inhibited epithelial-mesenchymal transition (EMT) by the blockade of TGF-beta/Smad and Jagged/Notch signaling pathways.	celastrol	10-19	transforming growth factor beta 2	Homo sapiens	89-97
31637185-8	2019	CONCLUSION: Our study demonstrates that celastrol could inhibit TGF-beta2-induced lens fibrosis and raises the possibility that celastrol could be a potential novel drug in prevention and treatment of fibrotic cataract.	celastrol	40-49	transforming growth factor beta 2	Homo sapiens	64-73
31454532-7	2019	As for macrophage M1/M2 polarization in liver, nano-celastrol reduced the expression of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in a dose-dependent manner and marginally increased the expression of macrophage M2 biomarkers (e.g., Arg-1, IL-10).	celastrol	52-61	interleukin 6	Mus musculus	120-124
31667381-4	2019	We further found that Celastrol, one of main components of TWHF, inhibits hERG with an IC50 of 0.83 muM.	celastrol	22-31	ETS transcription factor ERG	Homo sapiens	74-78
31667381-6	2019	Our data suggest that inhibition of hERG channel activity by Celastrol contributed to TWHF cardiotoxicity.	celastrol	61-70	ETS transcription factor ERG	Homo sapiens	36-40
31281953-0	2019	Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.	celastrol	0-9	TNF superfamily member 10	Homo sapiens	19-24
31281953-4	2019	Celastrol is a pleiotropic compound from a traditional Chinese medicine that has proven to be useful as a sensitizer for TRAIL treatment.	celastrol	0-9	TNF superfamily member 10	Homo sapiens	121-126
31281953-15	2019	Furthermore, celastrol upregulated death receptor 5 (DR5) at the mRNA and protein levels, and siRNA-mediated DR5 knockdown reduced the killing effect of the combination drug treatment on glioma cells and reduced the activation of caspase-3, caspase-8 and PARP.	celastrol	13-22	TNF receptor superfamily member 10b	Homo sapiens	35-51
31281953-15	2019	Furthermore, celastrol upregulated death receptor 5 (DR5) at the mRNA and protein levels, and siRNA-mediated DR5 knockdown reduced the killing effect of the combination drug treatment on glioma cells and reduced the activation of caspase-3, caspase-8 and PARP.	celastrol	13-22	TNF receptor superfamily member 10b	Homo sapiens	53-56
31281953-15	2019	Furthermore, celastrol upregulated death receptor 5 (DR5) at the mRNA and protein levels, and siRNA-mediated DR5 knockdown reduced the killing effect of the combination drug treatment on glioma cells and reduced the activation of caspase-3, caspase-8 and PARP.	celastrol	13-22	caspase 3	Homo sapiens	230-239
31281953-15	2019	Furthermore, celastrol upregulated death receptor 5 (DR5) at the mRNA and protein levels, and siRNA-mediated DR5 knockdown reduced the killing effect of the combination drug treatment on glioma cells and reduced the activation of caspase-3, caspase-8 and PARP.	celastrol	13-22	caspase 8	Homo sapiens	241-250
31281953-15	2019	Furthermore, celastrol upregulated death receptor 5 (DR5) at the mRNA and protein levels, and siRNA-mediated DR5 knockdown reduced the killing effect of the combination drug treatment on glioma cells and reduced the activation of caspase-3, caspase-8 and PARP.	celastrol	13-22	poly(ADP-ribose) polymerase 1	Homo sapiens	255-259
31281953-16	2019	CONCLUSIONS: Taken together, the results of our study demonstrate that celastrol sensitizes glioma cells to TRAIL via the death receptor pathway and that DR5 plays an important role in the effects of this cotreatment.	celastrol	71-80	TNF superfamily member 10	Homo sapiens	108-113
31454532-7	2019	As for macrophage M1/M2 polarization in liver, nano-celastrol reduced the expression of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in a dose-dependent manner and marginally increased the expression of macrophage M2 biomarkers (e.g., Arg-1, IL-10).	celastrol	52-61	interleukin 1 beta	Mus musculus	126-134
31454532-7	2019	As for macrophage M1/M2 polarization in liver, nano-celastrol reduced the expression of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in a dose-dependent manner and marginally increased the expression of macrophage M2 biomarkers (e.g., Arg-1, IL-10).	celastrol	52-61	tumor necrosis factor	Mus musculus	136-145
31454532-7	2019	As for macrophage M1/M2 polarization in liver, nano-celastrol reduced the expression of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in a dose-dependent manner and marginally increased the expression of macrophage M2 biomarkers (e.g., Arg-1, IL-10).	celastrol	52-61	nitric oxide synthase 2, inducible	Mus musculus	147-151
31454532-7	2019	As for macrophage M1/M2 polarization in liver, nano-celastrol reduced the expression of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in a dose-dependent manner and marginally increased the expression of macrophage M2 biomarkers (e.g., Arg-1, IL-10).	celastrol	52-61	arginase, liver	Mus musculus	255-260
31454532-7	2019	As for macrophage M1/M2 polarization in liver, nano-celastrol reduced the expression of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in a dose-dependent manner and marginally increased the expression of macrophage M2 biomarkers (e.g., Arg-1, IL-10).	celastrol	52-61	interleukin 10	Mus musculus	262-267
31276975-4	2019	Then we validated our predictions of four candidate targets (IKK-beta, JNK, COX-2, MEK1) by performing docking studies with celastrol.	celastrol	124-133	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	61-69
31488870-0	2019	Lipocalin 2 Does Not Play A Role in Celastrol-Mediated Reduction in Food Intake and Body Weight.	celastrol	36-45	asparagine-linked glycosylation 3 (alpha-1,3-mannosyltransferase)	Mus musculus	17-20
31488870-1	2019	Celastrol is a leptin-sensitizing agent with profound anti-obesity effects in diet-induced obese (DIO) mice.	celastrol	0-9	leptin	Mus musculus	15-21
31488870-2	2019	However, the genes and pathways that mediate celastrol-induced leptin sensitization have not been fully understood.	celastrol	45-54	leptin	Mus musculus	63-69
31488870-2	2019	However, the genes and pathways that mediate celastrol-induced leptin sensitization have not been fully understood.	celastrol	45-54	asparagine-linked glycosylation 3 (alpha-1,3-mannosyltransferase)	Mus musculus	89-92
31488870-3	2019	By comparing the hypothalamic transcriptomes of celastrol and vehicle-treated DIO mice, we identified lipocalin-2 (Lcn2) as the gene most strongly upregulated by celastrol.	celastrol	162-171	lipocalin 2	Mus musculus	102-113
31488870-3	2019	By comparing the hypothalamic transcriptomes of celastrol and vehicle-treated DIO mice, we identified lipocalin-2 (Lcn2) as the gene most strongly upregulated by celastrol.	celastrol	162-171	lipocalin 2	Mus musculus	115-119
31488870-5	2019	Celastrol increased LCN2 protein levels in hypothalamus, liver, fat, muscle, and bone marrow, as well as in the plasma.	celastrol	0-9	lipocalin 2	Mus musculus	20-24
31315437-9	2019	Finally, pharmacological inhibition of inflammation in ECs by celastrol rescued overexpression of VWF in cells expressing ApoE4.	celastrol	62-71	von Willebrand factor	Homo sapiens	98-101
31315437-9	2019	Finally, pharmacological inhibition of inflammation in ECs by celastrol rescued overexpression of VWF in cells expressing ApoE4.	celastrol	62-71	apolipoprotein E	Homo sapiens	122-127
31132532-0	2019	SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.	celastrol	13-22	sarcosine dehydrogenase	Homo sapiens	0-3
31132532-0	2019	SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.	celastrol	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-46
31132532-2	2019	Our previous work found that celastrol, a pentacyclic triterpene, bound to Nur77 to inhibit inflammation in a Nur77-dependent manner.	celastrol	29-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	75-80
31132532-2	2019	Our previous work found that celastrol, a pentacyclic triterpene, bound to Nur77 to inhibit inflammation in a Nur77-dependent manner.	celastrol	29-38	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-115
31132532-3	2019	Celastrol binding to Nur77 promotes Nur77 translocation from nucleus to cytoplasm, resulting in clearance of inflamed mitochondria and then alleviation of inflammation.	celastrol	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	21-26
31132532-3	2019	Celastrol binding to Nur77 promotes Nur77 translocation from nucleus to cytoplasm, resulting in clearance of inflamed mitochondria and then alleviation of inflammation.	celastrol	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	36-41
31132532-4	2019	Here, we report the design, synthesis, SAR study and biological evaluation of a series of celastrol analogs.	celastrol	90-99	sarcosine dehydrogenase	Homo sapiens	39-42
31276975-4	2019	Then we validated our predictions of four candidate targets (IKK-beta, JNK, COX-2, MEK1) by performing docking studies with celastrol.	celastrol	124-133	mitogen-activated protein kinase 8	Homo sapiens	71-74
31276975-4	2019	Then we validated our predictions of four candidate targets (IKK-beta, JNK, COX-2, MEK1) by performing docking studies with celastrol.	celastrol	124-133	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	76-81
31276975-4	2019	Then we validated our predictions of four candidate targets (IKK-beta, JNK, COX-2, MEK1) by performing docking studies with celastrol.	celastrol	124-133	mitogen-activated protein kinase kinase 1	Homo sapiens	83-87
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	matrix metallopeptidase 9	Homo sapiens	137-142
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	144-149
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	151-156
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	transforming growth factor beta 1	Homo sapiens	158-166
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	168-173
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	Janus kinase 1	Homo sapiens	175-180
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	Janus kinase 3	Homo sapiens	182-187
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	189-197
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	spleen associated tyrosine kinase	Homo sapiens	199-202
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	matrix metallopeptidase 3	Homo sapiens	204-209
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	mitogen-activated protein kinase 8	Homo sapiens	211-214
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	mitogen-activated protein kinase kinase 1	Homo sapiens	219-223
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	negative elongation factor complex member C/D	Homo sapiens	257-260
31124139-0	2019	Ca2+ signalling plays a role in celastrol-mediated suppression of synovial fibroblasts of rheumatoid arthritis patients and experimental arthritis in rats.	celastrol	32-41	carbonic anhydrase 2	Homo sapiens	0-3
31439870-9	2019	In addition, treatment with celastrol, an inhibitor of NLRP3 inflammasome, reduced the potency of macrophages to stimulate migration and invasion of melanoma cells.	celastrol	28-37	NLR family, pyrin domain containing 3	Mus musculus	55-60
31485297-7	2019	We found that celastrol, at higher concentrations (above 1 muM), significantly increased ROS amount in LOVO/DX cells at both cytoplasmic and mitochondrial levels.	celastrol	14-23	latexin	Homo sapiens	59-62
31124139-1	2019	BACKGROUND AND PURPOSE: Celastrol exhibits anti-arthritic effects in rheumatoid arthritis (RA), but the role of celastrol-mediated Ca2+ mobilization in treatment of RA remains undefined.	celastrol	112-121	carbonic anhydrase 2	Rattus norvegicus	131-134
31124139-2	2019	Here, we describe a regulatory role for celastrol-induced Ca2+ signalling in synovial fibroblasts of RA patients and adjuvant-induced arthritis (AIA) in rats.	celastrol	40-49	carbonic anhydrase 2	Homo sapiens	58-61
31124139-7	2019	KEY RESULTS: Celastrol inhibited SERCA to induce autophagy-dependent cytotoxicity in RASFs/RAFLS via Ca2+ /calmodulin-dependent kinase kinase-beta-AMP-activated protein kinase-mTOR pathway and repressed arthritis symptoms in AIA rats.	celastrol	13-22	carbonic anhydrase 2	Rattus norvegicus	101-104
31124139-7	2019	KEY RESULTS: Celastrol inhibited SERCA to induce autophagy-dependent cytotoxicity in RASFs/RAFLS via Ca2+ /calmodulin-dependent kinase kinase-beta-AMP-activated protein kinase-mTOR pathway and repressed arthritis symptoms in AIA rats.	celastrol	13-22	mechanistic target of rapamycin kinase	Rattus norvegicus	176-180
31124139-10	2019	Knockdown of calmodulin, calpains, and calcineurin in RAFLS confirmed the role of Ca2+ in celastrol-regulated gene expression.	celastrol	90-99	carbonic anhydrase 2	Rattus norvegicus	82-85
31124139-11	2019	CONCLUSION AND IMPLICATIONS: Celastrol triggered Ca2+ signalling to induce autophagic cell death in RASFs/RAFLS and ameliorated arthritis in AIA rats mediated by calcium-dependent/-binding proteins facilitating the exploitation of anti-arthritic drugs based on manipulation of Ca2+ signalling.	celastrol	29-38	carbonic anhydrase 2	Rattus norvegicus	49-52
31124139-11	2019	CONCLUSION AND IMPLICATIONS: Celastrol triggered Ca2+ signalling to induce autophagic cell death in RASFs/RAFLS and ameliorated arthritis in AIA rats mediated by calcium-dependent/-binding proteins facilitating the exploitation of anti-arthritic drugs based on manipulation of Ca2+ signalling.	celastrol	29-38	carbonic anhydrase 2	Rattus norvegicus	277-280
31588349-11	2019	Likewise, celastrol pretreatment improved the GR and CAT activities.	celastrol	10-19	glutathione-disulfide reductase	Rattus norvegicus	46-48
31588349-11	2019	Likewise, celastrol pretreatment improved the GR and CAT activities.	celastrol	10-19	catalase	Rattus norvegicus	53-56
31051401-3	2019	The mechanism of pharmacological research indicated that 29 possessed the ability to disrupt Hsp90-Cdc37 complex which was stronger than celastrol.	celastrol	137-146	heat shock protein 90 alpha family class A member 1	Homo sapiens	93-98
31051401-3	2019	The mechanism of pharmacological research indicated that 29 possessed the ability to disrupt Hsp90-Cdc37 complex which was stronger than celastrol.	celastrol	137-146	cell division cycle 37, HSP90 cochaperone	Homo sapiens	99-104
31285857-0	2019	Celastrol attenuates ox-LDL-induced mesangial cell proliferation via suppressing NLRP3 inflammasome activation.	celastrol	0-9	NLR family pyrin domain containing 3	Homo sapiens	81-86
31266528-0	2019	Correction to: Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells.	celastrol	15-24	mitogen-activated protein kinase 8	Homo sapiens	70-73
31266528-0	2019	Correction to: Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells.	celastrol	15-24	AKT serine/threonine kinase 1	Homo sapiens	78-81
31266528-0	2019	Correction to: Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells.	celastrol	15-24	mechanistic target of rapamycin kinase	Homo sapiens	82-86
31285857-8	2019	As expected, celastrol pretreatment strikingly inhibited NLRP3 inflammasome activation and MC proliferation triggered by ox-LDL.	celastrol	13-22	NLR family pyrin domain containing 3	Homo sapiens	57-62
31285857-9	2019	In summary, celastrol potently blocked ox-LDL-induced MC proliferation, possibly by inhibiting NLRP3 inflammasome activation.	celastrol	12-21	NLR family pyrin domain containing 3	Homo sapiens	95-100
30928629-4	2019	In the present study, we found that celastrol inhibited the caspase-like (beta1), trypsin-like (beta2) and chymotrypsin-like (beta5) proteasome activities of purified human 20S proteasomes, with half-maximal inhibitory concentration (IC50) values of 7.1, 6.3, and 9.3 mumol/L, respectively.	celastrol	36-45	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	74-79
30986447-0	2019	Celastrol-type HSP90 modulators allow for potent cardioprotective effects.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	15-20
30986447-3	2019	We have previously shown that celastrol, an HSP90 modulator, achieves cardioprotection through activation of cytoprotective HSP"s and heme-oxygenase-1 (HO-1).	celastrol	30-39	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	44-49
30986447-3	2019	We have previously shown that celastrol, an HSP90 modulator, achieves cardioprotection through activation of cytoprotective HSP"s and heme-oxygenase-1 (HO-1).	celastrol	30-39	heme oxygenase 1	Rattus norvegicus	134-150
30986447-3	2019	We have previously shown that celastrol, an HSP90 modulator, achieves cardioprotection through activation of cytoprotective HSP"s and heme-oxygenase-1 (HO-1).	celastrol	30-39	heme oxygenase 1	Rattus norvegicus	152-156
30986447-8	2019	KEY FINDINGS: From a variety of HSP90 modulator chemotypes, the celastrol family was most efficient in inducing cytoprotective HSP70 and HO-1 protein overexpression and cell survival in vitro.	celastrol	64-73	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	32-37
30986447-8	2019	KEY FINDINGS: From a variety of HSP90 modulator chemotypes, the celastrol family was most efficient in inducing cytoprotective HSP70 and HO-1 protein overexpression and cell survival in vitro.	celastrol	64-73	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	127-132
30986447-8	2019	KEY FINDINGS: From a variety of HSP90 modulator chemotypes, the celastrol family was most efficient in inducing cytoprotective HSP70 and HO-1 protein overexpression and cell survival in vitro.	celastrol	64-73	heme oxygenase 1	Rattus norvegicus	137-141
30986447-11	2019	SIGNIFICANCE: Celastrol backbone is essential for cardioprotection through HSP90 activity modulation.	celastrol	14-23	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	75-80
30928629-4	2019	In the present study, we found that celastrol inhibited the caspase-like (beta1), trypsin-like (beta2) and chymotrypsin-like (beta5) proteasome activities of purified human 20S proteasomes, with half-maximal inhibitory concentration (IC50) values of 7.1, 6.3, and 9.3 mumol/L, respectively.	celastrol	36-45	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	96-101
30928629-4	2019	In the present study, we found that celastrol inhibited the caspase-like (beta1), trypsin-like (beta2) and chymotrypsin-like (beta5) proteasome activities of purified human 20S proteasomes, with half-maximal inhibitory concentration (IC50) values of 7.1, 6.3, and 9.3 mumol/L, respectively.	celastrol	36-45	adaptor related protein complex 5 subunit beta 1	Homo sapiens	126-131
30928629-5	2019	Celastrol also inhibited human MM cellular beta1, beta2, and beta5 proteasome activities, with IC50 values of 2.3, 2.1, and 0.9 mumol/L, respectively.	celastrol	0-9	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	43-48
30928629-5	2019	Celastrol also inhibited human MM cellular beta1, beta2, and beta5 proteasome activities, with IC50 values of 2.3, 2.1, and 0.9 mumol/L, respectively.	celastrol	0-9	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	50-55
30928629-5	2019	Celastrol also inhibited human MM cellular beta1, beta2, and beta5 proteasome activities, with IC50 values of 2.3, 2.1, and 0.9 mumol/L, respectively.	celastrol	0-9	adaptor related protein complex 5 subunit beta 1	Homo sapiens	61-66
30821426-0	2019	The leptin sensitizer celastrol reduces age-associated obesity and modulates behavioral rhythms.	celastrol	22-31	leptin	Homo sapiens	4-10
30821426-4	2019	Here we demonstrate that celastrol, a natural phytochemical that was previously shown to act as a leptin sensitizer, induces weight loss in aged animals, but not in young controls.	celastrol	25-34	leptin	Homo sapiens	98-104
30894367-0	2019	Celastrol Reduces Obesity in MC4R Deficiency and Stimulates Sympathetic Nerve Activity Affecting Metabolic and Cardiovascular Functions.	celastrol	0-9	melanocortin 4 receptor	Mus musculus	29-33
30742994-0	2019	Treatment with celastrol protects against obesity through suppression of galanin-induced fat intake and activation of PGC-1alpha/GLUT4 axis-mediated glucose consumption.	celastrol	15-24	galanin and GMAP prepropeptide	Mus musculus	73-80
30742994-0	2019	Treatment with celastrol protects against obesity through suppression of galanin-induced fat intake and activation of PGC-1alpha/GLUT4 axis-mediated glucose consumption.	celastrol	15-24	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	118-128
30742994-0	2019	Treatment with celastrol protects against obesity through suppression of galanin-induced fat intake and activation of PGC-1alpha/GLUT4 axis-mediated glucose consumption.	celastrol	15-24	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	129-134
30742994-7	2019	More importantly, in addition to these direct anti-obesity activities, celastrol augmented the PGC-1alpha and GLUT4 expression in adipocytes and skeletal muscles to increase glucose uptake through AKT and P38 MAPK activation.	celastrol	71-80	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	95-105
30742994-7	2019	More importantly, in addition to these direct anti-obesity activities, celastrol augmented the PGC-1alpha and GLUT4 expression in adipocytes and skeletal muscles to increase glucose uptake through AKT and P38 MAPK activation.	celastrol	71-80	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	110-115
30742994-7	2019	More importantly, in addition to these direct anti-obesity activities, celastrol augmented the PGC-1alpha and GLUT4 expression in adipocytes and skeletal muscles to increase glucose uptake through AKT and P38 MAPK activation.	celastrol	71-80	thymoma viral proto-oncogene 1	Mus musculus	197-200
30742994-7	2019	More importantly, in addition to these direct anti-obesity activities, celastrol augmented the PGC-1alpha and GLUT4 expression in adipocytes and skeletal muscles to increase glucose uptake through AKT and P38 MAPK activation.	celastrol	71-80	mitogen-activated protein kinase 14	Mus musculus	205-213
30742994-8	2019	Celastrol also inhibited gluconeogenic activity through a CREB/PGC-1alpha pathway.	celastrol	0-9	cAMP responsive element binding protein 1	Mus musculus	58-62
30742994-8	2019	Celastrol also inhibited gluconeogenic activity through a CREB/PGC-1alpha pathway.	celastrol	0-9	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	63-73
30742994-9	2019	In conclusion, the weight-lowering effects of celastrol are driven by decreased galanin-induced food consumption.	celastrol	46-55	galanin and GMAP prepropeptide	Mus musculus	80-87
30894367-2	2019	Celastrol, a compound found in the roots of the Tripterygium wilfordii and known to reduce endoplasmic reticulum (ER) stress, has recently emerged as a promising candidate to treat obesity by improving leptin sensitivity.	celastrol	0-9	leptin	Mus musculus	202-208
30894367-4	2019	Using three different mouse models of obesity-diet-induced obesity (DIO), leptin receptor (LepR)-null, and melanocortin 4 receptor (MC4R)-null mice-in this study, we show that systemic celastrol administration substantially reduces food intake and body weight in MC4R-null comparable to DIO, proving the MC4R-independent antiobesity effect of celastrol.	celastrol	185-194	leptin receptor	Mus musculus	74-89
30894367-4	2019	Using three different mouse models of obesity-diet-induced obesity (DIO), leptin receptor (LepR)-null, and melanocortin 4 receptor (MC4R)-null mice-in this study, we show that systemic celastrol administration substantially reduces food intake and body weight in MC4R-null comparable to DIO, proving the MC4R-independent antiobesity effect of celastrol.	celastrol	185-194	leptin receptor	Mus musculus	91-95
30894367-4	2019	Using three different mouse models of obesity-diet-induced obesity (DIO), leptin receptor (LepR)-null, and melanocortin 4 receptor (MC4R)-null mice-in this study, we show that systemic celastrol administration substantially reduces food intake and body weight in MC4R-null comparable to DIO, proving the MC4R-independent antiobesity effect of celastrol.	celastrol	185-194	melanocortin 4 receptor	Mus musculus	107-130
30894367-4	2019	Using three different mouse models of obesity-diet-induced obesity (DIO), leptin receptor (LepR)-null, and melanocortin 4 receptor (MC4R)-null mice-in this study, we show that systemic celastrol administration substantially reduces food intake and body weight in MC4R-null comparable to DIO, proving the MC4R-independent antiobesity effect of celastrol.	celastrol	185-194	melanocortin 4 receptor	Mus musculus	132-136
30894367-4	2019	Using three different mouse models of obesity-diet-induced obesity (DIO), leptin receptor (LepR)-null, and melanocortin 4 receptor (MC4R)-null mice-in this study, we show that systemic celastrol administration substantially reduces food intake and body weight in MC4R-null comparable to DIO, proving the MC4R-independent antiobesity effect of celastrol.	celastrol	185-194	melanocortin 4 receptor	Mus musculus	263-267
30894367-4	2019	Using three different mouse models of obesity-diet-induced obesity (DIO), leptin receptor (LepR)-null, and melanocortin 4 receptor (MC4R)-null mice-in this study, we show that systemic celastrol administration substantially reduces food intake and body weight in MC4R-null comparable to DIO, proving the MC4R-independent antiobesity effect of celastrol.	celastrol	185-194	melanocortin 4 receptor	Mus musculus	263-267
30618198-0	2019	Celastrol protects human retinal pigment epithelial cells against hydrogen peroxide mediated oxidative stress, autophagy, and apoptosis through sirtuin 3 signal pathway.	celastrol	0-9	sirtuin 3	Homo sapiens	144-153
30798476-0	2019	Transferrin-functionalised microemulsion co-delivery of beta-elemene and celastrol for enhanced anti-lung cancer treatment and reduced systemic toxicity.	celastrol	73-82	transferrin	Mus musculus	0-11
30798476-1	2019	In this study, we developed an intravenously injectable, transferrin-functionalised microemulsion that simultaneously carries beta-elemene and celastrol (called Tf-EC-MEs) for enhanced anti-lung cancer treatment and reduced systemic toxicity.	celastrol	143-152	transferrin	Mus musculus	57-68
30618198-8	2019	Reverse transcription polymerase chain reaction and Western blot showed that celastrol elevated the messenger RNA (mRNA) and protein expression of sirtuin 3 (SIRT3) in H2 O2 -induced ARPE-19 cells.	celastrol	77-86	sirtuin 3	Homo sapiens	147-156
30618198-8	2019	Reverse transcription polymerase chain reaction and Western blot showed that celastrol elevated the messenger RNA (mRNA) and protein expression of sirtuin 3 (SIRT3) in H2 O2 -induced ARPE-19 cells.	celastrol	77-86	sirtuin 3	Homo sapiens	158-163
31152143-9	2019	RESULTS Sorafenib treatment induced the compensatory activation of the AKT pathway and autocrine VEGF in hepatoma cells, which could be reversed by celastrol.	celastrol	148-157	thymoma viral proto-oncogene 1	Mus musculus	71-74
30618198-9	2019	Inhibition of the level of SIRT3 by SIRT3 small interfering RNA (siRNA) reversed the effects of celastrol on oxidative stress, autophagy, and apoptosis in H2 O2 -induced ARPE-19 cells.	celastrol	96-105	sirtuin 3	Homo sapiens	27-32
30618198-9	2019	Inhibition of the level of SIRT3 by SIRT3 small interfering RNA (siRNA) reversed the effects of celastrol on oxidative stress, autophagy, and apoptosis in H2 O2 -induced ARPE-19 cells.	celastrol	96-105	sirtuin 3	Homo sapiens	36-41
30618198-10	2019	In conclusion, these observations suggest that celastrol activates the SIRT3 pathway in RPE cells and protects against H2 O2 -induced oxidative stress and apoptosis.	celastrol	47-56	sirtuin 3	Homo sapiens	71-76
31152143-9	2019	RESULTS Sorafenib treatment induced the compensatory activation of the AKT pathway and autocrine VEGF in hepatoma cells, which could be reversed by celastrol.	celastrol	148-157	vascular endothelial growth factor A	Mus musculus	97-101
31152143-11	2019	CONCLUSIONS Celastrol enhances the antitumor activity of sorafenib in HCC tumor cells by suppressing the AKT pathway and VEGF autocrine system.	celastrol	12-21	thymoma viral proto-oncogene 1	Mus musculus	105-108
31152143-11	2019	CONCLUSIONS Celastrol enhances the antitumor activity of sorafenib in HCC tumor cells by suppressing the AKT pathway and VEGF autocrine system.	celastrol	12-21	vascular endothelial growth factor A	Mus musculus	121-125
31053160-0	2019	Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells.	celastrol	0-9	mitogen-activated protein kinase 8	Homo sapiens	55-58
30989726-0	2019	Celastrol inhibits growth and metastasis of human gastric cancer cell MKN45 by down-regulating microRNA-21.	celastrol	0-9	microRNA 21	Homo sapiens	95-106
30989726-5	2019	Under celastrol treatment, overexpression of microRNA-21 (miR-21) increased cell viability, migration, and invasion and inhibited cell apoptosis compared with negative control (p &lt; .05, p &lt; .01, or p &lt; .001).	celastrol	6-15	microRNA 21	Homo sapiens	45-56
30989726-5	2019	Under celastrol treatment, overexpression of microRNA-21 (miR-21) increased cell viability, migration, and invasion and inhibited cell apoptosis compared with negative control (p &lt; .05, p &lt; .01, or p &lt; .001).	celastrol	6-15	microRNA 21	Homo sapiens	58-64
30989726-6	2019	In addition, the phosphorylation of PTEN was significantly up-regulated, whereas PI3K, AKT, p65, and IkappaBalpha phosphorylation was statistically decreased by celastrol (p &lt; .05 or p &lt; .01) and then further reversed by miR-21 overexpression (p &lt; .05 or p &lt; .01).	celastrol	161-170	phosphatase and tensin homolog	Homo sapiens	36-40
30989726-6	2019	In addition, the phosphorylation of PTEN was significantly up-regulated, whereas PI3K, AKT, p65, and IkappaBalpha phosphorylation was statistically decreased by celastrol (p &lt; .05 or p &lt; .01) and then further reversed by miR-21 overexpression (p &lt; .05 or p &lt; .01).	celastrol	161-170	AKT serine/threonine kinase 1	Homo sapiens	87-90
30989726-6	2019	In addition, the phosphorylation of PTEN was significantly up-regulated, whereas PI3K, AKT, p65, and IkappaBalpha phosphorylation was statistically decreased by celastrol (p &lt; .05 or p &lt; .01) and then further reversed by miR-21 overexpression (p &lt; .05 or p &lt; .01).	celastrol	161-170	RELA proto-oncogene, NF-kB subunit	Homo sapiens	92-95
30989726-6	2019	In addition, the phosphorylation of PTEN was significantly up-regulated, whereas PI3K, AKT, p65, and IkappaBalpha phosphorylation was statistically decreased by celastrol (p &lt; .05 or p &lt; .01) and then further reversed by miR-21 overexpression (p &lt; .05 or p &lt; .01).	celastrol	161-170	NFKB inhibitor alpha	Homo sapiens	101-113
30989726-6	2019	In addition, the phosphorylation of PTEN was significantly up-regulated, whereas PI3K, AKT, p65, and IkappaBalpha phosphorylation was statistically decreased by celastrol (p &lt; .05 or p &lt; .01) and then further reversed by miR-21 overexpression (p &lt; .05 or p &lt; .01).	celastrol	161-170	microRNA 21	Homo sapiens	227-233
30989726-8	2019	In conclusion, celastrol inhibits proliferation, migration, and invasion and inactivates PTEN/PI3K/AKT and nuclear factor kappaB signaling pathways in MKN45 cells by down-regulating miR-21.	celastrol	15-24	phosphatase and tensin homolog	Homo sapiens	89-93
31053160-0	2019	Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	63-66
31053160-0	2019	Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	67-71
31053160-8	2019	Celastrol increased the formation of autophagosomes, accumulation of LC3B and the expression of p62 protein.	celastrol	0-9	microtubule associated protein 1 light chain 3 beta	Homo sapiens	69-73
31053160-8	2019	Celastrol increased the formation of autophagosomes, accumulation of LC3B and the expression of p62 protein.	celastrol	0-9	nucleoporin 62	Homo sapiens	96-99
31053160-11	2019	Furthermore, celastrol induced JNK activation and ROS production and inhibited the activities of Akt and mTOR kinases.	celastrol	13-22	mitogen-activated protein kinase 8	Homo sapiens	31-34
31053160-11	2019	Furthermore, celastrol induced JNK activation and ROS production and inhibited the activities of Akt and mTOR kinases.	celastrol	13-22	AKT serine/threonine kinase 1	Homo sapiens	97-100
31053160-11	2019	Furthermore, celastrol induced JNK activation and ROS production and inhibited the activities of Akt and mTOR kinases.	celastrol	13-22	mechanistic target of rapamycin kinase	Homo sapiens	105-109
31053160-12	2019	JNK and ROS inhibitors significantly attenuated celastrol-trigged apoptosis and autophagy, while Akt and mTOR inhibitors had opposite effects.	celastrol	48-57	mitogen-activated protein kinase 8	Homo sapiens	0-3
31053160-13	2019	CONCLUSIONS: In conclusion, our study revealed that celastrol caused G2/M phase arrest and trigged apoptosis and autophagy by activating ROS/JNK signaling and blocking the Akt/mTOR signaling pathway.	celastrol	52-61	mitogen-activated protein kinase 8	Homo sapiens	141-144
31053160-13	2019	CONCLUSIONS: In conclusion, our study revealed that celastrol caused G2/M phase arrest and trigged apoptosis and autophagy by activating ROS/JNK signaling and blocking the Akt/mTOR signaling pathway.	celastrol	52-61	AKT serine/threonine kinase 1	Homo sapiens	172-175
31053160-13	2019	CONCLUSIONS: In conclusion, our study revealed that celastrol caused G2/M phase arrest and trigged apoptosis and autophagy by activating ROS/JNK signaling and blocking the Akt/mTOR signaling pathway.	celastrol	52-61	mechanistic target of rapamycin kinase	Homo sapiens	176-180
30989726-8	2019	In conclusion, celastrol inhibits proliferation, migration, and invasion and inactivates PTEN/PI3K/AKT and nuclear factor kappaB signaling pathways in MKN45 cells by down-regulating miR-21.	celastrol	15-24	AKT serine/threonine kinase 1	Homo sapiens	99-102
30989726-8	2019	In conclusion, celastrol inhibits proliferation, migration, and invasion and inactivates PTEN/PI3K/AKT and nuclear factor kappaB signaling pathways in MKN45 cells by down-regulating miR-21.	celastrol	15-24	microRNA 21	Homo sapiens	182-188
30768745-8	2019	Our results showed that celastrol could not only reduce contents of creatinine and urea nitrogen in blood but also reduce excretion of urinary protein in diabetic rats, improve renal pathological injury, and down-regulate the expression of p38MAPK and NF-kappaB p65.	celastrol	24-33	synaptotagmin 1	Rattus norvegicus	262-265
31022663-0	2019	Celastrol, a plant-derived triterpene, induces cisplatin-resistance nasopharyngeal carcinoma cancer cell apoptosis though ERK1/2 and p38 MAPK signaling pathway.	celastrol	0-9	mitogen-activated protein kinase 3	Homo sapiens	122-128
31022663-0	2019	Celastrol, a plant-derived triterpene, induces cisplatin-resistance nasopharyngeal carcinoma cancer cell apoptosis though ERK1/2 and p38 MAPK signaling pathway.	celastrol	0-9	mitogen-activated protein kinase 1	Homo sapiens	133-136
31022663-0	2019	Celastrol, a plant-derived triterpene, induces cisplatin-resistance nasopharyngeal carcinoma cancer cell apoptosis though ERK1/2 and p38 MAPK signaling pathway.	celastrol	0-9	mitogen-activated protein kinase 3	Homo sapiens	137-141
31022663-6	2019	With further analysis, we observed that celastrol-induced activation of caspases was accompanied by increased phosphorylation of MAPK pathway proteins, p38, ERK1/2.	celastrol	40-49	mitogen-activated protein kinase 3	Homo sapiens	129-133
31022663-6	2019	With further analysis, we observed that celastrol-induced activation of caspases was accompanied by increased phosphorylation of MAPK pathway proteins, p38, ERK1/2.	celastrol	40-49	mitogen-activated protein kinase 1	Homo sapiens	152-155
31022663-6	2019	With further analysis, we observed that celastrol-induced activation of caspases was accompanied by increased phosphorylation of MAPK pathway proteins, p38, ERK1/2.	celastrol	40-49	mitogen-activated protein kinase 3	Homo sapiens	157-163
30913029-0	2019	Tripterine inhibits proliferation, migration and invasion of breast cancer MDA-MB-231 cells by up-regulating microRNA-15a.	celastrol	0-10	microRNA 15a	Homo sapiens	109-121
30913029-8	2019	Moreover, tripterine up-regulated the expression of miR-15a in a concentration-dependent manner and miR-15a participated in the effects of tripterine on MDA-MB-231 cell proliferation, migration, invasion and apoptosis.	celastrol	10-20	microRNA 15a	Homo sapiens	52-59
30913029-8	2019	Moreover, tripterine up-regulated the expression of miR-15a in a concentration-dependent manner and miR-15a participated in the effects of tripterine on MDA-MB-231 cell proliferation, migration, invasion and apoptosis.	celastrol	139-149	microRNA 15a	Homo sapiens	100-107
30913029-9	2019	In addition, tripterine inactivated PI3K/AKT and JNK pathways in MDA-MB-231 cells by up-regulating miR-15a.	celastrol	13-23	AKT serine/threonine kinase 1	Homo sapiens	41-44
30913029-9	2019	In addition, tripterine inactivated PI3K/AKT and JNK pathways in MDA-MB-231 cells by up-regulating miR-15a.	celastrol	13-23	mitogen-activated protein kinase 8	Homo sapiens	49-52
30913029-9	2019	In addition, tripterine inactivated PI3K/AKT and JNK pathways in MDA-MB-231 cells by up-regulating miR-15a.	celastrol	13-23	microRNA 15a	Homo sapiens	99-106
30913029-10	2019	In conclusion, tripterine inhibited proliferation, migration and invasion of breast cancer MDA-MB-231 cells by up-regulating miR-15a and inactivating PI3K/AKT and JNK pathways.	celastrol	15-25	microRNA 15a	Homo sapiens	125-132
30913029-10	2019	In conclusion, tripterine inhibited proliferation, migration and invasion of breast cancer MDA-MB-231 cells by up-regulating miR-15a and inactivating PI3K/AKT and JNK pathways.	celastrol	15-25	AKT serine/threonine kinase 1	Homo sapiens	155-158
30913029-10	2019	In conclusion, tripterine inhibited proliferation, migration and invasion of breast cancer MDA-MB-231 cells by up-regulating miR-15a and inactivating PI3K/AKT and JNK pathways.	celastrol	15-25	mitogen-activated protein kinase 8	Homo sapiens	163-166
30820608-0	2019	Celastrol suppresses experimental autoimmune encephalomyelitis via MAPK/SGK1-regulated mediators of autoimmune pathology.	celastrol	0-9	mitogen-activated protein kinase 1	Mus musculus	67-71
30820608-0	2019	Celastrol suppresses experimental autoimmune encephalomyelitis via MAPK/SGK1-regulated mediators of autoimmune pathology.	celastrol	0-9	serum/glucocorticoid regulated kinase 1	Mus musculus	72-76
30820608-3	2019	We describe here a gene expression- and bioinformatics-based study showing that celastrol, a natural triterpenoid, acting via MAPK pathway regulates the downstream genes encoding serum/glucocorticoid regulated kinase 1 (SGK1), which plays a vital role in Th17/Treg differentiation, and brain-derived neurotrophic factor (BDNF), which is a neurotrophic factor, thereby offering protection against experimental autoimmune encephalomyelitis (EAE) in mice.	celastrol	80-89	mitogen-activated protein kinase 1	Mus musculus	126-130
30820608-3	2019	We describe here a gene expression- and bioinformatics-based study showing that celastrol, a natural triterpenoid, acting via MAPK pathway regulates the downstream genes encoding serum/glucocorticoid regulated kinase 1 (SGK1), which plays a vital role in Th17/Treg differentiation, and brain-derived neurotrophic factor (BDNF), which is a neurotrophic factor, thereby offering protection against experimental autoimmune encephalomyelitis (EAE) in mice.	celastrol	80-89	serum/glucocorticoid regulated kinase 1	Mus musculus	179-218
30820608-3	2019	We describe here a gene expression- and bioinformatics-based study showing that celastrol, a natural triterpenoid, acting via MAPK pathway regulates the downstream genes encoding serum/glucocorticoid regulated kinase 1 (SGK1), which plays a vital role in Th17/Treg differentiation, and brain-derived neurotrophic factor (BDNF), which is a neurotrophic factor, thereby offering protection against experimental autoimmune encephalomyelitis (EAE) in mice.	celastrol	80-89	serum/glucocorticoid regulated kinase 1	Mus musculus	220-224
30820608-3	2019	We describe here a gene expression- and bioinformatics-based study showing that celastrol, a natural triterpenoid, acting via MAPK pathway regulates the downstream genes encoding serum/glucocorticoid regulated kinase 1 (SGK1), which plays a vital role in Th17/Treg differentiation, and brain-derived neurotrophic factor (BDNF), which is a neurotrophic factor, thereby offering protection against experimental autoimmune encephalomyelitis (EAE) in mice.	celastrol	80-89	brain derived neurotrophic factor	Mus musculus	286-319
30820608-3	2019	We describe here a gene expression- and bioinformatics-based study showing that celastrol, a natural triterpenoid, acting via MAPK pathway regulates the downstream genes encoding serum/glucocorticoid regulated kinase 1 (SGK1), which plays a vital role in Th17/Treg differentiation, and brain-derived neurotrophic factor (BDNF), which is a neurotrophic factor, thereby offering protection against experimental autoimmune encephalomyelitis (EAE) in mice.	celastrol	80-89	brain derived neurotrophic factor	Mus musculus	321-325
30820608-5	2019	RESULTS: Interestingly, celastrol reversed the expression of many MOG-induced genes involved in inflammation and immune pathology.	celastrol	24-33	myelin oligodendrocyte glycoprotein	Mus musculus	66-69
30820608-6	2019	The MAPK pathway involving p38MAPK and ERK was identified as one of the mediators of celastrol action.	celastrol	85-94	mitogen-activated protein kinase 1	Mus musculus	4-8
30820608-6	2019	The MAPK pathway involving p38MAPK and ERK was identified as one of the mediators of celastrol action.	celastrol	85-94	mitogen-activated protein kinase 14	Mus musculus	27-34
30820608-6	2019	The MAPK pathway involving p38MAPK and ERK was identified as one of the mediators of celastrol action.	celastrol	85-94	mitogen-activated protein kinase 1	Mus musculus	39-42
30833749-0	2019	IL1R1 is required for celastrol"s leptin-sensitization and antiobesity effects.	celastrol	22-31	interleukin 1 receptor, type I	Mus musculus	0-5
30833749-1	2019	Celastrol, a pentacyclic triterpene, is the most potent antiobesity agent that has been reported thus far1.	celastrol	0-9	fatty acyl CoA reductase 1	Mus musculus	102-106
30833749-3	2019	In this study, we identified interleukin-1 receptor 1 (IL1R1) as a mediator of celastrol"s action by using temporally resolved analysis of the hypothalamic transcriptome in celastrol-treated DIO, lean, and db/db mice.	celastrol	79-88	interleukin 1 receptor, type I	Mus musculus	29-53
30833749-3	2019	In this study, we identified interleukin-1 receptor 1 (IL1R1) as a mediator of celastrol"s action by using temporally resolved analysis of the hypothalamic transcriptome in celastrol-treated DIO, lean, and db/db mice.	celastrol	79-88	interleukin 1 receptor, type I	Mus musculus	55-60
30833749-3	2019	In this study, we identified interleukin-1 receptor 1 (IL1R1) as a mediator of celastrol"s action by using temporally resolved analysis of the hypothalamic transcriptome in celastrol-treated DIO, lean, and db/db mice.	celastrol	173-182	interleukin 1 receptor, type I	Mus musculus	29-53
30833749-3	2019	In this study, we identified interleukin-1 receptor 1 (IL1R1) as a mediator of celastrol"s action by using temporally resolved analysis of the hypothalamic transcriptome in celastrol-treated DIO, lean, and db/db mice.	celastrol	173-182	interleukin 1 receptor, type I	Mus musculus	55-60
30833749-4	2019	We demonstrate that IL1R1-deficient mice are completely resistant to the effects of celastrol in leptin sensitization and treatment of obesity, diabetes, and nonalcoholic steatohepatitis.	celastrol	84-93	interleukin 1 receptor, type I	Mus musculus	20-25
30833749-5	2019	Thus, we conclude that IL1R1 is a gatekeeper for celastrol"s metabolic actions.	celastrol	49-58	interleukin 1 receptor, type I	Mus musculus	23-28
30798158-0	2019	Celastrol ameliorates Aspergillus fumigatus keratitis via inhibiting LOX-1.	celastrol	0-9	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	69-74
30798158-7	2019	RESULTS: C57BL/6 mice treated with CLT from 1 day post infection showed decreased disease, IL-1beta, TNF-alpha, IL-10, TGF-beta, MIP-2 and LOX-1 levels.	celastrol	35-38	interleukin 1 beta	Mus musculus	91-99
30798158-7	2019	RESULTS: C57BL/6 mice treated with CLT from 1 day post infection showed decreased disease, IL-1beta, TNF-alpha, IL-10, TGF-beta, MIP-2 and LOX-1 levels.	celastrol	35-38	tumor necrosis factor	Mus musculus	101-110
30798158-7	2019	RESULTS: C57BL/6 mice treated with CLT from 1 day post infection showed decreased disease, IL-1beta, TNF-alpha, IL-10, TGF-beta, MIP-2 and LOX-1 levels.	celastrol	35-38	interleukin 10	Mus musculus	112-117
30798158-7	2019	RESULTS: C57BL/6 mice treated with CLT from 1 day post infection showed decreased disease, IL-1beta, TNF-alpha, IL-10, TGF-beta, MIP-2 and LOX-1 levels.	celastrol	35-38	transforming growth factor, beta 1	Mus musculus	119-127
30798158-7	2019	RESULTS: C57BL/6 mice treated with CLT from 1 day post infection showed decreased disease, IL-1beta, TNF-alpha, IL-10, TGF-beta, MIP-2 and LOX-1 levels.	celastrol	35-38	chemokine (C-X-C motif) ligand 2	Mus musculus	129-134
30798158-7	2019	RESULTS: C57BL/6 mice treated with CLT from 1 day post infection showed decreased disease, IL-1beta, TNF-alpha, IL-10, TGF-beta, MIP-2 and LOX-1 levels.	celastrol	35-38	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	139-144
30798158-10	2019	CONCLUSION: These data provide evidences that CLT ameliorates A. fumigatus keratitis of C57BL/6 mice via inhibiting LOX-1.	celastrol	46-49	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	116-121
30287053-0	2019	Celastrol Reverses Palmitic Acid-Induced Insulin Resistance in HepG2 Cells via Restoring the miR-223 and GLUT4 Pathway.	celastrol	0-9	insulin	Homo sapiens	41-48
30287053-0	2019	Celastrol Reverses Palmitic Acid-Induced Insulin Resistance in HepG2 Cells via Restoring the miR-223 and GLUT4 Pathway.	celastrol	0-9	microRNA 223	Homo sapiens	93-100
30287053-0	2019	Celastrol Reverses Palmitic Acid-Induced Insulin Resistance in HepG2 Cells via Restoring the miR-223 and GLUT4 Pathway.	celastrol	0-9	solute carrier family 2 member 4	Homo sapiens	105-110
30287053-1	2019	OBJECTIVES: The natural triterpenoid compound celastrol ameliorates insulin resistance (IR) in animal models, but the underlying molecular mechanism is unclear.	celastrol	46-55	insulin	Homo sapiens	68-75
30287053-6	2019	The PA-induced GLUT4 and IRS1 downregulation and Ser307 phosphorylation on IRS1 was reversed by subsequent treatment with 600 nM celastrol for 6 h. We next investigated which IR-related miRNAs were possible upstream regulators of celastrol-mediated reversal of PA-induced HepG2 IR.	celastrol	129-138	solute carrier family 2 member 4	Homo sapiens	15-20
30287053-6	2019	The PA-induced GLUT4 and IRS1 downregulation and Ser307 phosphorylation on IRS1 was reversed by subsequent treatment with 600 nM celastrol for 6 h. We next investigated which IR-related miRNAs were possible upstream regulators of celastrol-mediated reversal of PA-induced HepG2 IR.	celastrol	129-138	insulin receptor substrate 1	Homo sapiens	75-79
30287053-7	2019	Two miRNAs, miR-150 and -223, were significantly downregulated by PA and were re-raised by subsequent celastrol treatment; and miR-223 was upstream of miR-150.	celastrol	102-111	microRNA 150	Homo sapiens	12-28
30287053-7	2019	Two miRNAs, miR-150 and -223, were significantly downregulated by PA and were re-raised by subsequent celastrol treatment; and miR-223 was upstream of miR-150.	celastrol	102-111	microRNA 150	Homo sapiens	12-19
30287053-8	2019	Moreover, knocking down miR-223 abolished celastrol"s anti-IR effects in the PA-induced model.	celastrol	42-51	microRNA 223	Homo sapiens	24-31
30287053-9	2019	CONCLUSIONS: Collectively, our results demonstrated that celastrol reverses PA-induced IR-related alterations, in part via miR-223 in HepG2 cells.	celastrol	57-66	microRNA 223	Homo sapiens	123-130
30816529-0	2019	Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non-small cell lung cancer cells.	celastrol	25-34	AXL receptor tyrosine kinase	Homo sapiens	0-3
30816529-5	2019	The inhibitory effect of celastrol on Axl protein expression level, cell viability and clonogenicity were identified in parental and gefitinib-resistant PC-9 cells.	celastrol	25-34	AXL receptor tyrosine kinase	Homo sapiens	38-41
30816529-5	2019	The inhibitory effect of celastrol on Axl protein expression level, cell viability and clonogenicity were identified in parental and gefitinib-resistant PC-9 cells.	celastrol	25-34	proprotein convertase subtilisin/kexin type 9	Homo sapiens	153-157
30816529-6	2019	In addition, treatment of PC-9/GR cells with celastrol and gefitinib in combination was demonstrated to synergistically suppress Axl protein expression level, cell proliferation and migration.	celastrol	45-54	proprotein convertase subtilisin/kexin type 9	Homo sapiens	26-30
30816529-6	2019	In addition, treatment of PC-9/GR cells with celastrol and gefitinib in combination was demonstrated to synergistically suppress Axl protein expression level, cell proliferation and migration.	celastrol	45-54	AXL receptor tyrosine kinase	Homo sapiens	129-132
30816529-8	2019	Furthermore, celastrol targets Axl to exert its anticancer effects in order to increase the susceptibility of PC-9/GR cells to gefitinib and overcome chemoresistance.	celastrol	13-22	AXL receptor tyrosine kinase	Homo sapiens	31-34
30816529-8	2019	Furthermore, celastrol targets Axl to exert its anticancer effects in order to increase the susceptibility of PC-9/GR cells to gefitinib and overcome chemoresistance.	celastrol	13-22	proprotein convertase subtilisin/kexin type 9	Homo sapiens	110-114
30396268-9	2019	Celastrol treatment had no impact on kindling progression but reduced postkindling seizure thresholds and enhanced microglia activation in CA1 and CA3.	celastrol	0-9	carbonic anhydrase 1	Mus musculus	139-142
30396268-9	2019	Celastrol treatment had no impact on kindling progression but reduced postkindling seizure thresholds and enhanced microglia activation in CA1 and CA3.	celastrol	0-9	carbonic anhydrase 3	Mus musculus	147-150
30773944-6	2019	In this study, we investigated the effects and mechanism of celastrol on nitric oxide synthase (NOS) and the angiogenesis pathway in colorectal cancer.	celastrol	60-69	nitric oxide synthase 2	Homo sapiens	73-94
30635274-1	2019	Celastrol-Induced Weight Loss Is Driven by Hypophagia and Independent From UCP1.	celastrol	0-9	uncoupling protein 1	Homo sapiens	75-79
30773944-9	2019	Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway.	celastrol	15-24	thymidine phosphorylase	Homo sapiens	148-152
30773944-9	2019	Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway.	celastrol	15-24	cadherin 5	Homo sapiens	154-158
30773944-9	2019	Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway.	celastrol	15-24	thrombospondin 2	Homo sapiens	160-165
30773944-9	2019	Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway.	celastrol	15-24	leptin	Homo sapiens	167-170
30773944-9	2019	Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway.	celastrol	15-24	matrix metallopeptidase 9	Homo sapiens	172-176
30773944-9	2019	Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway.	celastrol	15-24	tumor necrosis factor	Homo sapiens	182-185
30773944-9	2019	Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway.	celastrol	15-24	interleukin 1 beta	Homo sapiens	201-206
30773944-9	2019	Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway.	celastrol	15-24	matrix metallopeptidase 9	Homo sapiens	208-213
30773944-9	2019	Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway.	celastrol	15-24	serpin family E member 1	Homo sapiens	221-230
30773944-9	2019	Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway.	celastrol	15-24	TIMP metallopeptidase inhibitor 4	Homo sapiens	236-242
30596540-7	2019	RESULTS: Celastrol significantly inhibited LPS-induced expression of protein and mRNA expression levels encoding the proinflammatory cytokines, IL-6, IL-8, and MCP-1, in both HRPE and ARPE-19 cells.	celastrol	9-18	interleukin 6	Mus musculus	144-148
30596540-7	2019	RESULTS: Celastrol significantly inhibited LPS-induced expression of protein and mRNA expression levels encoding the proinflammatory cytokines, IL-6, IL-8, and MCP-1, in both HRPE and ARPE-19 cells.	celastrol	9-18	chemokine (C-X-C motif) ligand 15	Mus musculus	150-154
30596540-7	2019	RESULTS: Celastrol significantly inhibited LPS-induced expression of protein and mRNA expression levels encoding the proinflammatory cytokines, IL-6, IL-8, and MCP-1, in both HRPE and ARPE-19 cells.	celastrol	9-18	mast cell protease 1	Mus musculus	160-165
30596540-8	2019	Cell viability and apoptosis assays revealed that celastrol had no apparent cytotoxic effect and it inhibited apoptosis of RPE cells at concentrations of less than 1 muM.	celastrol	50-59	latexin	Homo sapiens	166-169
30596540-9	2019	Mechanistically, RPE cells that were pretreated with celastrol exhibited a substantial decrease in phosphorylation of the NF-kappaB pathway regulators, IKKalpha/beta and IkappaBalpha, and subsequently inactivated P65, suggesting that celastrol ameliorates LPS-induced inflammation by suppressing the NF-kappaB signaling pathway.	celastrol	53-62	RELA proto-oncogene, NF-kB subunit	Homo sapiens	213-216
30706713-9	2019	The mRNAs encoded by hepatic genes associated with lipid synthesis and catabolism, including Lpcat1, Pld1, Smpd3, and Sptc2, were altered in tyloxapol-induced hyperlipidemia, and significantly recovered by celastrol treatment.	celastrol	206-215	lysophosphatidylcholine acyltransferase 1	Mus musculus	93-99
30617157-7	2019	These observations demonstrated a novel role for celastrol in protecting against cholestatic liver injury through modulation of the SIRT1 and FXR.	celastrol	49-58	sirtuin 1	Mus musculus	132-137
30706713-9	2019	The mRNAs encoded by hepatic genes associated with lipid synthesis and catabolism, including Lpcat1, Pld1, Smpd3, and Sptc2, were altered in tyloxapol-induced hyperlipidemia, and significantly recovered by celastrol treatment.	celastrol	206-215	phospholipase D1	Mus musculus	101-105
30706713-9	2019	The mRNAs encoded by hepatic genes associated with lipid synthesis and catabolism, including Lpcat1, Pld1, Smpd3, and Sptc2, were altered in tyloxapol-induced hyperlipidemia, and significantly recovered by celastrol treatment.	celastrol	206-215	sphingomyelin phosphodiesterase 3, neutral	Mus musculus	107-112
30706713-10	2019	The effect of celastrol on lipid metabolism was significantly reduced in Fxr-null mice, resulting in decreased Cers6 and Acer2 mRNAs compared to wild-type mice.	celastrol	14-23	nuclear receptor subfamily 1, group H, member 4	Mus musculus	73-76
30706713-10	2019	The effect of celastrol on lipid metabolism was significantly reduced in Fxr-null mice, resulting in decreased Cers6 and Acer2 mRNAs compared to wild-type mice.	celastrol	14-23	ceramide synthase 6	Mus musculus	111-116
30706713-10	2019	The effect of celastrol on lipid metabolism was significantly reduced in Fxr-null mice, resulting in decreased Cers6 and Acer2 mRNAs compared to wild-type mice.	celastrol	14-23	alkaline ceramidase 2	Mus musculus	121-126
30706713-11	2019	These results establish that FXR was responsible in part for the effects of celastrol in controlling lipid metabolism and contributing to the recovery of aberrant lipid metabolism in obesity-related metabolic disorders.	celastrol	76-85	nuclear receptor subfamily 1, group H, member 4	Mus musculus	29-32
30617157-7	2019	These observations demonstrated a novel role for celastrol in protecting against cholestatic liver injury through modulation of the SIRT1 and FXR.	celastrol	49-58	nuclear receptor subfamily 1, group H, member 4	Mus musculus	142-145
30617157-0	2019	Celastrol Protects From Cholestatic Liver Injury Through Modulation of SIRT1-FXR Signaling.	celastrol	0-9	sirtuin 1	Mus musculus	71-76
30617157-0	2019	Celastrol Protects From Cholestatic Liver Injury Through Modulation of SIRT1-FXR Signaling.	celastrol	0-9	nuclear receptor subfamily 1, group H, member 4	Mus musculus	77-80
30617157-4	2019	Celastrol was found to activate sirtuin 1 (SIRT1), increase farnesoid X receptor (FXR) signaling and inhibit nuclear factor-kappa B and P53 signaling.	celastrol	0-9	sirtuin 1	Mus musculus	32-41
30617157-4	2019	Celastrol was found to activate sirtuin 1 (SIRT1), increase farnesoid X receptor (FXR) signaling and inhibit nuclear factor-kappa B and P53 signaling.	celastrol	0-9	sirtuin 1	Mus musculus	43-48
30617157-4	2019	Celastrol was found to activate sirtuin 1 (SIRT1), increase farnesoid X receptor (FXR) signaling and inhibit nuclear factor-kappa B and P53 signaling.	celastrol	0-9	nuclear receptor subfamily 1, group H, member 4	Mus musculus	82-85
30867764-9	2019	In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl-associated X protein, cytochrome c, caspase-3 and C/EBP homologous protein, and downregulated the expression of Bcl-2, poly(ADP-ribose) polymerase, 78 kDa glucose-regulated protein and caspase-9, whereas the expression of caspase-8 remained unchanged.	celastrol	34-43	cytochrome c, somatic	Homo sapiens	110-122
30617157-4	2019	Celastrol was found to activate sirtuin 1 (SIRT1), increase farnesoid X receptor (FXR) signaling and inhibit nuclear factor-kappa B and P53 signaling.	celastrol	0-9	transformation related protein 53, pseudogene	Mus musculus	136-139
30617157-5	2019	The protective role of celastrol in cholestatic liver injury was diminished in mice on co-administration of SIRT1 inhibitors.	celastrol	23-32	sirtuin 1	Mus musculus	108-113
30617157-6	2019	Further, the effects of celastrol on cholestatic liver injury were dramatically decreased in Fxr-null mice, suggesting that the SIRT1-FXR signaling pathway mediates the protective effects of celastrol.	celastrol	24-33	nuclear receptor subfamily 1, group H, member 4	Mus musculus	93-96
30617157-6	2019	Further, the effects of celastrol on cholestatic liver injury were dramatically decreased in Fxr-null mice, suggesting that the SIRT1-FXR signaling pathway mediates the protective effects of celastrol.	celastrol	191-200	nuclear receptor subfamily 1, group H, member 4	Mus musculus	93-96
30617157-6	2019	Further, the effects of celastrol on cholestatic liver injury were dramatically decreased in Fxr-null mice, suggesting that the SIRT1-FXR signaling pathway mediates the protective effects of celastrol.	celastrol	191-200	sirtuin 1	Mus musculus	128-133
30617157-6	2019	Further, the effects of celastrol on cholestatic liver injury were dramatically decreased in Fxr-null mice, suggesting that the SIRT1-FXR signaling pathway mediates the protective effects of celastrol.	celastrol	191-200	nuclear receptor subfamily 1, group H, member 4	Mus musculus	134-137
30867764-9	2019	In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl-associated X protein, cytochrome c, caspase-3 and C/EBP homologous protein, and downregulated the expression of Bcl-2, poly(ADP-ribose) polymerase, 78 kDa glucose-regulated protein and caspase-9, whereas the expression of caspase-8 remained unchanged.	celastrol	34-43	caspase 3	Homo sapiens	124-133
30867764-9	2019	In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl-associated X protein, cytochrome c, caspase-3 and C/EBP homologous protein, and downregulated the expression of Bcl-2, poly(ADP-ribose) polymerase, 78 kDa glucose-regulated protein and caspase-9, whereas the expression of caspase-8 remained unchanged.	celastrol	34-43	CCAAT enhancer binding protein alpha	Homo sapiens	138-143
30867764-9	2019	In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl-associated X protein, cytochrome c, caspase-3 and C/EBP homologous protein, and downregulated the expression of Bcl-2, poly(ADP-ribose) polymerase, 78 kDa glucose-regulated protein and caspase-9, whereas the expression of caspase-8 remained unchanged.	celastrol	34-43	BCL2 apoptosis regulator	Homo sapiens	200-205
30867764-9	2019	In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl-associated X protein, cytochrome c, caspase-3 and C/EBP homologous protein, and downregulated the expression of Bcl-2, poly(ADP-ribose) polymerase, 78 kDa glucose-regulated protein and caspase-9, whereas the expression of caspase-8 remained unchanged.	celastrol	34-43	caspase 9	Homo sapiens	273-282
30867764-9	2019	In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl-associated X protein, cytochrome c, caspase-3 and C/EBP homologous protein, and downregulated the expression of Bcl-2, poly(ADP-ribose) polymerase, 78 kDa glucose-regulated protein and caspase-9, whereas the expression of caspase-8 remained unchanged.	celastrol	34-43	caspase 8	Homo sapiens	310-319
30666129-0	2019	Celastrol inhibits colorectal cancer through TGF-beta1/Smad signaling.	celastrol	0-9	transforming growth factor beta 1	Homo sapiens	45-54
30668359-0	2019	Celastrol induces vincristine multidrug resistance oral cancer cell apoptosis by targeting JNK1/2 signaling pathway.	celastrol	0-9	mitogen-activated protein kinase 8	Homo sapiens	91-95
30668359-10	2019	The present study demonstrated that celastrol triggered apoptotic cell death by inducing cell cycle arrest at the G2/M phase via the intrinsic and extrinsic pathways (increased cleaved caspase-3, caspase-8, caspase-9, and PARP).	celastrol	36-45	caspase 3	Homo sapiens	185-194
30668359-10	2019	The present study demonstrated that celastrol triggered apoptotic cell death by inducing cell cycle arrest at the G2/M phase via the intrinsic and extrinsic pathways (increased cleaved caspase-3, caspase-8, caspase-9, and PARP).	celastrol	36-45	caspase 8	Homo sapiens	196-205
30668359-10	2019	The present study demonstrated that celastrol triggered apoptotic cell death by inducing cell cycle arrest at the G2/M phase via the intrinsic and extrinsic pathways (increased cleaved caspase-3, caspase-8, caspase-9, and PARP).	celastrol	36-45	caspase 9	Homo sapiens	207-216
30668359-10	2019	The present study demonstrated that celastrol triggered apoptotic cell death by inducing cell cycle arrest at the G2/M phase via the intrinsic and extrinsic pathways (increased cleaved caspase-3, caspase-8, caspase-9, and PARP).	celastrol	36-45	collagen type XI alpha 2 chain	Homo sapiens	222-226
30668359-12	2019	Celastrol mediated cell apoptosis through the downregulation of the expression of Bcl-2, not Bcl-xL.	celastrol	0-9	BCL2 apoptosis regulator	Homo sapiens	82-87
30668359-13	2019	Moreover, JNK1/2 signaling was the main pathway of celastrol-induced apoptosis.	celastrol	51-60	mitogen-activated protein kinase 8	Homo sapiens	10-14
31933862-13	2019	Furthermore, after CEL treatment, TUNEL-positive cells, the protein level of Bax and caspase-3 activity reduced, and the level of Bcl-xl in protein increased.	celastrol	19-22	BCL2 associated X, apoptosis regulator	Rattus norvegicus	77-80
31933862-13	2019	Furthermore, after CEL treatment, TUNEL-positive cells, the protein level of Bax and caspase-3 activity reduced, and the level of Bcl-xl in protein increased.	celastrol	19-22	caspase 3	Rattus norvegicus	85-94
31933862-13	2019	Furthermore, after CEL treatment, TUNEL-positive cells, the protein level of Bax and caspase-3 activity reduced, and the level of Bcl-xl in protein increased.	celastrol	19-22	Bcl2-like 1	Rattus norvegicus	130-136
30709873-0	2019	Correction: Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway.	celastrol	12-21	AKT serine/threonine kinase 1	Homo sapiens	90-93
30709873-0	2019	Correction: Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway.	celastrol	12-21	mechanistic target of rapamycin kinase	Homo sapiens	94-123
30569150-0	2019	Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL-induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species.	celastrol	38-47	TNF superfamily member 10	Homo sapiens	80-85
30569150-3	2019	The present study demonstrated that the anti-cancer and anti-inflammatory drug celastrol, through its anti-metastatic properties, may initiate TRAIL-mediated apoptotic cell death in lung cancer cells.	celastrol	79-88	TNF superfamily member 10	Homo sapiens	143-148
30569150-5	2019	Notably, treatment with celastrol caused an increase in microtubule-associated proteins 1A/1B light chain 3B-II and p62 levels, whereas co-treatment of celastrol and TRAIL increased active caspase 3 and 8 levels compared with the control, confirming inhibited autophagy flux.	celastrol	24-33	nucleoporin 62	Homo sapiens	116-119
30569150-5	2019	Notably, treatment with celastrol caused an increase in microtubule-associated proteins 1A/1B light chain 3B-II and p62 levels, whereas co-treatment of celastrol and TRAIL increased active caspase 3 and 8 levels compared with the control, confirming inhibited autophagy flux.	celastrol	152-161	caspase 3	Homo sapiens	189-198
30569150-6	2019	The combined use of TRAIL with celastrol may serve as a safe and adequate therapeutic technique for the treatment of TRAIL-resistant lung cancer, suggesting that celastrol-mediated autophagy flux inhibition sensitized TRAIL-initiated apoptosis via regulation of ROS and DeltaPsim.	celastrol	31-40	TNF superfamily member 10	Homo sapiens	117-122
30569150-6	2019	The combined use of TRAIL with celastrol may serve as a safe and adequate therapeutic technique for the treatment of TRAIL-resistant lung cancer, suggesting that celastrol-mediated autophagy flux inhibition sensitized TRAIL-initiated apoptosis via regulation of ROS and DeltaPsim.	celastrol	31-40	TNF superfamily member 10	Homo sapiens	117-122
30569150-6	2019	The combined use of TRAIL with celastrol may serve as a safe and adequate therapeutic technique for the treatment of TRAIL-resistant lung cancer, suggesting that celastrol-mediated autophagy flux inhibition sensitized TRAIL-initiated apoptosis via regulation of ROS and DeltaPsim.	celastrol	162-171	TNF superfamily member 10	Homo sapiens	20-25
30569150-6	2019	The combined use of TRAIL with celastrol may serve as a safe and adequate therapeutic technique for the treatment of TRAIL-resistant lung cancer, suggesting that celastrol-mediated autophagy flux inhibition sensitized TRAIL-initiated apoptosis via regulation of ROS and DeltaPsim.	celastrol	162-171	TNF superfamily member 10	Homo sapiens	117-122
30569150-6	2019	The combined use of TRAIL with celastrol may serve as a safe and adequate therapeutic technique for the treatment of TRAIL-resistant lung cancer, suggesting that celastrol-mediated autophagy flux inhibition sensitized TRAIL-initiated apoptosis via regulation of ROS and DeltaPsim.	celastrol	162-171	TNF superfamily member 10	Homo sapiens	117-122
30601470-1	2019	In this work, the hydrophobic small molecule NF-kappaB inhibitor celastrol was loaded into poly(ethylene glycol)-b-poly(propylene sulfide) (PEG-b-PPS) micelles.	celastrol	65-74	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	45-54
30601470-3	2019	Encapsulation of celastrol within these nanocarriers significantly reduced cytotoxicity compared to free celastrol, while simultaneously expanding the lower concentration range for effective inhibition of NF-kappaB signaling by nearly 50 000-fold.	celastrol	17-26	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	205-214
30601470-4	2019	Furthermore, celastrol-loaded micelles successfully reduced TNF-alpha secretion after LPS stimulation of RAW 264.7 cells and reduced the number of neutrophils and inflammatory monocytes within atherosclerotic plaques of ldlr-/- mice.	celastrol	13-22	tumor necrosis factor	Mus musculus	60-69
30601470-4	2019	Furthermore, celastrol-loaded micelles successfully reduced TNF-alpha secretion after LPS stimulation of RAW 264.7 cells and reduced the number of neutrophils and inflammatory monocytes within atherosclerotic plaques of ldlr-/- mice.	celastrol	13-22	low density lipoprotein receptor	Mus musculus	220-224
30666129-0	2019	Celastrol inhibits colorectal cancer through TGF-beta1/Smad signaling.	celastrol	0-9	SMAD family member 4	Homo sapiens	55-59
30666129-3	2019	Importantly, celastrol, a major components of the root extract of the traditional Chinese herb Tripterygium wilfordii Hook F, has been shown to inhibit the growth, adhesion, and metastasis of human CRC cells through the inhibition of TGF-beta1/Smad signaling.	celastrol	13-22	transforming growth factor beta 1	Homo sapiens	234-243
30666129-3	2019	Importantly, celastrol, a major components of the root extract of the traditional Chinese herb Tripterygium wilfordii Hook F, has been shown to inhibit the growth, adhesion, and metastasis of human CRC cells through the inhibition of TGF-beta1/Smad signaling.	celastrol	13-22	SMAD family member 4	Homo sapiens	244-248
30666129-5	2019	Results: Our results indicated that celastrol can reduce the expression levels of TGF-beta1, TGFbetaRI, and TGFbetaRII in HCT116 and SW620 cells.	celastrol	36-45	transforming growth factor beta 1	Homo sapiens	82-91
30666129-5	2019	Results: Our results indicated that celastrol can reduce the expression levels of TGF-beta1, TGFbetaRI, and TGFbetaRII in HCT116 and SW620 cells.	celastrol	36-45	transforming growth factor beta receptor 1	Homo sapiens	93-102
30666129-5	2019	Results: Our results indicated that celastrol can reduce the expression levels of TGF-beta1, TGFbetaRI, and TGFbetaRII in HCT116 and SW620 cells.	celastrol	36-45	transforming growth factor beta receptor 2	Homo sapiens	108-118
30666129-6	2019	Furthermore, celastrol could also prevent the increase in Smad4 and p-Smad2/3 in HCT116 and SW620 cells.	celastrol	13-22	SMAD family member 4	Homo sapiens	58-63
30666129-6	2019	Furthermore, celastrol could also prevent the increase in Smad4 and p-Smad2/3 in HCT116 and SW620 cells.	celastrol	13-22	SMAD family member 3	Homo sapiens	70-77
30666129-7	2019	Conclusion: Celastrol could inhibit tumor growth through TGF-beta1/Smad signaling and might be a promising therapeutic component against CRC.	celastrol	12-21	transforming growth factor beta 1	Homo sapiens	57-66
30666129-7	2019	Conclusion: Celastrol could inhibit tumor growth through TGF-beta1/Smad signaling and might be a promising therapeutic component against CRC.	celastrol	12-21	SMAD family member 4	Homo sapiens	67-71
30472522-5	2019	Celastrol simultaneously reduced the activation of microglia (especially M1 microglia) in the spinal cord, inhibited the pyroptosis-related proteins (NLRP3 ASC Caspase-1 GSDMD), reduced the release of TNF-alpha IL-1beta and IL-18 inflammatory factors, and increased the release of IL10 cytokines.	celastrol	0-9	NLR family, pyrin domain containing 3	Rattus norvegicus	150-155
30395883-0	2019	Celastrol ameliorates inflammatory pain and modulates HMGB1/NF-kappaB signaling pathway in dorsal root ganglion.	celastrol	0-9	high mobility group box 1	Rattus norvegicus	54-59
30395883-3	2019	We aim to investigate whether HMGB1 in dorsal root ganglion (DRG) participates in the effect of celastrol on inflammatory pain.	celastrol	96-105	high mobility group box 1	Rattus norvegicus	30-35
30395883-8	2019	These results showed that celastrol significantly suppressed HMGB1, NF-kappaB and IL-1beta mRNA and protein expression in DRG and alleviated CFA-evoked thermal hyperalgesia.	celastrol	26-35	high mobility group box 1	Rattus norvegicus	61-66
30395883-8	2019	These results showed that celastrol significantly suppressed HMGB1, NF-kappaB and IL-1beta mRNA and protein expression in DRG and alleviated CFA-evoked thermal hyperalgesia.	celastrol	26-35	interleukin 1 beta	Rattus norvegicus	82-90
30395883-9	2019	Furthermore, celastrol obviously inhibited COX-2 protein expression and down-regulated IL-6, IL-17, TNF-alpha, MCP-1, GFAP and CD11b mRNA levels in DRG of CFA rats.	celastrol	13-22	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	43-48
30395883-9	2019	Furthermore, celastrol obviously inhibited COX-2 protein expression and down-regulated IL-6, IL-17, TNF-alpha, MCP-1, GFAP and CD11b mRNA levels in DRG of CFA rats.	celastrol	13-22	interleukin 6	Rattus norvegicus	87-91
30395883-9	2019	Furthermore, celastrol obviously inhibited COX-2 protein expression and down-regulated IL-6, IL-17, TNF-alpha, MCP-1, GFAP and CD11b mRNA levels in DRG of CFA rats.	celastrol	13-22	interleukin 17A	Rattus norvegicus	93-98
30395883-9	2019	Furthermore, celastrol obviously inhibited COX-2 protein expression and down-regulated IL-6, IL-17, TNF-alpha, MCP-1, GFAP and CD11b mRNA levels in DRG of CFA rats.	celastrol	13-22	tumor necrosis factor	Rattus norvegicus	100-109
30395883-9	2019	Furthermore, celastrol obviously inhibited COX-2 protein expression and down-regulated IL-6, IL-17, TNF-alpha, MCP-1, GFAP and CD11b mRNA levels in DRG of CFA rats.	celastrol	13-22	mast cell protease 1-like 1	Rattus norvegicus	111-116
30395883-9	2019	Furthermore, celastrol obviously inhibited COX-2 protein expression and down-regulated IL-6, IL-17, TNF-alpha, MCP-1, GFAP and CD11b mRNA levels in DRG of CFA rats.	celastrol	13-22	glial fibrillary acidic protein	Rattus norvegicus	118-122
30395883-9	2019	Furthermore, celastrol obviously inhibited COX-2 protein expression and down-regulated IL-6, IL-17, TNF-alpha, MCP-1, GFAP and CD11b mRNA levels in DRG of CFA rats.	celastrol	13-22	integrin subunit alpha M	Rattus norvegicus	127-132
30395883-10	2019	Collectively, the present study firstly provide evidences of the anti-inflammatory effect of celastrol via suppressing CFA-induced the activation of HMGB1/NF-kappaB signaling pathway in DRG, which maybe a potential therapeutic target for celastrol alleviating inflammatory pain.	celastrol	93-102	high mobility group box 1	Rattus norvegicus	149-154
30362615-0	2019	Pharmacological induction of Heat Shock Protein 70 by celastrol protects motoneurons from excitotoxicity in rat spinal cord in vitro.	celastrol	54-63	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	29-50
30362615-5	2019	Despite its narrow range of drug safety in vitro, celastrol was not toxic to the rat spinal cord at 0.75 muM concentration and enhanced the expression of HSP70 by motoneurons.	celastrol	50-59	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	154-159
30791741-0	2019	Tripterine up-regulates miR-223 to alleviate lipopolysaccharide-induced damage in murine chondrogenic ATDC5 cells.	celastrol	0-10	microRNA 223	Mus musculus	24-31
30791741-8	2019	Tripterine protected ATDC5 cells against LPS-induced chondrocyte loss and the release of IL-6 and TNF-alpha.	celastrol	0-10	interleukin 6	Mus musculus	89-93
30791741-8	2019	Tripterine protected ATDC5 cells against LPS-induced chondrocyte loss and the release of IL-6 and TNF-alpha.	celastrol	0-10	tumor necrosis factor	Mus musculus	98-107
30791741-9	2019	miR-223 was down-regulated by LPS, while was up-regulated by tripterine.	celastrol	61-71	microRNA 223	Mus musculus	0-7
30791741-10	2019	The protective actions of tripterine were eliminated when miR-223 was silenced.	celastrol	26-36	microRNA 223	Mus musculus	58-65
30791741-11	2019	Besides, tripterine inhibited hypertrophic differentiation induced by LPS, and the inhibitory effects of tripterine on hypertrophic differentiation could be abolished when miR-223 was silenced.	celastrol	105-115	microRNA 223	Mus musculus	172-179
30791741-12	2019	Furthermore, tripterine activated PI3K/AKT pathway and deactivated NF-kappaB pathway.	celastrol	13-23	thymoma viral proto-oncogene 1	Mus musculus	39-42
30791741-12	2019	Furthermore, tripterine activated PI3K/AKT pathway and deactivated NF-kappaB pathway.	celastrol	13-23	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	67-76
30791741-13	2019	And the regulatory effects of tripterine on these two pathways were abolished by miR-223 silence.	celastrol	30-40	microRNA 223	Mus musculus	81-88
30791741-14	2019	This study revealed that tripterine protected ATDC5 cells against LPS-induced cell damage possibly via up-regulation of miR-223 and modulation of NF-kappaB and PI3K/AKT pathways.	celastrol	25-35	microRNA 223	Mus musculus	120-127
30791741-14	2019	This study revealed that tripterine protected ATDC5 cells against LPS-induced cell damage possibly via up-regulation of miR-223 and modulation of NF-kappaB and PI3K/AKT pathways.	celastrol	25-35	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	146-155
30791741-14	2019	This study revealed that tripterine protected ATDC5 cells against LPS-induced cell damage possibly via up-regulation of miR-223 and modulation of NF-kappaB and PI3K/AKT pathways.	celastrol	25-35	thymoma viral proto-oncogene 1	Mus musculus	165-168
30353639-6	2019	In addition, EA potentiated the inhibitory effects of the natural compound celastrol on lung cancer cells in vitro and in vivo by enhancing autophagy and down-regulating CIP2A.	celastrol	75-84	cell proliferation regulating inhibitor of protein phosphatase 2A	Mus musculus	170-175
30389635-0	2019	Celastrol strongly inhibits proliferation, migration and cancer stem cell properties through suppression of Pin1 in ovarian cancer cells.	celastrol	0-9	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	108-112
30389635-5	2019	Celastrol resulted in a G2/M cell cycle arrest, accompanied with the down-regulation of Cyclin D1, CDK2, and CDK4.	celastrol	0-9	cyclin D1	Homo sapiens	88-97
30389635-5	2019	Celastrol resulted in a G2/M cell cycle arrest, accompanied with the down-regulation of Cyclin D1, CDK2, and CDK4.	celastrol	0-9	cyclin dependent kinase 2	Homo sapiens	99-103
30389635-5	2019	Celastrol resulted in a G2/M cell cycle arrest, accompanied with the down-regulation of Cyclin D1, CDK2, and CDK4.	celastrol	0-9	cyclin dependent kinase 4	Homo sapiens	109-113
30389635-6	2019	Celastrol induced apoptosis primarily via up-regulation of caspase-3, caspase-8, and Bax, and down-regulation of Bcl-2.	celastrol	0-9	caspase 3	Homo sapiens	59-68
30389635-6	2019	Celastrol induced apoptosis primarily via up-regulation of caspase-3, caspase-8, and Bax, and down-regulation of Bcl-2.	celastrol	0-9	caspase 8	Homo sapiens	70-79
30389635-6	2019	Celastrol induced apoptosis primarily via up-regulation of caspase-3, caspase-8, and Bax, and down-regulation of Bcl-2.	celastrol	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	85-88
30389635-6	2019	Celastrol induced apoptosis primarily via up-regulation of caspase-3, caspase-8, and Bax, and down-regulation of Bcl-2.	celastrol	0-9	BCL2 apoptosis regulator	Homo sapiens	113-118
30389635-7	2019	Celastrol treatment inhibited the expression of stem cell marker CD44, Nanog, Klf4, and Oct4, and reduced a portion of the CD44highCD24low cell population.	celastrol	0-9	CD44 molecule (Indian blood group)	Homo sapiens	65-69
30389635-7	2019	Celastrol treatment inhibited the expression of stem cell marker CD44, Nanog, Klf4, and Oct4, and reduced a portion of the CD44highCD24low cell population.	celastrol	0-9	Nanog homeobox	Homo sapiens	71-76
30389635-7	2019	Celastrol treatment inhibited the expression of stem cell marker CD44, Nanog, Klf4, and Oct4, and reduced a portion of the CD44highCD24low cell population.	celastrol	0-9	Kruppel like factor 4	Homo sapiens	78-82
30389635-7	2019	Celastrol treatment inhibited the expression of stem cell marker CD44, Nanog, Klf4, and Oct4, and reduced a portion of the CD44highCD24low cell population.	celastrol	0-9	POU class 5 homeobox 1	Homo sapiens	88-92
30389635-7	2019	Celastrol treatment inhibited the expression of stem cell marker CD44, Nanog, Klf4, and Oct4, and reduced a portion of the CD44highCD24low cell population.	celastrol	0-9	CD44 molecule (Indian blood group)	Homo sapiens	123-127
30389635-8	2019	To further understand the cancer therapeutic target, we assessed the effect of celastrol on expression of Pin1, which is reportedly overexpressed in many human cancers and activates more than 40 oncogenes or inactivates more than 20 tumor suppressor genes.	celastrol	79-88	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	106-110
30389635-9	2019	We report that celastrol particularly suppressed Pin1 expression, thereby inhibiting Akt, STAT3, P38, JNK, P65, and IL-6 expression.	celastrol	15-24	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	49-53
30389635-9	2019	We report that celastrol particularly suppressed Pin1 expression, thereby inhibiting Akt, STAT3, P38, JNK, P65, and IL-6 expression.	celastrol	15-24	AKT serine/threonine kinase 1	Homo sapiens	85-88
30389635-9	2019	We report that celastrol particularly suppressed Pin1 expression, thereby inhibiting Akt, STAT3, P38, JNK, P65, and IL-6 expression.	celastrol	15-24	signal transducer and activator of transcription 3	Homo sapiens	90-95
30389635-9	2019	We report that celastrol particularly suppressed Pin1 expression, thereby inhibiting Akt, STAT3, P38, JNK, P65, and IL-6 expression.	celastrol	15-24	mitogen-activated protein kinase 14	Homo sapiens	97-100
30389635-9	2019	We report that celastrol particularly suppressed Pin1 expression, thereby inhibiting Akt, STAT3, P38, JNK, P65, and IL-6 expression.	celastrol	15-24	mitogen-activated protein kinase 8	Homo sapiens	102-105
30389635-9	2019	We report that celastrol particularly suppressed Pin1 expression, thereby inhibiting Akt, STAT3, P38, JNK, P65, and IL-6 expression.	celastrol	15-24	RELA proto-oncogene, NF-kB subunit	Homo sapiens	107-110
30389635-9	2019	We report that celastrol particularly suppressed Pin1 expression, thereby inhibiting Akt, STAT3, P38, JNK, P65, and IL-6 expression.	celastrol	15-24	interleukin 6	Homo sapiens	116-120
30389635-10	2019	Taken together, these findings indicate that celastrol is a potential therapeutic agent for ovarian cancer in humans via inhibition of Pin1 expression.	celastrol	45-54	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	135-139
31113607-0	2019	Celastrol Attenuates Intrahepatic Cholestasis of Pregnancy by Inhibiting Matrix Metalloproteinases-2 and 9.	celastrol	0-9	matrix metallopeptidase 2	Rattus norvegicus	73-106
31113607-2	2019	Meanwhile, ample evidences have demonstrated that celastrol inhibits the activity and expression of MMPs.	celastrol	50-59	matrix metallopeptidase 2	Homo sapiens	100-104
31113607-6	2019	RESULTS: In rats with ICP, both MMP-2 and -9 exhibited significantly elevated activities, which were inhibited by the administration of celastrol.	celastrol	136-145	matrix metallopeptidase 2	Rattus norvegicus	32-44
31113607-9	2019	CONCLUSION: Our findings described for the first time the effects of celastrol to attenuate ICP symptoms through an inhibition of both MMP-2 and -9, providing evidence for a potential role of celastrol as a new drug for the treatment of ICP.	celastrol	69-78	matrix metallopeptidase 2	Rattus norvegicus	135-147
31113607-9	2019	CONCLUSION: Our findings described for the first time the effects of celastrol to attenuate ICP symptoms through an inhibition of both MMP-2 and -9, providing evidence for a potential role of celastrol as a new drug for the treatment of ICP.	celastrol	192-201	matrix metallopeptidase 2	Rattus norvegicus	135-147
31032752-0	2019	Celastrol Protects RPE Cells from Oxidative Stress-Induced Cell Death via Activation of Nrf2 Signaling Pathway.	celastrol	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	88-92
31032752-11	2019	Treatment with celastrol enhanced the expression of transcription factor Nrf2 and its targets, GCLM and HO-1.	celastrol	15-24	NFE2 like bZIP transcription factor 2	Homo sapiens	73-77
31032752-11	2019	Treatment with celastrol enhanced the expression of transcription factor Nrf2 and its targets, GCLM and HO-1.	celastrol	15-24	glutamate-cysteine ligase modifier subunit	Homo sapiens	95-99
31032752-11	2019	Treatment with celastrol enhanced the expression of transcription factor Nrf2 and its targets, GCLM and HO-1.	celastrol	15-24	heme oxygenase 1	Homo sapiens	104-108
31032752-12	2019	Knockdown of Nrf2 expression by shRNA partially abolished the protective effects of celastrol.	celastrol	84-93	NFE2 like bZIP transcription factor 2	Homo sapiens	13-17
31032752-15	2019	CONCLUSION: This study provides evidence that treatment of RPE cells with celastrol shows potent protective effects against oxidative insults via activation of Nrf2 signaling pathway and upregulation of GCLM expression.	celastrol	74-83	NFE2 like bZIP transcription factor 2	Homo sapiens	160-164
31032752-15	2019	CONCLUSION: This study provides evidence that treatment of RPE cells with celastrol shows potent protective effects against oxidative insults via activation of Nrf2 signaling pathway and upregulation of GCLM expression.	celastrol	74-83	glutamate-cysteine ligase modifier subunit	Homo sapiens	203-207
30472522-5	2019	Celastrol simultaneously reduced the activation of microglia (especially M1 microglia) in the spinal cord, inhibited the pyroptosis-related proteins (NLRP3 ASC Caspase-1 GSDMD), reduced the release of TNF-alpha IL-1beta and IL-18 inflammatory factors, and increased the release of IL10 cytokines.	celastrol	0-9	interleukin 10	Rattus norvegicus	281-285
30472522-6	2019	In vitro studies showed that Celastrol reduced the toxicity resulting from the administration of LPS with ATP to BV-2 cells, inhibited the pyroptosis-related proteins (NLRP3 Caspase-1 GSDMD), and inhibited the release of corresponding inflammatory factors.	celastrol	29-38	NLR family, pyrin domain containing 3	Mus musculus	168-173
30626478-8	2018	Compared with the group without celastrol treatment, the mRNA and protein level of Bcl2 in A549 cells treated with (1, 3) mumol/L celastrol decreased significantly, while the expression levels of BAX, caspase-3, caspase-8, caspase-9, c-caspase-3, c-caspase-8, c-caspase-9 increased significantly.	celastrol	130-139	BCL2 apoptosis regulator	Homo sapiens	83-87
30525586-0	2018	Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.	celastrol	0-9	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	103-108
30525586-0	2018	Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.	celastrol	0-9	protein tyrosine phosphatase, non-receptor type 2	Mus musculus	113-118
30525586-2	2018	Celastrol-administered mice at 100 mug/kg decrease food consumption and body weight via a leptin-dependent mechanism, yet its molecular targets in this pathway remain elusive.	celastrol	0-9	leptin	Mus musculus	90-96
30525586-3	2018	Here, we demonstrate in vivo that celastrol-induced weight loss is largely mediated by the inhibition of leptin negative regulators protein tyrosine phosphatase (PTP) 1B (PTP1B) and T-cell PTP (TCPTP) in the arcuate nucleus (ARC) of the hypothalamus.	celastrol	34-43	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	171-176
30525586-3	2018	Here, we demonstrate in vivo that celastrol-induced weight loss is largely mediated by the inhibition of leptin negative regulators protein tyrosine phosphatase (PTP) 1B (PTP1B) and T-cell PTP (TCPTP) in the arcuate nucleus (ARC) of the hypothalamus.	celastrol	34-43	protein tyrosine phosphatase, non-receptor type 2	Mus musculus	194-199
30525586-4	2018	We show in vitro that celastrol binds reversibly and inhibits noncompetitively PTP1B and TCPTP.	celastrol	22-31	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	79-84
30525586-4	2018	We show in vitro that celastrol binds reversibly and inhibits noncompetitively PTP1B and TCPTP.	celastrol	22-31	protein tyrosine phosphatase, non-receptor type 2	Mus musculus	89-94
30525586-6	2018	By using a panel of PTPs implicated in hypothalamic leptin signaling, we show that celastrol additionally inhibited PTEN and SHP2 but had no activity toward other phosphatases of the PTP family.	celastrol	83-92	leptin	Mus musculus	52-58
30525586-6	2018	By using a panel of PTPs implicated in hypothalamic leptin signaling, we show that celastrol additionally inhibited PTEN and SHP2 but had no activity toward other phosphatases of the PTP family.	celastrol	83-92	phosphatase and tensin homolog	Mus musculus	116-120
30525586-6	2018	By using a panel of PTPs implicated in hypothalamic leptin signaling, we show that celastrol additionally inhibited PTEN and SHP2 but had no activity toward other phosphatases of the PTP family.	celastrol	83-92	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	125-129
30525586-7	2018	These results suggest that PTP1B and TCPTP in the ARC are essential for celastrol"s weight lowering effects in adult obese mice.	celastrol	72-81	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	27-32
30525586-7	2018	These results suggest that PTP1B and TCPTP in the ARC are essential for celastrol"s weight lowering effects in adult obese mice.	celastrol	72-81	protein tyrosine phosphatase, non-receptor type 2	Mus musculus	37-42
30588010-0	2018	Celastrol induces ubiquitin-dependent degradation of mTOR in breast cancer cells.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	53-57
30588010-2	2018	Celastrol inhibits PI3K-Akt-mTOR signaling, which is frequently dysregulated in tumors and critical for tumor-cell proliferation and survival, but the underlying mechanisms are still not fully understood.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	28-32
30588010-3	2018	In the present study, we investigated detailed mechanisms of celastrol inhibition of mTOR signaling in breast cancer cells.	celastrol	61-70	mechanistic target of rapamycin kinase	Homo sapiens	85-89
30588010-5	2018	Second, we examined the effects of celastrol on mTOR phosphorylation and expression using Western blot.	celastrol	35-44	mechanistic target of rapamycin kinase	Homo sapiens	48-52
30588010-6	2018	Furthermore, we investigated the cause of mTOR downregulation by celastrol using immunoprecipitation assays.	celastrol	65-74	mechanistic target of rapamycin kinase	Homo sapiens	42-46
30588010-9	2018	Celastrol inhibited mTOR phosphorylation and induced mTOR ubiquitination, resulting in its proteasomal degradation.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	20-24
30588010-9	2018	Celastrol inhibited mTOR phosphorylation and induced mTOR ubiquitination, resulting in its proteasomal degradation.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	53-57
30588010-10	2018	Mechanistically, we found that mTOR is a client of Hsp90-Cdc37 chaperone complex, and celastrol disrupts mTOR interaction with chaperone Hsp90 while promoting mTOR association with cochaperone Cdc37.	celastrol	86-95	heat shock protein 90 alpha family class A member 1	Homo sapiens	51-56
30588010-10	2018	Mechanistically, we found that mTOR is a client of Hsp90-Cdc37 chaperone complex, and celastrol disrupts mTOR interaction with chaperone Hsp90 while promoting mTOR association with cochaperone Cdc37.	celastrol	86-95	cell division cycle 37, HSP90 cochaperone	Homo sapiens	57-62
30588010-10	2018	Mechanistically, we found that mTOR is a client of Hsp90-Cdc37 chaperone complex, and celastrol disrupts mTOR interaction with chaperone Hsp90 while promoting mTOR association with cochaperone Cdc37.	celastrol	86-95	mechanistic target of rapamycin kinase	Homo sapiens	105-109
30588010-10	2018	Mechanistically, we found that mTOR is a client of Hsp90-Cdc37 chaperone complex, and celastrol disrupts mTOR interaction with chaperone Hsp90 while promoting mTOR association with cochaperone Cdc37.	celastrol	86-95	heat shock protein 90 alpha family class A member 1	Homo sapiens	137-142
30588010-10	2018	Mechanistically, we found that mTOR is a client of Hsp90-Cdc37 chaperone complex, and celastrol disrupts mTOR interaction with chaperone Hsp90 while promoting mTOR association with cochaperone Cdc37.	celastrol	86-95	mechanistic target of rapamycin kinase	Homo sapiens	105-109
30588010-10	2018	Mechanistically, we found that mTOR is a client of Hsp90-Cdc37 chaperone complex, and celastrol disrupts mTOR interaction with chaperone Hsp90 while promoting mTOR association with cochaperone Cdc37.	celastrol	86-95	cell division cycle 37, HSP90 cochaperone	Homo sapiens	193-198
30588010-11	2018	Conclusion: Our study reveals that celastrol suppresses mTOR signaling, at least in part through regulating its association with chaperones and inducing its ubiquitination.	celastrol	35-44	mechanistic target of rapamycin kinase	Homo sapiens	56-60
30316059-0	2018	Discovery of novel NO-releasing celastrol derivatives with Hsp90 inhibition and cytotoxic activities.	celastrol	32-41	heat shock protein 90 alpha family class A member 1	Homo sapiens	59-64
30626478-5	2018	The effects of celastrol on the expression of BAX, B-cell lymphoma 2 (Bcl2), caspase-3, caspase-8, caspase-9 mRNA in A549 cells were detected by real-time quantitative PCR.	celastrol	15-24	BCL2 associated X, apoptosis regulator	Homo sapiens	46-49
30626478-5	2018	The effects of celastrol on the expression of BAX, B-cell lymphoma 2 (Bcl2), caspase-3, caspase-8, caspase-9 mRNA in A549 cells were detected by real-time quantitative PCR.	celastrol	15-24	BCL2 apoptosis regulator	Homo sapiens	51-68
30626478-5	2018	The effects of celastrol on the expression of BAX, B-cell lymphoma 2 (Bcl2), caspase-3, caspase-8, caspase-9 mRNA in A549 cells were detected by real-time quantitative PCR.	celastrol	15-24	BCL2 apoptosis regulator	Homo sapiens	70-74
30626478-5	2018	The effects of celastrol on the expression of BAX, B-cell lymphoma 2 (Bcl2), caspase-3, caspase-8, caspase-9 mRNA in A549 cells were detected by real-time quantitative PCR.	celastrol	15-24	caspase 3	Homo sapiens	77-86
30626478-5	2018	The effects of celastrol on the expression of BAX, B-cell lymphoma 2 (Bcl2), caspase-3, caspase-8, caspase-9 mRNA in A549 cells were detected by real-time quantitative PCR.	celastrol	15-24	caspase 8	Homo sapiens	88-97
30626478-5	2018	The effects of celastrol on the expression of BAX, B-cell lymphoma 2 (Bcl2), caspase-3, caspase-8, caspase-9 mRNA in A549 cells were detected by real-time quantitative PCR.	celastrol	15-24	caspase 9	Homo sapiens	99-108
30626478-8	2018	Compared with the group without celastrol treatment, the mRNA and protein level of Bcl2 in A549 cells treated with (1, 3) mumol/L celastrol decreased significantly, while the expression levels of BAX, caspase-3, caspase-8, caspase-9, c-caspase-3, c-caspase-8, c-caspase-9 increased significantly.	celastrol	32-41	BCL2 apoptosis regulator	Homo sapiens	83-87
30439604-0	2018	Celastrol antagonizes high glucose-evoked podocyte injury, inflammation and insulin resistance by restoring the HO-1-mediated autophagy pathway.	celastrol	0-9	insulin	Homo sapiens	76-83
30439604-0	2018	Celastrol antagonizes high glucose-evoked podocyte injury, inflammation and insulin resistance by restoring the HO-1-mediated autophagy pathway.	celastrol	0-9	heme oxygenase 1	Homo sapiens	112-116
30439604-7	2018	Additionally, HG-elevated high transcripts and secretions of pro-inflammatory cytokines were reversed following celastrol treatment, including IL-1beta, TNF-alpha, IL-6.	celastrol	112-121	interleukin 1 beta	Homo sapiens	143-151
30439604-7	2018	Additionally, HG-elevated high transcripts and secretions of pro-inflammatory cytokines were reversed following celastrol treatment, including IL-1beta, TNF-alpha, IL-6.	celastrol	112-121	tumor necrosis factor	Homo sapiens	153-162
30439604-7	2018	Additionally, HG-elevated high transcripts and secretions of pro-inflammatory cytokines were reversed following celastrol treatment, including IL-1beta, TNF-alpha, IL-6.	celastrol	112-121	interleukin 6	Homo sapiens	164-168
30439604-8	2018	Simultaneously, the inhibitory effects of HG on insulin-triggered glucose uptake and nephrin expression were overturned after celastrol exposure.	celastrol	126-135	insulin	Homo sapiens	48-55
30439604-8	2018	Simultaneously, the inhibitory effects of HG on insulin-triggered glucose uptake and nephrin expression were overturned after celastrol exposure.	celastrol	126-135	NPHS1 adhesion molecule, nephrin	Homo sapiens	85-92
30439604-10	2018	Nevertheless, blocking the autophagy signaling by its antagonist 3-MA muted celastrol-protected against HG-evoked cell injury, inflammation and insulin resistance.	celastrol	76-85	insulin	Homo sapiens	144-151
30439604-11	2018	Importantly, celastrol enhanced heme oxygenase-1 (HO-1) expression in HG-stimulated podocytes.	celastrol	13-22	heme oxygenase 1	Homo sapiens	32-48
30439604-11	2018	Importantly, celastrol enhanced heme oxygenase-1 (HO-1) expression in HG-stimulated podocytes.	celastrol	13-22	heme oxygenase 1	Homo sapiens	50-54
30439604-12	2018	Notably, HO-1 cessation depressed autophagy pathway activation and subsequently blunted beneficial effects of celastrol on HG-exposed podocytes.	celastrol	110-119	heme oxygenase 1	Homo sapiens	9-13
30439604-13	2018	These finding suggest that celastrol may protect against HG-induced podocyte injury, inflammation and insulin resistance by restoring HO-1-mediated autophagy pathway, implying a promising therapeutic strategy against DN.	celastrol	27-36	insulin	Homo sapiens	102-109
30439604-13	2018	These finding suggest that celastrol may protect against HG-induced podocyte injury, inflammation and insulin resistance by restoring HO-1-mediated autophagy pathway, implying a promising therapeutic strategy against DN.	celastrol	27-36	heme oxygenase 1	Homo sapiens	134-138
30626478-8	2018	Compared with the group without celastrol treatment, the mRNA and protein level of Bcl2 in A549 cells treated with (1, 3) mumol/L celastrol decreased significantly, while the expression levels of BAX, caspase-3, caspase-8, caspase-9, c-caspase-3, c-caspase-8, c-caspase-9 increased significantly.	celastrol	130-139	caspase 8	Homo sapiens	212-221
30626478-8	2018	Compared with the group without celastrol treatment, the mRNA and protein level of Bcl2 in A549 cells treated with (1, 3) mumol/L celastrol decreased significantly, while the expression levels of BAX, caspase-3, caspase-8, caspase-9, c-caspase-3, c-caspase-8, c-caspase-9 increased significantly.	celastrol	130-139	caspase 9	Homo sapiens	223-232
30626478-8	2018	Compared with the group without celastrol treatment, the mRNA and protein level of Bcl2 in A549 cells treated with (1, 3) mumol/L celastrol decreased significantly, while the expression levels of BAX, caspase-3, caspase-8, caspase-9, c-caspase-3, c-caspase-8, c-caspase-9 increased significantly.	celastrol	130-139	caspase 3	Homo sapiens	236-245
30626478-8	2018	Compared with the group without celastrol treatment, the mRNA and protein level of Bcl2 in A549 cells treated with (1, 3) mumol/L celastrol decreased significantly, while the expression levels of BAX, caspase-3, caspase-8, caspase-9, c-caspase-3, c-caspase-8, c-caspase-9 increased significantly.	celastrol	130-139	caspase 8	Homo sapiens	249-258
30626478-8	2018	Compared with the group without celastrol treatment, the mRNA and protein level of Bcl2 in A549 cells treated with (1, 3) mumol/L celastrol decreased significantly, while the expression levels of BAX, caspase-3, caspase-8, caspase-9, c-caspase-3, c-caspase-8, c-caspase-9 increased significantly.	celastrol	130-139	caspase 9	Homo sapiens	262-271
30333251-0	2018	Systematic identification of Celastrol-binding proteins reveals that Shoc2 is inhibited by Celastrol.	celastrol	29-38	SHOC2 leucine rich repeat scaffold protein	Homo sapiens	69-74
30333251-0	2018	Systematic identification of Celastrol-binding proteins reveals that Shoc2 is inhibited by Celastrol.	celastrol	91-100	SHOC2 leucine rich repeat scaffold protein	Homo sapiens	69-74
30333251-8	2018	Celastrol significantly inhibited ERK1/2 phosphorylation in cell lines and xenograft tumors.	celastrol	0-9	mitogen-activated protein kinase 3	Homo sapiens	34-40
30333251-12	2018	In summary, we unraveled the anti-CRC function of Celastrol and confirmed for the first time that it inhibited the ERK1/2 pathway through binding to Shoc2.	celastrol	50-59	mitogen-activated protein kinase 3	Homo sapiens	115-121
30333251-12	2018	In summary, we unraveled the anti-CRC function of Celastrol and confirmed for the first time that it inhibited the ERK1/2 pathway through binding to Shoc2.	celastrol	50-59	SHOC2 leucine rich repeat scaffold protein	Homo sapiens	149-154
29355035-0	2018	Simultaneous targeting therapy for lung metastasis and breast tumor by blocking the NF-kappaB signaling pathway using Celastrol-loaded micelles.	celastrol	118-127	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	84-93
30510417-1	2018	Purpose: A transferrin-modified microemulsion carrying coix seed oil and tripterine (Tf-CT-MEs) was developed for improved tumor-specific accumulation and penetration to enhance cervical cancer treatment.	celastrol	73-83	transferrin	Homo sapiens	11-22
30158241-0	2018	Celastrol-Induced Weight Loss Is Driven by Hypophagia and Independent From UCP1.	celastrol	0-9	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	75-79
30158241-5	2018	Protein tyrosine phosphatase 1 (PTP1B), a leptin negative-feedback regulator, has been previously reported to be one of celastrol"s targets.	celastrol	120-129	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	32-37
30158241-6	2018	However, we found that global PTP1B knockout (KO) and wild-type (WT) mice have comparable weight loss and hypophagia when treated with celastrol.	celastrol	135-144	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	30-35
30158241-7	2018	Increased levels of uncoupling protein 1 (UCP1) in subcutaneous white and brown adipose tissue suggest celastrol-induced thermogenesis as a further mechanism.	celastrol	103-112	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	20-40
30158241-7	2018	Increased levels of uncoupling protein 1 (UCP1) in subcutaneous white and brown adipose tissue suggest celastrol-induced thermogenesis as a further mechanism.	celastrol	103-112	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	42-46
30498444-0	2018	Celastrol Alleviates Chronic Obstructive Pulmonary Disease by Inhibiting Cellular Inflammation Induced by Cigarette Smoke via the Ednrb/Kng1 Signaling Pathway.	celastrol	0-9	endothelin receptor type B	Mus musculus	130-135
30498444-0	2018	Celastrol Alleviates Chronic Obstructive Pulmonary Disease by Inhibiting Cellular Inflammation Induced by Cigarette Smoke via the Ednrb/Kng1 Signaling Pathway.	celastrol	0-9	kininogen 1	Mus musculus	136-140
30498444-13	2018	Compared to mice in the COPD group, mice treated with Celastrol had significantly reduced levels of inflammatory cytokines interleukin-8, tumor necrosis factor alpha and monocyte chemoattractant protein-1 in the serum and bronchoalveolar lavage fluid, and significantly increased levels of oxidative stress factors superoxide dismutase and catalase.	celastrol	54-63	chemokine (C-X-C motif) ligand 15	Mus musculus	123-136
30498444-13	2018	Compared to mice in the COPD group, mice treated with Celastrol had significantly reduced levels of inflammatory cytokines interleukin-8, tumor necrosis factor alpha and monocyte chemoattractant protein-1 in the serum and bronchoalveolar lavage fluid, and significantly increased levels of oxidative stress factors superoxide dismutase and catalase.	celastrol	54-63	tumor necrosis factor	Mus musculus	138-165
30498444-13	2018	Compared to mice in the COPD group, mice treated with Celastrol had significantly reduced levels of inflammatory cytokines interleukin-8, tumor necrosis factor alpha and monocyte chemoattractant protein-1 in the serum and bronchoalveolar lavage fluid, and significantly increased levels of oxidative stress factors superoxide dismutase and catalase.	celastrol	54-63	chemokine (C-C motif) ligand 2	Mus musculus	170-204
30498444-13	2018	Compared to mice in the COPD group, mice treated with Celastrol had significantly reduced levels of inflammatory cytokines interleukin-8, tumor necrosis factor alpha and monocyte chemoattractant protein-1 in the serum and bronchoalveolar lavage fluid, and significantly increased levels of oxidative stress factors superoxide dismutase and catalase.	celastrol	54-63	catalase	Mus musculus	340-348
30498444-18	2018	Additionally, Celastrol effectively reduced Ednrb/Kng1 expression in both cell and animal models.	celastrol	14-23	endothelin receptor type B	Mus musculus	44-49
30498444-18	2018	Additionally, Celastrol effectively reduced Ednrb/Kng1 expression in both cell and animal models.	celastrol	14-23	kininogen 1	Mus musculus	50-54
30498444-19	2018	Celastrol has a therapeutic effect on COPD and may alleviate COPD by inhibiting inflammation development by suppressing the Ednrb/Kng1 signaling pathway.	celastrol	0-9	endothelin receptor type B	Mus musculus	124-129
30498444-19	2018	Celastrol has a therapeutic effect on COPD and may alleviate COPD by inhibiting inflammation development by suppressing the Ednrb/Kng1 signaling pathway.	celastrol	0-9	kininogen 1	Mus musculus	130-134
29355035-2	2018	To inhibit the metastasis and growth of breast tumor simultaneously, a Celastrol (Cela) loaded glucolipid-like conjugates (CSOSA/Cela) with alphavbeta3-ligand Tetraiodothyroacetic acid (TET) modification (TET-CSOSA/Cela) were established to block nuclear factor-kappa B (NF-kappaB) signaling pathway.	celastrol	71-80	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	247-269
29355035-2	2018	To inhibit the metastasis and growth of breast tumor simultaneously, a Celastrol (Cela) loaded glucolipid-like conjugates (CSOSA/Cela) with alphavbeta3-ligand Tetraiodothyroacetic acid (TET) modification (TET-CSOSA/Cela) were established to block nuclear factor-kappa B (NF-kappaB) signaling pathway.	celastrol	71-80	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	271-280
29355035-2	2018	To inhibit the metastasis and growth of breast tumor simultaneously, a Celastrol (Cela) loaded glucolipid-like conjugates (CSOSA/Cela) with alphavbeta3-ligand Tetraiodothyroacetic acid (TET) modification (TET-CSOSA/Cela) were established to block nuclear factor-kappa B (NF-kappaB) signaling pathway.	celastrol	71-75	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	247-269
29355035-2	2018	To inhibit the metastasis and growth of breast tumor simultaneously, a Celastrol (Cela) loaded glucolipid-like conjugates (CSOSA/Cela) with alphavbeta3-ligand Tetraiodothyroacetic acid (TET) modification (TET-CSOSA/Cela) were established to block nuclear factor-kappa B (NF-kappaB) signaling pathway.	celastrol	71-75	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	271-280
29355035-4	2018	The results demonstrated that TET-CSOSA/Cela significantly suppressed Bcl-2 activation of lung metastatic cells and reduced MMP-9 expression of 4T1 breast tumor cells by blocking NF-kappaB.	celastrol	40-44	B cell leukemia/lymphoma 2	Mus musculus	70-75
29355035-4	2018	The results demonstrated that TET-CSOSA/Cela significantly suppressed Bcl-2 activation of lung metastatic cells and reduced MMP-9 expression of 4T1 breast tumor cells by blocking NF-kappaB.	celastrol	40-44	matrix metallopeptidase 9	Mus musculus	124-129
29355035-4	2018	The results demonstrated that TET-CSOSA/Cela significantly suppressed Bcl-2 activation of lung metastatic cells and reduced MMP-9 expression of 4T1 breast tumor cells by blocking NF-kappaB.	celastrol	40-44	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	179-188
30268856-4	2018	KEY FINDINGS: Pkd1 miRNA transgenic (Pkd1 miR TG) mice treated with 1 mg/kg/day of celastrol exhibited a lower renal cystic index (by 21.5%) than the vehicle-treated controls, but the fractional kidney weights and blood urea nitrogen levels were not significantly affected with celastrol treatment.	celastrol	83-92	polycystin 1, transient receptor potential channel interacting	Mus musculus	14-18
30221712-0	2018	Celastrol inhibits glucocorticoid-induced osteoporosis in rat via the PI3K/AKT and Wnt signaling pathways.	celastrol	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	75-78
30221712-3	2018	The findings of the current study revealed that Celastrol reduced body weight, urine calcium/creatinine, tartrate-resistant acid phosphatase 5b, C-terminal telopeptide of type I collagen, and induced osteocalcin in GIOP rats.	celastrol	48-57	bone gamma-carboxyglutamate protein	Rattus norvegicus	200-211
30221712-5	2018	Celastrol inhibited prostaglandin E2 and caspase-3 protein expression levels, and induced phosphoinositol 3-kinase (PI3K), phosphorylated-protein kinase B (AKT) and glycogen synthase kinase-3 phosphorylation, Wnt and beta-catenin protein expression in GIOP rats.	celastrol	0-9	caspase 3	Rattus norvegicus	41-50
30221712-5	2018	Celastrol inhibited prostaglandin E2 and caspase-3 protein expression levels, and induced phosphoinositol 3-kinase (PI3K), phosphorylated-protein kinase B (AKT) and glycogen synthase kinase-3 phosphorylation, Wnt and beta-catenin protein expression in GIOP rats.	celastrol	0-9	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta	Rattus norvegicus	90-114
30221712-5	2018	Celastrol inhibited prostaglandin E2 and caspase-3 protein expression levels, and induced phosphoinositol 3-kinase (PI3K), phosphorylated-protein kinase B (AKT) and glycogen synthase kinase-3 phosphorylation, Wnt and beta-catenin protein expression in GIOP rats.	celastrol	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	156-159
30221712-5	2018	Celastrol inhibited prostaglandin E2 and caspase-3 protein expression levels, and induced phosphoinositol 3-kinase (PI3K), phosphorylated-protein kinase B (AKT) and glycogen synthase kinase-3 phosphorylation, Wnt and beta-catenin protein expression in GIOP rats.	celastrol	0-9	catenin beta 1	Rattus norvegicus	217-229
30221712-6	2018	The present study demonstrated that Celastrol may inhibit GIOP in rats via the PI3K/AKT and Wnt signaling pathways.	celastrol	36-45	AKT serine/threonine kinase 1	Rattus norvegicus	84-87
30268856-7	2018	Moreover, celastrol reduced the renal mRNA expression levels of tumor necrosis factor-alpha, interleukin-1beta, P2RX7, F4/80, CD68, transforming growth factor-beta, collagen-1, and fibronectin, which were high in the Pkd1 miR TG mice.	celastrol	10-19	polycystin 1, transient receptor potential channel interacting	Mus musculus	217-221
30268856-7	2018	Moreover, celastrol reduced the renal mRNA expression levels of tumor necrosis factor-alpha, interleukin-1beta, P2RX7, F4/80, CD68, transforming growth factor-beta, collagen-1, and fibronectin, which were high in the Pkd1 miR TG mice.	celastrol	10-19	microRNA 615	Mus musculus	222-225
30268856-4	2018	KEY FINDINGS: Pkd1 miRNA transgenic (Pkd1 miR TG) mice treated with 1 mg/kg/day of celastrol exhibited a lower renal cystic index (by 21.5%) than the vehicle-treated controls, but the fractional kidney weights and blood urea nitrogen levels were not significantly affected with celastrol treatment.	celastrol	83-92	polycystin 1, transient receptor potential channel interacting	Mus musculus	37-41
30268856-4	2018	KEY FINDINGS: Pkd1 miRNA transgenic (Pkd1 miR TG) mice treated with 1 mg/kg/day of celastrol exhibited a lower renal cystic index (by 21.5%) than the vehicle-treated controls, but the fractional kidney weights and blood urea nitrogen levels were not significantly affected with celastrol treatment.	celastrol	83-92	microRNA 615	Mus musculus	19-22
30268856-4	2018	KEY FINDINGS: Pkd1 miRNA transgenic (Pkd1 miR TG) mice treated with 1 mg/kg/day of celastrol exhibited a lower renal cystic index (by 21.5%) than the vehicle-treated controls, but the fractional kidney weights and blood urea nitrogen levels were not significantly affected with celastrol treatment.	celastrol	278-287	polycystin 1, transient receptor potential channel interacting	Mus musculus	14-18
30268856-7	2018	Moreover, celastrol reduced the renal mRNA expression levels of tumor necrosis factor-alpha, interleukin-1beta, P2RX7, F4/80, CD68, transforming growth factor-beta, collagen-1, and fibronectin, which were high in the Pkd1 miR TG mice.	celastrol	10-19	tumor necrosis factor	Mus musculus	64-91
30268856-7	2018	Moreover, celastrol reduced the renal mRNA expression levels of tumor necrosis factor-alpha, interleukin-1beta, P2RX7, F4/80, CD68, transforming growth factor-beta, collagen-1, and fibronectin, which were high in the Pkd1 miR TG mice.	celastrol	10-19	interleukin 1 beta	Mus musculus	93-110
30268856-7	2018	Moreover, celastrol reduced the renal mRNA expression levels of tumor necrosis factor-alpha, interleukin-1beta, P2RX7, F4/80, CD68, transforming growth factor-beta, collagen-1, and fibronectin, which were high in the Pkd1 miR TG mice.	celastrol	10-19	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	112-117
30268856-7	2018	Moreover, celastrol reduced the renal mRNA expression levels of tumor necrosis factor-alpha, interleukin-1beta, P2RX7, F4/80, CD68, transforming growth factor-beta, collagen-1, and fibronectin, which were high in the Pkd1 miR TG mice.	celastrol	10-19	adhesion G protein-coupled receptor E1	Mus musculus	119-124
30268856-7	2018	Moreover, celastrol reduced the renal mRNA expression levels of tumor necrosis factor-alpha, interleukin-1beta, P2RX7, F4/80, CD68, transforming growth factor-beta, collagen-1, and fibronectin, which were high in the Pkd1 miR TG mice.	celastrol	10-19	CD68 antigen	Mus musculus	126-130
30268856-7	2018	Moreover, celastrol reduced the renal mRNA expression levels of tumor necrosis factor-alpha, interleukin-1beta, P2RX7, F4/80, CD68, transforming growth factor-beta, collagen-1, and fibronectin, which were high in the Pkd1 miR TG mice.	celastrol	10-19	fibronectin 1	Mus musculus	181-192
29667734-6	2018	Bioinformatics and cellular experiments showed that both celastrol and PA could bind MD2, and that celastrol could expel PA from cells.	celastrol	57-66	lymphocyte antigen 96	Homo sapiens	85-88
30015859-0	2018	Effect of celastrol on toll-like receptor 4-mediated inflammatory response in free fatty acid-induced HepG2 cells.	celastrol	10-19	toll like receptor 4	Homo sapiens	23-43
30015859-2	2018	Our previous study demonstrated that celastrol treatment was able to improve hepatic steatosis and inhibit the TLR4 signaling cascade pathway in type 2 diabetic rats.	celastrol	37-46	toll-like receptor 4	Rattus norvegicus	111-115
30015859-6	2018	To directly elucidate whether TLR4 was the blocking target of celastrol upon FFA exposure, the cellular response to inflammation was determined upon transfection with TLR4 siRNA.	celastrol	62-71	toll like receptor 4	Homo sapiens	30-34
30015859-7	2018	The results revealed that celastrol significantly reduced triglyceride accumulation in the steatotic HepG2 cells, and downregulated the expression levels of TLR4, MyD88 and phospho-NF-kappaBp65, as well as of the downstream inflammatory cytokines interleukin-1beta and tumor necrosis factor alpha.	celastrol	26-35	toll like receptor 4	Homo sapiens	157-161
30015859-7	2018	The results revealed that celastrol significantly reduced triglyceride accumulation in the steatotic HepG2 cells, and downregulated the expression levels of TLR4, MyD88 and phospho-NF-kappaBp65, as well as of the downstream inflammatory cytokines interleukin-1beta and tumor necrosis factor alpha.	celastrol	26-35	MYD88 innate immune signal transduction adaptor	Homo sapiens	163-168
30015859-7	2018	The results revealed that celastrol significantly reduced triglyceride accumulation in the steatotic HepG2 cells, and downregulated the expression levels of TLR4, MyD88 and phospho-NF-kappaBp65, as well as of the downstream inflammatory cytokines interleukin-1beta and tumor necrosis factor alpha.	celastrol	26-35	interleukin 1 beta	Homo sapiens	247-296
29873512-10	2018	Another drug, celastrol, which enhanced expression of ER and cytosolic chaperones in GECs, tended to reduce actinin-4 aggregation but did not decrease the tight association of actinin-4 K256E with F-actin and did not reduce albuminuria in actinin-4 K256E transgenic mice.	celastrol	14-23	actinin alpha 4	Mus musculus	108-117
30268831-7	2018	FINDINGS: In vivo, after celastrol treatment, cisplatin-induced kidney injury was significantly ameliorated as shown by the improvement of renal function (BUN, serum creatinine, and cystatin C), kidney morphology (PAS staining) and oxidative stress (MDA) and the suppression of renal tubular injury markers of KIM-1 and NGAL.	celastrol	25-34	cystatin C	Mus musculus	182-192
30268831-7	2018	FINDINGS: In vivo, after celastrol treatment, cisplatin-induced kidney injury was significantly ameliorated as shown by the improvement of renal function (BUN, serum creatinine, and cystatin C), kidney morphology (PAS staining) and oxidative stress (MDA) and the suppression of renal tubular injury markers of KIM-1 and NGAL.	celastrol	25-34	hepatitis A virus cellular receptor 1	Mus musculus	310-315
29667734-0	2018	Celastrol reverses palmitic acid (PA)-caused TLR4-MD2 activation-dependent insulin resistance via disrupting MD2-related cellular binding to PA.	celastrol	0-9	toll like receptor 4	Homo sapiens	45-49
29667734-0	2018	Celastrol reverses palmitic acid (PA)-caused TLR4-MD2 activation-dependent insulin resistance via disrupting MD2-related cellular binding to PA.	celastrol	0-9	lymphocyte antigen 96	Homo sapiens	50-53
29667734-0	2018	Celastrol reverses palmitic acid (PA)-caused TLR4-MD2 activation-dependent insulin resistance via disrupting MD2-related cellular binding to PA.	celastrol	0-9	insulin	Homo sapiens	75-82
29667734-0	2018	Celastrol reverses palmitic acid (PA)-caused TLR4-MD2 activation-dependent insulin resistance via disrupting MD2-related cellular binding to PA.	celastrol	0-9	lymphocyte antigen 96	Homo sapiens	109-112
29667734-8	2018	Taking together, we proved that celastrol could reverses PA-caused TLR4-MD2 activation-dependent insulin resistance via disrupting PA binding to MD2.	celastrol	32-41	toll like receptor 4	Homo sapiens	67-71
29667734-8	2018	Taking together, we proved that celastrol could reverses PA-caused TLR4-MD2 activation-dependent insulin resistance via disrupting PA binding to MD2.	celastrol	32-41	lymphocyte antigen 96	Homo sapiens	72-75
29667734-8	2018	Taking together, we proved that celastrol could reverses PA-caused TLR4-MD2 activation-dependent insulin resistance via disrupting PA binding to MD2.	celastrol	32-41	insulin	Homo sapiens	97-104
29667734-4	2018	As celastrol is reported to directly target MD2, we thought disrupting the binding between FFAs and MD2 might be one of the ways for celastrol to inhibit FFAs-caused inflammation and insulin resistance.	celastrol	3-12	lymphocyte antigen 96	Homo sapiens	44-47
29667734-8	2018	Taking together, we proved that celastrol could reverses PA-caused TLR4-MD2 activation-dependent insulin resistance via disrupting PA binding to MD2.	celastrol	32-41	lymphocyte antigen 96	Homo sapiens	145-148
29667734-4	2018	As celastrol is reported to directly target MD2, we thought disrupting the binding between FFAs and MD2 might be one of the ways for celastrol to inhibit FFAs-caused inflammation and insulin resistance.	celastrol	3-12	lymphocyte antigen 96	Homo sapiens	100-103
29667734-4	2018	As celastrol is reported to directly target MD2, we thought disrupting the binding between FFAs and MD2 might be one of the ways for celastrol to inhibit FFAs-caused inflammation and insulin resistance.	celastrol	133-142	lymphocyte antigen 96	Homo sapiens	44-47
30255683-6	2018	With the increase of the concentration of celastrol, the ratio of Bax/Bcl-2 protein was up-regulated.	celastrol	42-51	BCL2 associated X, apoptosis regulator	Homo sapiens	66-69
29667734-4	2018	As celastrol is reported to directly target MD2, we thought disrupting the binding between FFAs and MD2 might be one of the ways for celastrol to inhibit FFAs-caused inflammation and insulin resistance.	celastrol	133-142	lymphocyte antigen 96	Homo sapiens	100-103
29667734-4	2018	As celastrol is reported to directly target MD2, we thought disrupting the binding between FFAs and MD2 might be one of the ways for celastrol to inhibit FFAs-caused inflammation and insulin resistance.	celastrol	133-142	insulin	Homo sapiens	183-190
29667734-5	2018	In this study, we found evidence to support our hypothesis: celastrol could reverse PA-caused TLR4/MD2 activation-dependent insulin resistance, as determined by glucose-lowering ability, cellular glucose uptake, insulin action-related proteins and TLR4/MD2/NF-kappaB activation.	celastrol	60-69	toll like receptor 4	Homo sapiens	94-98
29667734-5	2018	In this study, we found evidence to support our hypothesis: celastrol could reverse PA-caused TLR4/MD2 activation-dependent insulin resistance, as determined by glucose-lowering ability, cellular glucose uptake, insulin action-related proteins and TLR4/MD2/NF-kappaB activation.	celastrol	60-69	lymphocyte antigen 96	Homo sapiens	99-102
29667734-5	2018	In this study, we found evidence to support our hypothesis: celastrol could reverse PA-caused TLR4/MD2 activation-dependent insulin resistance, as determined by glucose-lowering ability, cellular glucose uptake, insulin action-related proteins and TLR4/MD2/NF-kappaB activation.	celastrol	60-69	insulin	Homo sapiens	124-131
29667734-5	2018	In this study, we found evidence to support our hypothesis: celastrol could reverse PA-caused TLR4/MD2 activation-dependent insulin resistance, as determined by glucose-lowering ability, cellular glucose uptake, insulin action-related proteins and TLR4/MD2/NF-kappaB activation.	celastrol	60-69	insulin	Homo sapiens	212-219
29667734-5	2018	In this study, we found evidence to support our hypothesis: celastrol could reverse PA-caused TLR4/MD2 activation-dependent insulin resistance, as determined by glucose-lowering ability, cellular glucose uptake, insulin action-related proteins and TLR4/MD2/NF-kappaB activation.	celastrol	60-69	toll like receptor 4	Homo sapiens	248-252
29667734-5	2018	In this study, we found evidence to support our hypothesis: celastrol could reverse PA-caused TLR4/MD2 activation-dependent insulin resistance, as determined by glucose-lowering ability, cellular glucose uptake, insulin action-related proteins and TLR4/MD2/NF-kappaB activation.	celastrol	60-69	lymphocyte antigen 96	Homo sapiens	253-256
30106429-7	2018	Pretreatment with the PERK inhibitor GSK2656157 significantly promoted celastrol-induced death and attenuated HOS cell autophagy.	celastrol	71-80	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	22-26
30106429-9	2018	The ERS/PERK pathway may protect HOS cells from apoptosis by celastrol and may play a complicated role in the process of autophagy.	celastrol	61-70	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	8-12
30015859-10	2018	These results suggest that celastrol exerts its protective effect partly via inhibiting the TLR4-mediated immune and inflammatory response in steatotic HepG2 cells.	celastrol	27-36	toll like receptor 4	Homo sapiens	92-96
30255683-6	2018	With the increase of the concentration of celastrol, the ratio of Bax/Bcl-2 protein was up-regulated.	celastrol	42-51	BCL2 apoptosis regulator	Homo sapiens	70-75
30255683-7	2018	The Caspase-3/7 protein was cleaved and activated after treatment with celastrol.	celastrol	71-80	caspase 3	Homo sapiens	4-15
30255683-9	2018	Taken together, these results indicated that celastrol effectively inhibited the proliferation of adult T-cell leukemia cells by regulating the expression of Bcl-2 family protein, and induced cell apoptosis by activating Caspase dependent pathway.	celastrol	45-54	BCL2 apoptosis regulator	Homo sapiens	158-163
30103947-4	2018	We found that celastrol, a c-Myb inhibitor, inhibited NK-92 cells more strongly than any other inhibitors of transcription factor candidates.	celastrol	14-23	MYB proto-oncogene, transcription factor	Homo sapiens	27-32
30093405-6	2018	Pharmacological up-regulation of Hsp70 by the Hsp90 inhibitors celastrol and herbimycin A attenuated the aggregation of mutant PKCgamma in primary cultured Purkinje cells.	celastrol	63-72	heat shock protein, 2	Mus musculus	46-51
30093405-6	2018	Pharmacological up-regulation of Hsp70 by the Hsp90 inhibitors celastrol and herbimycin A attenuated the aggregation of mutant PKCgamma in primary cultured Purkinje cells.	celastrol	63-72	protein kinase C, gamma	Mus musculus	127-135
30093405-9	2018	Extending our in vitro observations, administration of celastrol to mice up-regulated cerebellar Hsp70.	celastrol	55-64	heat shock protein 1B	Mus musculus	97-102
30093405-6	2018	Pharmacological up-regulation of Hsp70 by the Hsp90 inhibitors celastrol and herbimycin A attenuated the aggregation of mutant PKCgamma in primary cultured Purkinje cells.	celastrol	63-72	heat shock protein 1B	Mus musculus	33-38
30103947-6	2018	We also found that celastrol inhibits NK-92-cell-mediated cytotoxicity via the downregulation of NKG2D and granzyme B.	celastrol	19-28	killer cell lectin like receptor K1	Homo sapiens	97-102
30103947-6	2018	We also found that celastrol inhibits NK-92-cell-mediated cytotoxicity via the downregulation of NKG2D and granzyme B.	celastrol	19-28	granzyme B	Homo sapiens	107-117
30839692-8	2018	Furthermore, it was confirmed that celastrol, a positive drug for the treatment of RA, inhibited SW982 cell migration as well as TRAP activity in the cell-cultured microfluidic chips.	celastrol	35-44	acid phosphatase 5, tartrate resistant	Mus musculus	129-133
29913408-9	2018	Tripterine alleviated LPS-induced reduction of cell viability, increase of apoptosis and the release of IL-6 and TNF-alpha in HaCaT cells.	celastrol	0-10	tumor necrosis factor	Homo sapiens	113-122
29927769-0	2018	Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.	celastrol	0-9	epidermal growth factor receptor	Homo sapiens	47-51
29927769-0	2018	Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.	celastrol	0-9	epidermal growth factor receptor	Homo sapiens	102-106
29927769-5	2018	In this study, we showed that celastrol combined with EGFR-TKIs significantly suppressed cell invasion of lung cancer cells with a T790M mutation by suppressing the EGFR pathway.	celastrol	30-39	epidermal growth factor receptor	Homo sapiens	165-169
29927769-7	2018	Together, these results suggested that combined therapy with EGFR-TKIs and celastrol may be a more effective treatment of patients with non-small-cell lung cancer with T790M mutations of the EGFR.	celastrol	75-84	epidermal growth factor receptor	Homo sapiens	191-195
29913408-0	2018	Tripterine alleviates LPS-induced inflammatory injury by up-regulation of miR-146a in HaCaT cells.	celastrol	0-10	microRNA 146a	Homo sapiens	74-82
29913408-9	2018	Tripterine alleviated LPS-induced reduction of cell viability, increase of apoptosis and the release of IL-6 and TNF-alpha in HaCaT cells.	celastrol	0-10	interleukin 6	Homo sapiens	104-108
29614269-3	2018	Here, we found that celastrol dose-dependently suppressed IL-13 induced CD206 expression both in RAW264.7 and in primary macrophages.	celastrol	20-29	interleukin 13	Homo sapiens	58-63
29614269-3	2018	Here, we found that celastrol dose-dependently suppressed IL-13 induced CD206 expression both in RAW264.7 and in primary macrophages.	celastrol	20-29	mannose receptor C-type 1	Homo sapiens	72-77
29614269-4	2018	Consistently, celastrol also inhibited the expression of M2-like specific genes, including MRC1, Arg1, Fizz1, Mgl2 and CD11c.	celastrol	14-23	mannose receptor C-type 1	Homo sapiens	91-95
29614269-4	2018	Consistently, celastrol also inhibited the expression of M2-like specific genes, including MRC1, Arg1, Fizz1, Mgl2 and CD11c.	celastrol	14-23	arginase 1	Homo sapiens	97-101
29614269-4	2018	Consistently, celastrol also inhibited the expression of M2-like specific genes, including MRC1, Arg1, Fizz1, Mgl2 and CD11c.	celastrol	14-23	resistin like beta	Homo sapiens	103-108
29614269-4	2018	Consistently, celastrol also inhibited the expression of M2-like specific genes, including MRC1, Arg1, Fizz1, Mgl2 and CD11c.	celastrol	14-23	integrin subunit alpha X	Homo sapiens	119-124
29614269-6	2018	Mechanistically, celastrol completely ameliorated STAT6 phosphorylation, which is the key signal molecule responsible for M2 polarization.	celastrol	17-26	signal transducer and activator of transcription 6	Homo sapiens	50-55
29614269-7	2018	Our research puts forward a new application of celastrol in anti-cancer metastasis, by intervening M2-like polarization through inhibiting STAT6.	celastrol	47-56	signal transducer and activator of transcription 6	Homo sapiens	139-144
29913408-11	2018	Further, inhibition of miR-146a abolished the protective effect of tripterine on cell damage triggered by LPS.	celastrol	67-77	microRNA 146a	Homo sapiens	23-31
29913408-12	2018	Finally, tripterine deactivated JNK and NF-kappaB pathways through up-regulation of miR-146a.	celastrol	9-19	mitogen-activated protein kinase 8	Homo sapiens	32-35
29913408-12	2018	Finally, tripterine deactivated JNK and NF-kappaB pathways through up-regulation of miR-146a.	celastrol	9-19	microRNA 146a	Homo sapiens	84-92
29913408-13	2018	CONCLUSION: These results demonstrated that tripterine could attenuate LPS-induced inflammatory injury and deactivate JNK and NF-kappaB pathways by up-regulation of miR-146a.	celastrol	44-54	mitogen-activated protein kinase 8	Homo sapiens	118-121
29913408-13	2018	CONCLUSION: These results demonstrated that tripterine could attenuate LPS-induced inflammatory injury and deactivate JNK and NF-kappaB pathways by up-regulation of miR-146a.	celastrol	44-54	microRNA 146a	Homo sapiens	165-173
30081592-7	2018	Interestingly, 6 of them (miR-22, miR-27a, miR-96, miR-142, miR-223, and miR-296) were further modulated by celastrol treatment.	celastrol	108-117	microRNA 296	Rattus norvegicus	73-80
30220146-0	2018	[Influence of celastrol on toll-like receptor 4-mediated signaling pathway in the free fatty acids-induced HepG2 cells].	celastrol	14-23	toll like receptor 4	Homo sapiens	27-47
30220146-10	2018	Conclusion: Celastrol exerts its protective effect partly via inhibiting the TLR4-mediated signaling pathways in the steatotic HepG2 cells.	celastrol	12-21	toll like receptor 4	Homo sapiens	77-81
30081592-7	2018	Interestingly, 6 of them (miR-22, miR-27a, miR-96, miR-142, miR-223, and miR-296) were further modulated by celastrol treatment.	celastrol	108-117	microRNA 22	Rattus norvegicus	26-32
30081592-7	2018	Interestingly, 6 of them (miR-22, miR-27a, miR-96, miR-142, miR-223, and miR-296) were further modulated by celastrol treatment.	celastrol	108-117	microRNA 27a	Rattus norvegicus	34-41
30081592-7	2018	Interestingly, 6 of them (miR-22, miR-27a, miR-96, miR-142, miR-223, and miR-296) were further modulated by celastrol treatment.	celastrol	108-117	microRNA 96	Rattus norvegicus	43-49
30081592-7	2018	Interestingly, 6 of them (miR-22, miR-27a, miR-96, miR-142, miR-223, and miR-296) were further modulated by celastrol treatment.	celastrol	108-117	microRNA 142	Rattus norvegicus	51-58
30081592-7	2018	Interestingly, 6 of them (miR-22, miR-27a, miR-96, miR-142, miR-223, and miR-296) were further modulated by celastrol treatment.	celastrol	108-117	microRNA 223	Rattus norvegicus	60-67
30081592-8	2018	Interestingly, serum levels of miR-142, miR-155, and miR-223 were higher in arthritic versus control rats, whereas miR-212 showed increased expression in celastrol-treated rats compared with arthritic rats or control rats.	celastrol	154-163	microRNA 212	Rattus norvegicus	115-122
29631379-10	2018	Furthermore, treatment of Caco-2 cells with celastrol (NF-kappaB inhibitor) blocked the inhibitory effect caused by TNF-alpha on AA uptake, SVCT-1 protein, and mRNA expression, as well as the activity of SLC23A1 promoter.	celastrol	44-53	nuclear factor kappa B subunit 1	Homo sapiens	55-64
29631379-10	2018	Furthermore, treatment of Caco-2 cells with celastrol (NF-kappaB inhibitor) blocked the inhibitory effect caused by TNF-alpha on AA uptake, SVCT-1 protein, and mRNA expression, as well as the activity of SLC23A1 promoter.	celastrol	44-53	tumor necrosis factor	Homo sapiens	116-125
29631379-10	2018	Furthermore, treatment of Caco-2 cells with celastrol (NF-kappaB inhibitor) blocked the inhibitory effect caused by TNF-alpha on AA uptake, SVCT-1 protein, and mRNA expression, as well as the activity of SLC23A1 promoter.	celastrol	44-53	solute carrier family 23 member 1	Homo sapiens	140-146
29631379-10	2018	Furthermore, treatment of Caco-2 cells with celastrol (NF-kappaB inhibitor) blocked the inhibitory effect caused by TNF-alpha on AA uptake, SVCT-1 protein, and mRNA expression, as well as the activity of SLC23A1 promoter.	celastrol	44-53	solute carrier family 23 member 1	Homo sapiens	204-211
29631379-11	2018	Treatment of TNF-alpha also led to a significant decrease in the expression of hepatocyte nuclear factor-1-alpha, which drives the basal activity of SLC23A1 promoter, and this effect was reversed by celastrol.	celastrol	199-208	tumor necrosis factor	Homo sapiens	13-22
29631379-11	2018	Treatment of TNF-alpha also led to a significant decrease in the expression of hepatocyte nuclear factor-1-alpha, which drives the basal activity of SLC23A1 promoter, and this effect was reversed by celastrol.	celastrol	199-208	HNF1 homeobox A	Homo sapiens	79-112
29631379-11	2018	Treatment of TNF-alpha also led to a significant decrease in the expression of hepatocyte nuclear factor-1-alpha, which drives the basal activity of SLC23A1 promoter, and this effect was reversed by celastrol.	celastrol	199-208	solute carrier family 23 member 1	Homo sapiens	149-156
29987023-8	2018	Finally, high-throughput screening demonstrated that celastrol, an antioxidant and antiinflammatory agent, reduced the expressions of CyPA and Bsg in the heart and the lung, ameliorating cardiac dysfunction and postcapillary PH induced by TAC.	celastrol	53-62	peptidylprolyl isomerase A	Mus musculus	134-138
29394529-13	2018	Celastrol reverts these cellular changes in rat lungs, and it was found that celastrol regulates EMT through the inhibition of heat shock protein 90 (HSP 90).	celastrol	77-86	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	127-148
29394529-13	2018	Celastrol reverts these cellular changes in rat lungs, and it was found that celastrol regulates EMT through the inhibition of heat shock protein 90 (HSP 90).	celastrol	77-86	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	150-156
29987023-8	2018	Finally, high-throughput screening demonstrated that celastrol, an antioxidant and antiinflammatory agent, reduced the expressions of CyPA and Bsg in the heart and the lung, ameliorating cardiac dysfunction and postcapillary PH induced by TAC.	celastrol	53-62	basigin	Mus musculus	143-146
29987023-9	2018	Thus, by differentially affecting CyPA and Bsg expressions, ROCK1 protects and ROCK2 jeopardizes the heart from pressure-overload HF with postcapillary PH, for which celastrol may be a promising agent.	celastrol	166-175	peptidylprolyl isomerase A	Mus musculus	34-38
29987023-9	2018	Thus, by differentially affecting CyPA and Bsg expressions, ROCK1 protects and ROCK2 jeopardizes the heart from pressure-overload HF with postcapillary PH, for which celastrol may be a promising agent.	celastrol	166-175	basigin	Mus musculus	43-46
29987023-9	2018	Thus, by differentially affecting CyPA and Bsg expressions, ROCK1 protects and ROCK2 jeopardizes the heart from pressure-overload HF with postcapillary PH, for which celastrol may be a promising agent.	celastrol	166-175	Rho-associated coiled-coil containing protein kinase 1	Mus musculus	60-65
29987023-9	2018	Thus, by differentially affecting CyPA and Bsg expressions, ROCK1 protects and ROCK2 jeopardizes the heart from pressure-overload HF with postcapillary PH, for which celastrol may be a promising agent.	celastrol	166-175	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	79-84
30093945-7	2018	Following celastrol pretreatment, mice showed increased mortality rate and aggravated inflammation evidenced by further enhanced inflammatory markers of IL-6, IL-1beta, TNF-alpha, IL-18, MCP-1, and ICAM-1 in circulation, liver, and kidney after LPS treatment.	celastrol	10-19	interleukin 6	Mus musculus	153-157
30093945-7	2018	Following celastrol pretreatment, mice showed increased mortality rate and aggravated inflammation evidenced by further enhanced inflammatory markers of IL-6, IL-1beta, TNF-alpha, IL-18, MCP-1, and ICAM-1 in circulation, liver, and kidney after LPS treatment.	celastrol	10-19	interleukin 1 beta	Mus musculus	159-167
30093945-7	2018	Following celastrol pretreatment, mice showed increased mortality rate and aggravated inflammation evidenced by further enhanced inflammatory markers of IL-6, IL-1beta, TNF-alpha, IL-18, MCP-1, and ICAM-1 in circulation, liver, and kidney after LPS treatment.	celastrol	10-19	intercellular adhesion molecule 1	Mus musculus	198-204
30093945-7	2018	Following celastrol pretreatment, mice showed increased mortality rate and aggravated inflammation evidenced by further enhanced inflammatory markers of IL-6, IL-1beta, TNF-alpha, IL-18, MCP-1, and ICAM-1 in circulation, liver, and kidney after LPS treatment.	celastrol	10-19	tumor necrosis factor	Mus musculus	169-178
30093945-8	2018	The serum levels of ALT, AST, and LDH were further increased in parallel with the deteriorated liver morphological damage (H&amp;E) and oxidative stress in celastrol-treated mice, indicating an aggravated liver injury.	celastrol	156-165	glutamic pyruvic transaminase, soluble	Mus musculus	20-23
30093945-7	2018	Following celastrol pretreatment, mice showed increased mortality rate and aggravated inflammation evidenced by further enhanced inflammatory markers of IL-6, IL-1beta, TNF-alpha, IL-18, MCP-1, and ICAM-1 in circulation, liver, and kidney after LPS treatment.	celastrol	10-19	interleukin 18	Mus musculus	180-185
30093945-8	2018	The serum levels of ALT, AST, and LDH were further increased in parallel with the deteriorated liver morphological damage (H&amp;E) and oxidative stress in celastrol-treated mice, indicating an aggravated liver injury.	celastrol	156-165	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	25-28
30093945-9	2018	In kidney, the expressions of tubular injury markers of kidney injury molecule-1 (KIM-1) and gelatinase-associated lipocalin (NGAL) were further upregulated along with higher levels of blood urea nitrogen (BUN), creatinine (Cr), and MDA in celastrol-treated mice.	celastrol	240-249	hepatitis A virus cellular receptor 1	Mus musculus	56-80
30093945-9	2018	In kidney, the expressions of tubular injury markers of kidney injury molecule-1 (KIM-1) and gelatinase-associated lipocalin (NGAL) were further upregulated along with higher levels of blood urea nitrogen (BUN), creatinine (Cr), and MDA in celastrol-treated mice.	celastrol	240-249	hepatitis A virus cellular receptor 1	Mus musculus	82-87
30093945-7	2018	Following celastrol pretreatment, mice showed increased mortality rate and aggravated inflammation evidenced by further enhanced inflammatory markers of IL-6, IL-1beta, TNF-alpha, IL-18, MCP-1, and ICAM-1 in circulation, liver, and kidney after LPS treatment.	celastrol	10-19	mast cell protease 1	Mus musculus	187-192
29553945-5	2018	Celastrol treatment also decreased the PI3K/AKT pathway components, and MMP3 and MMP7 expression levels.	celastrol	0-9	matrix metallopeptidase 7	Homo sapiens	81-85
29553945-0	2018	Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway.	celastrol	0-9	matrix metallopeptidase 3	Homo sapiens	93-97
29694830-0	2018	Celastrol attenuates symptoms of preeclampsia in rats by inhibiting matrix metalloproteinase-9.	celastrol	0-9	matrix metallopeptidase 9	Rattus norvegicus	68-94
29553945-6	2018	In addition, knockdown of AKT, not mTOR, inhibited MMP3 and MMP7 expression levels and AKT silencing promoted the celastrol-induced effects on CRC cell proliferation and migration.	celastrol	114-123	AKT serine/threonine kinase 1	Homo sapiens	87-90
29553945-0	2018	Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway.	celastrol	0-9	matrix metallopeptidase 7	Homo sapiens	102-106
29553945-0	2018	Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	119-122
29553945-5	2018	Celastrol treatment also decreased the PI3K/AKT pathway components, and MMP3 and MMP7 expression levels.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	44-47
29553945-7	2018	Taken together, these findings indicated that the celastrol-induced antitumor effects were mediated through MMP3 and MMP7 by the PI3K/AKT signaling pathway.	celastrol	50-59	matrix metallopeptidase 3	Homo sapiens	108-112
29553945-5	2018	Celastrol treatment also decreased the PI3K/AKT pathway components, and MMP3 and MMP7 expression levels.	celastrol	0-9	matrix metallopeptidase 3	Homo sapiens	72-76
29553945-7	2018	Taken together, these findings indicated that the celastrol-induced antitumor effects were mediated through MMP3 and MMP7 by the PI3K/AKT signaling pathway.	celastrol	50-59	matrix metallopeptidase 7	Homo sapiens	117-121
29553945-7	2018	Taken together, these findings indicated that the celastrol-induced antitumor effects were mediated through MMP3 and MMP7 by the PI3K/AKT signaling pathway.	celastrol	50-59	AKT serine/threonine kinase 1	Homo sapiens	134-137
29493374-4	2018	OBJECTIVE: This study investigated the effect of celastrol on mRNA expression and concentration levels of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL6) that are induced by influenza A/Puerto Rico/8/34 (H1N1; PR8) in Madin-Darby Canine Kidney (MDCK) cells.	celastrol	49-58	tumor necrosis factor	Homo sapiens	166-174
29793976-5	2018	Application of a pan-Nox inhibitor, celastrol, during the time of optic nerve (ON) outgrowth resulted in significant expansion of the ganglion cell layer (GCL), thinning of the ON, and a decrease in retinal axons reaching the optic tectum (OT).	celastrol	36-45	germ cell-less, spermatogenesis associated	Danio rerio	155-158
29694830-9	2018	Urinary mRNA levels of podocin and nephrin, as well as PlGF, MMP-9 and sFlt-1, were all reversed in preeclampsia plus celastrol group compared to rats in the preeclampsia group without celastrol treatments.	celastrol	118-127	NPHS2 stomatin family member, podocin	Rattus norvegicus	23-30
29694830-9	2018	Urinary mRNA levels of podocin and nephrin, as well as PlGF, MMP-9 and sFlt-1, were all reversed in preeclampsia plus celastrol group compared to rats in the preeclampsia group without celastrol treatments.	celastrol	118-127	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	35-42
29694830-9	2018	Urinary mRNA levels of podocin and nephrin, as well as PlGF, MMP-9 and sFlt-1, were all reversed in preeclampsia plus celastrol group compared to rats in the preeclampsia group without celastrol treatments.	celastrol	118-127	placental growth factor	Rattus norvegicus	55-59
29694830-9	2018	Urinary mRNA levels of podocin and nephrin, as well as PlGF, MMP-9 and sFlt-1, were all reversed in preeclampsia plus celastrol group compared to rats in the preeclampsia group without celastrol treatments.	celastrol	118-127	matrix metallopeptidase 9	Rattus norvegicus	61-66
29694830-10	2018	MMP-9 overexpression in rats completely abolished the alleviating effect of celastrol.	celastrol	76-85	matrix metallopeptidase 9	Rattus norvegicus	0-5
29694830-11	2018	We hereby presented the first evidence that celastrol attenuated preeclampsia symptoms in an L-NAME-induced rat model of preeclampsia through inhibition of MMP-9 expression, supporting the potential therapeutic value of celastrol in the treatment of preeclampsia.	celastrol	44-53	matrix metallopeptidase 9	Rattus norvegicus	156-161
29694830-11	2018	We hereby presented the first evidence that celastrol attenuated preeclampsia symptoms in an L-NAME-induced rat model of preeclampsia through inhibition of MMP-9 expression, supporting the potential therapeutic value of celastrol in the treatment of preeclampsia.	celastrol	220-229	matrix metallopeptidase 9	Rattus norvegicus	156-161
28984147-7	2018	Also, celastrol posttreatments attenuated the APAP-induced oxidative stress by raising glutathione peroxidase, glutathione reductase, and catalase activities.	celastrol	6-15	glutathione-disulfide reductase	Homo sapiens	111-132
29928421-10	2018	The downregulation of p-Akt and p-ERK induced by Apatinib and Tripterine was further inhibited in the combination group (P&lt;0.05), and the expression levels of Caspase-3 and Bax were also significantly increased in the combination group (P&lt;0.05).	celastrol	62-72	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	32-37
29928421-10	2018	The downregulation of p-Akt and p-ERK induced by Apatinib and Tripterine was further inhibited in the combination group (P&lt;0.05), and the expression levels of Caspase-3 and Bax were also significantly increased in the combination group (P&lt;0.05).	celastrol	62-72	caspase 3	Homo sapiens	162-171
29928421-10	2018	The downregulation of p-Akt and p-ERK induced by Apatinib and Tripterine was further inhibited in the combination group (P&lt;0.05), and the expression levels of Caspase-3 and Bax were also significantly increased in the combination group (P&lt;0.05).	celastrol	62-72	BCL2 associated X, apoptosis regulator	Homo sapiens	176-179
29928421-11	2018	The combination of Apatinib and Tripterine significantly inhibited the proliferation, migration and invasion ability and promoted the apoptosis of Hep3B cells by downregulating the expression of p-Akt and p-ERK, and upregulating the expression of Caspase-3 and Bax.	celastrol	32-42	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	205-210
29928421-11	2018	The combination of Apatinib and Tripterine significantly inhibited the proliferation, migration and invasion ability and promoted the apoptosis of Hep3B cells by downregulating the expression of p-Akt and p-ERK, and upregulating the expression of Caspase-3 and Bax.	celastrol	32-42	caspase 3	Homo sapiens	247-256
29928421-11	2018	The combination of Apatinib and Tripterine significantly inhibited the proliferation, migration and invasion ability and promoted the apoptosis of Hep3B cells by downregulating the expression of p-Akt and p-ERK, and upregulating the expression of Caspase-3 and Bax.	celastrol	32-42	BCL2 associated X, apoptosis regulator	Homo sapiens	261-264
29493374-4	2018	OBJECTIVE: This study investigated the effect of celastrol on mRNA expression and concentration levels of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL6) that are induced by influenza A/Puerto Rico/8/34 (H1N1; PR8) in Madin-Darby Canine Kidney (MDCK) cells.	celastrol	49-58	interleukin 6	Homo sapiens	195-198
29493374-9	2018	RESULTS: mRNA expression and concentrations of TNFalpha and IL6 increased significantly in control virus compared to cell control, and decreased significantly when compared with control virus after celastrol treatment.	celastrol	198-207	tumor necrosis factor	Homo sapiens	47-55
29493374-9	2018	RESULTS: mRNA expression and concentrations of TNFalpha and IL6 increased significantly in control virus compared to cell control, and decreased significantly when compared with control virus after celastrol treatment.	celastrol	198-207	interleukin 6	Homo sapiens	60-63
29493374-11	2018	CONCLUSION: Due to reducing mRNA expression and concentrations of TNFalpha and IL6, celastrol can serve as a suitable choice to control cytokine-induced inflammation in IAV infection, and therefore it can be used with current antiviral drugs.	celastrol	84-93	tumor necrosis factor	Homo sapiens	66-74
29493374-11	2018	CONCLUSION: Due to reducing mRNA expression and concentrations of TNFalpha and IL6, celastrol can serve as a suitable choice to control cytokine-induced inflammation in IAV infection, and therefore it can be used with current antiviral drugs.	celastrol	84-93	interleukin 6	Homo sapiens	79-82
29274099-0	2018	Effects of celastrol on Tau hyperphosphorylation and expression of HSF-1 and HSP70 in SH-SY5Y neuroblastoma cells induced by amyloid-beta peptides.	celastrol	11-20	heat shock transcription factor 1	Homo sapiens	67-72
29789558-0	2018	Celastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression.	celastrol	0-9	cannabinoid receptor 2 (macrophage)	Mus musculus	52-74
29789558-7	2018	Furthermore, celastrol potentiated the expression of the anti-fibrotic factor cannabinoid receptor 2 (CB2R) in established mouse fibrotic kidney tissues and transforming growth factor beta1 (TGF-beta1)-stimulated human kidney 2 (HK-2) cells.	celastrol	13-22	cannabinoid receptor 2 (macrophage)	Mus musculus	78-100
29789558-7	2018	Furthermore, celastrol potentiated the expression of the anti-fibrotic factor cannabinoid receptor 2 (CB2R) in established mouse fibrotic kidney tissues and transforming growth factor beta1 (TGF-beta1)-stimulated human kidney 2 (HK-2) cells.	celastrol	13-22	cannabinoid receptor 2 (macrophage)	Mus musculus	102-106
29789558-8	2018	In addition, the CB2R antagonist (SR144528) abolished celastrol-mediated beneficial effects on renal fibrosis.	celastrol	54-63	cannabinoid receptor 2 (macrophage)	Mus musculus	17-21
29789558-9	2018	Moreover, UUO- or TGF-beta1-induced activation of the pro-fibrotic factor SMAD family member 3 (Smad3) was markedly inhibited by celastrol.	celastrol	129-138	transforming growth factor, beta 1	Mus musculus	18-27
29789558-9	2018	Moreover, UUO- or TGF-beta1-induced activation of the pro-fibrotic factor SMAD family member 3 (Smad3) was markedly inhibited by celastrol.	celastrol	129-138	SMAD family member 3	Mus musculus	96-101
29789558-11	2018	In conclusion, our study provides the first direct evidence that celastrol significantly alleviated renal fibrosis, by contributing to the upregulation of CB2R expression through inhibiting Smad3 signaling pathway activation.	celastrol	65-74	cannabinoid receptor 2 (macrophage)	Mus musculus	155-159
29789558-11	2018	In conclusion, our study provides the first direct evidence that celastrol significantly alleviated renal fibrosis, by contributing to the upregulation of CB2R expression through inhibiting Smad3 signaling pathway activation.	celastrol	65-74	SMAD family member 3	Mus musculus	190-195
29274099-0	2018	Effects of celastrol on Tau hyperphosphorylation and expression of HSF-1 and HSP70 in SH-SY5Y neuroblastoma cells induced by amyloid-beta peptides.	celastrol	11-20	heat shock protein family A (Hsp70) member 4	Homo sapiens	77-82
29274099-5	2018	Meanwhile, both celastrol treatment and knockdown of HSP70 or HSF-1 in SH-SY5Y cells significantly inhibited the Tau hyperphosphorylation and HSP90 expression induced by Abeta1-42 .	celastrol	16-25	heat shock protein 90 alpha family class A member 1	Homo sapiens	142-147
29484434-0	2018	miR-33a-5p enhances the sensitivity of lung adenocarcinoma cells to celastrol by regulating mTOR signaling.	celastrol	68-77	MLX interacting protein	Homo sapiens	0-3
29484434-13	2018	In summary, miR-33a-5p inhibited the proliferation of lung adenocarcinoma cells, enhanced the antitumor effect of celastrol, and improved sensitivity to celastrol by targeting mTOR in lung adenocarcinoma in vitro and in vivo.	celastrol	153-162	mechanistic target of rapamycin kinase	Homo sapiens	176-180
29765532-4	2018	With the use of flow cytometry we have shown that celastrol reduces the cell size of the SP (side population; subpopulation of cancer cells enriched with cancer stem cells), increases frequency of apoptosis and binds to Pgp protein in cell membranes inhibiting its transport function.	celastrol	50-59	phosphoglycolate phosphatase	Homo sapiens	220-223
29484434-0	2018	miR-33a-5p enhances the sensitivity of lung adenocarcinoma cells to celastrol by regulating mTOR signaling.	celastrol	68-77	mechanistic target of rapamycin kinase	Homo sapiens	92-96
29484434-6	2018	Following treatment with celastrol, miR-33a-5p expression was upregulated, and miR-33a-5p could enhance cellular sensitivity to celastrol.	celastrol	25-34	MLX interacting protein	Homo sapiens	36-39
29484434-6	2018	Following treatment with celastrol, miR-33a-5p expression was upregulated, and miR-33a-5p could enhance cellular sensitivity to celastrol.	celastrol	25-34	MLX interacting protein	Homo sapiens	79-82
29484434-6	2018	Following treatment with celastrol, miR-33a-5p expression was upregulated, and miR-33a-5p could enhance cellular sensitivity to celastrol.	celastrol	128-137	MLX interacting protein	Homo sapiens	79-82
29484434-7	2018	Western blot analysis revealed that the expression of mTOR, p-p70S6K and p-4EBP1 decreased following celastrol treatment.	celastrol	101-110	mechanistic target of rapamycin kinase	Homo sapiens	54-58
29484434-7	2018	Western blot analysis revealed that the expression of mTOR, p-p70S6K and p-4EBP1 decreased following celastrol treatment.	celastrol	101-110	ribosomal protein S6 kinase B1	Homo sapiens	62-68
29484434-7	2018	Western blot analysis revealed that the expression of mTOR, p-p70S6K and p-4EBP1 decreased following celastrol treatment.	celastrol	101-110	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	75-80
29484434-8	2018	These results suggested that mTOR was involved in the mechanism by which miR-33a-5p enhanced the sensitivity of lung adenocarcinoma cells to celastrol.	celastrol	141-150	mechanistic target of rapamycin kinase	Homo sapiens	29-33
29484434-8	2018	These results suggested that mTOR was involved in the mechanism by which miR-33a-5p enhanced the sensitivity of lung adenocarcinoma cells to celastrol.	celastrol	141-150	MLX interacting protein	Homo sapiens	73-76
29484434-12	2018	In addition, celastrol upregulated the expression of miR-33a-5p, and high expression of miR-33a-5p inhibited mTOR and its downstream effectors.	celastrol	13-22	MLX interacting protein	Homo sapiens	53-56
29484434-12	2018	In addition, celastrol upregulated the expression of miR-33a-5p, and high expression of miR-33a-5p inhibited mTOR and its downstream effectors.	celastrol	13-22	MLX interacting protein	Homo sapiens	88-91
29484434-12	2018	In addition, celastrol upregulated the expression of miR-33a-5p, and high expression of miR-33a-5p inhibited mTOR and its downstream effectors.	celastrol	13-22	mechanistic target of rapamycin kinase	Homo sapiens	109-113
29484434-13	2018	In summary, miR-33a-5p inhibited the proliferation of lung adenocarcinoma cells, enhanced the antitumor effect of celastrol, and improved sensitivity to celastrol by targeting mTOR in lung adenocarcinoma in vitro and in vivo.	celastrol	114-123	MLX interacting protein	Homo sapiens	12-15
29484434-13	2018	In summary, miR-33a-5p inhibited the proliferation of lung adenocarcinoma cells, enhanced the antitumor effect of celastrol, and improved sensitivity to celastrol by targeting mTOR in lung adenocarcinoma in vitro and in vivo.	celastrol	153-162	MLX interacting protein	Homo sapiens	12-15
29476742-8	2018	Celastrol suppressed the expression of glucose transporter, Glut1, and the rate-limiting enzyme, HK2, in addition to mTOR, HIF-1alpha, c-Myc and Akt expression in Th17 cells.	celastrol	0-9	hexokinase 2	Rattus norvegicus	97-100
29534015-2	2018	Here, we report the antitumor effect of celastrol, an anti-inflammatory compound and a recognized HSP90 inhibitor, in Hodgkin and Reed-Sternberg cell lines.	celastrol	40-49	heat shock protein 90 alpha family class A member 1	Homo sapiens	98-103
29534015-4	2018	In KM-H2 cells, celastrol inhibited cell proliferation, induced G0/G1 arrest, and triggered apoptosis through the activation of caspase-3/7.	celastrol	16-25	caspase 3	Homo sapiens	128-137
29534015-6	2018	A proteomic screening identified a total of 262 differentially expressed proteins in sensitive KM-H2 cells and revealed that celastrol"s toxicity involved the suppression of the MAPK/ERK (extracellular signal regulated kinase/mitogen activated protein kinase) pathway.	celastrol	125-134	mitogen-activated protein kinase 3	Homo sapiens	178-182
29534015-6	2018	A proteomic screening identified a total of 262 differentially expressed proteins in sensitive KM-H2 cells and revealed that celastrol"s toxicity involved the suppression of the MAPK/ERK (extracellular signal regulated kinase/mitogen activated protein kinase) pathway.	celastrol	125-134	mitogen-activated protein kinase 3	Homo sapiens	183-186
29534015-8	2018	The L428 resistant cells exhibited a marked induction of HSP27 mRNA and protein after celastrol treatment.	celastrol	86-95	heat shock protein family B (small) member 1	Homo sapiens	57-62
29534015-9	2018	Our results provide the first evidence that celastrol has antitumor effects in cHL cells through the suppression of the MAPK/ERK pathway.	celastrol	44-53	mitogen-activated protein kinase 3	Homo sapiens	120-124
29534015-9	2018	Our results provide the first evidence that celastrol has antitumor effects in cHL cells through the suppression of the MAPK/ERK pathway.	celastrol	44-53	mitogen-activated protein kinase 3	Homo sapiens	125-128
29534015-10	2018	Resistance to celastrol has rarely been described, and our results suggest that in cHL it may be mediated by the upregulation of HSP27.	celastrol	14-23	heat shock protein family B (small) member 1	Homo sapiens	129-134
29540209-0	2018	Celastrol treatment protects against acute ischemic stroke-induced brain injury by promoting an IL-33/ST2 axis-mediated microglia/macrophage M2 polarization.	celastrol	0-9	interleukin 33	Homo sapiens	96-101
29540209-0	2018	Celastrol treatment protects against acute ischemic stroke-induced brain injury by promoting an IL-33/ST2 axis-mediated microglia/macrophage M2 polarization.	celastrol	0-9	ST2	Homo sapiens	102-105
29540209-7	2018	Furthermore, in vitro experiments confirmed that celastrol treatment decreased inflammatory cytokine expression induced by OGD through an IL-33/ST2 axis-mediated M2 microglia/macrophage polarization.	celastrol	49-58	interleukin 33	Homo sapiens	138-143
29540209-7	2018	Furthermore, in vitro experiments confirmed that celastrol treatment decreased inflammatory cytokine expression induced by OGD through an IL-33/ST2 axis-mediated M2 microglia/macrophage polarization.	celastrol	49-58	ST2	Homo sapiens	144-147
29475002-0	2018	Celastrol pretreatment attenuates rat myocardial ischemia/ reperfusion injury by inhibiting high mobility group box 1 protein expression via the PI3K/Akt pathway.	celastrol	0-9	high mobility group box 1	Rattus norvegicus	92-117
29475002-0	2018	Celastrol pretreatment attenuates rat myocardial ischemia/ reperfusion injury by inhibiting high mobility group box 1 protein expression via the PI3K/Akt pathway.	celastrol	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	150-153
29475002-2	2018	This study aimed to investigate the cardioprotective effects of celastrol pretreatment on I/R injury and to further explore whether its mechanism of action was associated with the inhibition of high mobility group box 1 protein (HMGB1) expression via the phosphoinositide 3-kinase (PI3K)/Akt pathway.	celastrol	64-73	high mobility group box 1	Rattus norvegicus	229-234
29475002-2	2018	This study aimed to investigate the cardioprotective effects of celastrol pretreatment on I/R injury and to further explore whether its mechanism of action was associated with the inhibition of high mobility group box 1 protein (HMGB1) expression via the phosphoinositide 3-kinase (PI3K)/Akt pathway.	celastrol	64-73	AKT serine/threonine kinase 1	Rattus norvegicus	288-291
29475002-7	2018	Additionally, celastrol downregulated HMGB1 expression and upregulated p-Akt expression in the myocardium.	celastrol	14-23	high mobility group box 1	Rattus norvegicus	38-43
29475002-7	2018	Additionally, celastrol downregulated HMGB1 expression and upregulated p-Akt expression in the myocardium.	celastrol	14-23	AKT serine/threonine kinase 1	Rattus norvegicus	73-76
29475002-8	2018	LY294002, a specific pI3k inhibitor, partially reversed the decreased HMGB1 expression, increased p-Akt expression induced by celastrol, and abolished the anti-apoptotic, anti-inflammatory and anti-oxidative effects of celastrol.	celastrol	126-135	AKT serine/threonine kinase 1	Rattus norvegicus	100-103
29476742-8	2018	Celastrol suppressed the expression of glucose transporter, Glut1, and the rate-limiting enzyme, HK2, in addition to mTOR, HIF-1alpha, c-Myc and Akt expression in Th17 cells.	celastrol	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	117-121
29475002-9	2018	CONCLUSION: These findings suggest that short-term pretreatment with celastrol protects against myocardial I/R injury by suppressing myocardial apoptosis, inflammatory response and oxidative stress via pI3k/Akt pathway activation and HMGB1 inhibition.	celastrol	69-78	AKT serine/threonine kinase 1	Rattus norvegicus	207-210
29475002-9	2018	CONCLUSION: These findings suggest that short-term pretreatment with celastrol protects against myocardial I/R injury by suppressing myocardial apoptosis, inflammatory response and oxidative stress via pI3k/Akt pathway activation and HMGB1 inhibition.	celastrol	69-78	high mobility group box 1	Rattus norvegicus	234-239
29476742-8	2018	Celastrol suppressed the expression of glucose transporter, Glut1, and the rate-limiting enzyme, HK2, in addition to mTOR, HIF-1alpha, c-Myc and Akt expression in Th17 cells.	celastrol	0-9	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	123-133
29476742-8	2018	Celastrol suppressed the expression of glucose transporter, Glut1, and the rate-limiting enzyme, HK2, in addition to mTOR, HIF-1alpha, c-Myc and Akt expression in Th17 cells.	celastrol	0-9	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	135-140
29476742-2	2018	Celastrol, a Chinese herbal compound that has anti-inflammatory and immunosuppressive properties, has been indicated to suppress T cell proliferation and Th17 cell induction, while facilitating Forkhead box P3 (Foxp3) expression and Treg cell generation.	celastrol	0-9	forkhead box P3	Rattus norvegicus	194-209
29476742-2	2018	Celastrol, a Chinese herbal compound that has anti-inflammatory and immunosuppressive properties, has been indicated to suppress T cell proliferation and Th17 cell induction, while facilitating Forkhead box P3 (Foxp3) expression and Treg cell generation.	celastrol	0-9	forkhead box P3	Rattus norvegicus	211-216
29476742-5	2018	Initially, we determined that Interleukin (IL)-17 expression by celastrol-treated Th17 was significantly decreased compared with untreated cells; however, the frequency of Foxp3+ cells was increased in celastrol-treated cells.	celastrol	64-73	interleukin 17A	Rattus norvegicus	30-49
29476742-5	2018	Initially, we determined that Interleukin (IL)-17 expression by celastrol-treated Th17 was significantly decreased compared with untreated cells; however, the frequency of Foxp3+ cells was increased in celastrol-treated cells.	celastrol	202-211	forkhead box P3	Rattus norvegicus	172-177
29476742-6	2018	We verified that celastrol inhibited phospho-STAT3 expression in cultured Th17 cells and up-regulated phospho-STAT5 expression in iTreg cells.	celastrol	17-26	signal transducer and activator of transcription 3	Rattus norvegicus	45-50
29476742-8	2018	Celastrol suppressed the expression of glucose transporter, Glut1, and the rate-limiting enzyme, HK2, in addition to mTOR, HIF-1alpha, c-Myc and Akt expression in Th17 cells.	celastrol	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	145-148
29476742-9	2018	Conversely, celastrol promoted FAO of lipids by up-regulating CPT1A and AMPKalpha expression in iTreg cells.	celastrol	12-21	carnitine palmitoyltransferase 1A	Rattus norvegicus	62-67
29476742-6	2018	We verified that celastrol inhibited phospho-STAT3 expression in cultured Th17 cells and up-regulated phospho-STAT5 expression in iTreg cells.	celastrol	17-26	signal transducer and activator of transcription 5A	Rattus norvegicus	110-115
29476742-8	2018	Celastrol suppressed the expression of glucose transporter, Glut1, and the rate-limiting enzyme, HK2, in addition to mTOR, HIF-1alpha, c-Myc and Akt expression in Th17 cells.	celastrol	0-9	solute carrier family 2 member 1	Rattus norvegicus	60-65
30250883-2	2018	We recently identified a critical role of nuclear receptor Nur77 and celastrol in priming inflamed mitochondria for autophagy through its mitochondrial targeting and interaction with tumor necrosis factor receptor-associated factor 2 (TRAF2) and the autophagic adaptor p62/SQSTM1.	celastrol	69-78	TNF receptor associated factor 2	Homo sapiens	183-233
30250883-2	2018	We recently identified a critical role of nuclear receptor Nur77 and celastrol in priming inflamed mitochondria for autophagy through its mitochondrial targeting and interaction with tumor necrosis factor receptor-associated factor 2 (TRAF2) and the autophagic adaptor p62/SQSTM1.	celastrol	69-78	TNF receptor associated factor 2	Homo sapiens	235-240
30250883-2	2018	We recently identified a critical role of nuclear receptor Nur77 and celastrol in priming inflamed mitochondria for autophagy through its mitochondrial targeting and interaction with tumor necrosis factor receptor-associated factor 2 (TRAF2) and the autophagic adaptor p62/SQSTM1.	celastrol	69-78	sequestosome 1	Homo sapiens	269-272
30250883-2	2018	We recently identified a critical role of nuclear receptor Nur77 and celastrol in priming inflamed mitochondria for autophagy through its mitochondrial targeting and interaction with tumor necrosis factor receptor-associated factor 2 (TRAF2) and the autophagic adaptor p62/SQSTM1.	celastrol	69-78	sequestosome 1	Homo sapiens	273-279
29090408-5	2018	Small interfering RNA (siRNA) knockdown of HSPA6 and HSPA1A resulted in loss of the protective effect of co-application of celastrol/arimoclomol.	celastrol	123-132	heat shock protein family A (Hsp70) member 6	Homo sapiens	43-48
28726161-0	2018	Celastrol specifically inhibits the activation of NLRP3 inflammasome.	celastrol	0-9	NLR family pyrin domain containing 3	Homo sapiens	50-55
29394256-0	2018	The natural anti-tumor compound Celastrol targets a Myb-C/EBPbeta-p300 transcriptional module implicated in myeloid gene expression.	celastrol	32-41	myeloblastosis oncogene	Mus musculus	52-55
29394256-0	2018	The natural anti-tumor compound Celastrol targets a Myb-C/EBPbeta-p300 transcriptional module implicated in myeloid gene expression.	celastrol	32-41	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	56-65
29394256-0	2018	The natural anti-tumor compound Celastrol targets a Myb-C/EBPbeta-p300 transcriptional module implicated in myeloid gene expression.	celastrol	32-41	E1A binding protein p300	Mus musculus	66-70
29394256-2	2018	Using a myeloid cell line with a stably integrated Myb-inducible reporter gene as a screening tool we have previously identified Celastrol, a natural compound with anti-tumor activity, as a potent Myb inhibitor that disrupts the interaction of Myb with the co-activator p300.	celastrol	129-138	myeloblastosis oncogene	Mus musculus	51-54
29394256-2	2018	Using a myeloid cell line with a stably integrated Myb-inducible reporter gene as a screening tool we have previously identified Celastrol, a natural compound with anti-tumor activity, as a potent Myb inhibitor that disrupts the interaction of Myb with the co-activator p300.	celastrol	129-138	myeloblastosis oncogene	Mus musculus	197-200
29394256-2	2018	Using a myeloid cell line with a stably integrated Myb-inducible reporter gene as a screening tool we have previously identified Celastrol, a natural compound with anti-tumor activity, as a potent Myb inhibitor that disrupts the interaction of Myb with the co-activator p300.	celastrol	129-138	myeloblastosis oncogene	Mus musculus	197-200
29394256-2	2018	Using a myeloid cell line with a stably integrated Myb-inducible reporter gene as a screening tool we have previously identified Celastrol, a natural compound with anti-tumor activity, as a potent Myb inhibitor that disrupts the interaction of Myb with the co-activator p300.	celastrol	129-138	E1A binding protein p300	Mus musculus	270-274
29394256-3	2018	We showed that Celastrol inhibits the proliferation of acute myeloid leukemia (AML) cells and prolongs the survival of mice in an in vivo model of AML, demonstrating that targeting Myb with a small-molecule inhibitor is feasible and might have potential as a therapeutic approach against AML.	celastrol	15-24	myeloblastosis oncogene	Mus musculus	181-184
29394256-5	2018	By re-investigating the inhibitory potential of Celastrol we have found that Celastrol also strongly inhibits the activity of C/EBPbeta by disrupting its interaction with the Taz2 domain of p300.	celastrol	48-57	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	126-135
29394256-5	2018	By re-investigating the inhibitory potential of Celastrol we have found that Celastrol also strongly inhibits the activity of C/EBPbeta by disrupting its interaction with the Taz2 domain of p300.	celastrol	48-57	E1A binding protein p300	Mus musculus	190-194
29394256-5	2018	By re-investigating the inhibitory potential of Celastrol we have found that Celastrol also strongly inhibits the activity of C/EBPbeta by disrupting its interaction with the Taz2 domain of p300.	celastrol	77-86	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	126-135
29394256-5	2018	By re-investigating the inhibitory potential of Celastrol we have found that Celastrol also strongly inhibits the activity of C/EBPbeta by disrupting its interaction with the Taz2 domain of p300.	celastrol	77-86	E1A binding protein p300	Mus musculus	190-194
29394256-6	2018	Together with previous studies our work reveals that Celastrol independently targets Myb and C/EBPbeta by disrupting the interaction of both transcription factors with p300.	celastrol	53-62	myeloblastosis oncogene	Mus musculus	85-88
29394256-6	2018	Together with previous studies our work reveals that Celastrol independently targets Myb and C/EBPbeta by disrupting the interaction of both transcription factors with p300.	celastrol	53-62	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	93-102
29394256-6	2018	Together with previous studies our work reveals that Celastrol independently targets Myb and C/EBPbeta by disrupting the interaction of both transcription factors with p300.	celastrol	53-62	E1A binding protein p300	Mus musculus	168-172
29394256-8	2018	We hypothesize that the ability of Celastrol to disrupt the activity of a transcriptional Myb-C/EBPbeta-p300 module might explain its promising anti-leukemic activity.	celastrol	35-44	myeloblastosis oncogene	Mus musculus	90-93
29394256-8	2018	We hypothesize that the ability of Celastrol to disrupt the activity of a transcriptional Myb-C/EBPbeta-p300 module might explain its promising anti-leukemic activity.	celastrol	35-44	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	94-103
29394256-8	2018	We hypothesize that the ability of Celastrol to disrupt the activity of a transcriptional Myb-C/EBPbeta-p300 module might explain its promising anti-leukemic activity.	celastrol	35-44	E1A binding protein p300	Mus musculus	104-108
29090408-5	2018	Small interfering RNA (siRNA) knockdown of HSPA6 and HSPA1A resulted in loss of the protective effect of co-application of celastrol/arimoclomol.	celastrol	123-132	heat shock protein family A (Hsp70) member 1A	Homo sapiens	53-59
30068874-6	2018	Western blot analysis revealed that expression of indoleamine 2,3-dioxygenase (IDO), the enzyme catalyzing Trp to generate Kyn, was dramatically inhibited in colon cancer cells after celastrol treatment, with a dose-dependent manner.	celastrol	183-192	indoleamine 2,3-dioxygenase 1	Homo sapiens	50-77
29434967-6	2018	Celastrol may also decrease the phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) and the B cell lymphoma-2 (Bcl-2)/Bcl-2 associated C protein (Bax) ratio.	celastrol	0-9	signal transducer and activator of transcription 3	Homo sapiens	58-108
29434967-6	2018	Celastrol may also decrease the phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) and the B cell lymphoma-2 (Bcl-2)/Bcl-2 associated C protein (Bax) ratio.	celastrol	0-9	signal transducer and activator of transcription 3	Homo sapiens	110-115
29434967-6	2018	Celastrol may also decrease the phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) and the B cell lymphoma-2 (Bcl-2)/Bcl-2 associated C protein (Bax) ratio.	celastrol	0-9	BCL2 apoptosis regulator	Homo sapiens	125-142
29434967-6	2018	Celastrol may also decrease the phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) and the B cell lymphoma-2 (Bcl-2)/Bcl-2 associated C protein (Bax) ratio.	celastrol	0-9	BCL2 apoptosis regulator	Homo sapiens	144-149
29434967-6	2018	Celastrol may also decrease the phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) and the B cell lymphoma-2 (Bcl-2)/Bcl-2 associated C protein (Bax) ratio.	celastrol	0-9	BCL2 apoptosis regulator	Homo sapiens	151-156
29434967-6	2018	Celastrol may also decrease the phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) and the B cell lymphoma-2 (Bcl-2)/Bcl-2 associated C protein (Bax) ratio.	celastrol	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	179-182
29445341-2	2018	Numerous studies have shown that Interleukin (IL)-17 producing CD4+T cells (Th17 cells), which could be inhibited by celastrol, is essential in mediating steroid-resistant AHR.	celastrol	117-126	interleukin 17A	Mus musculus	33-52
29445341-12	2018	Moreover, celastrol treatment decreased the frequency of Th17 cell expansion and reduced the production of IL-17A in both lung and serum.	celastrol	10-19	interleukin 17A	Mus musculus	107-113
29069290-3	2018	Dietary celastrol (31.25 ppm in rodent diet from 8 weeks to 25 weeks of age) is well tolerated and protects against LPS-induced acute inflammation in C57BL/6 mice, potently suppressing LPS-induction of inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, Interleukin (IL)-6 and IL-1beta.	celastrol	8-17	nitric oxide synthase 2, inducible	Mus musculus	202-233
29069290-3	2018	Dietary celastrol (31.25 ppm in rodent diet from 8 weeks to 25 weeks of age) is well tolerated and protects against LPS-induced acute inflammation in C57BL/6 mice, potently suppressing LPS-induction of inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, Interleukin (IL)-6 and IL-1beta.	celastrol	8-17	nitric oxide synthase 2, inducible	Mus musculus	235-239
29069290-3	2018	Dietary celastrol (31.25 ppm in rodent diet from 8 weeks to 25 weeks of age) is well tolerated and protects against LPS-induced acute inflammation in C57BL/6 mice, potently suppressing LPS-induction of inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, Interleukin (IL)-6 and IL-1beta.	celastrol	8-17	cytochrome c oxidase II, mitochondrial	Mus musculus	242-264
29069290-3	2018	Dietary celastrol (31.25 ppm in rodent diet from 8 weeks to 25 weeks of age) is well tolerated and protects against LPS-induced acute inflammation in C57BL/6 mice, potently suppressing LPS-induction of inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, Interleukin (IL)-6 and IL-1beta.	celastrol	8-17	interleukin 6	Mus musculus	266-284
29069290-3	2018	Dietary celastrol (31.25 ppm in rodent diet from 8 weeks to 25 weeks of age) is well tolerated and protects against LPS-induced acute inflammation in C57BL/6 mice, potently suppressing LPS-induction of inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, Interleukin (IL)-6 and IL-1beta.	celastrol	8-17	interleukin 1 beta	Mus musculus	289-297
29069290-6	2018	Celastrol chemoprevention of CAC in this new model of intestinal neoplasia was associated with significant suppression of iNOS at 4 months of age, and iNOS, COX-2 and NFkappaB at 6 months of age, with significant reduction in inflammatory cytokines, IL-6 and IL-1beta.	celastrol	0-9	nitric oxide synthase 2, inducible	Mus musculus	122-126
29069290-6	2018	Celastrol chemoprevention of CAC in this new model of intestinal neoplasia was associated with significant suppression of iNOS at 4 months of age, and iNOS, COX-2 and NFkappaB at 6 months of age, with significant reduction in inflammatory cytokines, IL-6 and IL-1beta.	celastrol	0-9	nitric oxide synthase 2, inducible	Mus musculus	151-155
29069290-6	2018	Celastrol chemoprevention of CAC in this new model of intestinal neoplasia was associated with significant suppression of iNOS at 4 months of age, and iNOS, COX-2 and NFkappaB at 6 months of age, with significant reduction in inflammatory cytokines, IL-6 and IL-1beta.	celastrol	0-9	cytochrome c oxidase II, mitochondrial	Mus musculus	157-162
29069290-6	2018	Celastrol chemoprevention of CAC in this new model of intestinal neoplasia was associated with significant suppression of iNOS at 4 months of age, and iNOS, COX-2 and NFkappaB at 6 months of age, with significant reduction in inflammatory cytokines, IL-6 and IL-1beta.	celastrol	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	167-175
29069290-6	2018	Celastrol chemoprevention of CAC in this new model of intestinal neoplasia was associated with significant suppression of iNOS at 4 months of age, and iNOS, COX-2 and NFkappaB at 6 months of age, with significant reduction in inflammatory cytokines, IL-6 and IL-1beta.	celastrol	0-9	interleukin 6	Mus musculus	250-254
29069290-6	2018	Celastrol chemoprevention of CAC in this new model of intestinal neoplasia was associated with significant suppression of iNOS at 4 months of age, and iNOS, COX-2 and NFkappaB at 6 months of age, with significant reduction in inflammatory cytokines, IL-6 and IL-1beta.	celastrol	0-9	interleukin 1 beta	Mus musculus	259-267
30068874-6	2018	Western blot analysis revealed that expression of indoleamine 2,3-dioxygenase (IDO), the enzyme catalyzing Trp to generate Kyn, was dramatically inhibited in colon cancer cells after celastrol treatment, with a dose-dependent manner.	celastrol	183-192	indoleamine 2,3-dioxygenase 1	Homo sapiens	79-82
30068874-7	2018	These results suggest that suppression of IDO expression and tryptophan catabolism may be part of the mechanisms of celastrol in its cytotoxic effect against HCT116 colon cancer cells.	celastrol	116-125	indoleamine 2,3-dioxygenase 1	Homo sapiens	42-45
28994112-0	2018	Celastrol attenuates pain and cartilage damage via SDF-1/CXCR4 signalling pathway in osteoarthritis rats.	celastrol	0-9	C-X-C motif chemokine receptor 4	Rattus norvegicus	57-62
28994112-1	2018	OBJECTIVES: Celastrol has attracted wide interests for its anticancer and anti-inflammation properties, and studies have demonstrated that celastrol negatively modulates the stromal cell-derived factor-1 (SDF-1) and receptor C-X-C chemokine receptor type 4 (CXCR4) signalling.	celastrol	139-148	C-X-C motif chemokine ligand 12	Rattus norvegicus	174-203
28994112-1	2018	OBJECTIVES: Celastrol has attracted wide interests for its anticancer and anti-inflammation properties, and studies have demonstrated that celastrol negatively modulates the stromal cell-derived factor-1 (SDF-1) and receptor C-X-C chemokine receptor type 4 (CXCR4) signalling.	celastrol	139-148	C-X-C motif chemokine ligand 12	Rattus norvegicus	205-210
28994112-1	2018	OBJECTIVES: Celastrol has attracted wide interests for its anticancer and anti-inflammation properties, and studies have demonstrated that celastrol negatively modulates the stromal cell-derived factor-1 (SDF-1) and receptor C-X-C chemokine receptor type 4 (CXCR4) signalling.	celastrol	139-148	C-X-C motif chemokine receptor 4	Rattus norvegicus	225-256
28994112-1	2018	OBJECTIVES: Celastrol has attracted wide interests for its anticancer and anti-inflammation properties, and studies have demonstrated that celastrol negatively modulates the stromal cell-derived factor-1 (SDF-1) and receptor C-X-C chemokine receptor type 4 (CXCR4) signalling.	celastrol	139-148	C-X-C motif chemokine receptor 4	Rattus norvegicus	258-263
28994112-5	2018	KEY FINDINGS: Celastrol significantly attenuated the joint pain and cartilage damage induced by MIA in OA rats and suppressed the upregulation of SDF-1/CXCR4 and associated genes caused by MIA injections.	celastrol	14-23	C-X-C motif chemokine ligand 12	Rattus norvegicus	146-151
28994112-5	2018	KEY FINDINGS: Celastrol significantly attenuated the joint pain and cartilage damage induced by MIA in OA rats and suppressed the upregulation of SDF-1/CXCR4 and associated genes caused by MIA injections.	celastrol	14-23	C-X-C motif chemokine receptor 4	Rattus norvegicus	152-157
28994112-7	2018	CONCLUSIONS: Celastrol ameliorate OA in vivo as evidenced by the attenuated joint pain and less cartilage damage in OA rats given celastrol treatments, an effect mediated via suppression of the SDF-1/CXCR4 pathway.	celastrol	13-22	C-X-C motif chemokine ligand 12	Rattus norvegicus	194-199
28994112-7	2018	CONCLUSIONS: Celastrol ameliorate OA in vivo as evidenced by the attenuated joint pain and less cartilage damage in OA rats given celastrol treatments, an effect mediated via suppression of the SDF-1/CXCR4 pathway.	celastrol	13-22	C-X-C motif chemokine receptor 4	Rattus norvegicus	200-205
28994112-7	2018	CONCLUSIONS: Celastrol ameliorate OA in vivo as evidenced by the attenuated joint pain and less cartilage damage in OA rats given celastrol treatments, an effect mediated via suppression of the SDF-1/CXCR4 pathway.	celastrol	130-139	C-X-C motif chemokine ligand 12	Rattus norvegicus	194-199
28994112-7	2018	CONCLUSIONS: Celastrol ameliorate OA in vivo as evidenced by the attenuated joint pain and less cartilage damage in OA rats given celastrol treatments, an effect mediated via suppression of the SDF-1/CXCR4 pathway.	celastrol	130-139	C-X-C motif chemokine receptor 4	Rattus norvegicus	200-205
29256892-10	2017	Moreover, treatment with 50 nM celastrol significantly downregulated mRNA and protein expression of TNF-alpha and IL-1ss.	celastrol	31-40	tumor necrosis factor	Rattus norvegicus	100-109
29902110-0	2018	Celastrol enhances Atoh1 expression in inner ear stem cells and promotes their differentiation into functional auditory neuronal-like cells.	celastrol	0-9	atonal bHLH transcription factor 1	Mus musculus	19-24
29902110-11	2018	Most notably, these effects were apparently associated with the upregulation of Atoh1 in response to Celastrol treatment.	celastrol	101-110	atonal bHLH transcription factor 1	Mus musculus	80-85
29270590-9	2017	Pharmacological inhibitors of MEK (PD98059, 10 mumol/L) or Akt (MK2206, 10 mumol/L) could reverse the phosphorylation of ERK1/2 and Akt, and abolish up-regulation of GCLC and GST induced by celastrol at mRNA levels.	celastrol	190-199	midkine	Mus musculus	30-33
29270590-9	2017	Pharmacological inhibitors of MEK (PD98059, 10 mumol/L) or Akt (MK2206, 10 mumol/L) could reverse the phosphorylation of ERK1/2 and Akt, and abolish up-regulation of GCLC and GST induced by celastrol at mRNA levels.	celastrol	190-199	thymoma viral proto-oncogene 1	Mus musculus	59-62
29270590-9	2017	Pharmacological inhibitors of MEK (PD98059, 10 mumol/L) or Akt (MK2206, 10 mumol/L) could reverse the phosphorylation of ERK1/2 and Akt, and abolish up-regulation of GCLC and GST induced by celastrol at mRNA levels.	celastrol	190-199	mitogen-activated protein kinase 3	Mus musculus	121-127
29270590-10	2017	Taken together, we conclude that celastrol exerts a beneficial antioxidant effect in SOD1G93ANSC34 cells, which might be dependent on MEK/ERK and PI3K/Akt signaling pathway activation.	celastrol	33-42	superoxide dismutase 1, soluble	Mus musculus	85-89
29270590-10	2017	Taken together, we conclude that celastrol exerts a beneficial antioxidant effect in SOD1G93ANSC34 cells, which might be dependent on MEK/ERK and PI3K/Akt signaling pathway activation.	celastrol	33-42	midkine	Mus musculus	134-137
29270590-10	2017	Taken together, we conclude that celastrol exerts a beneficial antioxidant effect in SOD1G93ANSC34 cells, which might be dependent on MEK/ERK and PI3K/Akt signaling pathway activation.	celastrol	33-42	mitogen-activated protein kinase 1	Mus musculus	138-141
29270590-10	2017	Taken together, we conclude that celastrol exerts a beneficial antioxidant effect in SOD1G93ANSC34 cells, which might be dependent on MEK/ERK and PI3K/Akt signaling pathway activation.	celastrol	33-42	thymoma viral proto-oncogene 1	Mus musculus	151-154
29270590-2	2017	SOD1G93A transfected NSC34 cells were treated with different doses of H2O2 and celastrol.	celastrol	79-88	superoxide dismutase 1, soluble	Mus musculus	0-4
29270590-6	2017	The results showed that pre-incubation of celastrol (50 nmol/L) for 4 h prior to H2O2 (10 mumol/L) co-treatment for another 24 h significantly attenuated H2O2-induced cell death and MDA level in SOD1G93A transfected NSC34 cells.	celastrol	42-51	superoxide dismutase 1, soluble	Mus musculus	195-199
29270590-7	2017	Real-time PCR showed that the mRNA expressions of GCLC and GST were enhanced with pre-incubation of celastrol.	celastrol	100-109	glutamate-cysteine ligase, catalytic subunit	Mus musculus	50-54
29270590-8	2017	Celastrol quickly induced phosphorylation of ERK1/2 and Akt within 30 min and 1 h respectively in SOD1G93A transfected NSC34 cells.	celastrol	0-9	mitogen-activated protein kinase 3	Mus musculus	45-51
29270590-8	2017	Celastrol quickly induced phosphorylation of ERK1/2 and Akt within 30 min and 1 h respectively in SOD1G93A transfected NSC34 cells.	celastrol	0-9	thymoma viral proto-oncogene 1	Mus musculus	56-59
29270590-8	2017	Celastrol quickly induced phosphorylation of ERK1/2 and Akt within 30 min and 1 h respectively in SOD1G93A transfected NSC34 cells.	celastrol	0-9	superoxide dismutase 1, soluble	Mus musculus	98-102
29202812-0	2017	Celastrol improves self-renewal and differentiation of human tendon-derived stem cells by suppressing Smad7 through hypoxia.	celastrol	0-9	SMAD family member 7	Homo sapiens	102-107
29202812-9	2017	Celastrol elicited hypoxia and subsequently suppressed the expression of Smad7 through direct association with the hypoxia response element consensus sequence.	celastrol	0-9	SMAD family member 7	Homo sapiens	73-78
29202812-10	2017	Further, we demonstrated that both Smad7 and HIF1alpha were involved in the beneficial effects of celastrol on the differentiation and self-renewal of hTSCs.	celastrol	98-107	SMAD family member 7	Homo sapiens	35-40
29202812-10	2017	Further, we demonstrated that both Smad7 and HIF1alpha were involved in the beneficial effects of celastrol on the differentiation and self-renewal of hTSCs.	celastrol	98-107	hypoxia inducible factor 1 subunit alpha	Homo sapiens	45-54
29256892-12	2017	CONCLUSION: Our study demonstrated that low-dose celastrol could prevent MIRI in cardiomyocytes by inhibiting the activation of NF-K B, and celastrol may be a potential therapeutic agent for preventing MIRI.	celastrol	49-58	nuclear factor kappa B subunit 1	Rattus norvegicus	128-134
28944849-0	2017	Celastrol alleviates angiotensin II-mediated vascular smooth muscle cell senescence via induction of autophagy.	celastrol	0-9	angiotensinogen	Homo sapiens	21-35
29048668-0	2017	Celastrol downregulates E2F1 to induce growth inhibitory effects in hepatocellular carcinoma HepG2 cells.	celastrol	0-9	E2F transcription factor 1	Homo sapiens	24-28
29048668-5	2017	E2F1 was potently downregulated by celastrol in a dose- and time-dependent manner at both the mRNA and protein levels.	celastrol	35-44	E2F transcription factor 1	Homo sapiens	0-4
29048668-6	2017	Moreover, siRNA-mediated E2F1 silencing enhanced celastrol-induced apoptosis and inhibition of proliferation.	celastrol	49-58	E2F transcription factor 1	Homo sapiens	25-29
29048668-7	2017	Our data imply that downregulation of E2F1 may be a key factor in the celastrol-mediated inhibitory effects in HepG2 cells, and celastrol can serve as a leading compound for the development of compounds designed to inactivate E2F1 for HCC therapy.	celastrol	70-79	E2F transcription factor 1	Homo sapiens	38-42
29048668-7	2017	Our data imply that downregulation of E2F1 may be a key factor in the celastrol-mediated inhibitory effects in HepG2 cells, and celastrol can serve as a leading compound for the development of compounds designed to inactivate E2F1 for HCC therapy.	celastrol	70-79	E2F transcription factor 1	Homo sapiens	226-230
27931154-0	2017	Inhibition of IKKbeta by celastrol and its analogues - an in silico and in vitro approach.	celastrol	25-34	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	14-21
27931154-4	2017	OBJECTIVE: This study determines the neuroprotective and inhibitory effect of celastrol on amyloid beta1-42 (Abeta1-42) induced cytotoxicity and IKKbeta activity, respectively.	celastrol	78-87	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	145-152
27931154-6	2017	We screened 36 celastrol analogues for the IKKbeta inhibition by molecular docking and evaluated their drug like properties to delineate the neuroprotective effects.	celastrol	15-24	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	43-50
27931154-7	2017	RESULTS: Celastrol (1 muM) inhibited Abeta1-42 (10 muM) induced IkappaBalpha phosphorylation and protected IMR-32 cells from cell death.	celastrol	9-18	NFKB inhibitor alpha	Homo sapiens	64-76
27931154-8	2017	Celastrol and 25 analogues showed strong binding affinity with IKKbeta as evidenced by strong hydrogen-bonding interactions with critical active site residues.	celastrol	0-9	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	63-70
27931154-12	2017	The neuroprotective potentials of celastrol and its analogues may be related to IKK inhibition.	celastrol	34-43	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	80-83
29040966-0	2017	Natural product celastrol suppressed macrophage M1 polarization against inflammation in diet-induced obese mice via regulating Nrf2/HO-1, MAP kinase and NF-kappaB pathways.	celastrol	16-25	nuclear factor, erythroid derived 2, like 2	Mus musculus	127-131
29040966-0	2017	Natural product celastrol suppressed macrophage M1 polarization against inflammation in diet-induced obese mice via regulating Nrf2/HO-1, MAP kinase and NF-kappaB pathways.	celastrol	16-25	heme oxygenase 1	Mus musculus	132-136
29040966-5	2017	Celastrol down-regulated the mRNA levels of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in cell culture and in mice.	celastrol	0-9	interleukin 6	Mus musculus	76-80
29040966-5	2017	Celastrol down-regulated the mRNA levels of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in cell culture and in mice.	celastrol	0-9	interleukin 1 beta	Mus musculus	82-90
29040966-5	2017	Celastrol down-regulated the mRNA levels of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in cell culture and in mice.	celastrol	0-9	tumor necrosis factor	Mus musculus	92-101
29040966-5	2017	Celastrol down-regulated the mRNA levels of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in cell culture and in mice.	celastrol	0-9	nitric oxide synthase 2, inducible	Mus musculus	103-107
29040966-7	2017	Our results demonstrated that celastrol might control macrophage polarization through modulating the cross-talk between the following three mechanisms: 1) suppressing LPS-induced activation of MAP kinases (e.g., ERK1/2, p38, JNK) in a concentration dependent manner; 2) attenuating LPS-induced nuclear translocation of NF-kappaB p65 subunit in a time dependent manner; 3) activating Nrf2 and subsequently inducing HO-1 expression.	celastrol	30-39	mitogen-activated protein kinase 3	Mus musculus	212-218
29040966-7	2017	Our results demonstrated that celastrol might control macrophage polarization through modulating the cross-talk between the following three mechanisms: 1) suppressing LPS-induced activation of MAP kinases (e.g., ERK1/2, p38, JNK) in a concentration dependent manner; 2) attenuating LPS-induced nuclear translocation of NF-kappaB p65 subunit in a time dependent manner; 3) activating Nrf2 and subsequently inducing HO-1 expression.	celastrol	30-39	mitogen-activated protein kinase 14	Mus musculus	220-223
29040966-7	2017	Our results demonstrated that celastrol might control macrophage polarization through modulating the cross-talk between the following three mechanisms: 1) suppressing LPS-induced activation of MAP kinases (e.g., ERK1/2, p38, JNK) in a concentration dependent manner; 2) attenuating LPS-induced nuclear translocation of NF-kappaB p65 subunit in a time dependent manner; 3) activating Nrf2 and subsequently inducing HO-1 expression.	celastrol	30-39	mitogen-activated protein kinase 8	Mus musculus	225-228
29040966-7	2017	Our results demonstrated that celastrol might control macrophage polarization through modulating the cross-talk between the following three mechanisms: 1) suppressing LPS-induced activation of MAP kinases (e.g., ERK1/2, p38, JNK) in a concentration dependent manner; 2) attenuating LPS-induced nuclear translocation of NF-kappaB p65 subunit in a time dependent manner; 3) activating Nrf2 and subsequently inducing HO-1 expression.	celastrol	30-39	nuclear factor, erythroid derived 2, like 2	Mus musculus	383-387
29040966-7	2017	Our results demonstrated that celastrol might control macrophage polarization through modulating the cross-talk between the following three mechanisms: 1) suppressing LPS-induced activation of MAP kinases (e.g., ERK1/2, p38, JNK) in a concentration dependent manner; 2) attenuating LPS-induced nuclear translocation of NF-kappaB p65 subunit in a time dependent manner; 3) activating Nrf2 and subsequently inducing HO-1 expression.	celastrol	30-39	heme oxygenase 1	Mus musculus	414-418
29040966-8	2017	HO-1 inhibitor SnPP diminished the inhibitory effects of celastrol on the activation of NF-kappaB pathway and the pro-inflammatory M1 macrophage polarization.	celastrol	57-66	heme oxygenase 1	Mus musculus	0-4
28935193-0	2017	Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells.	celastrol	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	99-103
28935193-1	2017	BACKGROUND AND PURPOSE: Celastrol, a quinone methide triterpene isolated from the root extracts of Tripterygium wilfordii, can greatly induce the gene expression activity of heme oxygenase-1 (HO-1) to achieve disease prevention and control.	celastrol	24-33	heme oxygenase 1	Homo sapiens	192-196
28935193-10	2017	These antiviral effects were abrogated by treatment with the HO-1-specific inhibitor SnMP or silencing of HO-1 expression by transfection of shRNA, which indicates that HO-1 induction contributes to the anti-HCV activity of celastrol.	celastrol	224-233	heme oxygenase 1	Homo sapiens	61-65
28935193-10	2017	These antiviral effects were abrogated by treatment with the HO-1-specific inhibitor SnMP or silencing of HO-1 expression by transfection of shRNA, which indicates that HO-1 induction contributes to the anti-HCV activity of celastrol.	celastrol	224-233	heme oxygenase 1	Homo sapiens	106-110
28935193-5	2017	The anti-HCV mechanism of celastrol targeting HO-1 expression was clarified using specific inhibitors against several signaling pathways.	celastrol	26-35	heme oxygenase 1	Homo sapiens	46-50
28935193-10	2017	These antiviral effects were abrogated by treatment with the HO-1-specific inhibitor SnMP or silencing of HO-1 expression by transfection of shRNA, which indicates that HO-1 induction contributes to the anti-HCV activity of celastrol.	celastrol	224-233	heme oxygenase 1	Homo sapiens	106-110
28935193-9	2017	Celastrol-induced heme oxygenase 1 (HO-1) expression promoted antiviral interferon responses and inhibition of NS3/4A protease activity, thereby blocking HCV replication.	celastrol	0-9	heme oxygenase 1	Homo sapiens	36-40
28935193-11	2017	JNK mitogen-activated protein kinase and nuclear factor erythroid 2-related factor 2 (Nrf2) were confirmed to be involved in the inductive effect of celastrol on HO-1 expression.	celastrol	149-158	NFE2 like bZIP transcription factor 2	Homo sapiens	86-90
28878153-8	2017	The expression of several chemokine genes, including CCL2 , CXCL10 , CXCL12 , CCR2 and CXCR4 , was significantly changed after celastrol treatment.	celastrol	127-136	C-C motif chemokine ligand 2	Homo sapiens	53-57
28935193-11	2017	JNK mitogen-activated protein kinase and nuclear factor erythroid 2-related factor 2 (Nrf2) were confirmed to be involved in the inductive effect of celastrol on HO-1 expression.	celastrol	149-158	heme oxygenase 1	Homo sapiens	162-166
28878153-8	2017	The expression of several chemokine genes, including CCL2 , CXCL10 , CXCL12 , CCR2 and CXCR4 , was significantly changed after celastrol treatment.	celastrol	127-136	C-X-C motif chemokine ligand 10	Homo sapiens	60-66
28878153-8	2017	The expression of several chemokine genes, including CCL2 , CXCL10 , CXCL12 , CCR2 and CXCR4 , was significantly changed after celastrol treatment.	celastrol	127-136	C-X-C motif chemokine ligand 12	Homo sapiens	69-75
28878153-8	2017	The expression of several chemokine genes, including CCL2 , CXCL10 , CXCL12 , CCR2 and CXCR4 , was significantly changed after celastrol treatment.	celastrol	127-136	C-C motif chemokine receptor 2	Homo sapiens	78-82
28878153-8	2017	The expression of several chemokine genes, including CCL2 , CXCL10 , CXCL12 , CCR2 and CXCR4 , was significantly changed after celastrol treatment.	celastrol	127-136	C-X-C motif chemokine receptor 4	Homo sapiens	87-92
28789395-6	2017	The level of cleaved caspases-3, -8, and -9 and poly (ADP-ribose) polymerase 1 increased in cells treated with celastrol.	celastrol	111-120	poly(ADP-ribose) polymerase 1	Homo sapiens	21-78
31966802-7	2017	However, celastrol pre-treatment compromised the increased MPO, MDA, TNF-alpha, IL-1beta, IL-6 (all P&lt;0.01) and significantly increased SOD (P=0.035&lt;0.05) and IL-10 (P&lt;0.01).	celastrol	9-18	myeloperoxidase	Mus musculus	59-62
31966802-7	2017	However, celastrol pre-treatment compromised the increased MPO, MDA, TNF-alpha, IL-1beta, IL-6 (all P&lt;0.01) and significantly increased SOD (P=0.035&lt;0.05) and IL-10 (P&lt;0.01).	celastrol	9-18	tumor necrosis factor	Mus musculus	69-78
31966802-7	2017	However, celastrol pre-treatment compromised the increased MPO, MDA, TNF-alpha, IL-1beta, IL-6 (all P&lt;0.01) and significantly increased SOD (P=0.035&lt;0.05) and IL-10 (P&lt;0.01).	celastrol	9-18	interleukin 1 alpha	Mus musculus	80-88
31966802-7	2017	However, celastrol pre-treatment compromised the increased MPO, MDA, TNF-alpha, IL-1beta, IL-6 (all P&lt;0.01) and significantly increased SOD (P=0.035&lt;0.05) and IL-10 (P&lt;0.01).	celastrol	9-18	interleukin 6	Mus musculus	90-94
31966802-7	2017	However, celastrol pre-treatment compromised the increased MPO, MDA, TNF-alpha, IL-1beta, IL-6 (all P&lt;0.01) and significantly increased SOD (P=0.035&lt;0.05) and IL-10 (P&lt;0.01).	celastrol	9-18	interleukin 10	Mus musculus	165-170
27891586-0	2017	Celastrol Attenuates Cadmium-Induced Neuronal Apoptosis via Inhibiting Ca2+ -CaMKII-Dependent Akt/mTOR Pathway.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	94-97
27891586-0	2017	Celastrol Attenuates Cadmium-Induced Neuronal Apoptosis via Inhibiting Ca2+ -CaMKII-Dependent Akt/mTOR Pathway.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	98-102
27891586-2	2017	Recently, we have shown that celastrol prevents Cd-induced neuronal cell death partially by suppressing Akt/mTOR pathway.	celastrol	29-38	AKT serine/threonine kinase 1	Homo sapiens	104-107
27891586-2	2017	Recently, we have shown that celastrol prevents Cd-induced neuronal cell death partially by suppressing Akt/mTOR pathway.	celastrol	29-38	mechanistic target of rapamycin kinase	Homo sapiens	108-112
27891586-5	2017	Celastrol prevented Cd-induced neuronal apoptosis by inhibiting Akt-mediated mTOR pathway, as inhibition of Akt with Akt inhibitor X or ectopic expression of dominant negative Akt reinforced celastrol"s prevention of Cd-induced phosphorylation of S6K1/4E-BP1 and cell apoptosis.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	64-67
27891586-5	2017	Celastrol prevented Cd-induced neuronal apoptosis by inhibiting Akt-mediated mTOR pathway, as inhibition of Akt with Akt inhibitor X or ectopic expression of dominant negative Akt reinforced celastrol"s prevention of Cd-induced phosphorylation of S6K1/4E-BP1 and cell apoptosis.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	77-81
27891586-5	2017	Celastrol prevented Cd-induced neuronal apoptosis by inhibiting Akt-mediated mTOR pathway, as inhibition of Akt with Akt inhibitor X or ectopic expression of dominant negative Akt reinforced celastrol"s prevention of Cd-induced phosphorylation of S6K1/4E-BP1 and cell apoptosis.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	108-111
27891586-5	2017	Celastrol prevented Cd-induced neuronal apoptosis by inhibiting Akt-mediated mTOR pathway, as inhibition of Akt with Akt inhibitor X or ectopic expression of dominant negative Akt reinforced celastrol"s prevention of Cd-induced phosphorylation of S6K1/4E-BP1 and cell apoptosis.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	108-111
27891586-5	2017	Celastrol prevented Cd-induced neuronal apoptosis by inhibiting Akt-mediated mTOR pathway, as inhibition of Akt with Akt inhibitor X or ectopic expression of dominant negative Akt reinforced celastrol"s prevention of Cd-induced phosphorylation of S6K1/4E-BP1 and cell apoptosis.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	108-111
27891586-6	2017	Furthermore, chelating intracellular Ca2+ with BAPTA/AM or preventing [Ca2+ ]i elevation using EGTA potentiated celastrol"s repression of Cd-induced [Ca2+ ]i elevation and consequential activation of Akt/mTOR pathway and cell apoptosis.	celastrol	112-121	AKT serine/threonine kinase 1	Homo sapiens	200-203
27891586-6	2017	Furthermore, chelating intracellular Ca2+ with BAPTA/AM or preventing [Ca2+ ]i elevation using EGTA potentiated celastrol"s repression of Cd-induced [Ca2+ ]i elevation and consequential activation of Akt/mTOR pathway and cell apoptosis.	celastrol	112-121	mechanistic target of rapamycin kinase	Homo sapiens	204-208
27891586-8	2017	Inhibiting CaMKII with KN93 or silencing CaMKII attenuated Cd activation of Akt/mTOR pathway and cell apoptosis, and this was strengthened by celastrol.	celastrol	142-151	AKT serine/threonine kinase 1	Homo sapiens	76-79
27891586-8	2017	Inhibiting CaMKII with KN93 or silencing CaMKII attenuated Cd activation of Akt/mTOR pathway and cell apoptosis, and this was strengthened by celastrol.	celastrol	142-151	mechanistic target of rapamycin kinase	Homo sapiens	80-84
27891586-9	2017	Taken together, these data demonstrate that celastrol attenuates Cd-induced neuronal apoptosis via inhibiting Ca2+ -CaMKII-dependent Akt/mTOR pathway.	celastrol	44-53	AKT serine/threonine kinase 1	Homo sapiens	133-136
27891586-9	2017	Taken together, these data demonstrate that celastrol attenuates Cd-induced neuronal apoptosis via inhibiting Ca2+ -CaMKII-dependent Akt/mTOR pathway.	celastrol	44-53	mechanistic target of rapamycin kinase	Homo sapiens	137-141
28789395-8	2017	Celastrol induced an increase in Fas, Fas-associated via death domain, TNF receptor superfamily members (TNRSF) 1A and 10B, and TNFRSF1A associated via death domain, and induced a dose-dependent reduction in mitochondrial membrane potential.	celastrol	0-9	TNF receptor superfamily member 1A	Homo sapiens	71-122
28789395-8	2017	Celastrol induced an increase in Fas, Fas-associated via death domain, TNF receptor superfamily members (TNRSF) 1A and 10B, and TNFRSF1A associated via death domain, and induced a dose-dependent reduction in mitochondrial membrane potential.	celastrol	0-9	TNF receptor superfamily member 1A	Homo sapiens	128-136
28789395-9	2017	Celastrol inhibited activation of mitogen-activated protein kinase (MAPK) 1/3 and 14, and induced MAPK 8/9 activation.	celastrol	0-9	mitogen-activated protein kinase 8	Homo sapiens	98-104
28389259-8	2017	Celastrol increased the expressions of Beclin 1 and Vps 34, promoted the up-regulation of Atg5-Atg12-16 formation and enhanced the lipidation of LC3I to LC3II suggesting induction of autophagy by celastrol provide protection against lung fibrosis.	celastrol	0-9	beclin 1	Rattus norvegicus	39-47
28389259-8	2017	Celastrol increased the expressions of Beclin 1 and Vps 34, promoted the up-regulation of Atg5-Atg12-16 formation and enhanced the lipidation of LC3I to LC3II suggesting induction of autophagy by celastrol provide protection against lung fibrosis.	celastrol	0-9	autophagy related 5	Rattus norvegicus	90-94
28389259-9	2017	Further, we revealed that celastrol activates autophagy by inhibiting PI3K/Akt mediated mTOR expression.	celastrol	26-35	AKT serine/threonine kinase 1	Rattus norvegicus	75-78
28389259-9	2017	Further, we revealed that celastrol activates autophagy by inhibiting PI3K/Akt mediated mTOR expression.	celastrol	26-35	mechanistic target of rapamycin kinase	Rattus norvegicus	88-92
28389259-10	2017	In addition, we show evidences that lack of autophagy leads to accumulation of p62, an autophagy adaptor protein that is degraded by celastrol.	celastrol	133-142	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	79-82
28458159-0	2017	Celastrol reduces IL-1beta induced matrix catabolism, oxidative stress and inflammation in human nucleus pulposus cells and attenuates rat intervertebral disc degeneration in vivo.	celastrol	0-9	interleukin 1 beta	Homo sapiens	18-26
28621943-9	2017	Two compounds, sanguinarine (1) and celastrol (2), were found to be cytostatic against lung and prostate cancer cell lines and cytotoxic against prostate cancer cell lines in vitro, although the dependence of RGS17 on these phenomena remains elusive, a result that is perhaps not surprising given the multimodal cytostatic and cytotoxic activities of many natural products.	celastrol	36-45	regulator of G protein signaling 17	Homo sapiens	209-214
28458159-3	2017	In this study, we evaluated the effect of celastrol on IDD in IL-1beta treated human nucleus pulposus cells in vitro as well as in puncture induced rat IDD model in vivo.	celastrol	42-51	interleukin 1 beta	Homo sapiens	62-70
28458159-6	2017	Together, our study demonstrates that celastrol could reduce IL-1beta induced matrix catabolism, oxidative stress and inflammation in human nucleus pulposus cells and attenuates rat intervertebral disc degeneration in vivo, which shows its potential to be a therapeutic drug for IDD.	celastrol	38-47	interleukin 1 beta	Homo sapiens	61-69
28458159-4	2017	Our results showed that celastrol reduced the expression of catabolic genes (MMP-3, 9, 13, ADAMTS-4, 5), oxidative stress factors (COX-2, iNOS) and pro-inflammatory factors (IL-6, TNF-a) induced by IL-1beta in nucleus pulposus cells, also phosphorylation of IkappaBalpha and p65 were attenuated by celastrol, indicating NF-kappaB pathway was inhibited by celastrol in nucleus pulposus cells.	celastrol	24-33	matrix metallopeptidase 3	Rattus norvegicus	77-89
28458159-4	2017	Our results showed that celastrol reduced the expression of catabolic genes (MMP-3, 9, 13, ADAMTS-4, 5), oxidative stress factors (COX-2, iNOS) and pro-inflammatory factors (IL-6, TNF-a) induced by IL-1beta in nucleus pulposus cells, also phosphorylation of IkappaBalpha and p65 were attenuated by celastrol, indicating NF-kappaB pathway was inhibited by celastrol in nucleus pulposus cells.	celastrol	24-33	ADAM metallopeptidase with thrombospondin type 1 motif, 4	Rattus norvegicus	91-99
28458159-4	2017	Our results showed that celastrol reduced the expression of catabolic genes (MMP-3, 9, 13, ADAMTS-4, 5), oxidative stress factors (COX-2, iNOS) and pro-inflammatory factors (IL-6, TNF-a) induced by IL-1beta in nucleus pulposus cells, also phosphorylation of IkappaBalpha and p65 were attenuated by celastrol, indicating NF-kappaB pathway was inhibited by celastrol in nucleus pulposus cells.	celastrol	24-33	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	131-136
28458159-4	2017	Our results showed that celastrol reduced the expression of catabolic genes (MMP-3, 9, 13, ADAMTS-4, 5), oxidative stress factors (COX-2, iNOS) and pro-inflammatory factors (IL-6, TNF-a) induced by IL-1beta in nucleus pulposus cells, also phosphorylation of IkappaBalpha and p65 were attenuated by celastrol, indicating NF-kappaB pathway was inhibited by celastrol in nucleus pulposus cells.	celastrol	24-33	nitric oxide synthase 2	Rattus norvegicus	138-142
28458159-4	2017	Our results showed that celastrol reduced the expression of catabolic genes (MMP-3, 9, 13, ADAMTS-4, 5), oxidative stress factors (COX-2, iNOS) and pro-inflammatory factors (IL-6, TNF-a) induced by IL-1beta in nucleus pulposus cells, also phosphorylation of IkappaBalpha and p65 were attenuated by celastrol, indicating NF-kappaB pathway was inhibited by celastrol in nucleus pulposus cells.	celastrol	24-33	interleukin 6	Rattus norvegicus	174-178
28458159-4	2017	Our results showed that celastrol reduced the expression of catabolic genes (MMP-3, 9, 13, ADAMTS-4, 5), oxidative stress factors (COX-2, iNOS) and pro-inflammatory factors (IL-6, TNF-a) induced by IL-1beta in nucleus pulposus cells, also phosphorylation of IkappaBalpha and p65 were attenuated by celastrol, indicating NF-kappaB pathway was inhibited by celastrol in nucleus pulposus cells.	celastrol	24-33	tumor necrosis factor	Rattus norvegicus	180-185
28458159-4	2017	Our results showed that celastrol reduced the expression of catabolic genes (MMP-3, 9, 13, ADAMTS-4, 5), oxidative stress factors (COX-2, iNOS) and pro-inflammatory factors (IL-6, TNF-a) induced by IL-1beta in nucleus pulposus cells, also phosphorylation of IkappaBalpha and p65 were attenuated by celastrol, indicating NF-kappaB pathway was inhibited by celastrol in nucleus pulposus cells.	celastrol	24-33	interleukin 1 beta	Rattus norvegicus	198-206
28458159-4	2017	Our results showed that celastrol reduced the expression of catabolic genes (MMP-3, 9, 13, ADAMTS-4, 5), oxidative stress factors (COX-2, iNOS) and pro-inflammatory factors (IL-6, TNF-a) induced by IL-1beta in nucleus pulposus cells, also phosphorylation of IkappaBalpha and p65 were attenuated by celastrol, indicating NF-kappaB pathway was inhibited by celastrol in nucleus pulposus cells.	celastrol	24-33	NFKB inhibitor alpha	Rattus norvegicus	258-270
28458159-4	2017	Our results showed that celastrol reduced the expression of catabolic genes (MMP-3, 9, 13, ADAMTS-4, 5), oxidative stress factors (COX-2, iNOS) and pro-inflammatory factors (IL-6, TNF-a) induced by IL-1beta in nucleus pulposus cells, also phosphorylation of IkappaBalpha and p65 were attenuated by celastrol, indicating NF-kappaB pathway was inhibited by celastrol in nucleus pulposus cells.	celastrol	24-33	synaptotagmin 1	Rattus norvegicus	275-278
28673005-8	2017	At the molecular level, celastrol blocked the canonical NF-kappaB pathway by inhibiting IkappaBalpha phosphorylation, and preventing IkappaBalpha degradation and p65 accumulation.	celastrol	24-33	NFKB inhibitor alpha	Homo sapiens	88-100
28673005-8	2017	At the molecular level, celastrol blocked the canonical NF-kappaB pathway by inhibiting IkappaBalpha phosphorylation, and preventing IkappaBalpha degradation and p65 accumulation.	celastrol	24-33	NFKB inhibitor alpha	Homo sapiens	133-145
28673005-8	2017	At the molecular level, celastrol blocked the canonical NF-kappaB pathway by inhibiting IkappaBalpha phosphorylation, and preventing IkappaBalpha degradation and p65 accumulation.	celastrol	24-33	RELA proto-oncogene, NF-kB subunit	Homo sapiens	162-165
28673005-9	2017	Furthermore, the expression and activity of the NF-kappaB target protein MMP-9, but not MMP-2, were inhibited by celastrol.	celastrol	113-122	matrix metallopeptidase 9	Homo sapiens	73-78
28435131-5	2017	The results indicated that both celastrol and BBG pretreatments, especially when combined together, curbed APAP-induced hepatocellular injury (ALT, AST and LDH) and death (necrosis and apoptosis).	celastrol	32-41	glutamic pyruvic transaminase, soluble	Mus musculus	143-146
28978034-0	2017	Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation.	celastrol	0-9	NLR family pyrin domain containing 3	Homo sapiens	57-62
28978034-3	2017	Here, we show that celastrol abolishes the NLRP3 inflammasome activation, inhibits subsequent caspase-1 activation and IL-1beta secretion both in vitro and in vivo.	celastrol	19-28	NLR family pyrin domain containing 3	Homo sapiens	43-48
28978034-3	2017	Here, we show that celastrol abolishes the NLRP3 inflammasome activation, inhibits subsequent caspase-1 activation and IL-1beta secretion both in vitro and in vivo.	celastrol	19-28	caspase 1	Homo sapiens	94-103
28978034-3	2017	Here, we show that celastrol abolishes the NLRP3 inflammasome activation, inhibits subsequent caspase-1 activation and IL-1beta secretion both in vitro and in vivo.	celastrol	19-28	interleukin 1 beta	Homo sapiens	119-127
28978034-4	2017	Notably, interruption of ASC oligomerization and autophagy activation are involved in NLRP3 inflammasome inactivation by celastrol.	celastrol	121-130	PYD and CARD domain containing	Homo sapiens	25-28
28978034-4	2017	Notably, interruption of ASC oligomerization and autophagy activation are involved in NLRP3 inflammasome inactivation by celastrol.	celastrol	121-130	NLR family pyrin domain containing 3	Homo sapiens	86-91
28978034-5	2017	Importantly, in vivo results indicate that celastrol attenuates NLRP3 inflammasome-dependent inflammation diseases via autophagy-related pathway.	celastrol	43-52	NLR family pyrin domain containing 3	Homo sapiens	64-69
28978034-6	2017	Our results thus reveal celastrol as an inhibitor of NLRP3 inflammasome, implying the potential for clinical use of celastrol in treatment of NLRP3 inflammasome-driven inflammatory diseases.	celastrol	24-33	NLR family pyrin domain containing 3	Homo sapiens	53-58
28978034-6	2017	Our results thus reveal celastrol as an inhibitor of NLRP3 inflammasome, implying the potential for clinical use of celastrol in treatment of NLRP3 inflammasome-driven inflammatory diseases.	celastrol	24-33	NLR family pyrin domain containing 3	Homo sapiens	142-147
28978034-6	2017	Our results thus reveal celastrol as an inhibitor of NLRP3 inflammasome, implying the potential for clinical use of celastrol in treatment of NLRP3 inflammasome-driven inflammatory diseases.	celastrol	116-125	NLR family pyrin domain containing 3	Homo sapiens	142-147
28435131-5	2017	The results indicated that both celastrol and BBG pretreatments, especially when combined together, curbed APAP-induced hepatocellular injury (ALT, AST and LDH) and death (necrosis and apoptosis).	celastrol	32-41	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	148-151
28730769-1	2017	PURPOSE: To investigate the effect and related molecular mechanisms of lapatinib/celastrol combination or single-agent treatment in HER2/neu-overexpressing MDA-MB-453 breast cancer cells.	celastrol	81-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-140
28730769-8	2017	RESULTS: Combination celastrol and lapatinib produced strong synergy in growth inhibition and apoptosis in comparison to single-agent treatment in HER2/neu-overexpressing MDA-MB-453 cells.	celastrol	21-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-155
28730769-0	2017	Downregulation and subcellular distribution of HER2 involved in MDA-MB-453 breast cancer cell apoptosis induced by lapatinib/celastrol combination.	celastrol	125-134	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
28730769-9	2017	Interestingly, compared with celastrol treatment alone, lapatinib/celastrol combination induced more HER2 membrane protein downregulation and ectopic to cytoplasm and nucleus in MDA-MB-453 cells.	celastrol	66-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
28730769-1	2017	PURPOSE: To investigate the effect and related molecular mechanisms of lapatinib/celastrol combination or single-agent treatment in HER2/neu-overexpressing MDA-MB-453 breast cancer cells.	celastrol	81-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
28730769-10	2017	CONCLUSION: The combination of celastrol and lapatinib could be used as a novel combination regimen which provides a strong anticancer synergy in the treatment of HER2/neu-overexpressing cancer cells.	celastrol	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-167
28730769-10	2017	CONCLUSION: The combination of celastrol and lapatinib could be used as a novel combination regimen which provides a strong anticancer synergy in the treatment of HER2/neu-overexpressing cancer cells.	celastrol	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	168-171
28522217-0	2017	Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway.	celastrol	0-9	cellular inhibitor of PP2A	Homo sapiens	92-97
28522217-0	2017	Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway.	celastrol	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	98-103
28522217-3	2017	F.) called celastrol can directly bound CIP2A protein and effectively inhibit cell proliferation and induce apoptosis in several cancer cells.	celastrol	11-20	cellular inhibitor of PP2A	Homo sapiens	40-45
28522217-7	2017	In addition, celastrol inhibited the expression of CIP2A, c-MYC, and suppressed apoptotic proteins BAX and caspase-8 in human CS cells, on the other hand, it induced the expression of antiapoptotic protein Bcl-2.	celastrol	13-22	cellular inhibitor of PP2A	Homo sapiens	51-56
28522217-7	2017	In addition, celastrol inhibited the expression of CIP2A, c-MYC, and suppressed apoptotic proteins BAX and caspase-8 in human CS cells, on the other hand, it induced the expression of antiapoptotic protein Bcl-2.	celastrol	13-22	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	58-63
28522217-7	2017	In addition, celastrol inhibited the expression of CIP2A, c-MYC, and suppressed apoptotic proteins BAX and caspase-8 in human CS cells, on the other hand, it induced the expression of antiapoptotic protein Bcl-2.	celastrol	13-22	BCL2 associated X, apoptosis regulator	Homo sapiens	99-102
28522217-7	2017	In addition, celastrol inhibited the expression of CIP2A, c-MYC, and suppressed apoptotic proteins BAX and caspase-8 in human CS cells, on the other hand, it induced the expression of antiapoptotic protein Bcl-2.	celastrol	13-22	caspase 8	Homo sapiens	107-116
28522217-7	2017	In addition, celastrol inhibited the expression of CIP2A, c-MYC, and suppressed apoptotic proteins BAX and caspase-8 in human CS cells, on the other hand, it induced the expression of antiapoptotic protein Bcl-2.	celastrol	13-22	BCL2 apoptosis regulator	Homo sapiens	206-211
28522217-9	2017	To sum up, we found that celastrol had effects on inhibiting proliferation, migration, invasion and inducing apoptosis through suppression CIP2A/c-MYC signaling pathway in vitro, which may provide a new therapeutic regimen for CS.	celastrol	25-34	cellular inhibitor of PP2A	Homo sapiens	139-144
28522217-9	2017	To sum up, we found that celastrol had effects on inhibiting proliferation, migration, invasion and inducing apoptosis through suppression CIP2A/c-MYC signaling pathway in vitro, which may provide a new therapeutic regimen for CS.	celastrol	25-34	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	145-150
28459364-10	2017	In conclusion, our results suggest that celastrol induces cytotoxicity through involvement of Bcl2 family proteins and death receptor, and modulation of phospho-NF-kappaB, Akt, and mitogen-activated protein kinase in association with endoplasmic reticulum stress and reactive oxygen species production in anaplastic thyroid carcinoma cells.	celastrol	40-49	BCL2 apoptosis regulator	Homo sapiens	94-98
28459364-10	2017	In conclusion, our results suggest that celastrol induces cytotoxicity through involvement of Bcl2 family proteins and death receptor, and modulation of phospho-NF-kappaB, Akt, and mitogen-activated protein kinase in association with endoplasmic reticulum stress and reactive oxygen species production in anaplastic thyroid carcinoma cells.	celastrol	40-49	AKT serine/threonine kinase 1	Homo sapiens	172-175
28129433-5	2017	Also, N-acetyl-l-cysteine, a ROS scavenger, potentiated celastrol"s inhibition of the events in the cells triggered by Cd, implying neuroprotection by celastrol via blocking Cd-evoked NOX2-derived ROS.	celastrol	56-65	cytochrome b-245 beta chain	Rattus norvegicus	184-188
28129433-0	2017	Celastrol ameliorates Cd-induced neuronal apoptosis by targeting NOX2-derived ROS-dependent PP5-JNK signaling pathway.	celastrol	0-9	cytochrome b-245 beta chain	Rattus norvegicus	65-69
28388439-0	2017	Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy.	celastrol	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	18-23
28388439-0	2017	Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy.	celastrol	0-9	TNF receptor associated factor 2	Homo sapiens	41-46
28388439-3	2017	Here, we report that celastrol, a potent anti-inflammatory pentacyclic triterpene, binds Nur77 to inhibit inflammation and induce autophagy in a Nur77-dependent manner.	celastrol	21-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
28388439-3	2017	Here, we report that celastrol, a potent anti-inflammatory pentacyclic triterpene, binds Nur77 to inhibit inflammation and induce autophagy in a Nur77-dependent manner.	celastrol	21-30	nuclear receptor subfamily 4 group A member 1	Homo sapiens	145-150
28388439-4	2017	Celastrol promotes Nur77 translocation from the nucleus to mitochondria, where it interacts with tumor necrosis factor receptor-associated factor 2 (TRAF2), a scaffold protein and E3 ubiquitin ligase important for inflammatory signaling.	celastrol	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	19-24
28388439-4	2017	Celastrol promotes Nur77 translocation from the nucleus to mitochondria, where it interacts with tumor necrosis factor receptor-associated factor 2 (TRAF2), a scaffold protein and E3 ubiquitin ligase important for inflammatory signaling.	celastrol	0-9	TNF receptor associated factor 2	Homo sapiens	97-147
28388439-4	2017	Celastrol promotes Nur77 translocation from the nucleus to mitochondria, where it interacts with tumor necrosis factor receptor-associated factor 2 (TRAF2), a scaffold protein and E3 ubiquitin ligase important for inflammatory signaling.	celastrol	0-9	TNF receptor associated factor 2	Homo sapiens	149-154
28388439-7	2017	Together, our results identify Nur77 as a critical intracellular target for celastrol and unravel a mechanism of Nur77-dependent clearance of inflamed mitochondria to alleviate inflammation.	celastrol	76-85	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-36
28397045-0	2017	Celastrol protects TGF-beta1-induced endothelial-mesenchymal transition.	celastrol	0-9	transforming growth factor beta 1	Homo sapiens	19-28
28397045-2	2017	In this study, the effects and molecular mechanisms of celastrol (CEL) on transforming growth factor-beta1 (TGF-beta1)-induced EndMT in human umbilical vein endothelial (HUVEC-12) cells were investigated.	celastrol	55-64	transforming growth factor beta 1	Homo sapiens	74-106
28397045-2	2017	In this study, the effects and molecular mechanisms of celastrol (CEL) on transforming growth factor-beta1 (TGF-beta1)-induced EndMT in human umbilical vein endothelial (HUVEC-12) cells were investigated.	celastrol	55-64	transforming growth factor beta 1	Homo sapiens	108-117
28397045-2	2017	In this study, the effects and molecular mechanisms of celastrol (CEL) on transforming growth factor-beta1 (TGF-beta1)-induced EndMT in human umbilical vein endothelial (HUVEC-12) cells were investigated.	celastrol	66-69	transforming growth factor beta 1	Homo sapiens	74-106
28397045-2	2017	In this study, the effects and molecular mechanisms of celastrol (CEL) on transforming growth factor-beta1 (TGF-beta1)-induced EndMT in human umbilical vein endothelial (HUVEC-12) cells were investigated.	celastrol	66-69	transforming growth factor beta 1	Homo sapiens	108-117
28397045-6	2017	The in vitro scratch assay showed that CEL inhibited the migration capacity of the transitioned endothelial cells induced by TGF-beta1.	celastrol	39-42	transforming growth factor beta 1	Homo sapiens	125-134
28397045-7	2017	Further experiments showed that the beneficial effect of CEL on blocking the EndMT in HUVEC-12 cells was associated with the suppression of the TGF-beta1/Smads signalling pathway, which was also confirmed by the inhibition of its downstream transcription factor snail1, twist1, twist2, ZEB1 and ZEB2.	celastrol	57-60	transforming growth factor beta 1	Homo sapiens	144-153
28397045-7	2017	Further experiments showed that the beneficial effect of CEL on blocking the EndMT in HUVEC-12 cells was associated with the suppression of the TGF-beta1/Smads signalling pathway, which was also confirmed by the inhibition of its downstream transcription factor snail1, twist1, twist2, ZEB1 and ZEB2.	celastrol	57-60	snail family transcriptional repressor 1	Homo sapiens	262-268
28397045-7	2017	Further experiments showed that the beneficial effect of CEL on blocking the EndMT in HUVEC-12 cells was associated with the suppression of the TGF-beta1/Smads signalling pathway, which was also confirmed by the inhibition of its downstream transcription factor snail1, twist1, twist2, ZEB1 and ZEB2.	celastrol	57-60	twist family bHLH transcription factor 1	Homo sapiens	270-276
28397045-7	2017	Further experiments showed that the beneficial effect of CEL on blocking the EndMT in HUVEC-12 cells was associated with the suppression of the TGF-beta1/Smads signalling pathway, which was also confirmed by the inhibition of its downstream transcription factor snail1, twist1, twist2, ZEB1 and ZEB2.	celastrol	57-60	twist family bHLH transcription factor 2	Homo sapiens	278-284
28397045-7	2017	Further experiments showed that the beneficial effect of CEL on blocking the EndMT in HUVEC-12 cells was associated with the suppression of the TGF-beta1/Smads signalling pathway, which was also confirmed by the inhibition of its downstream transcription factor snail1, twist1, twist2, ZEB1 and ZEB2.	celastrol	57-60	zinc finger E-box binding homeobox 1	Homo sapiens	286-290
28397045-7	2017	Further experiments showed that the beneficial effect of CEL on blocking the EndMT in HUVEC-12 cells was associated with the suppression of the TGF-beta1/Smads signalling pathway, which was also confirmed by the inhibition of its downstream transcription factor snail1, twist1, twist2, ZEB1 and ZEB2.	celastrol	57-60	zinc finger E-box binding homeobox 2	Homo sapiens	295-299
28129433-0	2017	Celastrol ameliorates Cd-induced neuronal apoptosis by targeting NOX2-derived ROS-dependent PP5-JNK signaling pathway.	celastrol	0-9	protein phosphatase 5, catalytic subunit	Rattus norvegicus	92-95
28129433-0	2017	Celastrol ameliorates Cd-induced neuronal apoptosis by targeting NOX2-derived ROS-dependent PP5-JNK signaling pathway.	celastrol	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	96-99
28129433-2	2017	Recently, we have reported that cadmium (Cd) activates c-Jun N-terminal kinase (JNK) pathway leading to neuronal cell death by inducing ROS inactivation of protein phosphatase 5 (PP5), and celastrol prevents Cd-activated JNK pathway against neuronal apoptosis.	celastrol	189-198	mitogen-activated protein kinase 8	Rattus norvegicus	55-78
28129433-2	2017	Recently, we have reported that cadmium (Cd) activates c-Jun N-terminal kinase (JNK) pathway leading to neuronal cell death by inducing ROS inactivation of protein phosphatase 5 (PP5), and celastrol prevents Cd-activated JNK pathway against neuronal apoptosis.	celastrol	189-198	mitogen-activated protein kinase 8	Rattus norvegicus	80-83
28129433-3	2017	Therefore, we hypothesized that celastrol could hinder Cd induction of ROS-dependent PP5-JNK signaling pathway from apoptosis in neuronal cells.	celastrol	32-41	protein phosphatase 5, catalytic subunit	Rattus norvegicus	85-88
28129433-3	2017	Therefore, we hypothesized that celastrol could hinder Cd induction of ROS-dependent PP5-JNK signaling pathway from apoptosis in neuronal cells.	celastrol	32-41	mitogen-activated protein kinase 8	Rattus norvegicus	89-92
28129433-4	2017	Here, we show that celastrol attenuated Cd-induced expression of NADPH oxidase 2 (NOX2) and its regulatory proteins (p22phox , p40phox , p47phox , p67phox , and Rac1), as well as the generation of ROS in PC12 cells and primary neurons.	celastrol	19-28	cytochrome b-245 beta chain	Rattus norvegicus	65-80
28129433-4	2017	Here, we show that celastrol attenuated Cd-induced expression of NADPH oxidase 2 (NOX2) and its regulatory proteins (p22phox , p40phox , p47phox , p67phox , and Rac1), as well as the generation of ROS in PC12 cells and primary neurons.	celastrol	19-28	cytochrome b-245 beta chain	Rattus norvegicus	82-86
28129433-6	2017	Further research revealed that celastrol was involved in the regulation of PP5 inactivation and JNK/c-Jun activation induced by Cd, as celastrol prevented Cd from reducing PP5 expression, and over-expression of wild-type PP5 or dominant negative c-Jun strengthened celastrol"s inhibition of Cd-induced phosphorylation of JNK and/or c-Jun, as well as apoptosis in neuronal cells.	celastrol	31-40	protein phosphatase 5, catalytic subunit	Rattus norvegicus	75-78
28129433-4	2017	Here, we show that celastrol attenuated Cd-induced expression of NADPH oxidase 2 (NOX2) and its regulatory proteins (p22phox , p40phox , p47phox , p67phox , and Rac1), as well as the generation of ROS in PC12 cells and primary neurons.	celastrol	19-28	cytochrome b-245 alpha chain	Rattus norvegicus	117-124
28129433-6	2017	Further research revealed that celastrol was involved in the regulation of PP5 inactivation and JNK/c-Jun activation induced by Cd, as celastrol prevented Cd from reducing PP5 expression, and over-expression of wild-type PP5 or dominant negative c-Jun strengthened celastrol"s inhibition of Cd-induced phosphorylation of JNK and/or c-Jun, as well as apoptosis in neuronal cells.	celastrol	31-40	mitogen-activated protein kinase 8	Rattus norvegicus	96-99
28129433-6	2017	Further research revealed that celastrol was involved in the regulation of PP5 inactivation and JNK/c-Jun activation induced by Cd, as celastrol prevented Cd from reducing PP5 expression, and over-expression of wild-type PP5 or dominant negative c-Jun strengthened celastrol"s inhibition of Cd-induced phosphorylation of JNK and/or c-Jun, as well as apoptosis in neuronal cells.	celastrol	31-40	protein phosphatase 5, catalytic subunit	Rattus norvegicus	172-175
28129433-4	2017	Here, we show that celastrol attenuated Cd-induced expression of NADPH oxidase 2 (NOX2) and its regulatory proteins (p22phox , p40phox , p47phox , p67phox , and Rac1), as well as the generation of ROS in PC12 cells and primary neurons.	celastrol	19-28	neutrophil cytosolic factor 1	Rattus norvegicus	137-144
28129433-6	2017	Further research revealed that celastrol was involved in the regulation of PP5 inactivation and JNK/c-Jun activation induced by Cd, as celastrol prevented Cd from reducing PP5 expression, and over-expression of wild-type PP5 or dominant negative c-Jun strengthened celastrol"s inhibition of Cd-induced phosphorylation of JNK and/or c-Jun, as well as apoptosis in neuronal cells.	celastrol	31-40	protein phosphatase 5, catalytic subunit	Rattus norvegicus	172-175
28129433-6	2017	Further research revealed that celastrol was involved in the regulation of PP5 inactivation and JNK/c-Jun activation induced by Cd, as celastrol prevented Cd from reducing PP5 expression, and over-expression of wild-type PP5 or dominant negative c-Jun strengthened celastrol"s inhibition of Cd-induced phosphorylation of JNK and/or c-Jun, as well as apoptosis in neuronal cells.	celastrol	31-40	mitogen-activated protein kinase 8	Rattus norvegicus	321-324
28129433-4	2017	Here, we show that celastrol attenuated Cd-induced expression of NADPH oxidase 2 (NOX2) and its regulatory proteins (p22phox , p40phox , p47phox , p67phox , and Rac1), as well as the generation of ROS in PC12 cells and primary neurons.	celastrol	19-28	Rac family small GTPase 1	Rattus norvegicus	161-165
28129433-9	2017	These findings indicate that celastrol ameliorates Cd-induced neuronal apoptosis via targeting NOX2-derived ROS-dependent PP5-JNK signaling pathway.	celastrol	29-38	protein phosphatase 5, catalytic subunit	Rattus norvegicus	122-125
28129433-9	2017	These findings indicate that celastrol ameliorates Cd-induced neuronal apoptosis via targeting NOX2-derived ROS-dependent PP5-JNK signaling pathway.	celastrol	29-38	mitogen-activated protein kinase 8	Rattus norvegicus	126-129
28129433-6	2017	Further research revealed that celastrol was involved in the regulation of PP5 inactivation and JNK/c-Jun activation induced by Cd, as celastrol prevented Cd from reducing PP5 expression, and over-expression of wild-type PP5 or dominant negative c-Jun strengthened celastrol"s inhibition of Cd-induced phosphorylation of JNK and/or c-Jun, as well as apoptosis in neuronal cells.	celastrol	135-144	protein phosphatase 5, catalytic subunit	Rattus norvegicus	172-175
28129433-6	2017	Further research revealed that celastrol was involved in the regulation of PP5 inactivation and JNK/c-Jun activation induced by Cd, as celastrol prevented Cd from reducing PP5 expression, and over-expression of wild-type PP5 or dominant negative c-Jun strengthened celastrol"s inhibition of Cd-induced phosphorylation of JNK and/or c-Jun, as well as apoptosis in neuronal cells.	celastrol	135-144	protein phosphatase 5, catalytic subunit	Rattus norvegicus	172-175
28129433-6	2017	Further research revealed that celastrol was involved in the regulation of PP5 inactivation and JNK/c-Jun activation induced by Cd, as celastrol prevented Cd from reducing PP5 expression, and over-expression of wild-type PP5 or dominant negative c-Jun strengthened celastrol"s inhibition of Cd-induced phosphorylation of JNK and/or c-Jun, as well as apoptosis in neuronal cells.	celastrol	135-144	protein phosphatase 5, catalytic subunit	Rattus norvegicus	172-175
28129433-6	2017	Further research revealed that celastrol was involved in the regulation of PP5 inactivation and JNK/c-Jun activation induced by Cd, as celastrol prevented Cd from reducing PP5 expression, and over-expression of wild-type PP5 or dominant negative c-Jun strengthened celastrol"s inhibition of Cd-induced phosphorylation of JNK and/or c-Jun, as well as apoptosis in neuronal cells.	celastrol	135-144	protein phosphatase 5, catalytic subunit	Rattus norvegicus	172-175
28129433-7	2017	Of importance, inhibiting NOX2 with apocynin or silencing NOX2 by RNA interference enhanced the inhibitory effects of celastrol on Cd-induced inactivation of PP5, activation of JNK/c-Jun, ROS, and apoptosis in the cells.	celastrol	118-127	cytochrome b-245 beta chain	Rattus norvegicus	26-30
28129433-7	2017	Of importance, inhibiting NOX2 with apocynin or silencing NOX2 by RNA interference enhanced the inhibitory effects of celastrol on Cd-induced inactivation of PP5, activation of JNK/c-Jun, ROS, and apoptosis in the cells.	celastrol	118-127	cytochrome b-245 beta chain	Rattus norvegicus	58-62
28129433-7	2017	Of importance, inhibiting NOX2 with apocynin or silencing NOX2 by RNA interference enhanced the inhibitory effects of celastrol on Cd-induced inactivation of PP5, activation of JNK/c-Jun, ROS, and apoptosis in the cells.	celastrol	118-127	protein phosphatase 5, catalytic subunit	Rattus norvegicus	158-161
28129433-7	2017	Of importance, inhibiting NOX2 with apocynin or silencing NOX2 by RNA interference enhanced the inhibitory effects of celastrol on Cd-induced inactivation of PP5, activation of JNK/c-Jun, ROS, and apoptosis in the cells.	celastrol	118-127	mitogen-activated protein kinase 8	Rattus norvegicus	177-180
28129433-8	2017	Furthermore, we noticed that expression of wild-type PP5 or dominant negative c-Jun, or pretreatment with JNK inhibitor SP600125 reinforced celastrol"s suppression of Cd-induced NOX2 and its regulatory proteins, and consequential ROS in neuronal cells.	celastrol	140-149	protein phosphatase 5, catalytic subunit	Rattus norvegicus	53-56
28129433-8	2017	Furthermore, we noticed that expression of wild-type PP5 or dominant negative c-Jun, or pretreatment with JNK inhibitor SP600125 reinforced celastrol"s suppression of Cd-induced NOX2 and its regulatory proteins, and consequential ROS in neuronal cells.	celastrol	140-149	mitogen-activated protein kinase 8	Rattus norvegicus	106-109
28129433-8	2017	Furthermore, we noticed that expression of wild-type PP5 or dominant negative c-Jun, or pretreatment with JNK inhibitor SP600125 reinforced celastrol"s suppression of Cd-induced NOX2 and its regulatory proteins, and consequential ROS in neuronal cells.	celastrol	140-149	cytochrome b-245 beta chain	Rattus norvegicus	178-182
28129433-9	2017	These findings indicate that celastrol ameliorates Cd-induced neuronal apoptosis via targeting NOX2-derived ROS-dependent PP5-JNK signaling pathway.	celastrol	29-38	cytochrome b-245 beta chain	Rattus norvegicus	95-99
28189063-3	2017	Protective effect of celastrol (1mg/kg, i.p., 1h before CLP) was illustrated after 24h by preventing CLP-induced hepatic histopathological changes and elevation in serum hepatic biomarkers [alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB) and gamma aminotransferase (gamma-GT)] without affecting mortality.	celastrol	21-30	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	222-248
28161417-0	2017	Celastrol attenuates mitochondrial dysfunction and inflammation in palmitate-mediated insulin resistance in C3A hepatocytes.	celastrol	0-9	insulin	Homo sapiens	86-93
28161417-2	2017	Celastrol, an anti-inflammatory compound from the root of Tripterygium Wilfordii has been reported to mitigate insulin resistance and inflammation in animal disease models.	celastrol	0-9	insulin	Homo sapiens	111-118
28161417-4	2017	The present study sought to explore the mechanistic roles of celastrol upon insulin resistance induced by palmitate in C3A human hepatocytes.	celastrol	61-70	insulin	Homo sapiens	76-83
28161417-8	2017	However, celastrol at the optimum concentration of 30nM was able to reverse these deleterious occasions and protected the cells from mitochondrial dysfunction and insulin resistance.	celastrol	9-18	insulin	Homo sapiens	163-170
28161417-9	2017	Importantly, we presented evidence for the first time that celastrol efficiently prevented palmitate-induced insulin resistance in hepatocytes at least, via improved mitochondrial functions and insulin signaling pathways.	celastrol	59-68	insulin	Homo sapiens	109-116
28161417-9	2017	Importantly, we presented evidence for the first time that celastrol efficiently prevented palmitate-induced insulin resistance in hepatocytes at least, via improved mitochondrial functions and insulin signaling pathways.	celastrol	59-68	insulin	Homo sapiens	194-201
28189063-3	2017	Protective effect of celastrol (1mg/kg, i.p., 1h before CLP) was illustrated after 24h by preventing CLP-induced hepatic histopathological changes and elevation in serum hepatic biomarkers [alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB) and gamma aminotransferase (gamma-GT)] without affecting mortality.	celastrol	21-30	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	250-253
28189063-4	2017	Celastrol anti-inflammatory effect was illustrated by inhibiting increased serum and hepatic mRNA expression of interleukin-6 (IL-6) without affecting IL-10 elevation.	celastrol	0-9	interleukin 6	Rattus norvegicus	112-125
28189063-4	2017	Celastrol anti-inflammatory effect was illustrated by inhibiting increased serum and hepatic mRNA expression of interleukin-6 (IL-6) without affecting IL-10 elevation.	celastrol	0-9	interleukin 6	Rattus norvegicus	127-131
28189063-5	2017	Furthermore, celastrol inhibited CLP-induced elevations in hepatic mRNA expression of nuclear factor inhibitory protein kappa-B alpha (NFkappaBia), TLR-4, 5-lipoxygenase (5-LOX) and prevented NF-kappaB/p65 nuclear translocation and activation.	celastrol	13-22	toll-like receptor 4	Rattus norvegicus	148-153
28189063-5	2017	Furthermore, celastrol inhibited CLP-induced elevations in hepatic mRNA expression of nuclear factor inhibitory protein kappa-B alpha (NFkappaBia), TLR-4, 5-lipoxygenase (5-LOX) and prevented NF-kappaB/p65 nuclear translocation and activation.	celastrol	13-22	lysyl oxidase	Rattus norvegicus	173-176
28189063-5	2017	Furthermore, celastrol inhibited CLP-induced elevations in hepatic mRNA expression of nuclear factor inhibitory protein kappa-B alpha (NFkappaBia), TLR-4, 5-lipoxygenase (5-LOX) and prevented NF-kappaB/p65 nuclear translocation and activation.	celastrol	13-22	synaptotagmin 1	Rattus norvegicus	202-205
28189063-6	2017	In conclusion, celastrol prevented CLP-induced acute hepatic dysfunction through its anti-inflammatory effect by attenuating NF-kappaB activation, TLR-4 and 5-LOX expression with subsequent reduction in pro-inflammatory IL-6.	celastrol	15-24	toll-like receptor 4	Rattus norvegicus	147-152
28189063-6	2017	In conclusion, celastrol prevented CLP-induced acute hepatic dysfunction through its anti-inflammatory effect by attenuating NF-kappaB activation, TLR-4 and 5-LOX expression with subsequent reduction in pro-inflammatory IL-6.	celastrol	15-24	lysyl oxidase	Rattus norvegicus	159-162
28189063-6	2017	In conclusion, celastrol prevented CLP-induced acute hepatic dysfunction through its anti-inflammatory effect by attenuating NF-kappaB activation, TLR-4 and 5-LOX expression with subsequent reduction in pro-inflammatory IL-6.	celastrol	15-24	interleukin 6	Rattus norvegicus	220-224
28119074-0	2017	Celastrol attenuates angiotensin II mediated human umbilical vein endothelial cells damage through activation of Nrf2/ERK1/2/Nox2 signal pathway.	celastrol	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	113-117
28119074-0	2017	Celastrol attenuates angiotensin II mediated human umbilical vein endothelial cells damage through activation of Nrf2/ERK1/2/Nox2 signal pathway.	celastrol	0-9	cytochrome b-245 beta chain	Homo sapiens	125-129
28119074-0	2017	Celastrol attenuates angiotensin II mediated human umbilical vein endothelial cells damage through activation of Nrf2/ERK1/2/Nox2 signal pathway.	celastrol	0-9	mitogen-activated protein kinase 3	Homo sapiens	118-124
28119074-6	2017	In contrast, celastrol effectively suppressed reactive oxygen species generation, improved endothelial cell activity, and ameliorated Ang II-mediated HUVEC injury through activation of Nrf2, inhibition of Nox2/AT1 receptor expression, and upregulated phosphorylation of ERK1/2.	celastrol	13-22	NFE2 like bZIP transcription factor 2	Homo sapiens	185-189
28119074-6	2017	In contrast, celastrol effectively suppressed reactive oxygen species generation, improved endothelial cell activity, and ameliorated Ang II-mediated HUVEC injury through activation of Nrf2, inhibition of Nox2/AT1 receptor expression, and upregulated phosphorylation of ERK1/2.	celastrol	13-22	cytochrome b-245 beta chain	Homo sapiens	205-209
28027722-7	2017	These results suggest that celastrol may exert its regulatory activity by inhibiting poly(I:C)-induced expression of pro-inflammatory mediators by suppressing activation of JNK MAPK-STAT1/NF-kappaB in astrocytes.	celastrol	27-36	signal transducer and activator of transcription 1	Homo sapiens	182-187
28119074-6	2017	In contrast, celastrol effectively suppressed reactive oxygen species generation, improved endothelial cell activity, and ameliorated Ang II-mediated HUVEC injury through activation of Nrf2, inhibition of Nox2/AT1 receptor expression, and upregulated phosphorylation of ERK1/2.	celastrol	13-22	mitogen-activated protein kinase 3	Homo sapiens	270-276
28119074-7	2017	After treatment with brusatol, a specific inhibitor of Nrf2, the protective effects of celastrol on Ang II-induced damage in HUVECs were remarkably alleviated.	celastrol	87-96	NFE2 like bZIP transcription factor 2	Homo sapiens	55-59
28119074-8	2017	Taken together, celastrol-induced activation of Nrf2 and inhibition of NADPH oxidase activity were critical for the inhibition of Ang II-mediated endothelial dysfunction, and demonstrated the potential application of celastrol in CVD therapy.	celastrol	16-25	NFE2 like bZIP transcription factor 2	Homo sapiens	48-52
28119074-8	2017	Taken together, celastrol-induced activation of Nrf2 and inhibition of NADPH oxidase activity were critical for the inhibition of Ang II-mediated endothelial dysfunction, and demonstrated the potential application of celastrol in CVD therapy.	celastrol	217-226	NFE2 like bZIP transcription factor 2	Homo sapiens	48-52
27910878-0	2017	Lipids: Celastrol protects against fatty liver through SIRT1.	celastrol	8-17	sirtuin 1	Homo sapiens	55-60
28027722-0	2017	Celastrol suppresses expression of adhesion molecules and chemokines by inhibiting JNK-STAT1/NF-kappaB activation in poly(I:C)-stimulated astrocytes.	celastrol	0-9	mitogen-activated protein kinase 8	Homo sapiens	83-86
27847245-10	2017	This antiviral effect of celastrol was associated with celastrol-induced interferon-alpha (IFN-alpha) expression and was attenuated by a specific inhibitor of the JAK-STAT signaling pathway downstream of IFN-alpha or specific shRNA.	celastrol	25-34	interferon alpha	Mus musculus	73-89
27847245-10	2017	This antiviral effect of celastrol was associated with celastrol-induced interferon-alpha (IFN-alpha) expression and was attenuated by a specific inhibitor of the JAK-STAT signaling pathway downstream of IFN-alpha or specific shRNA.	celastrol	25-34	interferon alpha	Mus musculus	91-100
27847245-10	2017	This antiviral effect of celastrol was associated with celastrol-induced interferon-alpha (IFN-alpha) expression and was attenuated by a specific inhibitor of the JAK-STAT signaling pathway downstream of IFN-alpha or specific shRNA.	celastrol	25-34	interferon alpha	Mus musculus	204-213
27847245-10	2017	This antiviral effect of celastrol was associated with celastrol-induced interferon-alpha (IFN-alpha) expression and was attenuated by a specific inhibitor of the JAK-STAT signaling pathway downstream of IFN-alpha or specific shRNA.	celastrol	55-64	interferon alpha	Mus musculus	73-89
27847245-10	2017	This antiviral effect of celastrol was associated with celastrol-induced interferon-alpha (IFN-alpha) expression and was attenuated by a specific inhibitor of the JAK-STAT signaling pathway downstream of IFN-alpha or specific shRNA.	celastrol	55-64	interferon alpha	Mus musculus	91-100
27847245-12	2017	CONCLUSION: Celastrol represents a potential anti-DENV agent that induces IFN-alpha expression and stimulates a downstream antiviral response, making the therapy a promising drug or dietary supplement for the treatment of DENV-infected patients.	celastrol	12-21	interferon alpha 1	Homo sapiens	74-83
27764525-0	2017	Celastrol prevents cadmium-induced neuronal cell death by blocking reactive oxygen species-mediated mammalian target of rapamycin pathway.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	100-129
27764525-7	2017	RESULTS: Celastrol attenuated Cd-induced apoptosis by suppressing Cd activation of mTOR, which was attributed to preventing Cd inactivation of AMPK.	celastrol	9-18	mechanistic target of rapamycin kinase	Homo sapiens	83-87
27764525-7	2017	RESULTS: Celastrol attenuated Cd-induced apoptosis by suppressing Cd activation of mTOR, which was attributed to preventing Cd inactivation of AMPK.	celastrol	9-18	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	143-147
27764525-8	2017	Inhibition of AMPK with compound C or expression of dominant negative AMPKalpha prevented celastrol from hindering Cd-induced dephosphorylation of AMPKalpha, activation of mTOR and apoptosis.	celastrol	90-99	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	14-18
27764525-8	2017	Inhibition of AMPK with compound C or expression of dominant negative AMPKalpha prevented celastrol from hindering Cd-induced dephosphorylation of AMPKalpha, activation of mTOR and apoptosis.	celastrol	90-99	mechanistic target of rapamycin kinase	Homo sapiens	172-176
27764525-9	2017	Inhibition of mTOR with rapamycin or knockdown of mTOR potentiated prevention by celastrol, of Cd-induced phosphorylation of p70 S6 kinase 1/eukaryotic initiation factor 4E binding protein 1 and apoptosis.	celastrol	81-90	mechanistic target of rapamycin kinase	Homo sapiens	14-18
27764525-9	2017	Inhibition of mTOR with rapamycin or knockdown of mTOR potentiated prevention by celastrol, of Cd-induced phosphorylation of p70 S6 kinase 1/eukaryotic initiation factor 4E binding protein 1 and apoptosis.	celastrol	81-90	mechanistic target of rapamycin kinase	Homo sapiens	50-54
27764525-11	2017	CONCLUSIONS AND IMPLICATIONS: Celastrol prevented the inactivation of AMPK by mitochondrial ROS, thus attenuating Cd-induced mTOR activation and neuronal apoptosis.	celastrol	30-39	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	70-74
27764525-11	2017	CONCLUSIONS AND IMPLICATIONS: Celastrol prevented the inactivation of AMPK by mitochondrial ROS, thus attenuating Cd-induced mTOR activation and neuronal apoptosis.	celastrol	30-39	mechanistic target of rapamycin kinase	Homo sapiens	125-129
28027722-0	2017	Celastrol suppresses expression of adhesion molecules and chemokines by inhibiting JNK-STAT1/NF-kappaB activation in poly(I:C)-stimulated astrocytes.	celastrol	0-9	signal transducer and activator of transcription 1	Homo sapiens	87-92
28027722-0	2017	Celastrol suppresses expression of adhesion molecules and chemokines by inhibiting JNK-STAT1/NF-kappaB activation in poly(I:C)-stimulated astrocytes.	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	93-102
28027722-4	2017	Celastrol significantly inhibited poly(I:C)-induced expression of adhesion molecules, such as ICAM-1/VCAM-1, and chemokines, such as CCL2, CXCL8, and CXCL10, in CRT-MG human astroglioma cells.	celastrol	0-9	intercellular adhesion molecule 1	Homo sapiens	94-100
28027722-4	2017	Celastrol significantly inhibited poly(I:C)-induced expression of adhesion molecules, such as ICAM-1/VCAM-1, and chemokines, such as CCL2, CXCL8, and CXCL10, in CRT-MG human astroglioma cells.	celastrol	0-9	vascular cell adhesion molecule 1	Homo sapiens	101-107
28027722-4	2017	Celastrol significantly inhibited poly(I:C)-induced expression of adhesion molecules, such as ICAM-1/VCAM-1, and chemokines, such as CCL2, CXCL8, and CXCL10, in CRT-MG human astroglioma cells.	celastrol	0-9	C-C motif chemokine ligand 2	Homo sapiens	133-137
28027722-4	2017	Celastrol significantly inhibited poly(I:C)-induced expression of adhesion molecules, such as ICAM-1/VCAM-1, and chemokines, such as CCL2, CXCL8, and CXCL10, in CRT-MG human astroglioma cells.	celastrol	0-9	C-X-C motif chemokine ligand 8	Homo sapiens	139-144
28027722-4	2017	Celastrol significantly inhibited poly(I:C)-induced expression of adhesion molecules, such as ICAM-1/VCAM-1, and chemokines, such as CCL2, CXCL8, and CXCL10, in CRT-MG human astroglioma cells.	celastrol	0-9	C-X-C motif chemokine ligand 10	Homo sapiens	150-156
28027722-7	2017	These results suggest that celastrol may exert its regulatory activity by inhibiting poly(I:C)-induced expression of pro-inflammatory mediators by suppressing activation of JNK MAPK-STAT1/NF-kappaB in astrocytes.	celastrol	27-36	nuclear factor kappa B subunit 1	Homo sapiens	188-197
27273088-7	2016	Celastrol activates heat shock transcription factor 1 (HSF1), the master regulator of Hsp gene transcription, and also exhibits potent anti-inflammatory and anti-oxidant activities.	celastrol	0-9	heat shock transcription factor 1	Homo sapiens	20-53
28027722-5	2017	In addition, celastrol significantly suppressed poly(I:C)-induced activation of JNK MAPK and STAT1 signaling pathways.	celastrol	13-22	mitogen-activated protein kinase 8	Homo sapiens	80-83
28027722-5	2017	In addition, celastrol significantly suppressed poly(I:C)-induced activation of JNK MAPK and STAT1 signaling pathways.	celastrol	13-22	signal transducer and activator of transcription 1	Homo sapiens	93-98
28027722-6	2017	Furthermore, celastrol significantly suppressed poly(I:C)-induced activation of the NF-kappaB signaling pathway.	celastrol	13-22	nuclear factor kappa B subunit 1	Homo sapiens	84-93
28027722-7	2017	These results suggest that celastrol may exert its regulatory activity by inhibiting poly(I:C)-induced expression of pro-inflammatory mediators by suppressing activation of JNK MAPK-STAT1/NF-kappaB in astrocytes.	celastrol	27-36	mitogen-activated protein kinase 8	Homo sapiens	173-176
27823626-7	2016	Celastrol induced occludin, claudin-5 and zonula occludens-1 (ZO-1) in endothelial cells.	celastrol	0-9	occludin	Mus musculus	18-26
27823626-7	2016	Celastrol induced occludin, claudin-5 and zonula occludens-1 (ZO-1) in endothelial cells.	celastrol	0-9	claudin 5	Mus musculus	28-37
27823626-7	2016	Celastrol induced occludin, claudin-5 and zonula occludens-1 (ZO-1) in endothelial cells.	celastrol	0-9	tight junction protein 1	Mus musculus	42-60
27823626-7	2016	Celastrol induced occludin, claudin-5 and zonula occludens-1 (ZO-1) in endothelial cells.	celastrol	0-9	tight junction protein 1	Mus musculus	62-66
27823626-9	2016	Further mechanistic studies revealed that celastrol induced the expression of occludin and ZO-1) via activating MAPKs and PI3K/Akt/mTOR pathway.	celastrol	42-51	occludin	Mus musculus	78-86
27823626-9	2016	Further mechanistic studies revealed that celastrol induced the expression of occludin and ZO-1) via activating MAPKs and PI3K/Akt/mTOR pathway.	celastrol	42-51	tight junction protein 1	Mus musculus	91-95
27823626-9	2016	Further mechanistic studies revealed that celastrol induced the expression of occludin and ZO-1) via activating MAPKs and PI3K/Akt/mTOR pathway.	celastrol	42-51	thymoma viral proto-oncogene 1	Mus musculus	127-130
27823626-9	2016	Further mechanistic studies revealed that celastrol induced the expression of occludin and ZO-1) via activating MAPKs and PI3K/Akt/mTOR pathway.	celastrol	42-51	mechanistic target of rapamycin kinase	Mus musculus	131-135
27823626-10	2016	We also observed that celastrol regulated claudin-5 expression through different mechanisms.	celastrol	22-31	claudin 5	Mus musculus	42-51
27647369-0	2016	Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.	celastrol	42-51	heat shock protein 90 alpha family class A member 1	Homo sapiens	67-72
27647369-0	2016	Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.	celastrol	42-51	cell division cycle 37, HSP90 cochaperone	Homo sapiens	73-78
27647369-5	2016	Celastrol, as a natural product, can disrupt the Hsp90-Cdc37 interaction and induce degradation of kinase clients.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	49-54
27647369-5	2016	Celastrol, as a natural product, can disrupt the Hsp90-Cdc37 interaction and induce degradation of kinase clients.	celastrol	0-9	cell division cycle 37, HSP90 cochaperone	Homo sapiens	55-60
27647369-6	2016	The study conducted here attempted to elucidate the structure-activity relationship of celastrol derivatives as Hsp90-Cdc37 disruptors and to improve the druglike properties.	celastrol	87-96	heat shock protein 90 alpha family class A member 1	Homo sapiens	112-117
27647369-6	2016	The study conducted here attempted to elucidate the structure-activity relationship of celastrol derivatives as Hsp90-Cdc37 disruptors and to improve the druglike properties.	celastrol	87-96	cell division cycle 37, HSP90 cochaperone	Homo sapiens	118-123
27900015-0	2016	Celastrol negatively regulates cell invasion and migration ability of human osteosarcoma via downregulation of the PI3K/Akt/NF-kappaB signaling pathway in vitro.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	120-123
27900015-0	2016	Celastrol negatively regulates cell invasion and migration ability of human osteosarcoma via downregulation of the PI3K/Akt/NF-kappaB signaling pathway in vitro.	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	124-133
27900015-9	2016	We observed that the PI3K/Akt/NF-kappaB signaling pathway was inhibited following Celastrol treatment.	celastrol	82-91	AKT serine/threonine kinase 1	Homo sapiens	26-29
27900015-9	2016	We observed that the PI3K/Akt/NF-kappaB signaling pathway was inhibited following Celastrol treatment.	celastrol	82-91	nuclear factor kappa B subunit 1	Homo sapiens	30-39
27900015-10	2016	In addition, the expression levels of MMP-2 and -9 proteins were also reduced significantly following Celastrol treatment.	celastrol	102-111	matrix metallopeptidase 2	Homo sapiens	38-50
27900015-11	2016	Therefore, we confirmed that Celastrol suppressed osteosarcoma U-2OS cell metastasis via downregulation of the PI3K/Akt/NF-kappaB signaling pathway in vitro.	celastrol	29-38	AKT serine/threonine kinase 1	Homo sapiens	116-119
27900015-11	2016	Therefore, we confirmed that Celastrol suppressed osteosarcoma U-2OS cell metastasis via downregulation of the PI3K/Akt/NF-kappaB signaling pathway in vitro.	celastrol	29-38	nuclear factor kappa B subunit 1	Homo sapiens	120-129
27597642-0	2016	Celastrol modulates inflammation through inhibition of the catalytic activity of mediators of arachidonic acid pathway: Secretory phospholipase A2 group IIA, 5-lipoxygenase and cyclooxygenase-2.	celastrol	0-9	arachidonate 5-lipoxygenase	Homo sapiens	158-172
27597642-0	2016	Celastrol modulates inflammation through inhibition of the catalytic activity of mediators of arachidonic acid pathway: Secretory phospholipase A2 group IIA, 5-lipoxygenase and cyclooxygenase-2.	celastrol	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	177-193
27597642-5	2016	We provide the first evidence for celastrol"s ability to inhibit the catalytic activity of sPLA2IIA, 5-LOX and COX-2 enzymes.	celastrol	34-43	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	91-99
27597642-5	2016	We provide the first evidence for celastrol"s ability to inhibit the catalytic activity of sPLA2IIA, 5-LOX and COX-2 enzymes.	celastrol	34-43	arachidonate 5-lipoxygenase	Homo sapiens	101-106
27597642-5	2016	We provide the first evidence for celastrol"s ability to inhibit the catalytic activity of sPLA2IIA, 5-LOX and COX-2 enzymes.	celastrol	34-43	prostaglandin-endoperoxide synthase 2	Homo sapiens	111-116
27597642-6	2016	Celastrol significantly inhibited the catalytic activity of sPLA2IIA (IC50=6muM) in vitro, which is independent of substrate and calcium concentration.	celastrol	0-9	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	60-68
27597642-7	2016	In addition, celastrol inhibited the catalytic activities of 5-LOX (IC50=5muM) and COX-2 (IC50=20muM) in vitro; sPLA2IIA-induced edema and carrageenan-induced edema in mice; and lipopolysaccharide-stimulated production of PGE2 in human neutrophils.	celastrol	13-22	arachidonate 5-lipoxygenase	Mus musculus	61-66
27597642-7	2016	In addition, celastrol inhibited the catalytic activities of 5-LOX (IC50=5muM) and COX-2 (IC50=20muM) in vitro; sPLA2IIA-induced edema and carrageenan-induced edema in mice; and lipopolysaccharide-stimulated production of PGE2 in human neutrophils.	celastrol	13-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	83-88
27597642-7	2016	In addition, celastrol inhibited the catalytic activities of 5-LOX (IC50=5muM) and COX-2 (IC50=20muM) in vitro; sPLA2IIA-induced edema and carrageenan-induced edema in mice; and lipopolysaccharide-stimulated production of PGE2 in human neutrophils.	celastrol	13-22	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	112-120
27768597-3	2016	This study investigates the impact of celastrol on the expression of death receptors 4/5 (DR4/5) on OS cell lines (HOS, U2OS) and cancer cell lysis by gammadelta T cells.	celastrol	38-47	TNF receptor superfamily member 10a	Homo sapiens	69-95
27768597-4	2016	The results showed that celastrol increased transcription of DR4/5 in HOS and U2OS, leading to increased cell surface, and total DR4/5 protein expression.	celastrol	24-33	TNF receptor superfamily member 10a	Homo sapiens	61-66
27768597-4	2016	The results showed that celastrol increased transcription of DR4/5 in HOS and U2OS, leading to increased cell surface, and total DR4/5 protein expression.	celastrol	24-33	TNF receptor superfamily member 10a	Homo sapiens	129-134
27768597-8	2016	Taken together, our data show that celastrol up-regulated DR4/5 on OS cells to be responsible for intercellular TRAIL/APO-2L crosslink that confers increased cancer cell lysis by gammadelta T cells.	celastrol	35-44	TNF receptor superfamily member 10a	Homo sapiens	58-63
27768597-8	2016	Taken together, our data show that celastrol up-regulated DR4/5 on OS cells to be responsible for intercellular TRAIL/APO-2L crosslink that confers increased cancer cell lysis by gammadelta T cells.	celastrol	35-44	TNF superfamily member 10	Homo sapiens	112-124
27840916-0	2016	Effects of celastrol on enhancing apoptosis of ovarian cancer cells via the downregulation of microRNA-21 and the suppression of the PI3K/Akt-NF-kappaB signaling pathway in an in vitro model of ovarian carcinoma.	celastrol	11-20	microRNA 21	Homo sapiens	94-105
27840916-0	2016	Effects of celastrol on enhancing apoptosis of ovarian cancer cells via the downregulation of microRNA-21 and the suppression of the PI3K/Akt-NF-kappaB signaling pathway in an in vitro model of ovarian carcinoma.	celastrol	11-20	AKT serine/threonine kinase 1	Homo sapiens	138-141
27840916-5	2016	In OVCAR3 cells, celastrol was observed to suppress cellular proliferation, induce apoptosis and increase caspase-9 and -3 activity in a dose- and time-dependent manner.	celastrol	17-26	caspase 9	Homo sapiens	106-122
27840916-6	2016	The expression levels of microRNA-21 (miRNA-21) were reduced, in addition to a reduction in the levels of phosphoinositide 3-kinase (PI3K)/p-Akt-NF (NF)-kappaB following treatment with celastrol.	celastrol	185-194	microRNA 21	Homo sapiens	25-36
27840916-6	2016	The expression levels of microRNA-21 (miRNA-21) were reduced, in addition to a reduction in the levels of phosphoinositide 3-kinase (PI3K)/p-Akt-NF (NF)-kappaB following treatment with celastrol.	celastrol	185-194	microRNA 21	Homo sapiens	38-46
27840916-7	2016	Notably, reduced expression of miRNA-21 replicated the effect of celastrol on OVCAR3 cells and inhibited the PI3K/p-Akt-NF-kappaB signaling pathway in an in vitro model of ovarian carcinoma.	celastrol	65-74	microRNA 21	Homo sapiens	31-39
27840916-8	2016	To the best of our knowledge this is the first study to indicate that celastrol may represent a potential agent for the treatment of human ovarian carcinoma, via the induction of apoptosis through the downregulation of miRNA-21 and the PI3K/Akt-NF-kappaB signaling pathway in an in vitro model of ovarian carcinoma.	celastrol	70-79	microRNA 21	Homo sapiens	219-227
27840916-8	2016	To the best of our knowledge this is the first study to indicate that celastrol may represent a potential agent for the treatment of human ovarian carcinoma, via the induction of apoptosis through the downregulation of miRNA-21 and the PI3K/Akt-NF-kappaB signaling pathway in an in vitro model of ovarian carcinoma.	celastrol	70-79	AKT serine/threonine kinase 1	Homo sapiens	241-244
28123944-0	2017	Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1.	celastrol	0-9	sirtuin 1	Mus musculus	79-84
28123944-6	2017	RESULTS: When WT mice receiving a high-fat diet (HFD) were treated with Celastrol, reductions in body weight, subcutaneous and visceral fat content, and liver lipid droplet formation were observed, along with reduced hepatic intracellular triglyceride and serum triglyceride, free fatty acid, and ALT concentrations.	celastrol	72-81	glutamic pyruvic transaminase, soluble	Mus musculus	297-300
28123944-7	2017	Furthermore, Celastrol decreased hepatic sterol regulatory element binding protein 1c (Srebp-1c) expression, enhanced the phosphorylation of hepatic AMP-activated protein kinase alpha (AMPKalpha), and increased the expression of hepatic serine-threonine liver kinase B1 (LKB1).	celastrol	13-22	sterol regulatory element binding transcription factor 1	Mus musculus	41-85
28123944-7	2017	Furthermore, Celastrol decreased hepatic sterol regulatory element binding protein 1c (Srebp-1c) expression, enhanced the phosphorylation of hepatic AMP-activated protein kinase alpha (AMPKalpha), and increased the expression of hepatic serine-threonine liver kinase B1 (LKB1).	celastrol	13-22	sterol regulatory element binding transcription factor 1	Mus musculus	87-95
28123944-7	2017	Furthermore, Celastrol decreased hepatic sterol regulatory element binding protein 1c (Srebp-1c) expression, enhanced the phosphorylation of hepatic AMP-activated protein kinase alpha (AMPKalpha), and increased the expression of hepatic serine-threonine liver kinase B1 (LKB1).	celastrol	13-22	serine/threonine kinase 11	Mus musculus	254-269
28123944-7	2017	Furthermore, Celastrol decreased hepatic sterol regulatory element binding protein 1c (Srebp-1c) expression, enhanced the phosphorylation of hepatic AMP-activated protein kinase alpha (AMPKalpha), and increased the expression of hepatic serine-threonine liver kinase B1 (LKB1).	celastrol	13-22	serine/threonine kinase 11	Mus musculus	271-275
28123944-9	2017	Celastrol administration also improved the anti-inflammatory and anti-oxidative status by inhibiting nuclear factor kappa B (NFkappaB) activity and the mRNA levels of proinflammatory cytokines and increasing mitochondrial DNA copy number and anti-oxidative stress genes expression in WT mice liver, in vivo and in vitro.	celastrol	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	101-123
28123944-9	2017	Celastrol administration also improved the anti-inflammatory and anti-oxidative status by inhibiting nuclear factor kappa B (NFkappaB) activity and the mRNA levels of proinflammatory cytokines and increasing mitochondrial DNA copy number and anti-oxidative stress genes expression in WT mice liver, in vivo and in vitro.	celastrol	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	125-133
28123944-10	2017	Moreover, Celastrol induced hepatic Sirt1 expression in WT mice, in vivo and in vitro.	celastrol	10-19	sirtuin 1	Mus musculus	36-41
28123944-12	2017	It was more interesting that Celastrol aggravated HFD-induced liver damage in LKO mice fed a HFD by inhibiting the phosphorylation of AMPKalpha and boosting the translocation of NFkappaB into the nucleus, thereby resulting in the increase of Srebp-1c expression and the mRNA levels of liver proinflammatory cytokines.	celastrol	29-38	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	178-186
28123944-12	2017	It was more interesting that Celastrol aggravated HFD-induced liver damage in LKO mice fed a HFD by inhibiting the phosphorylation of AMPKalpha and boosting the translocation of NFkappaB into the nucleus, thereby resulting in the increase of Srebp-1c expression and the mRNA levels of liver proinflammatory cytokines.	celastrol	29-38	sterol regulatory element binding transcription factor 1	Mus musculus	242-250
28123944-14	2017	And Sirt1 has an important role in Celastrol-ameliorating liver metabolic damage caused by HFD.	celastrol	35-44	sirtuin 1	Mus musculus	4-9
27658784-0	2016	The ROS derived mitochondrial respirstion not from NADPH oxidase plays key role in Celastrol against angiotensin II-mediated HepG2 cell proliferation.	celastrol	83-92	angiotensinogen	Homo sapiens	101-115
27658784-2	2016	Whether celastrol can effectively suppress AngII mediated cell proliferation remains unknown.	celastrol	8-17	angiotensinogen	Homo sapiens	43-48
27658784-3	2016	In this study, we studied the effect of celastrol on AngII-induced HepG2 cell proliferation and evaluated its underlying mechanism.	celastrol	40-49	angiotensinogen	Homo sapiens	53-58
27658784-7	2016	celastrol dramatically enhanced ROS generation, thereby causing cell apoptosis through inhibiting mitochodrial respiratory function and boosting the expression levels of AngII type 2 (AT2) receptor without influencing NADPH oxidase activity.	celastrol	0-9	angiotensin II receptor type 2	Homo sapiens	170-182
27658784-7	2016	celastrol dramatically enhanced ROS generation, thereby causing cell apoptosis through inhibiting mitochodrial respiratory function and boosting the expression levels of AngII type 2 (AT2) receptor without influencing NADPH oxidase activity.	celastrol	0-9	angiotensin II receptor type 2	Homo sapiens	184-187
27501757-0	2016	Downregulation of miR-17-92a cluster promotes autophagy induction in response to celastrol treatment in prostate cancer cells.	celastrol	81-90	microRNA 17	Homo sapiens	18-24
27501757-3	2016	In the present study, we demonstrate that the miR-17-92a cluster plays a negative role in celastrol induced-autophagy.	celastrol	90-99	microRNA 17	Homo sapiens	46-52
27501757-6	2016	Celastrol induced autophagy was inhibited by miR-20a or miR-17, while the inhibitory effects were rescued in the presence of pcDNA-ATG7 lacking 3" UTR, demonstrating that these two members target ATG7 to inhibit celastrol-induced autophagy.	celastrol	0-9	microRNA 20a	Homo sapiens	45-52
27501757-6	2016	Celastrol induced autophagy was inhibited by miR-20a or miR-17, while the inhibitory effects were rescued in the presence of pcDNA-ATG7 lacking 3" UTR, demonstrating that these two members target ATG7 to inhibit celastrol-induced autophagy.	celastrol	0-9	microRNA 17	Homo sapiens	56-62
27501757-6	2016	Celastrol induced autophagy was inhibited by miR-20a or miR-17, while the inhibitory effects were rescued in the presence of pcDNA-ATG7 lacking 3" UTR, demonstrating that these two members target ATG7 to inhibit celastrol-induced autophagy.	celastrol	0-9	autophagy related 7	Homo sapiens	131-135
27501757-6	2016	Celastrol induced autophagy was inhibited by miR-20a or miR-17, while the inhibitory effects were rescued in the presence of pcDNA-ATG7 lacking 3" UTR, demonstrating that these two members target ATG7 to inhibit celastrol-induced autophagy.	celastrol	0-9	autophagy related 7	Homo sapiens	196-200
27501757-7	2016	As celastrol degrades androgen receptor (AR), a key transcription factor in prostate cancer cells, we further investigated whether AR affected miR-17-92a expression in prostate cancer cells.	celastrol	3-12	androgen receptor	Homo sapiens	22-39
27501757-7	2016	As celastrol degrades androgen receptor (AR), a key transcription factor in prostate cancer cells, we further investigated whether AR affected miR-17-92a expression in prostate cancer cells.	celastrol	3-12	androgen receptor	Homo sapiens	41-43
27501757-11	2016	In summary, our results demonstrate that celastrol downregulates AR and its target miR-17-92a, leading to autophagy induction in prostate cancer cells.	celastrol	41-50	androgen receptor	Homo sapiens	65-67
27501757-11	2016	In summary, our results demonstrate that celastrol downregulates AR and its target miR-17-92a, leading to autophagy induction in prostate cancer cells.	celastrol	41-50	microRNA 17	Homo sapiens	83-89
27273088-7	2016	Celastrol activates heat shock transcription factor 1 (HSF1), the master regulator of Hsp gene transcription, and also exhibits potent anti-inflammatory and anti-oxidant activities.	celastrol	0-9	heat shock transcription factor 1	Homo sapiens	55-59
27273088-7	2016	Celastrol activates heat shock transcription factor 1 (HSF1), the master regulator of Hsp gene transcription, and also exhibits potent anti-inflammatory and anti-oxidant activities.	celastrol	0-9	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	86-89
27273088-10	2016	Co-application of celastrol and arimoclomol induced higher Hsp levels compared to heat shock paired with arimoclomol.	celastrol	18-27	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	59-62
27496961-0	2016	Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors.	celastrol	0-9	TNF superfamily member 10	Homo sapiens	34-39
27484716-0	2016	Celastrol inhibits IL-1beta-induced inflammation in orbital fibroblasts through the suppression of NF-kappaB activity.	celastrol	0-9	interleukin 1 beta	Homo sapiens	19-27
27484716-6	2016	Reverse transcription-polymerase chain reaction, western blotting and ELISAs were performed to examine the effect of celastrol on interleukin (IL)-1beta-induced inflammation in orbital fibroblasts from patients with GO.	celastrol	117-126	interleukin 1 beta	Homo sapiens	130-152
27484716-7	2016	The results demonstrated that celastrol significantly attenuated the expression of IL-6, IL-8, cyclooxygenase (COX)-2 and intercellular adhesion molecule-1 (ICAM-1), and inhibited IL-1beta-induced increases in the expression of IL-6, IL-8, ICAM-1 and COX-2.	celastrol	30-39	interleukin 6	Homo sapiens	83-87
27484716-7	2016	The results demonstrated that celastrol significantly attenuated the expression of IL-6, IL-8, cyclooxygenase (COX)-2 and intercellular adhesion molecule-1 (ICAM-1), and inhibited IL-1beta-induced increases in the expression of IL-6, IL-8, ICAM-1 and COX-2.	celastrol	30-39	C-X-C motif chemokine ligand 8	Homo sapiens	89-93
27484716-7	2016	The results demonstrated that celastrol significantly attenuated the expression of IL-6, IL-8, cyclooxygenase (COX)-2 and intercellular adhesion molecule-1 (ICAM-1), and inhibited IL-1beta-induced increases in the expression of IL-6, IL-8, ICAM-1 and COX-2.	celastrol	30-39	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	95-117
27484716-7	2016	The results demonstrated that celastrol significantly attenuated the expression of IL-6, IL-8, cyclooxygenase (COX)-2 and intercellular adhesion molecule-1 (ICAM-1), and inhibited IL-1beta-induced increases in the expression of IL-6, IL-8, ICAM-1 and COX-2.	celastrol	30-39	intercellular adhesion molecule 1	Homo sapiens	122-155
27484716-7	2016	The results demonstrated that celastrol significantly attenuated the expression of IL-6, IL-8, cyclooxygenase (COX)-2 and intercellular adhesion molecule-1 (ICAM-1), and inhibited IL-1beta-induced increases in the expression of IL-6, IL-8, ICAM-1 and COX-2.	celastrol	30-39	intercellular adhesion molecule 1	Homo sapiens	157-163
27484716-7	2016	The results demonstrated that celastrol significantly attenuated the expression of IL-6, IL-8, cyclooxygenase (COX)-2 and intercellular adhesion molecule-1 (ICAM-1), and inhibited IL-1beta-induced increases in the expression of IL-6, IL-8, ICAM-1 and COX-2.	celastrol	30-39	interleukin 1 beta	Homo sapiens	180-188
27484716-7	2016	The results demonstrated that celastrol significantly attenuated the expression of IL-6, IL-8, cyclooxygenase (COX)-2 and intercellular adhesion molecule-1 (ICAM-1), and inhibited IL-1beta-induced increases in the expression of IL-6, IL-8, ICAM-1 and COX-2.	celastrol	30-39	interleukin 6	Homo sapiens	228-232
27484716-7	2016	The results demonstrated that celastrol significantly attenuated the expression of IL-6, IL-8, cyclooxygenase (COX)-2 and intercellular adhesion molecule-1 (ICAM-1), and inhibited IL-1beta-induced increases in the expression of IL-6, IL-8, ICAM-1 and COX-2.	celastrol	30-39	C-X-C motif chemokine ligand 8	Homo sapiens	234-238
27484716-7	2016	The results demonstrated that celastrol significantly attenuated the expression of IL-6, IL-8, cyclooxygenase (COX)-2 and intercellular adhesion molecule-1 (ICAM-1), and inhibited IL-1beta-induced increases in the expression of IL-6, IL-8, ICAM-1 and COX-2.	celastrol	30-39	intercellular adhesion molecule 1	Homo sapiens	240-246
27484716-7	2016	The results demonstrated that celastrol significantly attenuated the expression of IL-6, IL-8, cyclooxygenase (COX)-2 and intercellular adhesion molecule-1 (ICAM-1), and inhibited IL-1beta-induced increases in the expression of IL-6, IL-8, ICAM-1 and COX-2.	celastrol	30-39	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	251-256
27484716-8	2016	The levels of prostaglandin E2 in orbital fibroblasts induced by IL-1beta were also suppressed by celastrol.	celastrol	98-107	interleukin 1 beta	Homo sapiens	65-73
27484716-9	2016	Further investigation revealed that celastrol suppressed the IL-1beta-induced inflammatory responses in orbital fibroblasts through inhibiting the activation of nuclear factor (NF)-kappaB.	celastrol	36-45	interleukin 1 beta	Homo sapiens	61-69
27484716-9	2016	Further investigation revealed that celastrol suppressed the IL-1beta-induced inflammatory responses in orbital fibroblasts through inhibiting the activation of nuclear factor (NF)-kappaB.	celastrol	36-45	nuclear factor kappa B subunit 1	Homo sapiens	161-187
27484716-10	2016	Taken together, these results suggested that celastrol attenuated the IL-1beta-induced pro-inflammatory pathway in orbital fibroblasts from patients with GO, which was associated with the suppression of NF-kappaB activation.	celastrol	45-54	interleukin 1 beta	Homo sapiens	70-78
27181068-9	2016	Meanwhile, Celastrol suppressed the expression of the protein MDM2, activated the intrinsic mitochondrial apoptosis pathway induced by p53, inhibited anti-apoptotic Bcl-2 and Bcl-xl, induced the pro-apoptotic Bax, cytochrome C, PARP and caspases.	celastrol	11-20	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	135-138
27181068-9	2016	Meanwhile, Celastrol suppressed the expression of the protein MDM2, activated the intrinsic mitochondrial apoptosis pathway induced by p53, inhibited anti-apoptotic Bcl-2 and Bcl-xl, induced the pro-apoptotic Bax, cytochrome C, PARP and caspases.	celastrol	11-20	BCL2, apoptosis regulator	Rattus norvegicus	165-170
27181068-9	2016	Meanwhile, Celastrol suppressed the expression of the protein MDM2, activated the intrinsic mitochondrial apoptosis pathway induced by p53, inhibited anti-apoptotic Bcl-2 and Bcl-xl, induced the pro-apoptotic Bax, cytochrome C, PARP and caspases.	celastrol	11-20	Bcl2-like 1	Rattus norvegicus	175-181
27181068-9	2016	Meanwhile, Celastrol suppressed the expression of the protein MDM2, activated the intrinsic mitochondrial apoptosis pathway induced by p53, inhibited anti-apoptotic Bcl-2 and Bcl-xl, induced the pro-apoptotic Bax, cytochrome C, PARP and caspases.	celastrol	11-20	BCL2 associated X, apoptosis regulator	Rattus norvegicus	209-212
27181068-9	2016	Meanwhile, Celastrol suppressed the expression of the protein MDM2, activated the intrinsic mitochondrial apoptosis pathway induced by p53, inhibited anti-apoptotic Bcl-2 and Bcl-xl, induced the pro-apoptotic Bax, cytochrome C, PARP and caspases.	celastrol	11-20	poly (ADP-ribose) polymerase family, member 1	Mus musculus	228-232
27181068-9	2016	Meanwhile, Celastrol suppressed the expression of the protein MDM2, activated the intrinsic mitochondrial apoptosis pathway induced by p53, inhibited anti-apoptotic Bcl-2 and Bcl-xl, induced the pro-apoptotic Bax, cytochrome C, PARP and caspases.	celastrol	11-20	caspase 9	Mus musculus	237-245
27425825-7	2016	A small chemical library composed of synthetic compounds and natural extracts were screened with the method, two natural products, namely, demethylzeylasteral and celastrol, were identified as new inhibitors to block the Bcl-XL-Bid interaction.	celastrol	163-172	BCL2 like 1	Homo sapiens	221-227
27425825-7	2016	A small chemical library composed of synthetic compounds and natural extracts were screened with the method, two natural products, namely, demethylzeylasteral and celastrol, were identified as new inhibitors to block the Bcl-XL-Bid interaction.	celastrol	163-172	BH3 interacting domain death agonist	Homo sapiens	228-231
27181068-8	2016	Moreover, Celastrol obviously improved the hepatic pathological lesions and decreased the elevated levels of ALT, AST, ALP and AFP.	celastrol	10-19	glutamic pyruvic transaminase, soluble	Mus musculus	109-112
27181068-8	2016	Moreover, Celastrol obviously improved the hepatic pathological lesions and decreased the elevated levels of ALT, AST, ALP and AFP.	celastrol	10-19	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	114-117
27181068-8	2016	Moreover, Celastrol obviously improved the hepatic pathological lesions and decreased the elevated levels of ALT, AST, ALP and AFP.	celastrol	10-19	alpha-fetoprotein	Rattus norvegicus	127-130
27181068-9	2016	Meanwhile, Celastrol suppressed the expression of the protein MDM2, activated the intrinsic mitochondrial apoptosis pathway induced by p53, inhibited anti-apoptotic Bcl-2 and Bcl-xl, induced the pro-apoptotic Bax, cytochrome C, PARP and caspases.	celastrol	11-20	MDM2 proto-oncogene	Rattus norvegicus	62-66
26842874-5	2016	Notably, several food compounds, such as teasaponins, resveratrol, celastrol, caffeine, and taurine among others, are able to restore the leptin signaling in neurons by overexpressing anorexigenic peptides (proopiomelanocortin) and/or repressing orexigenic peptides (neuropeptide Y/agouti-related peptide), thus decreasing food intake.	celastrol	67-76	leptin	Homo sapiens	138-144
27235383-1	2016	Celastrol (CEL), a plant-derived triterpenoid, is a known inhibitor of Hsp90 and NF-kappaB activation pathways and has recently been suggested to be of therapeutic importance in various cancers.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	71-76
27235383-1	2016	Celastrol (CEL), a plant-derived triterpenoid, is a known inhibitor of Hsp90 and NF-kappaB activation pathways and has recently been suggested to be of therapeutic importance in various cancers.	celastrol	11-14	heat shock protein 90 alpha family class A member 1	Homo sapiens	71-76
27159672-11	2016	The results indicated that celastrol is a substrate of P-glycoprotein but not multidrug resistance protein 2 or the breast cancer resistance protein.	celastrol	27-36	ATP binding cassette subfamily B member 1	Homo sapiens	55-69
27159672-8	2016	Additionally, the effects of celastrol on the activity of P-glycoprotein were evaluated using the rhodamine 123 uptake assay.	celastrol	29-38	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
27405485-5	2016	Identification of the molecular targets of celastrol such as the NF-kappaB pathway, MAPK pathway, JAK/STAT pathway and RANKL/OPG pathway has unraveled its strategic checkpoints in controlling arthritic inflammation and tissue damage in AA.	celastrol	43-52	basic transcription factor 3 pseudogene 11	Homo sapiens	125-128
27374097-4	2016	Firstly, multiple assays indicated that celastrol could induce apoptosis of APL cells via p53-activated mitochondrial pathway.	celastrol	40-49	tumor protein p53	Homo sapiens	90-93
27374097-9	2016	Celastrol could also decrease uridine and DHODH protein level in tumor tissues.	celastrol	0-9	dihydroorotate dehydrogenase (quinone)	Homo sapiens	42-47
27017606-12	2016	An in vitro isotope tracing experiment showed that COT and its bioactive ingredients, such as celastrol, ursolic acid, oleanolic acid, and quercetin, significantly increased the efflux of (3)H-cholesterol.	celastrol	94-103	mitogen-activated protein kinase kinase kinase 8	Mus musculus	51-54
27049825-0	2016	Celastrol attenuates oxidative stress in the skeletal muscle of diabetic rats by regulating the AMPK-PGC1alpha-SIRT3 signaling pathway.	celastrol	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	96-100
27398312-0	2016	Mutations Y493G and K546D in human HSP90 disrupt binding of celastrol and reduce interaction with Cdc37.	celastrol	60-69	heat shock protein 90 alpha family class A member 1	Homo sapiens	35-40
27398312-1	2016	Celastrol, a natural compound derived from the Chinese herb Tripterygium wilfordii Hook F, has been proven to inhibit heat shock protein 90 (HSP90) activity and has attracted much attention because of its promising effects in cancer treatment and in ameliorating degenerative neuron diseases.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	141-146
27398312-2	2016	However, the HSP90 structure involved in celastrol interaction is not known.	celastrol	41-50	heat shock protein 90 alpha family class A member 1	Homo sapiens	13-18
27398312-3	2016	Here, we report a novel celastrol-binding pocket in the HSP90 dimer, predicted by molecular docking.	celastrol	24-33	heat shock protein 90 alpha family class A member 1	Homo sapiens	56-61
27398312-4	2016	Mutation of the two key binding pocket amino acids (Lys546 and Tyr493) disrupted the binding of celastrol to HSP90 dimers, as detected by isothermal titration calorimetry (ITC).	celastrol	96-105	heat shock protein 90 alpha family class A member 1	Homo sapiens	109-114
27398312-5	2016	Interestingly, such mutations also reduced binding between HSP90 and the cochaperone Cdc37, thus providing a new explanation for reported findings that celastrol shows more obvious effects in disrupting binding between HSP90 and Cdc37 than between HSP90 and other cochaperones.	celastrol	152-161	heat shock protein 90 alpha family class A member 1	Homo sapiens	59-64
27398312-5	2016	Interestingly, such mutations also reduced binding between HSP90 and the cochaperone Cdc37, thus providing a new explanation for reported findings that celastrol shows more obvious effects in disrupting binding between HSP90 and Cdc37 than between HSP90 and other cochaperones.	celastrol	152-161	cell division cycle 37, HSP90 cochaperone	Homo sapiens	85-90
27398312-5	2016	Interestingly, such mutations also reduced binding between HSP90 and the cochaperone Cdc37, thus providing a new explanation for reported findings that celastrol shows more obvious effects in disrupting binding between HSP90 and Cdc37 than between HSP90 and other cochaperones.	celastrol	152-161	heat shock protein 90 alpha family class A member 1	Homo sapiens	219-224
27398312-5	2016	Interestingly, such mutations also reduced binding between HSP90 and the cochaperone Cdc37, thus providing a new explanation for reported findings that celastrol shows more obvious effects in disrupting binding between HSP90 and Cdc37 than between HSP90 and other cochaperones.	celastrol	152-161	cell division cycle 37, HSP90 cochaperone	Homo sapiens	229-234
27398312-5	2016	Interestingly, such mutations also reduced binding between HSP90 and the cochaperone Cdc37, thus providing a new explanation for reported findings that celastrol shows more obvious effects in disrupting binding between HSP90 and Cdc37 than between HSP90 and other cochaperones.	celastrol	152-161	heat shock protein 90 alpha family class A member 1	Homo sapiens	219-224
27398312-6	2016	In short, our work discloses a novel binding pocket in HSP90 dimer for celastrol and provides an explanation as to why celastrol has a strong effect on HSP90 and Cdc37 binding.	celastrol	71-80	heat shock protein 90 alpha family class A member 1	Homo sapiens	55-60
27398312-6	2016	In short, our work discloses a novel binding pocket in HSP90 dimer for celastrol and provides an explanation as to why celastrol has a strong effect on HSP90 and Cdc37 binding.	celastrol	71-80	heat shock protein 90 alpha family class A member 1	Homo sapiens	152-157
27398312-6	2016	In short, our work discloses a novel binding pocket in HSP90 dimer for celastrol and provides an explanation as to why celastrol has a strong effect on HSP90 and Cdc37 binding.	celastrol	71-80	cell division cycle 37, HSP90 cochaperone	Homo sapiens	162-167
27398312-6	2016	In short, our work discloses a novel binding pocket in HSP90 dimer for celastrol and provides an explanation as to why celastrol has a strong effect on HSP90 and Cdc37 binding.	celastrol	119-128	heat shock protein 90 alpha family class A member 1	Homo sapiens	55-60
27398312-6	2016	In short, our work discloses a novel binding pocket in HSP90 dimer for celastrol and provides an explanation as to why celastrol has a strong effect on HSP90 and Cdc37 binding.	celastrol	119-128	heat shock protein 90 alpha family class A member 1	Homo sapiens	152-157
27398312-6	2016	In short, our work discloses a novel binding pocket in HSP90 dimer for celastrol and provides an explanation as to why celastrol has a strong effect on HSP90 and Cdc37 binding.	celastrol	119-128	cell division cycle 37, HSP90 cochaperone	Homo sapiens	162-167
27049825-0	2016	Celastrol attenuates oxidative stress in the skeletal muscle of diabetic rats by regulating the AMPK-PGC1alpha-SIRT3 signaling pathway.	celastrol	0-9	PPARG coactivator 1 alpha	Rattus norvegicus	101-110
27049825-0	2016	Celastrol attenuates oxidative stress in the skeletal muscle of diabetic rats by regulating the AMPK-PGC1alpha-SIRT3 signaling pathway.	celastrol	0-9	sirtuin 3	Rattus norvegicus	111-116
27049825-11	2016	Celastrol exerted antioxidant effects on skeletal muscle partly by regulating the AMPK-PGC1alpha-Sirt3 signaling pathway.	celastrol	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	82-86
27049825-11	2016	Celastrol exerted antioxidant effects on skeletal muscle partly by regulating the AMPK-PGC1alpha-Sirt3 signaling pathway.	celastrol	0-9	PPARG coactivator 1 alpha	Rattus norvegicus	87-96
27049825-11	2016	Celastrol exerted antioxidant effects on skeletal muscle partly by regulating the AMPK-PGC1alpha-Sirt3 signaling pathway.	celastrol	0-9	sirtuin 3	Homo sapiens	97-102
27110686-6	2016	In addition, we show that short-term in vivo treatment with low dosages of two molecularly distinct proteasome inhibitors celastrol and epoxomicin reverse hyperglycemia in mice with beta-cell failure by increasing insulin production and insulin sensitivity.	celastrol	122-131	insulin	Homo sapiens	214-221
27085773-0	2016	Cascade regulation of PPARgamma(2) and C/EBPalpha signaling pathways by celastrol impairs adipocyte differentiation and stimulates lipolysis in 3T3-L1 adipocytes.	celastrol	72-81	peroxisome proliferator activated receptor gamma	Mus musculus	22-34
27085773-0	2016	Cascade regulation of PPARgamma(2) and C/EBPalpha signaling pathways by celastrol impairs adipocyte differentiation and stimulates lipolysis in 3T3-L1 adipocytes.	celastrol	72-81	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	39-49
27085773-6	2016	RESULTS: Treatment of celastrol not only inhibited adipocyte differentiation (lipid accumulation, glyceraldehyde-3-phosphate dehydrogenase activity and triglyceride content) but also increased lipolysis (glycerol release and free fatty acid release) in 3T3-L1 adipocytes.	celastrol	22-31	glyceraldehyde-3-phosphate dehydrogenase	Mus musculus	98-138
27085773-7	2016	In addition, all celastrol-regulated functional activities were controlled by PPARgamma(2) and C/EBPalpha signaling pathways in duration of celastrol"s treatment in 3T3-L1 adipocytes.	celastrol	17-26	peroxisome proliferator activated receptor gamma	Mus musculus	78-90
27085773-7	2016	In addition, all celastrol-regulated functional activities were controlled by PPARgamma(2) and C/EBPalpha signaling pathways in duration of celastrol"s treatment in 3T3-L1 adipocytes.	celastrol	17-26	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	95-105
27085773-7	2016	In addition, all celastrol-regulated functional activities were controlled by PPARgamma(2) and C/EBPalpha signaling pathways in duration of celastrol"s treatment in 3T3-L1 adipocytes.	celastrol	140-149	peroxisome proliferator activated receptor gamma	Mus musculus	78-90
27085773-7	2016	In addition, all celastrol-regulated functional activities were controlled by PPARgamma(2) and C/EBPalpha signaling pathways in duration of celastrol"s treatment in 3T3-L1 adipocytes.	celastrol	140-149	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	95-105
27085773-8	2016	CONCLUSION: Our initial data from in vitro celastrol signaling studies suggest novel insights into the role of PPARgamma(2) and C/EBPalpha as probable mediators of the action of celastrol in regulating adipocyte differentiation and lipolysis in 3T3-L1 adipocytes.	celastrol	178-187	peroxisome proliferator activated receptor gamma	Mus musculus	111-123
27085773-8	2016	CONCLUSION: Our initial data from in vitro celastrol signaling studies suggest novel insights into the role of PPARgamma(2) and C/EBPalpha as probable mediators of the action of celastrol in regulating adipocyte differentiation and lipolysis in 3T3-L1 adipocytes.	celastrol	178-187	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	128-138
27144550-0	2016	Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO/C-KIT Oncoprotein in t(8;21) Leukemia.	celastrol	0-9	RUNX family transcription factor 1	Homo sapiens	68-72
27144550-0	2016	Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO/C-KIT Oncoprotein in t(8;21) Leukemia.	celastrol	0-9	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	73-76
27144550-0	2016	Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO/C-KIT Oncoprotein in t(8;21) Leukemia.	celastrol	0-9	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	77-82
27144550-6	2016	In addition, we found that celastrol downregulated the AML1-ETO fusion protein, therefore downregulating C-KIT kinases and inhibiting AKT, STAT3 and Erk1/2.	celastrol	27-36	RUNX family transcription factor 1	Homo sapiens	55-59
27144550-6	2016	In addition, we found that celastrol downregulated the AML1-ETO fusion protein, therefore downregulating C-KIT kinases and inhibiting AKT, STAT3 and Erk1/2.	celastrol	27-36	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	60-63
27144550-6	2016	In addition, we found that celastrol downregulated the AML1-ETO fusion protein, therefore downregulating C-KIT kinases and inhibiting AKT, STAT3 and Erk1/2.	celastrol	27-36	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	105-110
27144550-6	2016	In addition, we found that celastrol downregulated the AML1-ETO fusion protein, therefore downregulating C-KIT kinases and inhibiting AKT, STAT3 and Erk1/2.	celastrol	27-36	AKT serine/threonine kinase 1	Homo sapiens	134-137
27144550-6	2016	In addition, we found that celastrol downregulated the AML1-ETO fusion protein, therefore downregulating C-KIT kinases and inhibiting AKT, STAT3 and Erk1/2.	celastrol	27-36	signal transducer and activator of transcription 3	Homo sapiens	139-144
27144550-6	2016	In addition, we found that celastrol downregulated the AML1-ETO fusion protein, therefore downregulating C-KIT kinases and inhibiting AKT, STAT3 and Erk1/2.	celastrol	27-36	mitogen-activated protein kinase 3	Homo sapiens	149-155
27181127-6	2016	RESULTS: The results showed that celastrol could effectively inhibit PA-caused TLR4-dependent NF-kappaB activation in the HepG2 cells; PA also activated IRAKs, which were inhibited by celastrol.	celastrol	33-42	toll like receptor 4	Homo sapiens	79-83
27021137-3	2016	Celastrol treatment significantly alleviated DSS-induced colitis in mice, as revealed by the body weight, colon length, scores of rectal bleeding and diarrhea, serum TNF-alpha level, and histological analysis results.	celastrol	0-9	tumor necrosis factor	Mus musculus	166-175
27021137-7	2016	Quantitative real-time PCR analysis revealed that the liver expression of stearoyl-coenzyme A desaturase 1 (SCD1), the key enzyme controlling the desaturation of saturated fatty acid, was dramatically inhibited in IBD mice, and was obviously recovered after celastrol treatment.	celastrol	258-267	stearoyl-Coenzyme A desaturase 1	Mus musculus	74-106
27021137-7	2016	Quantitative real-time PCR analysis revealed that the liver expression of stearoyl-coenzyme A desaturase 1 (SCD1), the key enzyme controlling the desaturation of saturated fatty acid, was dramatically inhibited in IBD mice, and was obviously recovered after celastrol treatment.	celastrol	258-267	stearoyl-Coenzyme A desaturase 1	Mus musculus	108-112
27021137-8	2016	These results suggest that the increased saturated LPC/unsaturated LPC (and saturated fatty acid/unsaturated fatty acid) ratios associated with SCD1 down-regulation could be regarded as biomarkers of colitis, and celastrol alleviates DSS-induced colitis partially via up-regulation of SCD1, restoring the altered balance between stearic acid- and oleic acid-derived lipid species, which plays an important role in alleviating colitis.	celastrol	213-222	stearoyl-Coenzyme A desaturase 1	Mus musculus	285-289
27110686-6	2016	In addition, we show that short-term in vivo treatment with low dosages of two molecularly distinct proteasome inhibitors celastrol and epoxomicin reverse hyperglycemia in mice with beta-cell failure by increasing insulin production and insulin sensitivity.	celastrol	122-131	insulin	Homo sapiens	237-244
26631113-4	2016	We have identified the triterpenoid Celastrol as a potent low-molecular-weight inhibitor of the interaction of Myb with its cooperation partner p300.	celastrol	36-45	MYB proto-oncogene, transcription factor	Homo sapiens	111-114
26980429-0	2016	Celastrol, an NF-kappaB inhibitor, ameliorates hypercalciuria and articular cartilage lesions in a mouse model of secondary osteoporosis.	celastrol	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	14-23
26980429-2	2016	In this study, therefore, we evaluated the role of celastrol, an NF-kappaB inhibitor, in a mouse model of secondary osteoporosis.	celastrol	51-60	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	65-74
26980429-6	2016	Moreover, other important events were observed after celastrol treatment, covering substantial decrements in serum concentrations of PTH, TRAP-5b, CTX and DPD, improved structure of articular cartilage and cancellous bone (revealed by H&amp;E and safranin-O staining), and significant decline in levels of NF-kappaB (P65), MMP-1, and MMP-9.	celastrol	53-62	parathyroid hormone	Mus musculus	133-136
26980429-6	2016	Moreover, other important events were observed after celastrol treatment, covering substantial decrements in serum concentrations of PTH, TRAP-5b, CTX and DPD, improved structure of articular cartilage and cancellous bone (revealed by H&amp;E and safranin-O staining), and significant decline in levels of NF-kappaB (P65), MMP-1, and MMP-9.	celastrol	53-62	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	306-315
26980429-6	2016	Moreover, other important events were observed after celastrol treatment, covering substantial decrements in serum concentrations of PTH, TRAP-5b, CTX and DPD, improved structure of articular cartilage and cancellous bone (revealed by H&amp;E and safranin-O staining), and significant decline in levels of NF-kappaB (P65), MMP-1, and MMP-9.	celastrol	53-62	matrix metallopeptidase 13	Mus musculus	323-328
26980429-6	2016	Moreover, other important events were observed after celastrol treatment, covering substantial decrements in serum concentrations of PTH, TRAP-5b, CTX and DPD, improved structure of articular cartilage and cancellous bone (revealed by H&amp;E and safranin-O staining), and significant decline in levels of NF-kappaB (P65), MMP-1, and MMP-9.	celastrol	53-62	matrix metallopeptidase 9	Mus musculus	334-339
26631113-4	2016	We have identified the triterpenoid Celastrol as a potent low-molecular-weight inhibitor of the interaction of Myb with its cooperation partner p300.	celastrol	36-45	E1A binding protein p300	Homo sapiens	144-148
26793111-6	2015	Mechanically, celastrol treatment significantly prevented AOM/DSS-induced up-regulation of expression levels of oncologic markers including mutated p53 and phospho-p53, beta-catenin and proliferating cell nuclear antigen (PCNA).	celastrol	14-23	transformation related protein 53, pseudogene	Mus musculus	148-151
26768587-0	2016	Celastrol enhances Nrf2 mediated antioxidant enzymes and exhibits anti-fibrotic effect through regulation of collagen production against bleomycin-induced pulmonary fibrosis.	celastrol	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	19-23
26768587-8	2016	Celastrol also reduces inflammation in BLM-induced rats as evidenced by decrease in the expressions of mast cells, Tumor necrosis factor-alpha (TNF- alpha) and matrix metalloproteinases (MMPs) 2 and 9.	celastrol	0-9	tumor necrosis factor	Rattus norvegicus	115-142
26768587-8	2016	Celastrol also reduces inflammation in BLM-induced rats as evidenced by decrease in the expressions of mast cells, Tumor necrosis factor-alpha (TNF- alpha) and matrix metalloproteinases (MMPs) 2 and 9.	celastrol	0-9	tumor necrosis factor	Rattus norvegicus	144-154
26768587-9	2016	Further, Western blot analysis shows that celastrol is a potent inducer of NF-E2-related factor 2 (Nrf2) and it restores the activities of Phase II enzymes such as hemoxygenase-1 (HO-1), glutathione-S-transferase (GSTs) and NADP(H): quinine oxidoreductase (NQO1) which were declined upon BLM administration.	celastrol	42-51	NFE2 like bZIP transcription factor 2	Rattus norvegicus	99-103
26793111-6	2015	Mechanically, celastrol treatment significantly prevented AOM/DSS-induced up-regulation of expression levels of oncologic markers including mutated p53 and phospho-p53, beta-catenin and proliferating cell nuclear antigen (PCNA).	celastrol	14-23	transformation related protein 53, pseudogene	Mus musculus	164-167
26793111-6	2015	Mechanically, celastrol treatment significantly prevented AOM/DSS-induced up-regulation of expression levels of oncologic markers including mutated p53 and phospho-p53, beta-catenin and proliferating cell nuclear antigen (PCNA).	celastrol	14-23	catenin (cadherin associated protein), beta 1	Mus musculus	169-181
26793111-6	2015	Mechanically, celastrol treatment significantly prevented AOM/DSS-induced up-regulation of expression levels of oncologic markers including mutated p53 and phospho-p53, beta-catenin and proliferating cell nuclear antigen (PCNA).	celastrol	14-23	proliferating cell nuclear antigen	Mus musculus	186-220
26793111-6	2015	Mechanically, celastrol treatment significantly prevented AOM/DSS-induced up-regulation of expression levels of oncologic markers including mutated p53 and phospho-p53, beta-catenin and proliferating cell nuclear antigen (PCNA).	celastrol	14-23	proliferating cell nuclear antigen	Mus musculus	222-226
26793111-7	2015	In addition, treatment with celastrol inhibited inflammatory responses, as indicated by the decrease of serum tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, down-regulation of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and inactivation of nuclear factor kappaB (NF-kappaB).	celastrol	28-37	tumor necrosis factor	Mus musculus	110-137
26793111-7	2015	In addition, treatment with celastrol inhibited inflammatory responses, as indicated by the decrease of serum tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, down-regulation of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and inactivation of nuclear factor kappaB (NF-kappaB).	celastrol	28-37	tumor necrosis factor	Mus musculus	139-148
26793111-7	2015	In addition, treatment with celastrol inhibited inflammatory responses, as indicated by the decrease of serum tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, down-regulation of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and inactivation of nuclear factor kappaB (NF-kappaB).	celastrol	28-37	interleukin 1 beta	Mus musculus	151-173
26793111-7	2015	In addition, treatment with celastrol inhibited inflammatory responses, as indicated by the decrease of serum tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, down-regulation of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and inactivation of nuclear factor kappaB (NF-kappaB).	celastrol	28-37	interleukin 6	Mus musculus	178-182
26793111-7	2015	In addition, treatment with celastrol inhibited inflammatory responses, as indicated by the decrease of serum tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, down-regulation of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and inactivation of nuclear factor kappaB (NF-kappaB).	celastrol	28-37	prostaglandin-endoperoxide synthase 2	Mus musculus	203-219
26793111-7	2015	In addition, treatment with celastrol inhibited inflammatory responses, as indicated by the decrease of serum tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, down-regulation of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and inactivation of nuclear factor kappaB (NF-kappaB).	celastrol	28-37	prostaglandin-endoperoxide synthase 2	Mus musculus	221-226
26793111-7	2015	In addition, treatment with celastrol inhibited inflammatory responses, as indicated by the decrease of serum tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, down-regulation of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and inactivation of nuclear factor kappaB (NF-kappaB).	celastrol	28-37	nitric oxide synthase 2, inducible	Mus musculus	232-263
26793111-7	2015	In addition, treatment with celastrol inhibited inflammatory responses, as indicated by the decrease of serum tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, down-regulation of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and inactivation of nuclear factor kappaB (NF-kappaB).	celastrol	28-37	nitric oxide synthase 2, inducible	Mus musculus	265-269
26793111-8	2015	Moreover, celastrol obviously suppressed epithelial-mesenchymal transition (EMT) through up-regulating E-cadherin and down-regulating N-cadherin, Vimentin and Snail.	celastrol	10-19	cadherin 1	Mus musculus	103-113
26793111-8	2015	Moreover, celastrol obviously suppressed epithelial-mesenchymal transition (EMT) through up-regulating E-cadherin and down-regulating N-cadherin, Vimentin and Snail.	celastrol	10-19	cadherin 2	Mus musculus	134-144
26793111-8	2015	Moreover, celastrol obviously suppressed epithelial-mesenchymal transition (EMT) through up-regulating E-cadherin and down-regulating N-cadherin, Vimentin and Snail.	celastrol	10-19	vimentin	Mus musculus	146-154
26793111-8	2015	Moreover, celastrol obviously suppressed epithelial-mesenchymal transition (EMT) through up-regulating E-cadherin and down-regulating N-cadherin, Vimentin and Snail.	celastrol	10-19	snail family zinc finger 1	Mus musculus	159-164
27160852-0	2016	Celastrol-Induced Suppression of the MiR-21/ERK Signalling Pathway Attenuates Cardiac Fibrosis and Dysfunction.	celastrol	0-9	microRNA 21a	Mus musculus	37-43
27671821-5	2016	The major cell signaling pathways modulated by celastrol include the NF-kB pathway, MAPK pathway, JAK/STAT pathway, PI3K/Akt/mTOR pathway, and antioxidant defense mechanisms.	celastrol	47-56	AKT serine/threonine kinase 1	Homo sapiens	121-124
27671821-5	2016	The major cell signaling pathways modulated by celastrol include the NF-kB pathway, MAPK pathway, JAK/STAT pathway, PI3K/Akt/mTOR pathway, and antioxidant defense mechanisms.	celastrol	47-56	mechanistic target of rapamycin kinase	Homo sapiens	125-129
27160852-11	2016	RESULTS: Celastrol treatment reduced the increased collagen deposition and down-regulated alpha-smooth muscle actin (alpha-SMA), atrial natriuretic peptide (ANP), brain natriuretic peptides (BNP), beta-myosin heavy chain (beta-MHC), miR-21 and p-ERK/ERK.	celastrol	9-18	myosin, heavy polypeptide 7, cardiac muscle, beta	Mus musculus	222-230
26760966-9	2016	Celastrol therapy inhibited Hsp90 mRNA and protein levels and up-regulated the expressions of receptor Flk-1 in TD-affected tibial growth plates significantly (P &lt; 0.05) in addition to rectifying the damaging effects of thiram on the liver by decreasing the levels of aspartate aminotransferase, alanine aminotransferase and malondialdehyde and correcting the oxidative imbalance.	celastrol	0-9	kinase insert domain receptor	Gallus gallus	103-108
27160852-0	2016	Celastrol-Induced Suppression of the MiR-21/ERK Signalling Pathway Attenuates Cardiac Fibrosis and Dysfunction.	celastrol	0-9	mitogen-activated protein kinase 1	Mus musculus	44-47
27160852-11	2016	RESULTS: Celastrol treatment reduced the increased collagen deposition and down-regulated alpha-smooth muscle actin (alpha-SMA), atrial natriuretic peptide (ANP), brain natriuretic peptides (BNP), beta-myosin heavy chain (beta-MHC), miR-21 and p-ERK/ERK.	celastrol	9-18	microRNA 21a	Mus musculus	233-239
27160852-11	2016	RESULTS: Celastrol treatment reduced the increased collagen deposition and down-regulated alpha-smooth muscle actin (alpha-SMA), atrial natriuretic peptide (ANP), brain natriuretic peptides (BNP), beta-myosin heavy chain (beta-MHC), miR-21 and p-ERK/ERK.	celastrol	9-18	actin alpha 2, smooth muscle, aorta	Mus musculus	90-115
27160852-11	2016	RESULTS: Celastrol treatment reduced the increased collagen deposition and down-regulated alpha-smooth muscle actin (alpha-SMA), atrial natriuretic peptide (ANP), brain natriuretic peptides (BNP), beta-myosin heavy chain (beta-MHC), miR-21 and p-ERK/ERK.	celastrol	9-18	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	244-249
27160852-11	2016	RESULTS: Celastrol treatment reduced the increased collagen deposition and down-regulated alpha-smooth muscle actin (alpha-SMA), atrial natriuretic peptide (ANP), brain natriuretic peptides (BNP), beta-myosin heavy chain (beta-MHC), miR-21 and p-ERK/ERK.	celastrol	9-18	mitogen-activated protein kinase 1	Mus musculus	246-249
27160852-13	2016	Celastrol treatment reduced myocardial fibroblast viability and collagen content and down-regulated alpha-SMA in cultured CFs in vitro.	celastrol	0-9	actin alpha 2, smooth muscle, aorta	Mus musculus	100-109
27160852-11	2016	RESULTS: Celastrol treatment reduced the increased collagen deposition and down-regulated alpha-smooth muscle actin (alpha-SMA), atrial natriuretic peptide (ANP), brain natriuretic peptides (BNP), beta-myosin heavy chain (beta-MHC), miR-21 and p-ERK/ERK.	celastrol	9-18	actin alpha 2, smooth muscle, aorta	Mus musculus	117-126
27160852-14	2016	Celastrol also inhibited the miR-21/ERK signalling pathway.	celastrol	0-9	microRNA 21a	Mus musculus	29-35
27160852-11	2016	RESULTS: Celastrol treatment reduced the increased collagen deposition and down-regulated alpha-smooth muscle actin (alpha-SMA), atrial natriuretic peptide (ANP), brain natriuretic peptides (BNP), beta-myosin heavy chain (beta-MHC), miR-21 and p-ERK/ERK.	celastrol	9-18	natriuretic peptide type A	Mus musculus	129-155
27160852-14	2016	Celastrol also inhibited the miR-21/ERK signalling pathway.	celastrol	0-9	mitogen-activated protein kinase 1	Mus musculus	36-39
27160852-15	2016	Celastrol attenuated miR-21 up-regulation by TGF-beta1 and decreased elevated p-ERK/ERK levels in CFs transfected with miR-21.	celastrol	0-9	microRNA 21a	Mus musculus	21-27
27160852-11	2016	RESULTS: Celastrol treatment reduced the increased collagen deposition and down-regulated alpha-smooth muscle actin (alpha-SMA), atrial natriuretic peptide (ANP), brain natriuretic peptides (BNP), beta-myosin heavy chain (beta-MHC), miR-21 and p-ERK/ERK.	celastrol	9-18	natriuretic peptide type B	Mus musculus	191-194
27160852-15	2016	Celastrol attenuated miR-21 up-regulation by TGF-beta1 and decreased elevated p-ERK/ERK levels in CFs transfected with miR-21.	celastrol	0-9	transforming growth factor, beta 1	Mus musculus	45-54
27160852-15	2016	Celastrol attenuated miR-21 up-regulation by TGF-beta1 and decreased elevated p-ERK/ERK levels in CFs transfected with miR-21.	celastrol	0-9	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	78-83
27160852-15	2016	Celastrol attenuated miR-21 up-regulation by TGF-beta1 and decreased elevated p-ERK/ERK levels in CFs transfected with miR-21.	celastrol	0-9	mitogen-activated protein kinase 1	Mus musculus	80-83
27160852-11	2016	RESULTS: Celastrol treatment reduced the increased collagen deposition and down-regulated alpha-smooth muscle actin (alpha-SMA), atrial natriuretic peptide (ANP), brain natriuretic peptides (BNP), beta-myosin heavy chain (beta-MHC), miR-21 and p-ERK/ERK.	celastrol	9-18	myosin, heavy polypeptide 7, cardiac muscle, beta	Mus musculus	197-220
27160852-15	2016	Celastrol attenuated miR-21 up-regulation by TGF-beta1 and decreased elevated p-ERK/ERK levels in CFs transfected with miR-21.	celastrol	0-9	microRNA 21a	Mus musculus	119-125
27160852-17	2016	Celastrol ameliorates myocardial fibrosis and cardiac dysfunction, these probably related to miR-21/ERK signaling pathways in vitro and in vivo.	celastrol	0-9	microRNA 21a	Mus musculus	93-99
27057550-0	2016	Protective Effects of Celastrol on Diabetic Liver Injury via TLR4/MyD88/NF-kappaB Signaling Pathway in Type 2 Diabetic Rats.	celastrol	22-31	toll-like receptor 4	Rattus norvegicus	61-65
27160852-17	2016	Celastrol ameliorates myocardial fibrosis and cardiac dysfunction, these probably related to miR-21/ERK signaling pathways in vitro and in vivo.	celastrol	0-9	mitogen-activated protein kinase 1	Mus musculus	100-103
27072230-1	2016	AIM OF STUDY: Embelin and celastrol, inhibitors of XIAP and NF-kappaB proteins respectively, have been derived from natural sources and shown anti-tumor activities against different cancer cell lines.	celastrol	26-35	X-linked inhibitor of apoptosis	Homo sapiens	51-55
27072230-12	2016	Therefore targeting XIAP and NF-kappaB pathways simultaneously can be investigated in more detail to make use of embelin and celastrol as a combination therapy of cancer.	celastrol	125-134	X-linked inhibitor of apoptosis	Homo sapiens	20-24
27057550-0	2016	Protective Effects of Celastrol on Diabetic Liver Injury via TLR4/MyD88/NF-kappaB Signaling Pathway in Type 2 Diabetic Rats.	celastrol	22-31	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	66-71
27057550-9	2016	We firstly found that celastrol treatment could delay the progression of diabetic liver disease in type 2 diabetic rats via inhibition of TLR4/MyD88/NF-kappaB signaling cascade pathways and its downstream inflammatory effectors.	celastrol	22-31	toll-like receptor 4	Rattus norvegicus	138-142
27057550-9	2016	We firstly found that celastrol treatment could delay the progression of diabetic liver disease in type 2 diabetic rats via inhibition of TLR4/MyD88/NF-kappaB signaling cascade pathways and its downstream inflammatory effectors.	celastrol	22-31	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	143-148
26658436-0	2015	Decrease of CD68 Synovial Macrophages in Celastrol Treated Arthritic Rats.	celastrol	41-50	Cd68 molecule	Rattus norvegicus	12-16
26658436-4	2015	We have shown, in vitro, that celastrol inhibits both IL-1beta and TNF, which play an important role in RA, and, in vivo, that celastrol has significant anti-inflammatory properties.	celastrol	30-39	interleukin 1 beta	Rattus norvegicus	54-62
26658436-4	2015	We have shown, in vitro, that celastrol inhibits both IL-1beta and TNF, which play an important role in RA, and, in vivo, that celastrol has significant anti-inflammatory properties.	celastrol	30-39	tumor necrosis factor	Rattus norvegicus	67-70
26658436-5	2015	Our main goal in this work was to test the effect of celastrol in the number of sublining CD68 macrophages (a biomarker of therapeutic response for novel RA treatments) and on the overall synovial tissue cellularity and joint structure in the adjuvant-induced rat model of arthritis (AIA).	celastrol	53-62	Cd68 molecule	Rattus norvegicus	90-94
26658436-9	2015	RESULTS: Here we report that celastrol significantly decreases the number of sublining CD68 macrophages and the overall synovial inflammatory cellularity, and halted joint destruction without side effects.	celastrol	29-38	Cd68 molecule	Rattus norvegicus	87-91
26510321-0	2015	Targeting Mast Cells and Basophils with Anti-FcepsilonRIalpha Fab-Conjugated Celastrol-Loaded Micelles Suppresses Allergic Inflammation.	celastrol	77-86	FA complementation group B	Homo sapiens	62-65
26454701-8	2015	Our results showed that celastrol treatment ameliorated the severity of colitis, decreased the level of interleukin (IL)-1beta, IL-6 and myeloperoxidase (MPO) and upregulated the level of E-cadherin in colitis mice.	celastrol	24-33	myeloperoxidase	Mus musculus	137-152
26454701-8	2015	Our results showed that celastrol treatment ameliorated the severity of colitis, decreased the level of interleukin (IL)-1beta, IL-6 and myeloperoxidase (MPO) and upregulated the level of E-cadherin in colitis mice.	celastrol	24-33	myeloperoxidase	Mus musculus	154-157
26454701-8	2015	Our results showed that celastrol treatment ameliorated the severity of colitis, decreased the level of interleukin (IL)-1beta, IL-6 and myeloperoxidase (MPO) and upregulated the level of E-cadherin in colitis mice.	celastrol	24-33	cadherin 1	Mus musculus	188-198
26454701-10	2015	On the mechanism, decreased level of necroptosis factors RIP3 and MLKL, and increased level of active caspase-8 were detected after celastrol treatment.	celastrol	132-141	receptor-interacting serine-threonine kinase 3	Mus musculus	57-61
26454701-10	2015	On the mechanism, decreased level of necroptosis factors RIP3 and MLKL, and increased level of active caspase-8 were detected after celastrol treatment.	celastrol	132-141	mixed lineage kinase domain-like	Mus musculus	66-70
26454701-10	2015	On the mechanism, decreased level of necroptosis factors RIP3 and MLKL, and increased level of active caspase-8 were detected after celastrol treatment.	celastrol	132-141	caspase 8	Mus musculus	102-111
26454701-11	2015	Taken together, our results demonstrated that celastrol exerted beneficial effects in colitis treatment via suppressing the RIP3/MLKL necroptosis pathway.	celastrol	46-55	receptor-interacting serine-threonine kinase 3	Mus musculus	124-128
26454701-11	2015	Taken together, our results demonstrated that celastrol exerted beneficial effects in colitis treatment via suppressing the RIP3/MLKL necroptosis pathway.	celastrol	46-55	mixed lineage kinase domain-like	Mus musculus	129-133
26510321-3	2015	Our present study aims at targeted delivery of anti-FcepsilonRIalpha Fab-conjugated celastrol-loaded micelles toward FcepsilonRIalpha receptors expressed on mast cells and basophils to have enhanced anti-allergic effect.	celastrol	84-93	FA complementation group B	Homo sapiens	69-72
26510321-6	2015	The anti-FcepsilonRIalpha Fab-conjugated celastrol-loaded micelles revealed uniform particle size (93.43 +- 12.93 nm) with high loading percentage (21.2 +- 1.5% w/w).	celastrol	41-50	FA complementation group B	Homo sapiens	26-29
26510321-11	2015	In addition, in mouse model of passive cutaneous anaphylaxis, anti-FcepsilonRIalpha Fab-conjugated celastrol-loaded micelles treatment significantly decreased extravasated evan"s in the ear.	celastrol	99-108	FA complementation group B	Homo sapiens	84-87
26510321-12	2015	These results indicate that anti-FcepsilonRIalpha Fab-conjugated celastrol-loaded micelles can target and selectively kill mast cells and basophils which express FcepsilonRIalpha, and may be efficient reagents for the treatment of allergic disorders and mast cell related diseases.	celastrol	65-74	FA complementation group B	Homo sapiens	50-53
26552919-0	2015	Inhibiting inducible miR-223 further reduces viable cells in human cancer cell lines MCF-7 and PC3 treated by celastrol.	celastrol	110-119	microRNA 223	Homo sapiens	21-28
26552919-0	2015	Inhibiting inducible miR-223 further reduces viable cells in human cancer cell lines MCF-7 and PC3 treated by celastrol.	celastrol	110-119	chromobox 8	Homo sapiens	95-98
26552919-3	2015	METHODS AND RESULTS: Here, we report that celastrol treatment can elevate miR-223 in human breast cancer cell line MCF-7 and prostate cancer PC3.	celastrol	42-51	microRNA 223	Homo sapiens	74-81
26552919-3	2015	METHODS AND RESULTS: Here, we report that celastrol treatment can elevate miR-223 in human breast cancer cell line MCF-7 and prostate cancer PC3.	celastrol	42-51	chromobox 8	Homo sapiens	141-144
26552919-4	2015	Down-regulating miR-223 could increase the number of viable cells, yet it further reduced viable cells in samples that were treated by celastrol; up-regulation of miR-223 displayed opposite effects.	celastrol	135-144	microRNA 223	Homo sapiens	16-23
26552919-5	2015	Celastrol"s miR-223 induction might be due to NF-kappaB inhibition and transient mTOR activation: these two events occurred prior to miR-223 elevation in celastrol-treated cells.	celastrol	0-9	microRNA 223	Homo sapiens	12-19
26552919-5	2015	Celastrol"s miR-223 induction might be due to NF-kappaB inhibition and transient mTOR activation: these two events occurred prior to miR-223 elevation in celastrol-treated cells.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	81-85
26552919-5	2015	Celastrol"s miR-223 induction might be due to NF-kappaB inhibition and transient mTOR activation: these two events occurred prior to miR-223 elevation in celastrol-treated cells.	celastrol	0-9	microRNA 223	Homo sapiens	133-140
26552919-6	2015	NF-kappaB inhibitor, like celastrol, could induce miR-223; the induction of miR-223 by NF-kappaB inhibitor or celastrol was reduced by the use of mTOR inhibitor.	celastrol	26-35	microRNA 223	Homo sapiens	50-57
26552919-6	2015	NF-kappaB inhibitor, like celastrol, could induce miR-223; the induction of miR-223 by NF-kappaB inhibitor or celastrol was reduced by the use of mTOR inhibitor.	celastrol	26-35	microRNA 223	Homo sapiens	76-83
26552919-6	2015	NF-kappaB inhibitor, like celastrol, could induce miR-223; the induction of miR-223 by NF-kappaB inhibitor or celastrol was reduced by the use of mTOR inhibitor.	celastrol	26-35	mechanistic target of rapamycin kinase	Homo sapiens	146-150
26552919-6	2015	NF-kappaB inhibitor, like celastrol, could induce miR-223; the induction of miR-223 by NF-kappaB inhibitor or celastrol was reduced by the use of mTOR inhibitor.	celastrol	110-119	microRNA 223	Homo sapiens	50-57
26552919-6	2015	NF-kappaB inhibitor, like celastrol, could induce miR-223; the induction of miR-223 by NF-kappaB inhibitor or celastrol was reduced by the use of mTOR inhibitor.	celastrol	110-119	microRNA 223	Homo sapiens	76-83
26552919-6	2015	NF-kappaB inhibitor, like celastrol, could induce miR-223; the induction of miR-223 by NF-kappaB inhibitor or celastrol was reduced by the use of mTOR inhibitor.	celastrol	110-119	mechanistic target of rapamycin kinase	Homo sapiens	146-150
26552919-7	2015	Finally and interestingly, miR-223 also could affect NF-kappaB and mTOR and the effects were different between cells treated or not treated with celastrol, thus providing an explanation for differing effects of miR-223 alteration on cellular viability in the presence of celastrol or not.	celastrol	145-154	microRNA 223	Homo sapiens	27-34
26552919-7	2015	Finally and interestingly, miR-223 also could affect NF-kappaB and mTOR and the effects were different between cells treated or not treated with celastrol, thus providing an explanation for differing effects of miR-223 alteration on cellular viability in the presence of celastrol or not.	celastrol	145-154	mechanistic target of rapamycin kinase	Homo sapiens	67-71
26552919-7	2015	Finally and interestingly, miR-223 also could affect NF-kappaB and mTOR and the effects were different between cells treated or not treated with celastrol, thus providing an explanation for differing effects of miR-223 alteration on cellular viability in the presence of celastrol or not.	celastrol	145-154	microRNA 223	Homo sapiens	211-218
26552919-7	2015	Finally and interestingly, miR-223 also could affect NF-kappaB and mTOR and the effects were different between cells treated or not treated with celastrol, thus providing an explanation for differing effects of miR-223 alteration on cellular viability in the presence of celastrol or not.	celastrol	271-280	microRNA 223	Homo sapiens	27-34
26552919-8	2015	CONCLUSIONS: For the first time, we disclose that celastrol could induce miR-223 in breast and prostate cancer cells, and that inhibiting miR-223 could further reduce the living cells in celastrol-treated cancer cell lines.	celastrol	50-59	microRNA 223	Homo sapiens	73-80
26552919-8	2015	CONCLUSIONS: For the first time, we disclose that celastrol could induce miR-223 in breast and prostate cancer cells, and that inhibiting miR-223 could further reduce the living cells in celastrol-treated cancer cell lines.	celastrol	187-196	microRNA 223	Homo sapiens	138-145
26344102-0	2015	Celastrol Protects against Obesity and Metabolic Dysfunction through Activation of a HSF1-PGC1alpha Transcriptional Axis.	celastrol	0-9	heat shock factor 1	Mus musculus	85-89
26391399-7	2015	Additional Hsp90 inhibitors, including 17-(allylamino)-17-demethoxygeldanamycin, celastrol, and novobiocin also suppressed PMA-induced H1R gene up-regulation.	celastrol	81-90	heat shock protein 90 alpha family class A member 1	Homo sapiens	11-16
26391399-7	2015	Additional Hsp90 inhibitors, including 17-(allylamino)-17-demethoxygeldanamycin, celastrol, and novobiocin also suppressed PMA-induced H1R gene up-regulation.	celastrol	81-90	histamine receptor H1	Homo sapiens	135-138
26500453-0	2015	Celastrol induces cell cycle arrest by MicroRNA-21-mTOR-mediated inhibition p27 protein degradation in gastric cancer.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	51-55
26500453-0	2015	Celastrol induces cell cycle arrest by MicroRNA-21-mTOR-mediated inhibition p27 protein degradation in gastric cancer.	celastrol	0-9	interferon alpha inducible protein 27	Homo sapiens	76-79
26500453-8	2015	RESULTS: Celastrol caused G2/M cell-cycle arrest that was accompanied by the down-regulation of miR-21 expression.	celastrol	9-18	microRNA 21	Homo sapiens	96-102
26500453-9	2015	In particular, miR-21 overexpression reversed cell cycle arrest effects of celastrol.	celastrol	75-84	microRNA 21	Homo sapiens	15-21
26500453-10	2015	Further study showed that celastrol increased levels of the p27 protein by inhibiting its degradation.	celastrol	26-35	interferon alpha inducible protein 27	Homo sapiens	60-63
26500453-11	2015	miR-21 and mTOR signaling pathway was involved in the increase of p27 protein expression in BGC-823 and MGC-803 cells treated with celastrol.	celastrol	131-140	microRNA 21	Homo sapiens	0-6
26500453-11	2015	miR-21 and mTOR signaling pathway was involved in the increase of p27 protein expression in BGC-823 and MGC-803 cells treated with celastrol.	celastrol	131-140	mechanistic target of rapamycin kinase	Homo sapiens	11-15
26500453-11	2015	miR-21 and mTOR signaling pathway was involved in the increase of p27 protein expression in BGC-823 and MGC-803 cells treated with celastrol.	celastrol	131-140	interferon alpha inducible protein 27	Homo sapiens	66-69
26500453-12	2015	Significantly, miR-21 overexpression restored the decrease of mTOR activity in cells exposed celastrol.	celastrol	93-102	microRNA 21	Homo sapiens	15-21
26500453-12	2015	Significantly, miR-21 overexpression restored the decrease of mTOR activity in cells exposed celastrol.	celastrol	93-102	mechanistic target of rapamycin kinase	Homo sapiens	62-66
26500453-13	2015	CONCLUSIONS: The effect of celastrol on cell cycle arrest of gastric cancer cells was due to an increase of p27 protein level via inhibiting miR-21-mTOR signaling pathway.	celastrol	27-36	interferon alpha inducible protein 27	Homo sapiens	108-111
26500453-13	2015	CONCLUSIONS: The effect of celastrol on cell cycle arrest of gastric cancer cells was due to an increase of p27 protein level via inhibiting miR-21-mTOR signaling pathway.	celastrol	27-36	microRNA 21	Homo sapiens	141-147
26500453-13	2015	CONCLUSIONS: The effect of celastrol on cell cycle arrest of gastric cancer cells was due to an increase of p27 protein level via inhibiting miR-21-mTOR signaling pathway.	celastrol	27-36	mechanistic target of rapamycin kinase	Homo sapiens	148-152
26447544-5	2015	Treatment with celastrol alone led to the decreased expressions of HSP90 client proteins including survivin, AKT, EGFR, which was enhanced by the addition of triptolide.	celastrol	15-24	heat shock protein 90 alpha family class A member 1	Homo sapiens	67-72
26447544-5	2015	Treatment with celastrol alone led to the decreased expressions of HSP90 client proteins including survivin, AKT, EGFR, which was enhanced by the addition of triptolide.	celastrol	15-24	AKT serine/threonine kinase 1	Homo sapiens	109-112
26447544-5	2015	Treatment with celastrol alone led to the decreased expressions of HSP90 client proteins including survivin, AKT, EGFR, which was enhanced by the addition of triptolide.	celastrol	15-24	epidermal growth factor receptor	Homo sapiens	114-118
26447544-6	2015	Additionally, the celastrol-induced expression of HSP70 and HSP27 was abrogated by triptolide.	celastrol	18-27	heat shock protein family A (Hsp70) member 4	Homo sapiens	50-55
26447544-6	2015	Additionally, the celastrol-induced expression of HSP70 and HSP27 was abrogated by triptolide.	celastrol	18-27	heat shock protein family B (small) member 1	Homo sapiens	60-65
26474287-0	2015	Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.	celastrol	47-56	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	21-26
26474287-0	2015	Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.	celastrol	61-70	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	21-26
26474287-3	2015	We report here that the naturally-occurring triterpenoid celastrol is an inhibitor of the c-Myc (Myc) oncoprotein, which is over-expressed in many human cancers.	celastrol	57-66	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	90-95
26474287-3	2015	We report here that the naturally-occurring triterpenoid celastrol is an inhibitor of the c-Myc (Myc) oncoprotein, which is over-expressed in many human cancers.	celastrol	57-66	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	92-95
26474287-11	2015	These studies indicate that certain pharmacologically undesirable properties of celastrol such as Michael adduct formation can be eliminated while increasing selectivity and potency toward Myc and N-Myc.	celastrol	80-89	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	189-192
26474287-11	2015	These studies indicate that certain pharmacologically undesirable properties of celastrol such as Michael adduct formation can be eliminated while increasing selectivity and potency toward Myc and N-Myc.	celastrol	80-89	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	197-202
26344102-0	2015	Celastrol Protects against Obesity and Metabolic Dysfunction through Activation of a HSF1-PGC1alpha Transcriptional Axis.	celastrol	0-9	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	90-99
26344102-4	2015	Genetic modulation of HSF1 levels altered white fat remodeling and thermogenesis, and pharmacological activation of HSF1 via celastrol was associated with enhanced energy expenditure, increased mitochondrial function in fat and muscle and protection against obesity, insulin resistance, and hepatic steatosis during high-fat diet regimens.	celastrol	125-134	heat shock factor 1	Mus musculus	116-120
26344102-5	2015	The beneficial metabolic changes elicited by celastrol were abrogated in HSF1 knockout mice.	celastrol	45-54	heat shock factor 1	Mus musculus	73-77
26344102-6	2015	Overall, our findings identify the temperature sensor HSF1 as a regulator of energy metabolism and demonstrate that augmenting HSF1 via celastrol represents a possible therapeutic strategy to treat obesity and its myriad metabolic consequences.	celastrol	136-145	heat shock factor 1	Mus musculus	127-131
26165547-6	2015	The effect of celastrol on the apoptotic rate of the cells was evaluated by flow cytometry using Annexin V-PE/7-AAD staining assay.	celastrol	14-23	annexin A5	Homo sapiens	97-106
26227505-6	2015	Recently, several plant-derived small molecules have been discovered exhibiting inhibitory activity towards Hsp90, such as epigallocatechin gallate, gedunin, lentiginosine, celastrol, and deguelin.	celastrol	173-182	heat shock protein 90 alpha family class A member 1	Homo sapiens	108-113
26165547-10	2015	Furthermore, we observed that celastrol upregulated the expression of the pro-apoptotic proteins Bax and cytochrome c and altered the ratio of Bax/Bcl-2, and triggered the mitochondrial apoptotic pathway, resulting in caspase-3 and -9 activation and PARP cleavage.	celastrol	30-39	BCL2 associated X, apoptosis regulator	Homo sapiens	97-100
26165547-10	2015	Furthermore, we observed that celastrol upregulated the expression of the pro-apoptotic proteins Bax and cytochrome c and altered the ratio of Bax/Bcl-2, and triggered the mitochondrial apoptotic pathway, resulting in caspase-3 and -9 activation and PARP cleavage.	celastrol	30-39	cytochrome c, somatic	Homo sapiens	105-117
26165547-10	2015	Furthermore, we observed that celastrol upregulated the expression of the pro-apoptotic proteins Bax and cytochrome c and altered the ratio of Bax/Bcl-2, and triggered the mitochondrial apoptotic pathway, resulting in caspase-3 and -9 activation and PARP cleavage.	celastrol	30-39	BCL2 associated X, apoptosis regulator	Homo sapiens	143-146
26165547-10	2015	Furthermore, we observed that celastrol upregulated the expression of the pro-apoptotic proteins Bax and cytochrome c and altered the ratio of Bax/Bcl-2, and triggered the mitochondrial apoptotic pathway, resulting in caspase-3 and -9 activation and PARP cleavage.	celastrol	30-39	BCL2 apoptosis regulator	Homo sapiens	147-152
26165547-10	2015	Furthermore, we observed that celastrol upregulated the expression of the pro-apoptotic proteins Bax and cytochrome c and altered the ratio of Bax/Bcl-2, and triggered the mitochondrial apoptotic pathway, resulting in caspase-3 and -9 activation and PARP cleavage.	celastrol	30-39	caspase 3	Homo sapiens	218-234
26165547-10	2015	Furthermore, we observed that celastrol upregulated the expression of the pro-apoptotic proteins Bax and cytochrome c and altered the ratio of Bax/Bcl-2, and triggered the mitochondrial apoptotic pathway, resulting in caspase-3 and -9 activation and PARP cleavage.	celastrol	30-39	collagen type XI alpha 2 chain	Homo sapiens	250-254
25891850-0	2015	Celastrol induces proteasomal degradation of FANCD2 to sensitize lung cancer cells to DNA crosslinking agents.	celastrol	0-9	FA complementation group D2	Homo sapiens	45-51
26116162-0	2015	Celastrol blocks binding of lipopolysaccharides to a Toll-like receptor4/myeloid differentiation factor2 complex in a thiol-dependent manner.	celastrol	0-9	toll-like receptor 4	Mus musculus	53-72
26116162-3	2015	AIM OF THE STUDY: We investigated whether celastrol suppressed binding of lipopolysaccharides (LPS) to myeloid differentiation factor 2 (MD2), thereby downregulating Toll-like receptor4 (TLR4) activation in mouse primary macrophages.	celastrol	42-51	lymphocyte antigen 96	Mus musculus	103-135
26116162-3	2015	AIM OF THE STUDY: We investigated whether celastrol suppressed binding of lipopolysaccharides (LPS) to myeloid differentiation factor 2 (MD2), thereby downregulating Toll-like receptor4 (TLR4) activation in mouse primary macrophages.	celastrol	42-51	lymphocyte antigen 96	Mus musculus	137-140
26116162-3	2015	AIM OF THE STUDY: We investigated whether celastrol suppressed binding of lipopolysaccharides (LPS) to myeloid differentiation factor 2 (MD2), thereby downregulating Toll-like receptor4 (TLR4) activation in mouse primary macrophages.	celastrol	42-51	toll-like receptor 4	Mus musculus	166-185
26116162-3	2015	AIM OF THE STUDY: We investigated whether celastrol suppressed binding of lipopolysaccharides (LPS) to myeloid differentiation factor 2 (MD2), thereby downregulating Toll-like receptor4 (TLR4) activation in mouse primary macrophages.	celastrol	42-51	toll-like receptor 4	Mus musculus	187-191
26116162-8	2015	Celastrol suppressed LPS binding to MD2, as shown by the in vitro binding assay, whereas it did not inhibit TBK1.	celastrol	0-9	lymphocyte antigen 96	Mus musculus	36-39
26116162-9	2015	In addition, co-localization of LPS with MD2 in BMDMs was blocked by celastrol.	celastrol	69-78	lymphocyte antigen 96	Mus musculus	41-44
26116162-10	2015	The inhibitory effects of celastrol on LPS binding to MD2 were reversed by thiol donors (N-acetyl-L-cysteine and dithiothreitol), suggesting that the thiol reactivity of celastrol contributes to its inhibitory effects on TLR4 activation in macrophages.	celastrol	26-35	lymphocyte antigen 96	Mus musculus	54-57
26116162-10	2015	The inhibitory effects of celastrol on LPS binding to MD2 were reversed by thiol donors (N-acetyl-L-cysteine and dithiothreitol), suggesting that the thiol reactivity of celastrol contributes to its inhibitory effects on TLR4 activation in macrophages.	celastrol	26-35	toll-like receptor 4	Mus musculus	221-225
26116162-10	2015	The inhibitory effects of celastrol on LPS binding to MD2 were reversed by thiol donors (N-acetyl-L-cysteine and dithiothreitol), suggesting that the thiol reactivity of celastrol contributes to its inhibitory effects on TLR4 activation in macrophages.	celastrol	170-179	lymphocyte antigen 96	Mus musculus	54-57
26116162-10	2015	The inhibitory effects of celastrol on LPS binding to MD2 were reversed by thiol donors (N-acetyl-L-cysteine and dithiothreitol), suggesting that the thiol reactivity of celastrol contributes to its inhibitory effects on TLR4 activation in macrophages.	celastrol	170-179	toll-like receptor 4	Mus musculus	221-225
26116162-11	2015	CONCLUSION: Our results demonstrate that celastrol suppresses TLR4 activation through the inhibition of LPS binding to the TLR4/MD2 complex.	celastrol	41-50	toll-like receptor 4	Mus musculus	62-66
26116162-11	2015	CONCLUSION: Our results demonstrate that celastrol suppresses TLR4 activation through the inhibition of LPS binding to the TLR4/MD2 complex.	celastrol	41-50	toll-like receptor 4	Mus musculus	123-127
26116162-11	2015	CONCLUSION: Our results demonstrate that celastrol suppresses TLR4 activation through the inhibition of LPS binding to the TLR4/MD2 complex.	celastrol	41-50	lymphocyte antigen 96	Mus musculus	128-131
26126538-2	2015	The expression of HDAC3 was decreased in cancer cell lines resistant to anti-cancer drugs such as celastrol and taxol.	celastrol	98-107	histone deacetylase 3	Homo sapiens	18-23
28717468-0	2015	Natural products triptolide, celastrol, and withaferin A inhibit the chaperone activity of peroxiredoxin I.	celastrol	29-38	peroxiredoxin 1	Homo sapiens	91-106
28717468-6	2015	We have also identified celastrol and withaferin A as novel Prx I chaperone inhibitors that are even more potent than triptolide in the chaperone activity assay.	celastrol	24-33	peroxiredoxin 1	Homo sapiens	60-65
25891850-3	2015	In the present study, we aimed to identify FANCD2-targeting agents, and found that the natural compound celastrol induced degradation of FANCD2 through the ubiquitin-proteasome pathway.	celastrol	104-113	FA complementation group D2	Homo sapiens	43-49
25891850-3	2015	In the present study, we aimed to identify FANCD2-targeting agents, and found that the natural compound celastrol induced degradation of FANCD2 through the ubiquitin-proteasome pathway.	celastrol	104-113	FA complementation group D2	Homo sapiens	137-143
25891850-4	2015	We demonstrated that celastrol downregulated the basal and DNA damaging agent-induced monoubiquitination of FANCD2, followed by proteolytic degradation of the substrate.	celastrol	21-30	FA complementation group D2	Homo sapiens	108-114
25891850-5	2015	Furthermore, celastrol treatment abrogated the G2 checkpoint induced by IR, and enhanced the ICL agent-induced DNA damage and inhibitory effects on lung cancer cells through depletion of FANCD2.	celastrol	13-22	FA complementation group D2	Homo sapiens	187-193
25891850-6	2015	These results indicate that celastrol is a FANCD2 inhibitor that could interfere with the monoubiquitination and protein stability of FANCD2, providing a novel opportunity to develop FA pathway inhibitor and combinational therapy for malignant neoplasms.	celastrol	28-37	FA complementation group D2	Homo sapiens	43-49
25891850-6	2015	These results indicate that celastrol is a FANCD2 inhibitor that could interfere with the monoubiquitination and protein stability of FANCD2, providing a novel opportunity to develop FA pathway inhibitor and combinational therapy for malignant neoplasms.	celastrol	28-37	FA complementation group D2	Homo sapiens	134-140
25818165-0	2015	Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways.	celastrol	21-30	AKT serine/threonine kinase 1	Homo sapiens	159-162
26109308-8	2015	The results showed that celastrol inhibited adhesion, migration and invasion of ECA-109 cells and expressions of integrins beta1, beta4, alphav and beta-Catenin, LRP6 in Wnt signal pathway in a dose-dependent manner.	celastrol	24-33	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	123-135
26109308-8	2015	The results showed that celastrol inhibited adhesion, migration and invasion of ECA-109 cells and expressions of integrins beta1, beta4, alphav and beta-Catenin, LRP6 in Wnt signal pathway in a dose-dependent manner.	celastrol	24-33	catenin beta 1	Homo sapiens	148-160
26109308-8	2015	The results showed that celastrol inhibited adhesion, migration and invasion of ECA-109 cells and expressions of integrins beta1, beta4, alphav and beta-Catenin, LRP6 in Wnt signal pathway in a dose-dependent manner.	celastrol	24-33	LDL receptor related protein 6	Homo sapiens	162-166
25818165-11	2015	PI3K/Akt/mTOR inhibitor, PF-04691502 and mTOR inhibitor rapamycin enhanced the apoptosis-inducing effect of celastrol.	celastrol	108-117	AKT serine/threonine kinase 1	Homo sapiens	5-8
25818165-5	2015	Celastrol induced apoptosis in TNBC cells, were supported by DNA fragmentation, caspase-3 activation and PARP cleavage.	celastrol	0-9	caspase 3	Homo sapiens	80-89
25818165-11	2015	PI3K/Akt/mTOR inhibitor, PF-04691502 and mTOR inhibitor rapamycin enhanced the apoptosis-inducing effect of celastrol.	celastrol	108-117	mechanistic target of rapamycin kinase	Homo sapiens	9-13
25818165-5	2015	Celastrol induced apoptosis in TNBC cells, were supported by DNA fragmentation, caspase-3 activation and PARP cleavage.	celastrol	0-9	collagen type XI alpha 2 chain	Homo sapiens	105-109
25818165-11	2015	PI3K/Akt/mTOR inhibitor, PF-04691502 and mTOR inhibitor rapamycin enhanced the apoptosis-inducing effect of celastrol.	celastrol	108-117	mechanistic target of rapamycin kinase	Homo sapiens	41-45
25818165-12	2015	These data demonstrated that celastrol induces apoptosis in TNBC cells and indicated that apoptosis might be mediated through mitochondrial dysfunction and PI3K/Akt signaling pathway.	celastrol	29-38	AKT serine/threonine kinase 1	Homo sapiens	161-164
25818165-6	2015	Meanwhile, celastrol triggered reactive oxygen species production with collapse of mitochondrial membrane potential, down-regulation of Bcl-2 and up-regulation of Bax expression.	celastrol	11-20	BCL2 apoptosis regulator	Homo sapiens	136-141
25818165-6	2015	Meanwhile, celastrol triggered reactive oxygen species production with collapse of mitochondrial membrane potential, down-regulation of Bcl-2 and up-regulation of Bax expression.	celastrol	11-20	BCL2 associated X, apoptosis regulator	Homo sapiens	163-166
25818165-7	2015	Celastrol effectively decreased PI3K 110alpha/85alpha enzyme activity, phosphorylation of Akt(ser473) and p70S6K1 and 4E-BP1.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	90-93
25818165-7	2015	Celastrol effectively decreased PI3K 110alpha/85alpha enzyme activity, phosphorylation of Akt(ser473) and p70S6K1 and 4E-BP1.	celastrol	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	106-124
25818165-9	2015	It clearly indicates that celastrol acts through PI3k/Akt/mTOR axis.	celastrol	26-35	AKT serine/threonine kinase 1	Homo sapiens	54-57
25818165-9	2015	It clearly indicates that celastrol acts through PI3k/Akt/mTOR axis.	celastrol	26-35	mechanistic target of rapamycin kinase	Homo sapiens	58-62
25818165-10	2015	We also found that celastrol inhibited the Akt/GSK3beta and Akt/NFkB survival pathway.	celastrol	19-28	AKT serine/threonine kinase 1	Homo sapiens	43-46
25818165-10	2015	We also found that celastrol inhibited the Akt/GSK3beta and Akt/NFkB survival pathway.	celastrol	19-28	glycogen synthase kinase 3 beta	Homo sapiens	47-55
25818165-10	2015	We also found that celastrol inhibited the Akt/GSK3beta and Akt/NFkB survival pathway.	celastrol	19-28	AKT serine/threonine kinase 1	Homo sapiens	60-63
25359574-0	2015	ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.	celastrol	75-84	mitogen-activated protein kinase 8	Homo sapiens	141-144
25359574-0	2015	ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.	celastrol	75-84	activating transcription factor 2	Homo sapiens	145-149
25359574-6	2015	Celastrol-mediated ATF2/cJUN activity was measured.	celastrol	0-9	activating transcription factor 2	Homo sapiens	19-23
25359574-6	2015	Celastrol-mediated ATF2/cJUN activity was measured.	celastrol	0-9	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	24-28
25359574-9	2015	By contrast, Celastrol-mediated ATF2/cJUN functional inhibition restored the response to CDDP.	celastrol	13-22	activating transcription factor 2	Homo sapiens	32-36
25359574-9	2015	By contrast, Celastrol-mediated ATF2/cJUN functional inhibition restored the response to CDDP.	celastrol	13-22	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	37-41
25359574-13	2015	Altogether, our results indicate a potential increase in CDDP sensitivity, on Celastrol-mediated ATF2/cJUN inhibition.	celastrol	78-87	activating transcription factor 2	Homo sapiens	97-101
25359574-13	2015	Altogether, our results indicate a potential increase in CDDP sensitivity, on Celastrol-mediated ATF2/cJUN inhibition.	celastrol	78-87	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	102-106
25858875-0	2015	Celastrol ameliorates experimental colitis in IL-10 deficient mice via the up-regulation of autophagy.	celastrol	0-9	interleukin 10	Mus musculus	46-51
25961164-0	2015	Celastrol Protects against Antimycin A-Induced Insulin Resistance in Human Skeletal Muscle Cells.	celastrol	0-9	insulin	Homo sapiens	47-54
25961164-2	2015	The aim of the present study was to evaluate the functional roles of an anti-inflammatory compound, celastrol, in mitochondrial dysfunction and insulin resistance induced by antimycin A (AMA) in human skeletal muscle cells.	celastrol	100-109	insulin	Homo sapiens	144-151
25961164-3	2015	We found that celastrol treatment improved insulin-stimulated glucose uptake activity of AMA-treated cells, apparently via PI3K/Akt pathways, with significant enhancement of mitochondrial activities.	celastrol	14-23	insulin	Homo sapiens	43-50
25961164-3	2015	We found that celastrol treatment improved insulin-stimulated glucose uptake activity of AMA-treated cells, apparently via PI3K/Akt pathways, with significant enhancement of mitochondrial activities.	celastrol	14-23	AKT serine/threonine kinase 1	Homo sapiens	128-131
25961164-5	2015	Celastrol significantly increased protein phosphorylation of insulin signaling cascades with amplified expression of AMPK protein and attenuated NF-kappaB and PKC theta activation in human skeletal muscle treated with AMA.	celastrol	0-9	insulin	Homo sapiens	61-68
25961164-5	2015	Celastrol significantly increased protein phosphorylation of insulin signaling cascades with amplified expression of AMPK protein and attenuated NF-kappaB and PKC theta activation in human skeletal muscle treated with AMA.	celastrol	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	117-121
25961164-6	2015	The improvement of insulin signaling pathways by celastrol was also accompanied by augmented GLUT4 protein expression.	celastrol	49-58	insulin	Homo sapiens	19-26
25961164-6	2015	The improvement of insulin signaling pathways by celastrol was also accompanied by augmented GLUT4 protein expression.	celastrol	49-58	solute carrier family 2 member 4	Homo sapiens	93-98
25961164-7	2015	Taken together, these results suggest that celastrol may be advocated for use as a potential therapeutic molecule to protect against mitochondrial dysfunction-induced insulin resistance in human skeletal muscle cells.	celastrol	43-52	insulin	Homo sapiens	167-174
25858875-8	2015	RESULTS: The one-week administration of celastrol ameliorated established colitis in IL-10 deficient mice, associated with a reduction of marked histological inflammation, a decreased colon MPO concentration and suppression of colonic proinflammatory cytokine.	celastrol	40-49	interleukin 10	Mus musculus	85-90
25858875-8	2015	RESULTS: The one-week administration of celastrol ameliorated established colitis in IL-10 deficient mice, associated with a reduction of marked histological inflammation, a decreased colon MPO concentration and suppression of colonic proinflammatory cytokine.	celastrol	40-49	myeloperoxidase	Mus musculus	190-193
26000480-5	2015	Celastrol suppresses food intake, blocks reduction of energy expenditure, and leads to up to 45% weight loss in hyperleptinemic diet-induced obese (DIO) mice by increasing leptin sensitivity, but it is ineffective in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mouse models.	celastrol	0-9	leptin receptor	Mus musculus	235-261
25858875-10	2015	The Western blotting analysis of the PI3K/Akt/mTOR pathway and autophagy showed that celastrol treatment up-regulated the autophagy of colon tissue by suppressing the PI3K/Akt/mTOR signaling pathway.	celastrol	85-94	thymoma viral proto-oncogene 1	Mus musculus	42-45
25858875-2	2015	This study was aimed to investigate whether celastrol could ameliorate the inflammation of IL-10 deficient mice, a murine model of Crohn"s disease (CD) with the induction of autophagy.	celastrol	44-53	interleukin 10	Mus musculus	91-96
25858875-10	2015	The Western blotting analysis of the PI3K/Akt/mTOR pathway and autophagy showed that celastrol treatment up-regulated the autophagy of colon tissue by suppressing the PI3K/Akt/mTOR signaling pathway.	celastrol	85-94	mechanistic target of rapamycin kinase	Mus musculus	46-50
25611379-0	2015	Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study.	celastrol	0-9	mitogen-activated protein kinase 8	Homo sapiens	54-57
25858875-10	2015	The Western blotting analysis of the PI3K/Akt/mTOR pathway and autophagy showed that celastrol treatment up-regulated the autophagy of colon tissue by suppressing the PI3K/Akt/mTOR signaling pathway.	celastrol	85-94	thymoma viral proto-oncogene 1	Mus musculus	172-175
25858875-10	2015	The Western blotting analysis of the PI3K/Akt/mTOR pathway and autophagy showed that celastrol treatment up-regulated the autophagy of colon tissue by suppressing the PI3K/Akt/mTOR signaling pathway.	celastrol	85-94	mechanistic target of rapamycin kinase	Mus musculus	176-180
25858875-11	2015	CONCLUSIONS: Celastrol ameliorates experimental colitis in IL-10 deficient mice via the up-regulation of autophagy by suppressing the PI3K/Akt/mTOR signaling pathway.	celastrol	13-22	interleukin 10	Mus musculus	59-64
25858875-11	2015	CONCLUSIONS: Celastrol ameliorates experimental colitis in IL-10 deficient mice via the up-regulation of autophagy by suppressing the PI3K/Akt/mTOR signaling pathway.	celastrol	13-22	thymoma viral proto-oncogene 1	Mus musculus	139-142
25858875-11	2015	CONCLUSIONS: Celastrol ameliorates experimental colitis in IL-10 deficient mice via the up-regulation of autophagy by suppressing the PI3K/Akt/mTOR signaling pathway.	celastrol	13-22	mechanistic target of rapamycin kinase	Mus musculus	143-147
25903958-0	2015	Celastrol overcomes HSP72 gene silencing-mediated muscle atrophy and induces myofiber preservation.	celastrol	0-9	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	20-25
25903958-5	2015	CEL treatment, however, markedly increased the HSP72 expression and rendered the myotube size recovered to the NC level even in the siRNA-treated cells.	celastrol	0-3	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	47-52
25903958-6	2015	Moreover, the HSP72 siRNA upregulated forkhead box O3 (FoxO3) expression in the nucleus while CEL increased p-FoxO3 exclusively in the cytoplasm, thus leaving the p-FoxO3/FoxO3 balanced to the NC level by siRNA + CEL treatment.	celastrol	94-97	forkhead box O3	Rattus norvegicus	110-115
25903958-6	2015	Moreover, the HSP72 siRNA upregulated forkhead box O3 (FoxO3) expression in the nucleus while CEL increased p-FoxO3 exclusively in the cytoplasm, thus leaving the p-FoxO3/FoxO3 balanced to the NC level by siRNA + CEL treatment.	celastrol	94-97	forkhead box O3	Rattus norvegicus	110-115
25903958-6	2015	Moreover, the HSP72 siRNA upregulated forkhead box O3 (FoxO3) expression in the nucleus while CEL increased p-FoxO3 exclusively in the cytoplasm, thus leaving the p-FoxO3/FoxO3 balanced to the NC level by siRNA + CEL treatment.	celastrol	94-97	forkhead box O3	Rattus norvegicus	110-115
25571843-0	2015	Celastrol prevents circulatory failure via induction of heme oxygenase-1 and heat shock protein 70 in endotoxemic rats.	celastrol	0-9	heme oxygenase 1	Rattus norvegicus	56-72
25571843-0	2015	Celastrol prevents circulatory failure via induction of heme oxygenase-1 and heat shock protein 70 in endotoxemic rats.	celastrol	0-9	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	77-98
25571843-10	2015	The plasma levels of ALT, LDH, TNF-alpha, and nitric oxide metabolites increased markedly during sepsis, which significantly reduced after celastrol treatments.	celastrol	139-148	tumor necrosis factor	Rattus norvegicus	31-40
25571843-11	2015	Celastrol attenuated iNOS, TNF-alpha, NF-kappaB phospho-p65 expression, superoxide anion production, and caspase 3 activity in the cardiovascular system, all of which were markedly elevated after LPS challenge.	celastrol	0-9	nitric oxide synthase 2	Rattus norvegicus	21-25
25571843-11	2015	Celastrol attenuated iNOS, TNF-alpha, NF-kappaB phospho-p65 expression, superoxide anion production, and caspase 3 activity in the cardiovascular system, all of which were markedly elevated after LPS challenge.	celastrol	0-9	tumor necrosis factor	Rattus norvegicus	27-36
25571843-11	2015	Celastrol attenuated iNOS, TNF-alpha, NF-kappaB phospho-p65 expression, superoxide anion production, and caspase 3 activity in the cardiovascular system, all of which were markedly elevated after LPS challenge.	celastrol	0-9	caspase 3	Rattus norvegicus	105-114
25571843-12	2015	Furthermore, celastrol induced HO-1 and HSP70 expressions increase in nuclear levels of Nrf2 and HSF-1, respectively, and increase cardiac GSH level 8h after LPS challenge.	celastrol	13-22	heme oxygenase 1	Rattus norvegicus	31-35
25571843-12	2015	Furthermore, celastrol induced HO-1 and HSP70 expressions increase in nuclear levels of Nrf2 and HSF-1, respectively, and increase cardiac GSH level 8h after LPS challenge.	celastrol	13-22	NFE2 like bZIP transcription factor 2	Rattus norvegicus	88-92
25571843-12	2015	Furthermore, celastrol induced HO-1 and HSP70 expressions increase in nuclear levels of Nrf2 and HSF-1, respectively, and increase cardiac GSH level 8h after LPS challenge.	celastrol	13-22	heat shock transcription factor 1	Rattus norvegicus	97-102
25571843-14	2015	Induction of HO-1 and HSP70 by celastrol participates in these beneficial effects.	celastrol	31-40	heme oxygenase 1	Rattus norvegicus	13-17
25776492-4	2015	The accumulation of daunorubicin or rhodamine 123, fluorescent substrates of P-glycoprotein, in KB/MDR1 cells increased in the presence of caffeic acid phenetyl ester (CAPE), licochalcone A, anacardic acid, celastrol, xanthohumol, magnolol, and honokiol in a concentration-dependent manner.	celastrol	207-216	ATP binding cassette subfamily B member 1	Homo sapiens	77-91
25776492-6	2015	The ATPase activities of P-glycoprotein were stimulated by CAPE, licochalcone A, anacardic acid, celastrol, xanthohumol, magnolol, and honokiol.	celastrol	97-106	ATP binding cassette subfamily B member 1	Homo sapiens	25-39
25336054-6	2015	Examination of the underlying mechanisms indicated that the effect of tripterine is mediated by the induction of heat shock protein 32 expression and the inhibition of JNK activation.	celastrol	70-80	mitogen-activated protein kinase 8	Mus musculus	168-171
25059279-4	2015	In addition, the protective effect of celastrol was correlated with a reduction in pro-inflammatory mediators, such as inducible nitric oxide synthase, cyclooxygenase-2, and CC chemokine ligand 2.	celastrol	38-47	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	152-168
25059279-5	2015	Furthermore, celastrol significantly suppressed cytokine- induced signaling cascades leading to nuclear factor kappa B (NF-kappaB) activation, including IkappaB-kinase (IKK) activation, IkappaB degradation, p65 phosphorylation, and p65 DNA binding activity.	celastrol	13-22	synaptotagmin 1	Rattus norvegicus	207-210
25059279-5	2015	Furthermore, celastrol significantly suppressed cytokine- induced signaling cascades leading to nuclear factor kappa B (NF-kappaB) activation, including IkappaB-kinase (IKK) activation, IkappaB degradation, p65 phosphorylation, and p65 DNA binding activity.	celastrol	13-22	synaptotagmin 1	Rattus norvegicus	232-235
25529994-0	2015	Celastrol attenuates bone erosion in collagen-Induced arthritis mice and inhibits osteoclast differentiation and function in RANKL-induced RAW264.7.	celastrol	0-9	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	125-130
25529994-6	2015	When RAW264.7 cells were treated with RANKL, celastrol inhibited the formation of TRAP+ multinucleated cells and the bone-resorbing activity in dose-dependent manners.	celastrol	45-54	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	38-43
25529994-6	2015	When RAW264.7 cells were treated with RANKL, celastrol inhibited the formation of TRAP+ multinucleated cells and the bone-resorbing activity in dose-dependent manners.	celastrol	45-54	acid phosphatase 5, tartrate resistant	Mus musculus	82-86
25529994-7	2015	Furthermore, celastrol reduced the RANKL-induced expression of osteoclastic genes and transcriptional factors, as well as phosphorylation of NF-kB and mitogen-activated protein kinases (MAPK).	celastrol	13-22	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	35-40
25611379-5	2015	Exposure to celastrol resulted in the activation of caspase-3, -8, and -9, indicating that celastrol induced apoptosis through both extrinsic and intrinsic pathways.	celastrol	12-21	caspase 3	Homo sapiens	52-73
25611379-5	2015	Exposure to celastrol resulted in the activation of caspase-3, -8, and -9, indicating that celastrol induced apoptosis through both extrinsic and intrinsic pathways.	celastrol	91-100	caspase 3	Homo sapiens	52-73
25611379-9	2015	Celastrol also induced JNK activation and ROS generation.	celastrol	0-9	mitogen-activated protein kinase 8	Homo sapiens	23-26
25611379-10	2015	The JNK inhibitor significantly attenuated celastrol-triggered apoptosis and autophagy while ROS scavenger could completely reverse them.	celastrol	43-52	mitogen-activated protein kinase 8	Homo sapiens	4-7
25611379-14	2015	Taken together, our results revealed that celastrol caused G2/M phase arrest, induced apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells.	celastrol	42-51	mitogen-activated protein kinase 8	Homo sapiens	122-125
25657108-5	2015	Moreover, celastrol induced the release of cytochrome c and increased the activation of caspase-3 and caspase-9, suggesting that celastrol-induced apoptosis was related to the mitochondrial pathway.	celastrol	10-19	cytochrome c, somatic	Homo sapiens	43-55
25139619-7	2015	Biochemical and genetic assays using OSCC cells and modified murine embryonic fibroblasts demonstrated that intact PERK-eIF2-ATF4-CHOP signaling is required for pro-apoptotic UPR and OSCC death following celastrol treatment.	celastrol	204-213	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	115-119
25139619-7	2015	Biochemical and genetic assays using OSCC cells and modified murine embryonic fibroblasts demonstrated that intact PERK-eIF2-ATF4-CHOP signaling is required for pro-apoptotic UPR and OSCC death following celastrol treatment.	celastrol	204-213	eukaryotic translation initiation factor 2, subunit 2 (beta)	Mus musculus	120-124
25139619-7	2015	Biochemical and genetic assays using OSCC cells and modified murine embryonic fibroblasts demonstrated that intact PERK-eIF2-ATF4-CHOP signaling is required for pro-apoptotic UPR and OSCC death following celastrol treatment.	celastrol	204-213	activating transcription factor 4	Mus musculus	125-129
25657108-5	2015	Moreover, celastrol induced the release of cytochrome c and increased the activation of caspase-3 and caspase-9, suggesting that celastrol-induced apoptosis was related to the mitochondrial pathway.	celastrol	10-19	caspase 3	Homo sapiens	88-97
25657108-5	2015	Moreover, celastrol induced the release of cytochrome c and increased the activation of caspase-3 and caspase-9, suggesting that celastrol-induced apoptosis was related to the mitochondrial pathway.	celastrol	10-19	caspase 9	Homo sapiens	102-111
25657108-5	2015	Moreover, celastrol induced the release of cytochrome c and increased the activation of caspase-3 and caspase-9, suggesting that celastrol-induced apoptosis was related to the mitochondrial pathway.	celastrol	129-138	cytochrome c, somatic	Homo sapiens	43-55
25657108-5	2015	Moreover, celastrol induced the release of cytochrome c and increased the activation of caspase-3 and caspase-9, suggesting that celastrol-induced apoptosis was related to the mitochondrial pathway.	celastrol	129-138	caspase 3	Homo sapiens	88-97
25657108-5	2015	Moreover, celastrol induced the release of cytochrome c and increased the activation of caspase-3 and caspase-9, suggesting that celastrol-induced apoptosis was related to the mitochondrial pathway.	celastrol	129-138	caspase 9	Homo sapiens	102-111
26402060-0	2015	Tripterine treatment improves endothelial progenitor cell function via integrin-linked kinase.	celastrol	0-10	integrin linked kinase	Mus musculus	71-93
25866772-0	2015	Effect of celastrol on growth inhibition of prostate cancer cells through the regulation of hERG channel in vitro.	celastrol	10-19	ETS transcription factor ERG	Homo sapiens	92-96
25866772-11	2015	Overexpression of hERG channel was found in DU145 cells, while Celastrol could downregulate it at both protein and mRNA level in a dose-dependent manner (P &lt; 0.01).	celastrol	63-72	ETS transcription factor ERG	Homo sapiens	18-22
26402060-5	2015	Tripterine restored integrin-linked kinase (ILK) levels downregulated by ox-LDL in EPCs, suggesting the involvement of the ILK/Akt pathway.	celastrol	0-10	integrin linked kinase	Mus musculus	20-42
25866772-12	2015	CONCLUSIONS: Celastrol exhibits its antiprostate cancer effects partially through the downregulation of the expression level of hERG channel in DU145 cells, suggesting that Celastrol may be a potential agent against prostate cancer with a mechanism of blocking the hERG channel.	celastrol	13-22	ETS transcription factor ERG	Homo sapiens	128-132
25866772-12	2015	CONCLUSIONS: Celastrol exhibits its antiprostate cancer effects partially through the downregulation of the expression level of hERG channel in DU145 cells, suggesting that Celastrol may be a potential agent against prostate cancer with a mechanism of blocking the hERG channel.	celastrol	13-22	ETS transcription factor ERG	Homo sapiens	265-269
25866772-12	2015	CONCLUSIONS: Celastrol exhibits its antiprostate cancer effects partially through the downregulation of the expression level of hERG channel in DU145 cells, suggesting that Celastrol may be a potential agent against prostate cancer with a mechanism of blocking the hERG channel.	celastrol	173-182	ETS transcription factor ERG	Homo sapiens	128-132
26402060-5	2015	Tripterine restored integrin-linked kinase (ILK) levels downregulated by ox-LDL in EPCs, suggesting the involvement of the ILK/Akt pathway.	celastrol	0-10	integrin linked kinase	Mus musculus	44-47
25866772-12	2015	CONCLUSIONS: Celastrol exhibits its antiprostate cancer effects partially through the downregulation of the expression level of hERG channel in DU145 cells, suggesting that Celastrol may be a potential agent against prostate cancer with a mechanism of blocking the hERG channel.	celastrol	173-182	ETS transcription factor ERG	Homo sapiens	265-269
26402060-5	2015	Tripterine restored integrin-linked kinase (ILK) levels downregulated by ox-LDL in EPCs, suggesting the involvement of the ILK/Akt pathway.	celastrol	0-10	integrin linked kinase	Mus musculus	123-126
26402060-5	2015	Tripterine restored integrin-linked kinase (ILK) levels downregulated by ox-LDL in EPCs, suggesting the involvement of the ILK/Akt pathway.	celastrol	0-10	thymoma viral proto-oncogene 1	Mus musculus	127-130
26402060-7	2015	In atherosclerotic mice injected with green fluorescent protein-labeled EPCs to evaluate EPC function, tripterine decreased aortic lesions and plaque deposition, and injection of tripterine-treated EPCs restored ILK levels.	celastrol	179-189	integrin linked kinase	Mus musculus	212-215
26402060-8	2015	CONCLUSION: The present results suggest that tripterine improves vascular function in atherosclerosis by enhancing EPC function through a mechanism involving the ILK signaling pathway.	celastrol	45-55	integrin linked kinase	Mus musculus	162-165
25355627-6	2015	Proteotoxic stressors, such as celastrol and MG132, are known to activate HSF1, and are potent inducers of HSF1 binding and IER5 expression.	celastrol	31-40	heat shock transcription factor 1	Homo sapiens	74-78
25941817-4	2015	We found that celastrol can completely inhibit neutrophil oxidative burst and NET formation induced by tumor necrosis factor alpha (TNFalpha) with an IC50 of 0.34 microM and by ovalbumin:anti-ovalbumin immune complexes (Ova IC) with an IC50 of 1.53 microM.	celastrol	14-23	tumor necrosis factor	Homo sapiens	103-130
25941817-4	2015	We found that celastrol can completely inhibit neutrophil oxidative burst and NET formation induced by tumor necrosis factor alpha (TNFalpha) with an IC50 of 0.34 microM and by ovalbumin:anti-ovalbumin immune complexes (Ova IC) with an IC50 of 1.53 microM.	celastrol	14-23	tumor necrosis factor	Homo sapiens	132-140
25941817-6	2015	Further investigating into the mechanisms, we found that celastrol treatment downregulated the activation of spleen tyrosine kinase (SYK) and the concomitant phosphorylation of mitogen-activated protein kinase kinase (MAPKK/MEK), extracellular-signal-regulated kinase (ERK), and NFkappaB inhibitor alpha (IkappaBalpha), as well as citrullination of histones.	celastrol	57-66	spleen associated tyrosine kinase	Homo sapiens	133-136
25941817-6	2015	Further investigating into the mechanisms, we found that celastrol treatment downregulated the activation of spleen tyrosine kinase (SYK) and the concomitant phosphorylation of mitogen-activated protein kinase kinase (MAPKK/MEK), extracellular-signal-regulated kinase (ERK), and NFkappaB inhibitor alpha (IkappaBalpha), as well as citrullination of histones.	celastrol	57-66	mitogen-activated protein kinase kinase 7	Homo sapiens	224-227
25941817-6	2015	Further investigating into the mechanisms, we found that celastrol treatment downregulated the activation of spleen tyrosine kinase (SYK) and the concomitant phosphorylation of mitogen-activated protein kinase kinase (MAPKK/MEK), extracellular-signal-regulated kinase (ERK), and NFkappaB inhibitor alpha (IkappaBalpha), as well as citrullination of histones.	celastrol	57-66	mitogen-activated protein kinase 1	Homo sapiens	230-267
25941817-6	2015	Further investigating into the mechanisms, we found that celastrol treatment downregulated the activation of spleen tyrosine kinase (SYK) and the concomitant phosphorylation of mitogen-activated protein kinase kinase (MAPKK/MEK), extracellular-signal-regulated kinase (ERK), and NFkappaB inhibitor alpha (IkappaBalpha), as well as citrullination of histones.	celastrol	57-66	mitogen-activated protein kinase 1	Homo sapiens	269-272
25941817-6	2015	Further investigating into the mechanisms, we found that celastrol treatment downregulated the activation of spleen tyrosine kinase (SYK) and the concomitant phosphorylation of mitogen-activated protein kinase kinase (MAPKK/MEK), extracellular-signal-regulated kinase (ERK), and NFkappaB inhibitor alpha (IkappaBalpha), as well as citrullination of histones.	celastrol	57-66	NFKB inhibitor alpha	Homo sapiens	279-303
25941817-6	2015	Further investigating into the mechanisms, we found that celastrol treatment downregulated the activation of spleen tyrosine kinase (SYK) and the concomitant phosphorylation of mitogen-activated protein kinase kinase (MAPKK/MEK), extracellular-signal-regulated kinase (ERK), and NFkappaB inhibitor alpha (IkappaBalpha), as well as citrullination of histones.	celastrol	57-66	NFKB inhibitor alpha	Homo sapiens	305-317
25941817-7	2015	Our data reveals that celastrol potently inhibits neutrophil oxidative burst and NET formation induced by different inflammatory stimuli, possibly through downregulating the SYK-MEK-ERK-NFkappaB signaling cascade.	celastrol	22-31	spleen associated tyrosine kinase	Homo sapiens	174-177
25941817-7	2015	Our data reveals that celastrol potently inhibits neutrophil oxidative burst and NET formation induced by different inflammatory stimuli, possibly through downregulating the SYK-MEK-ERK-NFkappaB signaling cascade.	celastrol	22-31	mitogen-activated protein kinase kinase 7	Homo sapiens	178-181
25941817-7	2015	Our data reveals that celastrol potently inhibits neutrophil oxidative burst and NET formation induced by different inflammatory stimuli, possibly through downregulating the SYK-MEK-ERK-NFkappaB signaling cascade.	celastrol	22-31	mitogen-activated protein kinase 1	Homo sapiens	182-185
25941817-7	2015	Our data reveals that celastrol potently inhibits neutrophil oxidative burst and NET formation induced by different inflammatory stimuli, possibly through downregulating the SYK-MEK-ERK-NFkappaB signaling cascade.	celastrol	22-31	nuclear factor kappa B subunit 1	Homo sapiens	186-194
25989799-8	2015	Additionally, treatment with celastrol, which is also an inhibitor of the Hsp90-Cdc37 complex, decreased LRRK2 levels.	celastrol	29-38	heat shock protein 90 alpha family class A member 1	Homo sapiens	74-79
25989799-8	2015	Additionally, treatment with celastrol, which is also an inhibitor of the Hsp90-Cdc37 complex, decreased LRRK2 levels.	celastrol	29-38	cell division cycle 37, HSP90 cochaperone	Homo sapiens	80-85
25989799-8	2015	Additionally, treatment with celastrol, which is also an inhibitor of the Hsp90-Cdc37 complex, decreased LRRK2 levels.	celastrol	29-38	leucine rich repeat kinase 2	Homo sapiens	105-110
25989799-9	2015	Interestingly, treatment with WA in the presence of celastrol enhanced the clearance of LRRK2.	celastrol	52-61	leucine rich repeat kinase 2	Homo sapiens	88-93
25355627-6	2015	Proteotoxic stressors, such as celastrol and MG132, are known to activate HSF1, and are potent inducers of HSF1 binding and IER5 expression.	celastrol	31-40	heat shock transcription factor 1	Homo sapiens	107-111
25355627-6	2015	Proteotoxic stressors, such as celastrol and MG132, are known to activate HSF1, and are potent inducers of HSF1 binding and IER5 expression.	celastrol	31-40	immediate early response 5	Homo sapiens	124-128
25811791-0	2015	Inhibitory mechanisms of celastrol on human liver cytochrome P450 1A2, 2C19, 2D6, 2E1 and 3A4.	celastrol	25-34	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	50-69
25811791-5	2015	The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 muM (CYP3A4), 5.99 muM (CYP2C19), 6.27 muM (CYP2D6), 7.66 muM (CYP1A2) and 9.38 muM (CYP2E1), respectively.	celastrol	24-33	latexin	Homo sapiens	123-126
25811791-5	2015	The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 muM (CYP3A4), 5.99 muM (CYP2C19), 6.27 muM (CYP2D6), 7.66 muM (CYP1A2) and 9.38 muM (CYP2E1), respectively.	celastrol	24-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	128-134
25811791-5	2015	The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 muM (CYP3A4), 5.99 muM (CYP2C19), 6.27 muM (CYP2D6), 7.66 muM (CYP1A2) and 9.38 muM (CYP2E1), respectively.	celastrol	24-33	latexin	Homo sapiens	142-145
25811791-5	2015	The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 muM (CYP3A4), 5.99 muM (CYP2C19), 6.27 muM (CYP2D6), 7.66 muM (CYP1A2) and 9.38 muM (CYP2E1), respectively.	celastrol	24-33	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	147-154
25811791-5	2015	The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 muM (CYP3A4), 5.99 muM (CYP2C19), 6.27 muM (CYP2D6), 7.66 muM (CYP1A2) and 9.38 muM (CYP2E1), respectively.	celastrol	24-33	latexin	Homo sapiens	142-145
25811791-5	2015	The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 muM (CYP3A4), 5.99 muM (CYP2C19), 6.27 muM (CYP2D6), 7.66 muM (CYP1A2) and 9.38 muM (CYP2E1), respectively.	celastrol	24-33	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	167-173
25811791-5	2015	The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 muM (CYP3A4), 5.99 muM (CYP2C19), 6.27 muM (CYP2D6), 7.66 muM (CYP1A2) and 9.38 muM (CYP2E1), respectively.	celastrol	24-33	latexin	Homo sapiens	142-145
25811791-5	2015	The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 muM (CYP3A4), 5.99 muM (CYP2C19), 6.27 muM (CYP2D6), 7.66 muM (CYP1A2) and 9.38 muM (CYP2E1), respectively.	celastrol	24-33	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	186-192
25811791-5	2015	The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 muM (CYP3A4), 5.99 muM (CYP2C19), 6.27 muM (CYP2D6), 7.66 muM (CYP1A2) and 9.38 muM (CYP2E1), respectively.	celastrol	24-33	latexin	Homo sapiens	142-145
25811791-5	2015	The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 muM (CYP3A4), 5.99 muM (CYP2C19), 6.27 muM (CYP2D6), 7.66 muM (CYP1A2) and 9.38 muM (CYP2E1), respectively.	celastrol	24-33	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	208-214
25811791-6	2015	The data indicated that celastrol acted in different manners as an inhibitor of human cytochrome P450 isoforms, which showed that celastrol not only un-competitively inhibited the CYP1A2 and 2E1 activities, but also competitively inhibited the CYP2C19 and 2D6 activities with Ki values of 1.41, 2.29, 5.27 and 4.21 muM, respectively.	celastrol	24-33	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	180-186
25811791-6	2015	The data indicated that celastrol acted in different manners as an inhibitor of human cytochrome P450 isoforms, which showed that celastrol not only un-competitively inhibited the CYP1A2 and 2E1 activities, but also competitively inhibited the CYP2C19 and 2D6 activities with Ki values of 1.41, 2.29, 5.27 and 4.21 muM, respectively.	celastrol	24-33	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	244-251
25811791-6	2015	The data indicated that celastrol acted in different manners as an inhibitor of human cytochrome P450 isoforms, which showed that celastrol not only un-competitively inhibited the CYP1A2 and 2E1 activities, but also competitively inhibited the CYP2C19 and 2D6 activities with Ki values of 1.41, 2.29, 5.27 and 4.21 muM, respectively.	celastrol	24-33	latexin	Homo sapiens	315-318
25811791-6	2015	The data indicated that celastrol acted in different manners as an inhibitor of human cytochrome P450 isoforms, which showed that celastrol not only un-competitively inhibited the CYP1A2 and 2E1 activities, but also competitively inhibited the CYP2C19 and 2D6 activities with Ki values of 1.41, 2.29, 5.27 and 4.21 muM, respectively.	celastrol	130-139	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	180-186
25811791-6	2015	The data indicated that celastrol acted in different manners as an inhibitor of human cytochrome P450 isoforms, which showed that celastrol not only un-competitively inhibited the CYP1A2 and 2E1 activities, but also competitively inhibited the CYP2C19 and 2D6 activities with Ki values of 1.41, 2.29, 5.27 and 4.21 muM, respectively.	celastrol	130-139	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	244-251
25811791-6	2015	The data indicated that celastrol acted in different manners as an inhibitor of human cytochrome P450 isoforms, which showed that celastrol not only un-competitively inhibited the CYP1A2 and 2E1 activities, but also competitively inhibited the CYP2C19 and 2D6 activities with Ki values of 1.41, 2.29, 5.27 and 4.21 muM, respectively.	celastrol	130-139	latexin	Homo sapiens	315-318
25811791-7	2015	Celastrol was also a mixed-type inhibitor of CYP3A4, with Ki and Kis values of 2.02 and 5.49 muM, respectively.	celastrol	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
25811791-7	2015	Celastrol was also a mixed-type inhibitor of CYP3A4, with Ki and Kis values of 2.02 and 5.49 muM, respectively.	celastrol	0-9	latexin	Homo sapiens	93-96
25310109-0	2014	Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9.	celastrol	0-9	matrix metallopeptidase 9	Homo sapiens	105-110
25300680-7	2014	Comparing with model group, celastrol was able to effectively suppress weight and attenuate high fat mediated oxidative injury by improving ABCA1 expression, reducing the levels of TC, TG, LDL-c and Apo B in plasma, and increasing antioxidant enzymes activities and inhibiting NADPH oxidase activity, and decreasing the serum levels of Malondialdehyde (MDA) and reactive oxygen species in dose-dependent way.	celastrol	28-37	ATP binding cassette subfamily A member 1	Rattus norvegicus	140-145
25300680-7	2014	Comparing with model group, celastrol was able to effectively suppress weight and attenuate high fat mediated oxidative injury by improving ABCA1 expression, reducing the levels of TC, TG, LDL-c and Apo B in plasma, and increasing antioxidant enzymes activities and inhibiting NADPH oxidase activity, and decreasing the serum levels of Malondialdehyde (MDA) and reactive oxygen species in dose-dependent way.	celastrol	28-37	apolipoprotein B	Rattus norvegicus	199-204
25474091-3	2014	In the present study, we sought to investigate the direct effects of celastrol (potent NF-kappaB inhibitor) upon mitochondrial dysfunction-induced insulin resistance in 3T3-L1 adipocytes.	celastrol	69-78	nuclear factor kappa B subunit 1	Homo sapiens	87-96
25474091-3	2014	In the present study, we sought to investigate the direct effects of celastrol (potent NF-kappaB inhibitor) upon mitochondrial dysfunction-induced insulin resistance in 3T3-L1 adipocytes.	celastrol	69-78	insulin	Homo sapiens	147-154
24667175-6	2014	We also found an increase in phosphorylated AMPK following a decrease in all phosphorylated forms of AKT, mTOR and S6K after the treatment with celastrol.	celastrol	144-153	AKT serine/threonine kinase 1	Homo sapiens	101-104
24667175-6	2014	We also found an increase in phosphorylated AMPK following a decrease in all phosphorylated forms of AKT, mTOR and S6K after the treatment with celastrol.	celastrol	144-153	mechanistic target of rapamycin kinase	Homo sapiens	106-110
24667175-6	2014	We also found an increase in phosphorylated AMPK following a decrease in all phosphorylated forms of AKT, mTOR and S6K after the treatment with celastrol.	celastrol	144-153	ribosomal protein S6 kinase B1	Homo sapiens	115-118
25041185-4	2014	KEY RESULTS: In H9c2 cells, celastrol triggered reactive oxygen species (ROS) formation within minutes, induced nuclear translocation of the transcription factor heat shock factor 1 (HSF1) resulting in a heat shock response (HSR) leading to increased expression of heat shock proteins (HSPs).	celastrol	28-37	heat shock transcription factor 1	Rattus norvegicus	162-181
25041185-4	2014	KEY RESULTS: In H9c2 cells, celastrol triggered reactive oxygen species (ROS) formation within minutes, induced nuclear translocation of the transcription factor heat shock factor 1 (HSF1) resulting in a heat shock response (HSR) leading to increased expression of heat shock proteins (HSPs).	celastrol	28-37	heat shock transcription factor 1	Rattus norvegicus	183-187
25041185-6	2014	Celastrol improved H9c2 survival under hypoxic stress, and functional analysis revealed HSF1 and HO-1 as key effectors of the HSR, induced by celastrol, in promoting cytoprotection.	celastrol	142-151	heat shock transcription factor 1	Rattus norvegicus	88-92
25041185-6	2014	Celastrol improved H9c2 survival under hypoxic stress, and functional analysis revealed HSF1 and HO-1 as key effectors of the HSR, induced by celastrol, in promoting cytoprotection.	celastrol	142-151	heme oxygenase 1	Rattus norvegicus	97-101
25041185-8	2014	Celastrol triggered expression of cardioprotective HO-1 and inhibited fibrosis and infarct size.	celastrol	0-9	heme oxygenase 1	Rattus norvegicus	51-55
25041185-10	2014	CONCLUSIONS AND IMPLICATIONS: Celastrol treatment induced an HSR through activation of HSF1 with up-regulation of HO-1 as the key effector, promoting cardiomyocyte survival, reduction of injury and adverse remodelling with preservation of cardiac function.	celastrol	30-39	heat shock transcription factor 1	Rattus norvegicus	87-91
25041185-10	2014	CONCLUSIONS AND IMPLICATIONS: Celastrol treatment induced an HSR through activation of HSF1 with up-regulation of HO-1 as the key effector, promoting cardiomyocyte survival, reduction of injury and adverse remodelling with preservation of cardiac function.	celastrol	30-39	heme oxygenase 1	Rattus norvegicus	114-118
25310109-2	2014	In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2).	celastrol	39-48	tumor necrosis factor	Homo sapiens	61-88
25310109-2	2014	In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2).	celastrol	39-48	tumor necrosis factor	Homo sapiens	90-99
25310109-2	2014	In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2).	celastrol	39-48	caspase 8	Homo sapiens	143-152
25310109-2	2014	In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2).	celastrol	39-48	caspase 3	Homo sapiens	154-163
25310109-2	2014	In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2).	celastrol	39-48	collagen type XI alpha 2 chain	Homo sapiens	168-172
25310109-2	2014	In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2).	celastrol	39-48	baculoviral IAP repeat containing 2	Homo sapiens	296-301
25310109-2	2014	In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2).	celastrol	39-48	baculoviral IAP repeat containing 3	Homo sapiens	306-311
25310109-2	2014	In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2).	celastrol	39-48	CASP8 and FADD like apoptosis regulator	Homo sapiens	323-347
25310109-2	2014	In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2).	celastrol	39-48	BCL2 apoptosis regulator	Homo sapiens	360-377
25310109-2	2014	In the present study, we reported that celastrol potentiated tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, affected activation of caspase-8, caspase-3 and PARP cleavage, and inhibited the expression of anti-apoptotic proteins such as cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2), cellular FLICE-inhibitory protein (FLIP), and B-cell lymphoma 2 (Bcl-2).	celastrol	39-48	BCL2 apoptosis regulator	Homo sapiens	379-384
25310109-3	2014	In addition, celastrol significantly reduced the invasion of MDA-MB-231 human breast cancer cells after TNF-alpha stimulation.	celastrol	13-22	tumor necrosis factor	Homo sapiens	104-113
25310109-4	2014	As matrix metalloproteinase-9 (MMP-9) plays a critical role in tumor metastasis, we analyzed its expression with celastrol treatment.	celastrol	113-122	matrix metallopeptidase 9	Homo sapiens	3-29
25310109-4	2014	As matrix metalloproteinase-9 (MMP-9) plays a critical role in tumor metastasis, we analyzed its expression with celastrol treatment.	celastrol	113-122	matrix metallopeptidase 9	Homo sapiens	31-36
25310109-5	2014	Western blot analysis and real-time PCR showed that celastrol dose-dependently suppressed TNF-alpha-induced MMP-9 gene expression at both the mRNA and protein levels in MDA-MB-231 cells.	celastrol	52-61	tumor necrosis factor	Homo sapiens	90-99
25310109-5	2014	Western blot analysis and real-time PCR showed that celastrol dose-dependently suppressed TNF-alpha-induced MMP-9 gene expression at both the mRNA and protein levels in MDA-MB-231 cells.	celastrol	52-61	matrix metallopeptidase 9	Homo sapiens	108-113
25149175-5	2014	Inhibition of the IP3 receptor (IP3R) with 2-aminoethoxydiphenyl borate (2-APB) also effectively blocked celastrol-induced mitochondrial Ca2+ accumulation and subsequent paraptotic events.	celastrol	105-114	inositol 1,4,5-trisphosphate receptor type 3	Homo sapiens	18-30
25383959-0	2014	Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1alpha protein synthesis.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	94-97
25383959-0	2014	Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1alpha protein synthesis.	celastrol	0-9	ribosomal protein S6 kinase B1	Homo sapiens	98-104
25383959-0	2014	Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1alpha protein synthesis.	celastrol	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	137-168
25383959-3	2014	In this study, we reported for the first time that Celastrol could induce HIF-1alpha protein accumulation in multiple cancer cell lines in an oxygen-independent manner and that the enhanced HIF-1alpha protein entered the nucleus and promoted the transcription of the HIF-1 target genes VEGF and Glut-1.	celastrol	51-60	hypoxia inducible factor 1 subunit alpha	Homo sapiens	74-84
25383959-3	2014	In this study, we reported for the first time that Celastrol could induce HIF-1alpha protein accumulation in multiple cancer cell lines in an oxygen-independent manner and that the enhanced HIF-1alpha protein entered the nucleus and promoted the transcription of the HIF-1 target genes VEGF and Glut-1.	celastrol	51-60	hypoxia inducible factor 1 subunit alpha	Homo sapiens	74-79
25383959-3	2014	In this study, we reported for the first time that Celastrol could induce HIF-1alpha protein accumulation in multiple cancer cell lines in an oxygen-independent manner and that the enhanced HIF-1alpha protein entered the nucleus and promoted the transcription of the HIF-1 target genes VEGF and Glut-1.	celastrol	51-60	vascular endothelial growth factor A	Homo sapiens	286-290
25383959-3	2014	In this study, we reported for the first time that Celastrol could induce HIF-1alpha protein accumulation in multiple cancer cell lines in an oxygen-independent manner and that the enhanced HIF-1alpha protein entered the nucleus and promoted the transcription of the HIF-1 target genes VEGF and Glut-1.	celastrol	51-60	solute carrier family 2 member 1	Homo sapiens	295-301
25383959-5	2014	Instead, Celastrol induced the accumulation of the HIF-1alpha protein by inducing ROS and activating Akt/p70S6K signaling to promote HIF-1alpha translation.	celastrol	9-18	hypoxia inducible factor 1 subunit alpha	Homo sapiens	51-61
25383959-5	2014	Instead, Celastrol induced the accumulation of the HIF-1alpha protein by inducing ROS and activating Akt/p70S6K signaling to promote HIF-1alpha translation.	celastrol	9-18	AKT serine/threonine kinase 1	Homo sapiens	101-104
25383959-5	2014	Instead, Celastrol induced the accumulation of the HIF-1alpha protein by inducing ROS and activating Akt/p70S6K signaling to promote HIF-1alpha translation.	celastrol	9-18	ribosomal protein S6 kinase B1	Homo sapiens	105-111
25383959-5	2014	Instead, Celastrol induced the accumulation of the HIF-1alpha protein by inducing ROS and activating Akt/p70S6K signaling to promote HIF-1alpha translation.	celastrol	9-18	hypoxia inducible factor 1 subunit alpha	Homo sapiens	133-143
25383959-6	2014	In addition, we found that the activation of Akt by Celastrol was transient.	celastrol	52-61	AKT serine/threonine kinase 1	Homo sapiens	45-48
25383959-7	2014	With increased exposure time, inhibition of Hsp90 chaperone function by Celastrol led to the subsequent depletion of the Akt protein and thus to the suppression of Akt activity.	celastrol	72-81	AKT serine/threonine kinase 1	Homo sapiens	121-124
25383959-7	2014	With increased exposure time, inhibition of Hsp90 chaperone function by Celastrol led to the subsequent depletion of the Akt protein and thus to the suppression of Akt activity.	celastrol	72-81	AKT serine/threonine kinase 1	Homo sapiens	164-167
25383959-10	2014	Furthermore, our data showed that the dose required for Celastrol to induce HIF-1alpha protein accumulation and enhance HIF-1alpha transcriptional activation was below its cytotoxic threshold.	celastrol	56-65	hypoxia inducible factor 1 subunit alpha	Homo sapiens	76-86
25383959-11	2014	A cytotoxic dose of Celastrol for cancer cells did not display cytotoxicity in LO2 normal human liver cells, which indicated that the novel functions of Celastrol in regulating HIF-1 signaling and inducing autophagy might be used in new applications, such as in anti-inflammation and protection of cells against human neurodegenerative diseases.	celastrol	20-29	hypoxia inducible factor 1 subunit alpha	Homo sapiens	177-182
25383959-11	2014	A cytotoxic dose of Celastrol for cancer cells did not display cytotoxicity in LO2 normal human liver cells, which indicated that the novel functions of Celastrol in regulating HIF-1 signaling and inducing autophagy might be used in new applications, such as in anti-inflammation and protection of cells against human neurodegenerative diseases.	celastrol	153-162	hypoxia inducible factor 1 subunit alpha	Homo sapiens	177-182
25218987-8	2014	Moreover, celastrol treatment resulted in significant reduction in NF-kappaB expression, nitrites levels, as well as immunohistochemical expression of TLR2 and CD3+ T-lymphocytic count.	celastrol	10-19	toll-like receptor 2	Rattus norvegicus	151-155
24615207-0	2014	Simultaneous NF-kappaB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo.	celastrol	114-123	cadherin 1	Homo sapiens	38-48
24615207-5	2014	Interestingly, E-cadherin was dramatically downregulated in celastrol-resistant cancer cells, and E-cadherin expression was closely related to decreased sensitivity to celastrol.	celastrol	60-69	cadherin 1	Homo sapiens	15-25
24615207-5	2014	Interestingly, E-cadherin was dramatically downregulated in celastrol-resistant cancer cells, and E-cadherin expression was closely related to decreased sensitivity to celastrol.	celastrol	168-177	cadherin 1	Homo sapiens	98-108
24615207-8	2014	Taken together, our data demonstrated the synergistic anticancer effects of celastrol and SAHA due to their reciprocal sensitisation, which was simultaneously regulated by NF-kappaB and E-cadherin; thus, the combination of celastrol and SAHA was superior to other combination regimens that rely on a single mechanism.	celastrol	76-85	cadherin 1	Homo sapiens	186-196
25064159-7	2014	Furthermore, celastrol induced mRNA and protein expression of HO-1 as well as Nrf2 activation.	celastrol	13-22	NFE2 like bZIP transcription factor 2	Homo sapiens	78-82
25149175-0	2014	Release of Ca2+ from the endoplasmic reticulum and its subsequent influx into mitochondria trigger celastrol-induced paraptosis in cancer cells.	celastrol	99-108	carbonic anhydrase 2	Homo sapiens	11-14
25149175-3	2014	Celastrol treatment markedly increased mitochondrial Ca2+ levels and induced ER stress via proteasome inhibition in these cells.	celastrol	0-9	carbonic anhydrase 2	Homo sapiens	53-56
25149175-4	2014	Both MCU (mitochondrial Ca2+ uniporter) knockdown and pretreatment with ruthenium red, an inhibitor of MCU, inhibited celastrol-induced mitochondrial Ca2+ uptake, dilation of mitochondria/ER, accumulation of poly-ubiquitinated proteins, and cell death in MDA-MB 435S cells.	celastrol	118-127	mitochondrial calcium uniporter	Homo sapiens	5-8
25149175-4	2014	Both MCU (mitochondrial Ca2+ uniporter) knockdown and pretreatment with ruthenium red, an inhibitor of MCU, inhibited celastrol-induced mitochondrial Ca2+ uptake, dilation of mitochondria/ER, accumulation of poly-ubiquitinated proteins, and cell death in MDA-MB 435S cells.	celastrol	118-127	mitochondrial calcium uniporter	Homo sapiens	10-38
25149175-4	2014	Both MCU (mitochondrial Ca2+ uniporter) knockdown and pretreatment with ruthenium red, an inhibitor of MCU, inhibited celastrol-induced mitochondrial Ca2+ uptake, dilation of mitochondria/ER, accumulation of poly-ubiquitinated proteins, and cell death in MDA-MB 435S cells.	celastrol	118-127	mitochondrial calcium uniporter	Homo sapiens	103-106
25149175-4	2014	Both MCU (mitochondrial Ca2+ uniporter) knockdown and pretreatment with ruthenium red, an inhibitor of MCU, inhibited celastrol-induced mitochondrial Ca2+ uptake, dilation of mitochondria/ER, accumulation of poly-ubiquitinated proteins, and cell death in MDA-MB 435S cells.	celastrol	118-127	carbonic anhydrase 2	Homo sapiens	24-27
24700193-1	2014	Hsp70, Hsp32, and Hsp27 were induced by celastrol in rat cerebral cortical cultures at dosages that did not affect cell viability.	celastrol	40-49	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	0-5
24700193-1	2014	Hsp70, Hsp32, and Hsp27 were induced by celastrol in rat cerebral cortical cultures at dosages that did not affect cell viability.	celastrol	40-49	heme oxygenase 1	Rattus norvegicus	7-12
24700193-1	2014	Hsp70, Hsp32, and Hsp27 were induced by celastrol in rat cerebral cortical cultures at dosages that did not affect cell viability.	celastrol	40-49	heat shock protein family B (small) member 1	Rattus norvegicus	18-23
24700193-3	2014	Celastrol-induced Hsp70 localized to the cell body and cellular processes of neurons that were identified by neuron-specific betaIII-tubulin.	celastrol	0-9	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	18-23
25138213-3	2014	Celastrol and Taxol decreased the expression of HDAC3 in cancer cell lines sensitive to anti-cancer drugs.	celastrol	0-9	histone deacetylase 3	Homo sapiens	48-53
24954307-0	2014	The effect of celastrol, a triterpene with antitumorigenic activity, on conformational and functional aspects of the human 90kDa heat shock protein Hsp90alpha, a chaperone implicated in the stabilization of the tumor phenotype.	celastrol	14-23	heat shock protein 90 alpha family class A member 1	Homo sapiens	148-158
24954307-3	2014	RESULTS: In this work, we investigated the effect of celastrol on the conformational and functional aspects of Hsp90alpha.	celastrol	53-62	heat shock protein 90 alpha family class A member 1	Homo sapiens	111-121
24954307-4	2014	Interestingly, celastrol appeared to target Hsp90alpha directly as the compound induced the oligomerization of the chaperone via the C-terminal domain as demonstrated by experiments using a deletion mutant.	celastrol	15-24	heat shock protein 90 alpha family class A member 1	Homo sapiens	44-54
24954307-5	2014	The nature of the oligomers was investigated by biophysical tools demonstrating that a two-fold excess of celastrol induced the formation of a decameric Hsp90alpha bound throughout the C-terminal domain.	celastrol	106-115	heat shock protein 90 alpha family class A member 1	Homo sapiens	153-163
24954307-8	2014	CONCLUSION: Celastrol interferes with specific biological functions of Hsp90alpha.	celastrol	12-21	heat shock protein 90 alpha family class A member 1	Homo sapiens	71-81
24954307-9	2014	Our results suggest a model in which celastrol binds directly to the C-terminal domain of Hsp90alpha causing oligomerization.	celastrol	37-46	heat shock protein 90 alpha family class A member 1	Homo sapiens	90-100
24954307-11	2014	Therefore celastrol may act primarily by inducing specific oligomerization that affects some, but not all, of the functions of Hsp90alpha.	celastrol	10-19	heat shock protein 90 alpha family class A member 1	Homo sapiens	127-137
24954307-12	2014	GENERAL SIGNIFICANCE: To the best of our knowledge, this study is the first work to use multiple probes to investigate the effect that celastrol has on the stability and oligomerization of Hsp90alpha and on the binding of this chaperone to Tom70.	celastrol	135-144	heat shock protein 90 alpha family class A member 1	Homo sapiens	189-199
24954307-12	2014	GENERAL SIGNIFICANCE: To the best of our knowledge, this study is the first work to use multiple probes to investigate the effect that celastrol has on the stability and oligomerization of Hsp90alpha and on the binding of this chaperone to Tom70.	celastrol	135-144	translocase of outer mitochondrial membrane 70	Homo sapiens	240-245
24954307-13	2014	This work provides a novel mechanism by which celastrol binds Hsp90alpha.	celastrol	46-55	heat shock protein 90 alpha family class A member 1	Homo sapiens	62-72
24903326-12	2014	In addition, (b) using drugs (Celastrol or BGP-15) to increase Hsp70/Hsp110 levels protect cells against TBI, suggesting the beneficial effects of Hsp70/Hsp110 inducers to reduce the pathological consequences of TBI.	celastrol	30-39	heat shock protein 1B	Mus musculus	63-68
24903326-12	2014	In addition, (b) using drugs (Celastrol or BGP-15) to increase Hsp70/Hsp110 levels protect cells against TBI, suggesting the beneficial effects of Hsp70/Hsp110 inducers to reduce the pathological consequences of TBI.	celastrol	30-39	heat shock 105kDa/110kDa protein 1	Mus musculus	69-75
24903326-12	2014	In addition, (b) using drugs (Celastrol or BGP-15) to increase Hsp70/Hsp110 levels protect cells against TBI, suggesting the beneficial effects of Hsp70/Hsp110 inducers to reduce the pathological consequences of TBI.	celastrol	30-39	heat shock protein 1B	Mus musculus	147-152
24903326-12	2014	In addition, (b) using drugs (Celastrol or BGP-15) to increase Hsp70/Hsp110 levels protect cells against TBI, suggesting the beneficial effects of Hsp70/Hsp110 inducers to reduce the pathological consequences of TBI.	celastrol	30-39	heat shock 105kDa/110kDa protein 1	Mus musculus	153-159
25149175-5	2014	Inhibition of the IP3 receptor (IP3R) with 2-aminoethoxydiphenyl borate (2-APB) also effectively blocked celastrol-induced mitochondrial Ca2+ accumulation and subsequent paraptotic events.	celastrol	105-114	inositol 1,4,5-trisphosphate receptor type 3	Homo sapiens	32-36
25149175-5	2014	Inhibition of the IP3 receptor (IP3R) with 2-aminoethoxydiphenyl borate (2-APB) also effectively blocked celastrol-induced mitochondrial Ca2+ accumulation and subsequent paraptotic events.	celastrol	105-114	carbonic anhydrase 2	Homo sapiens	137-140
25149175-6	2014	Collectively, our results show that the IP3R-mediated release of Ca2+ from the ER and its subsequent MCU-mediatedinflux into mitochondria critically contribute to celastrol-induced paraptosis in cancer cells.	celastrol	163-172	inositol 1,4,5-trisphosphate receptor type 3	Homo sapiens	40-44
25149175-6	2014	Collectively, our results show that the IP3R-mediated release of Ca2+ from the ER and its subsequent MCU-mediatedinflux into mitochondria critically contribute to celastrol-induced paraptosis in cancer cells.	celastrol	163-172	carbonic anhydrase 2	Homo sapiens	65-68
25149175-6	2014	Collectively, our results show that the IP3R-mediated release of Ca2+ from the ER and its subsequent MCU-mediatedinflux into mitochondria critically contribute to celastrol-induced paraptosis in cancer cells.	celastrol	163-172	mitochondrial calcium uniporter	Homo sapiens	101-104
25116125-0	2014	Celastrol inhibits lung infiltration in differential syndrome animal models by reducing TNF-alpha and ICAM-1 levels while preserving differentiation in ATRA-induced acute promyelocytic leukemia cells.	celastrol	0-9	tumor necrosis factor	Homo sapiens	88-97
25116125-0	2014	Celastrol inhibits lung infiltration in differential syndrome animal models by reducing TNF-alpha and ICAM-1 levels while preserving differentiation in ATRA-induced acute promyelocytic leukemia cells.	celastrol	0-9	intercellular adhesion molecule 1	Homo sapiens	102-108
25116125-5	2014	In ATRA-treated NB4 cells, celastrol could potently inhibit ICAM-1 elevation and partially reduce TNF-alpha and IL-1beta secretion, though treatment showed no effects on IL-8 and MCP-1 levels.	celastrol	27-36	intercellular adhesion molecule 1	Homo sapiens	60-66
25116125-5	2014	In ATRA-treated NB4 cells, celastrol could potently inhibit ICAM-1 elevation and partially reduce TNF-alpha and IL-1beta secretion, though treatment showed no effects on IL-8 and MCP-1 levels.	celastrol	27-36	tumor necrosis factor	Homo sapiens	98-107
25116125-5	2014	In ATRA-treated NB4 cells, celastrol could potently inhibit ICAM-1 elevation and partially reduce TNF-alpha and IL-1beta secretion, though treatment showed no effects on IL-8 and MCP-1 levels.	celastrol	27-36	interleukin 1 beta	Homo sapiens	112-120
25116125-6	2014	Celastrol"s effect on ICAM-1 in ATRA-treated NB4 was related to reducing MEK1/ERK1 activation.	celastrol	0-9	intercellular adhesion molecule 1	Homo sapiens	22-28
25116125-6	2014	Celastrol"s effect on ICAM-1 in ATRA-treated NB4 was related to reducing MEK1/ERK1 activation.	celastrol	0-9	mitogen-activated protein kinase kinase 1	Homo sapiens	73-77
25116125-6	2014	Celastrol"s effect on ICAM-1 in ATRA-treated NB4 was related to reducing MEK1/ERK1 activation.	celastrol	0-9	mitogen-activated protein kinase 3	Homo sapiens	78-82
25101848-13	2014	Taken together, our results demonstrate the analgesia effects of celastrol through CB2 signaling and propose the potential of exploiting celastrol as a novel candidate for pain relief.	celastrol	65-74	cannabinoid receptor 2 (macrophage)	Mus musculus	83-86
25076938-15	2014	Furthermore, celastrol suppressed TGF-beta1 induced EMT in thyroid cancer cells and may have therapeutic potential.	celastrol	13-22	transforming growth factor, beta 1	Mus musculus	34-43
24859482-0	2014	Celastrol inhibits the HIF-1alpha pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells.	celastrol	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	23-33
25126165-7	2014	The expression of VEGF in the celastrol group was significantly less compared with the model group (P = 0.014), whereas the expression of VEGF in the atorvastatin group and the model group showed no significant differences.	celastrol	30-39	vascular endothelial growth factor A	Oryctolagus cuniculus	18-22
25126165-8	2014	CONCLUSION: Our findings suggest that celastrol effectively reduced the plaque ratio, decreased the serum levels of LDL and downregulated the expression of VEGF, suggesting an anti-AS effect of celastrol.	celastrol	38-47	vascular endothelial growth factor A	Oryctolagus cuniculus	156-160
25126165-8	2014	CONCLUSION: Our findings suggest that celastrol effectively reduced the plaque ratio, decreased the serum levels of LDL and downregulated the expression of VEGF, suggesting an anti-AS effect of celastrol.	celastrol	194-203	vascular endothelial growth factor A	Oryctolagus cuniculus	156-160
24859482-0	2014	Celastrol inhibits the HIF-1alpha pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	59-63
24859482-0	2014	Celastrol inhibits the HIF-1alpha pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells.	celastrol	0-9	ribosomal protein S6 kinase B1	Homo sapiens	64-70
24859482-0	2014	Celastrol inhibits the HIF-1alpha pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells.	celastrol	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	71-76
24859482-0	2014	Celastrol inhibits the HIF-1alpha pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells.	celastrol	0-9	mitogen-activated protein kinase 3	Homo sapiens	81-87
24859482-2	2014	In a search for HIF-1 inhibitors, we identified celastrol as an inhibitor of HIF-1 activation from Tripterygium wilfordii.	celastrol	48-57	hypoxia inducible factor 1 subunit alpha	Homo sapiens	16-21
24859482-2	2014	In a search for HIF-1 inhibitors, we identified celastrol as an inhibitor of HIF-1 activation from Tripterygium wilfordii.	celastrol	48-57	hypoxia inducible factor 1 subunit alpha	Homo sapiens	77-82
24859482-3	2014	In the present study, we demonstrated the effect of celastrol on HIF-1 activation.	celastrol	52-61	hypoxia inducible factor 1 subunit alpha	Homo sapiens	65-70
24859482-4	2014	Celastrol showed a potent inhibitory activity against HIF-1 activation induced by hypoxia in various human cancer cell lines.	celastrol	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	54-59
24859482-6	2014	Furthermore, celastrol prevented hypoxia-induced expression of HIF-1 target genes for vascular endothelial growth factor (VEGF) and erythropoietin (EPO).	celastrol	13-22	hypoxia inducible factor 1 subunit alpha	Homo sapiens	63-68
24859482-6	2014	Furthermore, celastrol prevented hypoxia-induced expression of HIF-1 target genes for vascular endothelial growth factor (VEGF) and erythropoietin (EPO).	celastrol	13-22	vascular endothelial growth factor A	Homo sapiens	86-120
24859482-6	2014	Furthermore, celastrol prevented hypoxia-induced expression of HIF-1 target genes for vascular endothelial growth factor (VEGF) and erythropoietin (EPO).	celastrol	13-22	vascular endothelial growth factor A	Homo sapiens	122-126
24859482-6	2014	Furthermore, celastrol prevented hypoxia-induced expression of HIF-1 target genes for vascular endothelial growth factor (VEGF) and erythropoietin (EPO).	celastrol	13-22	erythropoietin	Homo sapiens	132-146
24859482-6	2014	Furthermore, celastrol prevented hypoxia-induced expression of HIF-1 target genes for vascular endothelial growth factor (VEGF) and erythropoietin (EPO).	celastrol	13-22	erythropoietin	Homo sapiens	148-151
24859482-7	2014	Further analysis revealed that celastrol inhibited HIF-1alpha protein synthesis, without affecting the expression level of HIF-1alpha mRNA or degradation of HIF-1alpha protein.	celastrol	31-40	hypoxia inducible factor 1 subunit alpha	Homo sapiens	51-61
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	hypoxia inducible factor 1 subunit alpha	Homo sapiens	39-49
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	mechanistic target of rapamycin kinase	Homo sapiens	120-149
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	mechanistic target of rapamycin kinase	Homo sapiens	151-155
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	ribosomal protein S6 kinase B1	Homo sapiens	205-211
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	eukaryotic translation initiation factor 4E	Homo sapiens	217-248
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	eukaryotic translation initiation factor 4E	Homo sapiens	250-255
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	mitogen-activated protein kinase 1	Homo sapiens	261-298
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	mitogen-activated protein kinase 1	Homo sapiens	300-303
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	hypoxia inducible factor 1 subunit alpha	Homo sapiens	333-343
24859482-9	2014	In vivo studies further confirmed the inhibitory effect of celastrol on the expression of HIF-1alpha proteins, leading to a decreased growth of Hep3B cells in a xenograft tumor model.	celastrol	59-68	hypoxia inducible factor 1 subunit alpha	Homo sapiens	90-100
24859482-10	2014	Our data suggested that celastrol is an effective inhibitor of HIF-1 and provide new perspectives into the mechanism of its anticancer activity.	celastrol	24-33	hypoxia inducible factor 1 subunit alpha	Homo sapiens	63-68
24849358-7	2014	In vivo celastrol increased the HSF1 ChIP signal in hippocampus but not in liver.	celastrol	8-17	heat shock transcription factor 1	Homo sapiens	32-36
24927548-2	2014	Two of the 50 predicted hits had activity against either human FPPS (HsFPPS) or Trypanosoma brucei FPPS (TbFPPS), the most active being the quinone methide celastrol (IC50 versus TbFPPS ~ 20 microM).	celastrol	156-165	farnesyl diphosphate synthase	Homo sapiens	63-67
24810052-5	2014	Our studies indicate that celastrol promotes proteotoxic stress, supported by two feedback mechanisms: (i) impairment of protein quality control as revealed by accumulation of polyubiquitinated aggregates and the canonical autophagy substrate, p62, and (ii) the induction of heat-shock proteins, HSP72 and HSP90.	celastrol	26-35	nucleoporin 62	Homo sapiens	244-247
24810052-5	2014	Our studies indicate that celastrol promotes proteotoxic stress, supported by two feedback mechanisms: (i) impairment of protein quality control as revealed by accumulation of polyubiquitinated aggregates and the canonical autophagy substrate, p62, and (ii) the induction of heat-shock proteins, HSP72 and HSP90.	celastrol	26-35	heat shock protein family A (Hsp70) member 1A	Homo sapiens	296-301
24810052-5	2014	Our studies indicate that celastrol promotes proteotoxic stress, supported by two feedback mechanisms: (i) impairment of protein quality control as revealed by accumulation of polyubiquitinated aggregates and the canonical autophagy substrate, p62, and (ii) the induction of heat-shock proteins, HSP72 and HSP90.	celastrol	26-35	heat shock protein 90 alpha family class A member 1	Homo sapiens	306-311
24810052-9	2014	This study further emphasizes that targeting proteotoxic stress responses by inhibiting HSP90 with 17-N-Allylamino-17-demethoxygeldanamycin sensitizes human glioblastoma to celastrol treatment, thereby serving as a novel synergism to overcome drug resistance.	celastrol	173-182	heat shock protein 90 alpha family class A member 1	Homo sapiens	88-93
24293411-0	2014	Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer.	celastrol	60-69	cellular inhibitor of PP2A	Homo sapiens	0-27
24755677-0	2014	NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis.	celastrol	37-46	nuclear factor kappa B subunit 1	Homo sapiens	0-10
24755677-5	2014	Celastrol inhibited cell proliferation of LP-1 myeloma cell in a dose-dependent manner with IC50 values of 0.8817 microM, which was mediated through G1 cell cycle arrest and p27 induction.	celastrol	0-9	dynactin subunit 6	Homo sapiens	174-177
24755677-6	2014	Celastrol induced apoptosis in LP-1 and RPMI 8226 myeloma cells in a time and dose dependent manner, and it involved Caspase-3 activation and NF-kappaB pathway.	celastrol	0-9	caspase 3	Homo sapiens	117-126
24755677-6	2014	Celastrol induced apoptosis in LP-1 and RPMI 8226 myeloma cells in a time and dose dependent manner, and it involved Caspase-3 activation and NF-kappaB pathway.	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	142-151
24755677-7	2014	Celastrol down-modulated antiapoptotic proteins including Bcl-2 and survivin expression.	celastrol	0-9	BCL2 apoptosis regulator	Homo sapiens	58-63
24755677-8	2014	The expression of NF-kappaB and IKKa were decreased after celastrol treatment.	celastrol	58-67	nuclear factor kappa B subunit 1	Homo sapiens	18-27
24755677-8	2014	The expression of NF-kappaB and IKKa were decreased after celastrol treatment.	celastrol	58-67	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	32-36
24755677-9	2014	Celastrol effectively blocked the nuclear translocation of the p65 subunit and induced human multiple myeloma cell cycle arrest and apoptosis by p27 upregulation and NF-kB modulation.	celastrol	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	63-66
24755677-9	2014	Celastrol effectively blocked the nuclear translocation of the p65 subunit and induced human multiple myeloma cell cycle arrest and apoptosis by p27 upregulation and NF-kB modulation.	celastrol	0-9	dynactin subunit 6	Homo sapiens	145-148
24293411-1	2014	Celastrol binds CIP2A and enhances CIP2A-CHIP interaction, leading to ubiquitination/degradation of CIP2A and inhibition of lung cancer cells in vitro and in vivo.	celastrol	0-9	cellular inhibitor of PP2A	Homo sapiens	16-21
24293411-1	2014	Celastrol binds CIP2A and enhances CIP2A-CHIP interaction, leading to ubiquitination/degradation of CIP2A and inhibition of lung cancer cells in vitro and in vivo.	celastrol	0-9	cellular inhibitor of PP2A	Homo sapiens	35-40
24293411-1	2014	Celastrol binds CIP2A and enhances CIP2A-CHIP interaction, leading to ubiquitination/degradation of CIP2A and inhibition of lung cancer cells in vitro and in vivo.	celastrol	0-9	cellular inhibitor of PP2A	Homo sapiens	35-40
24293411-2	2014	Celastrol potentiates cisplatin"s efficacy by suppressing the CIP2A-Akt pathway, and therefore CIP2A inhibitors may represent novel therapeutics for cancer.	celastrol	0-9	cellular inhibitor of PP2A	Homo sapiens	62-71
24293411-2	2014	Celastrol potentiates cisplatin"s efficacy by suppressing the CIP2A-Akt pathway, and therefore CIP2A inhibitors may represent novel therapeutics for cancer.	celastrol	0-9	cellular inhibitor of PP2A	Homo sapiens	62-67
24664372-5	2014	Knockdown of IL-6 attenuated the anti-proliferative effect of celastrol on PC-3 cells.	celastrol	62-71	interleukin 6	Homo sapiens	13-17
24265268-5	2014	In a cell-free environment, IP-FCM could detect the direct effects of ATP and/or HSP90 inhibitors (17-N-allylamino-17-demethoxygeldanamycin or celastrol) in causing component dissociation and the time- and dose-effects of inhibitor-caused dissociation.	celastrol	143-152	heat shock protein 90 alpha family class A member 1	Homo sapiens	81-86
24965400-8	2014	Moreover, celastrol enhanced the ability of lapatinib to down regulate EGFR protein expression in HepG2 cells.	celastrol	10-19	epidermal growth factor receptor	Homo sapiens	71-75
25007672-9	2014	The potential mechanism may be related to the upregulation of NRF2 nuclear protein expression and GCLC cytoplasmic expression after celastrol pretreatment.	celastrol	132-141	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	98-102
24664372-0	2014	Celastrol blocks interleukin-6 gene expression via downregulation of NF-kappaB in prostate carcinoma cells.	celastrol	0-9	interleukin 6	Homo sapiens	17-30
24664372-0	2014	Celastrol blocks interleukin-6 gene expression via downregulation of NF-kappaB in prostate carcinoma cells.	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	69-78
24664372-6	2014	Results from ELISA and 5"-deletion transient gene expression assays indicated that celastrol treatment decreased IL-6 secretion and gene expression, and this effect is dependent on the NF-kappaB response element within IL-6 promoter area since mutation of the NF-kappaB response element from AAATGTCCCATTTTCCC to AAATGTTACATTTTCCC by site-directed mutagenesis abolished the inhibition of celastrol on the IL-6 promoter activity.	celastrol	83-92	interleukin 6	Homo sapiens	113-117
24664372-3	2014	In this study, we evaluated the molecular mechanisms of celastrol on cell proliferation and IL-6 gene expression in prostate carcinoma cells.	celastrol	56-65	interleukin 6	Homo sapiens	92-96
24664372-6	2014	Results from ELISA and 5"-deletion transient gene expression assays indicated that celastrol treatment decreased IL-6 secretion and gene expression, and this effect is dependent on the NF-kappaB response element within IL-6 promoter area since mutation of the NF-kappaB response element from AAATGTCCCATTTTCCC to AAATGTTACATTTTCCC by site-directed mutagenesis abolished the inhibition of celastrol on the IL-6 promoter activity.	celastrol	83-92	nuclear factor kappa B subunit 1	Homo sapiens	185-194
24664372-6	2014	Results from ELISA and 5"-deletion transient gene expression assays indicated that celastrol treatment decreased IL-6 secretion and gene expression, and this effect is dependent on the NF-kappaB response element within IL-6 promoter area since mutation of the NF-kappaB response element from AAATGTCCCATTTTCCC to AAATGTTACATTTTCCC by site-directed mutagenesis abolished the inhibition of celastrol on the IL-6 promoter activity.	celastrol	83-92	interleukin 6	Homo sapiens	219-223
24664372-6	2014	Results from ELISA and 5"-deletion transient gene expression assays indicated that celastrol treatment decreased IL-6 secretion and gene expression, and this effect is dependent on the NF-kappaB response element within IL-6 promoter area since mutation of the NF-kappaB response element from AAATGTCCCATTTTCCC to AAATGTTACATTTTCCC by site-directed mutagenesis abolished the inhibition of celastrol on the IL-6 promoter activity.	celastrol	83-92	nuclear factor kappa B subunit 1	Homo sapiens	260-269
24664372-6	2014	Results from ELISA and 5"-deletion transient gene expression assays indicated that celastrol treatment decreased IL-6 secretion and gene expression, and this effect is dependent on the NF-kappaB response element within IL-6 promoter area since mutation of the NF-kappaB response element from AAATGTCCCATTTTCCC to AAATGTTACATTTTCCC by site-directed mutagenesis abolished the inhibition of celastrol on the IL-6 promoter activity.	celastrol	83-92	interleukin 6	Homo sapiens	219-223
24664372-6	2014	Results from ELISA and 5"-deletion transient gene expression assays indicated that celastrol treatment decreased IL-6 secretion and gene expression, and this effect is dependent on the NF-kappaB response element within IL-6 promoter area since mutation of the NF-kappaB response element from AAATGTCCCATTTTCCC to AAATGTTACATTTTCCC by site-directed mutagenesis abolished the inhibition of celastrol on the IL-6 promoter activity.	celastrol	388-397	interleukin 6	Homo sapiens	219-223
24664372-6	2014	Results from ELISA and 5"-deletion transient gene expression assays indicated that celastrol treatment decreased IL-6 secretion and gene expression, and this effect is dependent on the NF-kappaB response element within IL-6 promoter area since mutation of the NF-kappaB response element from AAATGTCCCATTTTCCC to AAATGTTACATTTTCCC by site-directed mutagenesis abolished the inhibition of celastrol on the IL-6 promoter activity.	celastrol	388-397	interleukin 6	Homo sapiens	219-223
24664372-7	2014	Celastrol also attenuated the activation of PMA and TNFalpha on the gene expression and secretion of IL-6 in PC-3 cells.	celastrol	0-9	tumor necrosis factor	Homo sapiens	52-60
24664372-7	2014	Celastrol also attenuated the activation of PMA and TNFalpha on the gene expression and secretion of IL-6 in PC-3 cells.	celastrol	0-9	interleukin 6	Homo sapiens	101-105
24664372-8	2014	Immunoblot assays revealed that celastrol treatment downregulated the expressions of IKKalpha, p50 and p65, supporting the 5"-deletion transient gene expression assay result that celastrol blocked IL-6 expression through the NF-kappaB pathway in PC-3 cells.	celastrol	32-41	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	85-93
24664372-8	2014	Immunoblot assays revealed that celastrol treatment downregulated the expressions of IKKalpha, p50 and p65, supporting the 5"-deletion transient gene expression assay result that celastrol blocked IL-6 expression through the NF-kappaB pathway in PC-3 cells.	celastrol	32-41	nuclear factor kappa B subunit 1	Homo sapiens	95-98
24664372-8	2014	Immunoblot assays revealed that celastrol treatment downregulated the expressions of IKKalpha, p50 and p65, supporting the 5"-deletion transient gene expression assay result that celastrol blocked IL-6 expression through the NF-kappaB pathway in PC-3 cells.	celastrol	32-41	RELA proto-oncogene, NF-kB subunit	Homo sapiens	103-106
24664372-8	2014	Immunoblot assays revealed that celastrol treatment downregulated the expressions of IKKalpha, p50 and p65, supporting the 5"-deletion transient gene expression assay result that celastrol blocked IL-6 expression through the NF-kappaB pathway in PC-3 cells.	celastrol	32-41	interleukin 6	Homo sapiens	197-201
24664372-8	2014	Immunoblot assays revealed that celastrol treatment downregulated the expressions of IKKalpha, p50 and p65, supporting the 5"-deletion transient gene expression assay result that celastrol blocked IL-6 expression through the NF-kappaB pathway in PC-3 cells.	celastrol	32-41	nuclear factor kappa B subunit 1	Homo sapiens	225-234
24664372-8	2014	Immunoblot assays revealed that celastrol treatment downregulated the expressions of IKKalpha, p50 and p65, supporting the 5"-deletion transient gene expression assay result that celastrol blocked IL-6 expression through the NF-kappaB pathway in PC-3 cells.	celastrol	179-188	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	85-93
24664372-8	2014	Immunoblot assays revealed that celastrol treatment downregulated the expressions of IKKalpha, p50 and p65, supporting the 5"-deletion transient gene expression assay result that celastrol blocked IL-6 expression through the NF-kappaB pathway in PC-3 cells.	celastrol	179-188	nuclear factor kappa B subunit 1	Homo sapiens	95-98
24664372-8	2014	Immunoblot assays revealed that celastrol treatment downregulated the expressions of IKKalpha, p50 and p65, supporting the 5"-deletion transient gene expression assay result that celastrol blocked IL-6 expression through the NF-kappaB pathway in PC-3 cells.	celastrol	179-188	RELA proto-oncogene, NF-kB subunit	Homo sapiens	103-106
24664372-8	2014	Immunoblot assays revealed that celastrol treatment downregulated the expressions of IKKalpha, p50 and p65, supporting the 5"-deletion transient gene expression assay result that celastrol blocked IL-6 expression through the NF-kappaB pathway in PC-3 cells.	celastrol	179-188	interleukin 6	Homo sapiens	197-201
24664372-8	2014	Immunoblot assays revealed that celastrol treatment downregulated the expressions of IKKalpha, p50 and p65, supporting the 5"-deletion transient gene expression assay result that celastrol blocked IL-6 expression through the NF-kappaB pathway in PC-3 cells.	celastrol	179-188	nuclear factor kappa B subunit 1	Homo sapiens	225-234
24664372-9	2014	For the first time, our results concluded that celastrol attenuates PC-3 cell proliferation via downregulation of IL-6 gene expression through the NF-kappaB-dependent pathway.	celastrol	47-56	interleukin 6	Homo sapiens	114-118
24664372-9	2014	For the first time, our results concluded that celastrol attenuates PC-3 cell proliferation via downregulation of IL-6 gene expression through the NF-kappaB-dependent pathway.	celastrol	47-56	nuclear factor kappa B subunit 1	Homo sapiens	147-156
24384223-2	2014	Here, we investigated the effect of the novel NF-kappaB inhibitor celastrol on murine colitis.	celastrol	66-75	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	46-55
24589236-0	2014	Peptide deformylase inhibitor actinonin reduces celastrol"s HSP70 induction while synergizing proliferation inhibition in tumor cells.	celastrol	48-57	heat shock protein family A (Hsp70) member 4	Homo sapiens	60-65
24589236-1	2014	BACKGROUND: Celastrol is a promising anti-tumor agent, yet it also elevates heat shock proteins (HSPs), especially HSP70, this effect believed to reduce its anti-tumor effects.	celastrol	12-21	heat shock protein family A (Hsp70) member 4	Homo sapiens	115-120
24589236-2	2014	Concurrent use of siRNA to increase celastrol"s anti-tumor effects through HSP70 interference has been reported, but because siRNA technology is difficult to clinically apply, an alternative way to curb unwanted HSP70 elevation caused by celastrol treatment is worth exploring.	celastrol	36-45	heat shock protein family A (Hsp70) member 4	Homo sapiens	75-80
24589236-2	2014	Concurrent use of siRNA to increase celastrol"s anti-tumor effects through HSP70 interference has been reported, but because siRNA technology is difficult to clinically apply, an alternative way to curb unwanted HSP70 elevation caused by celastrol treatment is worth exploring.	celastrol	238-247	heat shock protein family A (Hsp70) member 4	Homo sapiens	212-217
24589236-4	2014	RESULTS: The first strategy was unsuccessful since celastrol treatment increased HSP70 in all 7 of the cancer cell types tested, this result related to HSF1 activation.	celastrol	51-60	heat shock protein family A (Hsp70) member 4	Homo sapiens	81-86
24589236-4	2014	RESULTS: The first strategy was unsuccessful since celastrol treatment increased HSP70 in all 7 of the cancer cell types tested, this result related to HSF1 activation.	celastrol	51-60	heat shock transcription factor 1	Homo sapiens	152-156
24589236-5	2014	The ubiquity of HSF1 expression in different cancer cells might explain why celastrol has no cell-type limitation for HSP70 induction.	celastrol	76-85	heat shock transcription factor 1	Homo sapiens	16-20
24589236-6	2014	The second strategy revealed that modification of celastrol"s carboxyl group abolished its ability to elevate HSP70, but also abolished celastrol"s tumor inhibition effects.	celastrol	50-59	heat shock protein family A (Hsp70) member 4	Homo sapiens	110-115
24589236-7	2014	In the third strategy, 11 inhibitors for 10 signaling proteins reportedly related to celastrol action were tested, and five of these could reduce celastrol-caused HSP70 elevation.	celastrol	146-155	heat shock protein family A (Hsp70) member 4	Homo sapiens	163-168
24589236-9	2014	CONCLUSIONS: Concurrent use of the chemical agent actinonin could reduce celastrol"s HSP70 elevation and also enhance proliferation inhibition by celastrol.	celastrol	73-82	heat shock protein family A (Hsp70) member 4	Homo sapiens	85-90
24465597-6	2014	RESULTS: Celastrol, resveratrol, sulphoraphane and curcumin inhibited the NF-kappaB promoter activity significantly and in a dose dependent manner.	celastrol	9-18	nuclear factor kappa B subunit 1	Homo sapiens	74-83
24157922-11	2014	VEGF levels decreased by 64.8, 84.4 and 92.9% after coexposure to celastrol at 0.025, 0.05 and 0.1 muM, respectively, compared to LPS alone.	celastrol	66-75	vascular endothelial growth factor A	Homo sapiens	0-4
24351928-4	2014	Celastrol interfered with the establishment of the heat-shock protein 90/Hsp90 cochaperone Cdc37/Hsp90-Hsp70-organizing protein chaperone complex with mutant GCase and reduced heat-shock protein 90-associated protein degradation.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	73-78
24351928-4	2014	Celastrol interfered with the establishment of the heat-shock protein 90/Hsp90 cochaperone Cdc37/Hsp90-Hsp70-organizing protein chaperone complex with mutant GCase and reduced heat-shock protein 90-associated protein degradation.	celastrol	0-9	cell division cycle 37, HSP90 cochaperone	Homo sapiens	91-96
24351928-4	2014	Celastrol interfered with the establishment of the heat-shock protein 90/Hsp90 cochaperone Cdc37/Hsp90-Hsp70-organizing protein chaperone complex with mutant GCase and reduced heat-shock protein 90-associated protein degradation.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	97-102
24351928-4	2014	Celastrol interfered with the establishment of the heat-shock protein 90/Hsp90 cochaperone Cdc37/Hsp90-Hsp70-organizing protein chaperone complex with mutant GCase and reduced heat-shock protein 90-associated protein degradation.	celastrol	0-9	heat shock protein family A (Hsp70) member 4	Homo sapiens	103-108
24351928-6	2014	Bcl2-associated athanogene 3 and heat shock 70kDa proteins 1A and 1B were significantly increased by celastrol.	celastrol	101-110	BAG cochaperone 3	Homo sapiens	0-28
24157922-0	2014	Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing TLR4-triggered nuclear factor-kappa B activation.	celastrol	0-9	toll like receptor 4	Homo sapiens	74-78
24157922-0	2014	Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing TLR4-triggered nuclear factor-kappa B activation.	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	89-111
24157922-9	2014	A 45-74% inhibition of LPS-dependent cell invasion was achieved in the presence of 0.025-0.1 muM celastrol.	celastrol	97-106	latexin	Homo sapiens	93-96
24157922-10	2014	Celastrol significantly downregulated LPS-induced TLR4 expression and inhibited LPS-induced VEGF secretion in LP-1 cells.	celastrol	0-9	toll like receptor 4	Homo sapiens	50-54
24157922-10	2014	Celastrol significantly downregulated LPS-induced TLR4 expression and inhibited LPS-induced VEGF secretion in LP-1 cells.	celastrol	0-9	vascular endothelial growth factor A	Homo sapiens	92-96
24157922-11	2014	VEGF levels decreased by 64.8, 84.4 and 92.9% after coexposure to celastrol at 0.025, 0.05 and 0.1 muM, respectively, compared to LPS alone.	celastrol	66-75	latexin	Homo sapiens	99-102
24157922-12	2014	Celastrol also inhibited the IkappaB kinase (IKK)/NF-kappaB pathway induced by LPS.	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	50-59
24157922-13	2014	Protein levels of NF-kappaB p65, IKKalpha and IkappaB-alpha decreased in a dose-dependent manner after coexposure to celastrol.	celastrol	117-126	nuclear factor kappa B subunit 1	Homo sapiens	18-27
24157922-13	2014	Protein levels of NF-kappaB p65, IKKalpha and IkappaB-alpha decreased in a dose-dependent manner after coexposure to celastrol.	celastrol	117-126	RELA proto-oncogene, NF-kB subunit	Homo sapiens	28-31
24157922-13	2014	Protein levels of NF-kappaB p65, IKKalpha and IkappaB-alpha decreased in a dose-dependent manner after coexposure to celastrol.	celastrol	117-126	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	33-41
24157922-13	2014	Protein levels of NF-kappaB p65, IKKalpha and IkappaB-alpha decreased in a dose-dependent manner after coexposure to celastrol.	celastrol	117-126	NFKB inhibitor alpha	Homo sapiens	46-59
24157922-14	2014	Celastrol also blocked nuclear translocation of the p65 subunit.	celastrol	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	52-55
24157922-15	2014	These results suggest that celastrol inhibits LPS-induced angiogenesis by suppressing TLR4-triggered NF-kappaB activation.	celastrol	27-36	toll like receptor 4	Homo sapiens	86-90
24157922-15	2014	These results suggest that celastrol inhibits LPS-induced angiogenesis by suppressing TLR4-triggered NF-kappaB activation.	celastrol	27-36	nuclear factor kappa B subunit 1	Homo sapiens	101-110
24111524-10	2014	The findings indicate that celastrol prevents Cd-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network.	celastrol	27-36	AKT serine/threonine kinase 1	Homo sapiens	104-107
24685625-10	2014	HSP-70 siRNA abolished celastrol mediated cytoprotection.	celastrol	23-32	heat shock protein family A (Hsp70) member 4	Homo sapiens	0-6
24685625-11	2014	CONCLUSION: This study demonstrates that celastrol reduced both LPS-induced cell death and Abeta production in vitro through increasing HSP-70 and Bcl-2 expression and reducing NFkappaB, COX-2, and GSK-3beta expression and oxidative stress.	celastrol	41-50	heat shock protein family A (Hsp70) member 4	Homo sapiens	136-142
24685625-11	2014	CONCLUSION: This study demonstrates that celastrol reduced both LPS-induced cell death and Abeta production in vitro through increasing HSP-70 and Bcl-2 expression and reducing NFkappaB, COX-2, and GSK-3beta expression and oxidative stress.	celastrol	41-50	BCL2 apoptosis regulator	Homo sapiens	147-152
24685625-11	2014	CONCLUSION: This study demonstrates that celastrol reduced both LPS-induced cell death and Abeta production in vitro through increasing HSP-70 and Bcl-2 expression and reducing NFkappaB, COX-2, and GSK-3beta expression and oxidative stress.	celastrol	41-50	nuclear factor kappa B subunit 1	Homo sapiens	177-185
24685625-11	2014	CONCLUSION: This study demonstrates that celastrol reduced both LPS-induced cell death and Abeta production in vitro through increasing HSP-70 and Bcl-2 expression and reducing NFkappaB, COX-2, and GSK-3beta expression and oxidative stress.	celastrol	41-50	prostaglandin-endoperoxide synthase 2	Homo sapiens	187-192
24685625-11	2014	CONCLUSION: This study demonstrates that celastrol reduced both LPS-induced cell death and Abeta production in vitro through increasing HSP-70 and Bcl-2 expression and reducing NFkappaB, COX-2, and GSK-3beta expression and oxidative stress.	celastrol	41-50	glycogen synthase kinase 3 beta	Homo sapiens	198-207
24144799-0	2014	Inhibitory effects of celastrol on rat liver cytochrome P450 1A2, 2C11, 2D6, 2E1 and 3A2 activity.	celastrol	22-31	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	45-64
24144799-4	2014	Inhibition of rat CYP isoforms (IC50) by celastrol in potency order was CYP2C11 (10.2 muM)&gt;CYP3A2 (23.2 muM)&gt;CYP1A2 (52.8 muM)&gt;CYP2E1 (74.2 muM)&gt;CYP2D6 (76.4 muM).	celastrol	41-50	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	72-79
24144799-4	2014	Inhibition of rat CYP isoforms (IC50) by celastrol in potency order was CYP2C11 (10.2 muM)&gt;CYP3A2 (23.2 muM)&gt;CYP1A2 (52.8 muM)&gt;CYP2E1 (74.2 muM)&gt;CYP2D6 (76.4 muM).	celastrol	41-50	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	94-100
24144799-4	2014	Inhibition of rat CYP isoforms (IC50) by celastrol in potency order was CYP2C11 (10.2 muM)&gt;CYP3A2 (23.2 muM)&gt;CYP1A2 (52.8 muM)&gt;CYP2E1 (74.2 muM)&gt;CYP2D6 (76.4 muM).	celastrol	41-50	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	115-121
24144799-4	2014	Inhibition of rat CYP isoforms (IC50) by celastrol in potency order was CYP2C11 (10.2 muM)&gt;CYP3A2 (23.2 muM)&gt;CYP1A2 (52.8 muM)&gt;CYP2E1 (74.2 muM)&gt;CYP2D6 (76.4 muM).	celastrol	41-50	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	136-142
24144799-4	2014	Inhibition of rat CYP isoforms (IC50) by celastrol in potency order was CYP2C11 (10.2 muM)&gt;CYP3A2 (23.2 muM)&gt;CYP1A2 (52.8 muM)&gt;CYP2E1 (74.2 muM)&gt;CYP2D6 (76.4 muM).	celastrol	41-50	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	157-163
24144799-5	2014	Enzyme kinetic studies showed that the celastrol was not only a competitive inhibitor of CYP1A2 and 2C11, but also a mixed-type inhibitor of CYP3A2, with Ki of 39.2 muM, 7.05 muM and 14.2 muM, respectively.	celastrol	39-48	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	89-95
24144799-5	2014	Enzyme kinetic studies showed that the celastrol was not only a competitive inhibitor of CYP1A2 and 2C11, but also a mixed-type inhibitor of CYP3A2, with Ki of 39.2 muM, 7.05 muM and 14.2 muM, respectively.	celastrol	39-48	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	141-147
24144799-6	2014	The data indicate that celastrol inhibited the metabolism of CYP1A2, 2C and 3A substrates in rat liver in vitro with a different mode of inhibition.	celastrol	23-32	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	61-67
24685625-9	2014	Western blot and immunofluorescence analysis showed that exposure to celastrol increased HSP-70 and Bcl-2 expression but decreased NFkappaB activity, phosphorylated glycogen synthase kinase-3beta (GSK-3beta) at tyrosine 216 and cyclooxygenase-2 (COX-2) expression, Abeta accumulation together with a reduction of superoxide and hydrogen peroxide generation.	celastrol	69-78	heat shock protein family A (Hsp70) member 4	Homo sapiens	89-95
24685625-9	2014	Western blot and immunofluorescence analysis showed that exposure to celastrol increased HSP-70 and Bcl-2 expression but decreased NFkappaB activity, phosphorylated glycogen synthase kinase-3beta (GSK-3beta) at tyrosine 216 and cyclooxygenase-2 (COX-2) expression, Abeta accumulation together with a reduction of superoxide and hydrogen peroxide generation.	celastrol	69-78	BCL2 apoptosis regulator	Homo sapiens	100-105
24685625-9	2014	Western blot and immunofluorescence analysis showed that exposure to celastrol increased HSP-70 and Bcl-2 expression but decreased NFkappaB activity, phosphorylated glycogen synthase kinase-3beta (GSK-3beta) at tyrosine 216 and cyclooxygenase-2 (COX-2) expression, Abeta accumulation together with a reduction of superoxide and hydrogen peroxide generation.	celastrol	69-78	nuclear factor kappa B subunit 1	Homo sapiens	131-139
24685625-9	2014	Western blot and immunofluorescence analysis showed that exposure to celastrol increased HSP-70 and Bcl-2 expression but decreased NFkappaB activity, phosphorylated glycogen synthase kinase-3beta (GSK-3beta) at tyrosine 216 and cyclooxygenase-2 (COX-2) expression, Abeta accumulation together with a reduction of superoxide and hydrogen peroxide generation.	celastrol	69-78	glycogen synthase kinase 3 beta	Homo sapiens	165-195
24685625-9	2014	Western blot and immunofluorescence analysis showed that exposure to celastrol increased HSP-70 and Bcl-2 expression but decreased NFkappaB activity, phosphorylated glycogen synthase kinase-3beta (GSK-3beta) at tyrosine 216 and cyclooxygenase-2 (COX-2) expression, Abeta accumulation together with a reduction of superoxide and hydrogen peroxide generation.	celastrol	69-78	glycogen synthase kinase 3 beta	Homo sapiens	197-206
24685625-9	2014	Western blot and immunofluorescence analysis showed that exposure to celastrol increased HSP-70 and Bcl-2 expression but decreased NFkappaB activity, phosphorylated glycogen synthase kinase-3beta (GSK-3beta) at tyrosine 216 and cyclooxygenase-2 (COX-2) expression, Abeta accumulation together with a reduction of superoxide and hydrogen peroxide generation.	celastrol	69-78	prostaglandin-endoperoxide synthase 2	Homo sapiens	228-244
24685625-9	2014	Western blot and immunofluorescence analysis showed that exposure to celastrol increased HSP-70 and Bcl-2 expression but decreased NFkappaB activity, phosphorylated glycogen synthase kinase-3beta (GSK-3beta) at tyrosine 216 and cyclooxygenase-2 (COX-2) expression, Abeta accumulation together with a reduction of superoxide and hydrogen peroxide generation.	celastrol	69-78	prostaglandin-endoperoxide synthase 2	Homo sapiens	246-251
24111524-0	2014	Celastrol prevents cadmium-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network.	celastrol	0-9	mitogen-activated protein kinase 8	Homo sapiens	69-72
24111524-0	2014	Celastrol prevents cadmium-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network.	celastrol	0-9	phosphatase and tensin homolog	Homo sapiens	77-81
24111524-0	2014	Celastrol prevents cadmium-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	82-85
24111524-0	2014	Celastrol prevents cadmium-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	86-90
24111524-5	2014	This is supported by the findings that celastrol strikingly attenuated Cd-induced viability reduction, morphological change, nuclear fragmentation, and condensation, as well as activation of caspase-3 in neuronal cells.	celastrol	39-48	caspase 3	Homo sapiens	191-200
24111524-6	2014	Concurrently, celastrol remarkably blocked Cd-induced phosphorylation of c-Jun N-terminal kinase (JNK), but not extracellular signal-regulated kinases 1/2 and p38, in neuronal cells.	celastrol	14-23	mitogen-activated protein kinase 8	Homo sapiens	73-96
24111524-6	2014	Concurrently, celastrol remarkably blocked Cd-induced phosphorylation of c-Jun N-terminal kinase (JNK), but not extracellular signal-regulated kinases 1/2 and p38, in neuronal cells.	celastrol	14-23	mitogen-activated protein kinase 8	Homo sapiens	98-101
24111524-7	2014	Inhibition of JNK by SP600125 or over-expression of dominant negative c-Jun potentiated celastrol protection against Cd-induced cell death.	celastrol	88-97	mitogen-activated protein kinase 8	Homo sapiens	14-17
24111524-10	2014	The findings indicate that celastrol prevents Cd-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network.	celastrol	27-36	mechanistic target of rapamycin kinase	Homo sapiens	108-112
24111524-7	2014	Inhibition of JNK by SP600125 or over-expression of dominant negative c-Jun potentiated celastrol protection against Cd-induced cell death.	celastrol	88-97	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	70-75
24111524-8	2014	Furthermore, pre-treatment with celastrol prevented Cd down-regulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and activation of phosphoinositide 3"-kinase/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling in neuronal cells.	celastrol	32-41	phosphatase and tensin homolog	Homo sapiens	131-135
24111524-14	2014	This study underscores that celastrol prevents Cd-induced neuronal apoptosis via inhibiting activation of JNK (c-Jun N-terminal kinase) and Akt/mTOR network.	celastrol	28-37	mitogen-activated protein kinase 8	Homo sapiens	106-109
24111524-8	2014	Furthermore, pre-treatment with celastrol prevented Cd down-regulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and activation of phosphoinositide 3"-kinase/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling in neuronal cells.	celastrol	32-41	protein tyrosine kinase 2 beta	Homo sapiens	182-198
24111524-8	2014	Furthermore, pre-treatment with celastrol prevented Cd down-regulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and activation of phosphoinositide 3"-kinase/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling in neuronal cells.	celastrol	32-41	AKT serine/threonine kinase 1	Homo sapiens	200-203
24111524-14	2014	This study underscores that celastrol prevents Cd-induced neuronal apoptosis via inhibiting activation of JNK (c-Jun N-terminal kinase) and Akt/mTOR network.	celastrol	28-37	mitogen-activated protein kinase 8	Homo sapiens	111-134
24111524-8	2014	Furthermore, pre-treatment with celastrol prevented Cd down-regulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and activation of phosphoinositide 3"-kinase/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling in neuronal cells.	celastrol	32-41	mechanistic target of rapamycin kinase	Homo sapiens	205-234
24111524-8	2014	Furthermore, pre-treatment with celastrol prevented Cd down-regulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and activation of phosphoinositide 3"-kinase/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling in neuronal cells.	celastrol	32-41	mechanistic target of rapamycin kinase	Homo sapiens	236-240
24111524-9	2014	Over-expression of wild-type PTEN enhanced celastrol inhibition of Cd-activated Akt/mTOR signaling and cell death in neuronal cells.	celastrol	43-52	phosphatase and tensin homolog	Homo sapiens	29-33
24111524-14	2014	This study underscores that celastrol prevents Cd-induced neuronal apoptosis via inhibiting activation of JNK (c-Jun N-terminal kinase) and Akt/mTOR network.	celastrol	28-37	AKT serine/threonine kinase 1	Homo sapiens	140-143
24111524-14	2014	This study underscores that celastrol prevents Cd-induced neuronal apoptosis via inhibiting activation of JNK (c-Jun N-terminal kinase) and Akt/mTOR network.	celastrol	28-37	mechanistic target of rapamycin kinase	Homo sapiens	144-148
24111524-15	2014	Celastrol suppresses Cd-activated Akt/mTOR pathway by elevating PTEN (phosphatase and tensin homolog).	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	34-37
24111524-9	2014	Over-expression of wild-type PTEN enhanced celastrol inhibition of Cd-activated Akt/mTOR signaling and cell death in neuronal cells.	celastrol	43-52	AKT serine/threonine kinase 1	Homo sapiens	80-83
24111524-15	2014	Celastrol suppresses Cd-activated Akt/mTOR pathway by elevating PTEN (phosphatase and tensin homolog).	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	38-42
24111524-9	2014	Over-expression of wild-type PTEN enhanced celastrol inhibition of Cd-activated Akt/mTOR signaling and cell death in neuronal cells.	celastrol	43-52	mechanistic target of rapamycin kinase	Homo sapiens	84-88
24111524-15	2014	Celastrol suppresses Cd-activated Akt/mTOR pathway by elevating PTEN (phosphatase and tensin homolog).	celastrol	0-9	phosphatase and tensin homolog	Homo sapiens	64-68
24111524-10	2014	The findings indicate that celastrol prevents Cd-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network.	celastrol	27-36	mitogen-activated protein kinase 8	Homo sapiens	91-94
24111524-10	2014	The findings indicate that celastrol prevents Cd-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network.	celastrol	27-36	phosphatase and tensin homolog	Homo sapiens	99-103
24713615-7	2014	An exception was the marked response to celastrol which reduced the steady-state levels of cytoplasmic HSP90 transcripts and protein.	celastrol	40-49	heat shock protein 90 alpha family class A member 1	Homo sapiens	103-108
23981709-7	2014	RESULTS: Celastrol significantly suppressed elevation of the renal function markers and the lipid peroxidation level, alleviated renal tubular damage, and decreased the levels of tumor necrosis factor-alpha, interleukin-1beta, and monocyte chemotactic protein-1 (MCP-1) messenger RNA in kidney caused by IR.	celastrol	9-18	tumor necrosis factor	Rattus norvegicus	179-206
23981709-7	2014	RESULTS: Celastrol significantly suppressed elevation of the renal function markers and the lipid peroxidation level, alleviated renal tubular damage, and decreased the levels of tumor necrosis factor-alpha, interleukin-1beta, and monocyte chemotactic protein-1 (MCP-1) messenger RNA in kidney caused by IR.	celastrol	9-18	interleukin 1 beta	Rattus norvegicus	208-225
23981709-7	2014	RESULTS: Celastrol significantly suppressed elevation of the renal function markers and the lipid peroxidation level, alleviated renal tubular damage, and decreased the levels of tumor necrosis factor-alpha, interleukin-1beta, and monocyte chemotactic protein-1 (MCP-1) messenger RNA in kidney caused by IR.	celastrol	9-18	C-C motif chemokine ligand 2	Rattus norvegicus	231-261
23981709-7	2014	RESULTS: Celastrol significantly suppressed elevation of the renal function markers and the lipid peroxidation level, alleviated renal tubular damage, and decreased the levels of tumor necrosis factor-alpha, interleukin-1beta, and monocyte chemotactic protein-1 (MCP-1) messenger RNA in kidney caused by IR.	celastrol	9-18	C-C motif chemokine ligand 2	Rattus norvegicus	263-268
23981709-8	2014	Moreover, celastrol prevented IR-induced expression of pro-inflammatory mediators, which was associated with suppression of nuclear translocation of NF-kappaB subunit p65.	celastrol	10-19	synaptotagmin 1	Rattus norvegicus	167-170
24214023-6	2014	Similarly, celastrol treatment inhibited cytochrome c release, Bax/Bcl-2 ratio changes, and caspase-9/3 activation.	celastrol	11-20	cytochrome c, somatic	Homo sapiens	41-53
24214023-6	2014	Similarly, celastrol treatment inhibited cytochrome c release, Bax/Bcl-2 ratio changes, and caspase-9/3 activation.	celastrol	11-20	BCL2 associated X, apoptosis regulator	Homo sapiens	63-66
24214023-6	2014	Similarly, celastrol treatment inhibited cytochrome c release, Bax/Bcl-2 ratio changes, and caspase-9/3 activation.	celastrol	11-20	BCL2 apoptosis regulator	Homo sapiens	67-72
24214023-6	2014	Similarly, celastrol treatment inhibited cytochrome c release, Bax/Bcl-2 ratio changes, and caspase-9/3 activation.	celastrol	11-20	caspase 9	Homo sapiens	92-103
24214023-7	2014	Celastrol specifically inhibited rotenone-evoked p38 mitogen-activated protein kinase activation in SH-SY5Y cells.	celastrol	0-9	mitogen-activated protein kinase 14	Homo sapiens	49-85
24713615-8	2014	As Hsp90 participates in the targeting of misfolded proteins to the proteasome pathway, its down-modulation in response to celastrol may partly account for the mechanism of improved homeostasis of L444P GCase mediated by this triterpene.	celastrol	123-132	heat shock protein 90 alpha family class A member 1	Homo sapiens	3-8
24144813-0	2013	Anti-invasive effects of celastrol in hypoxia-induced fibroblast-like synoviocyte through suppressing of HIF-1alpha/CXCR4 signaling pathway.	celastrol	25-34	hypoxia inducible factor 1 subunit alpha	Homo sapiens	105-115
24434352-0	2014	Celastrol induces apoptosis of gastric cancer cells by miR-21 inhibiting PI3K/Akt-NF-kappaB signaling pathway.	celastrol	0-9	microRNA 21	Homo sapiens	55-61
24434352-0	2014	Celastrol induces apoptosis of gastric cancer cells by miR-21 inhibiting PI3K/Akt-NF-kappaB signaling pathway.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	78-81
24434352-0	2014	Celastrol induces apoptosis of gastric cancer cells by miR-21 inhibiting PI3K/Akt-NF-kappaB signaling pathway.	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	82-91
24434352-3	2014	METHODS: The effect of celastrol on PI3K/Akt and the NF-kappaB signaling pathway was evaluated with Western blot and luciferase reporter assay.	celastrol	23-32	AKT serine/threonine kinase 1	Homo sapiens	41-44
24434352-3	2014	METHODS: The effect of celastrol on PI3K/Akt and the NF-kappaB signaling pathway was evaluated with Western blot and luciferase reporter assay.	celastrol	23-32	nuclear factor kappa B subunit 1	Homo sapiens	53-62
24434352-6	2014	RESULTS: It was identified that celastrol was capable of inducing apoptosis of gastric cancer cells, which was mediated via inhibiting the activation of PI3K/Akt and NF-kappaB.	celastrol	32-41	AKT serine/threonine kinase 1	Homo sapiens	158-161
24434352-6	2014	RESULTS: It was identified that celastrol was capable of inducing apoptosis of gastric cancer cells, which was mediated via inhibiting the activation of PI3K/Akt and NF-kappaB.	celastrol	32-41	nuclear factor kappa B subunit 1	Homo sapiens	166-175
24434352-7	2014	A strong activator of Akt, IGF-1 restored NF-kappaB activity in cells treated with celastrol.	celastrol	83-92	AKT serine/threonine kinase 1	Homo sapiens	22-25
24434352-7	2014	A strong activator of Akt, IGF-1 restored NF-kappaB activity in cells treated with celastrol.	celastrol	83-92	insulin like growth factor 1	Homo sapiens	27-32
24434352-7	2014	A strong activator of Akt, IGF-1 restored NF-kappaB activity in cells treated with celastrol.	celastrol	83-92	nuclear factor kappa B subunit 1	Homo sapiens	42-51
24434352-8	2014	Celastrol could also significantly suppress miR-21 expression.	celastrol	0-9	microRNA 21	Homo sapiens	44-50
24434352-10	2014	Notably, upregulation of miR-21 expression can increase PI3K/Akt and NF-kappaB activity and decrease apoptosis of gastric cancer cells treated with celastrol, which could be reversed by PI3K inhibitor.	celastrol	148-157	microRNA 21	Homo sapiens	25-31
24434352-10	2014	Notably, upregulation of miR-21 expression can increase PI3K/Akt and NF-kappaB activity and decrease apoptosis of gastric cancer cells treated with celastrol, which could be reversed by PI3K inhibitor.	celastrol	148-157	AKT serine/threonine kinase 1	Homo sapiens	61-64
24434352-10	2014	Notably, upregulation of miR-21 expression can increase PI3K/Akt and NF-kappaB activity and decrease apoptosis of gastric cancer cells treated with celastrol, which could be reversed by PI3K inhibitor.	celastrol	148-157	nuclear factor kappa B subunit 1	Homo sapiens	69-78
24434352-11	2014	CONCLUSIONS: Our data revealed that the effect of celastrol on apoptosis was due to miR-21 inhibiting the PI3K/Akt-dependent NF-kappaB pathway.	celastrol	50-59	microRNA 21	Homo sapiens	84-90
24434352-11	2014	CONCLUSIONS: Our data revealed that the effect of celastrol on apoptosis was due to miR-21 inhibiting the PI3K/Akt-dependent NF-kappaB pathway.	celastrol	50-59	AKT serine/threonine kinase 1	Homo sapiens	111-114
24434352-11	2014	CONCLUSIONS: Our data revealed that the effect of celastrol on apoptosis was due to miR-21 inhibiting the PI3K/Akt-dependent NF-kappaB pathway.	celastrol	50-59	nuclear factor kappa B subunit 1	Homo sapiens	125-134
24144813-9	2013	Meanwhile, it is revealed that celastrol inhibited the transcriptional activity of CXCR4 under hypoxic conditions by suppressing the binding activity of HIF-1alpha in the CXCR4 promoter, and blocked hypoxia-induced accumulation of nuclear HIF-1alpha.	celastrol	31-40	C-X-C motif chemokine receptor 4	Homo sapiens	83-88
24144813-9	2013	Meanwhile, it is revealed that celastrol inhibited the transcriptional activity of CXCR4 under hypoxic conditions by suppressing the binding activity of HIF-1alpha in the CXCR4 promoter, and blocked hypoxia-induced accumulation of nuclear HIF-1alpha.	celastrol	31-40	hypoxia inducible factor 1 subunit alpha	Homo sapiens	153-163
24144813-9	2013	Meanwhile, it is revealed that celastrol inhibited the transcriptional activity of CXCR4 under hypoxic conditions by suppressing the binding activity of HIF-1alpha in the CXCR4 promoter, and blocked hypoxia-induced accumulation of nuclear HIF-1alpha.	celastrol	31-40	C-X-C motif chemokine receptor 4	Homo sapiens	171-176
24144813-9	2013	Meanwhile, it is revealed that celastrol inhibited the transcriptional activity of CXCR4 under hypoxic conditions by suppressing the binding activity of HIF-1alpha in the CXCR4 promoter, and blocked hypoxia-induced accumulation of nuclear HIF-1alpha.	celastrol	31-40	hypoxia inducible factor 1 subunit alpha	Homo sapiens	239-249
24144813-11	2013	In conclusion, our results indicate that celastrol inhibits hypoxia-induced migration and invasion via suppression of HIF-1alpha mediated CXCR4 expression in FLSs under hypoxic conditions.	celastrol	41-50	hypoxia inducible factor 1 subunit alpha	Homo sapiens	118-128
24144813-11	2013	In conclusion, our results indicate that celastrol inhibits hypoxia-induced migration and invasion via suppression of HIF-1alpha mediated CXCR4 expression in FLSs under hypoxic conditions.	celastrol	41-50	C-X-C motif chemokine receptor 4	Homo sapiens	138-143
24144813-0	2013	Anti-invasive effects of celastrol in hypoxia-induced fibroblast-like synoviocyte through suppressing of HIF-1alpha/CXCR4 signaling pathway.	celastrol	25-34	C-X-C motif chemokine receptor 4	Homo sapiens	116-121
24144813-8	2013	In addition, we also found that celastrol inhibited hypoxia-induced CXCR4 expression at both the mRNA and the protein levels in RA-FLSs.	celastrol	32-41	C-X-C motif chemokine receptor 4	Homo sapiens	68-73
24056254-10	2013	Very interestingly, Sulforaphane, Withaferin A, Celastrol and EGCG all decreased the complemented NRL-Hsp90alpha/Cdc37-CRL activities in the concentration-dependent manner.	celastrol	48-57	heat shock protein 90 alpha family class A member 1	Homo sapiens	102-112
24056254-10	2013	Very interestingly, Sulforaphane, Withaferin A, Celastrol and EGCG all decreased the complemented NRL-Hsp90alpha/Cdc37-CRL activities in the concentration-dependent manner.	celastrol	48-57	cell division cycle 37, HSP90 cochaperone	Homo sapiens	113-118
24056254-10	2013	Very interestingly, Sulforaphane, Withaferin A, Celastrol and EGCG all decreased the complemented NRL-Hsp90alpha/Cdc37-CRL activities in the concentration-dependent manner.	celastrol	48-57	interleukin 31 receptor A	Homo sapiens	119-122
23734772-8	2013	CONCLUSION: These results suggest that 4E-BP1 plays a critical role in the mechanism by which TRAIL and celastrol together cause apoptotic cell death in human pancreatic tumour cells.	celastrol	104-113	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	39-45
23583203-6	2013	The results showed that silencing of Hsp70 by chitosan-TPP-Hsp70 siRNA treatment significantly reduced cell viability, and enhanced antiproliferative effects of celastrol in leukemia and glioblastoma cells.	celastrol	161-170	heat shock protein family A (Hsp70) member 4	Homo sapiens	37-42
23583203-6	2013	The results showed that silencing of Hsp70 by chitosan-TPP-Hsp70 siRNA treatment significantly reduced cell viability, and enhanced antiproliferative effects of celastrol in leukemia and glioblastoma cells.	celastrol	161-170	heat shock protein family A (Hsp70) member 4	Homo sapiens	59-64
23734772-0	2013	Role of the eIF4E binding protein 4E-BP1 in regulation of the sensitivity of human pancreatic cancer cells to TRAIL and celastrol-induced apoptosis.	celastrol	120-129	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	34-40
23850675-0	2013	Celastrol inhibits TGF-beta1-induced epithelial-mesenchymal transition by inhibiting Snail and regulating E-cadherin expression.	celastrol	0-9	transforming growth factor beta-1 proprotein	Canis lupus familiaris	19-28
23734772-2	2013	Although human pancreatic cancer cells show varying degrees of response they can be sensitised to the pro-apoptotic effects of TRAIL in the presence of celastrol, a natural compound extracted from the plant Tripterygium wilfordii Hook F. One important aspect of the cellular response to TRAIL is the control of protein synthesis, a key regulator of which is the eukaryotic initiation factor 4E-binding protein, 4E-BP1.	celastrol	152-161	TNF superfamily member 10	Homo sapiens	127-132
23734772-2	2013	Although human pancreatic cancer cells show varying degrees of response they can be sensitised to the pro-apoptotic effects of TRAIL in the presence of celastrol, a natural compound extracted from the plant Tripterygium wilfordii Hook F. One important aspect of the cellular response to TRAIL is the control of protein synthesis, a key regulator of which is the eukaryotic initiation factor 4E-binding protein, 4E-BP1.	celastrol	152-161	TNF superfamily member 10	Homo sapiens	287-292
23734772-2	2013	Although human pancreatic cancer cells show varying degrees of response they can be sensitised to the pro-apoptotic effects of TRAIL in the presence of celastrol, a natural compound extracted from the plant Tripterygium wilfordii Hook F. One important aspect of the cellular response to TRAIL is the control of protein synthesis, a key regulator of which is the eukaryotic initiation factor 4E-binding protein, 4E-BP1.	celastrol	152-161	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	411-417
23734772-4	2013	In cells that are normally resistant to TRAIL, synergistic effects of TRAIL plus celastrol on commitment to apoptosis and inhibition of protein synthesis were observed.	celastrol	81-90	TNF superfamily member 10	Homo sapiens	40-45
23239560-0	2013	AFM studied the effect of celastrol on beta1 integrin-mediated HUVEC adhesion and migration.	celastrol	26-35	integrin subunit beta 1	Homo sapiens	39-53
23239560-3	2013	Here, the mechanism underling the antiangiogenesis capacity of celastrol was investigated by exploring the effect of celastrol on beta1(CD29) integrin-mediated cell adhesion and migration.	celastrol	63-72	integrin subunit beta 1	Homo sapiens	136-140
23239560-3	2013	Here, the mechanism underling the antiangiogenesis capacity of celastrol was investigated by exploring the effect of celastrol on beta1(CD29) integrin-mediated cell adhesion and migration.	celastrol	117-126	integrin subunit beta 1	Homo sapiens	136-140
23239560-4	2013	Flow cytometry results showed that the HUVECs highly expressed CD29 and cell adhesion assay indicated that celastrol specifically inhibited the adhesion of HUVECs to fibronectin (FN) without affecting nonspecific adhesion to poly-L-lysine (PLL).	celastrol	107-116	integrin subunit beta 1	Homo sapiens	63-67
23239560-4	2013	Flow cytometry results showed that the HUVECs highly expressed CD29 and cell adhesion assay indicated that celastrol specifically inhibited the adhesion of HUVECs to fibronectin (FN) without affecting nonspecific adhesion to poly-L-lysine (PLL).	celastrol	107-116	fibronectin 1	Homo sapiens	166-177
23239560-4	2013	Flow cytometry results showed that the HUVECs highly expressed CD29 and cell adhesion assay indicated that celastrol specifically inhibited the adhesion of HUVECs to fibronectin (FN) without affecting nonspecific adhesion to poly-L-lysine (PLL).	celastrol	107-116	fibronectin 1	Homo sapiens	179-181
23239560-10	2013	Taken together, our results suggest that celastrol can be as an inhibitor of HUVEC adhesion to FN.	celastrol	41-50	fibronectin 1	Homo sapiens	95-97
23810294-0	2013	Inhibition of C2C12 myotube atrophy by a novel HSP70 inducer, celastrol, via activation of Akt1 and ERK1/2 pathways.	celastrol	62-71	heat shock protein family A (Hsp70) member 4	Homo sapiens	47-52
23810294-0	2013	Inhibition of C2C12 myotube atrophy by a novel HSP70 inducer, celastrol, via activation of Akt1 and ERK1/2 pathways.	celastrol	62-71	AKT serine/threonine kinase 1	Homo sapiens	91-95
23810294-0	2013	Inhibition of C2C12 myotube atrophy by a novel HSP70 inducer, celastrol, via activation of Akt1 and ERK1/2 pathways.	celastrol	62-71	mitogen-activated protein kinase 3	Homo sapiens	100-106
23810294-1	2013	Celastrol (CEL) is known as a potent inducer of heat shock protein (HSP) in non-muscle cells and exhibits cytoprotective function and inhibitory effects on proteasome and glucocorticoid receptor activities.	celastrol	0-9	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	48-66
23810294-1	2013	Celastrol (CEL) is known as a potent inducer of heat shock protein (HSP) in non-muscle cells and exhibits cytoprotective function and inhibitory effects on proteasome and glucocorticoid receptor activities.	celastrol	0-9	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	68-71
23810294-1	2013	Celastrol (CEL) is known as a potent inducer of heat shock protein (HSP) in non-muscle cells and exhibits cytoprotective function and inhibitory effects on proteasome and glucocorticoid receptor activities.	celastrol	11-14	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	48-66
23810294-1	2013	Celastrol (CEL) is known as a potent inducer of heat shock protein (HSP) in non-muscle cells and exhibits cytoprotective function and inhibitory effects on proteasome and glucocorticoid receptor activities.	celastrol	11-14	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	68-71
23810294-6	2013	Inhibition of Akt1 and ERK1/2 pathways by specific inhibitors confirmed CEL-induced anti-atrophic effect.	celastrol	72-75	AKT serine/threonine kinase 1	Homo sapiens	14-18
23810294-6	2013	Inhibition of Akt1 and ERK1/2 pathways by specific inhibitors confirmed CEL-induced anti-atrophic effect.	celastrol	72-75	mitogen-activated protein kinase 3	Homo sapiens	23-29
23850675-0	2013	Celastrol inhibits TGF-beta1-induced epithelial-mesenchymal transition by inhibiting Snail and regulating E-cadherin expression.	celastrol	0-9	cadherin 1	Canis lupus familiaris	106-116
23850675-5	2013	The downregulation of E-cadherin expression and upregulation of Snail in Madin-Darby Canine Kidney (MDCK) and A549 cell lines show that TGF-beta1-mediated the EMT in epithelial cells; however, celastrol markedly inhibited TGF-beta1-induced morphologic changes, Snail upregulation, and E-cadherin expression.	celastrol	193-202	transforming growth factor beta-1 proprotein	Canis lupus familiaris	136-145
23850675-6	2013	Migration and invasion assays revealed that celastrol completely inhibited TGF-beta1-mediated cellular migration in both cell lines.	celastrol	44-53	transforming growth factor beta-1 proprotein	Canis lupus familiaris	75-84
23850675-7	2013	These findings indicate that celastrol downregulates Snail expression, thereby inhibiting TGF-beta1-induced EMT in MDCK and A549 cells.	celastrol	29-38	transforming growth factor beta-1 proprotein	Canis lupus familiaris	90-99
23850675-8	2013	Thus, our findings provide new evidence that celastrol suppresses lung cancer invasion and migration by inhibiting TGF-beta1-induced EMT.	celastrol	45-54	transforming growth factor beta-1 proprotein	Canis lupus familiaris	115-124
23861949-6	2013	Furthermore, our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppressing the binding activity of NF-kappaB in the MMP-9 promoter, and suppressed the TLR4/MyD88/NF-kappaB pathway.	celastrol	39-48	matrix metallopeptidase 9	Homo sapiens	91-96
23846217-3	2013	Proteasome catalytic subunit beta1 was predicted by computational analysis to be a possible direct target of celastrol and confirmed by checking direct effect of celastrol on the activity of recombinant human proteasome subunit beta1 in vitro.	celastrol	109-118	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	29-34
23846217-3	2013	Proteasome catalytic subunit beta1 was predicted by computational analysis to be a possible direct target of celastrol and confirmed by checking direct effect of celastrol on the activity of recombinant human proteasome subunit beta1 in vitro.	celastrol	109-118	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	228-233
23846217-3	2013	Proteasome catalytic subunit beta1 was predicted by computational analysis to be a possible direct target of celastrol and confirmed by checking direct effect of celastrol on the activity of recombinant human proteasome subunit beta1 in vitro.	celastrol	162-171	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	29-34
23846217-3	2013	Proteasome catalytic subunit beta1 was predicted by computational analysis to be a possible direct target of celastrol and confirmed by checking direct effect of celastrol on the activity of recombinant human proteasome subunit beta1 in vitro.	celastrol	162-171	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	228-233
23846217-5	2013	Possible target-related proteins of celastrol such as endoplasmic reticulum protein 29 (ERP29) and mitochondrial import receptor Tom22 (TOM22) were found by 2-DE analysis of total cellular protein expression profiles.	celastrol	36-45	endoplasmic reticulum protein 29	Homo sapiens	54-86
23846217-5	2013	Possible target-related proteins of celastrol such as endoplasmic reticulum protein 29 (ERP29) and mitochondrial import receptor Tom22 (TOM22) were found by 2-DE analysis of total cellular protein expression profiles.	celastrol	36-45	endoplasmic reticulum protein 29	Homo sapiens	88-93
23846217-5	2013	Possible target-related proteins of celastrol such as endoplasmic reticulum protein 29 (ERP29) and mitochondrial import receptor Tom22 (TOM22) were found by 2-DE analysis of total cellular protein expression profiles.	celastrol	36-45	translocase of outer mitochondrial membrane 22	Homo sapiens	99-134
23846217-5	2013	Possible target-related proteins of celastrol such as endoplasmic reticulum protein 29 (ERP29) and mitochondrial import receptor Tom22 (TOM22) were found by 2-DE analysis of total cellular protein expression profiles.	celastrol	36-45	translocase of outer mitochondrial membrane 22	Homo sapiens	136-141
23846217-7	2013	Celastrol induced translocation of Bax into the mitochondria, which might be related to the upregulation of BH-3-only proteins such as BIM and the increase in the expression level of TOM22.	celastrol	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	35-38
23846217-7	2013	Celastrol induced translocation of Bax into the mitochondria, which might be related to the upregulation of BH-3-only proteins such as BIM and the increase in the expression level of TOM22.	celastrol	0-9	translocase of outer mitochondrial membrane 22	Homo sapiens	183-188
23846217-10	2013	The important role of glycogen synthase kinase-3beta (GSK3beta) in the signal cascades of celastrol was suggested.	celastrol	90-99	glycogen synthase kinase 3 beta	Homo sapiens	22-52
23846217-10	2013	The important role of glycogen synthase kinase-3beta (GSK3beta) in the signal cascades of celastrol was suggested.	celastrol	90-99	glycogen synthase kinase 3 beta	Homo sapiens	54-62
23846217-11	2013	Pretreatment of LiCL, an inhibitor of GSK3beta, could significantly ameliorate apoptosis induced by celastrol.	celastrol	100-109	glycogen synthase kinase 3 beta	Homo sapiens	38-46
23861949-0	2013	Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF-kappaB-mediated matrix metalloproteinase-9 expression.	celastrol	0-9	toll like receptor 4	Homo sapiens	120-124
23861949-5	2013	Results showed that celastrol suppressed LPS-stimulated FLS migration and invasion by inhibiting MMP-9 expression and activity.	celastrol	20-29	matrix metallopeptidase 9	Homo sapiens	97-102
23861949-6	2013	Furthermore, our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppressing the binding activity of NF-kappaB in the MMP-9 promoter, and suppressed the TLR4/MyD88/NF-kappaB pathway.	celastrol	39-48	matrix metallopeptidase 9	Homo sapiens	153-158
23861949-6	2013	Furthermore, our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppressing the binding activity of NF-kappaB in the MMP-9 promoter, and suppressed the TLR4/MyD88/NF-kappaB pathway.	celastrol	39-48	toll like receptor 4	Homo sapiens	188-192
23861949-6	2013	Furthermore, our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppressing the binding activity of NF-kappaB in the MMP-9 promoter, and suppressed the TLR4/MyD88/NF-kappaB pathway.	celastrol	39-48	MYD88 innate immune signal transduction adaptor	Homo sapiens	193-198
23861949-8	2013	In conclusion, celastrol might inhibit FLS migration and invasion induced by LPS by suppressing TLR4/NF-kappaB-mediated MMP-9 expression, providing a theoretical foundation for the clinical treatment of RA with celastrol.	celastrol	15-24	toll like receptor 4	Homo sapiens	96-100
23861949-8	2013	In conclusion, celastrol might inhibit FLS migration and invasion induced by LPS by suppressing TLR4/NF-kappaB-mediated MMP-9 expression, providing a theoretical foundation for the clinical treatment of RA with celastrol.	celastrol	15-24	matrix metallopeptidase 9	Homo sapiens	120-125
23861949-8	2013	In conclusion, celastrol might inhibit FLS migration and invasion induced by LPS by suppressing TLR4/NF-kappaB-mediated MMP-9 expression, providing a theoretical foundation for the clinical treatment of RA with celastrol.	celastrol	211-220	toll like receptor 4	Homo sapiens	96-100
23861949-8	2013	In conclusion, celastrol might inhibit FLS migration and invasion induced by LPS by suppressing TLR4/NF-kappaB-mediated MMP-9 expression, providing a theoretical foundation for the clinical treatment of RA with celastrol.	celastrol	211-220	matrix metallopeptidase 9	Homo sapiens	120-125
23618875-0	2013	Heterogeneity in the properties of NEFL mutants causing Charcot-Marie-Tooth disease results in differential effects on neurofilament assembly and susceptibility to intervention by the chaperone-inducer, celastrol.	celastrol	203-212	neurofilament, light polypeptide	Mus musculus	35-39
23618875-7	2013	Celastrol, an inducer of chaperone proteins, induced HSPA1 expression in motor neurons and prevented the formation of neurofilament inclusions and mitochondrial shortening induced by expression of NEFL(Q333P), but not in sensory neurons.	celastrol	0-9	neurofilament, light polypeptide	Mus musculus	197-201
23618875-8	2013	Conversely, celastrol had a protective effect against the toxicity of NEFL(P8R), a mutant which is sensitive to HSBP1 but not HSPA1 chaperoning, only in large-sized sensory neurons, not in motor neurons.	celastrol	12-21	neurofilament, light polypeptide	Mus musculus	70-74
23618875-8	2013	Conversely, celastrol had a protective effect against the toxicity of NEFL(P8R), a mutant which is sensitive to HSBP1 but not HSPA1 chaperoning, only in large-sized sensory neurons, not in motor neurons.	celastrol	12-21	heat shock factor binding protein 1	Mus musculus	112-117
23485335-5	2013	MnSOD was up-regulated by MG132 and celastrol, and GST-pi was up-regulated by MG132 and lactacystin.	celastrol	36-45	superoxide dismutase 2	Homo sapiens	0-5
23649759-0	2013	Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo.	celastrol	0-9	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	82-87
23649759-6	2013	Our results showed that Celastrol at high concentration (&gt;1.0 muM) induced G2/M arrest and apoptosis with the activation of Caspase3/7 in Huh7 cells whereas at low concentration (&lt;1.0 muM) had no obvious effects.	celastrol	24-33	caspase 3	Homo sapiens	127-135
23799016-0	2013	Celastrol prevents atherosclerosis via inhibiting LOX-1 and oxidative stress.	celastrol	0-9	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	50-55
23649759-6	2013	Our results showed that Celastrol at high concentration (&gt;1.0 muM) induced G2/M arrest and apoptosis with the activation of Caspase3/7 in Huh7 cells whereas at low concentration (&lt;1.0 muM) had no obvious effects.	celastrol	24-33	MIR7-3 host gene	Homo sapiens	141-145
23649759-7	2013	Low concentration Celastrol presented significant combined effects with PHA on Huh7 cells and Huh7 xenografts in terms of growth inhibition, migration inhibition and apoptosis induction.	celastrol	18-27	MIR7-3 host gene	Homo sapiens	79-83
23649759-7	2013	Low concentration Celastrol presented significant combined effects with PHA on Huh7 cells and Huh7 xenografts in terms of growth inhibition, migration inhibition and apoptosis induction.	celastrol	18-27	MIR7-3 host gene	Homo sapiens	94-98
23649759-8	2013	These results suggest that Celastrol and its combination with PHA present the therapeutic potential on c-Met-deficient hepatocellular carcinoma, and deserve further preclinical and clinical studies.	celastrol	27-36	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	103-108
23799016-4	2013	We found that celastrol significantly attenuated oxLDL-induced excessive expression of lectin-like oxidized low density lipoprotein receptor-1(LOX-1) and generation of reactive oxygen species (ROS) in cultured RAW264.7 macrophages.	celastrol	14-23	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	143-148
23799016-5	2013	Celastrol also decreased IkappaB phosphorylation and degradation and reduced production of inducible nitric oxide synthase (iNOS), nitric oxide (NO) and proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha and IL-6.	celastrol	0-9	nitric oxide synthase 2, inducible	Mus musculus	91-122
23799016-5	2013	Celastrol also decreased IkappaB phosphorylation and degradation and reduced production of inducible nitric oxide synthase (iNOS), nitric oxide (NO) and proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha and IL-6.	celastrol	0-9	nitric oxide synthase 2, inducible	Mus musculus	124-128
23799016-5	2013	Celastrol also decreased IkappaB phosphorylation and degradation and reduced production of inducible nitric oxide synthase (iNOS), nitric oxide (NO) and proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha and IL-6.	celastrol	0-9	tumor necrosis factor	Mus musculus	187-220
23799016-5	2013	Celastrol also decreased IkappaB phosphorylation and degradation and reduced production of inducible nitric oxide synthase (iNOS), nitric oxide (NO) and proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha and IL-6.	celastrol	0-9	interleukin 6	Mus musculus	225-229
23799016-7	2013	The expression of LOX-1 within the atherosclerotic lesions and generation of superoxide in mouse aorta were also significantly reduced by celastrol while the lipid profile was not improved.	celastrol	138-147	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	18-23
23497885-3	2013	Of the non-flavonoid phytochemicals tested, berberine, celastrol, ellagic acid, limonin, oleanolic acid, propyl gallate, sinapic acid and ursolic acid demonstrated significant inhibition of ABCG2-mediated transport.	celastrol	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	190-195
23799016-8	2013	In conclusion, our results show that celastrol inhibits atherosclerotic plaque developing in apoE(-/-) mice via inhibiting LOX-1 and oxidative stress.	celastrol	37-46	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	123-128
23706078-0	2013	Celastrol induces apoptosis of gastric cancer cells by miR-146a inhibition of NF-kappaB activity.	celastrol	0-9	microRNA 146a	Homo sapiens	55-63
23706078-5	2013	Finally, the effect of miR-146a on celastrol-induced anti-tumor activity was assessed using miR-146a inhibitor.	celastrol	35-44	microRNA 146a	Homo sapiens	23-31
23706078-5	2013	Finally, the effect of miR-146a on celastrol-induced anti-tumor activity was assessed using miR-146a inhibitor.	celastrol	35-44	microRNA 146a	Homo sapiens	92-100
23706078-7	2013	Celastrol also reduced IkappaB phosphorylation, nuclear P65 protein levels and NF-kappaB activity.	celastrol	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	56-59
23706078-8	2013	Furthermore, Celastrol could increase miR-146a expression and up-regulation of miR-146a expression could suppress NF-kappaB activity.	celastrol	13-22	microRNA 146a	Homo sapiens	38-46
23706078-9	2013	More important, down-regulation of miR-146a expression can reverse the effect of celastrol on NF-kappaB activity and apoptosis in gastric cancer cells.	celastrol	81-90	microRNA 146a	Homo sapiens	35-43
23706078-10	2013	CONCLUSIONS: In this study, we demonstrated that the effect of celastrol on apoptosis is due to miR-146a inhibition of NF-kappaB activity.	celastrol	63-72	microRNA 146a	Homo sapiens	96-104
23142250-5	2013	RESULTS: Anti-proliferation and apoptotic effects of celastrol were demonstrated by CCK-8 assay, Annexin-V/PI staining method, mitochondrial membrane potential (deltapsim) assay and caspase-3 assay.	celastrol	53-62	annexin A5	Homo sapiens	97-106
23637966-0	2013	Celastrol, an NF-kappaB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice.	celastrol	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	14-23
23637966-4	2013	We investigated the effects of the NF-kappaB inhibitor celastrol in db/db mice.	celastrol	55-64	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	35-44
23637966-7	2013	Celastrol reduced insulin resistance and lipid abnormalities and led to higher plasma adiponectin levels.	celastrol	0-9	adiponectin, C1Q and collagen domain containing	Mus musculus	86-97
23637966-10	2013	Celastrol treatment significantly lowered mesangial expansion and suppressed type IV collagen, PAI-1 and TGFbeta1 expressions in renal tissues.	celastrol	0-9	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	95-100
23637966-10	2013	Celastrol treatment significantly lowered mesangial expansion and suppressed type IV collagen, PAI-1 and TGFbeta1 expressions in renal tissues.	celastrol	0-9	transforming growth factor, beta 1	Mus musculus	105-113
23266469-6	2013	Inhibition of AMPK blocked celastrol-mediated p53 phosphorylation.	celastrol	27-36	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	14-18
23266469-6	2013	Inhibition of AMPK blocked celastrol-mediated p53 phosphorylation.	celastrol	27-36	tumor protein p53	Homo sapiens	46-49
23266469-7	2013	Moreover, celastrol increased the expression of tumor suppressor polo like kinase-2 (PLK-2) in a p53-dependent manner.	celastrol	10-19	polo like kinase 2	Homo sapiens	85-90
23266469-7	2013	Moreover, celastrol increased the expression of tumor suppressor polo like kinase-2 (PLK-2) in a p53-dependent manner.	celastrol	10-19	tumor protein p53	Homo sapiens	97-100
23266469-9	2013	Furthermore, add-back of PLK-2 resulted in an increase in both celastrol-mediated PARP-2 induction and celastrol-induced apoptotic index sub G1 population.	celastrol	63-72	polo like kinase 2	Homo sapiens	25-30
23266469-9	2013	Furthermore, add-back of PLK-2 resulted in an increase in both celastrol-mediated PARP-2 induction and celastrol-induced apoptotic index sub G1 population.	celastrol	63-72	poly(ADP-ribose) polymerase 2	Homo sapiens	82-88
23266469-9	2013	Furthermore, add-back of PLK-2 resulted in an increase in both celastrol-mediated PARP-2 induction and celastrol-induced apoptotic index sub G1 population.	celastrol	103-112	polo like kinase 2	Homo sapiens	25-30
23266469-10	2013	Together, these results suggest that celastrol may have anti-tumor effects on MCF-7 cells via AMPK-induced p53 and PLK-2 pathways.	celastrol	37-46	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	94-98
23266469-10	2013	Together, these results suggest that celastrol may have anti-tumor effects on MCF-7 cells via AMPK-induced p53 and PLK-2 pathways.	celastrol	37-46	tumor protein p53	Homo sapiens	107-110
23266469-10	2013	Together, these results suggest that celastrol may have anti-tumor effects on MCF-7 cells via AMPK-induced p53 and PLK-2 pathways.	celastrol	37-46	polo like kinase 2	Homo sapiens	115-120
23396231-0	2013	Celastrol, an inhibitor of heat shock protein 90beta potently suppresses the expression of matrix metalloproteinases, inducible nitric oxide synthase and cyclooxygenase-2 in primary human osteoarthritic chondrocytes.	celastrol	0-9	nitric oxide synthase 2	Homo sapiens	118-149
23396231-0	2013	Celastrol, an inhibitor of heat shock protein 90beta potently suppresses the expression of matrix metalloproteinases, inducible nitric oxide synthase and cyclooxygenase-2 in primary human osteoarthritic chondrocytes.	celastrol	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	154-170
23396231-6	2013	We found that treatment of primary human osteoarthritic chondrocytes with various concentrations of celastrol resulted in striking decrease in the expression of MMP-1, MMP-3, MMP-13, iNOS-2 and COX-2.	celastrol	100-109	matrix metallopeptidase 1	Homo sapiens	161-166
23396231-6	2013	We found that treatment of primary human osteoarthritic chondrocytes with various concentrations of celastrol resulted in striking decrease in the expression of MMP-1, MMP-3, MMP-13, iNOS-2 and COX-2.	celastrol	100-109	matrix metallopeptidase 3	Homo sapiens	168-173
23396231-6	2013	We found that treatment of primary human osteoarthritic chondrocytes with various concentrations of celastrol resulted in striking decrease in the expression of MMP-1, MMP-3, MMP-13, iNOS-2 and COX-2.	celastrol	100-109	matrix metallopeptidase 13	Homo sapiens	175-181
23396231-6	2013	We found that treatment of primary human osteoarthritic chondrocytes with various concentrations of celastrol resulted in striking decrease in the expression of MMP-1, MMP-3, MMP-13, iNOS-2 and COX-2.	celastrol	100-109	nitric oxide synthase 2	Homo sapiens	183-187
23396231-6	2013	We found that treatment of primary human osteoarthritic chondrocytes with various concentrations of celastrol resulted in striking decrease in the expression of MMP-1, MMP-3, MMP-13, iNOS-2 and COX-2.	celastrol	100-109	prostaglandin-endoperoxide synthase 2	Homo sapiens	194-199
23396231-7	2013	In addition, celastrol treatment of cells also inhibited the activation of nuclear factor-kappa B (NF-kappaB).	celastrol	13-22	nuclear factor kappa B subunit 1	Homo sapiens	75-97
23396231-7	2013	In addition, celastrol treatment of cells also inhibited the activation of nuclear factor-kappa B (NF-kappaB).	celastrol	13-22	nuclear factor kappa B subunit 1	Homo sapiens	99-108
23396231-8	2013	Taken together, we provide evidence that celastrol can protect human chondrocytes by downregulating the expression of MMPs, iNOS and COX-2.	celastrol	41-50	nitric oxide synthase 2	Homo sapiens	124-128
23396231-8	2013	Taken together, we provide evidence that celastrol can protect human chondrocytes by downregulating the expression of MMPs, iNOS and COX-2.	celastrol	41-50	prostaglandin-endoperoxide synthase 2	Homo sapiens	133-138
23266469-0	2013	Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway.	celastrol	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	64-92
23266469-0	2013	Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway.	celastrol	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	94-98
23266469-0	2013	Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway.	celastrol	0-9	tumor protein p53	Homo sapiens	108-111
23266469-0	2013	Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway.	celastrol	0-9	polo like kinase 2	Homo sapiens	132-137
23266469-2	2013	In this study, we found that celastrol suppressed the viability of breast cancer MCF-7 cells in an AMP-activated protein kinase (AMPK)-dependent fashion.	celastrol	29-38	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	99-127
23266469-2	2013	In this study, we found that celastrol suppressed the viability of breast cancer MCF-7 cells in an AMP-activated protein kinase (AMPK)-dependent fashion.	celastrol	29-38	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	129-133
23266469-3	2013	Celastrol also induced an increase in reactive oxygen species (ROS) levels, leading to AMPK phosphorylation.	celastrol	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	87-91
23266469-4	2013	Protein kinase C (PKC) zeta was also shown to play a role in celastrol-induced ROS generation.	celastrol	61-70	protein kinase C zeta	Homo sapiens	0-27
23266469-5	2013	In addition, celastrol increased phosphorylation of the pro-apoptotic effector, p53.	celastrol	13-22	tumor protein p53	Homo sapiens	80-83
22641218-9	2013	Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-beta1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-beta1- and tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB reporter gene activity.	celastrol	0-9	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	13-17
22641218-9	2013	Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-beta1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-beta1- and tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB reporter gene activity.	celastrol	0-9	transforming growth factor beta 1	Homo sapiens	112-121
22641218-9	2013	Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-beta1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-beta1- and tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB reporter gene activity.	celastrol	0-9	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	149-153
22641218-9	2013	Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-beta1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-beta1- and tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB reporter gene activity.	celastrol	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	158-162
22641218-9	2013	Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-beta1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-beta1- and tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB reporter gene activity.	celastrol	0-9	transforming growth factor beta 1	Homo sapiens	186-195
22641218-9	2013	Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-beta1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-beta1- and tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB reporter gene activity.	celastrol	0-9	tumor necrosis factor	Homo sapiens	201-228
22641218-9	2013	Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-beta1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-beta1- and tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB reporter gene activity.	celastrol	0-9	tumor necrosis factor	Homo sapiens	230-239
22641218-10	2013	Celastrol also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and Annexin V markers of apoptosis.	celastrol	0-9	annexin A5	Homo sapiens	91-100
22641218-15	2013	Celastrol highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-beta-NF-kappaB signal pathway.	celastrol	0-9	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	67-71
22641218-15	2013	Celastrol highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-beta-NF-kappaB signal pathway.	celastrol	0-9	transforming growth factor beta 1	Homo sapiens	108-116
23142250-5	2013	RESULTS: Anti-proliferation and apoptotic effects of celastrol were demonstrated by CCK-8 assay, Annexin-V/PI staining method, mitochondrial membrane potential (deltapsim) assay and caspase-3 assay.	celastrol	53-62	caspase 3	Homo sapiens	182-191
22949384-6	2013	The macrophage-conditioned media promoted SMC proliferation and MMP-2 production, which was dampened by 10-100 nM celastrol.	celastrol	114-123	matrix metallopeptidase 2	Homo sapiens	64-69
22865541-8	2013	Here, we demonstrate that celastrol, but not classical heat shock treatment, is effective in inducing a set of neuroprotective Hsps in cultures derived from cerebral cortices, including Hsp70, Hsp27 and Hsp32.	celastrol	26-35	heat shock protein family A (Hsp70) member 4	Homo sapiens	186-191
22865541-8	2013	Here, we demonstrate that celastrol, but not classical heat shock treatment, is effective in inducing a set of neuroprotective Hsps in cultures derived from cerebral cortices, including Hsp70, Hsp27 and Hsp32.	celastrol	26-35	heat shock protein family B (small) member 1	Homo sapiens	193-198
22865541-8	2013	Here, we demonstrate that celastrol, but not classical heat shock treatment, is effective in inducing a set of neuroprotective Hsps in cultures derived from cerebral cortices, including Hsp70, Hsp27 and Hsp32.	celastrol	26-35	heme oxygenase 1	Homo sapiens	203-208
22949384-9	2013	The resistin-induced shedding of integrin beta2/beta3 expression was demoted by celastrol, thereby contributing to the inhibition of collagen matrix-SMC interaction.	celastrol	80-89	integrin subunit beta 2	Homo sapiens	33-47
22949384-9	2013	The resistin-induced shedding of integrin beta2/beta3 expression was demoted by celastrol, thereby contributing to the inhibition of collagen matrix-SMC interaction.	celastrol	80-89	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	48-53
22949384-10	2013	Next, resistin-induced Toll-like receptor-4 (TLR-4) expression was abrogated by celastrol, indicating that TLR-4 was the resistin signaling receptor that was blocked by celastrol.	celastrol	80-89	toll like receptor 4	Homo sapiens	23-43
22949384-10	2013	Next, resistin-induced Toll-like receptor-4 (TLR-4) expression was abrogated by celastrol, indicating that TLR-4 was the resistin signaling receptor that was blocked by celastrol.	celastrol	80-89	toll like receptor 4	Homo sapiens	45-50
22949384-10	2013	Next, resistin-induced Toll-like receptor-4 (TLR-4) expression was abrogated by celastrol, indicating that TLR-4 was the resistin signaling receptor that was blocked by celastrol.	celastrol	80-89	toll like receptor 4	Homo sapiens	107-112
22949384-10	2013	Next, resistin-induced Toll-like receptor-4 (TLR-4) expression was abrogated by celastrol, indicating that TLR-4 was the resistin signaling receptor that was blocked by celastrol.	celastrol	169-178	toll like receptor 4	Homo sapiens	23-43
22949384-10	2013	Next, resistin-induced Toll-like receptor-4 (TLR-4) expression was abrogated by celastrol, indicating that TLR-4 was the resistin signaling receptor that was blocked by celastrol.	celastrol	169-178	toll like receptor 4	Homo sapiens	45-50
22949384-10	2013	Next, resistin-induced Toll-like receptor-4 (TLR-4) expression was abrogated by celastrol, indicating that TLR-4 was the resistin signaling receptor that was blocked by celastrol.	celastrol	169-178	toll like receptor 4	Homo sapiens	107-112
23711145-6	2013	Flow cytometry analysis with PI and Annexin V revealed that celastrol induced RA-FLS cell cycle arrest in the G2/M phase and apoptosis.	celastrol	60-69	annexin A5	Homo sapiens	36-45
23711145-7	2013	Furthermore, celastrol dramatically increased expression of Bax/Bcl-2, proteolytic cleavage of Caspase-3, -9, PARP, and decreased expression of FasR.	celastrol	13-22	BCL2 associated X, apoptosis regulator	Homo sapiens	60-63
23711145-7	2013	Furthermore, celastrol dramatically increased expression of Bax/Bcl-2, proteolytic cleavage of Caspase-3, -9, PARP, and decreased expression of FasR.	celastrol	13-22	BCL2 apoptosis regulator	Homo sapiens	64-69
23711145-7	2013	Furthermore, celastrol dramatically increased expression of Bax/Bcl-2, proteolytic cleavage of Caspase-3, -9, PARP, and decreased expression of FasR.	celastrol	13-22	caspase 3	Homo sapiens	95-108
23711145-7	2013	Furthermore, celastrol dramatically increased expression of Bax/Bcl-2, proteolytic cleavage of Caspase-3, -9, PARP, and decreased expression of FasR.	celastrol	13-22	collagen type XI alpha 2 chain	Homo sapiens	110-114
22954486-0	2012	Celastrol inhibits interleukin-17A-stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF-kappaB-mediated matrix metalloproteinase-9 expression.	celastrol	0-9	interleukin 17A	Homo sapiens	19-34
23988648-0	2013	miR-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells.	celastrol	24-33	microRNA 224	Homo sapiens	0-7
23988648-3	2013	Next, we assessed the effect of celastrol on NF-kappaB transcriptional activity in hepatocellular carcinoma cells using western blot and luciferase reporter assay.	celastrol	32-41	nuclear factor kappa B subunit 1	Homo sapiens	45-54
23988648-8	2013	Finally, we evaluated the effect of miR-224 on celastrol-induced anti-tumor activity using miR-224 precursor.	celastrol	47-56	microRNA 224	Homo sapiens	36-43
23988648-9	2013	RESULTS: Celastrol significantly impaired migration and invasion of HepG2 cells and inhibited the activation of NF-kappaB and Akt in dose-dependent manner.	celastrol	9-18	nuclear factor kappa B subunit 1	Homo sapiens	112-121
23988648-9	2013	RESULTS: Celastrol significantly impaired migration and invasion of HepG2 cells and inhibited the activation of NF-kappaB and Akt in dose-dependent manner.	celastrol	9-18	AKT serine/threonine kinase 1	Homo sapiens	126-129
23988648-10	2013	IGF (the strong stimulator of Akt) inhibited the transcriptional activity of NF-kappaB in cells treated with celastrol.	celastrol	109-118	AKT serine/threonine kinase 1	Homo sapiens	30-33
23988648-10	2013	IGF (the strong stimulator of Akt) inhibited the transcriptional activity of NF-kappaB in cells treated with celastrol.	celastrol	109-118	nuclear factor kappa B subunit 1	Homo sapiens	77-86
23988648-11	2013	Besides, celastrol efficiently decreased the expression of miR-224 and protein expression of MMP-2 and MMP-9.	celastrol	9-18	microRNA 224	Homo sapiens	59-66
23988648-11	2013	Besides, celastrol efficiently decreased the expression of miR-224 and protein expression of MMP-2 and MMP-9.	celastrol	9-18	matrix metallopeptidase 2	Homo sapiens	93-98
23988648-11	2013	Besides, celastrol efficiently decreased the expression of miR-224 and protein expression of MMP-2 and MMP-9.	celastrol	9-18	matrix metallopeptidase 9	Homo sapiens	103-108
23988648-12	2013	ChIP-qPCR showed that p65/NF-kappaB binding to the miR-224 promoter sharply decreased after exposure to celastrol in time-dependent manner.	celastrol	104-113	RELA proto-oncogene, NF-kB subunit	Homo sapiens	22-25
23988648-12	2013	ChIP-qPCR showed that p65/NF-kappaB binding to the miR-224 promoter sharply decreased after exposure to celastrol in time-dependent manner.	celastrol	104-113	nuclear factor kappa B subunit 1	Homo sapiens	26-35
23988648-12	2013	ChIP-qPCR showed that p65/NF-kappaB binding to the miR-224 promoter sharply decreased after exposure to celastrol in time-dependent manner.	celastrol	104-113	microRNA 224	Homo sapiens	51-58
23988648-14	2013	Most importantly, miR-224 precursor can reverse the effect of celastrol on impairment of migration and invasion in HepG2 and Huh7 cells.	celastrol	62-71	microRNA 224	Homo sapiens	18-25
23988648-15	2013	CONCLUSION: Celastrol treatment inhibits migration and invasion of HCC cell and that the effect is partly due to NF-kappaB regulating miR-224 expression.	celastrol	12-21	nuclear factor kappa B subunit 1	Homo sapiens	113-122
23988648-15	2013	CONCLUSION: Celastrol treatment inhibits migration and invasion of HCC cell and that the effect is partly due to NF-kappaB regulating miR-224 expression.	celastrol	12-21	microRNA 224	Homo sapiens	134-141
23554889-0	2013	Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-kappaB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer.	celastrol	0-9	ETS transcription factor ERG	Homo sapiens	63-66
23554889-0	2013	Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-kappaB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer.	celastrol	0-9	transmembrane serine protease 2	Homo sapiens	88-95
23554889-0	2013	Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-kappaB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer.	celastrol	0-9	ETS transcription factor ERG	Homo sapiens	96-99
23554889-8	2013	Our results show Celastrol can significantly inhibit the growth of T/E fusion expressing PCa cells both in vitro and in vivo through targeting three critical signaling pathways: AR, ERG and NF-kB in these cells.	celastrol	17-26	ETS transcription factor ERG	Homo sapiens	182-185
23065091-0	2012	Celastrol inhibits growth and induces apoptotic cell death in melanoma cells via the activation ROS-dependent mitochondrial pathway and the suppression of PI3K/AKT signaling.	celastrol	0-9	thymoma viral proto-oncogene 1	Mus musculus	160-163
23065091-4	2012	Pretreatment with caspase inhibitor modestly attenuated the celastrol-induced increase in PARP cleavage and sub-G1 cell population, implying that caspases play a partial role in celastrol-induced apoptosis.	celastrol	60-69	poly (ADP-ribose) polymerase family, member 1	Mus musculus	90-94
23065091-4	2012	Pretreatment with caspase inhibitor modestly attenuated the celastrol-induced increase in PARP cleavage and sub-G1 cell population, implying that caspases play a partial role in celastrol-induced apoptosis.	celastrol	178-187	poly (ADP-ribose) polymerase family, member 1	Mus musculus	90-94
23065091-6	2012	Blocking of ROS accumulation with ROS scavengers resulted in inhibition of celastrol-induced Bcl-2 family-mediated apoptosis, indicating that celastrol-induced apoptosis involves ROS generation as well as an increase in the Bax/Bcl-2 ratio leading to release of cytochrome c and AIF.	celastrol	75-84	B cell leukemia/lymphoma 2	Mus musculus	93-98
23065091-6	2012	Blocking of ROS accumulation with ROS scavengers resulted in inhibition of celastrol-induced Bcl-2 family-mediated apoptosis, indicating that celastrol-induced apoptosis involves ROS generation as well as an increase in the Bax/Bcl-2 ratio leading to release of cytochrome c and AIF.	celastrol	75-84	BCL2-associated X protein	Mus musculus	224-227
23065091-6	2012	Blocking of ROS accumulation with ROS scavengers resulted in inhibition of celastrol-induced Bcl-2 family-mediated apoptosis, indicating that celastrol-induced apoptosis involves ROS generation as well as an increase in the Bax/Bcl-2 ratio leading to release of cytochrome c and AIF.	celastrol	75-84	B cell leukemia/lymphoma 2	Mus musculus	228-233
23065091-6	2012	Blocking of ROS accumulation with ROS scavengers resulted in inhibition of celastrol-induced Bcl-2 family-mediated apoptosis, indicating that celastrol-induced apoptosis involves ROS generation as well as an increase in the Bax/Bcl-2 ratio leading to release of cytochrome c and AIF.	celastrol	75-84	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	279-282
23065091-6	2012	Blocking of ROS accumulation with ROS scavengers resulted in inhibition of celastrol-induced Bcl-2 family-mediated apoptosis, indicating that celastrol-induced apoptosis involves ROS generation as well as an increase in the Bax/Bcl-2 ratio leading to release of cytochrome c and AIF.	celastrol	142-151	B cell leukemia/lymphoma 2	Mus musculus	93-98
23065091-6	2012	Blocking of ROS accumulation with ROS scavengers resulted in inhibition of celastrol-induced Bcl-2 family-mediated apoptosis, indicating that celastrol-induced apoptosis involves ROS generation as well as an increase in the Bax/Bcl-2 ratio leading to release of cytochrome c and AIF.	celastrol	142-151	BCL2-associated X protein	Mus musculus	224-227
23065091-6	2012	Blocking of ROS accumulation with ROS scavengers resulted in inhibition of celastrol-induced Bcl-2 family-mediated apoptosis, indicating that celastrol-induced apoptosis involves ROS generation as well as an increase in the Bax/Bcl-2 ratio leading to release of cytochrome c and AIF.	celastrol	142-151	B cell leukemia/lymphoma 2	Mus musculus	228-233
23065091-6	2012	Blocking of ROS accumulation with ROS scavengers resulted in inhibition of celastrol-induced Bcl-2 family-mediated apoptosis, indicating that celastrol-induced apoptosis involves ROS generation as well as an increase in the Bax/Bcl-2 ratio leading to release of cytochrome c and AIF.	celastrol	142-151	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	279-282
23065091-7	2012	Importantly, silencing of AIF by transfection of siAIF into cells remarkably attenuated celastrol-induced apoptotic cell death.	celastrol	88-97	apoptosis-inducing factor, mitochondrion-associated 1	Mus musculus	26-29
23065091-8	2012	Moreover, celastrol inhibited the activation of PI3K/AKT/mTOR signaling cascade in B16 cells.	celastrol	10-19	thymoma viral proto-oncogene 1	Mus musculus	53-56
23065091-8	2012	Moreover, celastrol inhibited the activation of PI3K/AKT/mTOR signaling cascade in B16 cells.	celastrol	10-19	mechanistic target of rapamycin kinase	Mus musculus	57-61
23065091-9	2012	Our data reveal that celastrol inhibits growth and induces apoptosis in melanoma cells via the activation of ROS-mediated caspase-dependent and -independent pathways and the suppression of PI3K/AKT signaling.	celastrol	21-30	thymoma viral proto-oncogene 1	Mus musculus	194-197
22954486-0	2012	Celastrol inhibits interleukin-17A-stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF-kappaB-mediated matrix metalloproteinase-9 expression.	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	131-140
22954486-0	2012	Celastrol inhibits interleukin-17A-stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF-kappaB-mediated matrix metalloproteinase-9 expression.	celastrol	0-9	matrix metallopeptidase 9	Homo sapiens	150-176
22954486-6	2012	Results showed that treatment of RA-FLSs with celastrol suppressed the IL-17A-induced migration and invasion abilities of the cells.	celastrol	46-55	interleukin 17A	Homo sapiens	71-77
22954486-7	2012	In addition, celastrol inhibited IL-17A-induced matrix metalloproteinase (MMP)-9 mRNA and protein expression, and the proteolytic activity of MMP-9 in RA-FLSs.	celastrol	13-22	interleukin 17A	Homo sapiens	33-39
22954486-7	2012	In addition, celastrol inhibited IL-17A-induced matrix metalloproteinase (MMP)-9 mRNA and protein expression, and the proteolytic activity of MMP-9 in RA-FLSs.	celastrol	13-22	matrix metallopeptidase 9	Homo sapiens	48-80
22954486-7	2012	In addition, celastrol inhibited IL-17A-induced matrix metalloproteinase (MMP)-9 mRNA and protein expression, and the proteolytic activity of MMP-9 in RA-FLSs.	celastrol	13-22	matrix metallopeptidase 9	Homo sapiens	142-147
22954486-8	2012	Furthermore, our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the binding activity of nuclear factor-kappaB (NF-kappaB) in the MMP-9 promoter, and inhibited IkappaBalpha phosphorylation and nuclear translocation of NF-kappaB.	celastrol	39-48	matrix metallopeptidase 9	Homo sapiens	91-96
22954486-8	2012	Furthermore, our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the binding activity of nuclear factor-kappaB (NF-kappaB) in the MMP-9 promoter, and inhibited IkappaBalpha phosphorylation and nuclear translocation of NF-kappaB.	celastrol	39-48	nuclear factor kappa B subunit 1	Homo sapiens	139-160
22954486-8	2012	Furthermore, our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the binding activity of nuclear factor-kappaB (NF-kappaB) in the MMP-9 promoter, and inhibited IkappaBalpha phosphorylation and nuclear translocation of NF-kappaB.	celastrol	39-48	nuclear factor kappa B subunit 1	Homo sapiens	162-171
22954486-8	2012	Furthermore, our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the binding activity of nuclear factor-kappaB (NF-kappaB) in the MMP-9 promoter, and inhibited IkappaBalpha phosphorylation and nuclear translocation of NF-kappaB.	celastrol	39-48	matrix metallopeptidase 9	Homo sapiens	180-185
22954486-8	2012	Furthermore, our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the binding activity of nuclear factor-kappaB (NF-kappaB) in the MMP-9 promoter, and inhibited IkappaBalpha phosphorylation and nuclear translocation of NF-kappaB.	celastrol	39-48	NFKB inhibitor alpha	Homo sapiens	210-222
22954486-8	2012	Furthermore, our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the binding activity of nuclear factor-kappaB (NF-kappaB) in the MMP-9 promoter, and inhibited IkappaBalpha phosphorylation and nuclear translocation of NF-kappaB.	celastrol	39-48	nuclear factor kappa B subunit 1	Homo sapiens	268-277
22954486-9	2012	In conclusion, celastrol can inhibit IL-17A-induced migration and invasion by suppressing NF-kappaB-mediated MMP-9 expression in RA-FLSs.	celastrol	15-24	interleukin 17A	Homo sapiens	37-43
22954486-9	2012	In conclusion, celastrol can inhibit IL-17A-induced migration and invasion by suppressing NF-kappaB-mediated MMP-9 expression in RA-FLSs.	celastrol	15-24	nuclear factor kappa B subunit 1	Homo sapiens	90-99
22954486-9	2012	In conclusion, celastrol can inhibit IL-17A-induced migration and invasion by suppressing NF-kappaB-mediated MMP-9 expression in RA-FLSs.	celastrol	15-24	matrix metallopeptidase 9	Homo sapiens	109-114
23272499-0	2012	[Effects of tripterine on NF-kappaB and eotaxin in nasal mucosa of allergic rhinitis rat].	celastrol	12-22	C-C motif chemokine ligand 11	Rattus norvegicus	40-47
23272499-1	2012	OBJECTIVE: To investigate the relationship among the expressions of NF-kappaB, Eotaxin and the effects of tripterine in nasal mucosa of allergic rhinitis rat and to discuss the possible mechanism of tripterine on allergic rhinitis.	celastrol	199-209	C-C motif chemokine ligand 11	Rattus norvegicus	79-86
23272499-12	2012	CONCLUSION: Tripterine can inhibit expression of Eotaxin by restraining the activation of NF-kappaB.	celastrol	12-22	C-C motif chemokine ligand 11	Rattus norvegicus	49-56
22380712-8	2012	This led to the synthesis of biotinylated celastrols (23 and 24) that were used as affinity reagents in extracts of human Panc-1 cells to identify Annexin II, eEF1A, and beta-tubulin as potential targets of celastrol.	celastrol	42-52	annexin A2	Homo sapiens	147-157
22854193-9	2012	Celastrol-treated rats showed a significant reduction in the levels of chemokines (RANTES, MCP-1, MIP-1alpha, and GRO/KC) as well as cytokines (TNF-alpha and IL-1beta) that induce them, compared to the vehicle-treated rats.	celastrol	0-9	C-C motif chemokine ligand 5	Rattus norvegicus	83-89
22854193-9	2012	Celastrol-treated rats showed a significant reduction in the levels of chemokines (RANTES, MCP-1, MIP-1alpha, and GRO/KC) as well as cytokines (TNF-alpha and IL-1beta) that induce them, compared to the vehicle-treated rats.	celastrol	0-9	mast cell protease 1-like 1	Rattus norvegicus	91-96
22854193-9	2012	Celastrol-treated rats showed a significant reduction in the levels of chemokines (RANTES, MCP-1, MIP-1alpha, and GRO/KC) as well as cytokines (TNF-alpha and IL-1beta) that induce them, compared to the vehicle-treated rats.	celastrol	0-9	C-C motif chemokine ligand 3	Rattus norvegicus	98-108
22854193-9	2012	Celastrol-treated rats showed a significant reduction in the levels of chemokines (RANTES, MCP-1, MIP-1alpha, and GRO/KC) as well as cytokines (TNF-alpha and IL-1beta) that induce them, compared to the vehicle-treated rats.	celastrol	0-9	tumor necrosis factor	Rattus norvegicus	144-153
22854193-9	2012	Celastrol-treated rats showed a significant reduction in the levels of chemokines (RANTES, MCP-1, MIP-1alpha, and GRO/KC) as well as cytokines (TNF-alpha and IL-1beta) that induce them, compared to the vehicle-treated rats.	celastrol	0-9	interleukin 1 beta	Rattus norvegicus	158-166
22380712-8	2012	This led to the synthesis of biotinylated celastrols (23 and 24) that were used as affinity reagents in extracts of human Panc-1 cells to identify Annexin II, eEF1A, and beta-tubulin as potential targets of celastrol.	celastrol	42-51	annexin A2	Homo sapiens	147-157
22380712-8	2012	This led to the synthesis of biotinylated celastrols (23 and 24) that were used as affinity reagents in extracts of human Panc-1 cells to identify Annexin II, eEF1A, and beta-tubulin as potential targets of celastrol.	celastrol	42-51	eukaryotic translation elongation factor 1 alpha 1	Homo sapiens	159-164
22877649-0	2012	Beta-catenin mediates the apoptosis induction effect of celastrol in HT29 cells.	celastrol	56-65	catenin beta 1	Homo sapiens	0-12
22877649-1	2012	AIM: We evaluated the apoptosis induction effects of celastrol in human colorectal cancer cell line HT29 in WNT/beta-catenin pathway.	celastrol	53-62	catenin beta 1	Homo sapiens	112-124
22877649-7	2012	Celastrol induced HT29 cells apoptosis, and increased the nuclear translocation of beta-catenin.	celastrol	0-9	catenin beta 1	Homo sapiens	83-95
22877649-8	2012	Apoptosis induction effects of celastrol were significantly attenuated by beta-catenin siRNA transfection.	celastrol	31-40	catenin beta 1	Homo sapiens	74-86
22877649-10	2012	Beta-catenin siRNA significantly inhibited the expression of Bax and Bcl-2 in celastrol-treated HT29 cells.	celastrol	78-87	catenin beta 1	Homo sapiens	0-12
22877649-10	2012	Beta-catenin siRNA significantly inhibited the expression of Bax and Bcl-2 in celastrol-treated HT29 cells.	celastrol	78-87	BCL2 associated X, apoptosis regulator	Homo sapiens	61-64
22877649-10	2012	Beta-catenin siRNA significantly inhibited the expression of Bax and Bcl-2 in celastrol-treated HT29 cells.	celastrol	78-87	BCL2 apoptosis regulator	Homo sapiens	69-74
22877649-11	2012	SIGNIFICANCE: Beta-catenin mediates the apoptosis induction effects of celastrol in HT29 cells.	celastrol	71-80	catenin beta 1	Homo sapiens	14-26
22683631-0	2012	Celastrol inhibits vasculogenesis by suppressing the VEGF-induced functional activity of bone marrow-derived endothelial progenitor cells.	celastrol	0-9	vascular endothelial growth factor A	Homo sapiens	53-57
22683631-3	2012	The aims of this study are to investigate the effects of Celastrol on VEGF-induced functional activity of BM-EPCs and to identify any mechanisms associated with this process.	celastrol	57-66	vascular endothelial growth factor A	Homo sapiens	70-74
22683631-4	2012	Here, we show that Celastrol attenuates VEGF secretion in BM-EPCs in vitro.	celastrol	19-28	vascular endothelial growth factor A	Homo sapiens	40-44
22683631-6	2012	Additionally, Celastrol inhibits the phosphorylation of VEGFR2, endothelial nitric oxide synthase (eNOS), and Akt to attenuate cell functions.	celastrol	14-23	kinase insert domain receptor	Homo sapiens	56-62
22683631-6	2012	Additionally, Celastrol inhibits the phosphorylation of VEGFR2, endothelial nitric oxide synthase (eNOS), and Akt to attenuate cell functions.	celastrol	14-23	nitric oxide synthase 3	Homo sapiens	64-97
22683631-6	2012	Additionally, Celastrol inhibits the phosphorylation of VEGFR2, endothelial nitric oxide synthase (eNOS), and Akt to attenuate cell functions.	celastrol	14-23	AKT serine/threonine kinase 1	Homo sapiens	110-113
22683631-7	2012	Taken together, the present study demonstrates that Celastrol decreases Akt/eNOS signaling in BM-EPCs in vitro.	celastrol	52-61	AKT serine/threonine kinase 1	Homo sapiens	72-75
22380712-8	2012	This led to the synthesis of biotinylated celastrols (23 and 24) that were used as affinity reagents in extracts of human Panc-1 cells to identify Annexin II, eEF1A, and beta-tubulin as potential targets of celastrol.	celastrol	42-52	eukaryotic translation elongation factor 1 alpha 1	Homo sapiens	159-164
22334592-0	2012	Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells.	celastrol	0-9	fibroblast growth factor receptor 3	Homo sapiens	50-85
21866552-0	2012	Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90.	celastrol	65-74	heat shock protein 90 alpha family class A member 1	Homo sapiens	139-144
21866552-5	2012	Furthermore, MAPK pathways were activated by celastrol and inhibitors of MEK and p38 pathways could prevent the formation of cytoplasmic vacuolization.	celastrol	45-54	mitogen-activated protein kinase 14	Homo sapiens	81-84
21866552-10	2012	The potency of celastrol to induce paraptosis, apoptosis and autophagy at the same dose might be related to its capability to affect a variety of pathways including proteasome, ER stress and Hsp90.	celastrol	15-24	heat shock protein 90 alpha family class A member 1	Homo sapiens	191-196
22369852-5	2012	We observed that celastrol inhibited both constitutive and inducible STAT3 activation, and the suppression was mediated through the inhibition of activation of upstream kinases c-Src, as well as Janus-activated kinase-1 and -2.	celastrol	17-26	signal transducer and activator of transcription 3	Homo sapiens	69-74
22369852-5	2012	We observed that celastrol inhibited both constitutive and inducible STAT3 activation, and the suppression was mediated through the inhibition of activation of upstream kinases c-Src, as well as Janus-activated kinase-1 and -2.	celastrol	17-26	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	177-182
22369852-6	2012	Vanadate treatment reversed the celastrol-induced modulation of STAT3, suggesting the involvement of a tyrosine phosphatase.	celastrol	32-41	signal transducer and activator of transcription 3	Homo sapiens	64-69
22369852-7	2012	The inhibition of STAT3 activation by celastrol led to the suppression of various gene products involved in proliferation, survival, and angiogenesis.	celastrol	38-47	signal transducer and activator of transcription 3	Homo sapiens	18-23
22369852-9	2012	Finally, when administered intraperitoneally, celastrol inhibited STAT3 activation in tumor tissues and the growth of human HCC xenograft tumors in athymic nu/nu mice without any side effects.	celastrol	46-55	signal transducer and activator of transcription 3	Homo sapiens	66-71
22369852-0	2012	Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo.	celastrol	0-9	signal transducer and activator of transcription 3	Homo sapiens	110-115
22369852-0	2012	Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo.	celastrol	0-9	Janus kinase 2	Homo sapiens	116-120
22369852-10	2012	Overall, our results suggest for the first time that celastrol exerts its antiproliferative and proapoptotic effects through suppression of STAT3 signaling in HCC both in vitro and in vivo.	celastrol	53-62	signal transducer and activator of transcription 3	Homo sapiens	140-145
22334592-0	2012	Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells.	celastrol	0-9	fibroblast growth factor receptor 3	Homo sapiens	87-92
21683142-0	2011	Celastrol regulates innate immunity response via NF-kappaB and Hsp70 in human retinal pigment epithelial cells.	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	49-58
23284992-5	2012	In addition, our study unraveled that, upon Celastrol exposure, the activation of endoplasmic reticulum (ER) stress, specifically, the eIF2alpha-ATF4 pathway played indispensable roles in the activation of Noxa, which was validated by the observation that depletion of ATF4 significantly abrogated the Noxa elevation by Celastrol.	celastrol	44-53	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	302-306
23284992-5	2012	In addition, our study unraveled that, upon Celastrol exposure, the activation of endoplasmic reticulum (ER) stress, specifically, the eIF2alpha-ATF4 pathway played indispensable roles in the activation of Noxa, which was validated by the observation that depletion of ATF4 significantly abrogated the Noxa elevation by Celastrol.	celastrol	320-329	activating transcription factor 4	Homo sapiens	145-149
23284992-5	2012	In addition, our study unraveled that, upon Celastrol exposure, the activation of endoplasmic reticulum (ER) stress, specifically, the eIF2alpha-ATF4 pathway played indispensable roles in the activation of Noxa, which was validated by the observation that depletion of ATF4 significantly abrogated the Noxa elevation by Celastrol.	celastrol	320-329	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	206-210
23284992-6	2012	Our findings highlight a novel signaling pathway through which Celastrol increase Noxa expression, and suggest the potential use of ATF4-mediated regulation of Noxa as a promising strategy to improve the anti-cancer activities of ABT-737.	celastrol	63-72	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	82-86
22087583-0	2011	Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrol.	celastrol	69-78	heat shock protein 90 alpha family class A member 1	Homo sapiens	53-58
22087583-1	2011	Celastrol, an important natural product and Hsp90 inhibitor with a wide range of biological and medical activities and broad use as a biological probe, acts by an as yet undetermined mode of action.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	44-49
21951963-7	2011	Celastrol was found to be capable of inducing apoptosis in HaCaT cells as characterized by phosphatidyl-serine (PS) externalization, depolarization of mitochondrial membrane potential and activation of caspase-3.	celastrol	0-9	caspase 3	Homo sapiens	202-211
21951963-8	2011	The apoptosis induced by celastrol could be suppressed by Z-IETD-FMK and Z-LEHD-FMK, the respective caspase-8 and caspase-9 inhibitor.	celastrol	25-34	caspase 8	Homo sapiens	100-109
21951963-8	2011	The apoptosis induced by celastrol could be suppressed by Z-IETD-FMK and Z-LEHD-FMK, the respective caspase-8 and caspase-9 inhibitor.	celastrol	25-34	caspase 9	Homo sapiens	114-123
21951963-9	2011	In addition, western blot analysis revealed a significant augmentation in the protein expression of Bax and attenuation in Bcl-2, suggesting that the celastrol-induced apoptosis acts through both death receptor and mitochondrial pathways.	celastrol	150-159	BCL2 associated X, apoptosis regulator	Homo sapiens	100-103
21951963-9	2011	In addition, western blot analysis revealed a significant augmentation in the protein expression of Bax and attenuation in Bcl-2, suggesting that the celastrol-induced apoptosis acts through both death receptor and mitochondrial pathways.	celastrol	150-159	BCL2 apoptosis regulator	Homo sapiens	123-128
21506956-0	2011	Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells.	celastrol	0-9	signal transducer and activator of transcription 3	Homo sapiens	105-110
21506956-2	2011	Thus, in the present study, we investigated whether celastrol could suppress the proliferation and induce chemosensitization of MM cells by interfering with NF-kappaB and STAT3 activation pathways.	celastrol	52-61	signal transducer and activator of transcription 3	Homo sapiens	171-176
21506956-7	2011	These effects of celastrol were mediated through suppression of constitutively active NF-kappaB induced by inhibition of IkappaBalpha kinase activation; and the phosphorylation of IkappaBalpha and of p65.	celastrol	17-26	NFKB inhibitor alpha	Homo sapiens	121-133
21506956-7	2011	These effects of celastrol were mediated through suppression of constitutively active NF-kappaB induced by inhibition of IkappaBalpha kinase activation; and the phosphorylation of IkappaBalpha and of p65.	celastrol	17-26	NFKB inhibitor alpha	Homo sapiens	180-192
21506956-7	2011	These effects of celastrol were mediated through suppression of constitutively active NF-kappaB induced by inhibition of IkappaBalpha kinase activation; and the phosphorylation of IkappaBalpha and of p65.	celastrol	17-26	RELA proto-oncogene, NF-kB subunit	Homo sapiens	200-203
21506956-8	2011	Celastrol also inhibited both the constitutive and IL6-induced activation of STAT3, which induced apoptosis as indicated by an increase in the accumulation of cells in the sub-G1 phase, an increase in the expression of pro-apoptotic proteins and activation of caspase-3.	celastrol	0-9	interleukin 6	Homo sapiens	51-54
21506956-8	2011	Celastrol also inhibited both the constitutive and IL6-induced activation of STAT3, which induced apoptosis as indicated by an increase in the accumulation of cells in the sub-G1 phase, an increase in the expression of pro-apoptotic proteins and activation of caspase-3.	celastrol	0-9	signal transducer and activator of transcription 3	Homo sapiens	77-82
21506956-8	2011	Celastrol also inhibited both the constitutive and IL6-induced activation of STAT3, which induced apoptosis as indicated by an increase in the accumulation of cells in the sub-G1 phase, an increase in the expression of pro-apoptotic proteins and activation of caspase-3.	celastrol	0-9	caspase 3	Homo sapiens	260-269
21850367-0	2011	Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-kappaB pathway.	celastrol	28-37	nuclear factor kappa B subunit 1	Homo sapiens	84-93
21850367-11	2011	In addition, we showed that celastrol induces apoptosis of myeloma cells via activation of the caspase-3 and NF-kappaB pathways.	celastrol	28-37	caspase 3	Homo sapiens	95-104
21850367-11	2011	In addition, we showed that celastrol induces apoptosis of myeloma cells via activation of the caspase-3 and NF-kappaB pathways.	celastrol	28-37	nuclear factor kappa B subunit 1	Homo sapiens	109-118
22667125-7	2012	The data from in vitro BIAcore analysis showed that the recombinant PSMB1 could bind to celastrol.	celastrol	88-97	proteasome 20S subunit beta 1	Homo sapiens	68-73
22667125-8	2012	The binding affinity between PSMB1 and 10 micromol/L celastrol was more than 27RU.	celastrol	53-62	proteasome 20S subunit beta 1	Homo sapiens	29-34
23284992-0	2012	Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells.	celastrol	32-41	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	13-17
23284992-3	2012	The current study demonstrated that combining ABT-737 and Celastrol synergistically suppressed HCC cell proliferation, and induced apoptosis which was accompanied with the activation of caspase cascade and release of cytochrome c from mitochondria.	celastrol	58-67	HCC	Homo sapiens	95-98
23284992-3	2012	The current study demonstrated that combining ABT-737 and Celastrol synergistically suppressed HCC cell proliferation, and induced apoptosis which was accompanied with the activation of caspase cascade and release of cytochrome c from mitochondria.	celastrol	58-67	cytochrome c, somatic	Homo sapiens	217-229
23284992-4	2012	Further study revealed that the enhanced Noxa caused by Celastrol was the key factor for the synergy, since small interfering RNA-mediated knockdown of Noxa expression in HCC cells resulted in decreased apoptosis and attenuated anti-proliferative effects of the combination.	celastrol	56-65	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	41-45
23284992-4	2012	Further study revealed that the enhanced Noxa caused by Celastrol was the key factor for the synergy, since small interfering RNA-mediated knockdown of Noxa expression in HCC cells resulted in decreased apoptosis and attenuated anti-proliferative effects of the combination.	celastrol	56-65	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	152-156
23284992-4	2012	Further study revealed that the enhanced Noxa caused by Celastrol was the key factor for the synergy, since small interfering RNA-mediated knockdown of Noxa expression in HCC cells resulted in decreased apoptosis and attenuated anti-proliferative effects of the combination.	celastrol	56-65	HCC	Homo sapiens	171-174
23284992-5	2012	In addition, our study unraveled that, upon Celastrol exposure, the activation of endoplasmic reticulum (ER) stress, specifically, the eIF2alpha-ATF4 pathway played indispensable roles in the activation of Noxa, which was validated by the observation that depletion of ATF4 significantly abrogated the Noxa elevation by Celastrol.	celastrol	44-53	activating transcription factor 4	Homo sapiens	145-149
23284992-5	2012	In addition, our study unraveled that, upon Celastrol exposure, the activation of endoplasmic reticulum (ER) stress, specifically, the eIF2alpha-ATF4 pathway played indispensable roles in the activation of Noxa, which was validated by the observation that depletion of ATF4 significantly abrogated the Noxa elevation by Celastrol.	celastrol	44-53	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	206-210
23284992-5	2012	In addition, our study unraveled that, upon Celastrol exposure, the activation of endoplasmic reticulum (ER) stress, specifically, the eIF2alpha-ATF4 pathway played indispensable roles in the activation of Noxa, which was validated by the observation that depletion of ATF4 significantly abrogated the Noxa elevation by Celastrol.	celastrol	44-53	activating transcription factor 4	Homo sapiens	269-273
21683142-0	2011	Celastrol regulates innate immunity response via NF-kappaB and Hsp70 in human retinal pigment epithelial cells.	celastrol	0-9	heat shock protein family A (Hsp70) member 4	Homo sapiens	63-68
21683142-4	2011	Anti-inflammatory properties of celastrol were determined by measuring expression levels of IL-6 and endogenous NF-kappaB levels during lipopolysaccharide (LPS) exposure by using enzyme-linked immunosorbent assays (ELISA).	celastrol	32-41	interleukin 6	Homo sapiens	92-96
21683142-4	2011	Anti-inflammatory properties of celastrol were determined by measuring expression levels of IL-6 and endogenous NF-kappaB levels during lipopolysaccharide (LPS) exposure by using enzyme-linked immunosorbent assays (ELISA).	celastrol	32-41	nuclear factor kappa B subunit 1	Homo sapiens	112-121
21683142-7	2011	Simultaneous exposures to LPS and celastrol reduced IL-6 expression levels as well as activity of phosphorylated NF-kappaB at serine 536 (Ser536) in ARPE-19 cells when compared to LPS exposure alone.	celastrol	34-43	interleukin 6	Homo sapiens	52-56
21683142-7	2011	Simultaneous exposures to LPS and celastrol reduced IL-6 expression levels as well as activity of phosphorylated NF-kappaB at serine 536 (Ser536) in ARPE-19 cells when compared to LPS exposure alone.	celastrol	34-43	nuclear factor kappa B subunit 1	Homo sapiens	113-122
21683142-8	2011	In addition, inhibition of NF-kappaB RelA/p65 activity by celastrol was attenuated when Hsp70 response was silenced by siRNA.	celastrol	58-67	nuclear factor kappa B subunit 1	Homo sapiens	27-36
21683142-8	2011	In addition, inhibition of NF-kappaB RelA/p65 activity by celastrol was attenuated when Hsp70 response was silenced by siRNA.	celastrol	58-67	RELA proto-oncogene, NF-kB subunit	Homo sapiens	42-45
21683142-8	2011	In addition, inhibition of NF-kappaB RelA/p65 activity by celastrol was attenuated when Hsp70 response was silenced by siRNA.	celastrol	58-67	heat shock protein family A (Hsp70) member 4	Homo sapiens	88-93
21683142-10	2011	Our findings reveal that celastrol is a novel plant compound which suppresses innate immunity response in human retinal pigment epithelial cells via NF-kappaB and Hsp70 regulation, and that Hsp70 is a critical regulator of NF-kappaB.	celastrol	25-34	nuclear factor kappa B subunit 1	Homo sapiens	149-158
21683142-10	2011	Our findings reveal that celastrol is a novel plant compound which suppresses innate immunity response in human retinal pigment epithelial cells via NF-kappaB and Hsp70 regulation, and that Hsp70 is a critical regulator of NF-kappaB.	celastrol	25-34	heat shock protein family A (Hsp70) member 4	Homo sapiens	163-168
21683142-10	2011	Our findings reveal that celastrol is a novel plant compound which suppresses innate immunity response in human retinal pigment epithelial cells via NF-kappaB and Hsp70 regulation, and that Hsp70 is a critical regulator of NF-kappaB.	celastrol	25-34	heat shock protein family A (Hsp70) member 4	Homo sapiens	190-195
21683142-10	2011	Our findings reveal that celastrol is a novel plant compound which suppresses innate immunity response in human retinal pigment epithelial cells via NF-kappaB and Hsp70 regulation, and that Hsp70 is a critical regulator of NF-kappaB.	celastrol	25-34	nuclear factor kappa B subunit 1	Homo sapiens	223-232
21786165-0	2011	Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	142-145
21786165-5	2011	Growth inhibitory effects of celastrol correlated with a decrease in the levels of cyclin D1 and cyclin E, but concomitant increase in the levels of p21 and p27.	celastrol	29-38	cyclin D1	Homo sapiens	83-92
21786165-6	2011	The apoptosis induced by celastrol was indicated by the activation of caspase-8, bid cleavage, caspase-9 activation, caspase-3 activation, PARP cleavage and through the down regulation of anti-apoptototic proteins.	celastrol	25-34	caspase 3	Homo sapiens	117-126
21786165-5	2011	Growth inhibitory effects of celastrol correlated with a decrease in the levels of cyclin D1 and cyclin E, but concomitant increase in the levels of p21 and p27.	celastrol	29-38	H3 histone pseudogene 16	Homo sapiens	149-152
21786165-6	2011	The apoptosis induced by celastrol was indicated by the activation of caspase-8, bid cleavage, caspase-9 activation, caspase-3 activation, PARP cleavage and through the down regulation of anti-apoptototic proteins.	celastrol	25-34	poly(ADP-ribose) polymerase 1	Homo sapiens	139-143
21786165-5	2011	Growth inhibitory effects of celastrol correlated with a decrease in the levels of cyclin D1 and cyclin E, but concomitant increase in the levels of p21 and p27.	celastrol	29-38	interferon alpha inducible protein 27	Homo sapiens	157-160
21786165-7	2011	The apoptotic effects of celastrol were preceded by activation of JNK and down-regulation of Akt activation.	celastrol	25-34	mitogen-activated protein kinase 8	Homo sapiens	66-69
21786165-7	2011	The apoptotic effects of celastrol were preceded by activation of JNK and down-regulation of Akt activation.	celastrol	25-34	AKT serine/threonine kinase 1	Homo sapiens	93-96
21786165-6	2011	The apoptosis induced by celastrol was indicated by the activation of caspase-8, bid cleavage, caspase-9 activation, caspase-3 activation, PARP cleavage and through the down regulation of anti-apoptototic proteins.	celastrol	25-34	caspase 8	Homo sapiens	70-79
21786165-8	2011	JNK was needed for celastrol-induced apoptosis, and inhibition of JNK by pharmacological inhibitor abolished the apoptotic effects.	celastrol	19-28	mitogen-activated protein kinase 8	Homo sapiens	0-3
21786165-8	2011	JNK was needed for celastrol-induced apoptosis, and inhibition of JNK by pharmacological inhibitor abolished the apoptotic effects.	celastrol	19-28	mitogen-activated protein kinase 8	Homo sapiens	66-69
21786165-6	2011	The apoptosis induced by celastrol was indicated by the activation of caspase-8, bid cleavage, caspase-9 activation, caspase-3 activation, PARP cleavage and through the down regulation of anti-apoptototic proteins.	celastrol	25-34	BH3 interacting domain death agonist	Homo sapiens	81-84
21786165-9	2011	Overall, our results indicate that celastrol can inhibit cell proliferation and induce apoptosis through the activation of JNK, suppression of Akt, and down-regulation of anti-apoptotic protein expression.	celastrol	35-44	mitogen-activated protein kinase 8	Homo sapiens	123-126
21786165-9	2011	Overall, our results indicate that celastrol can inhibit cell proliferation and induce apoptosis through the activation of JNK, suppression of Akt, and down-regulation of anti-apoptotic protein expression.	celastrol	35-44	AKT serine/threonine kinase 1	Homo sapiens	143-146
21786165-6	2011	The apoptosis induced by celastrol was indicated by the activation of caspase-8, bid cleavage, caspase-9 activation, caspase-3 activation, PARP cleavage and through the down regulation of anti-apoptototic proteins.	celastrol	25-34	caspase 9	Homo sapiens	95-104
21501142-5	2011	KEY RESULTS: Low concentrations of celastrol completely inhibited NOX1, NOX2, NOX4 and NOX5 within minutes with concentration-response curves exhibiting higher Hill coefficients and lower IC50 values for NOX1 and NOX2 compared with NOX4 and NOX5, suggesting differences in their mode of action.	celastrol	35-44	NADPH oxidase 1	Homo sapiens	66-70
21501142-5	2011	KEY RESULTS: Low concentrations of celastrol completely inhibited NOX1, NOX2, NOX4 and NOX5 within minutes with concentration-response curves exhibiting higher Hill coefficients and lower IC50 values for NOX1 and NOX2 compared with NOX4 and NOX5, suggesting differences in their mode of action.	celastrol	35-44	cytochrome b-245 beta chain	Homo sapiens	72-76
21501142-5	2011	KEY RESULTS: Low concentrations of celastrol completely inhibited NOX1, NOX2, NOX4 and NOX5 within minutes with concentration-response curves exhibiting higher Hill coefficients and lower IC50 values for NOX1 and NOX2 compared with NOX4 and NOX5, suggesting differences in their mode of action.	celastrol	35-44	NADPH oxidase 4	Homo sapiens	78-82
21501142-5	2011	KEY RESULTS: Low concentrations of celastrol completely inhibited NOX1, NOX2, NOX4 and NOX5 within minutes with concentration-response curves exhibiting higher Hill coefficients and lower IC50 values for NOX1 and NOX2 compared with NOX4 and NOX5, suggesting differences in their mode of action.	celastrol	35-44	NADPH oxidase 5	Homo sapiens	87-91
21501142-5	2011	KEY RESULTS: Low concentrations of celastrol completely inhibited NOX1, NOX2, NOX4 and NOX5 within minutes with concentration-response curves exhibiting higher Hill coefficients and lower IC50 values for NOX1 and NOX2 compared with NOX4 and NOX5, suggesting differences in their mode of action.	celastrol	35-44	NADPH oxidase 1	Homo sapiens	204-208
21501142-5	2011	KEY RESULTS: Low concentrations of celastrol completely inhibited NOX1, NOX2, NOX4 and NOX5 within minutes with concentration-response curves exhibiting higher Hill coefficients and lower IC50 values for NOX1 and NOX2 compared with NOX4 and NOX5, suggesting differences in their mode of action.	celastrol	35-44	cytochrome b-245 beta chain	Homo sapiens	213-217
21501142-5	2011	KEY RESULTS: Low concentrations of celastrol completely inhibited NOX1, NOX2, NOX4 and NOX5 within minutes with concentration-response curves exhibiting higher Hill coefficients and lower IC50 values for NOX1 and NOX2 compared with NOX4 and NOX5, suggesting differences in their mode of action.	celastrol	35-44	NADPH oxidase 4	Homo sapiens	232-236
21501142-5	2011	KEY RESULTS: Low concentrations of celastrol completely inhibited NOX1, NOX2, NOX4 and NOX5 within minutes with concentration-response curves exhibiting higher Hill coefficients and lower IC50 values for NOX1 and NOX2 compared with NOX4 and NOX5, suggesting differences in their mode of action.	celastrol	35-44	NADPH oxidase 5	Homo sapiens	241-245
21501142-6	2011	In a cell-free system, celastrol had an IC50 of 1.24 and 8.4 microM for NOX2 and NOX5, respectively.	celastrol	23-32	cytochrome b-245 beta chain	Homo sapiens	72-76
21501142-6	2011	In a cell-free system, celastrol had an IC50 of 1.24 and 8.4 microM for NOX2 and NOX5, respectively.	celastrol	23-32	NADPH oxidase 5	Homo sapiens	81-85
21501142-8	2011	Celastrol bound to a recombinant p47(phox) and disrupted the binding of the proline rich region of p22(phox) to the tandem SH3 domain of p47(phox) and NOXO1, the cytosolic subunits of NOX2 and NOX1, respectively.	celastrol	0-9	pleckstrin	Homo sapiens	33-36
21501142-8	2011	Celastrol bound to a recombinant p47(phox) and disrupted the binding of the proline rich region of p22(phox) to the tandem SH3 domain of p47(phox) and NOXO1, the cytosolic subunits of NOX2 and NOX1, respectively.	celastrol	0-9	pleckstrin	Homo sapiens	37-41
21501142-8	2011	Celastrol bound to a recombinant p47(phox) and disrupted the binding of the proline rich region of p22(phox) to the tandem SH3 domain of p47(phox) and NOXO1, the cytosolic subunits of NOX2 and NOX1, respectively.	celastrol	0-9	calcineurin like EF-hand protein 1	Homo sapiens	99-102
21501142-8	2011	Celastrol bound to a recombinant p47(phox) and disrupted the binding of the proline rich region of p22(phox) to the tandem SH3 domain of p47(phox) and NOXO1, the cytosolic subunits of NOX2 and NOX1, respectively.	celastrol	0-9	pleckstrin	Homo sapiens	103-107
21501142-8	2011	Celastrol bound to a recombinant p47(phox) and disrupted the binding of the proline rich region of p22(phox) to the tandem SH3 domain of p47(phox) and NOXO1, the cytosolic subunits of NOX2 and NOX1, respectively.	celastrol	0-9	pleckstrin	Homo sapiens	33-42
21501142-8	2011	Celastrol bound to a recombinant p47(phox) and disrupted the binding of the proline rich region of p22(phox) to the tandem SH3 domain of p47(phox) and NOXO1, the cytosolic subunits of NOX2 and NOX1, respectively.	celastrol	0-9	NADPH oxidase organizer 1	Homo sapiens	151-156
21501142-8	2011	Celastrol bound to a recombinant p47(phox) and disrupted the binding of the proline rich region of p22(phox) to the tandem SH3 domain of p47(phox) and NOXO1, the cytosolic subunits of NOX2 and NOX1, respectively.	celastrol	0-9	cytochrome b-245 beta chain	Homo sapiens	184-188
21501142-8	2011	Celastrol bound to a recombinant p47(phox) and disrupted the binding of the proline rich region of p22(phox) to the tandem SH3 domain of p47(phox) and NOXO1, the cytosolic subunits of NOX2 and NOX1, respectively.	celastrol	0-9	NADPH oxidase 1	Homo sapiens	193-197
21501142-9	2011	CONCLUSIONS AND IMPLICATIONS: These results demonstrate that celastrol is a potent inhibitor of NOX enzymes in general with increased potency against NOX1 and NOX2.	celastrol	61-70	NADPH oxidase 1	Homo sapiens	150-154
21501142-9	2011	CONCLUSIONS AND IMPLICATIONS: These results demonstrate that celastrol is a potent inhibitor of NOX enzymes in general with increased potency against NOX1 and NOX2.	celastrol	61-70	cytochrome b-245 beta chain	Homo sapiens	159-163
21466843-9	2011	Celastrol also up-regulated the expression of pro-apoptotic Bax, down-regulated anti-apoptotic Bcl-2, and inhibited Akt phosphorylation.	celastrol	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	60-63
21866174-9	2011	HSP32 (also called heme oxygenase-1, HO-1) is the primary mediator of the protective effect of celastrol.	celastrol	95-104	heme oxygenase 1	Mus musculus	0-5
21866174-9	2011	HSP32 (also called heme oxygenase-1, HO-1) is the primary mediator of the protective effect of celastrol.	celastrol	95-104	heme oxygenase 1	Mus musculus	19-35
21866174-9	2011	HSP32 (also called heme oxygenase-1, HO-1) is the primary mediator of the protective effect of celastrol.	celastrol	95-104	heme oxygenase 1	Mus musculus	37-41
21866174-11	2011	Taken together, our data indicate that celastrol inhibits aminoglycoside ototoxicity via HSP32/HO-1 induction.	celastrol	39-48	heme oxygenase 1	Mus musculus	89-94
21866174-11	2011	Taken together, our data indicate that celastrol inhibits aminoglycoside ototoxicity via HSP32/HO-1 induction.	celastrol	39-48	heme oxygenase 1	Mus musculus	95-99
21466843-9	2011	Celastrol also up-regulated the expression of pro-apoptotic Bax, down-regulated anti-apoptotic Bcl-2, and inhibited Akt phosphorylation.	celastrol	0-9	BCL2 apoptosis regulator	Homo sapiens	95-100
21466843-0	2011	Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways.	celastrol	0-9	Fas ligand	Homo sapiens	113-117
21466843-6	2011	Celastrol induced A549 cells apoptosis as confirmed by annexin V/propidium iodide staining and DNA fragmentation.	celastrol	0-9	annexin A5	Homo sapiens	55-64
21466843-9	2011	Celastrol also up-regulated the expression of pro-apoptotic Bax, down-regulated anti-apoptotic Bcl-2, and inhibited Akt phosphorylation.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	116-119
21466843-7	2011	Celastrol-induced apoptosis was characterized by cleavage of caspase-9, caspase-8, caspase-3, and PARP protein, increased Fas and FasL expression, and a reduction in the mitochondrial membrane potential.	celastrol	0-9	caspase 9	Homo sapiens	61-70
21466843-10	2011	These results demonstrate that celastrol can induce apoptosis of human NSCLC A549 cells through activation of both mitochondria- and FasL-mediated pathways.	celastrol	31-40	Fas ligand	Homo sapiens	133-137
21466843-7	2011	Celastrol-induced apoptosis was characterized by cleavage of caspase-9, caspase-8, caspase-3, and PARP protein, increased Fas and FasL expression, and a reduction in the mitochondrial membrane potential.	celastrol	0-9	caspase 8	Homo sapiens	72-81
21569548-13	2011	NAC completely inhibited celastrol-induced decrease of HSP90 client proteins, catalase and thioredoxin.	celastrol	25-34	heat shock protein 90 alpha family class A member 1	Homo sapiens	55-60
21466843-7	2011	Celastrol-induced apoptosis was characterized by cleavage of caspase-9, caspase-8, caspase-3, and PARP protein, increased Fas and FasL expression, and a reduction in the mitochondrial membrane potential.	celastrol	0-9	caspase 3	Homo sapiens	83-92
21466843-7	2011	Celastrol-induced apoptosis was characterized by cleavage of caspase-9, caspase-8, caspase-3, and PARP protein, increased Fas and FasL expression, and a reduction in the mitochondrial membrane potential.	celastrol	0-9	collagen type XI alpha 2 chain	Homo sapiens	98-102
21466843-7	2011	Celastrol-induced apoptosis was characterized by cleavage of caspase-9, caspase-8, caspase-3, and PARP protein, increased Fas and FasL expression, and a reduction in the mitochondrial membrane potential.	celastrol	0-9	Fas ligand	Homo sapiens	130-134
21466843-8	2011	Furthermore, celastrol induced the release of cytochrome c.	celastrol	13-22	cytochrome c, somatic	Homo sapiens	46-58
21569548-9	2011	JNK phosphorylation induced by celastrol was suppressed by NAC and JNK inhibitor SP600125 (SP).	celastrol	31-40	mitogen-activated protein kinase 8	Homo sapiens	0-3
21569548-9	2011	JNK phosphorylation induced by celastrol was suppressed by NAC and JNK inhibitor SP600125 (SP).	celastrol	31-40	mitogen-activated protein kinase 8	Homo sapiens	67-70
21569548-13	2011	NAC completely inhibited celastrol-induced decrease of HSP90 client proteins, catalase and thioredoxin.	celastrol	25-34	catalase	Homo sapiens	78-86
21569548-10	2011	Moreover, SP significantly inhibited celastrol-induced loss of MMP, cleavage of PARP, caspase 9 and caspase 3, mitochondrial translocation of Bad, cytoplasmic release of cytochrome c, and cell death.	celastrol	37-46	collagen type XI alpha 2 chain	Homo sapiens	80-84
21569548-13	2011	NAC completely inhibited celastrol-induced decrease of HSP90 client proteins, catalase and thioredoxin.	celastrol	25-34	thioredoxin	Homo sapiens	91-102
21569548-10	2011	Moreover, SP significantly inhibited celastrol-induced loss of MMP, cleavage of PARP, caspase 9 and caspase 3, mitochondrial translocation of Bad, cytoplasmic release of cytochrome c, and cell death.	celastrol	37-46	caspase 9	Homo sapiens	86-95
21569548-10	2011	Moreover, SP significantly inhibited celastrol-induced loss of MMP, cleavage of PARP, caspase 9 and caspase 3, mitochondrial translocation of Bad, cytoplasmic release of cytochrome c, and cell death.	celastrol	37-46	caspase 3	Homo sapiens	100-109
21569548-10	2011	Moreover, SP significantly inhibited celastrol-induced loss of MMP, cleavage of PARP, caspase 9 and caspase 3, mitochondrial translocation of Bad, cytoplasmic release of cytochrome c, and cell death.	celastrol	37-46	cytochrome c, somatic	Homo sapiens	170-182
21569548-17	2011	JNK was activated by celastrol-induced ROS accumulation and then initiated mitochondrial-mediated apoptosis.	celastrol	21-30	mitogen-activated protein kinase 8	Homo sapiens	0-3
21569548-12	2011	Celastrol downregulated HSP90 client proteins but did not disrupt the interaction between HSP90 and cdc37.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	24-29
21569548-18	2011	Celastrol induced the downregulation of HSP90 client proteins through ROS accumulation and facilitated ROS accumulation by inhibiting MRC complex I activity.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	40-45
21414301-0	2011	Celastrol induces expression of heme oxygenase-1 through ROS/Nrf2/ARE signaling in the HaCaT cells.	celastrol	0-9	heme oxygenase 1	Homo sapiens	32-48
21306773-5	2011	Here we exploit a physiological molecular interaction between intercellular adhesion molecule (ICAM)-1 and lymphocyte function associated antigen (LFA)-1 to deliver a potent anti-inflammatory drug, celastrol, specifically and comprehensively to inflamed cells.	celastrol	198-207	intercellular adhesion molecule 1	Homo sapiens	62-102
21306773-5	2011	Here we exploit a physiological molecular interaction between intercellular adhesion molecule (ICAM)-1 and lymphocyte function associated antigen (LFA)-1 to deliver a potent anti-inflammatory drug, celastrol, specifically and comprehensively to inflamed cells.	celastrol	198-207	integrin subunit alpha L	Homo sapiens	107-153
21414301-0	2011	Celastrol induces expression of heme oxygenase-1 through ROS/Nrf2/ARE signaling in the HaCaT cells.	celastrol	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	61-65
21414301-1	2011	We previously demonstrated that celastrol, a quinone methide triterpenoid derived from the medicinal plant Tripterygium wilfordii, exerts its anti-inflammatory activity through up-regulation of heme oxygenase-1 (HO-1) expression in the keratinocytes.	celastrol	32-41	heme oxygenase 1	Homo sapiens	194-210
21414301-1	2011	We previously demonstrated that celastrol, a quinone methide triterpenoid derived from the medicinal plant Tripterygium wilfordii, exerts its anti-inflammatory activity through up-regulation of heme oxygenase-1 (HO-1) expression in the keratinocytes.	celastrol	32-41	heme oxygenase 1	Homo sapiens	212-216
21414301-2	2011	In this study, we examined the signaling pathways that lead to the up-regulation of HO-1 expression by celastrol.	celastrol	103-112	heme oxygenase 1	Homo sapiens	84-88
21414301-3	2011	In HaCaT cells, celastrol-induced HO-1 expression was dependent on ROS generation.	celastrol	16-25	heme oxygenase 1	Homo sapiens	34-38
21414301-4	2011	ERK and p38 MAPK were major MAPK pathways responsible for celastrol-induced HO-1 expression.	celastrol	58-67	mitogen-activated protein kinase 14	Homo sapiens	8-11
21414301-4	2011	ERK and p38 MAPK were major MAPK pathways responsible for celastrol-induced HO-1 expression.	celastrol	58-67	heme oxygenase 1	Homo sapiens	76-80
21414301-5	2011	Celastrol induced Nrf2 activation.	celastrol	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	18-22
21414301-6	2011	Nrf2 knockdown using small interfering RNA (siRNA) inhibited celastrol-induced HO-1 expression.	celastrol	61-70	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4
21414301-6	2011	Nrf2 knockdown using small interfering RNA (siRNA) inhibited celastrol-induced HO-1 expression.	celastrol	61-70	heme oxygenase 1	Homo sapiens	79-83
21414301-7	2011	Treatment with celastrol resulted in a marked increase in antioxidant response element (ARE)-driven transcriptional activity, which was dependent on ROS generation and activation of ERK and p38 MAPK.	celastrol	15-24	mitogen-activated protein kinase 14	Homo sapiens	190-193
21414301-8	2011	Furthermore, Nrf2 siRNA significantly reversed the inhibitory effect of celastrol on IFN-gamma-induced expression of ICAM-1 in the keratinocytes.	celastrol	72-81	NFE2 like bZIP transcription factor 2	Homo sapiens	13-17
21414301-8	2011	Furthermore, Nrf2 siRNA significantly reversed the inhibitory effect of celastrol on IFN-gamma-induced expression of ICAM-1 in the keratinocytes.	celastrol	72-81	interferon gamma	Homo sapiens	85-94
21414301-8	2011	Furthermore, Nrf2 siRNA significantly reversed the inhibitory effect of celastrol on IFN-gamma-induced expression of ICAM-1 in the keratinocytes.	celastrol	72-81	intercellular adhesion molecule 1	Homo sapiens	117-123
21414301-9	2011	Taken together, our results indicate that celastrol can activate the ROS-ERK/p38-Nrf2-ARE signaling cascades leading to the up-regulation of HO-1 which is partly responsible for its anti-inflammatory activity in the keratinocytes.	celastrol	42-51	mitogen-activated protein kinase 14	Homo sapiens	77-80
21414301-9	2011	Taken together, our results indicate that celastrol can activate the ROS-ERK/p38-Nrf2-ARE signaling cascades leading to the up-regulation of HO-1 which is partly responsible for its anti-inflammatory activity in the keratinocytes.	celastrol	42-51	NFE2 like bZIP transcription factor 2	Homo sapiens	81-85
21414301-9	2011	Taken together, our results indicate that celastrol can activate the ROS-ERK/p38-Nrf2-ARE signaling cascades leading to the up-regulation of HO-1 which is partly responsible for its anti-inflammatory activity in the keratinocytes.	celastrol	42-51	heme oxygenase 1	Homo sapiens	141-145
21168266-6	2011	Celastrol"s ability to modulate the expression of pro-inflammatory cytokines, MHC II, HO-1, iNOS, NF-kappaB, Notch-1, AKT/mTOR, CXCR4, TRAIL receptors DR4 and DR5, CHOP, JNK, VEGF, adhesion molecules, proteasome activity, topoisomerase II, potassium channels, and heat shock response has been reported.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	118-121
21168266-6	2011	Celastrol"s ability to modulate the expression of pro-inflammatory cytokines, MHC II, HO-1, iNOS, NF-kappaB, Notch-1, AKT/mTOR, CXCR4, TRAIL receptors DR4 and DR5, CHOP, JNK, VEGF, adhesion molecules, proteasome activity, topoisomerase II, potassium channels, and heat shock response has been reported.	celastrol	0-9	heme oxygenase 1	Homo sapiens	86-90
21168266-6	2011	Celastrol"s ability to modulate the expression of pro-inflammatory cytokines, MHC II, HO-1, iNOS, NF-kappaB, Notch-1, AKT/mTOR, CXCR4, TRAIL receptors DR4 and DR5, CHOP, JNK, VEGF, adhesion molecules, proteasome activity, topoisomerase II, potassium channels, and heat shock response has been reported.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	122-126
21168266-6	2011	Celastrol"s ability to modulate the expression of pro-inflammatory cytokines, MHC II, HO-1, iNOS, NF-kappaB, Notch-1, AKT/mTOR, CXCR4, TRAIL receptors DR4 and DR5, CHOP, JNK, VEGF, adhesion molecules, proteasome activity, topoisomerase II, potassium channels, and heat shock response has been reported.	celastrol	0-9	C-X-C motif chemokine receptor 4	Homo sapiens	128-133
21168266-6	2011	Celastrol"s ability to modulate the expression of pro-inflammatory cytokines, MHC II, HO-1, iNOS, NF-kappaB, Notch-1, AKT/mTOR, CXCR4, TRAIL receptors DR4 and DR5, CHOP, JNK, VEGF, adhesion molecules, proteasome activity, topoisomerase II, potassium channels, and heat shock response has been reported.	celastrol	0-9	inositol-3-phosphate synthase 1	Homo sapiens	92-96
21168266-6	2011	Celastrol"s ability to modulate the expression of pro-inflammatory cytokines, MHC II, HO-1, iNOS, NF-kappaB, Notch-1, AKT/mTOR, CXCR4, TRAIL receptors DR4 and DR5, CHOP, JNK, VEGF, adhesion molecules, proteasome activity, topoisomerase II, potassium channels, and heat shock response has been reported.	celastrol	0-9	notch receptor 1	Homo sapiens	109-116
21168266-6	2011	Celastrol"s ability to modulate the expression of pro-inflammatory cytokines, MHC II, HO-1, iNOS, NF-kappaB, Notch-1, AKT/mTOR, CXCR4, TRAIL receptors DR4 and DR5, CHOP, JNK, VEGF, adhesion molecules, proteasome activity, topoisomerase II, potassium channels, and heat shock response has been reported.	celastrol	0-9	major histocompatibility complex, class II, DR beta 4	Homo sapiens	151-154
21168266-6	2011	Celastrol"s ability to modulate the expression of pro-inflammatory cytokines, MHC II, HO-1, iNOS, NF-kappaB, Notch-1, AKT/mTOR, CXCR4, TRAIL receptors DR4 and DR5, CHOP, JNK, VEGF, adhesion molecules, proteasome activity, topoisomerase II, potassium channels, and heat shock response has been reported.	celastrol	0-9	TNF receptor superfamily member 10b	Homo sapiens	159-162
21168266-6	2011	Celastrol"s ability to modulate the expression of pro-inflammatory cytokines, MHC II, HO-1, iNOS, NF-kappaB, Notch-1, AKT/mTOR, CXCR4, TRAIL receptors DR4 and DR5, CHOP, JNK, VEGF, adhesion molecules, proteasome activity, topoisomerase II, potassium channels, and heat shock response has been reported.	celastrol	0-9	DNA damage inducible transcript 3	Homo sapiens	164-168
21168266-6	2011	Celastrol"s ability to modulate the expression of pro-inflammatory cytokines, MHC II, HO-1, iNOS, NF-kappaB, Notch-1, AKT/mTOR, CXCR4, TRAIL receptors DR4 and DR5, CHOP, JNK, VEGF, adhesion molecules, proteasome activity, topoisomerase II, potassium channels, and heat shock response has been reported.	celastrol	0-9	mitogen-activated protein kinase 8	Homo sapiens	170-173
21168266-6	2011	Celastrol"s ability to modulate the expression of pro-inflammatory cytokines, MHC II, HO-1, iNOS, NF-kappaB, Notch-1, AKT/mTOR, CXCR4, TRAIL receptors DR4 and DR5, CHOP, JNK, VEGF, adhesion molecules, proteasome activity, topoisomerase II, potassium channels, and heat shock response has been reported.	celastrol	0-9	vascular endothelial growth factor A	Homo sapiens	175-179
21425580-5	2011	Moreover, Celastrol decreased the expressions of p-Akt, survivin and Bcl-2 in the Akt signaling pathway.	celastrol	10-19	BCL2 apoptosis regulator	Homo sapiens	69-74
21159881-9	2011	Finally, inhibition of TAK1 by celastrol inhibited vGPCR-induced NF-kappaB activation, indicating this natural compound could be used as a potential therapeutic drug against KSHV malignancies involving vGPCR.	celastrol	31-40	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	23-27
21159881-9	2011	Finally, inhibition of TAK1 by celastrol inhibited vGPCR-induced NF-kappaB activation, indicating this natural compound could be used as a potential therapeutic drug against KSHV malignancies involving vGPCR.	celastrol	31-40	K14	Human gammaherpesvirus 8	51-56
21159881-9	2011	Finally, inhibition of TAK1 by celastrol inhibited vGPCR-induced NF-kappaB activation, indicating this natural compound could be used as a potential therapeutic drug against KSHV malignancies involving vGPCR.	celastrol	31-40	K14	Human gammaherpesvirus 8	202-207
21249311-0	2011	Enhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90.	celastrol	61-70	heat shock protein 90 alpha family class A member 1	Homo sapiens	100-105
21249311-4	2011	Celastrol inhibited the ATP-binding activity of Hsp90.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	48-53
21249311-5	2011	Furthermore, celastrol treatment dissociated an Hsp90 client protein, EGFR, and this in turn resulted in degradation of the client protein.	celastrol	13-22	heat shock protein 90 alpha family class A member 1	Homo sapiens	48-53
21249311-5	2011	Furthermore, celastrol treatment dissociated an Hsp90 client protein, EGFR, and this in turn resulted in degradation of the client protein.	celastrol	13-22	epidermal growth factor receptor	Homo sapiens	70-74
21249311-7	2011	Moreover celastrol treatment increased p53 levels by phosphorylating Ser15 and Ser20 residues as well as by inhibiting its proteasomal degradation.	celastrol	9-18	tumor protein p53	Homo sapiens	39-42
21249311-8	2011	Celastrol may be considered an effective radiosensitizer acting as an inhibitor of Hsp90 and a p53 activator.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	83-88
21249311-8	2011	Celastrol may be considered an effective radiosensitizer acting as an inhibitor of Hsp90 and a p53 activator.	celastrol	0-9	tumor protein p53	Homo sapiens	95-98
21134410-6	2011	Celastrol caused activation of caspase-7, -8, and -9, PARP cleavage, caspase-8-mediated bid cleavage, and release of cytochrome c and AIF.	celastrol	0-9	caspase 7	Homo sapiens	31-52
21134410-6	2011	Celastrol caused activation of caspase-7, -8, and -9, PARP cleavage, caspase-8-mediated bid cleavage, and release of cytochrome c and AIF.	celastrol	0-9	collagen type XI alpha 2 chain	Homo sapiens	54-58
21134410-6	2011	Celastrol caused activation of caspase-7, -8, and -9, PARP cleavage, caspase-8-mediated bid cleavage, and release of cytochrome c and AIF.	celastrol	0-9	caspase 8	Homo sapiens	69-78
21134410-6	2011	Celastrol caused activation of caspase-7, -8, and -9, PARP cleavage, caspase-8-mediated bid cleavage, and release of cytochrome c and AIF.	celastrol	0-9	cytochrome c, somatic	Homo sapiens	117-129
21134410-6	2011	Celastrol caused activation of caspase-7, -8, and -9, PARP cleavage, caspase-8-mediated bid cleavage, and release of cytochrome c and AIF.	celastrol	0-9	apoptosis inducing factor mitochondria associated 1	Homo sapiens	134-137
21134410-7	2011	In addition, celastrol decreased the expression of anti-apoptotic Bcl-2 protein and increased expression of pro-apoptotic Bax protein.	celastrol	13-22	BCL2 apoptosis regulator	Homo sapiens	66-71
21134410-7	2011	In addition, celastrol decreased the expression of anti-apoptotic Bcl-2 protein and increased expression of pro-apoptotic Bax protein.	celastrol	13-22	BCL2 associated X, apoptosis regulator	Homo sapiens	122-125
21129982-1	2011	Several Hsp90 modulators have been identified including the N-terminal ligand geldanamycin (GDA), the C-terminal ligand novobiocin (NB), and the co-chaperone disruptor celastrol.	celastrol	168-177	heat shock protein 90 alpha family class A member 1	Homo sapiens	8-13
21193311-4	2011	A search for estramustine phosphate analogs led to identification of two triterpenoids, enoxolone, and celastrol, having Shp2 PTP inhibitor activity.	celastrol	103-112	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	121-125
21193311-4	2011	A search for estramustine phosphate analogs led to identification of two triterpenoids, enoxolone, and celastrol, having Shp2 PTP inhibitor activity.	celastrol	103-112	protein tyrosine phosphatase receptor type U	Homo sapiens	126-129
21088503-0	2011	Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.	celastrol	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
21088503-3	2011	The triterpene natural product Celastrol inhibits HSP90 and several pathways relevant to ErbB2-dependent oncogenesis including the NFkappaB pathway and the proteasome, and has shown promising activity in other cancer models.	celastrol	31-40	heat shock protein 90 alpha family class A member 1	Homo sapiens	50-55
21088503-3	2011	The triterpene natural product Celastrol inhibits HSP90 and several pathways relevant to ErbB2-dependent oncogenesis including the NFkappaB pathway and the proteasome, and has shown promising activity in other cancer models.	celastrol	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-94
21088503-3	2011	The triterpene natural product Celastrol inhibits HSP90 and several pathways relevant to ErbB2-dependent oncogenesis including the NFkappaB pathway and the proteasome, and has shown promising activity in other cancer models.	celastrol	31-40	nuclear factor kappa B subunit 1	Homo sapiens	131-139
21088503-4	2011	Here, we demonstrate that Celastrol exhibits in vitro antitumor activity against a panel of human breast cancer cell lines with selectivity towards those overexpressing ErbB2.	celastrol	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-174
21088503-5	2011	Celastrol strongly synergized with ErbB2-targeted therapeutics Trastuzumab and Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol.	celastrol	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-40
21088503-5	2011	Celastrol strongly synergized with ErbB2-targeted therapeutics Trastuzumab and Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol.	celastrol	154-163	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-40
21088503-6	2011	Celastrol significantly retarded the rate of growth of ErbB2-overexpressing human breast cancer cells in a mouse xenograft model with only minor systemic toxicity.	celastrol	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-60
21088503-7	2011	Mechanistically, Celastrol not only induced the expected ubiquitinylation and degradation of ErbB2 and other HSP90 client proteins, but it also increased the levels of reactive oxygen species (ROS).	celastrol	17-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-98
21088503-7	2011	Mechanistically, Celastrol not only induced the expected ubiquitinylation and degradation of ErbB2 and other HSP90 client proteins, but it also increased the levels of reactive oxygen species (ROS).	celastrol	17-26	heat shock protein 90 alpha family class A member 1	Homo sapiens	109-114
21088503-8	2011	Our studies show that the Michael Acceptor functionality in Celastrol is important for its ability to destabilize ErbB2 and exert its bioactivity against ErbB2-overexpressing breast cancer cells.	celastrol	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-119
21088503-8	2011	Our studies show that the Michael Acceptor functionality in Celastrol is important for its ability to destabilize ErbB2 and exert its bioactivity against ErbB2-overexpressing breast cancer cells.	celastrol	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-159
21170316-10	2010	In addition, celastrol rapidly blocked cytosolic IkappaBalpha degradation and nuclear translocation of RelA.	celastrol	13-22	RELA proto-oncogene, NF-kB subunit	Homo sapiens	103-107
20934245-0	2011	Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor alpha.	celastrol	0-9	estrogen receptor 1	Homo sapiens	99-122
20934245-4	2011	However, ERalpha regulation by Celastrol has not been reported.	celastrol	31-40	estrogen receptor 1	Homo sapiens	9-16
20934245-6	2011	We observed that Celastrol decreased expression of ERalpha at both the mRNA and the protein levels in MCF7 and T47D human breast cancer cells.	celastrol	17-26	estrogen receptor 1	Homo sapiens	51-58
20934245-7	2011	Results from a luciferase assay showed that Celastrol decreased the transcriptional activity of ERalpha.	celastrol	44-53	estrogen receptor 1	Homo sapiens	96-103
20934245-8	2011	Also, Celastrol treatment inhibited ERalpha target gene expression, including expressions of cyclin D(1), progesterone receptor (PR), and c-Myb leading to cell cycle arrest and growth inhibition of breast cancer cells.	celastrol	6-15	estrogen receptor 1	Homo sapiens	36-43
20934245-8	2011	Also, Celastrol treatment inhibited ERalpha target gene expression, including expressions of cyclin D(1), progesterone receptor (PR), and c-Myb leading to cell cycle arrest and growth inhibition of breast cancer cells.	celastrol	6-15	cyclin D1	Homo sapiens	93-104
20934245-8	2011	Also, Celastrol treatment inhibited ERalpha target gene expression, including expressions of cyclin D(1), progesterone receptor (PR), and c-Myb leading to cell cycle arrest and growth inhibition of breast cancer cells.	celastrol	6-15	progesterone receptor	Homo sapiens	106-127
20934245-8	2011	Also, Celastrol treatment inhibited ERalpha target gene expression, including expressions of cyclin D(1), progesterone receptor (PR), and c-Myb leading to cell cycle arrest and growth inhibition of breast cancer cells.	celastrol	6-15	progesterone receptor	Homo sapiens	129-131
20934245-8	2011	Also, Celastrol treatment inhibited ERalpha target gene expression, including expressions of cyclin D(1), progesterone receptor (PR), and c-Myb leading to cell cycle arrest and growth inhibition of breast cancer cells.	celastrol	6-15	MYB proto-oncogene, transcription factor	Homo sapiens	138-143
20934245-9	2011	We propose that Celastrol, an anti-cancer drug extracted from natural sources, induces inhibition of cell growth through modulation of ERalpha in estrogen positive breast cancer cells and is a candidate for use in cancer chemotherapy for human breast cancer.	celastrol	16-25	estrogen receptor 1	Homo sapiens	135-142
21865725-0	2011	Celastrol inhibits breast cancer cell invasion via suppression of NF-kB-mediated matrix metalloproteinase-9 expression.	celastrol	0-9	matrix metallopeptidase 9	Homo sapiens	81-107
21865725-6	2011	We also found that celastrol inhibited PMA-induced MMP-9 expression at both the mRNA and the protein levels, and the proteolytic activity of MMP-9 in MCF-7 cells.	celastrol	19-28	matrix metallopeptidase 9	Homo sapiens	51-56
21865725-6	2011	We also found that celastrol inhibited PMA-induced MMP-9 expression at both the mRNA and the protein levels, and the proteolytic activity of MMP-9 in MCF-7 cells.	celastrol	19-28	matrix metallopeptidase 9	Homo sapiens	141-146
21865725-7	2011	Our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the DNA binding activity of NF-kappaB in the MMP-9 promoter, and inhibited degradation of IkappaBalpha and nuclear translocation of NF-kappaB.	celastrol	26-35	matrix metallopeptidase 9	Homo sapiens	78-83
21865725-7	2011	Our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the DNA binding activity of NF-kappaB in the MMP-9 promoter, and inhibited degradation of IkappaBalpha and nuclear translocation of NF-kappaB.	celastrol	26-35	nuclear factor kappa B subunit 1	Homo sapiens	130-139
21865725-7	2011	Our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the DNA binding activity of NF-kappaB in the MMP-9 promoter, and inhibited degradation of IkappaBalpha and nuclear translocation of NF-kappaB.	celastrol	26-35	matrix metallopeptidase 9	Homo sapiens	147-152
21865725-7	2011	Our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the DNA binding activity of NF-kappaB in the MMP-9 promoter, and inhibited degradation of IkappaBalpha and nuclear translocation of NF-kappaB.	celastrol	26-35	NFKB inhibitor alpha	Homo sapiens	192-204
21865725-7	2011	Our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the DNA binding activity of NF-kappaB in the MMP-9 promoter, and inhibited degradation of IkappaBalpha and nuclear translocation of NF-kappaB.	celastrol	26-35	nuclear factor kappa B subunit 1	Homo sapiens	234-243
21865725-8	2011	CONCLUSION: These results indicate that celastrol inhibits NF-kappaB-mediated MMP-9 expression, resulting in suppression of breast cancer cell invasion and migration that is induced by PMA.	celastrol	40-49	nuclear factor kappa B subunit 1	Homo sapiens	59-68
21865725-8	2011	CONCLUSION: These results indicate that celastrol inhibits NF-kappaB-mediated MMP-9 expression, resulting in suppression of breast cancer cell invasion and migration that is induced by PMA.	celastrol	40-49	matrix metallopeptidase 9	Homo sapiens	78-83
21170316-6	2010	We found that celastrol inhibited cell proliferation in all three AIPC cell lines (PC-3, DU145 and CL1), with IC50 in the range of 1-2 microM.	celastrol	14-23	adhesion G protein-coupled receptor L1	Homo sapiens	99-102
21170316-8	2010	Celastrol significantly induced apoptosis as evidenced by increased sub-G1 population, caspase activation and PARP cleavage.	celastrol	0-9	collagen type XI alpha 2 chain	Homo sapiens	110-114
21170316-9	2010	Moreover, celastrol promoted cleavage of the anti-apoptotic protein Mcl-1 and activated the pro-apoptotic protein Noxa.	celastrol	10-19	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	68-73
21170316-10	2010	In addition, celastrol rapidly blocked cytosolic IkappaBalpha degradation and nuclear translocation of RelA.	celastrol	13-22	NFKB inhibitor alpha	Homo sapiens	49-61
21170316-11	2010	Likewise, celastrol inhibited the expression of multiple NF-kappaB target genes that are involved in proliferation, invasion and anti-apoptosis.	celastrol	10-19	nuclear factor kappa B subunit 1	Homo sapiens	57-66
21170316-14	2010	CONCLUSIONS/SIGNIFICANCE: Our data suggest that, via targeting the proteasome, celastrol suppresses proliferation, invasion and angiogenesis by inducing the apoptotic machinery and attenuating constitutive NF-kappaB activity in AIPC both in vitro and in vivo.	celastrol	79-88	nuclear factor kappa B subunit 1	Homo sapiens	206-215
21170316-0	2010	Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB.	celastrol	29-38	nuclear factor kappa B subunit 1	Homo sapiens	136-145
21170316-1	2010	BACKGROUND: Celastrol is a natural proteasome inhibitor that exhibits promising anti-tumor effects in human malignancies, especially the androgen-independent prostate cancer (AIPC) with constitutive NF-kappaB activation.	celastrol	12-21	nuclear factor kappa B subunit 1	Homo sapiens	199-208
21170316-4	2010	In the current study, we aim to test the hypothesis that celastrol suppresses AIPC progression via inhibiting the constitutive NF-kappaB activity as well as modulating the Bcl-2 family proteins.	celastrol	57-66	nuclear factor kappa B subunit 1	Homo sapiens	127-136
20605676-0	2010	Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L.	celastrol	43-52	TNF receptor superfamily member 10a	Homo sapiens	17-33
20798912-0	2010	Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor.	celastrol	0-9	C-X-C motif chemokine receptor 4	Homo sapiens	111-116
20798912-0	2010	Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor.	celastrol	0-9	C-X-C motif chemokine receptor 4	Homo sapiens	117-135
20798912-3	2010	In the current report, we demonstrate that celastrol can downregulate the CXCR4 expression on breast cancer MCF-7 cells stably transfected with HER2, an oncogene known to induce the chemokine receptor.	celastrol	43-52	C-X-C motif chemokine receptor 4	Homo sapiens	74-79
20798912-3	2010	In the current report, we demonstrate that celastrol can downregulate the CXCR4 expression on breast cancer MCF-7 cells stably transfected with HER2, an oncogene known to induce the chemokine receptor.	celastrol	43-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148
20798912-3	2010	In the current report, we demonstrate that celastrol can downregulate the CXCR4 expression on breast cancer MCF-7 cells stably transfected with HER2, an oncogene known to induce the chemokine receptor.	celastrol	43-52	C-X-C motif chemokine receptor 4	Homo sapiens	182-200
20798912-6	2010	Quantitative reverse transcription polymerase chain reaction analysis revealed that downregulation of CXCR4 messenger RNA (mRNA) by celastrol occurred at the translational level.	celastrol	132-141	C-X-C motif chemokine receptor 4	Homo sapiens	102-107
20798912-8	2010	Abrogation of the chemokine receptor by celastrol or by gene-silencing was accompanied by suppression of invasiveness of colon cancer cells induced by CXCL12, the ligand for CXCR4.	celastrol	40-49	C-X-C motif chemokine receptor 4	Homo sapiens	18-36
20798912-8	2010	Abrogation of the chemokine receptor by celastrol or by gene-silencing was accompanied by suppression of invasiveness of colon cancer cells induced by CXCL12, the ligand for CXCR4.	celastrol	40-49	C-X-C motif chemokine ligand 12	Homo sapiens	151-157
20798912-8	2010	Abrogation of the chemokine receptor by celastrol or by gene-silencing was accompanied by suppression of invasiveness of colon cancer cells induced by CXCL12, the ligand for CXCR4.	celastrol	40-49	C-X-C motif chemokine receptor 4	Homo sapiens	174-179
20798912-9	2010	This effect was not cell type-specific as celastrol also abolished invasiveness of pancreatic tumor cells, and this effect again correlated with the disappearance of both the CXCR4 mRNA and CXCR4 protein.	celastrol	42-51	C-X-C motif chemokine receptor 4	Homo sapiens	175-180
20798912-9	2010	This effect was not cell type-specific as celastrol also abolished invasiveness of pancreatic tumor cells, and this effect again correlated with the disappearance of both the CXCR4 mRNA and CXCR4 protein.	celastrol	42-51	C-X-C motif chemokine receptor 4	Homo sapiens	190-195
20798912-11	2010	Overall, these results show that celastrol has potential in suppressing invasion and metastasis of cancer cells by down-modulation of CXCR4 expression.	celastrol	33-42	C-X-C motif chemokine receptor 4	Homo sapiens	134-139
20605676-5	2010	Taken together, the present study demonstrates that the enhanced mRNA and protein expression of DR4 and DR5 play prominent roles in the sensitization of celastrol to TRAIL/Apo-2L-induced apoptosis, in a p38 MAPK-independent manner.	celastrol	153-162	TNF receptor superfamily member 10a	Homo sapiens	96-99
20605676-5	2010	Taken together, the present study demonstrates that the enhanced mRNA and protein expression of DR4 and DR5 play prominent roles in the sensitization of celastrol to TRAIL/Apo-2L-induced apoptosis, in a p38 MAPK-independent manner.	celastrol	153-162	TNF receptor superfamily member 10b	Homo sapiens	104-107
20605676-5	2010	Taken together, the present study demonstrates that the enhanced mRNA and protein expression of DR4 and DR5 play prominent roles in the sensitization of celastrol to TRAIL/Apo-2L-induced apoptosis, in a p38 MAPK-independent manner.	celastrol	153-162	TNF superfamily member 10	Homo sapiens	172-178
20605676-0	2010	Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L.	celastrol	43-52	TNF superfamily member 10	Homo sapiens	96-102
20605676-5	2010	Taken together, the present study demonstrates that the enhanced mRNA and protein expression of DR4 and DR5 play prominent roles in the sensitization of celastrol to TRAIL/Apo-2L-induced apoptosis, in a p38 MAPK-independent manner.	celastrol	153-162	mitogen-activated protein kinase 14	Homo sapiens	203-206
20605676-1	2010	Our previous study demonstrated that celastrol combined with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo-2L) exhibited significant synergistic anti-cancer activities, thus we were promoted to investigate the molecular mechanism of this synergy.	celastrol	37-46	TNF superfamily member 10	Homo sapiens	124-130
20605676-2	2010	Here in this study, we show that celastrol up-regulates death receptor 4 (DR4) and 5 (DR5) expression at mRNA, total protein and cell surface levels, and the specific knockdown using DR4- or DR5-targeting siRNA transfection attenuates the PARP cleavage caused by the combination of celastrol and TRAIL/Apo-2L, denoting the critical roles of DR induction in this sensitization.	celastrol	33-42	TNF receptor superfamily member 10a	Homo sapiens	56-72
20605676-2	2010	Here in this study, we show that celastrol up-regulates death receptor 4 (DR4) and 5 (DR5) expression at mRNA, total protein and cell surface levels, and the specific knockdown using DR4- or DR5-targeting siRNA transfection attenuates the PARP cleavage caused by the combination of celastrol and TRAIL/Apo-2L, denoting the critical roles of DR induction in this sensitization.	celastrol	33-42	TNF receptor superfamily member 10a	Homo sapiens	74-77
20605676-2	2010	Here in this study, we show that celastrol up-regulates death receptor 4 (DR4) and 5 (DR5) expression at mRNA, total protein and cell surface levels, and the specific knockdown using DR4- or DR5-targeting siRNA transfection attenuates the PARP cleavage caused by the combination of celastrol and TRAIL/Apo-2L, denoting the critical roles of DR induction in this sensitization.	celastrol	33-42	TNF receptor superfamily member 10b	Homo sapiens	86-89
20605676-2	2010	Here in this study, we show that celastrol up-regulates death receptor 4 (DR4) and 5 (DR5) expression at mRNA, total protein and cell surface levels, and the specific knockdown using DR4- or DR5-targeting siRNA transfection attenuates the PARP cleavage caused by the combination of celastrol and TRAIL/Apo-2L, denoting the critical roles of DR induction in this sensitization.	celastrol	33-42	TNF receptor superfamily member 10a	Homo sapiens	183-186
20605676-2	2010	Here in this study, we show that celastrol up-regulates death receptor 4 (DR4) and 5 (DR5) expression at mRNA, total protein and cell surface levels, and the specific knockdown using DR4- or DR5-targeting siRNA transfection attenuates the PARP cleavage caused by the combination of celastrol and TRAIL/Apo-2L, denoting the critical roles of DR induction in this sensitization.	celastrol	33-42	TNF receptor superfamily member 10b	Homo sapiens	191-194
20605676-2	2010	Here in this study, we show that celastrol up-regulates death receptor 4 (DR4) and 5 (DR5) expression at mRNA, total protein and cell surface levels, and the specific knockdown using DR4- or DR5-targeting siRNA transfection attenuates the PARP cleavage caused by the combination of celastrol and TRAIL/Apo-2L, denoting the critical roles of DR induction in this sensitization.	celastrol	33-42	collagen type XI alpha 2 chain	Homo sapiens	239-243
20605676-2	2010	Here in this study, we show that celastrol up-regulates death receptor 4 (DR4) and 5 (DR5) expression at mRNA, total protein and cell surface levels, and the specific knockdown using DR4- or DR5-targeting siRNA transfection attenuates the PARP cleavage caused by the combination of celastrol and TRAIL/Apo-2L, denoting the critical roles of DR induction in this sensitization.	celastrol	33-42	TNF superfamily member 10	Homo sapiens	302-308
20605676-2	2010	Here in this study, we show that celastrol up-regulates death receptor 4 (DR4) and 5 (DR5) expression at mRNA, total protein and cell surface levels, and the specific knockdown using DR4- or DR5-targeting siRNA transfection attenuates the PARP cleavage caused by the combination of celastrol and TRAIL/Apo-2L, denoting the critical roles of DR induction in this sensitization.	celastrol	282-291	TNF receptor superfamily member 10a	Homo sapiens	56-72
20605676-2	2010	Here in this study, we show that celastrol up-regulates death receptor 4 (DR4) and 5 (DR5) expression at mRNA, total protein and cell surface levels, and the specific knockdown using DR4- or DR5-targeting siRNA transfection attenuates the PARP cleavage caused by the combination of celastrol and TRAIL/Apo-2L, denoting the critical roles of DR induction in this sensitization.	celastrol	282-291	TNF receptor superfamily member 10a	Homo sapiens	74-77
20605676-2	2010	Here in this study, we show that celastrol up-regulates death receptor 4 (DR4) and 5 (DR5) expression at mRNA, total protein and cell surface levels, and the specific knockdown using DR4- or DR5-targeting siRNA transfection attenuates the PARP cleavage caused by the combination of celastrol and TRAIL/Apo-2L, denoting the critical roles of DR induction in this sensitization.	celastrol	282-291	TNF receptor superfamily member 10b	Homo sapiens	86-89
20605676-3	2010	Of note is that although celastrol activates p38 mitogen activated protein kinases (p38 MAPK), SB203580, one specific inhibitor of p38, fails to interrupt celastrol-induced DR4 expression and the enhanced apoptosis caused by celastrol plus TRAIL/Apo-2L.	celastrol	25-34	mitogen-activated protein kinase 14	Homo sapiens	45-48
20480272-0	2010	Celastrol regulates multiple nuclear transcription factors belonging to HSP90"s clients in a dose- and cell type-dependent way.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	72-77
20480272-1	2010	Celastrol, a novel HSP90 inhibitor, has recently attracted much attention due to its potential in multiple applications, such as anti-inflammation use, degenerative neuron disease relief, and tumor management.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	19-24
20480272-2	2010	At present, the studies in celastrol"s effects on HSP90"s clients have focused on the kinase sub-population, while another key sub-population, nuclear transcription factors (TFs), is not being well-explored.	celastrol	27-36	heat shock protein 90 alpha family class A member 1	Homo sapiens	50-55
20480272-3	2010	In this study, we observe the effects of celastrol on 18 TFs (belonging to HSP90 clients) in three human cell lines: MCF-7 (breast cancer), HepG2 (hepatoma), and THP-1 (monocytic leukemia).	celastrol	41-50	heat shock protein 90 alpha family class A member 1	Homo sapiens	75-80
20480272-6	2010	Celastrol"s capability to affect multiple TFs was consistent with its altering HSP90/TFs interactions and disrupting HSP90/Hop interaction, in addition to the reported damaging HSP90/Cdc37 interaction.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	79-84
20480272-6	2010	Celastrol"s capability to affect multiple TFs was consistent with its altering HSP90/TFs interactions and disrupting HSP90/Hop interaction, in addition to the reported damaging HSP90/Cdc37 interaction.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	117-122
20480272-6	2010	Celastrol"s capability to affect multiple TFs was consistent with its altering HSP90/TFs interactions and disrupting HSP90/Hop interaction, in addition to the reported damaging HSP90/Cdc37 interaction.	celastrol	0-9	stress induced phosphoprotein 1	Homo sapiens	123-126
20480272-6	2010	Celastrol"s capability to affect multiple TFs was consistent with its altering HSP90/TFs interactions and disrupting HSP90/Hop interaction, in addition to the reported damaging HSP90/Cdc37 interaction.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	117-122
20480272-6	2010	Celastrol"s capability to affect multiple TFs was consistent with its altering HSP90/TFs interactions and disrupting HSP90/Hop interaction, in addition to the reported damaging HSP90/Cdc37 interaction.	celastrol	0-9	cell division cycle 37, HSP90 cochaperone	Homo sapiens	183-188
20480272-7	2010	This work confirms, for the first time, that celastrol has broad effects on TFs belonging to HSP90"s clients, casts new light on understanding these reported actions, and suggests new possible applications for celastrol, such as diabetes management.	celastrol	45-54	heat shock protein 90 alpha family class A member 1	Homo sapiens	93-98
20647545-6	2010	Although parthenolide and BMS-345541 had no inhibitory effects on osteoblast function, celastrol prevented IL1beta-induced TAK1 activation and inhibited osteoblast growth, differentiation, and bone nodule formation.	celastrol	87-96	interleukin 1 beta	Homo sapiens	107-114
20647545-6	2010	Although parthenolide and BMS-345541 had no inhibitory effects on osteoblast function, celastrol prevented IL1beta-induced TAK1 activation and inhibited osteoblast growth, differentiation, and bone nodule formation.	celastrol	87-96	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	123-127
20599745-8	2010	These results suggest that celastrol may exert anti-inflammatory responses by suppressing IFN-gamma-induced expression of ICAM-1 and subsequent monocyte adhesion via expression of HO-1 in the keratinocytes.	celastrol	27-36	interferon gamma	Homo sapiens	90-99
20414191-0	2010	Celastrol attenuates hypertension-induced inflammation and oxidative stress in vascular smooth muscle cells via induction of heme oxygenase-1.	celastrol	0-9	heme oxygenase 1	Rattus norvegicus	125-141
20414191-11	2010	Celastrol also blocked activation of extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and Akt signaling both in vivo and in vitro.	celastrol	0-9	Eph receptor B1	Rattus norvegicus	37-74
20414191-11	2010	Celastrol also blocked activation of extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and Akt signaling both in vivo and in vitro.	celastrol	0-9	Eph receptor B1	Rattus norvegicus	76-79
20414191-12	2010	More importantly, celastrol increased heme oxygenase-1 (HO-1) expression and activity, whereas zinc protoporphyrin 9 (ZnPP9), a HO-1 inhibitor, partially abolished the beneficial effects of celastrol on hypertensive rats and VSMCs.	celastrol	18-27	heme oxygenase 1	Rattus norvegicus	38-54
20472666-0	2010	Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway.	celastrol	0-9	mitogen-activated protein kinase 14	Mus musculus	140-143
20472666-6	2010	In understanding the underlying mechanisms, we found that celastrol activated p38 mitogen-activated protein kinase (MAPK) by phosphorylation before the decrement of phosphorylated FAK and that this action was independent of the presence of fibronectin.	celastrol	58-67	mitogen-activated protein kinase 14	Mus musculus	78-81
20472666-6	2010	In understanding the underlying mechanisms, we found that celastrol activated p38 mitogen-activated protein kinase (MAPK) by phosphorylation before the decrement of phosphorylated FAK and that this action was independent of the presence of fibronectin.	celastrol	58-67	PTK2 protein tyrosine kinase 2	Mus musculus	180-183
20472666-6	2010	In understanding the underlying mechanisms, we found that celastrol activated p38 mitogen-activated protein kinase (MAPK) by phosphorylation before the decrement of phosphorylated FAK and that this action was independent of the presence of fibronectin.	celastrol	58-67	fibronectin 1	Mus musculus	240-251
20472666-10	2010	Taken together, these data demonstrate for the first time that celastrol exerts potent antimetastatic activity both in vitro and in vivo, and they provide new evidence for the critical roles of p38 MAPK in the regulation of integrin function and cell adhesion.	celastrol	63-72	mitogen-activated protein kinase 14	Mus musculus	194-202
20599745-0	2010	Celastrol suppresses IFN-gamma-induced ICAM-1 expression and subsequent monocyte adhesiveness via the induction of heme oxygenase-1 in the HaCaT cells.	celastrol	0-9	interferon gamma	Homo sapiens	21-30
20599745-0	2010	Celastrol suppresses IFN-gamma-induced ICAM-1 expression and subsequent monocyte adhesiveness via the induction of heme oxygenase-1 in the HaCaT cells.	celastrol	0-9	intercellular adhesion molecule 1	Homo sapiens	39-45
20599745-0	2010	Celastrol suppresses IFN-gamma-induced ICAM-1 expression and subsequent monocyte adhesiveness via the induction of heme oxygenase-1 in the HaCaT cells.	celastrol	0-9	heme oxygenase 1	Homo sapiens	115-131
20599745-2	2010	In this study, we examined the suppressive effect of celastrol on IFN-gamma-induced expression of ICAM-1 and the molecular mechanism responsible for these activities.	celastrol	53-62	interferon gamma	Homo sapiens	66-75
20599745-2	2010	In this study, we examined the suppressive effect of celastrol on IFN-gamma-induced expression of ICAM-1 and the molecular mechanism responsible for these activities.	celastrol	53-62	intercellular adhesion molecule 1	Homo sapiens	98-104
20599745-3	2010	We found that celastrol induced mRNA and protein expression of heme oxygenase-1 (HO-1) in the human keratinocyte cell line HaCaT.	celastrol	14-23	heme oxygenase 1	Homo sapiens	63-79
20599745-3	2010	We found that celastrol induced mRNA and protein expression of heme oxygenase-1 (HO-1) in the human keratinocyte cell line HaCaT.	celastrol	14-23	heme oxygenase 1	Homo sapiens	81-85
20599745-4	2010	Treatment of HaCaT cells with tin protoporphyrin IX (SnPP), a specific inhibitor of HO-1, reversed the suppressive effect of celastrol on IFN-gamma-induced protein and mRNA expression of ICAM-1.	celastrol	125-134	heme oxygenase 1	Homo sapiens	84-88
20599745-4	2010	Treatment of HaCaT cells with tin protoporphyrin IX (SnPP), a specific inhibitor of HO-1, reversed the suppressive effect of celastrol on IFN-gamma-induced protein and mRNA expression of ICAM-1.	celastrol	125-134	interferon gamma	Homo sapiens	138-147
20599745-4	2010	Treatment of HaCaT cells with tin protoporphyrin IX (SnPP), a specific inhibitor of HO-1, reversed the suppressive effect of celastrol on IFN-gamma-induced protein and mRNA expression of ICAM-1.	celastrol	125-134	intercellular adhesion molecule 1	Homo sapiens	187-193
20599745-5	2010	HO-1 knockdown using small interfering RNA (siRNA) led to reverse inhibition of IFN-gamma-induced up-regulation of ICAM-1 by celastrol.	celastrol	125-134	heme oxygenase 1	Homo sapiens	0-4
20957029-6	2010	Heat stress- and other HSP inducer (CdCl(2), celastrol, MG132)-induced HSP70 expression could be inhibited by AICAR, an AMPK specific activator.	celastrol	45-54	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	23-26
20957029-6	2010	Heat stress- and other HSP inducer (CdCl(2), celastrol, MG132)-induced HSP70 expression could be inhibited by AICAR, an AMPK specific activator.	celastrol	45-54	heat shock protein family A (Hsp70) member 4	Homo sapiens	71-76
20957029-6	2010	Heat stress- and other HSP inducer (CdCl(2), celastrol, MG132)-induced HSP70 expression could be inhibited by AICAR, an AMPK specific activator.	celastrol	45-54	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	Homo sapiens	110-115
20723296-0	2010	[Celastrol down-regulates expression of P-Akt and cyclin D1 in HL-60 cells and induces apoptosis].	celastrol	1-10	cyclin D1	Homo sapiens	50-59
20723296-5	2010	The Celastrol suppressed the expression of pAkt and Cyclin D1 in HL-60 cells to a varying degree which showed obvious concentration-and time-dependent manners.	celastrol	4-13	cyclin D1	Homo sapiens	52-61
20599745-5	2010	HO-1 knockdown using small interfering RNA (siRNA) led to reverse inhibition of IFN-gamma-induced up-regulation of ICAM-1 by celastrol.	celastrol	125-134	interferon gamma	Homo sapiens	80-89
20599745-5	2010	HO-1 knockdown using small interfering RNA (siRNA) led to reverse inhibition of IFN-gamma-induced up-regulation of ICAM-1 by celastrol.	celastrol	125-134	intercellular adhesion molecule 1	Homo sapiens	115-121
20599745-8	2010	These results suggest that celastrol may exert anti-inflammatory responses by suppressing IFN-gamma-induced expression of ICAM-1 and subsequent monocyte adhesion via expression of HO-1 in the keratinocytes.	celastrol	27-36	intercellular adhesion molecule 1	Homo sapiens	122-128
20599745-6	2010	In addition, SnPP reversed suppression of IFN-gamma-induced promoter activity of ICAM-1 by celastrol.	celastrol	91-100	interferon gamma	Homo sapiens	42-51
20599745-6	2010	In addition, SnPP reversed suppression of IFN-gamma-induced promoter activity of ICAM-1 by celastrol.	celastrol	91-100	intercellular adhesion molecule 1	Homo sapiens	81-87
20599745-8	2010	These results suggest that celastrol may exert anti-inflammatory responses by suppressing IFN-gamma-induced expression of ICAM-1 and subsequent monocyte adhesion via expression of HO-1 in the keratinocytes.	celastrol	27-36	heme oxygenase 1	Homo sapiens	180-184
20599745-7	2010	Furthermore, blockage of HO-1 activity by SnPP and HO-1 siRNA reversed the inhibitory effect of celastrol on IFN-gamma-induced adhesion of monocytes to keratinocytes.	celastrol	96-105	heme oxygenase 1	Homo sapiens	25-29
20599745-7	2010	Furthermore, blockage of HO-1 activity by SnPP and HO-1 siRNA reversed the inhibitory effect of celastrol on IFN-gamma-induced adhesion of monocytes to keratinocytes.	celastrol	96-105	heme oxygenase 1	Homo sapiens	51-55
20188206-6	2010	Celastrol-induced HSP accumulation was mediated by HSF1-DNA binding activity since this response was inhibited by the HSF1 activation inhibitor, KNK437.	celastrol	0-9	heat shock 70kDa protein L homeolog	Xenopus laevis	18-21
20599745-7	2010	Furthermore, blockage of HO-1 activity by SnPP and HO-1 siRNA reversed the inhibitory effect of celastrol on IFN-gamma-induced adhesion of monocytes to keratinocytes.	celastrol	96-105	interferon gamma	Homo sapiens	109-118
20188206-0	2010	Celastrol can inhibit proteasome activity and upregulate the expression of heat shock protein genes, hsp30 and hsp70, in Xenopus laevis A6 cells.	celastrol	0-9	heat shock 70kDa protein L homeolog	Xenopus laevis	75-93
20188206-0	2010	Celastrol can inhibit proteasome activity and upregulate the expression of heat shock protein genes, hsp30 and hsp70, in Xenopus laevis A6 cells.	celastrol	0-9	heat shock protein 30E L homeolog	Xenopus laevis	101-106
20188206-0	2010	Celastrol can inhibit proteasome activity and upregulate the expression of heat shock protein genes, hsp30 and hsp70, in Xenopus laevis A6 cells.	celastrol	0-9	heat shock 70kDa protein L homeolog	Xenopus laevis	111-116
20188206-6	2010	Celastrol-induced HSP accumulation was mediated by HSF1-DNA binding activity since this response was inhibited by the HSF1 activation inhibitor, KNK437.	celastrol	0-9	heat shock factor protein	Xenopus laevis	51-55
20188206-6	2010	Celastrol-induced HSP accumulation was mediated by HSF1-DNA binding activity since this response was inhibited by the HSF1 activation inhibitor, KNK437.	celastrol	0-9	heat shock factor protein	Xenopus laevis	118-122
20188206-7	2010	Simultaneous exposure of cells with celastrol plus either mild heat shock or the proteasome inhibitor, MG132, produced an enhanced accumulation of HSP30 that was greater than the sum of the individual stressors alone.	celastrol	36-45	heat shock protein 30E L homeolog	Xenopus laevis	147-152
20188206-3	2010	In this study, we show that celastrol, a quinone methide triterpene and anti-inflammatory agent, inhibited proteasome activity and enhanced HSP accumulation in Xenopus laevis A6 kidney epithelial cells.	celastrol	28-37	heat shock 70kDa protein L homeolog	Xenopus laevis	140-143
20188206-8	2010	Immunocytochemical analysis revealed that celastrol-induced HSP30 accumulation occurred in the cytoplasm in a granular pattern supplemented with larger circular HSP30 staining structures.	celastrol	42-51	heat shock protein 30E L homeolog	Xenopus laevis	60-65
20188206-8	2010	Immunocytochemical analysis revealed that celastrol-induced HSP30 accumulation occurred in the cytoplasm in a granular pattern supplemented with larger circular HSP30 staining structures.	celastrol	42-51	heat shock protein 30E L homeolog	Xenopus laevis	161-166
20188206-11	2010	In conclusion, this study has shown that celastrol inhibited proteasome activity and induced HSF1-mediated expression of hsp genes in amphibian cells.	celastrol	41-50	heat shock factor protein	Xenopus laevis	93-97
20188206-11	2010	In conclusion, this study has shown that celastrol inhibited proteasome activity and induced HSF1-mediated expression of hsp genes in amphibian cells.	celastrol	41-50	heat shock 70kDa protein L homeolog	Xenopus laevis	121-124
20154087-8	2010	We found that celastrol also induced reactive oxygen species (ROS) generation, and ROS sequestration inhibited celastrol-induced expression of CHOP and DR5, and consequent sensitization to TRAIL.	celastrol	111-120	DNA damage inducible transcript 3	Homo sapiens	143-147
20398364-0	2010	HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way.	celastrol	17-26	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
20398364-2	2010	Recently, celastrol is identified both as a novel inhibitor of HSP90 and as a potential anti-tumor agent.	celastrol	10-19	heat shock protein 90 alpha family class A member 1	Homo sapiens	63-68
20398364-8	2010	CONCLUSIONS: Our results disclose a novel action of celastrol-- causing cell cycle arrest at G0/G1 phase based upon thiol-related HSP90 inhibition.	celastrol	52-61	heat shock protein 90 alpha family class A member 1	Homo sapiens	130-135
20154087-0	2010	Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors.	celastrol	0-9	TNF superfamily member 10	Homo sapiens	34-39
20154087-1	2010	Whether celastrol, a triterpene from traditional Chinese medicine, can modulate the anticancer effects of TRAIL, the cytokine that is currently in clinical trial, was investigated.	celastrol	8-17	TNF superfamily member 10	Homo sapiens	106-111
20154087-8	2010	We found that celastrol also induced reactive oxygen species (ROS) generation, and ROS sequestration inhibited celastrol-induced expression of CHOP and DR5, and consequent sensitization to TRAIL.	celastrol	111-120	TNF receptor superfamily member 10b	Homo sapiens	152-155
20154087-2	2010	As indicated by assays that measure plasma membrane integrity, phosphatidylserine exposure, mitochondrial activity, and activation of caspase-8, caspase-9, and caspase-3, celastrol potentiated the TRAIL-induced apoptosis in human breast cancer cells, and converted TRAIL-resistant cells to TRAIL-sensitive cells.	celastrol	171-180	caspase 8	Homo sapiens	134-143
20226165-4	2010	Celastrol (i) inhibits directly the IKKalpha and beta kinases, (ii) inactivates the Cdc37 and p23 proteins which are co-chaperones of HSP90, (iii) inhibits the function of proteasomes, and (iv) activates the HSF1 and subsequently triggers the heat shock response.	celastrol	0-9	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	36-53
20226165-4	2010	Celastrol (i) inhibits directly the IKKalpha and beta kinases, (ii) inactivates the Cdc37 and p23 proteins which are co-chaperones of HSP90, (iii) inhibits the function of proteasomes, and (iv) activates the HSF1 and subsequently triggers the heat shock response.	celastrol	0-9	cell division cycle 37, HSP90 cochaperone	Homo sapiens	84-89
20154087-2	2010	As indicated by assays that measure plasma membrane integrity, phosphatidylserine exposure, mitochondrial activity, and activation of caspase-8, caspase-9, and caspase-3, celastrol potentiated the TRAIL-induced apoptosis in human breast cancer cells, and converted TRAIL-resistant cells to TRAIL-sensitive cells.	celastrol	171-180	caspase 3	Homo sapiens	160-169
20154087-2	2010	As indicated by assays that measure plasma membrane integrity, phosphatidylserine exposure, mitochondrial activity, and activation of caspase-8, caspase-9, and caspase-3, celastrol potentiated the TRAIL-induced apoptosis in human breast cancer cells, and converted TRAIL-resistant cells to TRAIL-sensitive cells.	celastrol	171-180	TNF superfamily member 10	Homo sapiens	197-202
20154087-8	2010	We found that celastrol also induced reactive oxygen species (ROS) generation, and ROS sequestration inhibited celastrol-induced expression of CHOP and DR5, and consequent sensitization to TRAIL.	celastrol	111-120	TNF superfamily member 10	Homo sapiens	189-194
20154087-2	2010	As indicated by assays that measure plasma membrane integrity, phosphatidylserine exposure, mitochondrial activity, and activation of caspase-8, caspase-9, and caspase-3, celastrol potentiated the TRAIL-induced apoptosis in human breast cancer cells, and converted TRAIL-resistant cells to TRAIL-sensitive cells.	celastrol	171-180	TNF superfamily member 10	Homo sapiens	265-270
20226165-4	2010	Celastrol (i) inhibits directly the IKKalpha and beta kinases, (ii) inactivates the Cdc37 and p23 proteins which are co-chaperones of HSP90, (iii) inhibits the function of proteasomes, and (iv) activates the HSF1 and subsequently triggers the heat shock response.	celastrol	0-9	prostaglandin E synthase 3	Homo sapiens	94-97
20226165-4	2010	Celastrol (i) inhibits directly the IKKalpha and beta kinases, (ii) inactivates the Cdc37 and p23 proteins which are co-chaperones of HSP90, (iii) inhibits the function of proteasomes, and (iv) activates the HSF1 and subsequently triggers the heat shock response.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	134-139
20154087-2	2010	As indicated by assays that measure plasma membrane integrity, phosphatidylserine exposure, mitochondrial activity, and activation of caspase-8, caspase-9, and caspase-3, celastrol potentiated the TRAIL-induced apoptosis in human breast cancer cells, and converted TRAIL-resistant cells to TRAIL-sensitive cells.	celastrol	171-180	TNF superfamily member 10	Homo sapiens	265-270
20154087-4	2010	In addition, we found that celastrol induced the cell surface expression of both the TRAIL receptors DR4 and DR5.	celastrol	27-36	TNF superfamily member 10	Homo sapiens	85-90
20154087-4	2010	In addition, we found that celastrol induced the cell surface expression of both the TRAIL receptors DR4 and DR5.	celastrol	27-36	major histocompatibility complex, class II, DR beta 4	Homo sapiens	101-104
20154087-4	2010	In addition, we found that celastrol induced the cell surface expression of both the TRAIL receptors DR4 and DR5.	celastrol	27-36	TNF receptor superfamily member 10b	Homo sapiens	109-112
20154087-6	2010	Gene silencing of the death receptor abolished the effect of celastrol on TRAIL-induced apoptosis.	celastrol	61-70	TNF superfamily member 10	Homo sapiens	74-79
20226165-4	2010	Celastrol (i) inhibits directly the IKKalpha and beta kinases, (ii) inactivates the Cdc37 and p23 proteins which are co-chaperones of HSP90, (iii) inhibits the function of proteasomes, and (iv) activates the HSF1 and subsequently triggers the heat shock response.	celastrol	0-9	heat shock transcription factor 1	Homo sapiens	208-212
20154087-9	2010	Overall, our results demonstrate that celastrol can potentiate the apoptotic effects of TRAIL through down-regulation of cell survival proteins and up-regulation of death receptors via the ROS-mediated up-regulation of CHOP pathway.	celastrol	38-47	TNF superfamily member 10	Homo sapiens	88-93
20154087-7	2010	Induction of the death receptor by the triterpenoid was found to be p53-independent but required the induction of CAAT/enhancer-binding protein homologous protein (CHOP), inasmuch as gene silencing of CHOP abolished the induction of DR5 expression by celastrol and associated enhancement of TRAIL-induced apoptosis.	celastrol	251-260	DNA damage inducible transcript 3	Homo sapiens	164-168
20154087-7	2010	Induction of the death receptor by the triterpenoid was found to be p53-independent but required the induction of CAAT/enhancer-binding protein homologous protein (CHOP), inasmuch as gene silencing of CHOP abolished the induction of DR5 expression by celastrol and associated enhancement of TRAIL-induced apoptosis.	celastrol	251-260	DNA damage inducible transcript 3	Homo sapiens	201-205
20154087-9	2010	Overall, our results demonstrate that celastrol can potentiate the apoptotic effects of TRAIL through down-regulation of cell survival proteins and up-regulation of death receptors via the ROS-mediated up-regulation of CHOP pathway.	celastrol	38-47	DNA damage inducible transcript 3	Homo sapiens	219-223
19916747-2	2010	Moreover, the in vivo antitumor efficacy of TRAIL/APO-2L was dramatically increased by celastrol.	celastrol	87-96	TNF superfamily member 10	Homo sapiens	44-49
20346213-0	2010	Effects of Celastrol on growth inhibition of U937 leukemia cells through the regulation of the Notch1/NF-kappaB signaling pathway in vitro.	celastrol	11-20	notch receptor 1	Homo sapiens	95-101
20346213-0	2010	Effects of Celastrol on growth inhibition of U937 leukemia cells through the regulation of the Notch1/NF-kappaB signaling pathway in vitro.	celastrol	11-20	nuclear factor kappa B subunit 1	Homo sapiens	102-111
20346213-13	2010	Overexpression of Notch1 was found in U937 cells, while Celastrol could downregulate it at both the protein and mRNA level in a dose-dependent manner, and expression of NF-kappaB decreased in nuclei and increased in the cytoplasm (P &lt; 0.05).	celastrol	56-65	notch receptor 1	Homo sapiens	18-24
20211007-5	2010	We therefore explored whether the known NFkappaB inhibitor celastrol could represent a suitable compound for decreasing Abeta production and accumulation in vivo.	celastrol	59-68	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	40-48
20211007-5	2010	We therefore explored whether the known NFkappaB inhibitor celastrol could represent a suitable compound for decreasing Abeta production and accumulation in vivo.	celastrol	59-68	amyloid beta (A4) precursor protein	Mus musculus	120-125
20211007-6	2010	METHODS: The effect of celastrol on amyloid precursor protein (APP) processing, Abeta production and NFkappaB activation was investigated by western blotting and ELISAs using a cell line overexpressing APP.	celastrol	23-32	amyloid beta (A4) precursor protein	Mus musculus	36-61
20211007-8	2010	An acute treatment with celastrol was investigated by administering celastrol intraperitoneally at a dosage of 1 mg/Kg in 35 week-old Tg PS1/APPsw for 4 consecutive days.	celastrol	24-33	presenilin 1	Mus musculus	137-152
20211007-8	2010	An acute treatment with celastrol was investigated by administering celastrol intraperitoneally at a dosage of 1 mg/Kg in 35 week-old Tg PS1/APPsw for 4 consecutive days.	celastrol	68-77	presenilin 1	Mus musculus	137-152
20211007-9	2010	In addition, a chronic treatment (32 days) with celastrol was tested using a matrix-driven delivery pellet system implanted subcutaneously in 5 month-old Tg PS1/APPsw to ensure a continuous daily release of 2.5 mg/Kg of celastrol.	celastrol	48-57	presenilin 1	Homo sapiens	157-160
20211007-10	2010	RESULTS: In vitro, celastrol dose dependently prevented NFkappaB activation and inhibited BACE-1 expression.	celastrol	19-28	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	56-64
20211007-10	2010	RESULTS: In vitro, celastrol dose dependently prevented NFkappaB activation and inhibited BACE-1 expression.	celastrol	19-28	beta-site APP cleaving enzyme 1	Mus musculus	90-96
20211007-13	2010	In addition, a reduction in Abeta plaque burden and microglial activation was observed in the brains of Tg PS1/APPsw following a chronic administration of celastrol.	celastrol	155-164	amyloid beta (A4) precursor protein	Mus musculus	28-33
20211007-13	2010	In addition, a reduction in Abeta plaque burden and microglial activation was observed in the brains of Tg PS1/APPsw following a chronic administration of celastrol.	celastrol	155-164	presenilin 1	Homo sapiens	107-110
20211007-14	2010	CONCLUSIONS: Overall our data suggest that celastrol is a potent Abeta lowering compound that acts as an indirect BACE-1 inhibitor possibly by regulating BACE-1 expression level via an NFkappaB dependent mechanism.	celastrol	43-52	amyloid beta (A4) precursor protein	Mus musculus	65-70
20211007-14	2010	CONCLUSIONS: Overall our data suggest that celastrol is a potent Abeta lowering compound that acts as an indirect BACE-1 inhibitor possibly by regulating BACE-1 expression level via an NFkappaB dependent mechanism.	celastrol	43-52	beta-site APP cleaving enzyme 1	Mus musculus	114-120
20211007-14	2010	CONCLUSIONS: Overall our data suggest that celastrol is a potent Abeta lowering compound that acts as an indirect BACE-1 inhibitor possibly by regulating BACE-1 expression level via an NFkappaB dependent mechanism.	celastrol	43-52	beta-site APP cleaving enzyme 1	Mus musculus	154-160
20211007-14	2010	CONCLUSIONS: Overall our data suggest that celastrol is a potent Abeta lowering compound that acts as an indirect BACE-1 inhibitor possibly by regulating BACE-1 expression level via an NFkappaB dependent mechanism.	celastrol	43-52	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	185-193
20160026-0	2010	Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway.	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	78-81
20160026-0	2010	Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	82-111
20160026-6	2010	Furthermore, Celastrol abrogated VEGF-induced sprouting of the vessels from aortic rings and inhibited vascular formation in the Matrigel plug assay in vivo.	celastrol	13-22	vascular endothelial growth factor A	Homo sapiens	33-37
20160026-8	2010	Celastrol suppressed the VEGF-induced activation of AKT, mammalian target of rapamycin (mTOR), and ribosomal protein S6 kinase (P70S6K).	celastrol	0-9	vascular endothelial growth factor A	Homo sapiens	25-29
20160026-8	2010	Celastrol suppressed the VEGF-induced activation of AKT, mammalian target of rapamycin (mTOR), and ribosomal protein S6 kinase (P70S6K).	celastrol	0-9	AKT serine/threonine kinase 1	Homo sapiens	52-55
20160026-8	2010	Celastrol suppressed the VEGF-induced activation of AKT, mammalian target of rapamycin (mTOR), and ribosomal protein S6 kinase (P70S6K).	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	57-86
20160026-8	2010	Celastrol suppressed the VEGF-induced activation of AKT, mammalian target of rapamycin (mTOR), and ribosomal protein S6 kinase (P70S6K).	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	88-92
20160026-8	2010	Celastrol suppressed the VEGF-induced activation of AKT, mammalian target of rapamycin (mTOR), and ribosomal protein S6 kinase (P70S6K).	celastrol	0-9	ribosomal protein S6 kinase B1	Homo sapiens	128-134
20160026-9	2010	Additionally, we found that Celastrol inhibited the proliferation of prostate cancer cells and induced apoptosis, and these effects correlated with the extent of inhibition of AKT/mTOR/P70S6K signaling.	celastrol	28-37	AKT serine/threonine kinase 1	Homo sapiens	176-179
20160026-9	2010	Additionally, we found that Celastrol inhibited the proliferation of prostate cancer cells and induced apoptosis, and these effects correlated with the extent of inhibition of AKT/mTOR/P70S6K signaling.	celastrol	28-37	mechanistic target of rapamycin kinase	Homo sapiens	180-184
20160026-9	2010	Additionally, we found that Celastrol inhibited the proliferation of prostate cancer cells and induced apoptosis, and these effects correlated with the extent of inhibition of AKT/mTOR/P70S6K signaling.	celastrol	28-37	ribosomal protein S6 kinase B1	Homo sapiens	185-191
20160026-10	2010	Taken together, our results suggest that Celastrol targets the AKT/mTOR/P70S6K pathway, which leads to suppression of tumor growth and angiogenesis.	celastrol	41-50	AKT serine/threonine kinase 1	Homo sapiens	63-66
20160026-10	2010	Taken together, our results suggest that Celastrol targets the AKT/mTOR/P70S6K pathway, which leads to suppression of tumor growth and angiogenesis.	celastrol	41-50	mechanistic target of rapamycin kinase	Homo sapiens	67-71
20160026-10	2010	Taken together, our results suggest that Celastrol targets the AKT/mTOR/P70S6K pathway, which leads to suppression of tumor growth and angiogenesis.	celastrol	41-50	ribosomal protein S6 kinase B1	Homo sapiens	72-78
20007406-2	2010	Celastrol, isolated from a Chinese medicinal herb, is a novel heat shock protein 90 (Hsp90) inhibitor with potent anticancer activity against glioma in vitro and in vivo.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	62-83
20007406-2	2010	Celastrol, isolated from a Chinese medicinal herb, is a novel heat shock protein 90 (Hsp90) inhibitor with potent anticancer activity against glioma in vitro and in vivo.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	85-90
20007406-3	2010	In search of correlations between growth-inhibitory potency of celastrol in NCI-60 cell lines and microarray expression profiles of most known transporters, we found that expression of SLC7A11, the gene encoding the light chain subunit of x(c)(-), showed a strong negative correlation with celastrol activity.	celastrol	63-72	solute carrier family 7 member 11	Homo sapiens	185-192
20007406-3	2010	In search of correlations between growth-inhibitory potency of celastrol in NCI-60 cell lines and microarray expression profiles of most known transporters, we found that expression of SLC7A11, the gene encoding the light chain subunit of x(c)(-), showed a strong negative correlation with celastrol activity.	celastrol	290-299	solute carrier family 7 member 11	Homo sapiens	185-192
20007406-5	2010	In celastrol-resistant glioma cells that highly expressed SLC7A11, sensitivity to celastrol was consistently increased via treatment with x(c)(-) inhibitors, including glutamate, (S)-4-carboxyphenylglycine, sulfasalazine, and SLC7A11 small interfering RNA.	celastrol	3-12	solute carrier family 7 member 11	Homo sapiens	58-65
20007406-5	2010	In celastrol-resistant glioma cells that highly expressed SLC7A11, sensitivity to celastrol was consistently increased via treatment with x(c)(-) inhibitors, including glutamate, (S)-4-carboxyphenylglycine, sulfasalazine, and SLC7A11 small interfering RNA.	celastrol	82-91	solute carrier family 7 member 11	Homo sapiens	58-65
20007406-5	2010	In celastrol-resistant glioma cells that highly expressed SLC7A11, sensitivity to celastrol was consistently increased via treatment with x(c)(-) inhibitors, including glutamate, (S)-4-carboxyphenylglycine, sulfasalazine, and SLC7A11 small interfering RNA.	celastrol	82-91	solute carrier family 7 member 11	Homo sapiens	226-233
20007406-8	2010	Combined treatment of glioma cells with sulfasalazine and celastrol led to chemosensitization, as suggested by increased celastrol-induced cell cycle arrest, apoptosis, and down-regulation of the Hsp90 client protein, epidermal growth factor receptor.	celastrol	58-67	heat shock protein 90 alpha family class A member 1	Homo sapiens	196-201
20007406-8	2010	Combined treatment of glioma cells with sulfasalazine and celastrol led to chemosensitization, as suggested by increased celastrol-induced cell cycle arrest, apoptosis, and down-regulation of the Hsp90 client protein, epidermal growth factor receptor.	celastrol	58-67	epidermal growth factor receptor	Homo sapiens	218-250
20007406-8	2010	Combined treatment of glioma cells with sulfasalazine and celastrol led to chemosensitization, as suggested by increased celastrol-induced cell cycle arrest, apoptosis, and down-regulation of the Hsp90 client protein, epidermal growth factor receptor.	celastrol	121-130	heat shock protein 90 alpha family class A member 1	Homo sapiens	196-201
19996313-0	2010	Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the Co-chaperone p23.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	19-24
19996313-0	2010	Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the Co-chaperone p23.	celastrol	0-9	prostaglandin E synthase 3	Homo sapiens	105-108
19996313-3	2010	Here, we show that the small molecule celastrol inhibits the Hsp90 chaperoning machinery by inactivating the co-chaperone p23, resulting in a more selective destabilization of steroid receptors compared with kinase clients.	celastrol	38-47	heat shock protein 90 alpha family class A member 1	Homo sapiens	61-66
19996313-3	2010	Here, we show that the small molecule celastrol inhibits the Hsp90 chaperoning machinery by inactivating the co-chaperone p23, resulting in a more selective destabilization of steroid receptors compared with kinase clients.	celastrol	38-47	prostaglandin E synthase 3	Homo sapiens	122-125
19996313-4	2010	Our in vitro and in vivo results demonstrate that celastrol disrupts p23 function by altering its three-dimensional structure, leading to rapid formation of amyloid-like fibrils.	celastrol	50-59	prostaglandin E synthase 3	Homo sapiens	69-72
19916747-2	2010	Moreover, the in vivo antitumor efficacy of TRAIL/APO-2L was dramatically increased by celastrol.	celastrol	87-96	TNF superfamily member 10	Homo sapiens	50-56
19916747-4	2010	Taken together, our data firstly demonstrate the synergistic anticancer capabilities achieved by combining TRAIL/APO-2L and celastrol, and moreover, open new opportunities to enhance the effectiveness of future treatment regimens using TRAIL/APO-2L.	celastrol	124-133	TNF superfamily member 10	Homo sapiens	236-248
19858214-7	2009	Celastrol inhibits Hsp90 ATPase activity without blocking ATP binding.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	19-24
19858214-8	2009	Proteolytic fingerprinting indicates celastrol binds to Hsp90 C-terminal domain to protect it from trypsin digestion.	celastrol	37-46	heat shock protein 90 alpha family class A member 1	Homo sapiens	56-61
19858214-0	2009	Characterization of celastrol to inhibit hsp90 and cdc37 interaction.	celastrol	20-29	heat shock protein 90 alpha family class A member 1	Homo sapiens	41-46
19858214-9	2009	These data suggest that celastrol may represent a new class of Hsp90 inhibitor by modifying Hsp90 C terminus to allosterically regulate its chaperone activity and disrupt Hsp90-Cdc37 complex.	celastrol	24-33	heat shock protein 90 alpha family class A member 1	Homo sapiens	63-68
19858214-0	2009	Characterization of celastrol to inhibit hsp90 and cdc37 interaction.	celastrol	20-29	cell division cycle 37, HSP90 cochaperone	Homo sapiens	51-56
19858214-9	2009	These data suggest that celastrol may represent a new class of Hsp90 inhibitor by modifying Hsp90 C terminus to allosterically regulate its chaperone activity and disrupt Hsp90-Cdc37 complex.	celastrol	24-33	heat shock protein 90 alpha family class A member 1	Homo sapiens	92-97
19858214-6	2009	Celastrol disrupts Hsp90-Cdc37 complex formation, whereas the classical Hsp90 inhibitors (e.g. geldanamycin) have no effect.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	19-24
19858214-6	2009	Celastrol disrupts Hsp90-Cdc37 complex formation, whereas the classical Hsp90 inhibitors (e.g. geldanamycin) have no effect.	celastrol	0-9	cell division cycle 37, HSP90 cochaperone	Homo sapiens	25-30
19858214-9	2009	These data suggest that celastrol may represent a new class of Hsp90 inhibitor by modifying Hsp90 C terminus to allosterically regulate its chaperone activity and disrupt Hsp90-Cdc37 complex.	celastrol	24-33	heat shock protein 90 alpha family class A member 1	Homo sapiens	92-97
19858214-9	2009	These data suggest that celastrol may represent a new class of Hsp90 inhibitor by modifying Hsp90 C terminus to allosterically regulate its chaperone activity and disrupt Hsp90-Cdc37 complex.	celastrol	24-33	cell division cycle 37, HSP90 cochaperone	Homo sapiens	177-182
19934274-8	2009	CEL treatment increased the levels of ubiquitinated proteins, reduced the levels of tumor necrosis factor-alpha-induced IkappaB phosphorylation, and blocked NF-kappaB translocation to the nucleus.	celastrol	0-3	tumor necrosis factor	Homo sapiens	84-111
19934274-8	2009	CEL treatment increased the levels of ubiquitinated proteins, reduced the levels of tumor necrosis factor-alpha-induced IkappaB phosphorylation, and blocked NF-kappaB translocation to the nucleus.	celastrol	0-3	nuclear factor kappa B subunit 1	Homo sapiens	157-166
19934274-9	2009	Inhibition of NF-kappaB with small interfering RNA mimicked the ability of CEL to sensitize melanoma cells to TMZ, suggesting that inhibition of NF-kappaB may play a role in TMZ/CEL-induced cytotoxicity.	celastrol	75-78	nuclear factor kappa B subunit 1	Homo sapiens	14-23
19934274-9	2009	Inhibition of NF-kappaB with small interfering RNA mimicked the ability of CEL to sensitize melanoma cells to TMZ, suggesting that inhibition of NF-kappaB may play a role in TMZ/CEL-induced cytotoxicity.	celastrol	75-78	nuclear factor kappa B subunit 1	Homo sapiens	145-154
19671767-5	2009	Celastrol, BMS-345541, and parthenolide abolished IL1beta and tumor necrosis factor alpha-induced IkappaB phosphorylation and prevented nuclear translocation of NF-kappaB and DNA binding.	celastrol	0-9	interleukin 1 beta	Rattus norvegicus	50-57
19778460-0	2009	The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma.	celastrol	26-35	nuclear factor kappa B subunit 1	Homo sapiens	4-14
19778460-3	2009	In this study, the effects and mechanisms of GA and the NF-kappa B inhibitor celastrol on oral cancer cells were investigated.	celastrol	77-86	nuclear factor kappa B subunit 1	Homo sapiens	56-66
19778460-10	2009	The minimal cytotoxic dose of celastrol was able to effectively suppress the GA-induced NF-kappa B pathway activation.	celastrol	30-39	nuclear factor kappa B subunit 1	Homo sapiens	88-98
19723328-11	2009	We show that celastrol and minocycline, both having antioxidant and anti-inflammatory properties, confer potent dopaminergic neuroprotection in Drosophila DJ-1A model, while coQ10 shows no protective effect.	celastrol	13-22	DJ-1alpha	Drosophila melanogaster	155-160
19661812-4	2009	In in vitro experiments with human platelets, celastrol inhibits adenosine-5-diphosphate (ADP)-induced expression of the platelet activation marker P-selectin and glycoprotein IIb/IIIa activation with 50% inhibition values of 1.62 and 1.86 microM, respectively.	celastrol	46-55	selectin P	Homo sapiens	148-158
19661812-5	2009	Celastrol also inhibits thrombin-stimulated and phorbol 12-myristate 13-acetate-stimulated P-selectin expression on platelets.	celastrol	0-9	selectin P	Homo sapiens	91-101
19671767-6	2009	Celastrol and parthenolide but not BMS-345541 prevented the activation of both IKKalpha and IKKbeta, and celastrol inhibited IKKalpha/beta activation by preventing the phosphorylation of TAK1, a key receptor-associated factor upstream of IKK.	celastrol	105-114	component of inhibitor of nuclear factor kappa B kinase complex	Rattus norvegicus	125-133
19671767-6	2009	Celastrol and parthenolide but not BMS-345541 prevented the activation of both IKKalpha and IKKbeta, and celastrol inhibited IKKalpha/beta activation by preventing the phosphorylation of TAK1, a key receptor-associated factor upstream of IKK.	celastrol	105-114	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	187-241
19671767-7	2009	Celastrol and parthenolide markedly reduced the mRNA expression of matrix metalloproteinase 9 and urinary plasminogen activator, and inhibited W256 migration.	celastrol	0-9	matrix metallopeptidase 9	Rattus norvegicus	67-93
19549173-5	2009	RESULTS: Our in vitro experiments showed that celastrol suppressed not only LPS-stimulated generation of nitric oxide and prostaglandin E(2), but also expression of inducible nitric oxide synthase and cyclooxygenase-2 in RAW264.7 cells.	celastrol	46-55	prostaglandin-endoperoxide synthase 2	Mus musculus	201-217
19549173-6	2009	Similarly, celastrol inhibited LPS-induced production of inflammatory cytokines, including tumour necrosis factor-alpha and interleukin-6.	celastrol	11-20	interleukin 6	Mus musculus	124-137
19549173-7	2009	In an animal model, celastrol protected mice from TPA-induced ear oedema, possibly by inhibiting MPO activity and production of inflammatory cytokines.	celastrol	20-29	myeloperoxidase	Mus musculus	97-100
19671767-5	2009	Celastrol, BMS-345541, and parthenolide abolished IL1beta and tumor necrosis factor alpha-induced IkappaB phosphorylation and prevented nuclear translocation of NF-kappaB and DNA binding.	celastrol	0-9	tumor necrosis factor	Rattus norvegicus	62-89
19671767-6	2009	Celastrol and parthenolide but not BMS-345541 prevented the activation of both IKKalpha and IKKbeta, and celastrol inhibited IKKalpha/beta activation by preventing the phosphorylation of TAK1, a key receptor-associated factor upstream of IKK.	celastrol	0-9	component of inhibitor of nuclear factor kappa B kinase complex	Rattus norvegicus	79-87
19671767-6	2009	Celastrol and parthenolide but not BMS-345541 prevented the activation of both IKKalpha and IKKbeta, and celastrol inhibited IKKalpha/beta activation by preventing the phosphorylation of TAK1, a key receptor-associated factor upstream of IKK.	celastrol	0-9	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	92-99
19508391-7	2009	LPS + IFNgamma stimulated phosphorylation of ERK, JNK and Jak2, and degradation of IkappaB, but only Jak2 phosphorylation was sensitive to tripterine (50-200 nM).	celastrol	139-149	Janus kinase 2	Mus musculus	101-105
19719969-12	2009	Celastrol at each different dose level lowered the density of MVD significantly in tumor bearing nude mice compared to the control group.	celastrol	0-9	mevalonate (diphospho) decarboxylase	Mus musculus	62-65
19719969-13	2009	Immunohistochemistry experiments further revealed that celastrol also decreased the level of VEGFR-1 and VEGFR-2 expression, but not the level of VEGF expression.	celastrol	55-64	fms related receptor tyrosine kinase 1	Homo sapiens	93-100
19719969-13	2009	Immunohistochemistry experiments further revealed that celastrol also decreased the level of VEGFR-1 and VEGFR-2 expression, but not the level of VEGF expression.	celastrol	55-64	kinase insert domain receptor	Homo sapiens	105-112
19719969-13	2009	Immunohistochemistry experiments further revealed that celastrol also decreased the level of VEGFR-1 and VEGFR-2 expression, but not the level of VEGF expression.	celastrol	55-64	vascular endothelial growth factor A	Homo sapiens	93-97
19322522-5	2009	Celastrol-resistant B16F10 melanoma cells had a higher expression level of c-FLIP(L) and Snail as compared with a sensitive cell line.	celastrol	0-9	CASP8 and FADD-like apoptosis regulator	Mus musculus	75-81
19322522-5	2009	Celastrol-resistant B16F10 melanoma cells had a higher expression level of c-FLIP(L) and Snail as compared with a sensitive cell line.	celastrol	0-9	snail family zinc finger 1	Mus musculus	89-94
19508391-5	2009	These effects of LPS + IFNgamma were diminished by tripterine (50-200 nM).	celastrol	51-61	interferon gamma	Mus musculus	23-31
19508391-9	2009	CONCLUSION AND IMPLICATIONS: Our results indicate that, by preventing Jak2-dependent induction of iNOS and Nox1, tripterine inhibits peroxynitrite precursor synthesis, attenuates the increased activity of PP2A and consequently protects endothelial barrier function.	celastrol	113-123	Janus kinase 2	Mus musculus	70-74
19508391-9	2009	CONCLUSION AND IMPLICATIONS: Our results indicate that, by preventing Jak2-dependent induction of iNOS and Nox1, tripterine inhibits peroxynitrite precursor synthesis, attenuates the increased activity of PP2A and consequently protects endothelial barrier function.	celastrol	113-123	nitric oxide synthase 2, inducible	Mus musculus	98-102
19508391-9	2009	CONCLUSION AND IMPLICATIONS: Our results indicate that, by preventing Jak2-dependent induction of iNOS and Nox1, tripterine inhibits peroxynitrite precursor synthesis, attenuates the increased activity of PP2A and consequently protects endothelial barrier function.	celastrol	113-123	NADPH oxidase 1	Mus musculus	107-111
19508391-9	2009	CONCLUSION AND IMPLICATIONS: Our results indicate that, by preventing Jak2-dependent induction of iNOS and Nox1, tripterine inhibits peroxynitrite precursor synthesis, attenuates the increased activity of PP2A and consequently protects endothelial barrier function.	celastrol	113-123	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	205-209
19356729-0	2009	Celastrol binds to ERK and inhibits FcepsilonRI signaling to exert an anti-allergic effect.	celastrol	0-9	Eph receptor B1	Rattus norvegicus	19-22
19356729-2	2009	Celastrol decreased the secretion of beta-hexosaminidase, decreased the release of histamine, decreased the expression of Th2 cytokines and decreased calcium influx and cell adhesion in antigen-stimulated RBL2H3 cells.	celastrol	0-9	O-GlcNAcase	Rattus norvegicus	37-56
19356734-5	2009	Celastrol reduced the total number of inflammatory cells in the bronchoalveolar lavage fluid and in peribronchial areas, and decreased the airway hyperresponsiveness, mRNA and protein expression levels for inflammatory cytokines such as interleukin (IL)-4, IL-13, TNF-alpha and IFN-gamma, and for MMPs and TIMPs, MAP kinases and NF-kappaB activities in the bronchoalveolar lavage cells and in the lung tissues increased in ovalbumin-induced allergic asthma in mice.	celastrol	0-9	tumor necrosis factor	Mus musculus	264-273
19356734-5	2009	Celastrol reduced the total number of inflammatory cells in the bronchoalveolar lavage fluid and in peribronchial areas, and decreased the airway hyperresponsiveness, mRNA and protein expression levels for inflammatory cytokines such as interleukin (IL)-4, IL-13, TNF-alpha and IFN-gamma, and for MMPs and TIMPs, MAP kinases and NF-kappaB activities in the bronchoalveolar lavage cells and in the lung tissues increased in ovalbumin-induced allergic asthma in mice.	celastrol	0-9	interferon gamma	Mus musculus	278-287
19356729-2	2009	Celastrol decreased the secretion of beta-hexosaminidase, decreased the release of histamine, decreased the expression of Th2 cytokines and decreased calcium influx and cell adhesion in antigen-stimulated RBL2H3 cells.	celastrol	0-9	RB transcriptional corepressor like 2	Rattus norvegicus	205-209
19356734-5	2009	Celastrol reduced the total number of inflammatory cells in the bronchoalveolar lavage fluid and in peribronchial areas, and decreased the airway hyperresponsiveness, mRNA and protein expression levels for inflammatory cytokines such as interleukin (IL)-4, IL-13, TNF-alpha and IFN-gamma, and for MMPs and TIMPs, MAP kinases and NF-kappaB activities in the bronchoalveolar lavage cells and in the lung tissues increased in ovalbumin-induced allergic asthma in mice.	celastrol	0-9	matrix metallopeptidase 2	Mus musculus	297-301
19356729-3	2009	Exposure to celastrol decreased the phosphorylation of extracellular regulated kinase (ERK) and the ERK kinase activity was decreased in RBL2H3 cells.	celastrol	12-21	Eph receptor B1	Rattus norvegicus	55-85
19356734-5	2009	Celastrol reduced the total number of inflammatory cells in the bronchoalveolar lavage fluid and in peribronchial areas, and decreased the airway hyperresponsiveness, mRNA and protein expression levels for inflammatory cytokines such as interleukin (IL)-4, IL-13, TNF-alpha and IFN-gamma, and for MMPs and TIMPs, MAP kinases and NF-kappaB activities in the bronchoalveolar lavage cells and in the lung tissues increased in ovalbumin-induced allergic asthma in mice.	celastrol	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	329-338
19356734-5	2009	Celastrol reduced the total number of inflammatory cells in the bronchoalveolar lavage fluid and in peribronchial areas, and decreased the airway hyperresponsiveness, mRNA and protein expression levels for inflammatory cytokines such as interleukin (IL)-4, IL-13, TNF-alpha and IFN-gamma, and for MMPs and TIMPs, MAP kinases and NF-kappaB activities in the bronchoalveolar lavage cells and in the lung tissues increased in ovalbumin-induced allergic asthma in mice.	celastrol	0-9	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	423-432
19356729-3	2009	Exposure to celastrol decreased the phosphorylation of extracellular regulated kinase (ERK) and the ERK kinase activity was decreased in RBL2H3 cells.	celastrol	12-21	Eph receptor B1	Rattus norvegicus	87-90
19356734-6	2009	Our data suggest that oral administration of celastrol suppresses ovalbumin-induced airway inflammation, hyperresponsiveness, and tissue remodeling by regulating the imbalance of MMP-2/-9 and TIMP-1/-2 by inflammatory cytokines via MAP kinases/NF-kappaB in inflammatory cells.	celastrol	45-54	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	66-75
19356729-3	2009	Exposure to celastrol decreased the phosphorylation of extracellular regulated kinase (ERK) and the ERK kinase activity was decreased in RBL2H3 cells.	celastrol	12-21	Eph receptor B1	Rattus norvegicus	100-103
19356734-6	2009	Our data suggest that oral administration of celastrol suppresses ovalbumin-induced airway inflammation, hyperresponsiveness, and tissue remodeling by regulating the imbalance of MMP-2/-9 and TIMP-1/-2 by inflammatory cytokines via MAP kinases/NF-kappaB in inflammatory cells.	celastrol	45-54	matrix metallopeptidase 2	Mus musculus	179-187
19356734-6	2009	Our data suggest that oral administration of celastrol suppresses ovalbumin-induced airway inflammation, hyperresponsiveness, and tissue remodeling by regulating the imbalance of MMP-2/-9 and TIMP-1/-2 by inflammatory cytokines via MAP kinases/NF-kappaB in inflammatory cells.	celastrol	45-54	tissue inhibitor of metalloproteinase 1	Mus musculus	192-198
19356734-6	2009	Our data suggest that oral administration of celastrol suppresses ovalbumin-induced airway inflammation, hyperresponsiveness, and tissue remodeling by regulating the imbalance of MMP-2/-9 and TIMP-1/-2 by inflammatory cytokines via MAP kinases/NF-kappaB in inflammatory cells.	celastrol	45-54	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	244-253
19356729-4	2009	A molecular dynamics simulation showed binding of celastrol to a large pocket in ERK2, which serves as the ATP-binding site.	celastrol	50-59	mitogen activated protein kinase 1	Rattus norvegicus	81-85
19356729-5	2009	Exposure to celastrol inhibited the interaction between immunoglobulin Fc epsilon receptor I (FcepsilonRIgamma) and ERK and inhibited interaction between FcepsilonRIgamma and protein kinase C delta (PKCdelta).	celastrol	12-21	Eph receptor B1	Rattus norvegicus	56-119
19356729-8	2009	Celastrol regulated the expression of epithelial-mesenchymal transition (EMT)-related proteins through inhibition of PKCalpha, PKCdelta, and Rac1 in antigen-stimulated RBL2H3 cells.	celastrol	0-9	protein kinase C, alpha	Rattus norvegicus	117-125
19356729-8	2009	Celastrol regulated the expression of epithelial-mesenchymal transition (EMT)-related proteins through inhibition of PKCalpha, PKCdelta, and Rac1 in antigen-stimulated RBL2H3 cells.	celastrol	0-9	Rac family small GTPase 1	Rattus norvegicus	141-145
19356729-8	2009	Celastrol regulated the expression of epithelial-mesenchymal transition (EMT)-related proteins through inhibition of PKCalpha, PKCdelta, and Rac1 in antigen-stimulated RBL2H3 cells.	celastrol	0-9	RB transcriptional corepressor like 2	Rattus norvegicus	168-172
19356729-10	2009	Celastrol exerted a negative effect on FcepsilonRIbeta signaling by inhibiting the interaction between heat shock protein 90 (hsp90) and proteins, such as, FcepsilonRIbeta, Akt and PKCalpha.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	103-124
19356729-10	2009	Celastrol exerted a negative effect on FcepsilonRIbeta signaling by inhibiting the interaction between heat shock protein 90 (hsp90) and proteins, such as, FcepsilonRIbeta, Akt and PKCalpha.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	126-131
19356729-10	2009	Celastrol exerted a negative effect on FcepsilonRIbeta signaling by inhibiting the interaction between heat shock protein 90 (hsp90) and proteins, such as, FcepsilonRIbeta, Akt and PKCalpha.	celastrol	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	173-176
19356729-10	2009	Celastrol exerted a negative effect on FcepsilonRIbeta signaling by inhibiting the interaction between heat shock protein 90 (hsp90) and proteins, such as, FcepsilonRIbeta, Akt and PKCalpha.	celastrol	0-9	protein kinase C, alpha	Rattus norvegicus	181-189
19356729-11	2009	Celastrol exerted a negative effect on in vivo atopic dermatitis induced by 2, 4-dinitrofluorobenzene (DNFB), which requires ERK.	celastrol	0-9	Eph receptor B1	Rattus norvegicus	125-128
19356729-13	2009	In summary, celastrol binds to ERK and inhibits FcepsilonRI signaling to exert an anti-inflammatory effect.	celastrol	12-21	Eph receptor B1	Rattus norvegicus	31-34
19183864-4	2009	Although both arimoclomol and celastrol induced the expression of Hsp70, their effects on primary motoneurons in culture were significantly different.	celastrol	30-39	heat shock protein 1B	Mus musculus	66-71
19585625-0	2009	Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol.	celastrol	122-131	heat shock protein 90 alpha family class A member 1	Homo sapiens	63-68
19585625-0	2009	Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol.	celastrol	122-131	cell division cycle 37, HSP90 cochaperone	Homo sapiens	69-74
19183864-6	2009	Immunostaining of celastrol-treated cultures for hsp70 and activated caspase-3 revealed that celastrol treatment activates both the heat shock response and the apoptotic cell death cascade.	celastrol	18-27	heat shock protein 1B	Mus musculus	49-54
19183864-6	2009	Immunostaining of celastrol-treated cultures for hsp70 and activated caspase-3 revealed that celastrol treatment activates both the heat shock response and the apoptotic cell death cascade.	celastrol	18-27	caspase 3	Mus musculus	69-78
19183864-6	2009	Immunostaining of celastrol-treated cultures for hsp70 and activated caspase-3 revealed that celastrol treatment activates both the heat shock response and the apoptotic cell death cascade.	celastrol	93-102	heat shock protein 1B	Mus musculus	49-54
19183864-6	2009	Immunostaining of celastrol-treated cultures for hsp70 and activated caspase-3 revealed that celastrol treatment activates both the heat shock response and the apoptotic cell death cascade.	celastrol	93-102	caspase 3	Mus musculus	69-78
18726991-3	2008	We have previously reported that apoptosis induced by medicinal proteasome-inhibitory compound celastrol is associated with a decrease in AR protein levels.	celastrol	95-104	androgen receptor	Homo sapiens	138-140
18726991-4	2008	However celastrol-stimulated events contributing to this AR decrease have not been elucidated.	celastrol	8-17	androgen receptor	Homo sapiens	57-59
18726991-8	2008	Interestingly, proteasome inhibitor celastrol- and chemotherapeutic drug VP-16-stimulated AR breakdown was attenuated by calpain inhibitors calpastatin and N-acetyl-L-leucyl-L-leucyl-L-methioninal.	celastrol	36-45	androgen receptor	Homo sapiens	90-92
18726991-9	2008	Furthermore, AR proteolytic activity pulled down by calmodulin-agarose beads from celastrol-treated PC-3 cells showed immunoreactivity to a calpain antibody.	celastrol	82-91	androgen receptor	Homo sapiens	13-15
18577440-7	2008	The effects of tripterine were associated with decreased interleukin-1beta (IL-1beta) mRNA expression in ankle joint synovial membrane and tumor necrosis factor-alpha (TNF-alpha) mRNA expression in homogenized paws from adjuvant-induced arthritic rats.	celastrol	15-25	interleukin 1 beta	Rattus norvegicus	57-74
19138996-5	2008	Inhibitors of HSP90 [17-allylamino-17-demethoxygeldanamycin (17-AAG); celastrol] suppressed these inductive effects of PAHs.	celastrol	70-79	heat shock protein 90 alpha family class A member 1	Homo sapiens	14-19
19138996-6	2008	Treatment with 17-AAG and celastrol also caused a rapid and marked decrease in amounts of AhR protein without modulating levels of HSP90.	celastrol	26-35	aryl hydrocarbon receptor	Homo sapiens	90-93
19138996-6	2008	Treatment with 17-AAG and celastrol also caused a rapid and marked decrease in amounts of AhR protein without modulating levels of HSP90.	celastrol	26-35	heat shock protein 90 alpha family class A member 1	Homo sapiens	131-136
19138996-7	2008	The formation of B(a)P-induced DNA adducts in MSK-Leuk1 cells was inhibited by 17-AAG, celastrol, and alpha-naphthoflavone, a known AhR antagonist.	celastrol	87-96	aryl hydrocarbon receptor	Homo sapiens	132-135
19138996-8	2008	The reduction in B(a)P-induced DNA adducts was due, at least in part, to reduced metabolic activation of B(a)P. Collectively, these results suggest that 17-AAG and celastrol, inhibitors of HSP90, suppress the activation of AhR-dependent gene expression, leading, in turn, to reduced formation of B(a)P-induced DNA adducts.	celastrol	164-173	heat shock protein 90 alpha family class A member 1	Homo sapiens	189-194
19138996-8	2008	The reduction in B(a)P-induced DNA adducts was due, at least in part, to reduced metabolic activation of B(a)P. Collectively, these results suggest that 17-AAG and celastrol, inhibitors of HSP90, suppress the activation of AhR-dependent gene expression, leading, in turn, to reduced formation of B(a)P-induced DNA adducts.	celastrol	164-173	aryl hydrocarbon receptor	Homo sapiens	223-226
18577440-7	2008	The effects of tripterine were associated with decreased interleukin-1beta (IL-1beta) mRNA expression in ankle joint synovial membrane and tumor necrosis factor-alpha (TNF-alpha) mRNA expression in homogenized paws from adjuvant-induced arthritic rats.	celastrol	15-25	interleukin 1 beta	Rattus norvegicus	76-84
18577440-7	2008	The effects of tripterine were associated with decreased interleukin-1beta (IL-1beta) mRNA expression in ankle joint synovial membrane and tumor necrosis factor-alpha (TNF-alpha) mRNA expression in homogenized paws from adjuvant-induced arthritic rats.	celastrol	15-25	tumor necrosis factor	Rattus norvegicus	139-166
18577440-7	2008	The effects of tripterine were associated with decreased interleukin-1beta (IL-1beta) mRNA expression in ankle joint synovial membrane and tumor necrosis factor-alpha (TNF-alpha) mRNA expression in homogenized paws from adjuvant-induced arthritic rats.	celastrol	15-25	tumor necrosis factor	Rattus norvegicus	168-177
17943263-2	2007	In this paper, we show that celastrol, a compound recently shown to up-regulate hsp gene expression, significantly decreases killing of cells expressing mutant polyglutamine protein.	celastrol	28-37	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	80-83
18202019-4	2008	Here, we reported that celastrol disrupted Hsp90-Cdc37 interaction in the superchaperone complex to exhibit antitumor activity in vitro and in vivo.	celastrol	23-32	heat shock protein 86, pseudogene 1	Mus musculus	43-48
18202019-4	2008	Here, we reported that celastrol disrupted Hsp90-Cdc37 interaction in the superchaperone complex to exhibit antitumor activity in vitro and in vivo.	celastrol	23-32	cell division cycle 37	Mus musculus	49-54
18202019-5	2008	Molecular docking and molecular dynamic simulations showed that celastrol blocked the critical interaction of Glu33 (Hsp90) and Arg167 (Cdc37).	celastrol	64-73	heat shock protein 86, pseudogene 1	Mus musculus	117-122
18202019-5	2008	Molecular docking and molecular dynamic simulations showed that celastrol blocked the critical interaction of Glu33 (Hsp90) and Arg167 (Cdc37).	celastrol	64-73	cell division cycle 37	Mus musculus	136-141
18202019-6	2008	Immunoprecipitation confirmed that celastrol (10 micromol/L) disrupted the Hsp90-Cdc37 interaction in the pancreatic cancer cell line Panc-1.	celastrol	35-44	heat shock protein 86, pseudogene 1	Mus musculus	75-80
18202019-6	2008	Immunoprecipitation confirmed that celastrol (10 micromol/L) disrupted the Hsp90-Cdc37 interaction in the pancreatic cancer cell line Panc-1.	celastrol	35-44	cell division cycle 37	Mus musculus	81-86
18202019-6	2008	Immunoprecipitation confirmed that celastrol (10 micromol/L) disrupted the Hsp90-Cdc37 interaction in the pancreatic cancer cell line Panc-1.	celastrol	35-44	pancreas protein 1	Mus musculus	134-140
18202019-8	2008	However, celastrol (1-5 micromol/L) induced Hsp90 client protein degradation (Cdk4 and Akt) by 70% to 80% and increased Hsp70 expression by 12-fold.	celastrol	9-18	heat shock protein 86, pseudogene 1	Mus musculus	44-49
18202019-8	2008	However, celastrol (1-5 micromol/L) induced Hsp90 client protein degradation (Cdk4 and Akt) by 70% to 80% and increased Hsp70 expression by 12-fold.	celastrol	9-18	cyclin-dependent kinase 4	Mus musculus	78-82
18202019-8	2008	However, celastrol (1-5 micromol/L) induced Hsp90 client protein degradation (Cdk4 and Akt) by 70% to 80% and increased Hsp70 expression by 12-fold.	celastrol	9-18	thymoma viral proto-oncogene 1	Mus musculus	87-90
18202019-8	2008	However, celastrol (1-5 micromol/L) induced Hsp90 client protein degradation (Cdk4 and Akt) by 70% to 80% and increased Hsp70 expression by 12-fold.	celastrol	9-18	heat shock protein 1B	Mus musculus	120-125
18202019-9	2008	Celastrol induced apoptosis in vitro and significantly inhibited tumor growth in Panc-1 xenografts.	celastrol	0-9	pancreas protein 1	Mus musculus	81-87
18202019-10	2008	Moreover, celastrol (3 mg/kg) effectively suppressed tumor metastasis by more than 80% in RIP1-Tag2 transgenic mouse model with pancreatic islet cell carcinogenesis.	celastrol	10-19	receptor (TNFRSF)-interacting serine-threonine kinase 1	Mus musculus	90-94
18202019-11	2008	The data suggest that celastrol is a novel Hsp90 inhibitor to disrupt Hsp90-Cdc37 interaction against pancreatic cancer cells.	celastrol	22-31	heat shock protein 86, pseudogene 1	Mus musculus	43-48
18202019-11	2008	The data suggest that celastrol is a novel Hsp90 inhibitor to disrupt Hsp90-Cdc37 interaction against pancreatic cancer cells.	celastrol	22-31	heat shock protein 86, pseudogene 1	Mus musculus	70-75
18202019-11	2008	The data suggest that celastrol is a novel Hsp90 inhibitor to disrupt Hsp90-Cdc37 interaction against pancreatic cancer cells.	celastrol	22-31	cell division cycle 37	Mus musculus	76-81
18343027-4	2008	Interestingly, while celastrol had no effect on either the expression of VEGF or its mRNA levels, celastrol treatment lowered the expression levels of its receptors (VEGFR-1 and VEGFR-2) and their mRNA levels.	celastrol	98-107	FMS-like tyrosine kinase 1	Mus musculus	166-173
18343027-4	2008	Interestingly, while celastrol had no effect on either the expression of VEGF or its mRNA levels, celastrol treatment lowered the expression levels of its receptors (VEGFR-1 and VEGFR-2) and their mRNA levels.	celastrol	98-107	kinase insert domain protein receptor	Mus musculus	178-185
18343027-5	2008	These findings suggest that celastrol have potential to be used as an antiangiogenesis drug through its role in suppressing VEGF receptors expression that might consequently reduce the signal transduction between VEGF and VEGFR.	celastrol	28-37	vascular endothelial growth factor A	Mus musculus	124-128
18343027-5	2008	These findings suggest that celastrol have potential to be used as an antiangiogenesis drug through its role in suppressing VEGF receptors expression that might consequently reduce the signal transduction between VEGF and VEGFR.	celastrol	28-37	vascular endothelial growth factor A	Mus musculus	213-217
18199679-3	2008	The quinone methide triterpene celastrol, derived from a traditional Chinese medicinal herb, has numerous pharmacological properties, and it is a potent activator of the mammalian heat shock transcription factor HSF1.	celastrol	31-40	heat shock transcription factor 1	Homo sapiens	212-216
18199679-5	2008	We show here that celastrol activates Hsf1 in Saccharomyces cerevisiae at a similar effective concentration seen in mammalian cells.	celastrol	18-27	stress-responsive transcription factor HSF1	Saccharomyces cerevisiae S288C	38-42
18199679-7	2008	Celastrol activated the yeast Yap1 oxidant defense transcription factor via the carboxy-terminal redox center that responds to electrophilic compounds.	celastrol	0-9	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	30-34
18199679-9	2008	We report that celastrol"s biological effects, including inhibition of glucocorticoid receptor activity, can be blocked by the addition of excess free thiol, suggesting a chemical mechanism for biological activity based on modification of key reactive thiols by this natural product.	celastrol	15-24	nuclear receptor subfamily 3 group C member 1	Homo sapiens	71-94
18160842-0	2007	Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells.	celastrol	0-9	mitogen-activated protein kinase 1	Mus musculus	84-88
18160842-0	2007	Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells.	celastrol	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	113-122
18160842-2	2007	Here, we investigated whether celastrol, which has been used as a potent anti-inflammatory and anti-oxidative agent in Chinese medicine, attenuates excessive production of NO and proinflammatory cytokines such as TNF-alpha and IL-1betal in LPS-stimulated BV-2 cells, a mouse microglial cell line.	celastrol	30-39	tumor necrosis factor	Mus musculus	213-222
18160842-2	2007	Here, we investigated whether celastrol, which has been used as a potent anti-inflammatory and anti-oxidative agent in Chinese medicine, attenuates excessive production of NO and proinflammatory cytokines such as TNF-alpha and IL-1betal in LPS-stimulated BV-2 cells, a mouse microglial cell line.	celastrol	30-39	interleukin 1 complex	Mus musculus	227-231
18160842-3	2007	We report here that the LPS-elicited excessive production of NO, TNF-alpha, and IL-1beta in BV-2 cells was largely inhibited in the presence of celastrol, and the attenuation of inducible iNOS and these cytokines resulted from the reduced expression of mRNAs of iNOS and these cytokines, respectively.	celastrol	144-153	tumor necrosis factor	Mus musculus	65-74
18160842-3	2007	We report here that the LPS-elicited excessive production of NO, TNF-alpha, and IL-1beta in BV-2 cells was largely inhibited in the presence of celastrol, and the attenuation of inducible iNOS and these cytokines resulted from the reduced expression of mRNAs of iNOS and these cytokines, respectively.	celastrol	144-153	interleukin 1 beta	Mus musculus	80-88
18160842-4	2007	The molecular mechanisms that underlie celastrol-mediated attenuation were the inhibition of LPS-induced phosphorylation of MAPK/ERK1/2 and the DNA binding activity of NF-kappaB in BV-2 cells.	celastrol	39-48	mitogen-activated protein kinase 1	Mus musculus	124-128
18160842-4	2007	The molecular mechanisms that underlie celastrol-mediated attenuation were the inhibition of LPS-induced phosphorylation of MAPK/ERK1/2 and the DNA binding activity of NF-kappaB in BV-2 cells.	celastrol	39-48	mitogen-activated protein kinase 3	Mus musculus	129-135
18160842-4	2007	The molecular mechanisms that underlie celastrol-mediated attenuation were the inhibition of LPS-induced phosphorylation of MAPK/ERK1/2 and the DNA binding activity of NF-kappaB in BV-2 cells.	celastrol	39-48	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	168-177
18160842-5	2007	The results indicate that celastrol effectively attenuated NO and proinflammatory cytokine production via the inhibition of ERK1/2 phosphorylation and NF-kappaB activation in LPS-activated microglia.	celastrol	26-35	mitogen-activated protein kinase 3	Mus musculus	124-130
18160842-5	2007	The results indicate that celastrol effectively attenuated NO and proinflammatory cytokine production via the inhibition of ERK1/2 phosphorylation and NF-kappaB activation in LPS-activated microglia.	celastrol	26-35	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	151-160
16929507-6	2007	Tripterine decreased urine protein excretion and the level of serum anti-dsDNA antibodies and also suppressed the expression of collagen type IV and TGF-beta1 mRNA in the murine kidney tissue.	celastrol	0-10	transforming growth factor, beta 1	Mus musculus	149-158
17498488-5	2007	RESULTS: ATRA caused remarkable elevation of intercellular adhesion molecule-1 (ICAM-1) in NB4 cells, which could be significantly reduced by tripterine (P&lt;0.01).	celastrol	142-152	intercellular adhesion molecule 1	Homo sapiens	45-78
16929507-0	2007	Effects of tripterine on mRNA expression of TGF-beta1 and collagen IV expression in BW F1 mice.	celastrol	11-21	transforming growth factor, beta 1	Mus musculus	44-53
16929507-0	2007	Effects of tripterine on mRNA expression of TGF-beta1 and collagen IV expression in BW F1 mice.	celastrol	11-21	WD repeat and FYVE domain containing 3	Mus musculus	84-89
17498488-5	2007	RESULTS: ATRA caused remarkable elevation of intercellular adhesion molecule-1 (ICAM-1) in NB4 cells, which could be significantly reduced by tripterine (P&lt;0.01).	celastrol	142-152	intercellular adhesion molecule 1	Homo sapiens	80-86
17498488-6	2007	The expressions of E-selectin, vascular cell adhesion molecule-1 (VCAM-1) and ICAM-1 in HUVEC were elevated by conditioned medium from ATRA-induced NB4 (ATRA-NB4-CM) (P&lt;0.01), and inhibited by tripterine with inhibition rates being 25.3%, 42.4% and 61.0% respectively.	celastrol	196-206	selectin E	Homo sapiens	19-29
17498488-6	2007	The expressions of E-selectin, vascular cell adhesion molecule-1 (VCAM-1) and ICAM-1 in HUVEC were elevated by conditioned medium from ATRA-induced NB4 (ATRA-NB4-CM) (P&lt;0.01), and inhibited by tripterine with inhibition rates being 25.3%, 42.4% and 61.0% respectively.	celastrol	196-206	vascular cell adhesion molecule 1	Homo sapiens	66-72
17498488-6	2007	The expressions of E-selectin, vascular cell adhesion molecule-1 (VCAM-1) and ICAM-1 in HUVEC were elevated by conditioned medium from ATRA-induced NB4 (ATRA-NB4-CM) (P&lt;0.01), and inhibited by tripterine with inhibition rates being 25.3%, 42.4% and 61.0% respectively.	celastrol	196-206	intercellular adhesion molecule 1	Homo sapiens	78-84
16984800-0	2006	Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid.	celastrol	74-83	nuclear factor kappa B subunit 1	Homo sapiens	14-24
16984800-4	2006	Importantly, celastrol inhibited IKK activity and the constitutively active IKK beta activity in a dose-dependent manner without either affecting the NF-kappa B activation induced by RelA over-expression or directly suppressing the DNA-binding of activated NF-kappa B.	celastrol	13-22	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	33-36
16984800-3	2006	Preincubation of celastrol completely blocked the LPS-, TNF-alpha-, or PMA-induced degradation and phosphorylation of I kappa B alpha.	celastrol	17-26	tumor necrosis factor	Homo sapiens	56-65
16984800-4	2006	Importantly, celastrol inhibited IKK activity and the constitutively active IKK beta activity in a dose-dependent manner without either affecting the NF-kappa B activation induced by RelA over-expression or directly suppressing the DNA-binding of activated NF-kappa B.	celastrol	13-22	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	76-84
16984800-3	2006	Preincubation of celastrol completely blocked the LPS-, TNF-alpha-, or PMA-induced degradation and phosphorylation of I kappa B alpha.	celastrol	17-26	NFKB inhibitor alpha	Homo sapiens	118-133
16984800-4	2006	Importantly, celastrol inhibited IKK activity and the constitutively active IKK beta activity in a dose-dependent manner without either affecting the NF-kappa B activation induced by RelA over-expression or directly suppressing the DNA-binding of activated NF-kappa B.	celastrol	13-22	nuclear factor kappa B subunit 1	Homo sapiens	257-267
16984800-5	2006	However, mutation of cysteine 179 in the activation loop of IKK beta abolished sensitivity towards to celastrol, suggesting that celastrol suppressed the NF-kappa B activation by targeting cysteine 179 in the IKK.	celastrol	102-111	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	60-68
16769766-4	2006	In the present study, we show that in inflammatory conditions, mimicked by tumor necrosis factor alpha (TNF-alpha) stimulation, pretreatment for 6 h with tripterine at nontoxic concentrations of 20-200 nM inhibits the expression of E-selectin, vascular cell adhesion molecule (CAM)-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner.	celastrol	154-164	intercellular adhesion molecule 1	Homo sapiens	298-331
16984800-5	2006	However, mutation of cysteine 179 in the activation loop of IKK beta abolished sensitivity towards to celastrol, suggesting that celastrol suppressed the NF-kappa B activation by targeting cysteine 179 in the IKK.	celastrol	102-111	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	60-63
16984800-5	2006	However, mutation of cysteine 179 in the activation loop of IKK beta abolished sensitivity towards to celastrol, suggesting that celastrol suppressed the NF-kappa B activation by targeting cysteine 179 in the IKK.	celastrol	129-138	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	60-68
16984800-5	2006	However, mutation of cysteine 179 in the activation loop of IKK beta abolished sensitivity towards to celastrol, suggesting that celastrol suppressed the NF-kappa B activation by targeting cysteine 179 in the IKK.	celastrol	129-138	nuclear factor kappa B subunit 1	Homo sapiens	154-164
16984800-5	2006	However, mutation of cysteine 179 in the activation loop of IKK beta abolished sensitivity towards to celastrol, suggesting that celastrol suppressed the NF-kappa B activation by targeting cysteine 179 in the IKK.	celastrol	129-138	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	60-63
16984800-6	2006	To verify that celastrol is a NF-kappa B inhibitor, we investigated its effect on some NF-kappa B target genes expressions.	celastrol	15-24	nuclear factor kappa B subunit 1	Homo sapiens	30-40
16984800-6	2006	To verify that celastrol is a NF-kappa B inhibitor, we investigated its effect on some NF-kappa B target genes expressions.	celastrol	15-24	nuclear factor kappa B subunit 1	Homo sapiens	87-97
16984800-7	2006	Celastrol prevented not only LPS-induced mRNA expression of iNOS and TNF-alpha, but also TNF-alpha-induced Bfl-1/A1 expression, a prosurvival Bcl-2 homologue.	celastrol	0-9	nitric oxide synthase 2	Homo sapiens	60-64
16984800-7	2006	Celastrol prevented not only LPS-induced mRNA expression of iNOS and TNF-alpha, but also TNF-alpha-induced Bfl-1/A1 expression, a prosurvival Bcl-2 homologue.	celastrol	0-9	tumor necrosis factor	Homo sapiens	69-78
16984800-7	2006	Celastrol prevented not only LPS-induced mRNA expression of iNOS and TNF-alpha, but also TNF-alpha-induced Bfl-1/A1 expression, a prosurvival Bcl-2 homologue.	celastrol	0-9	tumor necrosis factor	Homo sapiens	89-98
16984800-7	2006	Celastrol prevented not only LPS-induced mRNA expression of iNOS and TNF-alpha, but also TNF-alpha-induced Bfl-1/A1 expression, a prosurvival Bcl-2 homologue.	celastrol	0-9	BCL2 related protein A1	Homo sapiens	107-112
16984800-7	2006	Celastrol prevented not only LPS-induced mRNA expression of iNOS and TNF-alpha, but also TNF-alpha-induced Bfl-1/A1 expression, a prosurvival Bcl-2 homologue.	celastrol	0-9	BCL2 apoptosis regulator	Homo sapiens	142-147
16984800-8	2006	Consistent with these results, celastrol significantly suppressed the production of NO and TNF-alpha in LPS-stimulated RAW264.7 cells, and increased the cytotoxicity of TNF-alpha in HT-1080 cells.	celastrol	31-40	tumor necrosis factor	Mus musculus	91-100
16984800-8	2006	Consistent with these results, celastrol significantly suppressed the production of NO and TNF-alpha in LPS-stimulated RAW264.7 cells, and increased the cytotoxicity of TNF-alpha in HT-1080 cells.	celastrol	31-40	tumor necrosis factor	Mus musculus	169-178
16984800-10	2006	Taken together, this study extends our understanding on the molecular mechanisms underlying the anti-inflammatory and anti-cancer activities of celastrol and celastrol-containing medicinal plant, which would be a valuable candidate for the intervention of NF-kappa B-dependent pathological conditions.	celastrol	144-153	nuclear factor kappa B subunit 1	Homo sapiens	256-266
16984800-10	2006	Taken together, this study extends our understanding on the molecular mechanisms underlying the anti-inflammatory and anti-cancer activities of celastrol and celastrol-containing medicinal plant, which would be a valuable candidate for the intervention of NF-kappa B-dependent pathological conditions.	celastrol	158-167	nuclear factor kappa B subunit 1	Homo sapiens	256-266
17010675-5	2006	Validating this prediction, we demonstrate that celastrol and gedunin inhibit HSP90 activity and HSP90 clients, including AR.	celastrol	48-57	heat shock protein 90 alpha family class A member 1	Homo sapiens	78-83
17010675-5	2006	Validating this prediction, we demonstrate that celastrol and gedunin inhibit HSP90 activity and HSP90 clients, including AR.	celastrol	48-57	heat shock protein 90 alpha family class A member 1	Homo sapiens	97-102
17010675-5	2006	Validating this prediction, we demonstrate that celastrol and gedunin inhibit HSP90 activity and HSP90 clients, including AR.	celastrol	48-57	androgen receptor	Homo sapiens	122-124
16769766-4	2006	In the present study, we show that in inflammatory conditions, mimicked by tumor necrosis factor alpha (TNF-alpha) stimulation, pretreatment for 6 h with tripterine at nontoxic concentrations of 20-200 nM inhibits the expression of E-selectin, vascular cell adhesion molecule (CAM)-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner.	celastrol	154-164	tumor necrosis factor	Homo sapiens	75-102
16769766-4	2006	In the present study, we show that in inflammatory conditions, mimicked by tumor necrosis factor alpha (TNF-alpha) stimulation, pretreatment for 6 h with tripterine at nontoxic concentrations of 20-200 nM inhibits the expression of E-selectin, vascular cell adhesion molecule (CAM)-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner.	celastrol	154-164	tumor necrosis factor	Homo sapiens	104-113
16769766-4	2006	In the present study, we show that in inflammatory conditions, mimicked by tumor necrosis factor alpha (TNF-alpha) stimulation, pretreatment for 6 h with tripterine at nontoxic concentrations of 20-200 nM inhibits the expression of E-selectin, vascular cell adhesion molecule (CAM)-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner.	celastrol	154-164	selectin E	Homo sapiens	232-242
16769766-4	2006	In the present study, we show that in inflammatory conditions, mimicked by tumor necrosis factor alpha (TNF-alpha) stimulation, pretreatment for 6 h with tripterine at nontoxic concentrations of 20-200 nM inhibits the expression of E-selectin, vascular cell adhesion molecule (CAM)-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner.	celastrol	154-164	cell adhesion molecule 1	Homo sapiens	253-283
16769766-4	2006	In the present study, we show that in inflammatory conditions, mimicked by tumor necrosis factor alpha (TNF-alpha) stimulation, pretreatment for 6 h with tripterine at nontoxic concentrations of 20-200 nM inhibits the expression of E-selectin, vascular cell adhesion molecule (CAM)-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner.	celastrol	154-164	vascular cell adhesion molecule 1	Homo sapiens	285-291
16769766-4	2006	In the present study, we show that in inflammatory conditions, mimicked by tumor necrosis factor alpha (TNF-alpha) stimulation, pretreatment for 6 h with tripterine at nontoxic concentrations of 20-200 nM inhibits the expression of E-selectin, vascular cell adhesion molecule (CAM)-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner.	celastrol	154-164	intercellular adhesion molecule 1	Homo sapiens	333-339
16769766-5	2006	Tripterine (200 nM) almost completely inhibits expression of VCAM-1 [50% inhibitory concentration (IC50) = 52 nM] and ICAM-1 (IC50 = 51 nM) and 73% of E-selectin (IC50 = 94 nM).	celastrol	0-10	vascular cell adhesion molecule 1	Homo sapiens	61-67
16769766-5	2006	Tripterine (200 nM) almost completely inhibits expression of VCAM-1 [50% inhibitory concentration (IC50) = 52 nM] and ICAM-1 (IC50 = 51 nM) and 73% of E-selectin (IC50 = 94 nM).	celastrol	0-10	intercellular adhesion molecule 1	Homo sapiens	118-124
16769766-5	2006	Tripterine (200 nM) almost completely inhibits expression of VCAM-1 [50% inhibitory concentration (IC50) = 52 nM] and ICAM-1 (IC50 = 51 nM) and 73% of E-selectin (IC50 = 94 nM).	celastrol	0-10	selectin E	Homo sapiens	151-161
16769766-7	2006	Effects on endothelial CAM of other proinflammatory cytokines, such as interleukin-1beta and interferon-gamma, were also inhibited significantly by tripterine.	celastrol	148-158	interleukin 1 beta	Homo sapiens	71-88
16769766-7	2006	Effects on endothelial CAM of other proinflammatory cytokines, such as interleukin-1beta and interferon-gamma, were also inhibited significantly by tripterine.	celastrol	148-158	interferon gamma	Homo sapiens	93-109
16769766-9	2006	In addition, tripterine inhibited adhesion of human monocytes and T lymphocytes to TNF-alpha-stimulated HUVEC.	celastrol	13-23	tumor necrosis factor	Homo sapiens	83-92
16769766-10	2006	Finally, tripterine inhibited TNF-alpha-driven CAM mRNA transcription and nuclear factor-kappaB nuclear (NF-kappaB) translocation.	celastrol	9-19	tumor necrosis factor	Homo sapiens	30-39
16092942-8	2005	Celastrol induced heat shock protein 70 within dopaminergic neurons and decreased tumor necrosis factor-alpha and nuclear factor kappa B immunostainings as well as astrogliosis.	celastrol	0-9	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	18-39
16407206-0	2006	Chronic inhibition of cardiac Kir2.1 and HERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking.	celastrol	68-77	potassium voltage-gated channel subfamily H member 2	Homo sapiens	41-45
16407206-5	2006	Further investigation of celastrol (3-hydroxy-24-nor-2-oxo-1 (10),3,5,7-friedelatetraen-29-oic acid), a cell-permeable dienonephenolic triterpene compound, revealed its potent inhibitory activity on both Kir2.1 and hERG potassium channels, causal to QT prolongation.	celastrol	25-34	potassium inwardly rectifying channel subfamily J member 2	Homo sapiens	204-210
16407206-5	2006	Further investigation of celastrol (3-hydroxy-24-nor-2-oxo-1 (10),3,5,7-friedelatetraen-29-oic acid), a cell-permeable dienonephenolic triterpene compound, revealed its potent inhibitory activity on both Kir2.1 and hERG potassium channels, causal to QT prolongation.	celastrol	25-34	ETS transcription factor ERG	Homo sapiens	215-219
16651429-7	2006	Inhibition of the proteasome activity by Celastrol in PC-3 (androgen receptor- or AR-negative) or LNCaP (AR-positive) cells results in the accumulation of ubiquitinated proteins and three natural proteasome substrates (IkappaB-alpha, Bax, and p27), accompanied by suppression of AR protein expression (in LNCaP cells) and induction of apoptosis.	celastrol	41-50	chromobox 8	Homo sapiens	54-58
16651429-7	2006	Inhibition of the proteasome activity by Celastrol in PC-3 (androgen receptor- or AR-negative) or LNCaP (AR-positive) cells results in the accumulation of ubiquitinated proteins and three natural proteasome substrates (IkappaB-alpha, Bax, and p27), accompanied by suppression of AR protein expression (in LNCaP cells) and induction of apoptosis.	celastrol	41-50	NFKB inhibitor alpha	Homo sapiens	219-232
16651429-7	2006	Inhibition of the proteasome activity by Celastrol in PC-3 (androgen receptor- or AR-negative) or LNCaP (AR-positive) cells results in the accumulation of ubiquitinated proteins and three natural proteasome substrates (IkappaB-alpha, Bax, and p27), accompanied by suppression of AR protein expression (in LNCaP cells) and induction of apoptosis.	celastrol	41-50	BCL2 associated X, apoptosis regulator	Homo sapiens	234-237
16651429-7	2006	Inhibition of the proteasome activity by Celastrol in PC-3 (androgen receptor- or AR-negative) or LNCaP (AR-positive) cells results in the accumulation of ubiquitinated proteins and three natural proteasome substrates (IkappaB-alpha, Bax, and p27), accompanied by suppression of AR protein expression (in LNCaP cells) and induction of apoptosis.	celastrol	41-50	interferon alpha inducible protein 27	Homo sapiens	243-246
16651429-8	2006	Treatment of PC-3 tumor-bearing nude mice with Celastrol (1-3 mg/kg/d, i.p., 1-31 days) resulted in significant inhibition (65-93%) of the tumor growth.	celastrol	47-56	chromobox 8	Mus musculus	13-17
16407206-0	2006	Chronic inhibition of cardiac Kir2.1 and HERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking.	celastrol	68-77	potassium inwardly rectifying channel subfamily J member 2	Homo sapiens	30-36
16092942-8	2005	Celastrol induced heat shock protein 70 within dopaminergic neurons and decreased tumor necrosis factor-alpha and nuclear factor kappa B immunostainings as well as astrogliosis.	celastrol	0-9	tumor necrosis factor	Rattus norvegicus	82-109
15509580-4	2004	From a structure/function examination, the celastrol structure is remarkably specific and activates heat shock transcription factor 1 (HSF1) with kinetics similar to those of heat stress, as determined by the induction of HSF1 DNA binding, hyperphosphorylation of HSF1, and expression of chaperone genes.	celastrol	43-52	heat shock transcription factor 1	Homo sapiens	100-133
16909005-8	2005	Celastrol treatment reduced TNF-alpha, iNOS, CD40, and GFAP immunoreactivity in the lumbar spinal cord sections of celastrol-treated G93A mice compared to untreated G93A mice.	celastrol	0-9	tumor necrosis factor	Mus musculus	28-37
16909005-8	2005	Celastrol treatment reduced TNF-alpha, iNOS, CD40, and GFAP immunoreactivity in the lumbar spinal cord sections of celastrol-treated G93A mice compared to untreated G93A mice.	celastrol	0-9	nitric oxide synthase 2, inducible	Mus musculus	39-43
16909005-8	2005	Celastrol treatment reduced TNF-alpha, iNOS, CD40, and GFAP immunoreactivity in the lumbar spinal cord sections of celastrol-treated G93A mice compared to untreated G93A mice.	celastrol	0-9	CD40 antigen	Mus musculus	45-49
16909005-8	2005	Celastrol treatment reduced TNF-alpha, iNOS, CD40, and GFAP immunoreactivity in the lumbar spinal cord sections of celastrol-treated G93A mice compared to untreated G93A mice.	celastrol	0-9	glial fibrillary acidic protein	Mus musculus	55-59
16909005-8	2005	Celastrol treatment reduced TNF-alpha, iNOS, CD40, and GFAP immunoreactivity in the lumbar spinal cord sections of celastrol-treated G93A mice compared to untreated G93A mice.	celastrol	115-124	glial fibrillary acidic protein	Mus musculus	55-59
16909005-10	2005	HSP70 immunoreactivity was increased in lumbar spinal cord neurons of celastrol-treated G93A mice.	celastrol	70-79	heat shock protein 1B	Mus musculus	0-5
15840409-4	2005	Treatment with tripterine 12 mg kg(-1) day(-1) for 15 days protected renal from glomerular injury with a concomitant reduction of serum autoantibodies and total immunoglobulin G (IgG) also with a improvement of splenocyte proliferation stimulated with concanavalin A and lipopolysaccharide.	celastrol	15-25	immunoglobulin heavy variable V1-62	Mus musculus	161-177
15840409-4	2005	Treatment with tripterine 12 mg kg(-1) day(-1) for 15 days protected renal from glomerular injury with a concomitant reduction of serum autoantibodies and total immunoglobulin G (IgG) also with a improvement of splenocyte proliferation stimulated with concanavalin A and lipopolysaccharide.	celastrol	15-25	immunoglobulin heavy variable V1-62	Mus musculus	179-182
15649316-8	2005	Of these, both juglone and celastrol were effective in reversing the abnormal cellular localization of full-length mutant huntingtin observed in mutant HdhQ111/Q111 striatal cells.	celastrol	27-36	huntingtin	Mus musculus	122-132
15509580-4	2004	From a structure/function examination, the celastrol structure is remarkably specific and activates heat shock transcription factor 1 (HSF1) with kinetics similar to those of heat stress, as determined by the induction of HSF1 DNA binding, hyperphosphorylation of HSF1, and expression of chaperone genes.	celastrol	43-52	heat shock transcription factor 1	Homo sapiens	135-139
15509580-4	2004	From a structure/function examination, the celastrol structure is remarkably specific and activates heat shock transcription factor 1 (HSF1) with kinetics similar to those of heat stress, as determined by the induction of HSF1 DNA binding, hyperphosphorylation of HSF1, and expression of chaperone genes.	celastrol	43-52	heat shock transcription factor 1	Homo sapiens	222-226
15509580-4	2004	From a structure/function examination, the celastrol structure is remarkably specific and activates heat shock transcription factor 1 (HSF1) with kinetics similar to those of heat stress, as determined by the induction of HSF1 DNA binding, hyperphosphorylation of HSF1, and expression of chaperone genes.	celastrol	43-52	heat shock transcription factor 1	Homo sapiens	222-226
12133425-2	2002	METHODS: Different doses of Tripterine were injected peritoneally to BW F1 mice at different stages.	celastrol	28-38	WD repeat and FYVE domain containing 3	Mus musculus	69-74
15130326-9	2004	In vitro, the concentration of histamine and eotaxin in coculture supernants and the expression of SCF protein in fibroblasts from coculture were (3.83 +/- 0.41) ng/ml, (5.79 +/- 0.40) ng/ml and (95 +/- 3)%, respectively; after tripterine intervention, the data changed to (2.88 +/- 0.35) ng/ml, (4.24 +/- 0.29) ng/ml, (17 +/- 5)% (all P &lt; 0.01).	celastrol	228-238	kit ligand	Mus musculus	99-102
15130326-10	2004	CONCLUSIONS: Tripterine might suppress airway inflammation in asthmatic mice, probably by downregulating the expression of SCF in fibroblasts, then inhibiting the production of histamine and eotaxin in mast cells.	celastrol	13-23	kit ligand	Mus musculus	123-126
15130326-10	2004	CONCLUSIONS: Tripterine might suppress airway inflammation in asthmatic mice, probably by downregulating the expression of SCF in fibroblasts, then inhibiting the production of histamine and eotaxin in mast cells.	celastrol	13-23	chemokine (C-C motif) ligand 11	Mus musculus	191-198
14640511-4	2003	The major terpenoid components, celastrol (6) and its methyl ester derivative, pristimerin (7), were significantly active against nine cancer cell lines, including A549, MCF-7, HCT-8, KB, KB-VIN, U-87-MG, PC-3, 1A9, and PTX10 cell lines, with ED(50) values ranging from 0.076 to 0.34 microg/mL.	celastrol	32-41	long intergenic non-protein coding RNA 1191	Homo sapiens	191-194
12508653-4	2002	Immunohistochemistry was used to examine the expression of Bax, Bcl-2 after treatment of triptolide and celastrol.	celastrol	104-113	BCL2 apoptosis regulator	Homo sapiens	64-69
12508653-7	2002	CONCLUSION: Triptolide and celastrol inhibit the proliferation of glioma cells in vitro, which was associated with promoting the expression of Bax and inhibiting the expression of Bcl-2 and accelerating cell apotosis.	celastrol	27-36	BCL2 associated X, apoptosis regulator	Homo sapiens	143-146
12508653-7	2002	CONCLUSION: Triptolide and celastrol inhibit the proliferation of glioma cells in vitro, which was associated with promoting the expression of Bax and inhibiting the expression of Bcl-2 and accelerating cell apotosis.	celastrol	27-36	BCL2 apoptosis regulator	Homo sapiens	180-185
12133425-4	2002	RESULTS: (1) Tripterine suppressed the development of proteinuria, decreased the level of serum anti-dsDNA antibodies, reduced the expressions of collagen type IV, fibronectin, TIMP-1, TIMP-2, TGF-beta(1) and improved the expressions of MMP-1, -2 in the murine kidney.	celastrol	13-23	fibronectin 1	Mus musculus	164-175
12133425-4	2002	RESULTS: (1) Tripterine suppressed the development of proteinuria, decreased the level of serum anti-dsDNA antibodies, reduced the expressions of collagen type IV, fibronectin, TIMP-1, TIMP-2, TGF-beta(1) and improved the expressions of MMP-1, -2 in the murine kidney.	celastrol	13-23	tissue inhibitor of metalloproteinase 1	Mus musculus	177-183
12133425-4	2002	RESULTS: (1) Tripterine suppressed the development of proteinuria, decreased the level of serum anti-dsDNA antibodies, reduced the expressions of collagen type IV, fibronectin, TIMP-1, TIMP-2, TGF-beta(1) and improved the expressions of MMP-1, -2 in the murine kidney.	celastrol	13-23	tissue inhibitor of metalloproteinase 2	Mus musculus	185-191
12133425-4	2002	RESULTS: (1) Tripterine suppressed the development of proteinuria, decreased the level of serum anti-dsDNA antibodies, reduced the expressions of collagen type IV, fibronectin, TIMP-1, TIMP-2, TGF-beta(1) and improved the expressions of MMP-1, -2 in the murine kidney.	celastrol	13-23	transforming growth factor, beta 1	Mus musculus	193-204
12133425-4	2002	RESULTS: (1) Tripterine suppressed the development of proteinuria, decreased the level of serum anti-dsDNA antibodies, reduced the expressions of collagen type IV, fibronectin, TIMP-1, TIMP-2, TGF-beta(1) and improved the expressions of MMP-1, -2 in the murine kidney.	celastrol	13-23	matrix metallopeptidase 13	Mus musculus	237-242
11601243-9	1999	Tripterine could upregulate Bax, c-myc expression and downregulate bcl-2 expression at protein level.	celastrol	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	28-31
11513350-5	2001	In low nanomolar concentrations celastrol was found to suppress the production by human monocytes and macrophages of the pro-inflammatory cytokines TNF-alpha and IL-1beta.	celastrol	32-41	tumor necrosis factor	Homo sapiens	148-157
11513350-5	2001	In low nanomolar concentrations celastrol was found to suppress the production by human monocytes and macrophages of the pro-inflammatory cytokines TNF-alpha and IL-1beta.	celastrol	32-41	interleukin 1 alpha	Homo sapiens	162-170
11601243-9	1999	Tripterine could upregulate Bax, c-myc expression and downregulate bcl-2 expression at protein level.	celastrol	0-10	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	33-38
11601243-9	1999	Tripterine could upregulate Bax, c-myc expression and downregulate bcl-2 expression at protein level.	celastrol	0-10	BCL2 apoptosis regulator	Homo sapiens	67-72
11601243-10	1999	CONCLUSION: Tripterine can efficiently induce HMC-1 cell apoptosis, occurring mainly in S phase, which is correlated with upregulating Bax, c-myc expression and downregulating bcl-2 expression.	celastrol	12-22	BCL2 associated X, apoptosis regulator	Homo sapiens	135-138
11601243-10	1999	CONCLUSION: Tripterine can efficiently induce HMC-1 cell apoptosis, occurring mainly in S phase, which is correlated with upregulating Bax, c-myc expression and downregulating bcl-2 expression.	celastrol	12-22	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	140-145
11601243-10	1999	CONCLUSION: Tripterine can efficiently induce HMC-1 cell apoptosis, occurring mainly in S phase, which is correlated with upregulating Bax, c-myc expression and downregulating bcl-2 expression.	celastrol	12-22	BCL2 apoptosis regulator	Homo sapiens	176-181
11367666-0	1998	[Effect of Tripterine on mRNA expression of c-myc and platelet derived growth factor of vascular smooth muscle cell in rats].	celastrol	11-21	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	44-49
9873452-2	1998	Tripterine and closely related triterpenoid derivatives as IL-1 beta release inhibitors are discussed.	celastrol	0-10	interleukin 1 beta	Homo sapiens	59-68
9934491-2	1998	Truncated analogs of tripterine as cytokine (IL-1 alpha, IL-1 beta, TNF-alpha, IL-6, and IL-8) release inhibitors are discussed.	celastrol	21-31	interleukin 1 alpha	Homo sapiens	45-55
9934491-2	1998	Truncated analogs of tripterine as cytokine (IL-1 alpha, IL-1 beta, TNF-alpha, IL-6, and IL-8) release inhibitors are discussed.	celastrol	21-31	interleukin 1 beta	Homo sapiens	57-66
9934491-2	1998	Truncated analogs of tripterine as cytokine (IL-1 alpha, IL-1 beta, TNF-alpha, IL-6, and IL-8) release inhibitors are discussed.	celastrol	21-31	tumor necrosis factor	Homo sapiens	68-77
9934491-2	1998	Truncated analogs of tripterine as cytokine (IL-1 alpha, IL-1 beta, TNF-alpha, IL-6, and IL-8) release inhibitors are discussed.	celastrol	21-31	interleukin 6	Homo sapiens	79-83
9934491-2	1998	Truncated analogs of tripterine as cytokine (IL-1 alpha, IL-1 beta, TNF-alpha, IL-6, and IL-8) release inhibitors are discussed.	celastrol	21-31	C-X-C motif chemokine ligand 8	Homo sapiens	89-93
11367666-1	1998	OBJECTIVE: To observe the effect of Tripterine on mRNA expression of c-myc and platelet derived growth factor (PDGF) in vascular smooth muscle cell (VSMC) of rats.	celastrol	36-46	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	69-74
11367666-6	1998	RESULTS: Tripterine inhibited the PDGF mRNA expression of VSMC and decreased c-myc mRNA expression in a dose-dependent manner, either vs. control.	celastrol	9-19	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	77-82
11367666-7	1998	CONCLUSION: Tripterine could inhibit mRNA expression of c-myc and PDGF in VSMC, therefore, it would inhibit overproliferation of VSMC.	celastrol	12-22	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	56-61
1821082-0	1991	[Inhibitory effect of tripterine on activities of IL-1, IL-2 and release of PGE2].	celastrol	22-32	interleukin 1 complex	Mus musculus	50-54
1821082-0	1991	[Inhibitory effect of tripterine on activities of IL-1, IL-2 and release of PGE2].	celastrol	22-32	interleukin 2	Mus musculus	56-60
1821082-4	1991	The results showed that tripterine (0.1-1.0 microgram/ml) significantly inhibited IL-1 activity of murine peritoneal macrophages induced by LPS.	celastrol	24-34	interleukin 1 complex	Mus musculus	82-86
1821082-5	1991	Because both intracellular and extracellular IL-1 activities were decreased, so tripterine might be able to reduce the production and release of IL-1.	celastrol	80-90	interleukin 1 complex	Mus musculus	45-49
1821082-5	1991	Because both intracellular and extracellular IL-1 activities were decreased, so tripterine might be able to reduce the production and release of IL-1.	celastrol	80-90	interleukin 1 complex	Mus musculus	145-149
1821082-6	1991	Besides, inhibition of IL-1 production was observed when macrophages were pretreated with the drug for 8 h and 16 h. A good relationship was found between the effect and concentration of tripterine which inhibited IL-2 production from ConA-activated murine splenocytes.	celastrol	187-197	interleukin 1 complex	Mus musculus	23-27
1821082-6	1991	Besides, inhibition of IL-1 production was observed when macrophages were pretreated with the drug for 8 h and 16 h. A good relationship was found between the effect and concentration of tripterine which inhibited IL-2 production from ConA-activated murine splenocytes.	celastrol	187-197	interleukin 2	Mus musculus	214-218
33945201-0	2021	Celastrol inhibit the proliferation, invasion and migration of human cervical HeLa cancer cells through down-regulation of MMP-2 and MMP-9.	celastrol	0-9	matrix metallopeptidase 2	Homo sapiens	123-128
33945201-0	2021	Celastrol inhibit the proliferation, invasion and migration of human cervical HeLa cancer cells through down-regulation of MMP-2 and MMP-9.	celastrol	0-9	matrix metallopeptidase 9	Homo sapiens	133-138
33945201-1	2021	The present study evaluated the anticancer potential of celastrol through down-regulation of matrix metalloproteinase-2 (MMP-2) and MMP-9.	celastrol	56-65	matrix metallopeptidase 2	Homo sapiens	93-119
33945201-1	2021	The present study evaluated the anticancer potential of celastrol through down-regulation of matrix metalloproteinase-2 (MMP-2) and MMP-9.	celastrol	56-65	matrix metallopeptidase 2	Homo sapiens	121-126
33945201-1	2021	The present study evaluated the anticancer potential of celastrol through down-regulation of matrix metalloproteinase-2 (MMP-2) and MMP-9.	celastrol	56-65	matrix metallopeptidase 9	Homo sapiens	132-137
33945201-5	2021	In addition, the expression level of MMP-2, MMP-9 and caspase-3 was evaluated following celastrol treatment.	celastrol	88-97	matrix metallopeptidase 2	Homo sapiens	37-42
33945201-5	2021	In addition, the expression level of MMP-2, MMP-9 and caspase-3 was evaluated following celastrol treatment.	celastrol	88-97	caspase 3	Homo sapiens	54-63
33945201-9	2021	Reduced expression of MMP-2 and MMP-9 and increased expression of caspase-3 were observed following celastrol treatment.	celastrol	100-109	matrix metallopeptidase 2	Homo sapiens	22-27
33945201-9	2021	Reduced expression of MMP-2 and MMP-9 and increased expression of caspase-3 were observed following celastrol treatment.	celastrol	100-109	matrix metallopeptidase 9	Homo sapiens	32-37
33945201-9	2021	Reduced expression of MMP-2 and MMP-9 and increased expression of caspase-3 were observed following celastrol treatment.	celastrol	100-109	caspase 3	Homo sapiens	66-75
34742058-0	2022	Glucose transporter 1 (GLUT1)-targeting and hypoxia-activated mitochondria-specific chemo-thermal therapy via a glycosylated poly(amido amine)/celastrol (PAMAM/Cel) complex.	celastrol	143-152	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	0-21
33808393-0	2021	Celastrol Prevents Oxidative Stress Effects on FSHR, PAPP, and CYP19A1 Gene Expression in Cultured Human Granulosa-Lutein Cells.	celastrol	0-9	follicle stimulating hormone receptor	Homo sapiens	47-51
33808393-0	2021	Celastrol Prevents Oxidative Stress Effects on FSHR, PAPP, and CYP19A1 Gene Expression in Cultured Human Granulosa-Lutein Cells.	celastrol	0-9	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	63-70
33808393-9	2021	In addition to the antioxidant activity, celastrol may well have an independent role on regulation of gene expression in hGL cells.	celastrol	41-50	LLGL scribble cell polarity complex component 2	Homo sapiens	121-124
25660987-6	2015	Furthermore, Celastrol limited the production of Th17-differentiating cytokines and chemokines (CCL3, CCL5).	celastrol	13-22	C-C motif chemokine ligand 3	Rattus norvegicus	96-100
25660987-6	2015	Furthermore, Celastrol limited the production of Th17-differentiating cytokines and chemokines (CCL3, CCL5).	celastrol	13-22	C-C motif chemokine ligand 5	Rattus norvegicus	102-106
34742058-0	2022	Glucose transporter 1 (GLUT1)-targeting and hypoxia-activated mitochondria-specific chemo-thermal therapy via a glycosylated poly(amido amine)/celastrol (PAMAM/Cel) complex.	celastrol	143-152	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	23-28
34510370-0	2022	Celastrol attenuates chronic constrictive injury-induced neuropathic pain and inhibits the TLR4/NF-kappaB signaling pathway in the spinal cord.	celastrol	0-9	toll-like receptor 4	Rattus norvegicus	91-95
34968902-0	2022	Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.	celastrol	39-48	receptor interacting serine/threonine kinase 1	Homo sapiens	107-111
34968902-0	2022	Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.	celastrol	39-48	myosin phosphatase Rho interacting protein	Homo sapiens	112-116
34968902-0	2022	Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.	celastrol	39-48	mixed lineage kinase domain like pseudokinase	Homo sapiens	117-121
34958783-7	2022	In the present study, we investigated the effect of four major components of TWHF, i.e. Triptolide (TPL), Celastrol (CL), and two alkaloids Wilforine (WFR) and Wilforgine (WFG) on the function of OATP1B1.	celastrol	106-115	solute carrier organic anion transporter family member 1B1	Homo sapiens	196-203
34510370-10	2022	Additionally, the levels of the proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha), interleukin 1beta and interleukin 6, detected by ELISA in the spinal cord of the rats with NP, were significantly inhibited by celastrol.	celastrol	226-235	tumor necrosis factor	Rattus norvegicus	87-96
34510370-10	2022	Additionally, the levels of the proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha), interleukin 1beta and interleukin 6, detected by ELISA in the spinal cord of the rats with NP, were significantly inhibited by celastrol.	celastrol	226-235	interleukin 1 beta	Rattus norvegicus	99-116
34510370-10	2022	Additionally, the levels of the proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha), interleukin 1beta and interleukin 6, detected by ELISA in the spinal cord of the rats with NP, were significantly inhibited by celastrol.	celastrol	226-235	interleukin 6	Rattus norvegicus	121-134
34510370-11	2022	Furthermore, celastrol treatment dramatically inhibited the expression of the TLR4/NF-kappaB signaling pathway in the spinal cord.	celastrol	13-22	toll-like receptor 4	Rattus norvegicus	78-82
34510370-10	2022	Additionally, the levels of the proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha), interleukin 1beta and interleukin 6, detected by ELISA in the spinal cord of the rats with NP, were significantly inhibited by celastrol.	celastrol	226-235	tumor necrosis factor	Rattus norvegicus	58-85
34942974-0	2021	Celastrol and Melatonin Modify SIRT1, SIRT6 and SIRT7 Gene Expression and Improve the Response of Human Granulosa-Lutein Cells to Oxidative Stress.	celastrol	0-9	sirtuin 1	Homo sapiens	31-36
34510370-12	2022	Taken together, our findings suggested that celastrol could attenuate mechanical and thermal pain in CCI-induced NP, and this protection might be attributed to inhibiting the TLR4/NF-kappaB signaling pathway and exerting anti-inflammatory effects in the spinal cord.	celastrol	44-53	toll-like receptor 4	Rattus norvegicus	175-179
34959287-1	2021	Herein, a flexible oral colon-targeting delivery system, mediated by electrostatic layer-by-layer alternate deposition with pectin-trimethyl chitosan (TMC) onto liposomes-loading celastrol (Cel/PT-LbL Lipo), was fabricated to enhance anti-UC efficacy.	celastrol	179-188	carboxyl ester lipase	Homo sapiens	190-193
34959287-3	2021	Based on its bilayer coating of polysaccharides, Cel/PT-LbL Lipo alleviated cytotoxicity of celastrol in colon epithelial NCM460 cells.	celastrol	92-101	carboxyl ester lipase	Homo sapiens	49-52
34560609-9	2021	The exposure of endometriotic cells to TAK1 inhibitor, celastrol caused activation of caspase-3 and -9 that led to PARP cleavage and induced apoptosis.	celastrol	55-64	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	39-43
34560609-9	2021	The exposure of endometriotic cells to TAK1 inhibitor, celastrol caused activation of caspase-3 and -9 that led to PARP cleavage and induced apoptosis.	celastrol	55-64	caspase 3	Homo sapiens	86-102
34560609-9	2021	The exposure of endometriotic cells to TAK1 inhibitor, celastrol caused activation of caspase-3 and -9 that led to PARP cleavage and induced apoptosis.	celastrol	55-64	collagen type XI alpha 2 chain	Homo sapiens	115-119
34030574-3	2021	The most potent compounds were found to be oleanic acid, betulinic acid and celastrol with IC50 values of 3.89-5.07 muM, that acted as mixed (uncompetitive plus non-competitive) inhibitors of COMT, representing a new skeleton of COMT inhibitor.	celastrol	76-85	catechol-O-methyltransferase	Homo sapiens	192-196
34030574-3	2021	The most potent compounds were found to be oleanic acid, betulinic acid and celastrol with IC50 values of 3.89-5.07 muM, that acted as mixed (uncompetitive plus non-competitive) inhibitors of COMT, representing a new skeleton of COMT inhibitor.	celastrol	76-85	catechol-O-methyltransferase	Homo sapiens	229-233
34942974-0	2021	Celastrol and Melatonin Modify SIRT1, SIRT6 and SIRT7 Gene Expression and Improve the Response of Human Granulosa-Lutein Cells to Oxidative Stress.	celastrol	0-9	sirtuin 6	Homo sapiens	38-43
34942974-0	2021	Celastrol and Melatonin Modify SIRT1, SIRT6 and SIRT7 Gene Expression and Improve the Response of Human Granulosa-Lutein Cells to Oxidative Stress.	celastrol	0-9	sirtuin 7	Homo sapiens	48-53
34942974-2	2021	SIRT1, SIRT6 and SIRT7 are involved in protection stress systems caused by OS, and they can be activated by antioxidants such as celastrol or melatonin.	celastrol	129-138	sirtuin 1	Homo sapiens	0-5
34942974-2	2021	SIRT1, SIRT6 and SIRT7 are involved in protection stress systems caused by OS, and they can be activated by antioxidants such as celastrol or melatonin.	celastrol	129-138	sirtuin 6	Homo sapiens	7-12
34942974-2	2021	SIRT1, SIRT6 and SIRT7 are involved in protection stress systems caused by OS, and they can be activated by antioxidants such as celastrol or melatonin.	celastrol	129-138	sirtuin 7	Homo sapiens	17-22
34942974-5	2021	In addition, melatonin induced SIRT1, SIRT6 and SIRT7 gene expression while celastrol only induced SIRT7 gene expression.	celastrol	76-85	sirtuin 7	Homo sapiens	99-104
34942974-7	2021	Our previous data for cultured hGL cells showed a dual role of celastrol as a free radical scavenger and as a protective agent by regulating gene expression.	celastrol	63-72	lipase F, gastric type	Homo sapiens	31-34
34942974-8	2021	This study shows a direct effect of celastrol on SIRT7 gene expression.	celastrol	36-45	sirtuin 7	Homo sapiens	49-54
34942974-10	2021	In conclusion, our results show increased hGL cells survival with melatonin or celastrol treatment under OS conditions, probably through the regulation of nuclear sirtuins" gene expression.	celastrol	79-88	lipase F, gastric type	Homo sapiens	42-45
34507130-0	2021	Corrigendum to "Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy" (Biomaterials 269 (2021) 120604).	celastrol	16-25	CD274 molecule	Homo sapiens	80-85
34304725-0	2021	Topical application of celastrol alleviates atopic dermatitis symptoms mediated through the regulation of thymic stromal lymphopoietin and group 2 innate lymphoid cells.	celastrol	23-32	thymic stromal lymphopoietin	Mus musculus	106-134
34304725-4	2021	The aim of this study was to investigate whether celastrol alleviated atopic dermatitis symptoms by regulating TSLP expression and ILC2 stimulation.	celastrol	49-58	thymic stromal lymphopoietin	Mus musculus	111-115
34304725-5	2021	Celastrol suppressed TSLP production in mouse keratinocyte cells by inhibiting NF-kB activation.	celastrol	0-9	thymic stromal lymphopoietin	Mus musculus	21-25
34304725-7	2021	Celastrol decreased the levels of TSLP in atopic dermatitis skin lesions of HDM-stimulated NC/Nga mice.	celastrol	0-9	thymic stromal lymphopoietin	Mus musculus	34-38
34304725-8	2021	Celastrol reduced levels of Th2 cytokines including IL-4, IL-5, and IL-13 in atopic dermatitis skin lesions of NC/Nga mice.	celastrol	0-9	interleukin 4	Mus musculus	52-56
34304725-8	2021	Celastrol reduced levels of Th2 cytokines including IL-4, IL-5, and IL-13 in atopic dermatitis skin lesions of NC/Nga mice.	celastrol	0-9	interleukin 5	Mus musculus	58-62
34304725-8	2021	Celastrol reduced levels of Th2 cytokines including IL-4, IL-5, and IL-13 in atopic dermatitis skin lesions of NC/Nga mice.	celastrol	0-9	interleukin 13	Mus musculus	68-73
34304725-10	2021	These results indicate that topical application of celastrol improved atopic dermatitis symptoms by lowering TSLP levels and concomitant immune responses.	celastrol	51-60	thymic stromal lymphopoietin	Mus musculus	109-113
34256125-0	2021	Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.	celastrol	62-71	ATP binding cassette subfamily B member 1	Homo sapiens	116-130
34256125-1	2021	A series of eleven celastrol derivatives was designed, synthesized, and evaluated for their in vitro cytotoxic activities against six human cancer cell lines (A549, HepG2, HepAD38, PC3, DLD-1 Bax-Bak WT and DKO) and three human normal cells (LO2, BEAS-2B, CCD19Lu).	celastrol	19-28	chromobox 8	Homo sapiens	181-184
34256125-1	2021	A series of eleven celastrol derivatives was designed, synthesized, and evaluated for their in vitro cytotoxic activities against six human cancer cell lines (A549, HepG2, HepAD38, PC3, DLD-1 Bax-Bak WT and DKO) and three human normal cells (LO2, BEAS-2B, CCD19Lu).	celastrol	19-28	BCL2 associated X, apoptosis regulator	Homo sapiens	192-195
34256125-1	2021	A series of eleven celastrol derivatives was designed, synthesized, and evaluated for their in vitro cytotoxic activities against six human cancer cell lines (A549, HepG2, HepAD38, PC3, DLD-1 Bax-Bak WT and DKO) and three human normal cells (LO2, BEAS-2B, CCD19Lu).	celastrol	19-28	BCL2 antagonist/killer 1	Homo sapiens	196-199
34732120-0	2022	Celastrol inhibits the proliferation and induces apoptosis of colorectal cancer cells via downregulating NF-kappaB/COX-2 signaling pathways.	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	105-114
34732120-0	2022	Celastrol inhibits the proliferation and induces apoptosis of colorectal cancer cells via downregulating NF-kappaB/COX-2 signaling pathways.	celastrol	0-9	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	115-120
34732120-8	2022	RESULTS: Celastrol effectively inhibited CRC cell proliferation by activating caspase-dependent cell apoptosis and facilitating G1 cell cycle arrest in a dose-dependent manner, as well as cell migration and invasion by downregulating the MMP2 and MMP9.	celastrol	9-18	matrix metallopeptidase 2	Homo sapiens	238-242
34732120-8	2022	RESULTS: Celastrol effectively inhibited CRC cell proliferation by activating caspase-dependent cell apoptosis and facilitating G1 cell cycle arrest in a dose-dependent manner, as well as cell migration and invasion by downregulating the MMP2 and MMP9.	celastrol	9-18	matrix metallopeptidase 9	Homo sapiens	247-251
34732120-9	2022	Mechanistic protein expression revealed that celastrol suppressed the expression of COX-2 by inhibiting the phosphorylation of NF-kappaB p65 and subsequently leading to cytoplasmic retention of p65 protein, thereby inhibiting its nuclear translocation and transcription activities.	celastrol	45-54	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	84-89
34732120-9	2022	Mechanistic protein expression revealed that celastrol suppressed the expression of COX-2 by inhibiting the phosphorylation of NF-kappaB p65 and subsequently leading to cytoplasmic retention of p65 protein, thereby inhibiting its nuclear translocation and transcription activities.	celastrol	45-54	RELA proto-oncogene, NF-kB subunit	Homo sapiens	127-140
34732120-9	2022	Mechanistic protein expression revealed that celastrol suppressed the expression of COX-2 by inhibiting the phosphorylation of NF-kappaB p65 and subsequently leading to cytoplasmic retention of p65 protein, thereby inhibiting its nuclear translocation and transcription activities.	celastrol	45-54	RELA proto-oncogene, NF-kB subunit	Homo sapiens	194-197
34732120-10	2022	CONCLUSION: These findings indicate that celastrol is an effective inhibitor for CRC, regulating the NF-kappaB/COX-2 pathway, leading to the inhibition of cell proliferation characterized by cell cycle arrest and caspase-dependent apoptosis, providing a potential alternative therapeutic agent for CRC patients.	celastrol	41-50	nuclear factor kappa B subunit 1	Homo sapiens	101-110
34732120-10	2022	CONCLUSION: These findings indicate that celastrol is an effective inhibitor for CRC, regulating the NF-kappaB/COX-2 pathway, leading to the inhibition of cell proliferation characterized by cell cycle arrest and caspase-dependent apoptosis, providing a potential alternative therapeutic agent for CRC patients.	celastrol	41-50	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	111-116
34702273-5	2021	Both in vitro and in vivo results demonstrated that celastrol inhibited the recruitment of M1 macrophage and the expression of TLR4 in corneal allografts through the TLR4/MyD88/NF-kappaB pathway, thereby significantly decreasing secretion of multiple pro-inflammatory cytokines to promote corneal allograft survival.	celastrol	52-61	toll like receptor 4	Homo sapiens	127-131
34702273-5	2021	Both in vitro and in vivo results demonstrated that celastrol inhibited the recruitment of M1 macrophage and the expression of TLR4 in corneal allografts through the TLR4/MyD88/NF-kappaB pathway, thereby significantly decreasing secretion of multiple pro-inflammatory cytokines to promote corneal allograft survival.	celastrol	52-61	toll like receptor 4	Homo sapiens	166-170
34702273-5	2021	Both in vitro and in vivo results demonstrated that celastrol inhibited the recruitment of M1 macrophage and the expression of TLR4 in corneal allografts through the TLR4/MyD88/NF-kappaB pathway, thereby significantly decreasing secretion of multiple pro-inflammatory cytokines to promote corneal allograft survival.	celastrol	52-61	MYD88 innate immune signal transduction adaptor	Homo sapiens	171-176
34702273-5	2021	Both in vitro and in vivo results demonstrated that celastrol inhibited the recruitment of M1 macrophage and the expression of TLR4 in corneal allografts through the TLR4/MyD88/NF-kappaB pathway, thereby significantly decreasing secretion of multiple pro-inflammatory cytokines to promote corneal allograft survival.	celastrol	52-61	nuclear factor kappa B subunit 1	Homo sapiens	177-186
34720529-5	2021	Several studies show that drugs targeting Sp downregulation or NR4A1 antagonists are highly effective inhibitors of Sp/NR4A1-regulated pathways and genes in pancreatic and other cancer cells, and the triterpenoid celastrol is a novel dual-acting agent that targets both Sp TFs and NR4A1.	celastrol	213-222	nuclear receptor subfamily 4 group A member 1	Homo sapiens	63-68
34720529-5	2021	Several studies show that drugs targeting Sp downregulation or NR4A1 antagonists are highly effective inhibitors of Sp/NR4A1-regulated pathways and genes in pancreatic and other cancer cells, and the triterpenoid celastrol is a novel dual-acting agent that targets both Sp TFs and NR4A1.	celastrol	213-222	nuclear receptor subfamily 4 group A member 1	Homo sapiens	119-124
34720529-5	2021	Several studies show that drugs targeting Sp downregulation or NR4A1 antagonists are highly effective inhibitors of Sp/NR4A1-regulated pathways and genes in pancreatic and other cancer cells, and the triterpenoid celastrol is a novel dual-acting agent that targets both Sp TFs and NR4A1.	celastrol	213-222	nuclear receptor subfamily 4 group A member 1	Homo sapiens	281-286
34579526-4	2021	The antitumor drug celastrol (CLT) and the photosensitizer indocyanine green (ICG) are then loaded in it to form CIPP.	celastrol	19-28	PATJ, crumbs cell polarity complex component	Mus musculus	113-117
34579526-4	2021	The antitumor drug celastrol (CLT) and the photosensitizer indocyanine green (ICG) are then loaded in it to form CIPP.	celastrol	30-33	PATJ, crumbs cell polarity complex component	Mus musculus	113-117
34796173-6	2021	In addition, we identified a small molecule compound Celastrol as an APE2 inhibitor that specifically compromises the binding of APE2 but not RPA to ssDNA and 3"-5" exonuclease activity of APE2 but not APE1.	celastrol	53-62	apurinic/apyrimidinic endodeoxyribonuclease 2	Homo sapiens	69-73
34796173-6	2021	In addition, we identified a small molecule compound Celastrol as an APE2 inhibitor that specifically compromises the binding of APE2 but not RPA to ssDNA and 3"-5" exonuclease activity of APE2 but not APE1.	celastrol	53-62	apurinic/apyrimidinic endodeoxyribonuclease 2	Homo sapiens	129-133
34796173-6	2021	In addition, we identified a small molecule compound Celastrol as an APE2 inhibitor that specifically compromises the binding of APE2 but not RPA to ssDNA and 3"-5" exonuclease activity of APE2 but not APE1.	celastrol	53-62	apurinic/apyrimidinic endodeoxyribonuclease 2	Homo sapiens	189-193
34796173-7	2021	The impairment of ATR-Chk1 DDR pathway by Celastrol in Xenopus egg extracts and human pancreatic cancer cells highlights the physiological significance of Celastrol in the regulation of APE2 functionalities in genome integrity.	celastrol	42-51	ATR serine/threonine kinase L homeolog	Xenopus laevis	18-21
34796173-7	2021	The impairment of ATR-Chk1 DDR pathway by Celastrol in Xenopus egg extracts and human pancreatic cancer cells highlights the physiological significance of Celastrol in the regulation of APE2 functionalities in genome integrity.	celastrol	42-51	checkpoint kinase 1 S homeolog	Xenopus laevis	22-26
34796173-7	2021	The impairment of ATR-Chk1 DDR pathway by Celastrol in Xenopus egg extracts and human pancreatic cancer cells highlights the physiological significance of Celastrol in the regulation of APE2 functionalities in genome integrity.	celastrol	42-51	apurinic/apyrimidinic endodeoxyribonuclease 2	Homo sapiens	186-190
34796173-7	2021	The impairment of ATR-Chk1 DDR pathway by Celastrol in Xenopus egg extracts and human pancreatic cancer cells highlights the physiological significance of Celastrol in the regulation of APE2 functionalities in genome integrity.	celastrol	155-164	apurinic/apyrimidinic endodeoxyribonuclease 2	Homo sapiens	186-190
34600334-0	2021	The Nrf2-NLRP3-caspase-1 axis mediates the neuroprotective effects of Celastrol in Parkinson"s disease.	celastrol	70-79	nuclear factor, erythroid derived 2, like 2	Mus musculus	4-8
34600334-0	2021	The Nrf2-NLRP3-caspase-1 axis mediates the neuroprotective effects of Celastrol in Parkinson"s disease.	celastrol	70-79	NLR family, pyrin domain containing 3	Mus musculus	9-14
34600334-0	2021	The Nrf2-NLRP3-caspase-1 axis mediates the neuroprotective effects of Celastrol in Parkinson"s disease.	celastrol	70-79	caspase 1	Mus musculus	15-24
34600334-4	2021	Here we show that celastrol protects against dopamine neuron loss, mitigates neuroinflammation, and relieves motor deficits in MPTP-induced PD mouse model and AAV-mediated human alpha-synuclein overexpression PD model.	celastrol	18-27	synuclein alpha	Homo sapiens	178-193
34600334-5	2021	Whole-genome deep sequencing analysis revealed that Nrf2, NLRP3 and caspase-1 in SNc may be associated with the neuroprotective actions of celastrol in PD.	celastrol	139-148	NFE2 like bZIP transcription factor 2	Homo sapiens	52-56
34600334-5	2021	Whole-genome deep sequencing analysis revealed that Nrf2, NLRP3 and caspase-1 in SNc may be associated with the neuroprotective actions of celastrol in PD.	celastrol	139-148	NLR family pyrin domain containing 3	Homo sapiens	58-63
34600334-5	2021	Whole-genome deep sequencing analysis revealed that Nrf2, NLRP3 and caspase-1 in SNc may be associated with the neuroprotective actions of celastrol in PD.	celastrol	139-148	caspase 1	Homo sapiens	68-77
34600334-6	2021	By using multiple genetically modified mice (Nrf2-KO, NLRP3-KO and Caspase-1-KO), we identified that celastrol inhibits NLRP3 inflammasome activation, relieves motor deficits and nigrostriatal dopaminergic degeneration through Nrf2-NLRP3-caspase-1 pathway.	celastrol	101-110	nuclear factor, erythroid derived 2, like 2	Mus musculus	45-49
34600334-6	2021	By using multiple genetically modified mice (Nrf2-KO, NLRP3-KO and Caspase-1-KO), we identified that celastrol inhibits NLRP3 inflammasome activation, relieves motor deficits and nigrostriatal dopaminergic degeneration through Nrf2-NLRP3-caspase-1 pathway.	celastrol	101-110	NLR family, pyrin domain containing 3	Mus musculus	54-59
34600334-6	2021	By using multiple genetically modified mice (Nrf2-KO, NLRP3-KO and Caspase-1-KO), we identified that celastrol inhibits NLRP3 inflammasome activation, relieves motor deficits and nigrostriatal dopaminergic degeneration through Nrf2-NLRP3-caspase-1 pathway.	celastrol	101-110	caspase 1	Mus musculus	67-76
34600334-6	2021	By using multiple genetically modified mice (Nrf2-KO, NLRP3-KO and Caspase-1-KO), we identified that celastrol inhibits NLRP3 inflammasome activation, relieves motor deficits and nigrostriatal dopaminergic degeneration through Nrf2-NLRP3-caspase-1 pathway.	celastrol	101-110	NLR family, pyrin domain containing 3	Mus musculus	120-125
34600334-6	2021	By using multiple genetically modified mice (Nrf2-KO, NLRP3-KO and Caspase-1-KO), we identified that celastrol inhibits NLRP3 inflammasome activation, relieves motor deficits and nigrostriatal dopaminergic degeneration through Nrf2-NLRP3-caspase-1 pathway.	celastrol	101-110	nuclear factor, erythroid derived 2, like 2	Mus musculus	227-231
34600334-6	2021	By using multiple genetically modified mice (Nrf2-KO, NLRP3-KO and Caspase-1-KO), we identified that celastrol inhibits NLRP3 inflammasome activation, relieves motor deficits and nigrostriatal dopaminergic degeneration through Nrf2-NLRP3-caspase-1 pathway.	celastrol	101-110	NLR family, pyrin domain containing 3	Mus musculus	232-237
34600334-6	2021	By using multiple genetically modified mice (Nrf2-KO, NLRP3-KO and Caspase-1-KO), we identified that celastrol inhibits NLRP3 inflammasome activation, relieves motor deficits and nigrostriatal dopaminergic degeneration through Nrf2-NLRP3-caspase-1 pathway.	celastrol	101-110	caspase 1	Mus musculus	238-247
34600334-7	2021	Taken together, these findings suggest that Nrf2-NLRP3-caspase-1 axis may serve as a key target of celastrol in PD treatment, and highlight the favorable properties of celastrol for neuroprotection, making celastrol as a promising disease-modifying agent for PD.	celastrol	99-108	nuclear factor, erythroid derived 2, like 2	Mus musculus	44-48
34600334-7	2021	Taken together, these findings suggest that Nrf2-NLRP3-caspase-1 axis may serve as a key target of celastrol in PD treatment, and highlight the favorable properties of celastrol for neuroprotection, making celastrol as a promising disease-modifying agent for PD.	celastrol	99-108	NLR family, pyrin domain containing 3	Mus musculus	49-54
34600334-7	2021	Taken together, these findings suggest that Nrf2-NLRP3-caspase-1 axis may serve as a key target of celastrol in PD treatment, and highlight the favorable properties of celastrol for neuroprotection, making celastrol as a promising disease-modifying agent for PD.	celastrol	99-108	caspase 1	Mus musculus	55-64
34676604-0	2022	Celastrol attenuates high-fructose diet-induced inflammation and insulin resistance via inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in rat adipose tissues.	celastrol	0-9	hydroxysteroid 11-beta dehydrogenase 1	Rattus norvegicus	102-144
34676604-4	2022	Herein, the present study was aimed to elucidate the mechanistic targets of celastrol co-administrations upon HFrD in rats and evaluate its potential to modulate 11beta-HSD1 activity.	celastrol	76-85	hydroxysteroid 11-beta dehydrogenase 1	Rattus norvegicus	162-173
34676604-6	2022	In rat adipose tissues, celastrol attenuated nuclear factor-kappa B (NF-kappaB)-driven inflammation, reduced c-Jun N-terminal kinases (JNK) phosphorylation, and mitigated oxidative stress via upregulated genes expression involved in mitochondrial biogenesis.	celastrol	24-33	mitogen-activated protein kinase 8	Rattus norvegicus	109-133
34676604-6	2022	In rat adipose tissues, celastrol attenuated nuclear factor-kappa B (NF-kappaB)-driven inflammation, reduced c-Jun N-terminal kinases (JNK) phosphorylation, and mitigated oxidative stress via upregulated genes expression involved in mitochondrial biogenesis.	celastrol	24-33	mitogen-activated protein kinase 8	Rattus norvegicus	135-138
34676604-8	2022	Celastrol exhibited a potent, selective and specific inhibitor of intracellular 11beta-HSD1 towards oxidoreductase activity (IC50 value = 4.3 nM) in comparison to other HSD-related enzymes.	celastrol	0-9	hydroxysteroid 11-beta dehydrogenase 1	Rattus norvegicus	80-91
34676604-10	2022	In conclusion, our results underscore the most likely conceivable mechanisms exhibited by celastrol against HFrD-induced metabolic dysregulations mainly through attenuating inflammation and insulin resistance, at least via specific inhibitions on 11beta-HSD1 activity in adipose tissues.	celastrol	90-99	hydroxysteroid 11-beta dehydrogenase 1	Rattus norvegicus	247-258
34645818-0	2021	Phase separation of Nur77 mediates celastrol-induced mitophagy by promoting the liquidity of p62/SQSTM1 condensates.	celastrol	35-44	nuclear receptor subfamily 4 group A member 1	Homo sapiens	20-25
34645818-0	2021	Phase separation of Nur77 mediates celastrol-induced mitophagy by promoting the liquidity of p62/SQSTM1 condensates.	celastrol	35-44	sequestosome 1	Homo sapiens	93-96
34645818-0	2021	Phase separation of Nur77 mediates celastrol-induced mitophagy by promoting the liquidity of p62/SQSTM1 condensates.	celastrol	35-44	sequestosome 1	Homo sapiens	97-103
34645818-3	2021	We previously discovered that nuclear receptor Nur77 (also called TR3, NGFI-B, or NR4A1) translocates from the nucleus to mitochondria to mediate celastrol-induced mitophagy through interaction with p62/SQSTM1.	celastrol	146-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	47-52
34645818-3	2021	We previously discovered that nuclear receptor Nur77 (also called TR3, NGFI-B, or NR4A1) translocates from the nucleus to mitochondria to mediate celastrol-induced mitophagy through interaction with p62/SQSTM1.	celastrol	146-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-69
34645818-3	2021	We previously discovered that nuclear receptor Nur77 (also called TR3, NGFI-B, or NR4A1) translocates from the nucleus to mitochondria to mediate celastrol-induced mitophagy through interaction with p62/SQSTM1.	celastrol	146-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-77
34645818-3	2021	We previously discovered that nuclear receptor Nur77 (also called TR3, NGFI-B, or NR4A1) translocates from the nucleus to mitochondria to mediate celastrol-induced mitophagy through interaction with p62/SQSTM1.	celastrol	146-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	82-87
34645818-3	2021	We previously discovered that nuclear receptor Nur77 (also called TR3, NGFI-B, or NR4A1) translocates from the nucleus to mitochondria to mediate celastrol-induced mitophagy through interaction with p62/SQSTM1.	celastrol	146-155	sequestosome 1	Homo sapiens	199-202
34645818-3	2021	We previously discovered that nuclear receptor Nur77 (also called TR3, NGFI-B, or NR4A1) translocates from the nucleus to mitochondria to mediate celastrol-induced mitophagy through interaction with p62/SQSTM1.	celastrol	146-155	sequestosome 1	Homo sapiens	203-209
34147915-0	2021	Celastrol inhibits rheumatoid arthritis through the ROS-NF-kappaB-NLRP3 inflammasome axis.	celastrol	0-9	nuclear factor kappa B subunit 1	Homo sapiens	56-65
34549728-0	2021	PERK in POMC neurons connects celastrol with metabolism.	celastrol	30-39	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	0-4
34549728-0	2021	PERK in POMC neurons connects celastrol with metabolism.	celastrol	30-39	pro-opiomelanocortin-alpha	Mus musculus	8-12
34549728-6	2021	The plant-based inhibitor of PERK, celastrol, increases leptin sensitivity, resulting in decreased food intake and body weight in a murine model of diet-induced obesity (DIO).	celastrol	35-44	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	29-33
34549728-6	2021	The plant-based inhibitor of PERK, celastrol, increases leptin sensitivity, resulting in decreased food intake and body weight in a murine model of diet-induced obesity (DIO).	celastrol	35-44	leptin	Mus musculus	56-62
34549728-7	2021	Our data extend these observations by demonstrating that celastrol-induced improvements in leptin sensitivity and energy balance were attenuated in mice with PERK deficiency in POMC neurons.	celastrol	57-66	leptin	Mus musculus	91-97
34549728-7	2021	Our data extend these observations by demonstrating that celastrol-induced improvements in leptin sensitivity and energy balance were attenuated in mice with PERK deficiency in POMC neurons.	celastrol	57-66	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	158-162
34549728-7	2021	Our data extend these observations by demonstrating that celastrol-induced improvements in leptin sensitivity and energy balance were attenuated in mice with PERK deficiency in POMC neurons.	celastrol	57-66	pro-opiomelanocortin-alpha	Mus musculus	177-181
34528509-4	2021	Importantly, brain treatment with celastrol, a pentacyclic triterpenoid, excites Oxt neurons and inhibits CAC progression, and this anti-tumor effect was significantly attenuated in Oxt neuron-lesioned mice.	celastrol	34-43	oxytocin	Mus musculus	81-84
34528509-4	2021	Importantly, brain treatment with celastrol, a pentacyclic triterpenoid, excites Oxt neurons and inhibits CAC progression, and this anti-tumor effect was significantly attenuated in Oxt neuron-lesioned mice.	celastrol	34-43	oxytocin	Mus musculus	182-185
34528509-5	2021	Furthermore, brain treatment with celastrol suppresses sympathetic neuronal activity in the celiac-superior mesenteric ganglion (CG-SMG), and activation of beta2 adrenergic receptor abolishes the anti-tumor effect of Oxt neuron activation or centrally administered celastrol.	celastrol	265-274	adrenergic receptor, beta 2	Mus musculus	156-181
34147915-0	2021	Celastrol inhibits rheumatoid arthritis through the ROS-NF-kappaB-NLRP3 inflammasome axis.	celastrol	0-9	NLR family pyrin domain containing 3	Homo sapiens	66-71
34147915-6	2021	The secretion of interleukin (IL)-1beta and IL-18 in the serum of CFA-induced rats and supernatants of THP-1 cells exposed to Cel was significantly decreased.	celastrol	126-129	interleukin 1 alpha	Rattus norvegicus	17-39
34147915-6	2021	The secretion of interleukin (IL)-1beta and IL-18 in the serum of CFA-induced rats and supernatants of THP-1 cells exposed to Cel was significantly decreased.	celastrol	126-129	interleukin 18	Rattus norvegicus	44-49
34526895-0	2021	Creation of an Anti-Inflammatory, Leptin-Dependent Anti-Obesity Celastrol Mimic with Better Druggability.	celastrol	64-73	leptin	Mus musculus	34-40
34174395-8	2021	Interestingly, Cel treatment increased the mRNA and protein levels of heme oxygenase-1 (HMOX-1), and reduced the levels of reactive oxygen species (ROS) in VSMCs.	celastrol	15-18	heme oxygenase 1	Rattus norvegicus	88-94
34250995-7	2021	For this purpose, we constructed a hybrid nanoplatform by fusing CLT (Celastrol)-Loaded PEGylated lipids with the DC2.4 cell membrane (M-LIP-CLT) to achieve targeted treatment of Kras-mutant pancreatic cancer.	celastrol	70-79	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	179-183
34372857-0	2021	Celastrol exerts a neuroprotective effect by directly binding to HMGB1 protein in cerebral ischemia-reperfusion.	celastrol	0-9	high mobility group box 1	Rattus norvegicus	65-70
34174395-0	2021	Up-regulation of heme oxygenase-1 by celastrol alleviates oxidative stress and vascular calcification in chronic kidney disease.	celastrol	37-46	heme oxygenase 1	Rattus norvegicus	17-33
34174395-8	2021	Interestingly, Cel treatment increased the mRNA and protein levels of heme oxygenase-1 (HMOX-1), and reduced the levels of reactive oxygen species (ROS) in VSMCs.	celastrol	15-18	heme oxygenase 1	Rattus norvegicus	70-86
34174395-9	2021	Furthermore, both pharmacological inhibition of HMOX-1 and knockdown of HMOX-1 by siRNA independently counteracted the inhibitory effect of Cel on vascular calcification.	celastrol	140-143	heme oxygenase 1	Rattus norvegicus	48-54
34174395-9	2021	Furthermore, both pharmacological inhibition of HMOX-1 and knockdown of HMOX-1 by siRNA independently counteracted the inhibitory effect of Cel on vascular calcification.	celastrol	140-143	heme oxygenase 1	Rattus norvegicus	72-78
34174395-12	2021	Collectively, our results suggest that up-regulation of HMOX-1 is required for the inhibitory effect of Cel on vascular calcification.	celastrol	104-107	heme oxygenase 1	Mus musculus	56-62
34490381-7	2021	This literature review therefore focuses on Celastrol"s anti-inflammatory and antioxidant activities, alongside its other potential therapeutic activities, and its ability to impede the pathways that are thought to be involved in the development of HFpEF, such as the JAK2/STAT pathway, to elucidate the potential therapeutic role of this bioactive compound, in the treatment of HFpEF.	celastrol	44-53	Janus kinase 2	Homo sapiens	268-272
34170694-2	2021	Celastrol, a natural friedelane triterpenoid, can disrupt the Hsp90-Cdc37 interaction to provide antitumor effects.	celastrol	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	62-67
34325521-7	2021	Consistent with genetic manipulation, pharmacological activation of Nur77 by celastrol showed beneficial effects against AAA.	celastrol	77-86	nuclear receptor subfamily 4, group A, member 1	Mus musculus	68-73
34367293-8	2021	Celastrol-treated cells increased quantities of proangiogenic cytokines compared to vehicle-pretreated cells, with a significant 3.0-fold and 1.8-fold increase of VEGFa and SDF-1alpha, respectively (p < 0.05).	celastrol	0-9	vascular endothelial growth factor A	Rattus norvegicus	163-168
34170694-2	2021	Celastrol, a natural friedelane triterpenoid, can disrupt the Hsp90-Cdc37 interaction to provide antitumor effects.	celastrol	0-9	cell division cycle 37, HSP90 cochaperone	Homo sapiens	68-73
34170694-3	2021	In this study, 31 new celastrol derivatives, 2a-2d, 3a-3g, and 4a-4t, were designed and synthesized, and their Hsp90-Cdc37 disruption activities and antiproliferative activities against cancer cells were evaluated.	celastrol	22-31	heat shock protein 90 alpha family class A member 1	Homo sapiens	111-116
34170694-3	2021	In this study, 31 new celastrol derivatives, 2a-2d, 3a-3g, and 4a-4t, were designed and synthesized, and their Hsp90-Cdc37 disruption activities and antiproliferative activities against cancer cells were evaluated.	celastrol	22-31	cell division cycle 37, HSP90 cochaperone	Homo sapiens	117-122
34305512-0	2021	Corrigendum: Neuroprotective Effects of Celastrol on Transient Global Cerebral Ischemia Rats via Regulating HMGB1/NF-kappaB Signaling Pathway.	celastrol	40-49	high mobility group box 1	Rattus norvegicus	108-113
34337076-6	2021	The results from Annexin V/PI staining and flow cytometry analysis suggested that celastrol enhanced tamoxifen-mediated apoptosis.	celastrol	82-91	annexin A5	Homo sapiens	17-26
34337076-8	2021	Moreover, the distribution of LC3 was monitored by immunofluorescence, and the changes in the LC3II and P62 levels detected by western blot analysis suggested that celastrol in combination with tamoxifen triggered autophagy.	celastrol	164-173	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	30-33
34337076-10	2021	However, in an MCF-7-implanted nude mouse model, it was possible to detect significantly decreased tumour volumes and tumour weights and decreased p-Akt and p-mTOR protein expression in the celastrol+tamoxifen group.	celastrol	190-199	thymoma viral proto-oncogene 1	Mus musculus	149-152
34337076-10	2021	However, in an MCF-7-implanted nude mouse model, it was possible to detect significantly decreased tumour volumes and tumour weights and decreased p-Akt and p-mTOR protein expression in the celastrol+tamoxifen group.	celastrol	190-199	mechanistic target of rapamycin kinase	Mus musculus	159-163
34285658-10	2021	Further, the inhibitory effect of LPS on a minimal SLC23A2 promoter was attenuated when either the binding site for the transcription factor Sp1 was mutated or cells were treated with the NF-kappaB inhibitor, celastrol.	celastrol	209-218	solute carrier family 23 member 2	Homo sapiens	51-58
34285658-10	2021	Further, the inhibitory effect of LPS on a minimal SLC23A2 promoter was attenuated when either the binding site for the transcription factor Sp1 was mutated or cells were treated with the NF-kappaB inhibitor, celastrol.	celastrol	209-218	nuclear factor kappa B subunit 1	Homo sapiens	188-197
34182541-9	2021	Celastrol protected blood-brain bairrer integrity through inhibiting MMP-9 expression and anti-neuroinflammatory effects.	celastrol	0-9	matrix metallopeptidase 9	Rattus norvegicus	69-74
34182541-10	2021	Additionally, necroptosis-related proteins RIP3 and MLKL were down-regulated and PI-positive cells in the basal cortex were less in the celastrol-treated SAH group than that in untreated SAH group.	celastrol	136-145	myosin phosphatase Rho interacting protein	Rattus norvegicus	43-47
34182541-10	2021	Additionally, necroptosis-related proteins RIP3 and MLKL were down-regulated and PI-positive cells in the basal cortex were less in the celastrol-treated SAH group than that in untreated SAH group.	celastrol	136-145	mixed lineage kinase domain like pseudokinase	Rattus norvegicus	52-56
34194230-0	2021	Celastrol Modulates Multiple Signaling Pathways to Inhibit Proliferation of Pancreatic Cancer via DDIT3 and ATF3 Up-Regulation and RRM2 and MCM4 Down-Regulation.	celastrol	0-9	DNA damage inducible transcript 3	Homo sapiens	98-103
34194230-0	2021	Celastrol Modulates Multiple Signaling Pathways to Inhibit Proliferation of Pancreatic Cancer via DDIT3 and ATF3 Up-Regulation and RRM2 and MCM4 Down-Regulation.	celastrol	0-9	activating transcription factor 3	Homo sapiens	108-112
34194230-0	2021	Celastrol Modulates Multiple Signaling Pathways to Inhibit Proliferation of Pancreatic Cancer via DDIT3 and ATF3 Up-Regulation and RRM2 and MCM4 Down-Regulation.	celastrol	0-9	ribonucleotide reductase regulatory subunit M2	Homo sapiens	131-135
34194230-0	2021	Celastrol Modulates Multiple Signaling Pathways to Inhibit Proliferation of Pancreatic Cancer via DDIT3 and ATF3 Up-Regulation and RRM2 and MCM4 Down-Regulation.	celastrol	0-9	minichromosome maintenance complex component 4	Homo sapiens	140-144
34194230-9	2021	Celastrol modulated many signaling genes and its cytotoxic effect was mainly mediated via over-expression of ATF3 and DDIT3, and down-expression of RRM2 and MCM4.	celastrol	0-9	activating transcription factor 3	Homo sapiens	109-113
34194230-9	2021	Celastrol modulated many signaling genes and its cytotoxic effect was mainly mediated via over-expression of ATF3 and DDIT3, and down-expression of RRM2 and MCM4.	celastrol	0-9	DNA damage inducible transcript 3	Homo sapiens	118-123
34194230-9	2021	Celastrol modulated many signaling genes and its cytotoxic effect was mainly mediated via over-expression of ATF3 and DDIT3, and down-expression of RRM2 and MCM4.	celastrol	0-9	ribonucleotide reductase regulatory subunit M2	Homo sapiens	148-152
34194230-9	2021	Celastrol modulated many signaling genes and its cytotoxic effect was mainly mediated via over-expression of ATF3 and DDIT3, and down-expression of RRM2 and MCM4.	celastrol	0-9	minichromosome maintenance complex component 4	Homo sapiens	157-161
34982057-0	2021	Celastrol promotes chondrocyte autophagy by regulating mTOR expression.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	55-59
34326694-0	2021	Celastrol ameliorates vascular neointimal hyperplasia through Wnt5a-involved autophagy.	celastrol	0-9	Wnt family member 5A	Homo sapiens	62-67
34326694-6	2021	It was revealed that autophagy promoted by celastrol could induce the lysosomal degradation of c-MYC, which might be a possible mechanism contributing to the reduction of VSMCs proliferation.	celastrol	43-52	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	95-100
34326694-7	2021	The Wnt5a/PKC/mTOR signaling pathway was found to be an underlying mechanism for celastrol to induce autophagy and inhibit the VSMCs proliferation.	celastrol	81-90	Wnt family member 5A	Homo sapiens	4-9
34326694-7	2021	The Wnt5a/PKC/mTOR signaling pathway was found to be an underlying mechanism for celastrol to induce autophagy and inhibit the VSMCs proliferation.	celastrol	81-90	mechanistic target of rapamycin kinase	Homo sapiens	14-18
34094828-7	2021	Taken together, our study identifies celastrol, which directly targets CAP1 in macrophages, might be a promising drug candidate for the treatment of inflammatory metabolic diseases, such as metabolic syndrome.	celastrol	37-46	CAP, adenylate cyclase-associated protein 1 (yeast)	Mus musculus	71-75
34149427-0	2021	Celastrol Attenuates RANKL-Induced Osteoclastogenesis in vitro and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss in vivo.	celastrol	0-9	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	21-26
34149427-5	2021	We demonstrated that celastrol inhibited the receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis and the bone resorptive function of osteoclasts in vitro by inhibiting the activation of transforming growth factor beta-activated kinase 1-mediated NF-kappaB and mitogen-activated protein kinase signaling pathways and downregulating osteoclastogenesis marker-related genes.	celastrol	21-30	mitogen-activated protein kinase kinase kinase 7	Mus musculus	212-262
34149427-5	2021	We demonstrated that celastrol inhibited the receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis and the bone resorptive function of osteoclasts in vitro by inhibiting the activation of transforming growth factor beta-activated kinase 1-mediated NF-kappaB and mitogen-activated protein kinase signaling pathways and downregulating osteoclastogenesis marker-related genes.	celastrol	21-30	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	272-281
34185400-0	2021	Celastrol alleviates comorbid obesity and depression by directly binding amygdala HnRNPA1 in a mouse model.	celastrol	0-9	heterogeneous nuclear ribonucleoprotein A1	Mus musculus	82-89
34094828-0	2021	Celastrol targets adenylyl cyclase-associated protein 1 to reduce macrophages-mediated inflammation and ameliorates high fat diet-induced metabolic syndrome in mice.	celastrol	0-9	CAP, adenylate cyclase-associated protein 1 (yeast)	Mus musculus	18-55
34094828-3	2021	Here, we report celastrol, a traditional Chinese medicine, can improve high fat diet-induced metabolic syndrome through suppressing resistin-induced inflammation.	celastrol	16-25	resistin	Mus musculus	132-140
34094828-4	2021	Mechanistically, celastrol binds to adenylyl cyclase associated protein 1 (CAP1) and inhibits the interaction between CAP1 and resistin, which restrains the cyclic adenylate monophosphate (cAMP)-protein kinase A (PKA)-nuclear factor kappa-B (NF-kappaB) signaling pathway and ameliorates high fat diet-induced murine metabolic syndrome.	celastrol	17-26	CAP, adenylate cyclase-associated protein 1 (yeast)	Mus musculus	36-73
34094828-4	2021	Mechanistically, celastrol binds to adenylyl cyclase associated protein 1 (CAP1) and inhibits the interaction between CAP1 and resistin, which restrains the cyclic adenylate monophosphate (cAMP)-protein kinase A (PKA)-nuclear factor kappa-B (NF-kappaB) signaling pathway and ameliorates high fat diet-induced murine metabolic syndrome.	celastrol	17-26	CAP, adenylate cyclase-associated protein 1 (yeast)	Mus musculus	75-79
34094828-4	2021	Mechanistically, celastrol binds to adenylyl cyclase associated protein 1 (CAP1) and inhibits the interaction between CAP1 and resistin, which restrains the cyclic adenylate monophosphate (cAMP)-protein kinase A (PKA)-nuclear factor kappa-B (NF-kappaB) signaling pathway and ameliorates high fat diet-induced murine metabolic syndrome.	celastrol	17-26	CAP, adenylate cyclase-associated protein 1 (yeast)	Mus musculus	118-122
34094828-4	2021	Mechanistically, celastrol binds to adenylyl cyclase associated protein 1 (CAP1) and inhibits the interaction between CAP1 and resistin, which restrains the cyclic adenylate monophosphate (cAMP)-protein kinase A (PKA)-nuclear factor kappa-B (NF-kappaB) signaling pathway and ameliorates high fat diet-induced murine metabolic syndrome.	celastrol	17-26	resistin	Mus musculus	127-135
34094828-4	2021	Mechanistically, celastrol binds to adenylyl cyclase associated protein 1 (CAP1) and inhibits the interaction between CAP1 and resistin, which restrains the cyclic adenylate monophosphate (cAMP)-protein kinase A (PKA)-nuclear factor kappa-B (NF-kappaB) signaling pathway and ameliorates high fat diet-induced murine metabolic syndrome.	celastrol	17-26	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	242-251
34114395-0	2021	Celastrol induces caspase-dependent apoptosis of hepatocellular carcinoma cells by suppression of mammalian target of rapamycin.	celastrol	0-9	caspase 8	Homo sapiens	18-25
34114395-0	2021	Celastrol induces caspase-dependent apoptosis of hepatocellular carcinoma cells by suppression of mammalian target of rapamycin.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	98-127
34114395-8	2021	Western blot assays indicated that celastrol up-regulated cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9, and cleaved-PARP by inhibiting the phosphorylation of mTOR in HepG2 cells.	celastrol	35-44	caspase 8	Homo sapiens	85-94
34114395-8	2021	Western blot assays indicated that celastrol up-regulated cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9, and cleaved-PARP by inhibiting the phosphorylation of mTOR in HepG2 cells.	celastrol	35-44	caspase 9	Homo sapiens	104-113
34114395-8	2021	Western blot assays indicated that celastrol up-regulated cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9, and cleaved-PARP by inhibiting the phosphorylation of mTOR in HepG2 cells.	celastrol	35-44	poly(ADP-ribose) polymerase 1	Homo sapiens	127-131
34114395-8	2021	Western blot assays indicated that celastrol up-regulated cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9, and cleaved-PARP by inhibiting the phosphorylation of mTOR in HepG2 cells.	celastrol	35-44	mechanistic target of rapamycin kinase	Homo sapiens	169-173
34114395-10	2021	Celastrol also induced caspase-dependent apoptosis (up-regulation of cleaved-caspase- 3, -8, -9, and cleaved-PARP) and inhibited the activation of mTOR in vivo.	celastrol	0-9	caspase 8	Homo sapiens	23-30
34114395-10	2021	Celastrol also induced caspase-dependent apoptosis (up-regulation of cleaved-caspase- 3, -8, -9, and cleaved-PARP) and inhibited the activation of mTOR in vivo.	celastrol	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	109-113
34114395-10	2021	Celastrol also induced caspase-dependent apoptosis (up-regulation of cleaved-caspase- 3, -8, -9, and cleaved-PARP) and inhibited the activation of mTOR in vivo.	celastrol	0-9	mechanistic target of rapamycin kinase	Homo sapiens	147-151
34114395-11	2021	CONCLUSION: Celastrol induces caspase-dependent apoptosis in HCC cells by inhibiting the activation of mTOR.	celastrol	12-21	caspase 8	Homo sapiens	30-37
34114395-11	2021	CONCLUSION: Celastrol induces caspase-dependent apoptosis in HCC cells by inhibiting the activation of mTOR.	celastrol	12-21	mechanistic target of rapamycin kinase	Homo sapiens	103-107
34072312-6	2021	Moreover, triterpenoids containing a lactone ring and/or quinone-like substructures, e.g., bruceantin, whitaferin A, withanolide F, celastrol, and pristimerin, displayed remarkable activity, with the latter two compounds acting as inhibitors of both NF-kappaB and proteasome chymotrypsin-like activity.	celastrol	132-141	nuclear factor kappa B subunit 1	Homo sapiens	250-259
35576663-0	2022	Celastrol and thymoquinone alleviate aluminum chloride-induced neurotoxicity: Behavioral psychomotor performance, neurotransmitter level, oxidative-inflammatory markers, and BDNF expression in rat brain.	celastrol	0-9	brain-derived neurotrophic factor	Rattus norvegicus	174-178
34112289-9	2021	CONCLUSIONS: Celastrol may regulate the expression and release of inflammatory factors by inhibiting the TLR4/NF-kappaB pathway, thereby alleviating the ALI induced by sepsis in rats.	celastrol	13-22	toll-like receptor 4	Rattus norvegicus	105-109
34428765-0	2021	Celastrol Exerts Cardioprotective Effect in Rheumatoid Arthritis by Inhibiting TLR2/HMGB1 Signaling Pathway-Mediated Autophagy.	celastrol	0-9	toll-like receptor 2	Rattus norvegicus	79-83
34428765-0	2021	Celastrol Exerts Cardioprotective Effect in Rheumatoid Arthritis by Inhibiting TLR2/HMGB1 Signaling Pathway-Mediated Autophagy.	celastrol	0-9	high mobility group box 1	Rattus norvegicus	84-89
34428765-10	2021	Compared with CIA model, Celastrol treatment could suppress the release of inflammatory cytokines, including TNF-alpha, IL-6, IL-1beta, as well as inhibiting the expressions of Bax, cleaved caspase3, collagen I, collagen III and alpha-SMA.	celastrol	25-34	tumor necrosis factor	Rattus norvegicus	109-118
34428765-10	2021	Compared with CIA model, Celastrol treatment could suppress the release of inflammatory cytokines, including TNF-alpha, IL-6, IL-1beta, as well as inhibiting the expressions of Bax, cleaved caspase3, collagen I, collagen III and alpha-SMA.	celastrol	25-34	interleukin 6	Rattus norvegicus	120-124
34428765-10	2021	Compared with CIA model, Celastrol treatment could suppress the release of inflammatory cytokines, including TNF-alpha, IL-6, IL-1beta, as well as inhibiting the expressions of Bax, cleaved caspase3, collagen I, collagen III and alpha-SMA.	celastrol	25-34	interleukin 1 alpha	Rattus norvegicus	126-134
34428765-10	2021	Compared with CIA model, Celastrol treatment could suppress the release of inflammatory cytokines, including TNF-alpha, IL-6, IL-1beta, as well as inhibiting the expressions of Bax, cleaved caspase3, collagen I, collagen III and alpha-SMA.	celastrol	25-34	BCL2 associated X, apoptosis regulator	Rattus norvegicus	177-180
34428765-10	2021	Compared with CIA model, Celastrol treatment could suppress the release of inflammatory cytokines, including TNF-alpha, IL-6, IL-1beta, as well as inhibiting the expressions of Bax, cleaved caspase3, collagen I, collagen III and alpha-SMA.	celastrol	25-34	caspase 3	Rattus norvegicus	190-198
34428765-11	2021	In addition to that, Celastrol treatment can attenuate cell apoptosis and fibrosis of cardiomyocytes and elevate Bcl-2 expression.	celastrol	21-30	BCL2, apoptosis regulator	Rattus norvegicus	113-118
34428765-12	2021	RA induced cell autophagy can be suppressed by Celastrol through inhibiting the activation of TLR2/HMGB1 signal pathway.	celastrol	47-56	toll-like receptor 2	Rattus norvegicus	94-98
34428765-12	2021	RA induced cell autophagy can be suppressed by Celastrol through inhibiting the activation of TLR2/HMGB1 signal pathway.	celastrol	47-56	high mobility group box 1	Rattus norvegicus	99-104
34428765-13	2021	CONCLUSION: Celastrol can regulate TLR2/HMGB1 signal pathway to suppress autophagy and therefore exert cardioprotective effect in RA.	celastrol	12-21	toll-like receptor 2	Rattus norvegicus	35-39
34428765-13	2021	CONCLUSION: Celastrol can regulate TLR2/HMGB1 signal pathway to suppress autophagy and therefore exert cardioprotective effect in RA.	celastrol	12-21	high mobility group box 1	Rattus norvegicus	40-45
34472389-0	2021	RETRACTION NOTICE: Tripterine up-regulates miR-223 to alleviate lipopolysaccharide-induced damage in murine chondrogenic ATDC5 cells.	celastrol	19-29	microRNA 223	Mus musculus	43-50
35596191-0	2022	Celastrol mitigates inflammation in sepsis by inhibiting the PKM2-dependent Warburg effect.	celastrol	0-9	pyruvate kinase, muscle	Mus musculus	61-65
35605435-0	2022	Phytosomal tripterine with selenium modification attenuates the cytotoxicity and restrains the inflammatory evolution via inhibiting NLRP3 inflammasome activation and pyroptosis.	celastrol	11-21	NLR family, pyrin domain containing 3	Mus musculus	133-138
35583119-3	2022	Celastrol (CST) was directly assembled into a discrete nanomedicine by precipitation, and then CST nanoparticles (CNPs) inhibited drug efflux pumps by activating HSF-1 expression and promoting HSF-1 translocation into nucleus to suppress the Pgp expression.	celastrol	0-9	heat shock transcription factor 1	Homo sapiens	162-167
35583119-3	2022	Celastrol (CST) was directly assembled into a discrete nanomedicine by precipitation, and then CST nanoparticles (CNPs) inhibited drug efflux pumps by activating HSF-1 expression and promoting HSF-1 translocation into nucleus to suppress the Pgp expression.	celastrol	0-9	heat shock transcription factor 1	Homo sapiens	193-198
35583119-3	2022	Celastrol (CST) was directly assembled into a discrete nanomedicine by precipitation, and then CST nanoparticles (CNPs) inhibited drug efflux pumps by activating HSF-1 expression and promoting HSF-1 translocation into nucleus to suppress the Pgp expression.	celastrol	0-9	phosphoglycolate phosphatase	Homo sapiens	242-245
35364220-2	2022	In this work, a biomimetic BBB-penetrating albumin nanosystem modified by a brain-targeting peptide was designed for co-delivering a TGF-beta receptor I (TGFbetaRI) inhibitor (LY2157299) and an mTOR inhibitor (celastrol).	celastrol	210-219	mechanistic target of rapamycin kinase	Mus musculus	194-198
35143937-8	2022	The hepatotoxicity induced by TP and Cel also inhibited PPARalpha and upregulated IL6-STAT3 axis, which could be alleviated following by PPARalpha activation.	celastrol	37-40	peroxisome proliferator activated receptor alpha	Mus musculus	56-65
35143937-8	2022	The hepatotoxicity induced by TP and Cel also inhibited PPARalpha and upregulated IL6-STAT3 axis, which could be alleviated following by PPARalpha activation.	celastrol	37-40	peroxisome proliferator activated receptor alpha	Mus musculus	137-146
35478244-0	2022	Celastrol suppresses the growth of vestibular schwannoma in mice by promoting the degradation of beta-catenin.	celastrol	0-9	catenin (cadherin associated protein), beta 1	Mus musculus	97-109
35478244-8	2022	In HEI-193 and SC4 cells, we demonstrated that celastrol (0.1, 0.5 muM) dose-dependently inhibited TOPFlash reporter activity and protein expression of beta-catenin, but not mRNA level of beta-catenin.	celastrol	47-56	catenin beta 1	Homo sapiens	188-200
35478244-9	2022	Furthermore, celastrol accelerated the degradation of beta-catenin by promoting the formation of the beta-catenin destruction complex.	celastrol	13-22	catenin beta 1	Homo sapiens	54-66
35478244-8	2022	In HEI-193 and SC4 cells, we demonstrated that celastrol (0.1, 0.5 muM) dose-dependently inhibited TOPFlash reporter activity and protein expression of beta-catenin, but not mRNA level of beta-catenin.	celastrol	47-56	catenin beta 1	Homo sapiens	152-164
35478244-9	2022	Furthermore, celastrol accelerated the degradation of beta-catenin by promoting the formation of the beta-catenin destruction complex.	celastrol	13-22	catenin beta 1	Homo sapiens	101-113
35478244-12	2022	Collectively, this study demonstrates that celastrol can inhibit Wnt/beta-catenin signaling by promoting the degradation of beta-catenin, consequently inhibiting the growth of VS.	celastrol	43-52	catenin (cadherin associated protein), beta 1	Mus musculus	69-81
35530963-9	2022	Results: 100 nmol/L Celastrol can significantly inhibit LPS-induced inflammatory responses and down-regulate the expression levels of cytokines such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX2), tumor necrosis factor-alpha (TNF-alpha), chemokines (CCL-2, and CXCL-10), as well as chemokines.	celastrol	20-29	nitric oxide synthase 2	Homo sapiens	152-183
35478244-12	2022	Collectively, this study demonstrates that celastrol can inhibit Wnt/beta-catenin signaling by promoting the degradation of beta-catenin, consequently inhibiting the growth of VS.	celastrol	43-52	catenin (cadherin associated protein), beta 1	Mus musculus	124-136
35530963-9	2022	Results: 100 nmol/L Celastrol can significantly inhibit LPS-induced inflammatory responses and down-regulate the expression levels of cytokines such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX2), tumor necrosis factor-alpha (TNF-alpha), chemokines (CCL-2, and CXCL-10), as well as chemokines.	celastrol	20-29	nitric oxide synthase 2	Homo sapiens	185-189
35530963-9	2022	Results: 100 nmol/L Celastrol can significantly inhibit LPS-induced inflammatory responses and down-regulate the expression levels of cytokines such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX2), tumor necrosis factor-alpha (TNF-alpha), chemokines (CCL-2, and CXCL-10), as well as chemokines.	celastrol	20-29	prostaglandin-endoperoxide synthase 2	Homo sapiens	192-208
35530963-9	2022	Results: 100 nmol/L Celastrol can significantly inhibit LPS-induced inflammatory responses and down-regulate the expression levels of cytokines such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX2), tumor necrosis factor-alpha (TNF-alpha), chemokines (CCL-2, and CXCL-10), as well as chemokines.	celastrol	20-29	prostaglandin-endoperoxide synthase 2	Homo sapiens	210-214
35530963-9	2022	Results: 100 nmol/L Celastrol can significantly inhibit LPS-induced inflammatory responses and down-regulate the expression levels of cytokines such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX2), tumor necrosis factor-alpha (TNF-alpha), chemokines (CCL-2, and CXCL-10), as well as chemokines.	celastrol	20-29	tumor necrosis factor	Homo sapiens	217-244
35530963-9	2022	Results: 100 nmol/L Celastrol can significantly inhibit LPS-induced inflammatory responses and down-regulate the expression levels of cytokines such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX2), tumor necrosis factor-alpha (TNF-alpha), chemokines (CCL-2, and CXCL-10), as well as chemokines.	celastrol	20-29	tumor necrosis factor	Homo sapiens	246-255
35530963-9	2022	Results: 100 nmol/L Celastrol can significantly inhibit LPS-induced inflammatory responses and down-regulate the expression levels of cytokines such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX2), tumor necrosis factor-alpha (TNF-alpha), chemokines (CCL-2, and CXCL-10), as well as chemokines.	celastrol	20-29	C-C motif chemokine ligand 2	Homo sapiens	270-275
35530963-9	2022	Results: 100 nmol/L Celastrol can significantly inhibit LPS-induced inflammatory responses and down-regulate the expression levels of cytokines such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX2), tumor necrosis factor-alpha (TNF-alpha), chemokines (CCL-2, and CXCL-10), as well as chemokines.	celastrol	20-29	C-X-C motif chemokine ligand 10	Homo sapiens	281-288
35530963-10	2022	And Celastrol could regulate mitochondrial fission and fusion by promoting the phosphorylation of the Drp1 at the Ser637 site, thereby inhibiting mitochondrial fission.	celastrol	4-13	dynamin 1 like	Homo sapiens	102-106
35530963-11	2022	At the same time, by up-regulating the level of the Mfn2, Celastrol also promoted mitochondrial fusion.	celastrol	58-67	mitofusin 2	Homo sapiens	52-56
35530963-13	2022	We also explored the relationship between Celastrol and the nuclear receptor Nur77 and found that it could up-regulate the expression of Nur77.	celastrol	42-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	77-82
35530963-13	2022	We also explored the relationship between Celastrol and the nuclear receptor Nur77 and found that it could up-regulate the expression of Nur77.	celastrol	42-51	nuclear receptor subfamily 4 group A member 1	Homo sapiens	137-142
35530963-14	2022	Conclusions: Our study found that Celastrol could reduce inflammation by regulating Drp1 dependent mitochondrial fission and fusion, as well as the ERK1/2, p38, NF-kappaB signaling pathways.	celastrol	34-43	dynamin 1 like	Homo sapiens	84-88
35530963-14	2022	Conclusions: Our study found that Celastrol could reduce inflammation by regulating Drp1 dependent mitochondrial fission and fusion, as well as the ERK1/2, p38, NF-kappaB signaling pathways.	celastrol	34-43	mitogen-activated protein kinase 3	Homo sapiens	148-154
35530963-14	2022	Conclusions: Our study found that Celastrol could reduce inflammation by regulating Drp1 dependent mitochondrial fission and fusion, as well as the ERK1/2, p38, NF-kappaB signaling pathways.	celastrol	34-43	mitogen-activated protein kinase 1	Homo sapiens	156-159
35530963-14	2022	Conclusions: Our study found that Celastrol could reduce inflammation by regulating Drp1 dependent mitochondrial fission and fusion, as well as the ERK1/2, p38, NF-kappaB signaling pathways.	celastrol	34-43	nuclear factor kappa B subunit 1	Homo sapiens	161-170
35107368-3	2022	Iinhibition of the Hsp90/Cdc37 complex by inhibitors (17-AAG and celastrol) or shRNAs significantly reduced expression levels of viral proteins and virus yield, suggesting that the Hsp90/Cdc37 chaperone complex functions in virus replication.	celastrol	65-74	heat shock protein 90 alpha family class A member 1	Homo sapiens	19-24
35419676-0	2022	Celastrol Induces Apoptosis and Autophagy via the AKT/mTOR Signaling Pathway in the Pituitary ACTH-secreting Adenoma Cells.	celastrol	0-9	thymoma viral proto-oncogene 1	Mus musculus	50-53
35419676-0	2022	Celastrol Induces Apoptosis and Autophagy via the AKT/mTOR Signaling Pathway in the Pituitary ACTH-secreting Adenoma Cells.	celastrol	0-9	mechanistic target of rapamycin kinase	Mus musculus	54-58
35419676-0	2022	Celastrol Induces Apoptosis and Autophagy via the AKT/mTOR Signaling Pathway in the Pituitary ACTH-secreting Adenoma Cells.	celastrol	0-9	pro-opiomelanocortin-alpha	Mus musculus	94-98
35419676-2	2022	Previous studies have shown that celastrol has antitumor effects on a variety of tumor cells via the AKT/mTOR signaling.	celastrol	33-42	thymoma viral proto-oncogene 1	Mus musculus	101-104
35419676-2	2022	Previous studies have shown that celastrol has antitumor effects on a variety of tumor cells via the AKT/mTOR signaling.	celastrol	33-42	mechanistic target of rapamycin kinase	Mus musculus	105-109
35419676-8	2022	Finally, the potential involvement of AKT/mTOR signaling in celastrol"s mechanism was assessed.	celastrol	60-69	mechanistic target of rapamycin kinase	Mus musculus	42-46
35419676-12	2022	CONCLUSION: Celastrol exerts potent antitumor effects on ACTH-secreting adenoma by downregulating the AKT/mTOR signaling in vitro and in vivo.	celastrol	12-21	pro-opiomelanocortin-alpha	Mus musculus	57-61
35419676-12	2022	CONCLUSION: Celastrol exerts potent antitumor effects on ACTH-secreting adenoma by downregulating the AKT/mTOR signaling in vitro and in vivo.	celastrol	12-21	thymoma viral proto-oncogene 1	Mus musculus	102-105
35419676-12	2022	CONCLUSION: Celastrol exerts potent antitumor effects on ACTH-secreting adenoma by downregulating the AKT/mTOR signaling in vitro and in vivo.	celastrol	12-21	mechanistic target of rapamycin kinase	Mus musculus	106-110
35238566-1	2022	To discover celastrol (CEL) derivatives with enhanced Hsp90-Cdc37 inhibition, C-20-COOH was introduced with various substituted imidazoles, which might affect the Michael addition of CEL by nucleophilic attack.	celastrol	12-21	heat shock protein 90 alpha family class A member 1	Homo sapiens	54-59
35238566-1	2022	To discover celastrol (CEL) derivatives with enhanced Hsp90-Cdc37 inhibition, C-20-COOH was introduced with various substituted imidazoles, which might affect the Michael addition of CEL by nucleophilic attack.	celastrol	12-21	cell division cycle 37, HSP90 cochaperone	Homo sapiens	60-65
35238566-1	2022	To discover celastrol (CEL) derivatives with enhanced Hsp90-Cdc37 inhibition, C-20-COOH was introduced with various substituted imidazoles, which might affect the Michael addition of CEL by nucleophilic attack.	celastrol	23-26	heat shock protein 90 alpha family class A member 1	Homo sapiens	54-59
35238566-1	2022	To discover celastrol (CEL) derivatives with enhanced Hsp90-Cdc37 inhibition, C-20-COOH was introduced with various substituted imidazoles, which might affect the Michael addition of CEL by nucleophilic attack.	celastrol	23-26	cell division cycle 37, HSP90 cochaperone	Homo sapiens	60-65
35238566-1	2022	To discover celastrol (CEL) derivatives with enhanced Hsp90-Cdc37 inhibition, C-20-COOH was introduced with various substituted imidazoles, which might affect the Michael addition of CEL by nucleophilic attack.	celastrol	183-186	heat shock protein 90 alpha family class A member 1	Homo sapiens	54-59
35238566-1	2022	To discover celastrol (CEL) derivatives with enhanced Hsp90-Cdc37 inhibition, C-20-COOH was introduced with various substituted imidazoles, which might affect the Michael addition of CEL by nucleophilic attack.	celastrol	183-186	cell division cycle 37, HSP90 cochaperone	Homo sapiens	60-65
35302751-0	2022	Integrated Mass Spectrometry Reveals Celastrol As a Novel Catechol-O-methyltransferase Inhibitor.	celastrol	37-46	catechol-O-methyltransferase	Homo sapiens	58-86
35107368-3	2022	Iinhibition of the Hsp90/Cdc37 complex by inhibitors (17-AAG and celastrol) or shRNAs significantly reduced expression levels of viral proteins and virus yield, suggesting that the Hsp90/Cdc37 chaperone complex functions in virus replication.	celastrol	65-74	cell division cycle 37, HSP90 cochaperone	Homo sapiens	25-30
35051865-12	2022	In IMQ-induced psoriatic dermatitis, Cel gel reduced the secretion of interleukin (IL)- 23 by Langerhans cells, suppressed the interaction between Langerhans cells and gammadeltaT cells, and decreased the number of activated gammadeltaT cells and related IL-17 secretion, alleviating psoriasis-like inflammation.	celastrol	37-40	interleukin 23, alpha subunit p19	Mus musculus	70-90
35302751-2	2022	Here, we used multiple mass-spectrometry-based approaches to identify catechol-O-methyltransferase (COMT) as a major binding target of celastrol and characterized their interaction comprehensively.	celastrol	135-144	catechol-O-methyltransferase	Homo sapiens	70-98
35302751-2	2022	Here, we used multiple mass-spectrometry-based approaches to identify catechol-O-methyltransferase (COMT) as a major binding target of celastrol and characterized their interaction comprehensively.	celastrol	135-144	catechol-O-methyltransferase	Homo sapiens	100-104
35302751-3	2022	Celastrol was found to inhibit the enzymatic activity of COMT and increased the dopamine level in neuroendocrine chromaffin cells significantly.	celastrol	0-9	catechol-O-methyltransferase	Homo sapiens	57-61
35302751-4	2022	Our study not only revealed a novel binding target of celastrol but also provided a new scaffold and cysteine hot spot for developing new generation COMT inhibitors in combating neurological disorders.	celastrol	54-63	catechol-O-methyltransferase	Homo sapiens	149-153
35359864-0	2022	Celastrol Alleviates Autoimmune Hepatitis Through the PI3K/AKT Signaling Pathway Based on Network Pharmacology and Experiments.	celastrol	0-9	thymoma viral proto-oncogene 1	Mus musculus	59-62
35359864-7	2022	Among them, PIK3R1, SRC, MAPK1, AKT1, and HRAS were selected as the top 5 closely related targets to celastrol.	celastrol	101-110	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	12-18
35359864-7	2022	Among them, PIK3R1, SRC, MAPK1, AKT1, and HRAS were selected as the top 5 closely related targets to celastrol.	celastrol	101-110	Rous sarcoma oncogene	Mus musculus	20-23
35359864-7	2022	Among them, PIK3R1, SRC, MAPK1, AKT1, and HRAS were selected as the top 5 closely related targets to celastrol.	celastrol	101-110	mitogen-activated protein kinase 1	Mus musculus	25-30
35359864-7	2022	Among them, PIK3R1, SRC, MAPK1, AKT1, and HRAS were selected as the top 5 closely related targets to celastrol.	celastrol	101-110	thymoma viral proto-oncogene 1	Mus musculus	32-36
35359864-7	2022	Among them, PIK3R1, SRC, MAPK1, AKT1, and HRAS were selected as the top 5 closely related targets to celastrol.	celastrol	101-110	Harvey rat sarcoma virus oncogene	Mus musculus	42-46
35359864-9	2022	Subsequently, celastrol administration significantly ameliorated hepatitis and liver fibrosis by reducing AKT1 and PI3K phosphorylation in both acute liver injury and chronic models of autoimmune hepatitis.	celastrol	14-23	thymoma viral proto-oncogene 1	Mus musculus	106-110
35359864-10	2022	Conclusion: In summary, celastrol significantly attenuates autoimmune hepatitis by suppressing the PI3K/AKT signaling pathway, confirmed by validated animal models.	celastrol	24-33	thymoma viral proto-oncogene 1	Mus musculus	104-107
35253615-0	2022	Celastrol, a TFEB (transcription factor EB) agonist, is a promising drug candidate for Alzheimer disease.	celastrol	0-9	transcription factor EB	Mus musculus	13-17
35253615-0	2022	Celastrol, a TFEB (transcription factor EB) agonist, is a promising drug candidate for Alzheimer disease.	celastrol	0-9	transcription factor EB	Mus musculus	19-42
35253615-7	2022	In a recent study, we showed that celastrol, a natural small molecule with an anti-obesity effect, is a novel TFEB activator, which enhances autophagy and lysosomal biogenesis both in vitro and in animal brains.	celastrol	34-43	transcription factor EB	Mus musculus	110-114
35253615-10	2022	Altogether, celastrol enhances TFEB-mediated autophagy and lysosomal biogenesis to ameliorate MAPT/tau pathology, suggesting that celastrol represents a novel anti-AD and other tauopathies drug candidate.Abbreviations: AD: Alzheimer disease; ALP: autophagy-lysosomal pathway; MAPT/tau: microtubule-associated protein tau; MTORC1: mechanistic target of rapamycin kinase complex 1; TFEB: transcription factor EB.	celastrol	12-21	transcription factor EB	Mus musculus	31-35
35253615-10	2022	Altogether, celastrol enhances TFEB-mediated autophagy and lysosomal biogenesis to ameliorate MAPT/tau pathology, suggesting that celastrol represents a novel anti-AD and other tauopathies drug candidate.Abbreviations: AD: Alzheimer disease; ALP: autophagy-lysosomal pathway; MAPT/tau: microtubule-associated protein tau; MTORC1: mechanistic target of rapamycin kinase complex 1; TFEB: transcription factor EB.	celastrol	130-139	transcription factor EB	Mus musculus	31-35
35051865-12	2022	In IMQ-induced psoriatic dermatitis, Cel gel reduced the secretion of interleukin (IL)- 23 by Langerhans cells, suppressed the interaction between Langerhans cells and gammadeltaT cells, and decreased the number of activated gammadeltaT cells and related IL-17 secretion, alleviating psoriasis-like inflammation.	celastrol	37-40	interleukin 17A	Mus musculus	255-260
35019905-5	2022	Celastrol was loaded into bovine serum albumin (BSA) nanoparticles to yield celastrol-BSA-NPs by high pressure homogenization.	celastrol	0-9	albumin	Mus musculus	33-46
35157199-0	2022	The Protective Role of Celastrol in Renal Ischemia-Reperfusion Injury by Activating Nrf2/HO-1, PI3K/AKT Signaling Pathways, Modulating NF-kappab Signaling Pathways, and Inhibiting ERK Phosphorylation.	celastrol	23-32	NFE2 like bZIP transcription factor 2	Rattus norvegicus	84-88
35157199-0	2022	The Protective Role of Celastrol in Renal Ischemia-Reperfusion Injury by Activating Nrf2/HO-1, PI3K/AKT Signaling Pathways, Modulating NF-kappab Signaling Pathways, and Inhibiting ERK Phosphorylation.	celastrol	23-32	heme oxygenase 1	Rattus norvegicus	89-93
35157199-0	2022	The Protective Role of Celastrol in Renal Ischemia-Reperfusion Injury by Activating Nrf2/HO-1, PI3K/AKT Signaling Pathways, Modulating NF-kappab Signaling Pathways, and Inhibiting ERK Phosphorylation.	celastrol	23-32	AKT serine/threonine kinase 1	Rattus norvegicus	100-103
35157199-0	2022	The Protective Role of Celastrol in Renal Ischemia-Reperfusion Injury by Activating Nrf2/HO-1, PI3K/AKT Signaling Pathways, Modulating NF-kappab Signaling Pathways, and Inhibiting ERK Phosphorylation.	celastrol	23-32	Eph receptor B1	Rattus norvegicus	180-183
35157199-2	2022	We investigated celastrol"s antioxidant potential through nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) and its effect on phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling, nuclear factor-kappa B (NF-kappaB) pathways, and extracellular signal-regulated kinase (ERK) activation in kidney ischemia-reperfusion injury (IRI) rat model.	celastrol	16-25	NFE2 like bZIP transcription factor 2	Rattus norvegicus	58-101
35157199-2	2022	We investigated celastrol"s antioxidant potential through nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) and its effect on phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling, nuclear factor-kappa B (NF-kappaB) pathways, and extracellular signal-regulated kinase (ERK) activation in kidney ischemia-reperfusion injury (IRI) rat model.	celastrol	16-25	NFE2 like bZIP transcription factor 2	Rattus norvegicus	103-107
35157199-2	2022	We investigated celastrol"s antioxidant potential through nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) and its effect on phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling, nuclear factor-kappa B (NF-kappaB) pathways, and extracellular signal-regulated kinase (ERK) activation in kidney ischemia-reperfusion injury (IRI) rat model.	celastrol	16-25	heme oxygenase 1	Rattus norvegicus	109-125
35157199-2	2022	We investigated celastrol"s antioxidant potential through nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) and its effect on phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling, nuclear factor-kappa B (NF-kappaB) pathways, and extracellular signal-regulated kinase (ERK) activation in kidney ischemia-reperfusion injury (IRI) rat model.	celastrol	16-25	heme oxygenase 1	Rattus norvegicus	127-131
35157199-2	2022	We investigated celastrol"s antioxidant potential through nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) and its effect on phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling, nuclear factor-kappa B (NF-kappaB) pathways, and extracellular signal-regulated kinase (ERK) activation in kidney ischemia-reperfusion injury (IRI) rat model.	celastrol	16-25	AKT serine/threonine kinase 1	Rattus norvegicus	202-205
35157199-2	2022	We investigated celastrol"s antioxidant potential through nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) and its effect on phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling, nuclear factor-kappa B (NF-kappaB) pathways, and extracellular signal-regulated kinase (ERK) activation in kidney ischemia-reperfusion injury (IRI) rat model.	celastrol	16-25	Eph receptor B1	Rattus norvegicus	267-304
35157199-2	2022	We investigated celastrol"s antioxidant potential through nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) and its effect on phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling, nuclear factor-kappa B (NF-kappaB) pathways, and extracellular signal-regulated kinase (ERK) activation in kidney ischemia-reperfusion injury (IRI) rat model.	celastrol	16-25	Eph receptor B1	Rattus norvegicus	306-309
35157199-6	2022	Celastrol pretreatment attenuated oxidative stress and increased Nrf2 gene expression and HO-1 level.	celastrol	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	65-69
35157199-6	2022	Celastrol pretreatment attenuated oxidative stress and increased Nrf2 gene expression and HO-1 level.	celastrol	0-9	heme oxygenase 1	Rattus norvegicus	90-94
35157199-8	2022	Conclusively, celastrol showed a reno-protective potential against renal IRI by suppressing oxidative stress through enhancing the Nrf2/HO-1 pathway, augmenting cell survival PI3K/AKT signaling pathways, and reducing inflammation by inhibiting NF-kappaB activation.	celastrol	14-23	NFE2 like bZIP transcription factor 2	Rattus norvegicus	131-135
35157199-8	2022	Conclusively, celastrol showed a reno-protective potential against renal IRI by suppressing oxidative stress through enhancing the Nrf2/HO-1 pathway, augmenting cell survival PI3K/AKT signaling pathways, and reducing inflammation by inhibiting NF-kappaB activation.	celastrol	14-23	heme oxygenase 1	Rattus norvegicus	136-140
35157199-8	2022	Conclusively, celastrol showed a reno-protective potential against renal IRI by suppressing oxidative stress through enhancing the Nrf2/HO-1 pathway, augmenting cell survival PI3K/AKT signaling pathways, and reducing inflammation by inhibiting NF-kappaB activation.	celastrol	14-23	AKT serine/threonine kinase 1	Rattus norvegicus	180-183
35138251-7	2022	On the other hand, celastrol-PEG4-alkyne was synthesized for identifying celastrol-bound proteins in RAW264.7 macrophages.	celastrol	19-28	small nuclear ribonucleoprotein N	Mus musculus	29-33
35138251-7	2022	On the other hand, celastrol-PEG4-alkyne was synthesized for identifying celastrol-bound proteins in RAW264.7 macrophages.	celastrol	73-82	small nuclear ribonucleoprotein N	Mus musculus	29-33
35138251-8	2022	ER chaperone GRP78 (78 kDa glucose-regulated protein) was identified by proteomics approach for celastrol binding to the residue Cys41.	celastrol	96-105	heat shock protein 5	Mus musculus	13-18
35138251-8	2022	ER chaperone GRP78 (78 kDa glucose-regulated protein) was identified by proteomics approach for celastrol binding to the residue Cys41.	celastrol	96-105	heat shock protein 5	Mus musculus	20-52
35138251-9	2022	Upon binding and conjugation, celastrol diminished the chaperone activity of GRP78 by 130-fold and reduced ER stress in palmitate-challenged cells, while celastrol analog lacking quinone methide failed to exhibit antiobesity effects.	celastrol	30-39	heat shock protein 5	Mus musculus	77-82
35187141-8	2021	We also found that celastrol can upregulate Cleaved Caspase-3 and Cleaved Caspase-9 protein expression levels to promote cell apoptosis, and can regulate cell cycle-related proteins to induce cell cycle arrest.	celastrol	19-28	caspase 3	Canis lupus familiaris	52-61
35187141-8	2021	We also found that celastrol can upregulate Cleaved Caspase-3 and Cleaved Caspase-9 protein expression levels to promote cell apoptosis, and can regulate cell cycle-related proteins to induce cell cycle arrest.	celastrol	19-28	caspase 9	Canis lupus familiaris	74-83
35123623-0	2022	(Effect of Celastrol Based on IRAK4/ERK/p38 Signaling Pathway on Proliferation and Apoptosis of Multiple Myeloma Cells).	celastrol	11-20	interleukin 1 receptor associated kinase 4	Homo sapiens	30-35
35134440-0	2022	Celastrol attenuates psoriasiform inflammation by targeting the IRF1/GSTM3 axis.	celastrol	0-9	interferon regulatory factor 1	Homo sapiens	64-68
35134440-0	2022	Celastrol attenuates psoriasiform inflammation by targeting the IRF1/GSTM3 axis.	celastrol	0-9	glutathione S-transferase mu 3	Homo sapiens	69-74
35113665-0	2022	Correction to: Celastrol Attenuates Angiotensin II-Induced Cardiac Remodeling by Targeting STAT3.	celastrol	15-24	signal transducer and activator of transcription 3	Homo sapiens	91-96
35282664-10	2022	Significantly decreased macrophage infiltration, reduced levels of pro-inflammatory cytokines, increased level of anti-inflammatory cytokine and inhibited NF-kappaB signaling pathway were observed in the lung tissues of rats treated with celastrol.	celastrol	238-247	nuclear factor kappa B subunit 1	Homo sapiens	155-164
35123623-9	2022	CONCLUSION: Celastrol can inhibit the proliferation and promote the apoptosis of H929 and ARP-1 cells, which may be related to inhibiting the phosphorylation of IRAK4 and blocking the activation of IRAK4/ERK/p38 signaling pathway.	celastrol	12-21	actin related protein 1A	Homo sapiens	90-95
35123623-0	2022	(Effect of Celastrol Based on IRAK4/ERK/p38 Signaling Pathway on Proliferation and Apoptosis of Multiple Myeloma Cells).	celastrol	11-20	mitogen-activated protein kinase 1	Homo sapiens	36-39
35123623-9	2022	CONCLUSION: Celastrol can inhibit the proliferation and promote the apoptosis of H929 and ARP-1 cells, which may be related to inhibiting the phosphorylation of IRAK4 and blocking the activation of IRAK4/ERK/p38 signaling pathway.	celastrol	12-21	interleukin 1 receptor associated kinase 4	Homo sapiens	161-166
35123623-0	2022	(Effect of Celastrol Based on IRAK4/ERK/p38 Signaling Pathway on Proliferation and Apoptosis of Multiple Myeloma Cells).	celastrol	11-20	mitogen-activated protein kinase 14	Homo sapiens	40-43
35123623-9	2022	CONCLUSION: Celastrol can inhibit the proliferation and promote the apoptosis of H929 and ARP-1 cells, which may be related to inhibiting the phosphorylation of IRAK4 and blocking the activation of IRAK4/ERK/p38 signaling pathway.	celastrol	12-21	interleukin 1 receptor associated kinase 4	Homo sapiens	198-203
35123623-9	2022	CONCLUSION: Celastrol can inhibit the proliferation and promote the apoptosis of H929 and ARP-1 cells, which may be related to inhibiting the phosphorylation of IRAK4 and blocking the activation of IRAK4/ERK/p38 signaling pathway.	celastrol	12-21	mitogen-activated protein kinase 1	Homo sapiens	204-207
35123623-9	2022	CONCLUSION: Celastrol can inhibit the proliferation and promote the apoptosis of H929 and ARP-1 cells, which may be related to inhibiting the phosphorylation of IRAK4 and blocking the activation of IRAK4/ERK/p38 signaling pathway.	celastrol	12-21	mitogen-activated protein kinase 14	Homo sapiens	208-211
35123623-10	2022	Celastrol combined with bortezomib has synergistic effect, which can more effectively inhibit the proliferation and induce apoptosis of H929 and ARP-1 cells.	celastrol	0-9	actin related protein 1A	Homo sapiens	145-150
35123623-1	2022	OBJECTIVE: To investigate the effect of celastrol on the proliferation and apoptosis of human multiple myeloma (MM) cell lines, reveal the relationship between IRAK4/ERK/p38 signaling pathway and celastrol regulating the proliferation and apoptosis of H929 and ARP-1 cells, and explore whether celastrol combined with bortezomib has synergistic effect.	celastrol	40-49	mitogen-activated protein kinase 1	Homo sapiens	166-169
35123623-1	2022	OBJECTIVE: To investigate the effect of celastrol on the proliferation and apoptosis of human multiple myeloma (MM) cell lines, reveal the relationship between IRAK4/ERK/p38 signaling pathway and celastrol regulating the proliferation and apoptosis of H929 and ARP-1 cells, and explore whether celastrol combined with bortezomib has synergistic effect.	celastrol	40-49	mitogen-activated protein kinase 14	Homo sapiens	170-173
35123623-1	2022	OBJECTIVE: To investigate the effect of celastrol on the proliferation and apoptosis of human multiple myeloma (MM) cell lines, reveal the relationship between IRAK4/ERK/p38 signaling pathway and celastrol regulating the proliferation and apoptosis of H929 and ARP-1 cells, and explore whether celastrol combined with bortezomib has synergistic effect.	celastrol	196-205	interleukin 1 receptor associated kinase 4	Homo sapiens	160-165
35123623-1	2022	OBJECTIVE: To investigate the effect of celastrol on the proliferation and apoptosis of human multiple myeloma (MM) cell lines, reveal the relationship between IRAK4/ERK/p38 signaling pathway and celastrol regulating the proliferation and apoptosis of H929 and ARP-1 cells, and explore whether celastrol combined with bortezomib has synergistic effect.	celastrol	196-205	mitogen-activated protein kinase 1	Homo sapiens	166-169
35123623-1	2022	OBJECTIVE: To investigate the effect of celastrol on the proliferation and apoptosis of human multiple myeloma (MM) cell lines, reveal the relationship between IRAK4/ERK/p38 signaling pathway and celastrol regulating the proliferation and apoptosis of H929 and ARP-1 cells, and explore whether celastrol combined with bortezomib has synergistic effect.	celastrol	196-205	mitogen-activated protein kinase 14	Homo sapiens	170-173
35123623-1	2022	OBJECTIVE: To investigate the effect of celastrol on the proliferation and apoptosis of human multiple myeloma (MM) cell lines, reveal the relationship between IRAK4/ERK/p38 signaling pathway and celastrol regulating the proliferation and apoptosis of H929 and ARP-1 cells, and explore whether celastrol combined with bortezomib has synergistic effect.	celastrol	294-303	interleukin 1 receptor associated kinase 4	Homo sapiens	160-165
35123623-1	2022	OBJECTIVE: To investigate the effect of celastrol on the proliferation and apoptosis of human multiple myeloma (MM) cell lines, reveal the relationship between IRAK4/ERK/p38 signaling pathway and celastrol regulating the proliferation and apoptosis of H929 and ARP-1 cells, and explore whether celastrol combined with bortezomib has synergistic effect.	celastrol	294-303	mitogen-activated protein kinase 1	Homo sapiens	166-169
35123623-2	2022	METHODS: CCK-8 method was used to detect the viability of MM cell lines H929 and ARP-1 treated by different concentrations of celastrol, bortezomib, and their combination, and the synergistic effect was determined by Kim"s formula.	celastrol	126-135	actin related protein 1A	Homo sapiens	81-86
35141331-0	2022	Radiosensitizing Effect of Celastrol by Inhibiting G2/M Phase Arrest Induced by the c-myc Gene of Human SW1353 Chondrosarcoma Cells: Network and Experimental Analyses.	celastrol	27-36	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	84-89
35123623-5	2022	RESULTS: Celastrol could significantly inhibit the proliferation of H929 and ARP-1 cells (r=0.9018, r=0.9244) and induce apoptosis in a time-dependent manner.	celastrol	9-18	actin related protein 1A	Homo sapiens	77-82
35141331-2	2022	This study is focused on the radiosensitization effect and apoptotic pathways of celastrol via the inhibition of the c-myc gene and the influence of which combined with radiotherapy on the proliferation, apoptosis, invasion, and metastasis of chondrosarcoma cells.	celastrol	81-90	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	117-122
35123623-6	2022	Compared with the control group, celastrol could significantly up-regulate the expression of PARP and cleaved caspase-3 while down-regulate the expression of p-IRAK4, p-ERK, and p-p38 in H929 and ARP-1 cells.	celastrol	33-42	poly(ADP-ribose) polymerase 1	Homo sapiens	93-97
35123623-6	2022	Compared with the control group, celastrol could significantly up-regulate the expression of PARP and cleaved caspase-3 while down-regulate the expression of p-IRAK4, p-ERK, and p-p38 in H929 and ARP-1 cells.	celastrol	33-42	caspase 3	Homo sapiens	110-119
35141331-5	2022	Clone formation assay, CCK-8 assay, flow cytometry, and transwell migration assay were applied to detect the effects of celastrol on the expression of c-myc gene, cell apoptosis, and cell cycle.	celastrol	120-129	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	151-156
35123623-6	2022	Compared with the control group, celastrol could significantly up-regulate the expression of PARP and cleaved caspase-3 while down-regulate the expression of p-IRAK4, p-ERK, and p-p38 in H929 and ARP-1 cells.	celastrol	33-42	interleukin 1 receptor associated kinase 4	Homo sapiens	160-165
35141331-8	2022	Celastrol can significantly inhibit the expression of the c-myc gene, induce G2/M phase arrest through regulation of G2/M phase-related proteins, and promote SW1353 cell apoptosis through the mitochondrial signaling pathway.	celastrol	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	58-63
35123623-6	2022	Compared with the control group, celastrol could significantly up-regulate the expression of PARP and cleaved caspase-3 while down-regulate the expression of p-IRAK4, p-ERK, and p-p38 in H929 and ARP-1 cells.	celastrol	33-42	mitogen-activated protein kinase 1	Homo sapiens	169-172
35141331-10	2022	Conclusions: Our study validated the radiosensitization effect of celastrol through knocking down the expression of the c-myc gene to induce G2/M phase arrest and provides a new idea for the treatment of refractory or recurrent chondrosarcoma that is not sensitive to radiotherapy.	celastrol	66-75	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	120-125
35123623-6	2022	Compared with the control group, celastrol could significantly up-regulate the expression of PARP and cleaved caspase-3 while down-regulate the expression of p-IRAK4, p-ERK, and p-p38 in H929 and ARP-1 cells.	celastrol	33-42	mitogen-activated protein kinase 14	Homo sapiens	180-183
35123623-6	2022	Compared with the control group, celastrol could significantly up-regulate the expression of PARP and cleaved caspase-3 while down-regulate the expression of p-IRAK4, p-ERK, and p-p38 in H929 and ARP-1 cells.	celastrol	33-42	actin related protein 1A	Homo sapiens	196-201
35123623-7	2022	Celastrol and bortezomib alone inhibited the proliferation of H929 and ARP-1 cells.	celastrol	0-9	actin related protein 1A	Homo sapiens	71-76
35273658-13	2022	Based on the potential of GDCA in PPPM, PARP-1 was found to be significantly correlated with the anticancer functions of celastrol.	celastrol	121-130	poly(ADP-ribose) polymerase 1	Homo sapiens	40-46
35273658-15	2022	In addition, PARP-1 was found to be an important target of GDCA that promotes CRC; therefore, celastrol may be a potential targeted therapy for CRC via its effects on PARP-1.	celastrol	94-103	poly(ADP-ribose) polymerase 1	Homo sapiens	13-19
35273658-15	2022	In addition, PARP-1 was found to be an important target of GDCA that promotes CRC; therefore, celastrol may be a potential targeted therapy for CRC via its effects on PARP-1.	celastrol	94-103	poly(ADP-ribose) polymerase 1	Homo sapiens	167-173
35035665-0	2022	Celastrol Protects against Cerebral Ischemia/Reperfusion Injury in Mice by Inhibiting Glycolysis through Targeting HIF-1alpha/PDK1 Axis.	celastrol	0-9	hypoxia inducible factor 1, alpha subunit	Mus musculus	115-125
35022380-6	2022	HPA and GEPIA determined the expression of tripterine anti-ovarian hub genes in tumor tissues.	celastrol	43-53	ELAV like RNA binding protein 2	Homo sapiens	67-70
35022380-11	2022	The expression of tripterine anti-ovarian hub genes ARHGAP11A, MUC1, and FUT8 were obtained by HPA and GEPIA.	celastrol	18-28	ELAV like RNA binding protein 2	Homo sapiens	42-45
35022380-11	2022	The expression of tripterine anti-ovarian hub genes ARHGAP11A, MUC1, and FUT8 were obtained by HPA and GEPIA.	celastrol	18-28	Rho GTPase activating protein 11A	Homo sapiens	52-61
35022380-11	2022	The expression of tripterine anti-ovarian hub genes ARHGAP11A, MUC1, and FUT8 were obtained by HPA and GEPIA.	celastrol	18-28	mucin 1, cell surface associated	Homo sapiens	63-67
35022380-11	2022	The expression of tripterine anti-ovarian hub genes ARHGAP11A, MUC1, and FUT8 were obtained by HPA and GEPIA.	celastrol	18-28	fucosyltransferase 8	Homo sapiens	73-77
35022380-14	2022	CONCLUSIONS Tripterine may be involved in megakaryocyte development and platelet production through potential genes ARHGAP11A, MUC1, HBB, RUNX1T1, and FUT8 and may have an anti-ovarian cancer effect in immune factors signaling, transporting and exchanging oxygen pathways, and autophagy pathways, through these 5 key genes.	celastrol	12-22	Rho GTPase activating protein 11A	Homo sapiens	116-125
35022380-14	2022	CONCLUSIONS Tripterine may be involved in megakaryocyte development and platelet production through potential genes ARHGAP11A, MUC1, HBB, RUNX1T1, and FUT8 and may have an anti-ovarian cancer effect in immune factors signaling, transporting and exchanging oxygen pathways, and autophagy pathways, through these 5 key genes.	celastrol	12-22	mucin 1, cell surface associated	Homo sapiens	127-131
35022380-14	2022	CONCLUSIONS Tripterine may be involved in megakaryocyte development and platelet production through potential genes ARHGAP11A, MUC1, HBB, RUNX1T1, and FUT8 and may have an anti-ovarian cancer effect in immune factors signaling, transporting and exchanging oxygen pathways, and autophagy pathways, through these 5 key genes.	celastrol	12-22	hemoglobin subunit beta	Homo sapiens	133-136
35022380-14	2022	CONCLUSIONS Tripterine may be involved in megakaryocyte development and platelet production through potential genes ARHGAP11A, MUC1, HBB, RUNX1T1, and FUT8 and may have an anti-ovarian cancer effect in immune factors signaling, transporting and exchanging oxygen pathways, and autophagy pathways, through these 5 key genes.	celastrol	12-22	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	138-145
35022380-14	2022	CONCLUSIONS Tripterine may be involved in megakaryocyte development and platelet production through potential genes ARHGAP11A, MUC1, HBB, RUNX1T1, and FUT8 and may have an anti-ovarian cancer effect in immune factors signaling, transporting and exchanging oxygen pathways, and autophagy pathways, through these 5 key genes.	celastrol	12-22	fucosyltransferase 8	Homo sapiens	151-155
35127390-5	2022	After loading celastrol into mannose-modified liposomes, they effectively inhibited the expression of maturation markers, including CD80, CD86 and MHC-II, on DCs both in vitro and in vivo.	celastrol	14-23	CD80 antigen	Mus musculus	132-136
35127390-5	2022	After loading celastrol into mannose-modified liposomes, they effectively inhibited the expression of maturation markers, including CD80, CD86 and MHC-II, on DCs both in vitro and in vivo.	celastrol	14-23	CD86 antigen	Mus musculus	138-142
35127390-5	2022	After loading celastrol into mannose-modified liposomes, they effectively inhibited the expression of maturation markers, including CD80, CD86 and MHC-II, on DCs both in vitro and in vivo.	celastrol	14-23	histocompatibility-2, MHC	Mus musculus	147-153
35035665-0	2022	Celastrol Protects against Cerebral Ischemia/Reperfusion Injury in Mice by Inhibiting Glycolysis through Targeting HIF-1alpha/PDK1 Axis.	celastrol	0-9	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	126-130
35035665-10	2022	In addition, celastrol significantly blocked I/R-induced increase of LDHA, GLUT1, HK2, and lactate production as well as decrease of ATP level and glucose content.	celastrol	13-22	lactate dehydrogenase A	Mus musculus	69-73
35035665-10	2022	In addition, celastrol significantly blocked I/R-induced increase of LDHA, GLUT1, HK2, and lactate production as well as decrease of ATP level and glucose content.	celastrol	13-22	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	75-80
35035665-10	2022	In addition, celastrol significantly blocked I/R-induced increase of LDHA, GLUT1, HK2, and lactate production as well as decrease of ATP level and glucose content.	celastrol	13-22	hexokinase 2	Mus musculus	82-85
35035665-11	2022	Moreover, celastrol inhibited the I/R-induced upregulation of HIF-1alpha and PDK1.	celastrol	10-19	hypoxia inducible factor 1, alpha subunit	Mus musculus	62-72
35035665-11	2022	Moreover, celastrol inhibited the I/R-induced upregulation of HIF-1alpha and PDK1.	celastrol	10-19	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	77-81
35035665-12	2022	Overexpression of HIF-1alpha by DMOG reversed the protective effect of celastrol on cerebral I/R injury and blocked celastrol-induced suppression of glycolysis.	celastrol	71-80	hypoxia inducible factor 1, alpha subunit	Mus musculus	18-28
35035665-12	2022	Overexpression of HIF-1alpha by DMOG reversed the protective effect of celastrol on cerebral I/R injury and blocked celastrol-induced suppression of glycolysis.	celastrol	116-125	hypoxia inducible factor 1, alpha subunit	Mus musculus	18-28
35035665-14	2022	Taken together, these results suggested that celastrol protected against cerebral I/R injury through inhibiting glycolysis via the HIF-1alpha/PDK1 axis.	celastrol	45-54	hypoxia inducible factor 1, alpha subunit	Mus musculus	131-141
35035665-14	2022	Taken together, these results suggested that celastrol protected against cerebral I/R injury through inhibiting glycolysis via the HIF-1alpha/PDK1 axis.	celastrol	45-54	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	142-146
34918393-7	2022	Subsequently, we confirmed that two medicinal plant-derived compounds, andrographolide, and celastrol, widely used as a nutritional or medicinal supplement are useful to attenuate DENV-induced plasma leakage through induction of the HO-1 expression in DENV-infected AG129 mice.	celastrol	92-101	heme oxygenase 1	Homo sapiens	233-237
35466134-4	2022	Increase in MAFbx1/atrogin-1 and MuRF-1 by 3D-clinorotation was significantly suppressed by treatment with C14-Cblin or celastrol, but there was no additive effect of simultaneous treatment.	celastrol	120-129	F-box protein 32	Rattus norvegicus	19-28
35466134-4	2022	Increase in MAFbx1/atrogin-1 and MuRF-1 by 3D-clinorotation was significantly suppressed by treatment with C14-Cblin or celastrol, but there was no additive effect of simultaneous treatment.	celastrol	120-129	tripartite motif containing 63	Rattus norvegicus	33-39
35466134-5	2022	However, celastrol significantly suppressed the upregulation of Cbl-b and HSP70 by 3D-clinorotation.	celastrol	9-18	Cbl proto-oncogene B	Rattus norvegicus	64-69
35466134-5	2022	However, celastrol significantly suppressed the upregulation of Cbl-b and HSP70 by 3D-clinorotation.	celastrol	9-18	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	74-79
35466134-6	2022	Whereas 3D-clinorotation decreased the protein level of IRS-1 in L6 myotubes, C14-Cblin and celastrol inhibited the degradation of IRS-1.	celastrol	92-101	insulin receptor substrate 1	Rattus norvegicus	131-136
35466134-7	2022	C14-Cblin and celastrol promoted the phosphorylation of FOXO3a even in microgravity condition.	celastrol	14-23	forkhead box O3	Rattus norvegicus	56-62